

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00001	ROSSC022-001517	ROSSC022-001517	4/22/1942	Letter from American Company to American Drug Manufacturers Association			
00002	W-MDL04782-00014935	W-MDL04782-00014940		NEW DRUG APPLICATION "PREMARIN TABLETS"			
00003	W-MDL04782-00014963	W-MDL04782-00014964	5/8/1942	FDA letter to Ayerst			
00004	W-MDL04782-00014968	W-MDL04782-00014969	5/16/1942	Ayerst letter to American Drug Manufacturers Association			
00005			10/10/1962	Kefauver-Harris Amendments to the Food, Drug, and Cosmetic Act are enacted			
00006	W-MDL04782-00015373	W-MDL04782-00015375		LIFE BEGINS AT FORTY			
00007	W-MDL04782-00015005	W-MDL04782-00015005	12/00/1964	Ayerst PREMARIN BRAND OF CONJUGATED ESTROGENS - (equine)			
00008	W-MDL04782-00015005	W-MDL04782-00015005	12/00/1964	Ayerst PREMARIN BRAND OF CONJUGATED ESTROGENS - (equine)			
00009	W-MDL04782-00015006	W-MDL04782-00015067		PREMARIN TABLETS			
00010			00/00/1966	Feminine Forever" Book by Dr. Robert Wilson			
00011	W-MDL04782-00015317	W-MDL04782-00015325		AT HER AGE ARE TRANQUILIZERS REALLY ENOUGH?			
00012	W-MDL04782-00017145	W-MDL04782-00017151	2/23/1972	SUGGESTED LABELING GUIDELINES FOR ESTROGENS			
00013	W-MDL04782-00015353	W-MDL04782-00015363		THERE'S A VOID IN THE LIFE OF MANY MIDDLE-AGED WOMEN.			
00014	BURRG002-000055	BURRG002-000072		Premarin			
00015	W-MDL04782-00027563	W-MDL04782-00027563	4/5/1973	PREMARIN TABLETS			
00016	W-MDL04782-00015343	W-MDL04782-00015347		PREMARIN BRAND OF CONJUGATED ESTROGENS TABLETS, U.S.P. gives back the natural estrogen support she's lost helps relieve symptoms ,returns a "sense of well-being"; DEPO: Andrew Panagy 7/13/06 EX 005: Advertisement			
00017	W-MDL04782-00016708	W-MDL04782-00016715		WHY STOP ESTROGEN REPLACEMENT THERAPY AFTER THE HOT FLUSHES HAVE SUBSIDED. WHEN THE DEFICIENCY IS STILL THERE?			
00018				1974 PROVERA LABEL			
00019	W-MDL04782-00016840	W-MDL04782-00016849		RE-EXAMINING THE VALUE OF LONG-TERM ESTROGEN THERAPY			
00020	W-MDL04782-00082752	W-MDL04782-00082755	2/27/1975	Commentary			
00021	W-MDL04782-00027344	W-MDL04782-00027513	12/16/1975	TRANSCRIPT OF PROCEEDINGS, OBSTETRICS AND GYNECOLOGY ADVISORY COMMITTEE			
00022	W-MDL04782-00064632	W-MDL04782-00064633	12/00/1975	Dear Doctor Letter from Dr. Jewell, Depo: Robert Essner 6/29/06 EX 008 & Allen, Susan 4/24/2007 EX 6: Dear Doctor Letter			
00022B	W-MDL04782-00067561	W-MDL04782-00067573	2/19/1986	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
00022C	W-MDL04782-00033664	W-MDL04782-00033664	8/4/1989	Wyeth Dear Doctor Letter signed by Joel Lipman, M.D.			
00022D	PANAA025-001943	PANAA025-001945	12/3/1990	Wyeth Dear Doctor Letter signed by Marc Deitch, M.D.			
00022E	CONNS001-000654	CONNS001-000656	3/18/1993	Dear Doctor letter - signed by Rofsky			
00022F	STRIS005-000435	STRIS005-000436	3/00/1998	Wyeth Dear Doctor Letter signed by Phillip de Vane, M.D.			
00022G	W-DDL-00000002	W-DDL-00000012	2/22/2000	Wyeth Dear Doctor Letter signed by Phillip de Vane, M.D.			
00022H	W-DDL-00000013	W-DDL-00000019	2/23/2000	Wyeth Dear Doctor Letter signed by Phillip de Vane, M.D.			
00022I	W-DDL-00000037	W-DDL-00000042	3/17/2000	Wyeth Dear Doctor Letter signed by Phillip de Vane, M.D.			
00022J	W-MDL527-00048273	W-MDL527-00048281	7/12/2001	(NDA 20-527)			
00022K	W-DDL-00000103	W-DDL-00000112	8/28/2002	Wyeth Dear Doctor Letter signed by Victoria Kusiak, M.D.			
00022L	W-DDL-00000113	W-DDL-00000124	1/6/2003	Wyeth Dear Doctor Letter signed by Victoria Kusiak, M.D.			
00022M	CONKJ020-000611	CONKJ020-000613	7/00/2002	Dear Doctor:			
00022N	DELCA008-001174	DELCA008-001174	2/00/2000	Wyeth Dear Doctor Letter signed by Phillip de Vane, M.D.			
00022O	ZUCAV008-029599	ZUCAV008-029601	5/28/2003	Dear Doctor Letter signed by Victoria Kusiak, M.D.			
00023	W-MDL04782-00082569	W-MDL04782-00082575	3/2/1976	FDA's Memoranda of Conferences with Ayerst's Representatives on January 7 and 12, 1976			
00024	W-MDL04782-00027339	W-MDL04782-00027342	1/12/1976	MEMORANDUM OF CONFERENCE, Between: Ayerst Laboratories Mr. Charles Hagen, General Counsel Mr. M. Silverstein, Counsel Dr. J. B. Jewell, Executive Vice Pres. Medical Affairs Dr. G. J. Carallito, Executive Vice Pres. for Scientific Affairs Dr. Henry Perd; Depo: Robert Essner 6/29/06 EX 009: Memo of Conference; DEPO: Andrew Panagy 7/13/06 EX 004: Memo			
00025	ROSSC022-001328	ROSSC022-001328	3/1/1976	FDA letter to Wyeth			
00026	W-MDL04782-00051786	W-MDL04782-00051788	3/17/1976	PREMARIN (conjugated estrogens Tablets, U.S.P.). Plans for Further Studies and Other Actions.			
00027	W-MDL04782-00029176	W-MDL04782-00029180	4/13/1976	Estrogens and Mammary Cancer			
00028	W-MDL04782-00029233	W-MDL04782-00029236	6/14/1976	Estrogens and Breast Cancer.; Depo: Constantine, Ginger 11/1/2005 EX 005: Estrogens and Breast Cancer.; Depo: Deitch, Marc 10/27/2005 EX 030: Estrogens and Breast Cancer.; Depo: Jane, Carol 7/14/2005 EX 007: Estrogens and Breast Cancer.			
00029	W-MDL04782-00029229	W-MDL04782-00029229	7/12/1976	Request for Preparation of an AHT.			
00030	W-MDL04782-00029230	W-MDL04782-00029231	7/16/1976	Estrogens and Mammary Cancer.			
00031	W-MDL04782-00029002	W-MDL04782-00029002	7/30/1976	Letter from Robert Hoover, M.D. to George Brice, M.D., Director of Medical Affairs, Ayerst; Depo: Constantine, Ginger 11/1/2005 EX 003			
00032	W-MDL04782-00029003	W-MDL04782-00029024		Menopausal Estrogens and Breast Cancer			
00033	W-MDL04782-00050784	W-MDL04782-00050792	8/13/1976	PROPOSAL Hysterectomy and Premarin: Analytical Plan for Collection of Data from Drs. Burch and Byrd, Nashville, Tenn.			
00034	W-MDL04782-00050783	W-MDL04782-00050783	8/18/1976	Plan Prepared by Genesee Computer Center, Inc. for Collection and Analysis of Data from the Records of Drs. Burch and Byrd.			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00035	W-MDL04782-00029027	W-MDL04782-00029032	8/20/1976	Statement of Ayerst Laboratories Regarding the Article "Menopausal Estrogen and Breast Cancer" in the 08191976, Issue of The New England Journal of Medicine			
00036	DEYMI018-000244	DEYMI018-000259	9/29/1976	Department of Health Education and Welfare. Food and Drug Administration (21 CFR Part 310) (Doc 76N-0384). Estrogens for General Use. Requirement for Labeling Directed to the Patient			
00037				1977 PROVERA LABEL			
00038	W-LABELS-000149	W-LABELS-000151	00/00/1977	1977 Premarin Label			
00039	SONKJ012-000729	SONKJ012-000766	4/11/1985	Report RA-85-03. Summary of Major for Activities Related to the Osteoporosis Indication for Estrogens			
00040	PANAA036-001091	PANAA036-001103	2/18/1977	Sixteenth Meeting			
00041	VICTJ005-000219	VICTJ005-000220	2/18/1977	Committee Recommendations: Estrogens for the Treatment of Osteoporosis			
00042			00/00/2005	21 CFR 310 – STATUTE			
00043	HOLSN005-000605	HOLSN005-000665	7/28/1977	Transcript of Obstetrics and Gynecology Advisory Committee Meeting			
00044			11/00/1977	FDA Consumer article			
00046	W-MDL04782-00032472	W-MDL04782-00032473	2/22/1979	Letter from Barbara Hulka, M.D. to George Brice, M.D., Director of Medical Affairs, Ayerst			
00047	W-MDL04782-00032465	W-MDL04782-00032468	2/21/1979	ESTROGEN USE AND THE OCCURRENCE OF BREAST CANCER AND OTHER HEALTH OUTCOMES			
00048	W-MDL04782-00032465	W-MDL04782-00032468	2/21/1979	ESTROGEN USE AND THE OCCURRENCE OF BREAST CANCER AND OTHER HEALTH OUTCOMES			
00049	W-MDL04782-00032469	W-MDL04782-00032469		Hulk Breast Cancer Memo			
00050	ROSSC002-000116	ROSSC002-000116		Conjugate Estrogen (CE) Use and the Risk of Breast Cancer in a Prepaid Health Plan.			
00051	ROSSC003-000878	ROSSC003-000878	4/2/1979	NDA 4-782; Premarin (Conjugated Estrogens Tablets, U.S.P.)			
00052	ROSSC002-000229	ROSSC002-000229	2/28/1980	NDA 4-782, Premarin (Conjugated Estrogens Tablets)			
00053	ROSSC002-000230	ROSSC002-000250		A Case Control Study of Menopausal Estrogen Therapy and Breast Cancer (1,2)			
00054	W-MDL04782-00032315	W-MDL04782-00032316	3/10/1980	Consultation with Dr. Brian Macmahon Harvard School of Public Health			
00055	W-MDL04782-00032331	W-MDL04782-00032333	3/17/1980	PREMARIN (R). Meeting with Dr. Brian Macmahon, School of Public Health, Harvard University, on the paper by Ross et al.			
00056	W-MDL04782-00032274	W-MDL04782-00032275	3/26/1980	Public Relations Plan relating to the JAMA publication of Ross / Mack report on breast cancer and estrogen.			
00057	W-MDL04782-00032254	W-MDL04782-00032254	4/8/1980	Meeting with Alan R. Feinstein, M.D., Yale University			
00058	DELCA008-000627	DELCA008-000631	4/25/1980	A Case-Control Study of Menopausal Estrogen Therapy and Breast Cancer; Depo: DelConte, Anthony 6/20/06 EX 029: Case-Control Study of Menopausal ET and Breast Cancer			
00059	W-MDL04782-00032480	W-MDL04782-00032504	12/19/1980	A Case-Control Study of Breast Cancer and Exogenous Estrogen			
00060	W-MDL04782-00032460	W-MDL04782-00032462	5/5/1981	Estrogens and Breast Cancer Comments on Dr. Hulka's Preliminary Report; Depo: Dey, Michael 6/26/06 EX 029: Memo; Depo: Justin Victoria 6/30/06 EX 003: Internal Memo			
00061	W-MDL04782-00032463	W-MDL04782-00032463		Table 1 Summary of Studies on Estrogen and Breast Cancer			
00062	W-MDL04782-00042950	W-MDL04782-00042951	8/6/1981	Letter from FDA to Henry Purdue, VP, Regulatory Affairs, Ayerst			
00063	W-MDL04782-00032201	W-MDL04782-00032202	8/28/1981	PREMARIN (R) and Breast Cancer. Preliminary Results of Yale Study.			
00064	PANAA036-001135	PANAA036-001136	11/11/1981	Memorandum of Meeting			
00065	W-MDL04782-00032192	W-MDL04782-00032192	1/19/1982	Letter from Ralph Horwitz, Yale University to George Brice, M.D.			
00066	W-IND-00000404	W-IND-00000845	3/9/1983	Premarin IND 21-696, Book 2			
00066A	W-IND-00000404	W-IND-00000407	3/9/1983	Premarin IND 21-696, Book 2 (partial)			
00067	W-MDL04782-00058976	W-MDL04782-00058977	2/22/1983	Premarin. Protocol Synopsis. Evaluation of Safety and Efficacy of Fixed Doses of Premarin and Medroxyprogesterone Acetate. Protocol No. 82-28-MD			
00068	W-MDL04782-00030691	W-MDL04782-00030693	9/15/1983	Estrogens Workshop Sponsored by the NHLBI-NIH, 09131983 - 09141983.; Depo: Dey, Michael 6/26/06 EX 030: Memo			
00069	W-MDL04782-00059871	W-MDL04782-00059872	9/22/1983	PREM-PAK. Desired Labeling and Indications.			
00070	W-MDL04782-00063068	W-MDL04782-00063083	12/8/1983	CITIZEN'S PETITION			
00071	W-MDL04782-00063066	W-MDL04782-00063067	12/20/1983	Citizen Petition by HRG (Estrogens Class Labeling)			
00072	PINIM017-000457	PINIM017-000457	00/00/1984	Handwritten Note regarding case control study from 1973 to 1975; Depo: Pinizzotto, Marie 8/23/2005 EX 014			
00073	W-MDL04782-00058978	W-MDL04782-00058978	2/7/1984	Premarin + Medroxyprogesterone. Protocol Synopsis. Evaluation of Estrogen and Progesterone Receptors, DNA-Thymidine Uptake Labelling, and Estradiol Dehydrogenase in Patients Receiving Fixed Doses of Premarin and Medroxyprogesterone. Protocol No. 83-13-MD			
00075	SONKJ012-000729	SONKJ012-000766	4/11/1985	Report RA-85-03. Summary of Major for Activities Related to the Osteoporosis Indication for Estrogens			
00076	W-MDL04782-00058980	W-MDL04782-00058981	5/21/1984	Premarin. Protocol Synopsis. Evaluation of Efficacy of Fixed Doses of Premarin and Medroxyprogesterone Acetate. Protocol No. 84-912-MD			
00077	W-MDL303-00081763	W-MDL303-00081765	7/17/1992	Chronology of meetings, teleconferences and written correspondence (NDA 20-303)			
00078	W-MDL04782-00038755	W-MDL04782-00038757	8/23/1984	NDA 04-782			
00079	W-MDL04782-00038770	W-MDL04782-00038770	8/24/1984	NDA 4-782. Premarin (R) (Conjugated Estrogens, U.S.P.)			
00080	W-LABELS-000190	W-LABELS-000194	00/00/1985	1985 Premarin Label			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00081	SONKJ012-000729	SONKJ012-000766	4/11/1985	Report RA-85-03. Summary of Major for Activities Related to the Osteoporosis Indication for Estrogens			
00082	NORMJ006-000610	NORMJ006-000610	4/30/1985	New Drug Submission P & P (Conjugated Estrogen Tablets & Medroxyprogesterone Acetate Tablets)			
00083	W-MDL527-00035136	W-MDL527-00035137	5/2/1985	FDA Contact Report (NDA 20-527)			
00084	W-MDL04782-00009302	W-MDL04782-00009302	6/27/1985	OGEN Promotion			
00085	W-IND-00003859	W-IND-00004310		Premarin IND 21-696, Amendment #7			
00086	GPIL008-002282	GPIL008-002286	8/28/1985	FDA letter to Abbott Laboratories regarding Ogen advertising and promotional materials			
00087	GPIL008-002293	GPIL008-002295	9/20/1985	General Discussion - Ogen Advertising Follow-Up Notice of Violation NOV Letter 8/28/85			
00088	W-LABELS-000195	W-LABELS-000199	00/00/1986	1986 Premarin Label			
00089	W-HUSAK01-00001306	W-HUSAK01-00001306		Information for Patient "Two Benefits vs. a Risk of Estrogen Replacement Therapy"			
00091	W-MDL04782-00030354	W-MDL04782-00030354	3/14/1986	PREMARIN and OGEN. Profile of Adverse Effects Reported to the FDA			
00091A	W-MDL04782-00030353	W-MDL04782-00030353		PROFILE OF ADVERSE EFFECTS REPORTED TO THE FDA FOR OGEN AND PREMARIN			
00092	W-MDL04782-00009643	W-MDL04782-00009644	7/21/1986	Premarin FDA Meeting			
000920A			04/00/1995	Essner Prempro Launch Speech			
00093	W-MCL003-027113	W-MCL003-027115	11/00/1986	Progesterone and Breast Cancer			
00094			2/9/1998	IARC document			
00095	PICKJ009-001654	PICKJ009-001667		P.M. Meeting; Depo: Pickar, James 9/20/2005 EX 023: P.M. Meeting			
00096	W-MDL04782-00013627	W-MDL04782-00013644	10/00/1987	GUIDELINE FOR PROFESSIONAL LABELING FOR ESTROGEN DRUG PRODUCTS [Docket No. 36N-0334]			
00096A	W-MDL04782-00013616	W-MDL04782-00013626	10/00/1987	GUIDELINE FOR PATIENT PACKAGE INSERTS FOR ESTROGEN DRUG PRODUCTS [Docket No. 86N-0334]			
00098	CONNS014-001645	CONNS014-001646	10/00/1987	Regarding effects of estrogen on the cardiovascular system; Depo: Robert Essner 6/29/06 EX 011; Depo: Jeanne Durocher 6/30/06 EX040			
00099	W-MDL04782-00013616	W-MDL04782-00013626	10/00/1987	GUIDELINE FOR PATIENT PACKAGE INSERTS FOR ESTROGEN DRUG PRODUCTS [Docket No. 86N-0334]			
00100	W-MDL04782-00013627	W-MDL04782-00013644	10/00/1987	GUIDELINE FOR PROFESSIONAL LABELING FOR ESTROGEN DRUG PRODUCTS [Docket No. 36N-0334]			
00102	W-MDL303-00081735	W-MDL303-00081738	8/7/1992	FDA meeting minutes (NDA 20-303)			
00103	PICKJ009-001519	PICKJ009-001521		Reproductive Endocrinology January Status Report			
00104	W-IND-00009083	W-IND-00009110	5/00/1988	Premarin IND 21-696 Progress Report			
00105	CONNS014-001627	CONNS014-001627	9/30/1988	Finance Committee Authorization			
00106	CONNS014-001602	CONNS014-001605	11/10/1988	Pharmaceutical Marketing Symposium			
00107	DUROJ029-000202	DUROJ029-000202	12/1/1988	Public Relations FDA Policy; Depo: Jeanne Durocher 6/30/06 EX007; Internal Correspondence to Distributionfrom Victoria			
00108	W-IND-00006856	W-IND-00006862	12/28/1988	Letter to FDA from Justin Victoria			
00109	W-MDL04782-00026508	W-MDL04782-00026511	6/25/1992	Premarin Osteoporosis Labeling Ayerst / FDA Chronology - Major Events			
00110	CONNS005-000398	CONNS005-000399	6/15/1989	Estrace Promotion			
00111	YAVUE010-000664	YAVUE010-000737	3/00/1990	Long-Term Effects of Estrogen Deprivation Proceedings of the Third Annual Symposium on the Long-Term Effects of Estrogen Deprivation			
00112	CONNS005-000396	CONNS005-000397	6/29/1989	Mead Johnson Estrace Promotion; Depo: Justin Victoria 6/30/06 EX 0014: Internal Correspondence			
00114	CONNS005-000346	CONNS005-000346	8/4/1989	The New England Journal of Medicine Article Entitled: "The Risk of Breast Cancer after Estrogen and Estrogen-Progestin Replacement"			
00115	PANAA035-000643	PANAA035-000644	10/3/1989	Premarin Proposals; Depo: Deitch, Marc 10/26/2005 EX 012: Premarin Proposals			
00116	W-MDL04782-00000299	W-MDL04782-00000299	10/20/1989	CLINICAL STUDIES SUPPORTING THE USE OF PREMARIN TO DECREASE THE RISK OF CORONARY HEART DISEASE IN POSTMENOPAUSAL WOMEN by Joel S. Lippman			
00117	W-MDL04782-00000297	W-MDL04782-00000298	10/26/1989	Premarin Cardioprotection Claim			
00118	W-MDL04782-00035524	W-MDL04782-00035525	11/9/1989	NDA No. 4-782			
00119	W-MDL04782-00035526	W-MDL04782-00035546		CLINICAL STUDIES SUPPORTING THE USE OF PREMARIN TO DECREASE THE RISK OF CORONARY HEART DISEASE IN POSTMENOPAUSAL WOMEN			
00120	W-MDL04782-00000202	W-MDL04782-00000202	11/27/1989	Premarin Cardioprotection Claim			
00121	RYANJ002-000495	RYANJ002-000523		One of a Kind Premarin (Conjugated Estrogens Tablets, U.S.P.); Depo: Ryan, John 6/14/2005 EX 012			
00122	PANAA030-001175	PANAA030-001176		Ideal Duration of ERT			
00123	ROSSC022-000828	ROSSC022-000828	1/3/1990	Wyeth letter to FDA enclosing exhaustive literature report			
00124	ROSSC002-000519	ROSSC002-000536		Estrogen Replacement Therapy and Breast Cancer: A Review of the Literature			
00125	VICTJ005-001727	VICTJ005-001727	1/8/1990	HRT/Cancer			
00126	CONTA012-001054	CONTA012-001054	1/21/1990	Wyeth to Dr. Hulka -- epidemiologist at University of N. Carolina			
00127	W-MCL004-01736	W-MCL004-01736	1/21/1990	Handwritten memo from Nick Marmontello to Marc Deitch, M.D.; Depo: Deitch, Marc 10/26/2005 EX 006			
00128	VICTJ005-001709	VICTJ005-001709	1/22/1990	FDA Advisory Committee HRT/ Breast Cancer and Endometrial Cancer			
00129	VICTJ005-001707	VICTJ005-001708	1/24/1990	FDA Advisory Committee HRT/ Breast Cancer and Endometrial Cancer; Depo: Deitch, Marc 10/26/2005 EX 008: FDA Advisory Committee HRT/ Breast Cancer and Endometrial Cancer			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00130	VICTJ005-001705	VICTJ005-001706	1/25/1990	FDA Advisory Committee HRT and Cancer; Depo: Deitch, Marc 10/26/2005 EX 009: FDA Advisory Committee HRT and Cancer			
00131	W-MDL04782-00001554	W-MDL04782-00001563	2/00/1990	LABELING GUIDANCE FOR ESTROGEN DRUG PRODUCTS PHYSICIAN LABELING			
00132	W-MDL04782-00001564	W-MDL04782-00001569	2/00/1990	LABELING GUIDANCE FOR ESTROGEN DRUG PRODUCTS PATIENT PACKAGE INSERT			
00133	CONNS017-000118	CONNS017-000118	2/2/1990	2/1 Advisory Committee Meeting; Depo: Robert Essner 6/29/06 EX 049: Memo			
00134	CONNS017-000031	CONNS017-000031	3/13/1990	Premarin February 1, 1990 Fertility and Maternal Health Advisory Committee Meeting			
00134A	CONNS017-000032	CONNS017-000035	2/1/1990	Summary Minutes			
00135	VICTJ005-001700	VICTJ005-001703	2/15/1990	Fertility and Maternal Health Advisory Committee Meeting February 1, 1990; Depo: Justin Victoria 6/30/06 EX 005: Internal Memo			
00136	PANAA026-001571	PANAA026-001572	2/21/1990	Premarin Cardiovascular Indication; Depo: Deitch, Marc 10/26/2005 EX 014: Premarin Cardiovascular Indication			
00137	W-MCL003-03011	W-MCL003-03012	4/6/1990	Incidence of Breast Cancer; Depo: Xue, Songlin 6/8/06 EX 003: Memo to Marc Deitch from M. Weber			
00138	W-MDL04782-00045227	W-MDL04782-00045228	5/15/1990	Premarin (Conjugated Estrogens, USP) Tablets NDA 4-782: Supplemental NDA			
00139	W-MDL04782-00045322	W-MDL04782-00045326		PREMARIN (conjugated estrogens tablets, USP)			
00140	PANAA010-000988	PANAA010-001102		DEPO: Buchhalter, Jeff 05/23/2008 EX 37: The Fourth Annual Symposium on the Long Term Effects of Estrogen Deprivation June 4, 5, 6, 1990 San Domenico Palace Sicily, Italy Proceedings Session II ERT Risks: Metabolic and Neoplastic			
00141	SONKJ012-000971	SONKJ012-001073	6/14/1990	Premarin Cardioprotection. Transcript of Advisory Committee Meeting June 14 1990			
00142	SONKJ012-001074	SONKJ012-001273	6/15/1990	Premarin Cardioprotection Transcript of Advisory Committee Meeting June 15, 1990			
00143	RHUDM005-000262	RHUDM005-000266	6/18/1990	Premarin - Cardiovascular Indication			
00144	PANAA034-001426	PANAA034-001427	8/22/1990	Estrogen/Progestin Packaging; Depo: DelConte, Anthony 1/19/2006 EX 010; Depo: Pickar, James 9/20/2005 EX 019; Depo: Justin Victoria 6/30/06 EX 017: Internal Correspondence			
00145	ROSSC023-001093	ROSSC023-001094	10/11/1990	Premarin Direct-to-Consumer Ad FDA Comments			
00146	VICTJ005-001644	VICTJ005-001644	12/3/1990	Premarin Toxicity/Carcinogenicity Review			
00147	CONNS011-000035	CONNS011-000046		World Health Organization, International Agency for Research on Cancer. IARC Monographs			
00149	CONNS008-000486	CONNS008-000486	12/20/1990	Direct-to-Consumer Advertising FDA Policy			
00150	DEYMI003-000013	DEYMI003-000025	1/00/1991	What Every Women Should Know About Estrogen; Depo: Dey, Michael 11/4/2005 EX 016: What Every Women Should Know About Estrogen			
00151	W-LABELS-000218	W-LABELS-000221	00/00/1991	1991 PREMARIN LABEL			
00152	DEYMI020-000790	DEYMI020-000790	1/10/1991	Dose Relationship of Endometrial Cancer			
00153	CONNS008-000473	CONNS008-000474	2/14/1991	Letter from Wyeth to FDA - DTC - FDA- MARKETING Re: Seasons magazine campaign; Depo: Deitch, Marc 10/27/2005 EX 020			
00154	W-MDL04782-00002391	W-MDL04782-00002393	2/25/1991	FDA letter to Joseph Morrison, Wyeth-Ayerst; Depo: Deitch, Marc 10/27/2005 EX 021; Depo: Robert Essner 6/29/06 EX 014: Letter; DEPO: Andrew Panagy 7/13/06 EX 017: Letter			
00155	CONNS008-000468	CONNS008-000469	2/27/1991	Premarin Women Health Program; Depo: Deitch, Marc 10/27/2005 EX 022: Premarin Women Health Program			
00156	CONNS008-000464	CONNS008-000464	3/7/1991	Prescription Drug Promotion FDA Oversight			
00157	CONNS008-000441	CONNS008-000441	4/4/1991	Premarin Duration of Therapy			
00158	W-MDL04782-00035765	W-MDL04782-00035769	4/16/1991	Wyeth-Ayerst letter to FDA			
00159	VICTJ005-001620	VICTJ005-001622	4/23/1991	Breast Cancer Language: Premarin Labeling			
00160	PANAA025-001866	PANAA025-001867	4/30/1991	Dear Doctor Letter signed by Marc Deitch, M.D.; Depo: Deitch, Marc 10/27/2005 EX 029			
00160A	PANAA025-001879	PANAA025-001884		Dear Doctor Letter from Deitch re: ERT and brca risk			
00161	W-MDL04782-00036168	W-MDL04782-00036185		Seasons. Volume 1, Issue 1			
00162	DEYMI020-000195	DEYMI020-000271		5th Annual Symposium on the Long-Term Effects of Estrogen Deprivation; Depo: Dey, Michael 11/4/2005 EX 011			
00163	W-MDL04782-00034052	W-MDL04782-00034062		Premarin (conjugated estrogens tablets, USP)			
00164	W-MDL04782-00034654	W-MDL04782-00034656	6/14/1991	Premarin (Conjugated Estrogens, USP) NDA 4-782/S-084			
00165	VICTJ005-001361	VICTJ005-001365	6/23/1991	Summary Minutes			
00166	VICTJ005-001373	VICTJ005-001379	7/11/1991	Fertility and Maternal Health Drugs Advisory Committee Meeting - June 20-21, 1991 Minutes of Meeting			
00167	W-MDL04782-00050223	W-MDL04782-00050223	7/16/1991	Premarin Cardiovascular Labeling			
00168	PANAA034-001796	PANAA034-001796	7/16/1991	Premarin CBL Program; Depo: Deitch, Marc 10/26/2005 EX 013; Depo: Robert Essner 6/29/06 EX 016: Premarin CBL Program			
00169	W-MDL04782-00050226	W-MDL04782-00050226		MEDICAL LECTURE SERIES DINNER MEETING			
00170	PANAA034-001711	PANAA034-001713	8/9/1991	Personal Communication			
00171	SINAM002-001012	SINAM002-001017		History of Premarin and Generic Conjugated Estrogens			
00172	PANAA025-001812	PANAA025-001813	8/19/1991	Ron Ross Breast Cancer Data			
00173	VICTJ005-001360		9/5/1991	Fertility and Maternal Health Drugs Advisory Committee Meeting - June 20-21, 1991 Minutes of Meeting			
00174	COBBP002-000106	COBBP002-000106	9/24/1991	Premarin : Prevention of CVD			
00175	W-MCL004-01712	W-MCL004-01719	9/30/1991	Royal Society of Medicine Anglo-American Conference on Hormone Replacement Therapy and Breast Cancer Risk London, UK, 9/24-26/91; Depo: Constantine, Ginger 11/1/2005 EX 018: Royal Society of Medicine Anglo-American Conference on Hormone Replacement Therapy and Breast Cancer Risk London, UK, 9/24-26/91; Depo: Robert Essner 6/29/06 EX 026: memo to Deitch; Fred Hassan 12/16/06 DEPO EX 017: Memo			
00176	W-MDL303-00081859	W-MDL303-00081886	10/31/1991	Premarin/MPA Labeling (NDA 20-303)			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00177	ROSSC023-000943	ROSSC023-000944	11/11/1991	Wyeth-Ayerst letter to FDA			
00178	ROSSC023-000940	ROSSC023-000940	11/25/1991	Premarin, Osteoporosis Advertising			
00179	YAVUE007-000244	YAVUE007-000486		Premarin: Sales Issues & Competitive Information; Depo: Mahady, Joseph 11/17/2005 EX 016: Premarin: Sales Issues & Competitive Information; Depo: Mahady, Joseph 11/17/2005 EX 018: Premarin: Sales Issues & Competitive Information; Depo: Ryan, John 6/14/2005 EX 028: Premarin: Sales Issues & Competitive Information; Depo: Robert Essner 6/29/06 EX 012: Premarin Sales Issues & Competitive Information			
00180	CONNS008-000386	CONNS008-000386	1/2/1992	Premarin CBL Campaign Seasons Magazine; Depo: Deitch, Marc 10/27/2005 EX 023: Premarin CBL Campaign Seasons Magazine			
00181	VICTJ005-001591	VICTJ005-001592	1/15/1992	Letter from Philip DiSaia, M.D., UC Irvine to Dan Rittick, M.D.; Depo: Deitch, Marc 10/27/2005 EX 032			
00182	DUROJ032-000320	DUROJ032-000320	1/15/1992	Premarin Cardiovascular Labeling			
00183	CONNS009-001315	CONNS009-001317	1/23/1992	Ciba-Geigy/FDA Correspondence Estraderm Advertising			
00184	PANAA014-001130	PANAA014-001130	1/23/1992	Premarin Cardiovascular Labeling; Depo: Deitch, Marc 10/26/2005 EX 015; Depo: Robert Essner 6/29/06 EX 017: Premarin/CV Labeling; Depo: Justin Victoria 6/30/06 EX 016: Internal Correspondence			
00185	W-HUSAK01-00000174	W-HUSAK01-00000175		Handwritten Notes from Sales Rep regarding Ettinger Study			
00186	VICTJ005-001581	VICTJ005-001581	2/6/1992	2/14 FDA Advisory Committee Meeting			
00187	VICTJ005-001583	VICTJ005-001588	2/14/1992	Draft Agenda			
00188	PANAA025-000820	PANAA025-000823	3/17/1992	February 14 Fertility and Maternal Health Drugs Advisory Committee Meeting; Depo: Justin Victoria 6/30/06 EX 008: Internal Correspondence			
00189	ROSSC005-000329	ROSSC005-000329	3/19/1992	Wyeth-Ayerst letter to FDA			
00190	CONNS005-000121	CONNS005-000126	3/24/1992	"Don't Know" -Menopause			
00191	HOLSN006-000703	HOLSN006-000704	3/24/1992	FDA Meeting to Discuss DTC Promotion for Estrogen Product for Osteoporosis			
00192	ROSSC005-000271	ROSSC005-000272	4/20/1992	Premarin			
00192A	GOLDG001-001435	GOLDG001-001499		Field Sales Promotional Policy 511			
00193	PICKJ004-000668	PICKJ004-000711	5/19/1992	Powerpoint slides "Breast Cancer"; Depo: Pickar, James 9/20/2005 EX 047			
00194	W-MDL303-00081836	W-MDL303-00081836	4/26/1992	Premarin/Cardiovascular Labeling (NDA 20-303)			
00195	CONNS008-000352	CONNS008-000354	5/14/1992	NDA 4-782			
00196	PANAA029-000670	PANAA029-000672	5/26/1992	FDA Letter on Proposed Premarin DTC Ad			
00197	ROSSC005-000160	ROSSC005-000161	6/3/1992	NDA 4-782; Depo: Deitch, Marc 10/27/2005 EX 024: NDA 4-782			
00198	CONNS008-000980	CONNS008-000982	6/3/1992	Premarin Seasons Magazine; Depo: Deitch, Marc 10/27/2005 EX 025: Premarin Seasons Magazine			
00199	ROSSC005-000162	ROSSC005-000166	6/8/1992	Wyeth-Ayerst letter to FDA			
00200	W-MDL303-00081784	W-MDL303-00081793	6/24/1992	Depo-Provera (NDA 20-303)			
00201	OLIVS008-001295	OLIVS008-001298	6/26/1992	Premarin / MPA FDA Meeting			
00202	CONNS005-000969	CONNS005-000970	6/29/1992	Tactical Plans			
00203	CONNS005-000061	CONNS005-000062	6/30/1992	Premarin Promotion			
00204	W-MDL303-00081763	W-MDL303-00081765	7/17/1992	Chronology of meetings, teleconferences and written correspondence (NDA 20-303)			
00205	ROSSC005-000092	ROSSC005-000092	7/21/1992	NDA 4-782; Depo: Jane, Carol 7/14/2005 EX 016: NDA 4-782			
00206	VICTJ006-001345	VICTJ006-001346	7/31/1992	Efficacy Supplements for Off-Label Uses			
00207	BURKM002-000168	BURKM002-000180	8/00/1992	Labeling Guidance for Estrogen Drug Products Physician Labeling			
00208	ROSSC005-000085	ROSSC005-000087	8/6/1992	Wyeth-Ayerst letter to FDA			
00209	CONNS005-000046	CONNS005-000047	8/6/1992	Premarin Help-Seeking Video			
00210	VICTJ001-000008	VICTJ001-000010	8/10/1992	Physicians Desk Reference, Premarin (Wyeth Ayerst) (Conjugated Estrogens Tablets, USP)			
00211	FISHG001-000277	FISHG001-000281	8/13/1992	Letter from Peter Hoyle, Ph.D. to Mark Hite, Sc.D. Wyeth			
00213	ROSSC005-000083	ROSSC005-000084	8/14/1992	FDA Letters Regarding Premarin Promotional Materials; Depo: Justin Victoria 6/30/06 EX 018: Internal Correspondence			
00214	W-MDL303-00081730	W-MDL303-00081733	8/14/1992	FDA Trip Report (NDA 20-303)			
00215	CONNS009-001295	CONNS009-001296	8/14/1992	Ciba-Geigy/FDA Interaction Estraderm Advertising			
00216	W-MDL04782-00026817	W-MDL04782-00026828	8/25/1992	CARDIAC - FDA - LABEL: FDA Letter to Wyeth			
00217	W-MDL303-00081683	W-MDL303-00081687	8/27/1992	Cardiovascular Labeling (NDA 20-303)			
00218	CONNS005-000043	CONNS005-000044	9/1/1992	Premarin "Two Women" Video and Norplant NRP: 105 VJOG			
00219	W-MDL303-00081664	W-MDL303-00081664	9/9/1992	Cardiovascular Labeling (NDA 20-303)			
00220	FISHG001-000267	FISHG001-000269	9/10/1992	Consultant Review of Ten-Day Safety Report on MPA; Depo: Fisher, Gerald 11/22/2004 EX 139: Consultant Review of Ten-Day Safety Report on MPA			
00221	PANAA038-000807	PANAA038-000808	9/10/1992	Women's Health Initiative (WHI) Drug Supply (Ref. 92-052-MA)			
00222	FISHG001-000201	FISHG001-000214		Medroxyprogesterone Acetate (MPA) : Interpretation of Studies in Laboratory Animals; Depo: Fisher, Gerald 11/22/2004 EX 137: Medroxyprogesterone Acetate (MPA) : Interpretation of Studies in Laboratory Animals			
00223	CONNS016-000199	CONNS016-000201	10/28/1992	Heart and Estrogen-Progestin Replacement Study (HERS) Fact Sheet			
00224	HOLSN004-000365	HOLSN004-000373	11/25/1992	Wyeth-Ayerst Premarin Tablets (Conjugated Estrogens) International Corporate Direction Circular			
00225	CONNS016-000210	CONNS016-000212	11/16/1992	Premarin and Medroxyprogesterone Acetate (MPA) IND 21,696 Serial 075			
00226	CONNS005-000023	CONNS005-000024	11/17/1992	Premarin Promotional Items PRM: 314 and PRM: 315			
00227	W-MDL303-00008975	W-MDL303-00009394		New Drug Application (NDA 20-303); Volume 1.40 of 1.174			
00228	DEMAE007-002468	DEMAE007-002468	1/12/1993	Women's Health Initiative (WHI) IND Cross Reference			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00229	DEMAE007-000664	DEMAE007-000664	1/26/1993	Premarin (Conjugated Estrogens) with Medroxyprogesterone Acetate (MPA) Tablets IND No. 21,696 Serial No. 079			
00230	DEYMI001-000115	DEYMI001-000229	2/00/1993	Premarin Issues Management System; Depo: Dey, Michael 11/4/2005 EX 021: Premarin Issues Management System			
00231	W-MDL303-00082105	W-MDL303-00082110	2/24/1993	Refusal to File Response (NDA 20-303)			
00232	PANAA015-000970	PANAA015-000971	3/2/1993	"Understanding Menopause Program"			
00234	PANAA036-001540	PANAA036-001559	8/31/1993	Seasons Subscribers/Non-Subscribers Surveys			
00235	FISHG001-000175	FISHG001-000175	4/6/1993	Premarin/MPA - Preclinical Dossier and Expert Report; Depo: Fisher, Gerald 11/22/2004 EX 133: Premarin/MPA - Preclinical Dossier and Expert Report			
00236	FISHG001-000173	FISHG001-000174	4/7/1993	Premarin/MPA - Preclinical Expert Report			
00237	PANAA019-000537	PANAA019-000539	4/22/1993	Extending Compliance Increases Sales; Depo: Sinapi 8/29/2005 EX 021: Extending Compliance Increases Sales			
00238	CONNS003-000069	CONNS003-000069	5/12/1993	OGEN Promotion			
00239	CONNS001-001434	CONNS001-001436	5/25/1993	Trip Report			
00240	W-MDL303-00081992	W-MDL303-00082002	5/26/1993	Memo re: FDA Correspondence on Osteoporosis Issues (NDA 20-303)			
00241	CONNS001-000130	CONNS001-000130	5/28/1993	Draft letter to FDA			
00242	PANAA016-000938	PANAA016-000945	00/00/1993	Health Words for Women what Every Woman Should Know about Estrogen and Breast Cancer			
00242B	PANAA016-000922	PANAA016-000929	00/00/1992	Health Words for Women Mammograms: The Very Best Defense Against Breast Cancer			
00242C	PANAA016-000914	PANAA016-000921	00/00/1992	Health Words for Women "Brittle Bones - How to Avoid Bad Breaks as you Get Older			
00242D	PANAA016-000930	PANAA016-000937	00/00/1993	Health Words for Women Bothered by Mood Swings? They're Often Preventable			
00242E	PANAA016-000938	PANAA016-000945	00/00/1993	Health Words for Women what Every Woman Should Know about Estrogen and Breast Cancer			
00242F	PANAA016-000946	PANAA016-000953	00/00/1993	Health Words for Women the Truth about Ovarian Cancer			
00243	CONNS019-000006	CONNS019-000006	6/15/1993	FDA Letter on Funding of Educational Programs			
00244	DEYMI020-001008	DEYMI020-001008	7/6/1993	Letter from Jean Delchambre, Wyeth France to Mike Dey			
00245	DEYMI020-001070	DEYMI020-001143		The Long-Term Effects of Estrogen Deprivation Seventh Annual Symposium			
00246	W-MDL303-00079264	W-MDL303-00079267	6/7/1994	Memorandum of Meeting (NDA 20-303)			
00247	W-MDL303-00079301	W-MDL303-00079316	11/5/1993	Transmittal of minutes 10/5/93 meeting (NDA 20-303)			
00248	CONNS013-000662	CONNS013-000664	11/10/1993	Estrogen and Alzheimer's Media Coverage			
00249	W-MCL029-000851	W-MCL029-000864	11/15/1993	More Reasons than Ever for HRT			
00250	DEYMI006-000036	DEYMI006-000037	12/6/1993	Consensus Conference on HRT and the Cardiovascular System / Impact on Premarin / MPA			
00251	PANAA027-000562	PANAA027-000562	12/8/1993	ECOG Breast Cancer Trial			
00252	CONNS022-000503	CONNS022-000503	12/30/1993	Premarin/MPA NDA Amendment			
00253	PANAA016-000465	PANAA016-000487		Women's Health Moves to the Forefront			
00254A	W-ANNREP93-0001	W-ANNREP93-0048	00/00/1993	American Home Products Corporation 1993 Annual Report			
00254B	W-ANNREP90-0001	W-ANNREP90-0044	00/00/1990	American Home Products Corporation 1990 Annual Report			
00254C	W-ANNREP91-0001	W-ANNREP91-0052	00/00/1991	American Home Products Corporation 1991 Annual Report			
00254D	W-ANNREP92-0001	W-ANNREP92-0060	00/00/1992	American Home Products Corporation 1992 Annual Report			
00254E	W-ANNREP94-0001	W-ANNREP94-0067	00/00/1994	American Home Products Corporation 1994 Annual Report			
00254F	W-ANNREP95-0001	W-ANNREP95-0054	00/00/1995	American Home Products Corporation 1995 Annual Report			
00254G	W-ANNREP96-0001	W-ANNREP96-0048	00/00/1996	American Home Products Corporation 1996 Annual Report			
00254H	W-ANNREP97-0001	W-ANNREP97-0050	00/00/1997	American Home Products Corporation 1997 Annual Report			
00254I	W-ANNREP98-0001	W-ANNREP98-0058	00/00/1998	American Home Products Corporation 1998 Annual Report			
00254J	W-ANNREP99-0001	W-ANNREP99-0064	00/00/1999	American Home Products Corporation 1999 Annual Report			
00254K	W-ANNREP00-0001	W-ANNREP00-0067	00/00/2000	American Home Products Corporation 2000 Annual Report			
00254L	W-ANNREP01-0001	W-ANNREP01-0074	00/00/2001	Wyeth 2001 Annual Report			
00254M	W-ANNREP02-0001	W-ANNREP02-0074	00/00/2002	Wyeth 2002 Annual Report			
00255				Premarin; Sales Issues and Competitive Information			
00256	DUOJ032-000210	DUOJ032-000210	1/7/1994	Premarin; Depo: Speroff, Leon 6/30/2005 EX 050: Premarin			
00257	CONNS001-000540	CONNS001-000541	1/13/1994	Solvay Complaints			
00258	PANAA016-001025	PANAA016-001027	1/13/1994	Health Words for Women Customized Hospital Newsletter			
00259	PANAA016-001028	PANAA016-001029		Healthwords for Women Executive Briefing Document			
00260	CONNS022-000501	CONNS022-000501	1/14/1994	Premarin/MPA NDA Amendment			
00261	DEYMI033-000038	DEYMI033-000038	1/31/1994	Wyeth-Ayerst/FDA Meeting Premarin/MPA Minimum Effective Dose Discussion; Depo: Dey, Michael 11/4/2005 EX 017			
00262	W-HUSAK02-00001911	W-HUSAK02-00001940	00/00/1994	Manual "Osteoporosis - The Only Cure Is Prevention"			
00263	PANAA014-000021	PANAA014-000021	2/00/1994	Net Sales Comparison			
00264	PANAA014-000020	PANAA014-000020	2/00/1994	Gross Sales Comparison			
00265	PANAA027-000561	PANAA027-000561	2/9/1994	ECOG Breast Cancer Study			
00266	CONNS001-001319	CONNS001-001320	2/9/1994	Wyeth letter to FDA Re: Solvay off label promotion			
00267	PANAA014-000016	PANAA014-000019	4/7/1994	February 1994 Analysis-Pharmaceuticals Products			
00268	PANAA021-000192	PANAA021-000195		Wyeth District Manager's Leader's Guide POA 2 1994; Depo: Deitch, Marc 10/27/2005 EX 026: Wyeth District Manager's Leader's Guide POA 2 1994			
00269	ROSSC005-000034	ROSSC005-000038	4/26/1994	NDA 04-782 Premarin			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00270	FISHG001-000153	FISHG001-000153	5/5/1994	Premelle (Premarin/MPA) - French Registration; Depo: Fisher, Gerald 11/22/2004 EX 132: Premelle (Premarin/MPA) - French Registration			
00271	SINAM002-000001	SINAM002-000103	6/00/1994	Hormone Replacement Market a Monograph			
00272	DEYMI027-000085	DEYMI027-000150		The Long-Term Effects of Estrogen Deprivation Eighth Annual Symposium			
00273	GASTM009-000537	GASTM009-000539	7/22/1994	Medical Affairs Alzheimer's Disease Program			
00274	CONNS001-000045	CONNS001-000046	7/26/1994	FDA Contact: Premarin DTC and Competitive Promotional Activities			
00275	HOLSN006-000671	HOLSN006-000673	8/4/1994	NDA 04-782 Premarin MACMIS 2195			
00276	CONNS010-001551	CONNS010-001551	8/5/1994	Premarin Labeling: 1992 FDA Estrogen Labeling Guidance; Depo: Deitch, Marc 10/27/2005 EX 035: Premarin Labeling: 1992 FDA Estrogen Labeling Guidance			
00277	W-MDL04782-00029538	W-MDL04782-00029557		Welcome to Seasons For the best times of a woman's life.			
00278	CONNS008-000869	CONNS008-000871	10/6/1994	FDA Contact: Premarin Promotion			
00279	BURRG002-000049	BURRG002-000053	10/31/1994	History of Premarin; Depo: Robert Essner 6/29/06 EX 004; DEPO: Jean Meaney 7/11/06 EX 013			
00280	VICTJ005-001358	VICTJ005-001359	11/8/1994	Premarin - Direction Circular Revision			
00281	VICTJ005-001356	VICTJ005-001357	11/11/1994	Premarin Labeling			
00282	ROSSC034-000134	ROSSC034-000134	11/15/1994	NDA 04-782 Premarin MACMIS File ID 2195			
00283	CONNS008-000751	CONNS008-000752	11/16/1994	FDA Comment on Premarin DTC Advertisement			
00284	W-MDL303-00083464	W-MDL303-00083465	12/2/1994	Telephone Contact: FDA Request for Clinical Data Analysis (NDA 20-303)			
00285	W-MDL303-00079838	W-MDL303-00079890	12/15/1994	Amendment to a Pending New Drug Application - Response to FDA Requests (Clinical) (NDA 20-303)			
00285C	W-MDL303-00079862	W-MDL30300079864		Data Regarding Breast Cancer-Wyeth Response to FDA Request (NDA 20-303)			
00286	W-MDL303-00083808	W-MDL303-00083823	2/13/1995	Prempro/Premphase Labeling Meeting (NDA 20-303); Depo: Pickar, James 9/20/2005 EX 044: Prempro/Premphase Labeling Meeting (NDA 20-303)			
00287	W-MDL303-00083215	W-MDL303-00083220	12/30/1994	Premarin/MPA Separate Tablets - APPROVAL LETTER (NDA 20-303)			
00288	W-MDL303-00083690	W-MDL303-00083805	2/16/1995	Premarin/MPA Separate Tablets; Medical Officer's Review (NDA 20-303)			
00289	W-MDL303-00079760	W-MDL303-00079762	12/30/1994	Submission of press release (NDA 20-303)			
00289R	W-MDL303-00079762	W-MDL303-00079762	12/29/1994	Wyeth Press Release			
00290	VICTJ001-000005	VICTJ001-000007	12/30/1994	NDA 20-303			
00291	SOLOJ022-000554	SOLOJ022-000561	00/00/1994	Alzheimer's Disease and Estrogen Backgrounder			
00293	CONTA003-000676	CONTA003-000725	00/00/1995	Estrogen Replacement Therapy (ERT) Hormone Replacement Therapy (HRT)			
00294	CONTA003-000847	CONTA003-000903	00/00/1995	Marketing Strategy and Selling Issues			
00295	CONNS005-001430	CONNS005-001430	1/13/1995	Premarin Opportunity with WTDI Series Lifestyles and Longevity			
00296	CONNS005-001431	CONNS005-001431		Broadcast and Marketing Services Agreement			
00297	PANAA027-000892	PANAA027-000892	1/19/1995	Letter from Max Borten, M.D., Harvard Medical School to Murry Greene, Wyeth			
00298	DEMAE007-000727	DEMAE007-000729	1/23/1995	Premarin : Selection for WHI; Depo: Deitch, Marc 10/28/2005 EX 011; Premarin : Selection for WHI; Depo: Lyttle, Richard 10/28/2005 EX 006; Premarin : Selection for WHI			
00299	PICKJ007-000280	PICKJ007-000281	1/24/1995	Premarin/MPA Breast Cancer Phase IV Commitment; Depo: Pickar, James 9/20/2005 EX 062; Premarin/MPA Breast Cancer Phase IV Commitment			
00300	CONNS005-001395	CONNS005-001397	1/26/1995	Health Management Program			
00301	CONTA021-000853	CONTA021-000853	2/3/1995	Project Team Meeting			
00302	VICTJ005-001336	VICTJ005-001337	2/14/1995	Breast Cancer Labeling Prempro/Premphase			
00303	W-MDL303-00081186	W-MDL303-00081186	3/3/1995	List of teleconference participants (NDA 20-303)			
00304	W-MDL303-00081125	W-MDL303-00081132	3/10/1995	DDMAC response to launch materials (NDA 20-303)			
00305	ROSSC006-001403	ROSSC006-001408	3/10/1995	NDA 20-303 Prempro / Premphase MACMIS ID 2820			
00306	W-HUSAK01-00000373	W-HUSAK01-00000382		Powerpoint slides "Premphase: To Bleed or Not To Bleed"			
00307	PANAA027-000800	PANAA027-000801	4/26/1995	The Good Housekeeping Guide to Women's Health			
00307A				Good Housekeeping Guide to Women's Health			
00307B			00/00/1995	Good Housekeeping Guide to Women's Health			
00308	PANAA019-000679	PANAA019-000684		Overview: Premarin and Women's Health			
00309	STRIS002-000024	STRIS002-000026	6/5/1995	Market Research Proposal Prempro Sales Feedback			
00310	PICKJ007-001220	PICKJ007-001228		Nurses Health Study Breast Cancer Risk Report (Addendum to PREMPRO Mini Meeting)			
00311	BURRG005-000705	BURRG005-000706	6/12/1995	Dear Doctor letter for Deitch's signature re: the publication of the Nurses Health Study			
00312	BURRG005-000709	BURRG005-000710	6/12/1995	Letter from Swingle to Field Force			
00313	BURRG005-000722	BURRG005-000722	6/12/1995	Draft letter for Speroff's signature			
00314	BURRG005-000716	BURRG005-000717	6/12/1995	Draft letter for sales force			
00315	BURRG005-000728	BURRG005-000728	6/13/1995	Email to ABC			
00316	BURRG005-000697	BURRG005-000704	6/13/1995	Q&A by Wyeth			
00317	BURRG005-000694	BURRG005-000696	6/12/1995	Draft Q & A for Leon Speroff			
00318	BURRG005-000690	BURRG005-000693	6/15/1995	Wyeth Press Release re: Publication of Nurses Health Study; Depo: Speroff, Leon 6/30/2006 EX 006			
00320	DELCA028-000021	DELCA028-000022	7/17/1996	Finance Committee Authorization the MRC Replacement Study; Depo: DeConte, Anthony 6/20/06 EX 030: AHP Finance Committee Authorization			
00321	PANAA031-000708	PANAA031-000709	7/18/1995	Letter from Trudy Bush, M.D. to Editor, Modern Maturity			
00322	STRIS002-000011	STRIS002-000013	7/20/1995	Market Research Proposal Colditz / JAMA Awareness Consumer Follow-up			
00323	STRIS002-000075	STRIS002-000076	8/17/1995	Premarin / Prempro Alzheimer's Study (95-048MA) The Effect of Postmenopausal Replacement Therapy on the Development and Progression of Dementia			
00324	W-MDL303-00081420	W-MDL303-00081423	8/24/1995	Request for meeting (NDA 20-303)			
00325	W-MDL303-00081420	W-MDL303-00081423	8/24/1995	Letter from Blitz at Wyeth to Sobel at FDA			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00326	W-MDL303-00081416	W-MDL303-00081418	9/1/1995	Request for meeting (NDA 20-303)			
00327	PANAA014-000517	PANAA014-000517		Handwritten Note on Fred Hassan stationery			
00328	PANAA028-000467	PANAA028-000536	9/19/1995	In Vitro Activities of Defined Premarin Components and Analyses of Samples from Fractionation of Premarin and Preserved Condensed Urine Desiccated (PCUD); Depo: Pickar, James 9/20/2005 EX 018			
00329	STRIS004-000197	STRIS004-000197	10/13/1995	Memo from Steve Strickland to Ayerst Sales Force; DEPO: Jean Meaney 7/11/06 EX 012: Internal Memo; DEPO: Nick Marmontello 7/28/06 EX 017: Memo			
00330	W-MDL303-00083890	W-MDL303-00083892	11/8/1995	FDA Meeting of November 3, 1995 (NDA 20-303)			
00331	DUROJ035-000545	DUROJ035-000546	1/24/1996	Profitability Analysis System SPC Gross Profit for 3669 Premarin Vag Cr			
00332	FISHG001-000139	FISHG001-000141	12/21/1995	Conjugated Oestrogens; Depo: Fisher, Gerald 11/22/2004 EX 131: Conjugated Oestrogens			
00333	W-LABELS-000001	W-LABELS-000008	00/00/1996	1996 Prempro Label			
00334	W-LABELS-000001	W-LABELS-000008	00/00/1996	1996 Prempro Label			
00335	BURKM014-001853	BURKM014-001853		Review of Global Labeling - CHD Reduction Risk			
00336	LUDMG005-001829	LUDMG005-001831		Putting Estrogen and the Risk for Breast Cancer in Perspective"; Depo: Ludmerer	Gail 5/25/2005 EX 009"		
00337	PICKJ004-000372	PICKJ004-000382		Premarin The Most Studied Estrogen			
00338	CHOOM022-001673	CHOOM022-001776		POA II 1996 Discussion Guide			
00340	CONNS005-001458	CONNS005-001459	1/22/1996	Effexor/Prempro FDA Acknowledgement Regarding Reprints			
00341	PICKJ007-001349	PICKJ007-001349	1/31/1996	DEPO: Buchalter, Jeff 05/29/08 EX 24; Breast Cancer Task Force Meeting 1/31/96; Depo: Pickar, James 9/20/2005 EX 073: Breast Cancer Task Force Meeting 1/31/96			
00341A	CHOOM057-001441	CHOOM057-001442		MEMO: Jeff Buchalter - Breast Cancer Task Force Meeting - Action Steps			
00341B	CHOOM057-001442			breast cancer task force meeting - action steps			
00342	HENRL008-000280	HENRL008-000299		Seasons; Depo: Henry, Lesa 2/9/2005 EX 008: Seasons; Depo: Sinapi 8/29/2005 EX 022: Seasons			
00343	FISHG001-000074	FISHG001-000096		Premarin Line Extension Strategy; Depo: Fisher, Gerald 11/22/2004 EX 130: Premarin Line Extension Strategy			
00344	CONNS007-000035	CONNS007-000039	3/27/1996	Letter of Agreement for the New Horizons Program			
00345	SOLOJ022-001040	SOLOJ022-001042	3/27/1996	Cummings Study: Revised Strategic Recommendations; Depo: Mahady, Joseph 11/17/2005 EX 017 and Buchalter, Jeff 05/29/2008 EX 25: Cummings Study: Revised Strategic Recommendations			
00346	SOLOJ022-001373	SOLOJ022-001374	4/23/1996	Bone Mineral Density Predicts the Risk of Breast Cancer in Older Women. The Study of Osteoporotic Fractures.; Depo: Zucal, Vincent 7/28/2005 EX 003 and Buchalter, Jeff 05/29/2008 EX 28: Bone Mineral Density Predicts the Risk of Breast Cancer in Older Women. The Study of Osteoporotic Fractures.			
00347	PICKJ007-000159	PICKJ007-000161	4/25/1996	ASGO Meeting - Strategic Recommendations; Depo: Pickar, James 9/20/2005 EX 058: ASGO Meeting - Strategic Recommendations			
00348	SOLOJ022-001022	SOLOJ022-001022		DEPO: Buchalter, Jeff 05/29/2008 EX 39; BCA Working Group			
00349	SOLOJ022-001019	SOLOJ022-001019		DEPO: Buchalter, Jeff 05/29/2008 EX 27: Breast CA			
00350	CONNS014-000210	CONNS014-000211	5/10/1996	Premarin Labeling			
00351	DUROJ023-000528	DUROJ023-000528	6/26/1996	Parkland PHS Issue -Reply			
00352	CHOOM002-000051	CHOOM002-000088	7/00/1996	Prempro (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets) a Simple New Way to Take Hormone Replacement Therapy			
00352A	CHOOM002-000051	CHOOM002-000088	7/00/1996	Prempro (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets) a Simple New Way to Take Hormone Replacement Therapy			
00353	DUROJ023-000527	DUROJ023-000527	7/17/1996	Rob Happe's Issues Regarding Parkland PHS Pricing for Premarin			
00354	DUROJ037-000582	DUROJ037-000635		10th Annual Symposium on the Long-Term Effects of Estrogen Deprivation			
00355	PICKJ007-001296	PICKJ007-001306		Breast Cancer and Hormone Replacement Therapy: A Medical Judgement			
00356	PICKJ007-001310	PICKJ007-001310	8/22/1996	Toltzis Communications Inc.Proposal 90072WAI			
00357	PICKJ007-001311	PICKJ007-001311	8/27/1996	Purchase Order Attachment. Prepare Manuscript Breast Cancer & HRT			
00358	PICKJ007-001287	PICKJ007-001287	9/9/1996	Request from Dr. Freitas, Brazil for support from Wyeth to attend Menopause Congress			
00359	PANAA019-000170	PANAA019-000175	10/11/1996	Women's Health Care Customer Management Assessment			
00360	PICKJ009-001232	PICKJ009-001233	12/3/1996	Breast Cancer and Hormone Replacement Therapy			
00361	STRIS004-000183	STRIS004-000184	12/20/1996	Business Brief - December; Depo: Strickland 9/8/2005 EX 005: Business Brief - December; Depo: Robert Essner 6/29/06 EX 021: Memo; DEPO: Nick Marmontello 7/28/06 EX 008: Letter			
00362	DEMAE007-002954	DEMAE007-002954	12/23/1996	The Million Woman Study - CVD Extension			
00363	PANAA023-000206	PANAA023-000210		1997 Budget projections			
00364	RYANJ003-000464	RYANJ003-000513		Powerpoint presentation; Depo: Ryan, John 6/14/2005 EX 013			
00365	CHOOM018-000033	CHOOM018-000043	1/00/1997	Growth through InterventionPOA I 1997; Depo: Robert Essner 6/29/06 EX 019			
00366	W-HUSAK01-00001219	W-HUSAK01-00001252	1/00/1997	Education Supplement to Contemporary OB/GYN "Postmenopausal Hormone Therapy and Breast Cancer"			
00367			1/16/1997	Madira Intake Form Inquiry ID: DE-11697-113626			
00368	FISHG001-000006	FISHG001-000006	1/31/1997	CEE - Transdermal			
00369	CHOOM022-000928	CHOOM022-000938	00/00/1997	For Four Decades, your Body Supplied All the Estrogen you Needed.			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00370	W-MDL303-00084283	W-MDL303-00084283	2/18/1997	FDA Contact Report - Prempro Premphase (NDA 20-303)			
00371	CONNS003-000002	CONNS003-000003	3/25/1997	Writing in regard to serious concerns arising from attached copy of the femScript promotional pamphlet...			
00372	HOLSN017-002460	HOLSN017-002476		SLV-001 [trans]			
00373	CONNS013-000646	CONNS013-000651	6/16/1997	Premarin / Prempro in the Treatment of Alzheimer's Disease Meeting Report (June 3 1997)			
00374	DEMAE007-002961	DEMAE007-002961	6/18/1997	Breast Cancer Study: Draft Outline of Letter to FDA			
00375	CONNS014-001058	CONNS014-001058	6/19/1997	Premarin - Cardiovascular/Health Benefits -Reply - Forwarded -Reply			
00376	CONNS006-000405	CONNS006-000407	6/24/1997	Seasons -- letter from woman who got lobular cancer after taking HRT for 15 years			
00377	SONKJ030-000991	SONKJ030-000994	6/30/1997	Wyeth internal memo regarding FDA meeting about DTC advertising			
00377A	SONKJ030-001001	SONKJ030-01006	6/30/1997	Wyeth internal meeting re DIA Annual Meeting			
00378	STRIS001-000034	STRIS001-000045	7/00/1997	For Four Decades, Her Body Supplied All the Estrogen She Needed.; Depo: Jane, Carol 7/14/2005 EX 017: For Four Decades, Her Body Supplied All the Estrogen She Needed.; Depo: Sorrentino, Matthew 5/3/2006 EX 006: For Four Decades, Her Body Supplied All the Estrogen She Needed.; Depo: Strickland 9/8/2005 EX 004: For Four Decades, Her Body Supplied All the Estrogen She Needed.			
00379	W-ADSBRO-001096	W-ADSBRO-001100	1/00/1999	"Menopause Isn't Gone In A Flash" detail piece			
00380	DEYMI007-000673	DEYMI007-000712		11th Annual Symposium on the Long-Term Effects of Estrogen Deprivation			
00381	PICKJ007-000182	PICKJ007-000184	9/25/1997	Phase IV Commitment; Depo: Pickar, James 9/20/2005 EX 059: Phase IV Commitment			
00382	DUROJ040-000104	DUROJ040-000109	10/10/1997	Premarin Global Harmonization Committee - Minutes of Meeting of October 1, 1997			
00383	DUROJ040-000084	DUROJ040-000085	10/11/1997	Breast Cancer and Hormone Replacement Therapy			
00384	DUROJ040-000086	DUROJ040-000092	10/11/1997	Breast Cancer and Hormone Replacement Therapy: Collaborative Reanalysis of Data from 51 Epidemiological Studies of 52 705 Women with Breast Cancer and 108 411 Women without Breast Cancer			
00385	BURRG005-000905	BURRG005-000913	10/31/1997	Wyeth's FDA Advisory Committee Media Strategy			
00386	W-MDL303-00084714	W-MDL303-00084714	11/12/1997	Correspondence re: NDA and investigation of breast cancer risk (NDA 20-303)			
00387	CHOOM002-002197	CHOOM002-002199		When Considering Menopause and Its Associated Estrogen Loss. Consider the Entire Body of Evidence			
00388	CONNS013-000605	CONNS013-000606	12/22/1997	Premarin Prempro in the Treatment of Alzheimers Disease FDA Minutes of September 23 1997 Meeting IND 51,128			
00389	CONNS013-000609	CONNS013-000609	12/23/1997	Alzheimer Trials Database			
00390				First quarter of 1998 to address			
00391	LUDMG002-001711	LUDMG002-001731		Executive Summary; Depo: Ludmerer, Gail 5/25/2005 EX 007: Executive Summary			
00392	BURRG005-001070	BURRG005-001072	12/10/1997	Press Release -- by Wyeth -- on approval of Raloxifen			
00393	ROSSC001-000773	ROSSC001-000790		Wyeth-Ayerst Comments to 1998 Draft Guidance Entitled "Labeling Guidance for Non-Contraceptive Estrogen Drug Products-Physician and Patient Labeling"			
00394	STRIS002-000403	STRIS002-000408	1/2/1998	Premarin Role Play Approved Early Adopter; Depo: Strickland 9/8/2005 EX 008: Premarin Role Play Approved Early Adopter			
00395	W-MDL04782-00094080	W-MDL04782-00094081	1/14/1998	FDA Contact; Depo: Robert Essner 6/29/06 EX 023: Memo			
00396	FISHG002-000028	FISHG002-000028		Wyeth-Ayerst Responds to Study in Chemical Research in Toxicology			
00397	W-HUSAK01-00001021	W-HUSAK01-00001028	2/00/1998	Clinical Courier "Cardiovascular Disease in Women"			
00398	CONNS013-000682	CONNS013-000683	2/2/1998	Premarin Family Brand Review			
00399	FISHG002-000028	FISHG002-000028		Wyeth-Ayerst Responds to Study in Chemical Research in Toxicology			
00400	CONNS003-000235	CONNS003-000238	2/17/1998	Evista (Raloxifene HCl)			
00401	CONNS003-000274	CONNS003-000274	2/10/1998	Estrogen Use and Alzheimers Disease			
00402	ROSSC034-000399	ROSSC034-000401	2/25/1998	NDA 20-527 Prempro (Conjugated Estrogens/Medroxyprogesterone Acetate) Tablets MACMIS 6272			
00404	CONNS014-000949	CONNS014-000950	3/3/1998	Contact Report Premarin NDA 04-782			
00405	CONNS014-001184	CONNS014-001187	3/19/1998	Meeting Minutes-Premarin Labeling			
00406	W-MDL04782-00095313	W-MDL04782-00095314	4/30/1998	FDA Contact Report			
00407	FISHG001-000750	FISHG001-000752	5/11/1998	Premarin			
00408	SOLOJ023-000870	SOLOJ023-000892	5/12/1998	Myths and Misperceptions Breast Cancer and HRT			
00409	W-MDL04782-00095369	W-MDL04782-00095371	5/19/1998	FDA Contact Report			
00410	W-MDL04782-00095382	W-MDL04782-00095384	5/20/1998	Premarin Tablets MACMIS #6663			
00411	YAVUE011-000332	YAVUE011-000337		"Creation of Long Term Business Partnerships Through the Development of Local HRT Advocates"			
00412	SOLOJ023-000976	SOLOJ023-000984		Cardiovascular Disease in Women			
00413	CONKJ012-000081	CONKJ012-000084	7/30/1998	Civil Action 1:94CV01306 (RCL). Order Granting Summary Judgment and Permanent Injunction. Washington Legal Foundation v. Michael A. Friedman			
00414	CONSG001-002239	CONSG001-002245	8/10/1998	Postmenopausal Hormone Therapy Does Not Decrease Risk of Heart Attack and Coronary Death in Women With Previous Heart Disease			
00414A	CONSG001-002237	CONSG001-002238	8/11/1998	Letter from Robert Levy, M.D. to Steven Hulley, M.D.			
00415	K-B15A-01558; KET-001561	K-B15A-01558; KET-001577		Transcript: Dr. Philip deVane, Interview for HERS B-Roll			
00416	CONSG001-002279	CONSG001-002286	8/12/1998	Questions and Answers Media Relations Responses			
00417	VICTJ001-001843	VICTJ001-001848	8/12/1998	Meeting Report FDA/Wyeth Ayerst Meeting on the Heart and Estrogen / Progestin Replacement Study (HERS)			
00418	CONNS014-001103	CONNS014-001103	8/14/1998	Premarin-NDA No. 04-782/S-106 "Other Health Benefits-Cardiovascular" "Not Approvable"			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00419	W-HUSAK01-00000499	W-HUSAK01-00000502		Detail piece - Results of the Heart Estrogen/Progestin Replacement Study (HERS)			
00420	W-ADSBRO-000040	W-ADSBRO-000067		Seasons Magazine, Vol. 8, Issue 3			
00421	YAVUE010-001069	YAVUE010-001094	9/00/1998	Guide to Understanding Recent Studies on ERT/HRT and Breast Cancer Incidence, Detection, & Mortality			
00422	CONKJ012-000765	CONKJ012-000818	9/00/1998	Therapeutic Options for Menopausal Health Monograph			
00423	W-HUSAK01-00000888	W-HUSAK01-00000943	9/00/1998	Therapeutic Options for Menopausal Health Monograph, sponsored by Duke University Medical Center			
00424	W-HUSAK01-00000183	W-HUSAK01-00000186		Selected Slides from Duke Monograph - cardiac			
00425	W-HUSAK01-00001308	W-HUSAK01-00001308		Selected Slides from Duke Monograph-breast cancer			
00426	CONKJ012-000759	CONKJ012-000764		Therapeutic Options for Menopausal Health Duke Monograph			
00427	W-HUSAK01-00001082	W-HUSAK01-00001089	9/00/1988	OB-GYN Rounds September 1988			
00428	W-HUSAK02-00000076	W-HUSAK02-00000094	9/00/1998	Patient booklet "Discover more about menopause and estrogen replacement therapy"			
00429	CONTA023-008303	CONTA023-008305	9/3/1998	Executive Summary			
00430			9/18/1998	CLINICAL COMMUNICATIONS inquiry:			
00431	DUROJ023-001355	DUROJ023-001357		"What ifs?"			
00432	SOLOJ023-000705	SOLOJ023-000727	10/5/1998	Myths and Misperceptions Breast Cancer and HRT			
00433	W-MDL04782-00095686	W-MDL04782-00095691	10/9/1998	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
00434			10/12/1998	CLINICAL COMMUNICATIONS inquiry:			
00434A			10/12/1998	CLINICAL COMMUNICATIONS inquiry:			
00435	LUDMG003-000423	LUDMG003-000426	10/15/1998	Summary of HERS Data - Impact on Physicians; Depo: Ludmerer, Gail 5/25/2005 EX 003: Summary of HERS Data - Impact on Physicians			
00436	WEBEM014-004069	WEBEM014-004108	11/2/1998	Powerpoint slides "AHP/Wyeth Pharma Strategy"			
00437	VICTJ006-000019	VICTJ006-000019	11/4/1998	Premarin-Alzheimer's 11/4/98			
00438	PICKJ031-001171	PICKJ031-001171	11/10/1998	Dr. Wulf Utian Presentation in Brazil			
00439	FARAN015-000894	FARAN015-000894	11/10/1998	Revised Final Year 1998 Flowcharts			
00440	HENRL002-000657	HENRL002-000657	11/11/1998	Premarin DTC Print for February; Depo: Weber, Margaret 6/21/06 EX 053: Internal correspondence			
00441	HENRL005-001314	HENRL005-001314	11/11/1998	New Unbranded Direct-to-Consumer (DTC) Advertising Campaign Video Tapes			
00442	W-MDL04782-00095839	W-MDL04782-00095843	11/11/1998	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
00443	DEMAE002-001676	DEMAE002-001676	11/11/1998	Protocol No. 0713X1-			
00443A	DEMAE002-001677	DEMAE002-001679	11/11/1998	Project Review and Approval Vascular Response to Premarin and Prempro			
00444	DUROJ041-002211	DUROJ041-002218	11/12/1998	Physician HRT Awareness and Use - Final Report (11/98)			
00445	SONKJ024-001757	SONKJ024-001776		Introduction			
00446	HENRL005-001388	HENRL005-001388	11/13/1998	Wyeth-Ayerst HRT Unbranded TV Schedule-Rev 1			
00447	HENRL001-000316	HENRL001-000318		Premarin HCP 1999 Budget			
00448	CONKJ012-000070	CONKJ012-000080	11/20/1998	21 CFR Parts 16 and 99 Dissemination of Information on Unapproved/New Uses for Marketed Drugs, Biologics, and Devices; Final Rule			
00449	W-MDL04782-00095887	W-MDL04782-00095889	11/20/1998	FDA Telephone Contact			
00450	VICTJ006-000016	VICTJ006-000016	11/24/1998	Update: Premarin-Alzheimers			
00452	BURRG005-000654	BURRG005-000655	12/00/1998	Document about Ketchum and Wyeth creating a program to develop Advocates and Grassroots			
00453	W-MDL527-00039708	W-MDL527-00039710	12/2/1998	FDA Contact Report (NDA 20-527): DEPO; Allen, Susan 4/24/2007 EX 13			
00454	ROSSC001-000773	ROSSC001-000790		Wyeth-Ayerst Comments to 1998 Draft Guidance Entitled "Labeling Guidance for Non-Contraceptive Estrogen Drug Products-Physician and Patient Labeling"			
00455	HOLSN013-000354	HOLSN013-000386		Your Body Gave You The Estrogen You Needed For 40 Years What About The Next 40? Living With Estrogen Loss; Depo: Henry, Lesa 2/9/2005 EX 018; Depo: Sinapi 8/29/2005 EX 012			
00456	CONTA023-008356	CONTA023-008361		List of articles and Dear Doctor letters			
00457	JANEC010-000163	JANEC010-000166		Office Of Global Business Affairs - 1999 Business Plan			
00458	DUROJ044-003012	DUROJ044-003012		Premarin Franchise 1999 Budget Summary; Depo: Deitch, Marc 10/27/2005 EX 027			
00459	STRIS016-041969	STRIS016-041969		Document discussing 1999 marketing budget			
00460			9/27/1999	IARC documents			
00461	HENRL005-000603	HENRL005-000617		The Role of the Consumer; Depo: Henry, Lesa 2/9/2005 EX 007: The Role of the Consumer			
00462	W-HUSAK01-00000786	W-HUSAK01-00000819		Cardiovascular Disease/Lipids Backgrounder			
00463	W-ADSBRO-000068	W-ADSBRO-000070	1/00/1999	"Menopause Isn't Gone in a Flash" advertisement; Depo: Robert Essner 6/29/06 EX 024: Brochure excerpts; DEPO: Andrew Panagy 7/13/06 EX 015: Advertisement; Depo: Sorrentino, Matthew 5/3/2006 EX 010			
00464	W-HUSAK01-00001017	W-HUSAK01-00001018	1/00/1999	Body of Evidence tear sheet			
00465			1/11/1999	DDMAC letter			
00466	PICKJ019-000045	PICKJ019-000045	1/12/1999	Funding Discussion; Depo: Pickar, James 9/20/2005 EX 082: Funding Discussion			
00467	STRIS016-075833	STRIS016-075942		Powerpoint slides "Focus on Growth: Components for Success"			
00468	LYTTR016-012074	LYTTR016-012074	3/29/1999	HERS			
00469	STRIS016-008854	STRIS016-008879	3/29/1999	Powerpoint slides "ERT/HRT Strategy Team"; Depo: Dey, Michael 11/3/2005 EX 004			
00470	DUROJ015-000540	DUROJ015-000543	2/22/1999	Memorandum of Meeting			
00471	DELCA028-000005	DELCA028-000008	2/22/1999	Wyeth-Ayerst Minutes of February 22, 1999 Meeting with DDMAC and DRUDP Prempro/Premphase (Conjugated Estrogens/Medroxyprogesterone Acetate) Tablets MACMIS 6819; Depo: DelConte, Anthony 6/20/06 EX 019: Meeting Minutes			
00472	CONSG001-002027	CONSG001-002046	2/25/1999	Tuning in on Hers: An Engineering Perspective			
00473	PICKJ020-001968	PICKJ020-001969	4/5/1999	HERS Resources			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00474	CONSG001-001960	CONSG001-001960	4/22/1999	American Heart Association 4/27 Journal Release			
00475	PICKJ023-002677	PICKJ023-002680	5/7/1999	Post-HERS Publication Strategy; Depo: Pickar, James 9/20/2005 EX 099: Post-HERS Publication Strategy			
EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00023	ROSSC022-001517	ROSSC022-001517	4/22/1943	Letter from American Company to American Drug Manufacturers Association			
00024	W-MDL04782-00014935	W-MDL04782-00014940		NEW DRUG APPLICATION "PREMARIN TABLETS"			
00025	W-MDL04782-00014963	W-MDL04782-00014964	5/8/1943	FDA letter to Ayerst			
00026	W-MDL04782-00014968	W-MDL04782-00014969	5/16/1943	Ayerst letter to American Drug Manufacturers Association			
00027			10/10/1963	Kefauver-Harris Amendments to the Food, Drug, and Cosmetic Act are enacted			
00028	W-MDL04782-00015373	W-MDL04782-00015375		LIFE BEGINS AT FORTY			
00029	W-MDL04782-00015005	W-MDL04782-00015005	12/00/1964	Ayerst PREMARIN BRAND OF CONJUGATED ESTROGENS - (equine)			
00030	W-MDL04782-00015005	W-MDL04782-00015005	12/00/1964	Ayerst PREMARIN BRAND OF CONJUGATED ESTROGENS - (equine)			
00031	W-MDL04782-00015006	W-MDL04782-00015067		PREMARIN TABLETS			
00032			00/00/1967	Feminine Forever" Book by Dr. Robert Wilson			
00033	W-MDL04782-00015317	W-MDL04782-00015325		AT HER AGE ARE TRANQUILIZERS REALLY ENOUGH?			
00034	W-MDL04782-00017145	W-MDL04782-00017151	2/23/1973	SUGGESTED LABELING GUIDELINES FOR ESTROGENS			
00035	W-MDL04782-00015353	W-MDL04782-00015363		THERE'S A VOID IN THE LIFE OF MANY MIDDLE-AGED WOMEN.			
00036	BURRG002-000055	BURRG002-000072		Premarin			
00037	W-MDL04782-00027563	W-MDL04782-00027563	4/5/1974	PREMARIN TABLETS			
00492	PICKJ042-012074	PICKJ042-012074		Memo from Mike Dey regarding Premarin Summit meeting			
00493	WEBEM004-002493	WEBEM004-002495		Marketing Response to Summit			
00494	W-HUSAK01-00000132	W-HUSAK01-00000133		Handwritten notes from sales rep re PEPI study			
00495	BURKM001-000841	BURKM001-000849		Premarin PEPI Labeling			
00496	CONTA023-002537	CONTA023-002538		WHC Thought Leader/Advocacy Plan			
00497	W-ADSBRO-00981	W-ADSBRO-00988	1/00/2000	Patient Advertisement "Past her Prime - Not on your life"; Depo: Robert Essner 6/29/06 EX 025: Brochure; Depo: Sorrentino, Matthew 5/3/2006 EX 013; DEPO: Andrew Panagy 7/13/06 EX 014: Advertisement; Depo: Sinapi 8/29/2005 EX 013			
00498	YAVUE008-001239	YAVUE008-001323	1/00/2000	Premarin/MPA Low Dose Study Report			
00499	FISHG001-000578	FISHG001-000578	1/10/2000	German Anti-Premarin Article			
00500	CONSG007-000045	CONSG007-000046	1/6/2000	HERS Fracture Paper			
00501	CONSG001-000433	CONSG001-000433		Fracture Paper			
00502	CONSG007-000075	CONSG007-000078		Fracture paper comments			
00503	CONSG007-000113	CONSG007-000114		Comments on fracture paper			
00504	DUROJ010-000201	DUROJ010-000204	1/00/2000	The Body of Evidence Concerning Menopause and its Associated Estrogen Loss; Depo: Jeanne Durocher 6/30/06 EX042: The body of evidence			
00505	ROSSC001-000328	ROSSC001-000330	1/11/2000	Premarin (Conjugated Estrogens Tablets, USP) NDA No. 04-782 Special Supplement - Changes Being Effectd			
00506	FISHG002-000003	FISHG002-000003	1/13/2000	German Anti-Premarin Article; Depo: Fisher, Gerald 11/22/2004 EX 149: German Anti-Premarin Article; Depo: Justin Victoria 6/30/06 EX 020: Internal Correspondence			
00507	DUROJ023-001712	DUROJ023-001712	1/18/2000	Strategic Publications Development Meeting Meeting Recap; Depo: Cobb, Pamela 11/17/2005 EX 026; Depo: Mittleman, Karen 5/3/2006 EX 128, 278			
00508	W-HUSAK01-00001129	W-HUSAK01-00001137	1/26/2000	Memo from Premarin Brand Team to Premarin Sales Team			
00509	BURKM012-000384	BURKM012-000400		CDS-CEE Tablets			
00510	RYANJ003-000837	RYANJ003-000839		Memo re: ACOG 2000			
00511	GASTM011-031055	GASTM011-031055	2/6/2000	Re: Speaker for ERT and Breast Cancer			
00512	PICKJ007-000891	PICKJ007-000894	2/7/2000	Breast Cancer Communications Action Summary 2/7/00. Women's Health Care Task Force			
00513	WEBEM011-001805	WEBEM011-001811	2/7/2000	Cardiovascular Disease Update			
00514	VICTJ003-000513	VICTJ003-000516		Breast Cancer Publication Summary (Current)			
00515	VICTJ003-000504	VICTJ003-000504	2/10/2000	Breast Cancer Communications Plan Executive Summary			
00516	DELCA008-000554	DELCA008-000554		RR of Breast Cancer with ERT/HRT; Depo: DelConte, Anthony 6/20/06 EX 031: RR of Breast Cancer with ERT/HRT			
00517	HENRL002-001383	HENRL002-001423	2/00/2000	Guidelines for Counseling Women on the Management of Menopause; Depo: Henry, Lesa 2/9/2005 EX 025: Guidelines for Counseling Women on the Management of Menopause			
00518	DELCA008-001182	DELCA008-001185	2/00/2000	Q & A for Sales Reps re breast cancer questions; Depo: DelConte, Anthony 1/19/2006 EX 014; Depo: Weber, Margaret 6/21/06 EX 070; Depo: Robert Essner 6/29/06 EX 053: Q&A Card; DEPO: Andrew Panagy 7/13/06 EX 022: Q&A			
00519	CONTA023-002996	CONTA023-002998	2/2/2000	Breast Cancer Containment and Communication Draft 2/2/00			
00520	PICKJ007-000888	PICKJ007-000890	2/3/2000	Teleconference Feedback Report Thursday February 3, 2000 JAMA Article Ayerst, Lederle, and Wyeth Field Trainers			
00521	PICKJ007-000868	PICKJ007-000870	2/4/2000	Voice Mail to the Field Re: Recent Breast Cancer Publications			
00521A	DUROJ020-000417	DUROJ020-000419		voicemail to the field from Delconte and Marquard re: recent brca pubs			
00522	CONTA023-002787	CONTA023-002788	2/4/2000	Breast Cancer Communications Plan Draft 2/4/00; Alice Perrone 8/30/06 DEPO EX 002: Product Training Manual			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00523	CHOOM001-002349	CHOOM001-002349	2/11/2000	Voicemail to sales reps by Jamie Duroche			
00527	OLIVS012-001921	OLIVS012-001922	2/25/2000	Breast Cancer Issue; Depo: Olivier, Sophie 9/14/2005 EX 014: Breast Cancer Issue			
00527A	OLIVS012-001923	OLIVS012-001925		Q&A			
00528			2/27/2000	Mike Ceppi to sales force team; Ryan Depo - 6-14-05 - Exhibit 4			
00530	W-HUSAK01-00001019	W-HUSAK01-00001020	3/00/2000	Keeping a balanced perspective on breast cancer risk - leave behind detail piece			
00531	CONSG001-000435	CONSG001-000435	3/20/2000	Fracture Paper			
00532	HOLSN004-000432	HOLSN004-000439	12/11/2000	The New Science of Hormone Replacement Therapy			
00534	CONSG001-000434	CONSG001-000434	3/21/2000	Fracture Paper			
00535	BURKM029-032927	BURKM029-032992	3/23/2000	rotp://f01u93b/EUDT/PSUR_Listi			
00536	VICTJ001-001155	VICTJ001-001188		Best Clinical Practices Chapter 13 from the International Position Paper on Women's Health and menopause: A Comprehensive Approach			
00537	W-HUSAK02-00001498	W-HUSAK02-00001499		Review of ERA Study			
00538	W-HUSAK02-00001489	W-HUSAK02-00001491		Postmenopausal HRT & CHD authored by Leon Speroff, M.D.			
00539	PETKD002-000179	PETKD002-000183		Postmenopausal Hormone Therapy and Coronary Heart Disease			
00540			5/00/2000	Responses to Objections about MPA			
00541	W-HUSAK01-00001016	W-HUSAK01-00001016	5/5/2000	Memo to Sales Force from Anthony DelConte, M.D.			
00542	W-HUSAK01-00000681	W-HUSAK01-00000688	5/00/2000	Symposium Highlights - Hormone Replacement Therapy in the Cardiovascular System			
00543	W-ADSBRO-001801	W-ADSBRO-001804	6/00/2000	Seasons Magazine, Vol. 1, Issue 1			
00544	HENRL011-000502	HENRL011-000509	6/00/2000	Consequence of Menopause Lecture Guide			
00545	SINAM001-000085	SINAM001-000103	6/1/2000	Premarin POA II Leader's Discussion Guide			
00546	DEMAE023-000059	DEMAE023-000061	6/1/2000	List of studies being funded by Wyeth			
00547	PANAA040-027590	PANAA040-027670		Example slides for segmentation analysis; DEPO: Andrew Panagy 7/13/06 EX 013: PPT Global ERT/HRT Strategy"			
00548	WEBEM015-006115	WEBEM015-006128	6/6/2000	Low-Dose HRT Advisory Board			
00549	PANAA009-000178	PANAA009-000554	6/9/2000	Perspective in ERT/HRT: Advisory Board Meeting; Depo: Weber, Margaret 6/21/2005 EX 038: Perspective in ERT/HRT: Advisory Board Meeting			
00550	WEBEM015-006093	WEBEM015-006113		Perspectives in ERT/HRT; Depo: DelConte, Anthony 1/19/2006 EX 005: Perspectives in ERT/HRT; Depo: Weber, Margaret 6/21/2005 EX 012: Perspectives in ERT/HRT			
00551	PANAA001-000010	PANAA001-000013	11/8/2001	Finance Committee Authorization Low-Dose Domestic Introductory Pricing and Contracting Strategy; Finance Committee Authorization Low-Dose Domestic Introductory Pricing and Contracting Strategy			
00552	WEBEM015-006342	WEBEM015-006346	6/20/2000	DRAFT: Adv			
00553	DELCA004-001066	DELCA004-001086		Clinical Platform			
00554	WEBEM015-006355	WEBEM015-006359		Health Care Providers			
00555	W-MDL04782-00128935	W-MDL04782-00128937	7/6/2000	Inadequacy Letter			
00556	LUDMG007-000445	LUDMG007-000451		Executive Summary; Depo: Ludmerer, Gail 5/25/2005 EX 015: Executive Summary			
00557	CORRA001-000125	CORRA001-000126	7/18/2000	Redux Lawsuits			
00558	VICTJ003-000082	VICTJ003-000093	7/31/2000	Medical Literature Substantiation for 07/30/00 Recommended Revisions to FDA's Proposed Breast Cancer Warning Verblage			
00559	ROSSC002-000845	ROSSC002-000846	8/3/2000	FDA Telephone Contact Report; DEPO: Allen, Susan 4/24/2007 EX 18			
00560	BURKM029-030493	BURKM029-030513	8/9/2000	Recommended Revisions to FDA's Proposed Breast Cancer Warning Verblage			
00561	ROSSC001-000349	ROSSC001-000350	8/10/2000	NDA 4-782			
00563	W-MDL303-00085228	W-MDL303-00085229	8/16/2000	Request for labeling change (NDA 20-303)			
00564	ROSSC040-001713	ROSSC040-001720		Premarin/Prempro Labeling			
00565	ROSSC001-000337	ROSSC001-000339	9/29/2000	NDA No. 04-782 Premarin (Conjugated Estrogens Tablets, USP) NDA No. 10-402 Premarin Intravenous (Conjugated Estrogens, USP) for Injection NDA No. 10-971 PMB (Conjugated Estrogens / Meproamate) Tablets NDA No. 11-074 Premarin H-C (Conjugated Estrogens / H			
00566	ROSSC001-000334	ROSSC001-000335	10/17/2000	FDA Telephone Contact. Premarin NDA 04-782 Prempro NDA 20-527			
00567	OLIVS018-035288	OLIVS018-035310	10/17/2000	Powerpoint slides "HRT Regional Dynamics North America"			
00568	CHOOM001-002318	CHOOM001-002323	10/26/2000	Wyeth publication plan; Depo: Speroff, Leon 6/30/2005 EX 007			
00569	W-MDL303-00085235	W-MDL303-00085236	10/31/2000	General Correspondence (NDA 20-303)			
00570	PANAA001-000017	PANAA001-000029	11/16/2000	Finance Committee Authorization Local CME, VSB, Unrestricted, Grants, Peer Selling			
00571	CONSG018-022078	CONSG018-022084	11/29/2000	BREAST DENSITY: REVIEW OF LITERATURE			
00572	HENRL008-000300	HENRL008-000310	12/5/2000	Preapproval / Off-Label Information			
00573	HENRL003-000575	HENRL003-000575	12/7/2000	Letter from Mike Collette to Lesa Henry; Depo: Henry, Lesa 2/9/2005 EX 009			
00574	W-ADSBRO-001142	W-ADSBRO-001155	12/00/2000	Physician advertisement "Her Questions, Your Answers"			
00575	JANEC007-001244	JANEC007-001246		Cobb speaking about federal hearings; Depo: Jane, Carol 7/14/2005 EX 009			
00576	JANEC007-001256	JANEC007-001257	12/15/2000	NTP Advisors Recommend (9-1) "Known Carcinogen" Listing for "Steroidal Estrogens"			
00577	STRIS016-003971	STRIS016-004138	12/17/2000	Transcript of Premia Advisory Board Meeting			
00578	OLIVS001-000953	OLIVS001-000954	7/3/2001	Justification Document Conjugated Estrogens and Conjugated Estrogens with Medroxyprogesterone (MPA) Breast Cancer; Depo: Olivier, Sophie 9/14/2005 EX 005: Justification Document Conjugated Estrogens and Conjugated Estrogens with Medroxyprogesterone (MPA) Breast Cancer			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00579	HOLSN004-000417	HOLSN004-000419		Your Health Concerns at Menopause			
00580	HOLSN004-000403	HOLSN004-000416	12/27/2000	What every Woman should Know about Estrogen/Hormone Replacement Therapy (ERT/HRT)			
00581	HOLSN004-000392	HOLSN004-000402	12/27/2000	Physician and Staff Guide			
00582	DEVAN010-001244	DEVAN010-001244		Info you Requested			
00583	PANAA001-000816	PANAA001-000842	1/00/2002	Premarin Family Forecast 2001-2012			
00584	FONTL006-001070	FONTL006-001081		Data Sheet; Depo: Fontaine, Leander 3/30/2005 EX 007: Data Sheet			
00585	CONTA023-006750	CONTA023-006762		Powerpoint slides on Publication Planning and Management; Alice Perrone 8/30/06 DEPO EX 014: PPT presentation			
00586	HENRL003-000490	HENRL003-000498	00/00/2001	Menopause & Hormone Replacement Therapy			
00587	W-ADSBRO-000270	W-ADSBRO-000275	1/23/2001	Seasons magazine enrollment form			
00588	W-HUSAK01-00000689	W-HUSAK01-00000727		Manual "Progestins and HRT: Issues and Implications"			
00589	HOLSN013-000128	HOLSN013-000140	00/00/2001	Understanding menopause			
00590	JANEC004-000974	JANEC004-001110		Premarin Fact Book 2001			
00591	PANAA001-000801	PANAA001-000801	1/21/2002	Global Reporting 2001 Premarin Family Sales 000's			
00592	PANAA001-000694	PANAA001-000698	4/8/2002	2001 U.S. Gross - Net Sales (Dollars in Thousands)			
00593	STRIS017-000708	STRIS017-000715		Standard sales representative responses to doctor questions			
00594	DEYMI024-000024	DEYMI024-000026		Product Performance and Outlook			
00595	RYAN # 2		1/00/2001	Letter from Mahady to all sales reps			
00596	DELCA025-000209	DELCA025-000210	1/24/2001	Wisdom Trial			
00597	W-HUSAK01-00000074	W-HUSAK01-00000076	11/00/2001	Patient Brochure "Ask your doctor about Prempro"			
00598	W-HUSAK02-00000095	W-HUSAK02-00000107		Dear Doctor Letter signed by Margaret Weber, M.D.			
00599	STRIS017-000076	STRIS017-000099		Powerpoint slides "Rationale for Lowering HRT Doses"			
00600	DUROJ017-001087	DUROJ017-001092		Deskside Briefing Media Response Fact Sheet			
00601	DELCA020-000373	DELCA020-000407	2/9/2001	Premarin Family Marketing Plan GSM			
00602	DELCA009-000251	DELCA009-000253	11/13/2001	Final Report of Findings: Consumer Evaluation of HRT Benefit Messages			
00603	STRIS016-047973	STRIS016-047978	2/21/2001	AHP Authorization Request for Pre-Launch and Launch activities for Premia .45/1.5 mg			
00604	DELCA017-000915	DELCA017-000946	3/7/2001	2001 Program Reviews (Agenda/Content); Depo: DelConte, Anthony 1/19/2006 EX 013: 2001 Program Reviews (Agenda/Content)			
00605	STRIS012-001518	STRIS012-001519	3/8/2001	FDA Telephone Contact: NDA No. 20-527/S-017			
00606	STRIS016-048841	STRIS016-048842	3/9/2001	Wyeth memo summarizing North American Operations Launch Team Meeting			
00607	BURKM029-026891	BURKM029-00026891	3/16/2001	Labeling Executive Committee Meeting			
00608	WEBEM014-003167	WEBEM014-003171	3/21/2001	Objectives and Discussion Points for the European Medical Directors Women's Health Care Meeting			
00609	CONTA018-000055	CONTA018-000055	3/21/2002	HERS Memo 921 HERS Publications			
00610	OLIVS008-001087	OLIVS008-001089	3/28/2001	Long-Term Benefits of HRT; Depo: Olivier, Sophie 9/14/2005 EX 004: Long-Term Benefits of HRT			
00611	DEYMI030-000117	DEYMI030-000122		Withdrawal of 0.3/1.5 mg Premarin/MPA; Depo: Poussot, Bernard 5/31/06 EX 018: Handwritten letter from Dey to Poussot			
00612	VICTJ001-001064	VICTJ001-001065		MD/Patient Learnings			
00613	CORRA001-000153	CORRA001-000157	4/00/2001	Release and Settlement Agreement			
00614	CORRA001-000158	CORRA001-000162	4/00/2001	Release and Settlement Agreement			
00615	CORRA001-000163	CORRA001-000167	4/00/2001	Release and Settlement Agreement			
00616			5/8/2001	WHI - JMinutes of WHI Data and Safety Board Members;			
00617	OLIVS018-011208	OLIVS018-011210		Risk of Ovarian Cancer with the Premarin Family Products; Depo: Olivier, Sophie 9/14/2005 EX 009			
00618	JANEC004-000968	JANEC004-000973	6/00/2001	Q&A Re: Cancer Risks & HRT; Depo: Jane, Carol 7/14/2005 EX 006: Q&A Re: Cancer Risks & HRT			
00619	PANAA011-000983	PANAA011-000988	6/12/2001	Memo from Andy Panagy re US African American Opportunity Quantification;			
00620	CONKJ019-007224	CONKJ019-007224	6/25/2001	Re: POA Meeting			
00621	BURKM029-024941	BURKM029-024944	6/29/2001	TO:			
00622	STRIS016-048243	STRIS016-048243	6/28/2001	Low Dose Publications Subcommittee Meeting Recap			
00623	STRIS003-000681	STRIS003-000699		Patti La Belle Creative Research Two Phase Qualitative Market Research Project			
00625	VICTJ001-002141	VICTJ001-002143	7/1/2001	Hormone Replacement Therapy and Cardiovascular Disease Media Plan			
00626	ZUCAV008-005665	ZUCAV008-005666	7/3/2001	Depo: Burlington, Bruce 8/9/2005 EX 006; Depo: Zucal, Vincent 7/28/2005 EX 014			
00627	BURKM029-024148	BURKM029-024149	7/3/2001	Justification Document, label revision WHI; Depo: Olivier, Sophie 9/14/2005 EX 007			
00628	ZUCAV008-042745	ZUCAV008-042746	7/3/2001	Depo: Olivier, Sophie 9/14/2005 EX 006: Unknown			
00629	W-MDL04782-00029027	W-MDL04782-00029032	8/20/1976	15th Annual Symposium on the Long-Term Effects of Estrogen Deprivation			
00630	W-MDL527-00043032	W-MDL527-00043032	7/25/2001	FDA Telephone Contact Report (NDA 20-527)			
00631	CONTA004-001489	CONTA004-001497		Premarin Task Force Development and Implementation Process			
00632	CONKJ009-000284	CONKJ009-000284	7/31/2001	The Vent			
00633	LAWT020-020635	LAWT020-020636	8/7/2001	Wyeth Draft letter to Premarin family sales reps			
00634	MARTN010-010357	MARTN010-010358	8/16/2001	Antw: Fwd: German criticism of Premarin			
00635	FISHG005-000174	FISHG005-000187	8/00/2001				
00651	LAWT021-009874	LAWT021-009918	11/8/2001	Affiliate Brand Plan			
00651R	LAWT021-009874	LAWT021-009918	11/8/2001	Wyeth Premarin U.S. Marketing Plan			
00656	FISHG005-000188	FISHG005-000190	11/16/2001	EMEA final advice letter for TSE-424 Combination			
00657	PANAA011-000963	PANAA011-000969		Powerpoint slides "Prempro-HRT Family P&L"			
00658	DEYMI024-000024	DEYMI024-000026		Product Performance and Outlook			
00659	PANAA001-000812	PANAA001-000812	5/3/2002	Prempro 1Q02 Vs. 1Q01 Gross to Net Comparison			
00660	BURKM014-001858	BURKM014-001873		Core SPC for Hormone Replacement Therapy			
00661	FISHG004-001735	FISHG004-001737		Wyeth PharmaceuticalSales Data for Premarin Family with TMG			
00662	DUROJ046-010953	DUROJ046-010956		2002 Estimated Budget for Seasons			
00663	STRIS017-000114	STRIS017-000117		2002 Marketing Budget			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00664	SOLOJ010-001369	SOLOJ010-001370		Study Description Total Cost 2002 Original Budget 2003 Estim			
00665	ROSSC005-001079	ROSSC005-001119	00/00/2002	Premarin Family POA Leader's Guide - POA 2			
00666	DEYMI025-000210	DEYMI025-000235	00/00/2002	Managing Marketing Medical Directories Meeting Miami Florida 2002 Photo Directory			
00667	W-HUSAK01-00001451	W-HUSAK01-00001458		Premarin Family Medical Education: A Guide to 2002			
00668	CONTA025-021009	CONTA025-021016	6/6/2002	PUBLICATION PLAN TRACKING REPORT			
00669	CONKJ018-033416	CONKJ018-033422		Name: Jeff Robertson			
00670			1/8/2002	Color copy of Woman's Day DTC Ad			
00670A			1/8/2002	Color copy of Woman's Day DTC Ad			
00670B			00/00/2001	Color copy of Woman's Day DTC Ad			
00670C			00/00/2001	Color copy of Woman's Day DTC Ad			
00671	PANAA012-001361	PANAA012-001362	1/11/2002	Breast Health			
00671A	PANAA012-001360	PANAA012-001360		Breast Health			
00672	HOLSN001-000001	HOLSN001-000001	1/21/2002	TRANSMITTAL OF ADVERTISEMENTS AND PROMOTIONAL LABELING FOR DRUGS AND BIOLOGICS FOR HUMAN USE: Prempro TM Premphase, conjugated estrogens medroxyprogesterone acetate tablets			
00673	PANAA040-018130	PANAA040-018132	1/17/2002	Wyeth Internal Correspondence regarding Prempro .45/1.5 Commerical Launch Meeting			
00674	DEYMI025-000275	DEYMI025-000277	1/18/2002	Lauren Hutton Remarks for MMMD Draft 01/18/02			
00675	OLIVS019-024695	OLIVS019-024695	1/22/2002	Investigator initiated proposal of dr. Franke; Depo: Olivier, Sophie 9/14/2005 EX 012: Investigator initiated proposal of dr. Franke			
00676	DUROJ046-018081	DUROJ046-018086		A Response to the Critics			
00677	DELCA032-002577	DELCA032-002577	1/24/2002	Clarkson			
00678	DEYMI025-000236	DEYMI025-000253	1/28/2002	MMMD Speech 01/28/02 - Draft 1			
00679	PANAA001-000713	PANAA001-000714	2/5/2002	Premarin Family Forecasts 2001-2012			
00680	COBBP013-000821	COBBP013-000822	2/5/2002	Sales Force Voicemail "Quality-of-Life and Depressive Symptoms in Postmenopausal Women after Receiving Hormone Therapy"			
00681	CONKJ003-000150	CONKJ003-000150	2/7/2002	email re HERS; Depo: Poussot, Bernard 5/31/06 EX 022: Email from Petkus			
00682			2/7/2002	USA Today editorial on HT			
00683	CONKJ003-000151	CONKJ003-000151		Response to editorial in USA Today			
00684	DEVAN009-000081	DEVAN009-000081	2/8/2002	Letter to USA Today editor from Susan Wysocki, RNC; Depo: DeVane, Natalie 1/25/2005 EX 007			
00685	CONKJ003-000161	CONKJ003-000162	2/11/2002	JAMA - HRT and Berast Cancer, Feb. 13, 2002 Issue			
00686	CONTA023-005036	CONTA023-005036	2/12/2002	Hormone Replacement Therapy in Relation to Breast Cancer			
00687	PARKA007-000121	PARKA007-000124		The Journal of Human Pharmacology and Drug Therapy			
00688	CONTA023-004211	CONTA023-004212	2/12/2002	Sales Force Voicemail			
00689	DEYMI038-019006	DEYMI038-019008	2/19/2002	Re: Low dose promotion & : IOF World Congress (Lisbon, Portugal) - May 10-14, 2002			
00690	DUROJ046-022047	DUROJ046-022067	2/20/2002	Powerpoint slides "Menopause Media Analysis"			
00691	CONKJ018-039166	CONKJ018-039167	2/24/2002	Susan,			
00692	CONSG001-000708	CONSG001-000709	2/27/2002	Letter from Ginger Constantine, M.D. to David Herrington, M.D.			
00693	PANAA039-000124	PANAA039-000139		Powerpoint slides "President's Golden Circle"; Depo: Dey, Michael 11/3/2005 EX 003			
00694	VICTJ001-001046	VICTJ001-001049		Persistence Study Patient Profile			
00695	W-HUSAK01-00000452	W-HUSAK01-00000452		"Breast Health"			
00696	HENRL023-000490	HENRL023-000490	3/6/2002	Letter from Ketchum to Susan Wysocki, RN			
00697	CONKJ018-056069	CONKJ018-056074	3/26/2002	Business Unit Name; Depo: DelConte, Anthony 1/19/2006 EX 006: Business Unit Name			
00698	CONTA025-022913	CONTA025-022913	3/27/2002	Impact of Estrogen on Acute Cognitive Changes at Menopause			
00699	PANAA001-000682	PANAA001-000691	4/23/2002	Women's Health - US Total All Products Actual Results - Year to Date 3/31/02 (\$ 000); Depo: Kusiak, Victoria 4/26&27/2005 EX 005: Women's Health - US Total All Products Actual Results - Year to Date 3/31/02 (\$ 000)			
00700	W-ADSBRO-000175	W-ADSBRO-000184	4/00/2002	Advertisement "Celebrating 60 Years of Trust and Innovation"			
00701	W-HUSAK01-00000669	W-HUSAK01-00000673	4/00/2002	"Hrt" and Cardiovascular Disease" by Ronald Young, M.D.			
00702	FISHG004-001374	FISHG004-001394	4/00/2002	GENERAL QUESTIONS - 1997			
00703	W-HUSAK01-00000322	W-HUSAK01-00000372	4/00/2002	VSF Manual			
00704	DEYMI020-000354	DEYMI020-000381		Direct-To-Consumer Advertising of Prescription Medicines			
00705	CONTA004-000008	CONTA004-000011		Hormone Symposium			
00706	W-HUSAK01-00000525	W-HUSAK01-00000526	4/17/2002	"Hormone Replacement Therapy Falls Out of Favor With Expert Committee"			
00707A			4/23/2002	Woman's Day - DTC Ads - Patti LaBelle			
00707B				Woman's Day - DTC Ads - Patti LaBelle			
00707C				Woman's Day - DTC Ads - Patti LaBelle			
00708	CONTA025-027130	CONTA025-027130	4/23/2002	Re: NEJM, JAMA, Lancet - former editors - follow-up			
00709	W-HUSAK01-00000535	W-HUSAK01-00000540	4/29/2002	Letter from Fred Viren, M.D. to patients regarding informed consent			
00710	DEYMI014-000587	DEYMI014-000597	5/23/2002	Women's Health Care Division P&L's - YTD 4/30/02			
00711	ROSSC005-001079	ROSSC005-001119	00/00/2002	Premarin Family POA Leader's Guide - POA 2			
00712	DUROJ046-018053	DUROJ046-018053	5/1/2002	JAMA - request to meet with editor			
00713	DUROJ046-018067	DUROJ046-018067	5/1/2002				
00714	VICTJ001-001055	VICTJ001-001055	5/2/2002	Packet			
00715	VICTJ001-001056	VICTJ001-001057		Basic Facts			
00716	PANAA001-000711	PANAA001-000712	5/9/2002	2002 Budget Premarin Studies Without Contracts			
00717	SOLOJ011-000514	SOLOJ011-000620	5/13/2002	Hormone Replacement Therapy Physician PsychProbe. HRG Strategic Planning May 13, 2002			
00718	SOLOJ020-000666	SOLOJ020-0000766	5/14/2002	Roller Coaster of Menopausal Counseling HRG Strategic Planning			
00719	CONTA025-017717	CONTA025-017722	5/20/2002	Adis Manuscript Template			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00720	SINAM001-000360	SINAM001-000372	5/20/2002	Premarin Diagnostic Report			
00721	PANAA002-000480	PANAA002-000497	5/20/2002	Patient Persistence & Value of a Patient			
00722	SENDM009-000252	SENDM009-000258	5/21/2002	Communication Messages: Premarin / Trimegestone Combination; Depo: Cobb , Pamela 11/17/2005 EX 003: Communication Messages: Premarin / Trimegestone Combination; Depo: Weber, Margaret 6/21/2005 EX 035: Communication Messages: Premarin / Trimegestone Combination			
00723	SOLOJ027-025750	SOLOJ027-025751	5/24/2002	Re: A Bad Sequel to a 1998 Feature			
00724	CONSG018-032099	CONSG018-032134		Powerpoint slides "Scientific Update: What's New?"			
00725	VICTJ001-001775	VICTJ001-001780		Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy. Heart and Estrogen / Progestin Replacement Study Follow-Up (HERS II).			
00726	CONTA023-005421	CONTA023-005423	5/31/2002	HERS II Media Strategy Draft May 31, 2002			
00727			5/31/2002	WHI - Minutes of Data and Safety Board			
00728	VICTJ001-001737	VICTJ001-001749	6/3/2002	JAMA Publication of HERS II Proposed Media Strategy			
00729	PANAA001-000663	PANAA001-000663	6/4/2002	Premarin Weekly Data Through May 24th.			
00730	MARTN010-015206	MARTN010-015207		H. Lee Moffitt Cancer Center & Research Institute New Release			
00731	MARTN010-015208	MARTN010-015209		New Research Shows HRT Improves Endothelial Function In Postmenopausal Women at Risk for Cardiovascular Disease			
00732	BURKM005-000817	BURKM005-000818		Letter from FDA to Wyeth			
00733	DEVAN010-000377	DEVAN010-000379	6/17/2002	Hormone Replacement Therapy (HRT) can Prevent Alzheimer's Disease and other Forms of Dementia			
00734	DEVAN010-000380	DEVAN010-000382	6/17/2002	Leading Experts Call for World-Wide Reversal of Breast Cancer Management: Cancer Sufferers Urged to Consider Hormone Replacement (HRT)			
00735	GASTM011-005161	GASTM011-005164	6/17/2002	RE: Clearance of WAVE Manuscript			
00736	PANAA011-000615	PANAA011-000615	6/19/2002	Analysis of Market Trends			
00736A	PANAA011-000616	PANAA011-000618	6/19/2002	US Strategic Forecasting			
00738	CONTA013-000420	CONTA013-000433	6/27/2002	Minutes From the Menopausal Health Publication Management Meeting June 27, 2002; Depo: Xue, Songlin 6/9/06 EX 058: Menopausal Health Publication Management Meeting Minutes			
00739	CONTA025-026442	CONTA025-026447		A Response to the Critics			
00740	W-HUSAK01-00000838	W-HUSAK01-00000839	7/00/2000	The Contraceptive Report, Vol. 11, No. 2			
00741	CONTA025-019619	CONTA025-019619	7/1/2002	FW: 3rd Annual Conference Session			
00742	PARKA007-000209	PARKA007-000211		Yearly Rates			
00743	CONKJ017-066160	CONKJ017-066161		On Tuesday morning at 9:30, the NIH will make a public press announcement that the Data Safety and Monitoring Board has decided to discontinue the Combination HRT arm of the WHI study			
00745	DEYMI015-000278	DEYMI015-000281		Meeting with Roussom			
00746	FISHG004-001350	FISHG004-001373	7/3/2002	American Home Products Corporation			
00747	FISHG003-000229	FISHG003-000231		Dear Colleague			
00748	DEYMI031-000580	DEYMI031-000589	7/8/2002	Questions and Answers			
00749	PANAA001-000651	PANAA001-000652	7/8/2002	U.S. Net Sales Forecast			
00750	KUSIV001-000251	KUSIV001-000270	7/7/2002	Questions and Answers General			
00751	PARKA007-000267	PARKA007-000277	7/9/2002	WHI Medical Presentation			
00752	STEPW014-005813	STEPW014-005833	7/22/2002	PREMIA ² 2.5 CONTINUOUS			
00753	OLIVS014-001893	OLIVS014-001902		Overall WHI design Review HRT trial; Depo: Olivier, Sophie 9/14/2005 EX 020: Overall WHI design Review HRT trial			
00754	FONTL035-001559	FONTL035-001562	7/15/2002	Attendance Sheet for Labeling Executive Committee			
00755			7/15/2002	The Pink Sheet, July 15, 2002			
00756			7/17/2002	Prempro, Premphase, Premarin retention policy			
00757	DUROJ046-010662	DUROJ046-010664	7/18/2002	FW: National Osteoporosis Advisory Board - WHI HRT Results -Feedback Requested			
00758	DUROJ046-010671	DUROJ046-010671	7/18/2002	Hi Jamie; Depo: Speroff, Leon 6/30/2005 EX 059			
00759	BRADK008-003294	BRADK008-003294	7/20/2002	Newspaper article "Europe Investigates hormone-contaminated waste in food chain"			
00760	DEVAN001-000120	DEVAN001-000122	7/23/2002	Main Message Points R. Essner Media Interviews (Following Release of Earnings on July 23, 2002); Depo: DeVane, Natalie 1/25/2005 EX 012			
00761	DEVAN001-000134	DEVAN001-000140	7/23/2002	Robert Essner's Remarks Regarding the Second Quarter and First Half 2002			
00762	BRADK008-001539	BRADK008-001545	7/23/2002	Morgan Stanley report "Framing the Prempro Liability Exposure"			
00763	STEPW014-008636	STEPW014-008643	7/23/2002	Letter from TGA to Wyeth Australia			
00764	BRADK002-000954	BRADK002-000955	7/24/2002	Pattonium, Inc. t/s/o Patti LaBelle -w- Bates Advertising As Agent for Wyeth-Ayerst			
00765	PETKD003-000367	PETKD003-000370	7/25/2002	Teleconference Call with Simon Bryceson on Media Management.; Depo: Petkus, Doug 8/18/2005 EX 016			
00766	BURKM029-011426	BURKM029-011453	7/25/2002	Letters/Emails between TGA and Wyeth; Depo: Olivier, Sophie 9/14/2005 EX 019:			
00767	SENDM009-000223	SENDM009-000224	7/26/2002	Premarin / TMG & T / TMG Publication Team Meeting Minutes July 26, 2002; Depo: Sendi, Mary 5/19/06 EX 010: Meeting Minutes			
00768	CONTA025-016503	CONTA025-016503	7/29/2002	Hi Jim, I want to thank you for including me in the great meeting at Half			
00769	SONKJ030-001284	SONKJ030-001298		Powerpoint slides "Relative Risk of Breast Cancer by Duration of HRT/ERT Usage"			
00770	BURKM029-030493	BURKM029-030513	8/9/2000	Recommended Revisions to FDA's Proposed Breast Cancer Warning Verbiage			
00771	SOLOJ010-001889	SOLOJ010-001954	8/12/2002	Premarin Family of Products 2003 US Budget.			
00772	RHUDM014-000732	RHUDM014-000737	8/19/2002	Subject PR Consultants; Depo: Dey, Michael 11/4/2005 EX 022			
00773			8/22/2002	Fred Hutch letter: WHI Clinical Coordinating Center			
00773A			4/30/2002	Fred Hutch letter: WHI Clinical Coordinating Center			
00775	PICKJ006-000925	PICKJ006-000941	8/29/2002	Draft Breast Cancer - Relative Risk			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00776	VICTJ001-000470	VICTJ001-000476		Breast Cancer Summary 1996 to Present			
00777	STEPW014-008246	STEPW014-008250	4/30/2002	Letter from Joseph Sonk to FDA			
00778	STEPW014-005895	STEPW014-005895		Email - thoughts from Bruce Burlington; Depo: Burlington, Bruce 8/9/2005 EX 007			
00779	STEPW014-005901	STEPW014-005902	7/24/2002	Email from Songlin Xue			
00780	DELCA030-001209	DELCA030-001210		Summary			
00781	PARKA002-001209	PARKA002-001213		Welcome to your Fast Start District Meeting			
00782	DEYMI014-000290	DEYMI014-000291	00/00/2002	Dear Doctor form letter regarding indemnification			
00783	KUSIV006-007077	KUSIV006-007077	7/24/2002	July 24, 2002 Essner Meetings Q & A; Depo: Kusiak, Victoria 4/26&27/2005 EX 014: July 24, 2002 Essner Meetings Q & A			
00784	DUROJ001-000071	DUROJ001-000107		External Communications Public Relations Activities and Recommendations			
00785	XUESO008-003933	XUESO008-003936		Objective 1:			
00786	SENDM009-000225	SENDM009-000235	9/3/2002	Preclinical and Clinical Experience with Trimegestone a Novel New Progestin; Depo: Cobb , Pamela 11/17/2005 EX 015; Depo: Weber, Margaret 6/21/2005 EX 026			
00787	WEBEM014-002380	WEBEM014-002381	9/4/2002	Wyeth Memo "WHI Core Team Announcement"; Depo: Dey, Michael 11/4/2005 EX 023			
00788	PANAA002-000247	PANAA002-000271	9/4/2002	ERT/HRT Update; Depo: Ryan, John 6/14/2005 EX 027: ERT/HRT Update; DEPO: Andrew Panagy 7/13/06 EX 010: PPT ERT/HRT Update"			
00789	DEYMI038-000555	DEYMI038-000555	9/6/2002	Fwd: Contact Report - B. Burlington/F. Houn			
00790	OLIVS019-005908	OLIVS019-005909	9/7/2002	Re: First stab at BC section; Depo: Olivier, Sophie 9/14/2005 EX 015: Re: First stab at BC section			
00791	PANAA002-000321	PANAA002-000322	9/9/2002	Wyeth-Ayerst 2003 Awards and Grants AHT - Confidential			
00792	DEYMI012-001094	DEYMI012-001104	9/9/2002	Premarin NDA 04-782/Prempro/Premphase NDA 20-527 Breast Cancer Labeling Chronology			
00793	SENDM009-000203	SENDM009-000206	9/20/2002	Premarin / TMG & 17 / TMG Publication Team Meeting Minutes September 20, 2002			
00794	CONKJ013-000173	CONKJ013-000175	9/23/2002	Premarin Family Pricing Recommendation			
00795	SENDM009-000244	SENDM009-000251		Trimegestone Parthenon's Publication Strategy			
00796	SONKJ031-008731	SONKJ031-008732	9/19/2002	Re: Fwd: Premelle: Inquiry Items from KIKO			
00797	SONKJ031-008737	SONKJ031-008737	9/19/2002	Fwd: Re: Premelle: Inquiry Items from KIKO			
00798	KUSIV006-001088	KUSIV006-001091	9/23/2002	Letter			
00799	BRADK002-000191	BRADK002-000197	9/26/2002	Remarks to Employees Simulcast September 27, 2002 Draft Noon 9/26/02			
00800	CONKJ020-062746	CONKJ020-062746	9/30/2002	Success			
00801			10/00/2000	Article in Vogue magazine Oct 2002 (black/white)			
00801A			10/00/2000	Article in Vogue magazine Oct 2002 (color)			
00802	DEYMI038-002792	DEYMI038-002796	10/4/2002				
00803	DEYMI013-001313	DEYMI013-001324	10/8/2002	Premarin Family			
00804	OLIVS014-002040	OLIVS014-002041	10/11/2002	10/11/2002 Minutes; Depo: Olivier, Sophie 9/14/2005 EX 016: 10/11/2002 Minutes			
00805	RHUDM002-000095	RHUDM002-000095	00/00/2002	Cancer Risk Reflections HRT and Recent Study Results			
00806	OLIVS019-011967	OLIVS019-011967	10/15/2002	Possible other estrogen-dependent tumors			
00807	PICKJ043-005192	PICKJ043-005192	10/16/2002	Presentation and Meeting with Garnet Anderson; Depo: Stephenson, Wendy 3/10/2005 EX 011: Presentation and Meeting with Garnet Anderson			
00808	DEYMI002-000166	DEYMI002-000167	10/16/2002	WHI Scientific Advisory Board Meeting October 16, 2002 Airport Marriott Philadelphia, PA Draft Agenda; Depo: Dey, Michael 11/4/2005 EX 009: WHI Scientific Advisory Board Meeting October 16, 2002 Airport Marriott Philadelphia, PA Draft Agenda			
00809	DEYMI002-000164	DEYMI002-000165		Handwritten notes on Philadelphia Marriott stationery; Depo: Dey, Michael 11/4/2005 EX 008			
00810	CONSG010-001664	CONSG010-001665	10/19/2002	WHI Investigators Concern about the Way in which Data from the E+P Trial may be Used by Wyeth			
00811	OLIVS018-003042	OLIVS018-003056		Core SPC for Hormone Replacement Therapy; Depo: Olivier, Sophie 9/14/2005 EX 017			
00812	DEVAN011-000095	DEVAN011-000096	10/22/2002	Worldwide Regulatory Affairs Telephone Contact Report; Depo: DeVane, Natalie 1/25/2005 EX 019: Worldwide Regulatory Affairs Telephone Contact Report			
00813	PICKJ043-005471	PICKJ043-005471		Breast Cancer			
00814	OLIVS021-014979	OLIVS021-014979	10/24/2002	HRT Meeting in Washington; Depo: Olivier, Sophie 9/14/2005 EX 018: HRT Meeting in Washington			
00815	DEYMI012-000104	DEYMI012-000106	10/28/2002	Final Text as Approved by Legal and Regulatory			
00816	DEYMI013-000858	DEYMI013-000922	10/31/2002	U.S. Business Review; Depo: Dey, Michael 11/4/2005 EX 025: U.S. Business Review			
00817	KUSIV009-009208	KUSIV009-009214	11/00/2002	19-Jul-2002; Depo: Kusiak, Victoria 4/26&27/2005 EX 002: July 19, 2002; Jeannemarie Durocher 8/2/06 DEPO EX 084: Letter			
00818			11/18/2002	Activella and breast cancer			
00819	FISHG004-001687	FISHG004-001729	11/19/2002	Premarin and Prempro			
00820	DEYMI012-000009	DEYMI012-000010	11/22/2002	FDA Sponsored - Women's Health Dialog; Depo: Dey, Michael 11/4/2005 EX 018: FDA Sponsored - Women's Health Dialog			
00821	MARRA014-013162	MARRA014-013162	11/29/2002	HRT and breastcancer- a Swedish study-abstract; Depo: Dey, Michael 11/4/2005 EX 019: HRT and breastcancer- a Swedish study-abstract			
00822	KUSIV007-000345	KUSIV007-000350	12/5/2002	WHI Study Update Steering Committee Meeting Dec 5-6, 2002			
00823	PINIM020-000264	PINIM020-000264	12/23/2002	CR&D Information			
00824	PARKA008-000257	PARKA008-000303	1/2/2003	Premarin Family U.S. Marketing Plan Women's Health Care Marketing Plan			
00825	MAHAJ017-002427	MAHAJ017-002495	8/1/2003	0318 Board Book C6d; Depo: Dey, Michael 11/4/2005 EX 024: 0318 Board Book C6d			
00826	CONKJ013-000297	CONKJ013-000299		2003 Strategic Options 3-Page Budget Allocation Briefing Document			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00827	DEYMI206-002257	DEYMI206-002275	00/00/2003	2003 Plan of Action Meeting Agenda for Premarin Family of Products			
00828	RHUDM002-000559	RHUDM002-000560	1/6/2003	HT Wyeth Case Report ID: HQ4374125Sep2002/W&C Letter Dated 11/14 (Received 12/9/02)			
00830	ZUCAV008-019693	ZUCAV008-019734	1/7/2003	08Jan2003.PDF			
00831	DEYMI206-001901	DEYMI206-001938	1/19/2003	Powerpoints slides " Menopausal Hormone Therapy: Wyeth Perspective post WHI"			
00832	DEYMI206-002174	DEYMI206-002174	1/23/2003	Letter to Wyeth employees from Bernard Poussot			
00833	AILOW003-002587	AILOW003-002588	2/5/2003	Letter to Wyeth employes from Joseph Mahady			
00834	DEYMI206-004012	DEYMI206-004030	2/5/2003	Summary Document - Launch Readiness Point for Premarin and Premarin/MPA Low Dose Formulations			
00835	BURLB013-001088	BURLB013-001089	2/28/2003	Message to U.S. Sales Representatives			
00836	DEYMI206-003320	DEYMI206-003350	2/24/2003	Powerpoint slides "Field Directed Mail Program Premarin Family"			
00837	W-HUSAK03-00000469	W-HUSAK03-00000469	4/13/2003	Wyeth letter to James Studdard, M.D.			
00838	DEYMI202-000255	DEYMI202-000271	4/14/2003	Powerpoint Slides "Premarin Family Strategic Business Review"			
00839	LEVIG002-005601	LEVIG002-005602	5/9/2003	Business Unit Name			
00840	W-HUSAK01-00001390	W-HUSAK01-00001407	5/15/2003	Texas Academy of Family Physicians CME Program			
00841	DEYMI206-008811	DEYMI206-008811	6/4/2003	Email from Songlin Xue			
00842	DEYMI206-008812	DEYMI206-008817		Draft "Additional Analyses of WHI Data"			
00843	PETKD003-000739	PETKD003-000740		Postmenopausal Hormone Therapy: A Valuable Treatment for the Right Women; Depo: Dey, Michael 11/3/2005 EX 006:			
00844			7/14/2003	WHI crisis.			
00845	DEYMI202-000627	DEYMI202-000642	10/8/2003	US Forecast - P and L's			
00846	W-HUSAK03-00000342	W-HUSAK03-00000342	9/23/2003	Email from Katherine Robertson to Team Survivors			
00847	W-HUSAK03-00000348	W-HUSAK03-00000348	9/24/2003	Email from Kathy Husak to Dr. Harkins			
00848	W-HUSAK03-00000367	W-HUSAK03-00000367	9/25/2003	Email from Patti Franklin to Area 73 Managers and District 73B			
00849	MAHAJ017-002402	MAHAJ017-002403	9/30/2003	JAMA Papers AP Coverage			
00850	FISHG004-001654	FISHG004-001657	10/22/2003	Launch Readiness Point (LRP)			
00851	DEYMI202-000517	DEYMI202-000541		Powerpoint slides "2004 Budget Discussion"			
00852	DEYMI206-018556	DEYMI206-018556		Description of Wyeth/FDA Meeting			
00853	DEYMI206-019364	DEYMI206-019364	12/3/2003	Email from Kate Moore to Michael Dey; Depo: Dey, Michael 11/4/2005 EX 015			
00854	DEMAE022-005283	DEMAE022-005289	12/8/2003	Fwd: Re: Please make every effort to attend - INDs to be Withdrawn			
00855	DEYMI202-000886	DEYMI202-000892	2/18/2004	Global Income Statement Forecast			
00856	DEYMI202-000029	DEYMI202-000029		WHC Global P&L Forecast Summary of Changes			
00857	DEYMI202-000091	DEYMI202-000092	5/3/2004	Email from Stephen Rentz to Joan Turman			
00858	DEYMI202-000082	DEYMI202-000083		Handwritten letter on Robert Becker stationery			
00859			8/9/2005	NAMS annual awards for 2005			
00860	REYNJ002-005063	REYNJ002-005064		Letter to Field Ssales from US Sales Council			
00861			3/1/2005	Statement by: Sandra L. Kweder, M.D., FDA Deputy Director,			
00862			8/9/2004	2005 Prempro Label			
00862A			7/15/2005	2005 Prempro Label			
00862B			1/00/2010	2010 Prempro Label			
00862C			1/1/2010	2010 Prempro Label			
00863A			6/00/2005	NIH Brochure -- Facts about Menopausal Therapy			
00863B			6/00/2005	NIH Brochure -- Facts about Menopausal Therapy (NIH)			
00864	W-GSSWHC-000001	W-GSSWHC-000002	11/1/2005	Global Safety Surveillance & Epidemiology and Global Labeling organizational chart			
00865	LUDMG006-001069	LUDMG006-001073		Prempro Concepts; Depo: Ludmerer, Gail 5/25/2005 EX 013: Prempro Concepts			
00866				IARC Monograp			
00866B				IARC monograph - combined estrogen-progestogen menopausal therapy			
00866C				Iarc 2011			
00867	FISHG004-001240	FISHG004-001243		Drug Safety and Metabolism Scientific Advisory Board			
00868	PICKJ006-000925	PICKJ006-000941	8/29/2002	Draft Breast Cancer - Relative Risk			
00869	STRIS003-001681	STRIS003-001682		Powerpoint slides of graph comparing the effects of Premarin/MPA, Premarin/TMG and Premarin/TSE			
00870	BURKM014-006814	BURKM014-006817		List of countries and information regarding labels			
00890				Call Notes: Duke Monograph			
00890A				Call Notes: Gifts			
00890B				call notes: promotional materials/handouts - Alabama			
00890C				call notes: duration/target population - Alabama			
00890D				call notes: medical school/residents - Alabama			
00890E				call notes: Wile paper - Alabama			
00891				Call Notes: Cardiac			
00891A				Call Notes: gifts			
00891B				Call Notes: Cardiac			
00891C				call notes: cardiac - Alabama			
00891R				Call Notes: Cardiac			
00892				Call Notes: Cognitive			
00892A				Call Notes: Alz			
00892C				call notes: Alz - Alabama			
00900	SOLOJ023-000519	SOLOJ023-000522	10/9/1997	Proposed Satellite Symposia and Plenary Sessions Educational Activities with Clinical Couriers and Check Studies 1998 Budget Summary			
00901	CHOOM001-002441	CHOOM001-002441		Total Premarin family Budgets for 1999 - 2004			
00902	CONTA023-001004	CONTA023-001011		PREMARIN Family Tactics 2003 Estimated Budget as of 11/20/2002			
00903	CONNS001-001257	CONNS001-001257	2/10/1994	Estimates of Losses: Therapeutic Substitution			
00904	W-SALES-000001	W-SALES-000015		Preamrin Sales 1994-2004			
00905	LAWT006-000913	LAWT006-000913		Historical Gross Sales Actuals Premarin Family \$(000)'s			
00907	PANAA011-000920	PANAA011-000942		Wyeth-Ayerst U.S. Pharmaceuticals Total Premarin Family - Base (\$000's)			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00908	DELCA009-000251	DELCA009-000253	11/13/2001	30-Aug-01.PDF			
00909			8/16/1995	STATUTE - Direct to Consumer promotion			
00910	SOLOJ025-000286	SOLOJ025-000355	3/10/1998	The US Market: A Case Study in the Success of Changing the HRT Paradigm; Depo: Solomon, Jeffrey 1/26/2006 EX 007: The US Market: A Case Study in the Success of Changing the HRT Paradigm; Depo: Strickland 9/8/2005 EX 003: The US Market: A Case Study in the Success of Changing the HRT Paradigm			
00912	CONSG006-000200	CONSG006-000203	10/9/1998	Premarin Osteoporosis Indication Chronology - Major Events			
00913	DUROJ013-000412	DUROJ013-000412		Premarin Treatment of Osteoporosis; Depo: Jeanne Durocher 6/30/06 EX003: Premarin Treatment of Osteoporosis			
00914	DUROJ013-000872	DUROJ013-000875	10/22/1997	Meeting Minutes; Depo: Jeanne Durocher 6/30/06 EX004: Meeting Minutes			
00915	NDA-PRO 0027456	NDA-PRO 0027465		PFIZER DOCUMENT - PROVERA/1990 Upjohn brochure.			
00916	PANAA016-001031	PANAA016-001031		Cost Effectiveness Analysis			
00917	CONTA021-000820	CONTA021-000829	3/10/1995	Sample Sizes for Premarin/MPA Breast Cancer Study			
00918			00/00/2006	21 CFR 201.57 - Labeling Requirements			
00918A			00/00/2006	21 CFR 201.200			
00919	SINAM002-000161	SINAM002-000190	3/00/1998	Raloxifene Competitive Product Information: Putting the Issue of HRT vs SERMs in Perspective			
00920				Pharmacia v. Wyeth			
00920A	MMSVC001-000013	MMSVC001-000018	04/00/1995	Essner Prempro Launch Speech			
00921	VICTJ002-000315	VICTJ002-000315	3/1/1999	You should be very cautious with Professor Lippert			
00922	W-MDL04782-00064631	W-MDL04782-00064631	12/00/1975	Letter from Ayerst to pharmacists			
00923	W-MDL527-00039573	W-MDL527-00039577	8/26/1998	Correspondence re: launch materials for EZ Dial Dispenser (NDA 20-527)			
00924	W-MDL527-00039714	W-MDL527-00039719	12/11/1998	MACMIS #6819 (Prempro/Premphase) (NDA 20-527)			
00925	W-MDL527-00039729	W-MDL527-00039731	1/4/1999	Prempro/Premphase Tablets MACMIS #6819 (NDA 20-527); DEPO: Allen, Susan 4/24/2007 EX 14			
00926	W-MDL527-00039757	W-MDL527-00039775	2/3/1999	Correspondence re: lipid lowering claim (NDA 20-527)			
00927	W-MDL527-00039929	W-MDL527-00039931	5/24/1999	Correspondence re: Meeting Minutes (NDA 20-527)			
00928	W-MDL527-00039903	W-MDL527-00039917	5/6/1999	Correspondence re: Meeting Minutes (NDA 20-527); DEPO: Allen, Susan 4/24/2007 EX 16			
00929	BURKM015-000097	BURKM015-000102	9/22/1999	Prempro/Premphase (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets) NDA No. 20-527 Special Supplement - Changes being Effected			
00930	W-MDL527-00040231	W-MDL527-00040233	10/22/1999	FDA Contact Report (NDA 20-527)			
00931	HOLSN006-000162	HOLSN006-000163	1/6/2000	Labeling, Prempro Physician Labeling (6096-01 issued January 6, 2000)			
00932A	W-MDL527-00041120	W-MDL527-00041213	1/19/2001	Special Supplement - Changes Being Effected (NDA 20-527)			
00932B	BURKM005-000298	BURKM005-000302	1/19/2001	NDA No. 20-527 Prempro /Premphase (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets) Special Supplement - Changes Being Effected			
00933	W-MDL527-00041401	W-MDL527-00041430	2/21/2001	Approval letter of labeling changes (NDA 20-527)			
00934	VICTJ006-000381	VICTJ006-000384	11/20/1991	Comments on Women's Health Initiative Prospectus			
00935	PICKJ011-003007	PICKJ011-003008	1/22/1988	Letter from Penny Budoff, M.D. to James Pickar, M.D.			
00936	CONTA025-020958	CONTA025-020959	6/8/2002	re: GBT and Publication planning; Depo: Mittleman, Karen 5/2/2006 EX 013: re: GBT and Publication planning; Jeannemarie Durocher 8/2/06 DEPO EX 067: Email			
00937	DWRITE065923	DWRITE 064941	5/15/1997	Premarin Publication Program; Depo: Sendi, Mary 5/19/06 EX 004: Premarin Publication Program; Depo: Weber, Margaret 6/21/06 EX 055: Premarin Publication program; Jeannemarie Durocher 8/2/06 DEPO EX 073: Premarin Publication Program			
00938	DWRITE065952	DWRITE065967	11/20/1998	Design Write 1998 proposal; Depo: Weber, Margaret 6/21/06 EX 056: Premarin Family Study Management Plan; Depo: Sendi, Mary 5/19/06 EX 005: Premarin Family of Products Study Management Plan; Depo: Cobb, Pamela 6/23/06 EX 006: Dwrite proposal; Jeannemarie Durocher 8/2/06 DEPO EX 071: Study Management Plan			
00940	HENRL025-001651	HENRL025-001653	10/26/2000	Premarin Family State of the Business Meeting Outline			
00942	DUROJ023-001689	DUROJ023-001696	11/6/2001	Estrogens and the Skin Draft Outline Author and Target Journal TBD			
00943	DUROJ023-001781	DUROJ023-001782	12/5/2000	Strategic Publications Development Meeting Meeting Agenda			
00944	DUROJ023-001868	DUROJ023-001870	7/5/2000	Strategic Publications Development Tracking Report			
00945	DUROJ037-000183	DUROJ037-000227		ERT/HRT Franchise Three Year Strategic Plan 1996 - 1998			
00946	HENRL001-000067	HENRL001-000082	4/16/1998	Direct Marketing Spend 1998 Budget			
00947	PANAA001-000919	PANAA001-000921	5/3/2001	Direct Marketing Spend 2001 Summary - Account Detail (\$ Thousands)			
00948	PANAA011-000760	PANAA011-000779		Premarin Family Business Review 2002			
00949	DUROJ007-000004	DUROJ007-000148		Volume 3 Slide Kit & Lecture Guide			
00950A	CONTA025-030538	CONTA025-030539	6/15/2000	Strategic Publications Development Meeting Depo: Cobb, Pamela 11/17/2005 EX 022: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EX 204, 118, 236; Alice Perrone 8/31/06 DEPO EX 040: meeting recap			
00950B	DWRITE066935		7/27/2000	Strategic Publications Development Meeting			
00950C	DWRITE003353			Project Assignment Form			
00950D	DWRITE066449		10/3/2000	Payment to Pruiett			
00950E	MARTN010-010296	MARTN010-010297	7/23/2001	Strategic Publications Development Meeting			
00950F	SOLOJ027-048916	SOLOJ027-048917	8/14/2001	Strategic Publications Development Meeting			
00950G	DWRITE067253		1/28/2002	Strategic Publications Development Committee:			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
00950H	DWRITE066322		1/24/2005	Strategic Publication Plan Tracking Report			
00950I	DWRITE071118	DWRITE071147		J. Eden paper - Australia			
00950J	DWRITE071148	DWRITE071150	3/7/2002	Design Write's email to J. Eden			
00950K			9/20/2002	Article "Progestins and Breast Cancer" by John Eden, M.D.			
00950L	OLIVS006-000852	OLIVS006-000875		Progestins and Breast Cancer			
00950W				John Eden's documents			
00950Z	Various	Various		various 00950-- exhibits combined as one (A-B-C-D-F-G-J-K-L)			
00951	W-MDL04782-00050261	W-MDL04782-00050262	7/9/1991	Premarin Advocates Meeting Publication of Proceedings			
00952	W-LABELS-000246	W-LABELS-000249	00/00/1998	Menopause conference in Hot Springs, Arkansas			
00954	CONTA025-022310	CONTA025-022311	5/13/2002	Menopausal Health Pub Mgt Agenda			
00955	CONTA025-024637	CONTA025-024638	11/15/2001	update on National Hormone Council; Depo: Lynch, Rosie 5/4/2006 EX 035: update on National Hormone Council			
00956	CONTA025-019892	CONTA025-019893		Potential Slides to Describe and Emphasize the Importance			
00958	MDLreq12- 000001	MDLreq12-0000010		Response to MDL Request # 12 - List of payments			
00961	PANAA035-002045	PANAA035-002047	7/25/1990	Letter from Robert Kreisberg, M.D. to Dan Prince, Wyeth			
00962	PICKJ016-000912	PICKJ016-000913	6/19/1990	Memo from Fred Hassan to The Premarin Team; Depo: Robert Essner 6/29/06 EX 050; Fred Hassan 12/16/06 DEPO EX 005: Memo			
00963	PANAA025-001950	PANAA025-001951	5/31/1990	Presentation of Breast Cancer Study Results; DEPO: Andrew Panagy 7/13/06 EX 009: Internal Correspondence			
00963A	PANAA025-001952	PANAA025-001955	6/14/1990	Presentation of Breast Cancer Study Results; DEPO: Andrew Panagy 7/13/06 EX 009: Internal Correspondence // handwritten note: "position paper to be included in press kit"			
00964	W-MDL04782-00001933	W-MDL04782-00001933	5/30/1990	Estrace Advertising			
00965	PANAA031-001645	PANAA031-001645	5/17/1990	Wish List Involving the NOF			
00966	PICKJ011-002828	PICKJ011-002828	5/4/1990	Letter from Gordon Schwartz, M.D. to Wyeth			
00967	W-MDL04782-00000930	W-MDL04782-00000931	1/26/1990	Premarin Cardiovascular Promotion; Depo: Robert Essner 6/29/06 EX 013: Premarin CV Promotion; DEPO: Nick Marmontello 7/28/06 EX 002: Internal Correspondence			
00968	CONNS005-000193	CONNS005-000196	11/29/1989	1990 Premarin Public Relations Media Program			
00969	PANAA035-001886	PANAA035-001888	8/31/1989	Finance Committee Authorization			
00970	CAMAJ001-000033	CAMAJ001-000043		Handwritten notes			
00971	PICKJ009-001483	PICKJ009-001483	1/7/1988	FDA Menopause Meeting January 6, 1988			
00973	PICKJ009-001775	PICKJ009-001776	10/7/1987	Wyeth-Ayerst Menopause Program			
00974	LUDMG003-000367	LUDMG003-000370	10/30/1998	1999 Creative Campaign: Prempro Journal Ad Test			
00975	VICTJ001-002183	VICTJ001-002183	1/6/2000	Stampfer Publication			
00977	VICTJ001-000981	VICTJ001-000981		Premarin Family-Length of Therapy			
00978	VICTJ001-000494	VICTJ001-000547		Breast Neoplasia: Epidemiology, Case Reports, Clinical Trials			
00979	CONSG001-000712	CONSG001-000731		Estrogen Replacement and Atherosclerosis (ERA) Trial			
00980			9/16/2005	American Cancer Society -- website			
00980B				American Cancer Society -- website			
00980C				American Cancer Society -- website			
00981			5/00/1998	ACOG Educational Bulletin on HRT Number 247			
00982			10/00/1992	ACOG Patient Piece			
00982A	W-MDL04782-00013616	W-MDL04782-00013626	10/00/1987	ACOG brochures			
00983	CONTA021-000830	CONTA021-000831	3/14/1995	Handwritten notes			
00984	PICKJ007-000321	PICKJ007-000327	5/10/1995	Sample Sizes for Premarin/MPA Breast Cancer Study			
00985			4/25/1997	FOSAMAX Approval letter for Fosamax for prevention of osteoporosis			
00986	CONNS006-000452	CONNS006-000452		Get a Piece of the Pie!			
00987			3/00/1973	Contemporary Ob/Gyn			
00988			7/00/1973	Contemporary Ob/Gyn			
00989	SONKJ026-000165	SONKJ026-000167		Regulatory Affairs Review			
00990			00/00/1993	Projected costs for NIH WHI study [Cost of WHI			
00991	BRADK001-001261	BRADK001-001573		Additional Analyses of WHI Data (Report 1); Depo: Xue, Songlin 6/9/06 EX 009: Additional Analyses of WHI Data			
00992	HENRL011-000450	HENRL011-000469		Power of Consumer Communications; DEPO: Lesa Henry 7/21/06 EX 004: PPT Power of Consumer Communications**			
00993	MARTN010-002439	MARTN010-002439		PRODUCT CONCEPT STATEMENT			
00994	RYANJ003-001532	RYANJ003-001533		Q & A document			
00995	FARAN026-018781	FARAN026-018839	10/00/2002	Market Understanding and Concept Testing for Bazedoxefine			
00996	PICKJ009-001271	PICKJ009-001275		Response to Reviewer's Comments on the Proposed Extension of the Million Women Study			
00997	CONNS008-001274	CONNS008-001274	1/5/1990	Press Statement			
00998	PANAA026-001672	PANAA026-001675	10/26/1989	Women and Heart Disease Conference Topical Agenda			
00999	PANAA026-001690	PANAA026-001690	10/27/1989	Women Underestimate Risk of Heart Disease, Panel of Experts Says			
01000	PANAA026-001629	PANAA026-001649	10/26/1989	American Heart Association Women & Heart Disease Conference			
01002	W-SEASONS-000001	W-SEASONS-000029	00/00/1993	Seasons Magainze, Vol. 3, Issue 1			
01003	DEMAE022-003232	DEMAE022-003233	1/30/2004	Return/Disposal of Study Medicine			
01004			10/30/2000	FEDERAL REGULATIONS 21 CFR 314 and 601			
01005			00/00/1996	1996 Prempro Label			
01006	DUROJ046-018658	DUROJ046-018658	4/22/2002	Re: Request from Prof John Eden			
01007	DUROJ046-018657	DUROJ046-018657	4/22/2002	Fwd: Re: Request from Prof John Eden			
01008	GASTM011-009296	GASTM011-009296	10/29/2002	RE: Hormone replacement therapy after a diagnosis of breastcancer cancer recurrerc			
01009	DUROJ020-001008	DUROJ020-001011	3/19/1999	1999 Premarin Budget Women's Health Care			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01010	PANAA018-000513	PANAA018-000528		Circular & Booklet - Detail			
01011				Wyeth's payments to Rogerio Lobo			
01012				Wyeth's payments to David Archer			
01013				Wyeth's payments to Creasman			
01014				Wyeth's payments to DiSaia			
01015	PANAA017-000117	PANAA017-000118	12/12/1994	Scott-Levin Image Survey			
01016	PANAA019-000315	PANAA019-000315	12/6/1994	Premarin Details against OBGs			
01017	PICKJ007-000283	PICKJ007-000284	11/28/1994	FDA Request for W-A to Consider Postapproved Studies to Assess the Incidence of Breast Cancer			
01018	PANAA014-001652	PANAA014-001657	10/00/1994	Should Cardiologists Routinely Administer Estrogen Replacement Therapy to Postmenopausal Women?			
01019	PANAA023-000632	PANAA023-000632	9/16/1994	Letter from American College of Physicians to Wyeth			
01020	PANAA027-001006	PANAA027-001008	9/9/1994	Sales Impact Update			
01021	PANAA027-000995	PANAA027-000995	9/8/1994	New England Journal of Medicine Article			
01022	PANAA025-000370	PANAA025-000373	9/7/1994	Breast Cancer and ERT: Risk in Perspective Campaign			
01023	PANAA019-000589	PANAA019-000589	8/26/1994	Premarin - Powerhouse of the '90s!			
01024	FARAN008-002445	FARAN008-002445	8/16/1994	Highlights of Focus Groups Prempro Advertising			
01025	CONTA020-002304	CONTA020-002305	8/15/1994	93-001-MA Support for the Nurse's Health Study			
01026	PANAA027-000837	PANAA027-000837	8/8/1994	Osteopathic Residency Programs			
01027	PANAA026-000058	PANAA026-000058	8/1/1994	Letter from Francine Grodstein, M.D. to David Colasante, M.D.			
01028	PANAA026-000042	PANAA026-000042	8/1/1994	Women's Health Positioning Plan / Meetings with Burson-Marsteller			
01029	W-MDL04782-00143259	W-MDL04782-00143262	7/28/1994	Premarin DTC Image Ad			
01030	SOLOJ022-001057	SOLOJ022-001059	7/25/1994	Breast Cancer & ERT: Risk in Perspective Campaign - Preliminary Recommendations			
01031	CONNS006-000556	CONNS006-000557		Seasons Persistency Research			
01032	MARTN001-000672	MARTN001-000691	7/00/1994	Individualized Hormone Replenishment Therapy That Addresses the Changing Needs of the Estrogen-deficient Woman			
01033	DUROJ035-000120	DUROJ035-000120	6/30/1994	Detailing Reporting Form; Depo: Jeanne Durocher 6/30/06 EX024: Detailing Reporting Form			
01034	CONNS001-001230	CONNS001-001231	6/28/1994	Letter from Wyeth to DDMAC			
01035	PANAA019-000306	PANAA019-000308	6/20/1994	Sales Programs Feedback and Suggestions			
01036	PANAA019-000301	PANAA019-000302	6/20/1994	Region W6000 District Sales Conference Feedback			
01037	PANAA026-000290	PANAA026-000290	6/17/1994	Audited Minutes Per Detail			
01038	PANAA019-000309	PANAA019-000312	6/14/1994	Internal memo from Howard Salik to David Dodd, M.D.			
01039	PANAA026-000232	PANAA026-000233	6/10/1994	Premarin Audited Detail Activity			
01040	GPIL008-000996	GPIL008-001010	6/8/1994	Clinical Drug Safety Surveillance Weight Gain with Premarin Therapy			
01041	PANAA026-000897	PANAA026-000897	5/31/1994	Estrace Syndicated Column			
01042	PANAA026-000231	PANAA026-000231	5/31/1994	Premarin Detailing Analysis			
01043	CONTA021-001903	CONTA021-001904	5/26/1994	Annual Premarin Symposium (Santa Barbara)			
01044	CONNS001-001170	CONNS001-001170	5/23/1994	Correspondence from Solvay Pharmaceuticals to Ewan G. Robertson, MD			
01045	CONNS010-000449	CONNS010-000449	5/16/1994	Letter from Wyeth to Bristol Meyers			
01046	GPIL007-000354	GPIL007-000355	7/19/1994	Consensus Conference on HRT July 16, 1994			
01047	PANAA026-000891	PANAA026-000891	5/10/1994	Projected Market Size - Premarin & HRT			
01048	PANAA026-000332	PANAA026-000342	6/6/1994	Status Report for May 1994 HRT Group 1994 Projects			
01049	DUROJ034-002177	DUROJ034-002177		Marketing Plan HRT			
01050	W-MDL04782-00051052		5/6/1977	Estriol and Breast Cancer.			
01051	GPIL041-001226	GPIL041-001247	00/00/1977	Assessment of Estrogen and Progestin Therapy in Gynecology and Obstetrics			
01052	W-MDL04782-00051004	W-MDL04782-00051014	6/00/1977	THE ROLE OF HORMONES IN THE ETIOLOGY OF HUMAN BREAST CANCER			
01053	CHOOM034-000407	CHOOM034-000407	12/2/1997	Memo re 12th Edition Novak's Gynecology; Depo: Weber, Margaret 6/21/06 EX 054: Internal correspondence			
01054	W-MCL015-01288	W-MCL015-01293	6/27/1977	Sequential Progestogen Administration with Estrogen Replacement			
01055	W-MCL026-01788	W-MCL026-01789	7/4/1977	JAMA Editorial "Estrogen Receptors in Human Cancers"			
01056	W-MDL04782-00051673	W-MDL04782-00051675		PREMARIN and Prevention of Loss of Bone Mass (Osteoporosis)			
01057	W-MCL015-01287	W-MCL015-01287	8/24/1977	Sequential Progestin Administration with Estrogen Replacement			
01059	W-MDL04782-00052358		10/5/1976	Estrogen Article			
01061	CHOOM034-000407		12/2/1997	12th Edition Novak's Gynecology			
01062	W-MCL016-01455		4/18/1986	Letter from Wyeth to doctors regarding lupus			
01063	W-MDL04782-00009643	W-MDL04782-00009644	7/21/1986	Premarin FDA Meeting			
01064	DUROJ046-004837	DUROJ046-004842	10/31/2002	WOMEN S HEALTH CARE PHARMACY ADVISORY BOARD; Depo: Jeanne Durocher 6/30/06 EX032: Women's Health Care Pharmacy Advisory Board Executive Summary			
01065	CONNS005-000998	CONNS005-001002	4/26/1994	NDA 04-782 Premarin			
01066	SINAM002-000883	SINAM002-000884	4/23/1994	Premarin vs. Estrace			
01067	PICKJ013-001549	PICKJ013-001550	4/21/1994	Premarin Support Group Thursday, April 21, 1994 Agenda			
01068	CONNS010-000464	CONNS010-000464	4/19/1994	FDA Complaint			
01069	PANAA026-000234	PANAA026-000236		PSA Details (000) by Detail Order - Apr 94 - Apr 94			
01070	PICKJ016-000439	PICKJ016-000442		Premarin Support Team			
01071	PICKJ027-001847	PICKJ027-001849	3/25/1994	A Randomised Controlled Trial to Determine the Long-Term Effects of Hormone Replacement Therapy			
01072	PICKJ018-000150	PICKJ018-000152	3/16/1994	Cowen Health Conference - Osteoporosis; DEPO: Jean Meaney 7/11/06 EX 007: Internal correspondence			
01073	PANAA027-000561	PANAA027-000561	2/9/1994	ECOG Breast Cancer Study			
01074	DUROJ030-001679	DUROJ030-001680	2/9/1994	Letter from Wyeth to FDA regarding Solvay Pharmaceuticals promotional activities; Depo: Jeanne Durocher 6/30/06 EX015: Letter to Zimney from Barton			
01075	W-MDL04782-00142375	W-MDL04782-00142378	1/31/1994	Premarin Cardiovascular Labeling Meeting			
01076	PICKJ027-001990	PICKJ027-001992	1/19/1994	MRC Hormone Replacement Study			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01077	W-MDL04782-00142456	W-MDL04782-00142465	1/7/1994	Cardiovascular Labeling			
01078	PANAA027-000461	PANAA027-000461	1/17/1994	Don Gambrell, MD - Solvay Presentation			
01079	SOLOJ020-000476	SOLOJ020-000482	1/13/1994	Finance Committee Authorization Prempro/Premphase Launch			
01080	PANAA016-000125	PANAA016-000127	1/13/1994	Wyeth Internal Memo from Kate Moore to David Dodd			
01081	DUROJ030-001660	DUROJ030-001661	8/5/1993	Solvay Complaints; Depo: Jeanne Durocher 6/30/06 EX014: Wyeth- Ayerst Laboratories, Regulatory Affairs Distribution List Advertising-- Promotion			
01082	PANAA037-000103	PANAA037-000105	1/10/1994	Letter from National Osteoporosis Foundation to Carrie Smith Cox			
01083	W-MDL04782-00142490	W-MDL04782-00142499	1/7/1994	Final Position Statement			
01084	DUROJ043-001053	DUROJ043-001058		Premarin 1994 Strategic Options; Depo: Jeanne Durocher 6/30/06 EX031: Premarin 1994 Strategic Options			
01085	PANAA026-000644	PANAA026-000645	12/22/1993	Upjohn			
01086	DUROJ032-000211	DUROJ032-000212	12/14/1993	Letter from Trudy Bush, M.D. to Stephen Sasson, Ph.D., Wyeth; Depo: Jeanne Durocher 6/30/06 EX018: Letter to Sasson from Bush			
01087	SOLOJ025-000490	SOLOJ025-000490	12/7/1993	Letter to FDA on Solvay			
01088	DEYMI006-000036	DEYMI006-000037	12/6/1993	Consensus Conference on HRT and the Cardiovascular System / Impact on Premarin / MPA			
01089	SINAM002-000841	SINAM002-000841	11/29/1993	Premarin Presentation			
01090	PANAA025-000702	PANAA025-000703	11/22/1993	Letter from Eastern Oncology Cooperative Group to Carrie Smith Cox			
01091	W-MDL04782-00140169	W-MDL04782-00140188	11/11/1993	Solvay Pharmaceuticals Promotions			
01092	CONNS009-000624	CONNS009-000625	10/26/1993	Premarin Patient Education Program			
01093	RHUDM011-001147	RHUDM011-001147	10/21/1993	Premarin Speakers			
01094	PANAA033-002322	PANAA033-002323	10/14/1993	The Waning Effect of Postmenopausal Estrogen Therapy on Osteoporosis			
01095	SONKJ015-000494	SONKJ015-000501	10/5/1993	Memorandum of Meeting Premarin/MPA Refusal to File NDA No. 20-303			
01096	PANAA026-001303	PANAA026-001304	9/15/1993	State Targets Legislative Roundtables			
01097	PANAA026-001204	PANAA026-001204	9/14/1993	Internal Memo to Jim Donovan re: Could we suggest to ACOG that the booklets should be revised (there's no mention of heart disease)?"	RE: ACOG Patient Brochures	Carrie Smith-Cox	
01098	FARAN004-000975	FARAN004-000979	8/13/1993	Research for HealthWords for Women			
01099	PANAA014-001511	PANAA014-001511	7/12/1993	Premarin Cardiovascular Labeling			
01100	PANAA025-000981	PANAA025-000981	7/8/1993	Nurses Health Study Breast Cancer Met-Analysis			
01101	PANAA014-001529	PANAA014-001529	7/7/1993	Cardiovascular Labeling for Premarin			
01102	PANAA026-001037	PANAA026-001041	6/22/1993	First Quarter Report - 1993 Wyeth-Ayerst Medical Education Programs Department a) Visiting Professor Programs (ViPP) Dept. b) Continuing Medical Education (CME) Dept.			
01103	PANAA035-001049	PANAA035-001049	5/19/1993	Letter from Marc Deitch to patients taking Premarin			
01104	RIGGB004-001119	RIGGB004-001121	5/3/1993	Update on HERS Recruitment Communications Activities			
01105	PICKJ021-002204	PICKJ021-002211	3/31/1993	Womens Health Institute Initiative Investigators Committee Meeting March 31 - April 1, 1993 Seattle Washington Minutes			
01106	PANAA033-001354	PANAA033-001354	3/1/1993	Estrogen Competition			
01107	W-MDL04782-00060553	W-MDL04782-00060576	00/00/1993	Seasons. Volume 3, Issue 1			
01108	W-MDL04782-00060268	W-MDL04782-00060295	00/00/1993	Seasons Volume 3, Issue 4			
01109	W-MDL04782-00060615	W-MDL04782-00060615		Renewal Form The Seasons Magazine Women's Health Program Physician Personalization			
01110	W-MDL04782-00060613	W-MDL04782-00060614	12/10/1992	Letter to doctor requesting permission to print doctor's name in Seasons magazine			
01111	DEMAE007-000727	DEMAE007-000729	1/23/1995	Premarin : Selection for WHI			
01112	DUROJ042-000403	DUROJ042-000403	12/15/1992	Dear Colleague letter from Robert Essner regarding HERS study; Depo: Jeanne Durocher 6/30/06 EX029: Dear Colleague Letter			
01113	DUROJ018-000058	DUROJ018-000058		Facts about Wyeth-Ayerst/AHP; Depo: Jeanne Durocher 6/30/06 EX005: Facts about Wyeth- Ayerst/ AHP			
01114	PANAA036-002640	PANAA036-002640	10/27/1992	Internal Memo from H. Sharma to Ellen Giesel			
01115	PANAA036-002646	PANAA036-002646	10/12/1992	Bulletin PM-058 Seasons Magazine Distribution			
01116	PANAA035-002509	PANAA035-002510	10/8/1992	1993 Phase IV Program			
01117	DEMAE007-000825	DEMAE007-000825	10/5/1992	Women's Health Initiative (WHI) Drug Supply Specifics 92-952-MA			
01118	PANAA036-002653	PANAA036-002653	10/2/1992	Premarin Women's Health Program			
01119	FARAN004-001168	FARAN004-001175	00/00/1992	Mammograms: The very Best Defense against Breast Cancer			
01120	W-MDL303-00081635	W-MDL303-00081638	9/24/1992	Cardiovascular Labeling (NDA 20-303)			
01121	PANAA036-002643	PANAA036-002643	9/21/1992	Wyeth-Ayerst "Seasons" Program			
01122	DEMAE007-000832	DEMAE007-000832	9/15/1992	Women's Health Initiative (WHI) Photo Session			
01123	PANAA036-001310	PANAA036-001310	9/15/1992	Details to OB/GYN Residents			
01124	DUROJ041-000765	DUROJ041-000767	9/11/1992	Pending Alt Status; Depo: Jeanne Durocher 6/30/06 EX026: Pending AHT Status			
01125	GPIL044-001095	GPIL044-001095	9/9/1992	Premarin / Cardiovascular Labeling			
01126	PANAA036-002662	PANAA036-002662	9/8/1992	Wyeth Ayerst Premarin Women's Healthcare Program "Seasons" Magazine			
01127	PANAA036-002649	PANAA036-002649	9/8/1992	Wyeth Ayerst Premarin Program and C.E.			
01128	VICTJ005-001555	VICTJ005-001555	9/3/1992	Upcoming Publications			
01129	PANAA036-002641	PANAA036-002641	9/31/1992	Bulletin PM- 130 Premarin Seasons Program			
01130	CONNS005-000966	CONNS005-000968	8/27/1992	Premarin Goals for 1993			
01131	PANAA036-002642	PANAA036-002642	8/19/1992	Seasons			
01132	PANAA036-002644	PANAA036-002644	8/18/1992	Wyeth Ayerst Women's Health Program			
01133	PANAA036-002645	PANAA036-002645	8/17/1992	Wyeth Ayerst Premarin Woman's Healthcare Program "Seasons" Magazine			
01134	PICKJ021-002686	PICKJ021-002687	8/10/1992	Women's Health Initiative WHI Drug Supply Specifics 92-952-MA			
01135	PANAA036-002661	PANAA036-002661	8/10/1992	Premarin/Seasons Magazine			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01136	PANAA030-001008	PANAA030-001008	8/10/1992	HRS Proposal			
01137	PICKJ013-000997	PICKJ013-000999	8/6/1992	Premarin Support Agenda			
01138	ROSSC005-000085	ROSSC005-000087	8/6/1992	Letter from Wyeth to FDA			
01139	PANAA031-000733	PANAA031-000733	8/5/1992	Luncheon Orientation Meeting for the North American Menopause Society Annual Meeting			
01140	DUROJ039-002167	DUROJ039-002206	7/31/1992	Public Relations Recommendations to Support Wyeth-Ayerst/EPICH Trial NIH/Women's Health Initiative; Depo: Jeanne Durocher 6/30/06 EX025: Public Relations Recommendation to Support Wyeth- Ayerst/ EPICH Trial NIH/ Women's Health Initiative			
01141	W-MDL04782-00025717	W-MDL04782-00025719	7/28/1992	FDA Letters Regarding Premarin Promotional Materials			
01142	GPIL044-001635	GPIL044-001635	7/20/1992	Premarin/MPA Labeling			
01143	PANAA036-002609	PANAA036-002609	7/10/1992	Wyeth Ayerst Premarin Program			
01144	RIGGB007-002072	RIGGB007-002072	7/6/1992	Hulley Trial			
01145	PANAA036-000803	PANAA036-000803	7/6/1992	First Annual Menopause Report			
01146	CONNS005-000969	CONNS005-000970	6/29/1992	Tactical Plans			
01147	DUROJ021-002436	DUROJ021-002439	6/26/1992	Premarin/MPA FDA Meeting; Depo: Jeanne Durocher 6/30/06 EX006: Internal Correspondence to Distribution from Marani			
01148	RIGGB007-001286	RIGGB007-001292		Hulley Sales Impact			
01149	PANAA038-000819	PANAA038-000819	6/19/1992	HHS letter to David Colasante, M.D.			
01150	RIGGB006-000643	RIGGB006-000643	6/18/1992	Hulley Study ROI			
01151	DELCA011-000001	DELCA011-000001	3/13/2000	Email from Leon Speroff to Anthony DelConte; Depo: Speroff, Leon 6/30/2005 EX 034			
01152	PANAA031-000548	PANAA031-000548	6/17/1992	Blue Cross Blue Shield Presentation			
01153	PANAA019-000558	PANAA019-000559	00/00/1991	1991 ACOG Meeting Highlights			
01154	PANAA036-000434	PANAA036-000435	00/00/1991	More Research Needed on Estrogen and Coronary Heart Disease			
01155	FARAN003-001513	FARAN003-001513	1/4/1991	Letter from Vanderveer Group to Nick Marmontello			
01156	FARAN003-001516	FARAN003-001516	1/24/1991	Letter from Vanderverr Group to Nick Marmontello			
01157	GPIL008-000497	GPIL008-000497	1/25/1991	The Sixth International Congress on the Menopause			
01158	PANAA036-000371	PANAA036-000433	2/6/1991	Wyeth-Ayerst/Premarin Media Placement Report Henderson Study: Archives of Internal Medicine, 1/91			
01159	PANAA036-000370	PANAA036-000370	2/12/1991	Henderson Study - PR Results			
01160	PICKJ013-001427	PICKJ013-001428	2/14/1991	Premarin Support Group Meeting of January 24, 1991			
01161	PANAA024-002445	PANAA024-002448	2/21/1991	FDA Trip Report February 20, 1991			
01162	PANAA035-002226	PANAA035-002231	2/26/1991	Premarin Phase IV Studies			
01163	PANAA030-001422	PANAA030-001424	3/00/1991	Executive Summary IM Perceptions of the New Cardiovascular Claims for Premarin			
01164	CONNS008-000464	CONNS008-000464	3/7/1991	Prescription Drug Promotion FDA Oversight			
01165	ROSSC023-001022	ROSSC023-001023	3/8/1991	Premarin Concept Statements			
01166	W-MDL04782-00002323	W-MDL04782-00002324	3/11/1991	American Heart Association Brochure on Women and Heart Disease			
01167	GPIL045-002211	GPIL045-002211	3/12/1991	Premarin Cardiovascular Labeling			
01168	PICKJ013-001424	PICKJ013-001424	3/21/1991	Premarin Support Team Meeting Agenda			
01169	PANAA029-000554	PANAA029-000560		Age Distribution for Premarin New Therapy			
01170	PANAA029-000553	PANAA029-000553	6/16/1992	Age Distribution - Premarin New Therapy			
01171	FARAN002-000800	FARAN002-000801	6/10/1992	Media Effect of CV Benefits of ERT: A Revisit			
01172	SONKJ015-000477	SONKJ015-000482	5/27/1992	FDA Advisory Committee: Osteoporosis			
01173	PANAA038-000746	PANAA038-000749	5/28/1992	WHI - Notes from 5/27/92 Meeting			
01174	PICKJ024-000994	PICKJ024-000996	6/4/1992	Hulley Study Cardioprotective Indication			
01175	DUROJ030-000383	DUROJ030-000385	4/14/1992	Competitive Tracking: Weekly Report; Depo: Jeanne Durocher 6/30/06 EX 009: Internal Correspondence to marmontello from Westerfield			
01176	DUROJ041-001011	DUROJ041-001011	4/7/1992	NIH - Women's Health Initiative (WHI); Depo: Jeanne Durocher 6/30/06 EX028: Internal Correspondence to Distribution from Colasante			
01177	COBBP002-000154	COBBP002-000154	4/6/1992	Premarin 2 Cardiovascular Prevention Study (HRS)			
01178	DUROJ041-001008	DUROJ041-001009	3/31/1992	Premarin Cardiovascular Studies Meeting Summary; Depo: Jeanne Durocher 6/30/06 EX027:Internal Correspondence to Distribution from Colasante			
01179	DUROJ030-000446	DUROJ030-000446	3/5/1992	Detail Verbatims for Estraderm; Depo: Jeanne Durocher 6/30/06 EX010: Detail Verbatims for Estraderm			
01180	PANAA036-000521	PANAA036-000524	2/27/1992	Premarin Public Relations			
01181	DUROJ030-000471	DUROJ030-000472	2/19/1992	Competitive Tracking: Estraderm; Depo: Jeanne Durocher 6/30/06 EX011:Internal Correspondence to Hassan from Westerfield/Chen			
01182	PANAA025-000817	PANAA025-000818	2/11/1992	Meir Stampfer Paper			
01183	PANAA014-001130	PANAA014-001130	1/23/1992	Premarin Cardiovascular Labeling			
01184	DUROJ030-001375	DUROJ030-001377	1/23/1992	Ciba-Geigy/FDA Correspondence Estraderm Advertising; Depo: Jeanne Durocher 6/30/06 EX012:Internal Correspondence to Distribution from Victoria			
01185	PANAA019-000543	PANAA019-000543	1/15/1992	Special Edition			
01186	PANAA025-001795	PANAA025-001795	1/8/1992	Premarin Defense Strategy Regarding Breast Cancer			
01187	PANAA029-000395	PANAA029-000408	12/26/1991	Wyeth-Ayerst/Premarin Crisis/Issue Management Audit Report			
01188	PANAA029-000384	PANAA029-000385	12/26/1991	Letter from Burton-Marsteller to Carrie Smith Cox			
01189	PANAA029-000377	PANAA029-000377		Crisis Preparedness Plan Time and Events Schedule			
01190	PANAA029-000376	PANAA029-000376	12/11/1991	Letter from Burton-Marsteller to Carrie Smith Cox			
01191	PANAA029-001107	PANAA029-001107	12/9/1991	FDA Advisory Group Meeting			
01192	COBBP002-000127	COBBP002-000128	12/4/1991	Letter from Marc Deitch, M.D. to Stephen Hulley, M.D.			
01193	PANAA035-002291	PANAA035-002298	12/00/1991	Premarin Phase IV Studies - December 1991 by Indication			
01194	PICKJ013-001161	PICKJ013-001162	11/27/1991	Premarin Support Agenda			
01195	PANAA034-001526	PANAA034-001529	11/20/1991	Comments on Women's Health Initiative Prospectus			
01196	DEMAE007-000919	DEMAE007-000921	10/29/1991	NIH Public Hearing on Women's Health Initiative			
01197	W-MDL04782-00048699	W-MDL04782-00048700	10/29/1991	Estrace			
01198	PANAA033-000029	PANAA033-000030	10/2/1991	Trip Report: Meeting in Boston with Drs. Stampfer and Colditz Nurses Health Study - 9/20/91			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01199	RIGGB007-001742	RIGGB007-001742	9/18/1991	Premarin Cardiovascular Labeling			
01200	ROSSC023-000521	ROSSC023-000521	9/5/1991	Premarin Journal Ad Found Misleading; Depo: Justin Victoria 6/30/06 EX 019: Internal Correspondence; DEPO: Nick Marmontello 7/28/06 EX 004: Internal Correspondence			
01201	PANAA035-000450	PANAA035-000451	9/5/1991	Minutes: Premarin Studies Review Committee Meeting			
01202	RIGGB007-001525	RIGGB007-001526	8/15/1991	Premarin Cardiovascular Action Group			
01203	PICKJ022-002836	PICKJ022-002837	8/2/1991	Letter from David Colasante, M.D. to Stephen Hulley, M.D.			
01204	RIGGB007-001801	RIGGB007-001802	8/1/1991	Premarin Cardiovascular Action Group Minutes of 7/31/91 Meeting			
01205	PANAA035-002269	PANAA035-002272	6/24/1991	Premarin Team Meeting Minutes			
01206	FARAN005-000592	FARAN005-000595	7/22/1991	NFO Consumer Survey			
01207	PICKJ013-001216	PICKJ013-001216	7/17/1991	Premarin Support Group Wednesday, July 17, 1991 Agenda			
01208	PANAA034-001796	PANAA034-001796	7/16/1991	Premarin CBL Program			
01209	W-MDL04782-00050231	W-MDL04782-00050233	7/12/1991	Premarin Advocates Meeting Publication of Proceedings			
01210	GPIL008-000614	GPIL008-000620	7/11/1991	Fertility and Maternal Health Drugs Advisory Committee Meeting - June 20-21, 1991 Minutes of Meeting			
01211	PANAA026-001765	PANAA026-001766	7/10/1991	Letter from David Colasante, M.D. to Meir Stampfer, M.D.			
01212	W-MDL04782-00050260	W-MDL04782-00050262	7/9/1991	Premarin Advocates Meeting Publication of Proceedings			
01213	PICKJ013-001212	PICKJ013-001213	7/9/1991	Letter from William Dupont, Ph.D., Vanderbilt, to Marc Deitch, M.D.			
01214	PANAA038-001018	PANAA038-001018	6/28/1991	Parke Davis Promotion of Loestrin			
01215	COBBP002-000136	COBBP002-000140	6/14/1991	Perspectives on Premarin Cardiovascular Prevention Trials; Memo Colasante to Rofsky			
01216	PANAA030-001425	PANAA030-001426	6/11/1991	Premarin C.V. Awareness - Physician Survey			
01217	DUROJ030-001544	DUROJ030-001545	6/10/1991	Letter from FDA to CIBA-GEIGY; Depo: Jeanne Durocher 6/30/06 EX013:Letter to Birch from Cavanaugh			
01218	CONNS009-001326	CONNS009-001327	6/3/1991	Preliminary Response to May 31, 1991 FDA/Ciba-Geigy Letter Concerning the Promotional Activities for Estraderm (Estradiol Transdermal System USP), NDA 19-081, during the Thirty-Ninth Annual Clinical Meeting of the American College of Obstetricians and Gyn			
01219	PANAA035-000574	PANAA035-000575	6/3/1991	Premarin Support Group Meeting of May 17, 1991			
01220	PICKJ013-001419	PICKJ013-001420	5/2/1991	Premarin Support Team Meeting Agenda			
01221	PANAA035-000508	PANAA035-000509	5/14/1991	Letter from Drs. Colditz and Stampfer to Wyeth			
01222	PICKJ013-001384	PICKJ013-001385	5/17/1991	Premarin Support Team Meeting Agenda			
01223	FARAN003-001514	FARAN003-001515	12/27/1991	Premarin Cardiovascular Promotional Strategy			
01224	PANAA014-001177	PANAA014-001178	2/22/1991	Letter from Wyeth to FDA			
01225	GPIL044-000250	GPIL044-000250	4/1/1991	Premarin Cardiovascular Labeling			
01226	PICKJ013-001413	PICKJ013-001415	4/1/1991	Premarin Support Group Meeting of March 21, 1991			
01227	W-MDL04782-00035814	W-MDL04782-00035817		Now, give your PREMARIN (conjugated estrogens tablets, USP) patients more than a prescription. Given them ongoing information for long-term health			
01228	RIGGB007-001821	RIGGB007-001821	4/7/1992	NIH - Women's Health Initiative (WHI)			
01229	PANAA035-001629	PANAA035-001629	4/9/1991	NHLBI Proposal for Study on ERT Prevention of Cardiovascular Disease			
01230	DUROJ031-000126	DUROJ031-000131	4/10/1991	Estrogen and Coronary Heart Disease in Women; Depo: Jeanne Durocher 6/30/06 EX017: Estrogen and Coronary Heart Disease in Women			
01231	CONNS001-000260	CONNS001-000260	4/18/1991	Letter From: Wyeth (Eric Gibson), To: Peter Penna of Group Health Cooperative			
01232	PANAA025-001907	PANAA025-001908	4/19/1991	JAMA Breast Cancer Study - Media Coverage			
01233	PANAA026-001950	PANAA026-001951	4/22/1991	Letter from Vanderveer Group to Nick Marmontello			
01234	FARAN003-001504	FARAN003-001504	4/24/1991	Letter from Vanderveer Group to David Chen, Wyeth			
01235	GPIL009-000127	GPIL009-000128	4/30/1991	Addressing Breast Cancer Risk Language Premarin Labelling			
01236	PANAA025-001879	PANAA025-001880	4/30/1991	Dear Doctor Letter signed by Marc Deitch, M.D.			
01237	PANAA025-001863	PANAA025-001864	4/30/1991	Letter from Wyeth to Graham Colditz, M.D.			
01238	PICKJ016-000878	PICKJ016-000880	12/14/1990	AHA			
01239	PANAA025-001946	PANAA025-001947	12/14/1990	Letter from Wyeth to Meir Stampfer, M.D.			
01240	W-MDL04782-00002190	W-MDL04782-00002191	12/13/1990	FACSIMILE TRANSMISSION			
01241	PANAA025-001888	PANAA025-001889	12/3/1990	Dear Doctor Letter signed by Marc Deitch, M.D.			
01242	GPIL017-001549	GPIL017-001549	11/27/1990	ERT/Cardioprotection			
01243	PANAA025-001705	PANAA025-001706	11/26/1990	Letter from Robert Essner to Wyeth employees			
01244	PICKJ013-001452	PICKJ013-001456	11/19/1990	Premarin Support Group Meeting of November 13, 1990			
01245	GPIL017-001550	GPIL017-001551	11/19/1990	Premarin Cardioprotection Claim			
01246	CONNS020-000389	CONNS020-000391	11/7/1990	HRT Research Team Meeting			
01247	PANAA035-002192	PANAA035-002192	11/5/1990	Letter from John Hurley to Ron Ross, M.D.			
01248	W-MCL010-01200	W-MCL010-01202	11/1/1990	Letter from Margaret Weber, M.D. to W. Skinner, M.D.			
01249	CONNS011-000050	CONNS011-000051	11/1/1990				
01250	PICKJ013-001493	PICKJ013-001493	9/24/1990	September 26 Premarin Support Team Meeting Agenda			
01251	W-MDL04782-00001184	W-MDL04782-00001193	9/20/1990	Regulatory Issues			
01252	W-MDL04782-00001204	W-MDL04782-00001205	9/14/1990	Premarin Promotional Activities			
01253	PANAA034-001698	PANAA034-001698	9/13/1990	FDA Advisory Committee Combination HRT Product OC Labeling			
01254	PANAA038-000388	PANAA038-000388	9/6/1990	Wyeth Ayerst and American Heart Association			
01255	PANAA035-002061	PANAA035-002064	8/10/1990	Premarin Phase IV			
01256	W-MDL04782-00001658	W-MDL04782-00001659	7/6/1990	Premarin - Cardiovascular			
01257	PANAA035-001945	PANAA035-001947	7/5/1990	Premarin Phase IV			
01258	GPIL045-002323	GPIL045-002325	6/20/1990	Premarin Cardioprotective Indication Follow-Up			
01259	PICKJ016-000910	PICKJ016-000911	6/18/1990	Premarin Cardiovascular Clinical Studies			
01260	PANAA026-001575	PANAA026-001581	6/18/1990	Premarin - Cardiovascular Indication			
01261	PANAA014-001044	PANAA014-001062	6/22/1990	Summary Minutes			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01262	DUROJ030-002197	DUROJ030-002198	6/15/1990	Ogen Advertising Brochure 97-0315/R1-15-October 1989; Depo: Jeanne Durocher 6/30/06 EX016: Internal Correspondence to Hertel from Morrison			
01263	PANAA023-000328	PANAA023-000328	6/6/1990	Letter from John Garvey, Wyeth to Dr. Argenio			
01264	PANAA010-000988	PANAA010-001102	6/4/1990	DEPO: Buchalter, Jeff 05/29/2008 EX 37;The Fourth Annual Symposium on the Long Term Effects of Estrogen Deprivation June 4, 5, 6, 1990 San Dominico Palace Sicily, Italy Proceedings Session II ERT Risks: Metabolic and Neoplastic			
01265	PANAA025-001950	PANAA025-001951	5/31/1990	Presentation of Breast Cancer Study Results			
01266	W-MDL04782-00001932	W-MDL04782-00001933	5/30/1990	Estrace Advertising; Depo: Justin Victoria 6/30/06 EX 015: Memo			
01267	PANAA026-001740	PANAA026-001741	5/18/1990	Premarin - Primary Care Projections			
01268	PANAA031-001645	PANAA031-001645	5/17/1990	Wish List Involving the NOF			
01269	W-MDL04782-00000353	W-MDL04782-00000355	5/16/1990	Premarin Cardiovascular Claim Regulatory History			
01270	GPIL016-001353	GPIL016-001353	5/16/1990	Estrogen Wrinkle Cream			
01271	PANAA034-002385	PANAA034-002385	1/25/1990	Research Grant on the Importance of Pharmacists in Drug Selection			
01272	FARAN003-001630	FARAN003-001630	5/1/1990	Labelling Change - Premarin and Decreased Risk of Coronary Heart Disease in Postmenopausal Women			
01273	GPIL044-000485	GPIL044-000485	3/29/1990	Premarin Cardioprotective Indication			
01274	W-MDL04782-00000397	W-MDL04782-00000399	3/23/1990	Premarin Cardioprotective Indication			
01275	GPIL045-002398	GPIL045-002400	3/21/1990	Premarin (Conjugated Estrogens) Cardiovascular Indication Minutes of FDA Meeting			
01276	CONNS006-001071	CONNS006-001071	2/7/1990	Premarin Team Meeting Agenda			
01277	PICKJ013-000713	PICKJ013-000715	2/6/1990	Premarin Support			
01278	W-MDL04782-00000894	W-MDL04782-00000895	2/5/1990	Premarin Ad			
01279	GPIL009-000115	GPIL009-000116	2/5/1990	FDA Advisory Committee Meeting			
01280	CONNS017-000032	CONNS017-000035	2/6/1990	Summary Minutes			
01281	W-MDL04782-00035178	W-MDL04782-00035179	1/29/1990	Letter from Justin Victoria to FDA			
01282	W-MDL04782-00000903	W-MDL04782-00000905	1/29/1990	Premarin Journal Advertisement			
01283	GPIL008-000134	GPIL008-000136	1/29/1990	Premarin - Cardioprotection			
01284	W-MDL04782-00000930	W-MDL04782-00000931	1/26/1990	Premarin Cardiovascular Promotion; Depo: Justin Victoria 6/30/06 EX 004: Internal Correspondence			
01285	VICTJ005-001705	VICTJ005-001706	1/25/1990	FDA Advisory Committee HRT and Cancer			
01286	CONNS017-000138	CONNS017-000139	1/24/1990	FDA Advisory Committee			
01287	VICTJ005-001707	VICTJ005-001708	1/24/1990	FDA Advisory Committee HRT/ Breast Cancer and Endometrial Cancer			
01288	VICTJ005-001709	VICTJ005-001709	1/22/1990	FDA Advisory Committee HRT/ Breast Cancer and Endometrial Cancer			
01289	CONNS008-001274	CONNS008-001274	1/5/1990	Press Statement			
01290	FARAN005-001481	FARAN005-001482		1990 Premarin DTC Print Ad Program R-O-I Analysis			
01291	PANAA025-000770	PANAA025-000770	12/20/1989	Letter from Wyeth to Burson-Marsteller			
01292	VICTJ005-001760	VICTJ005-001760	12/19/1989	FDA Advisory Committee			
01293	PICKJ016-001055	PICKJ016-001055	11/28/1989	Premarin Cardioprotective Indication			
01294	W-MDL04782-00000382	W-MDL04782-00000383	11/27/1989	Premarin Cardioprotection Claim			
01295	PICKJ016-001053	PICKJ016-001053	11/27/1989	Premarin Cardioprotective Indication			
01296	W-MDL04782-00000203	W-MDL04782-00000204	11/22/1989	Premarin Cardioprotection Submission			
01297	W-MDL04782-00000275	W-MDL04782-00000276	11/13/1989	Premarin Journal Advertisement			
01298	W-MDL04782-00000277	W-MDL04782-00000278	11/10/1989	Premarin Journal Advertisement			
01299	W-MDL04782-00000279	W-MDL04782-00000280	11/7/1989	Premarin Journal Advertisement			
01300	PANAA025-001425	PANAA025-001425	10/23/1989	Handwritten note from Donna Rothman to Jay Rachelli			
01301	NORMJ007-000419	NORMJ007-000419	10/20/1989	Premarin/Provera - Scientific Rationale. Ref. your Fax Oct. 19			
01302	PANAA035-001886	PANAA035-001888	8/31/1989	Finance Committee Authorization			
01303	GPIL008-002352	GPIL008-002353	8/31/1989	Cardioprotection - Premarin			
01304	YAVUE005-000496	YAVUE005-000496	8/15/1989	Premarin: Home-Study Guide			
01305	PANAA030-000008	PANAA030-000008	8/8/1989	Senile Urinary Incontinence			
01306	W-MDL04782-00033664	W-MDL04782-00033664	8/4/1989	Dear Doctor Letter from Dr. Lippman			
01307	PANAA025-001382	PANAA025-001382	8/4/1989	The New England Journal of Medicine Article Entitled: "The Risk of Breast Cancer after Estrogen and Estrogen-Progestin Replacement"			
01308	PANAA025-001471	PANAA025-001472	8/2/1989	Press Response			
01309	PANAA025-001421	PANAA025-001424	8/2/1989	Media Update on NEJM Article			
01310	PANAA025-001447	PANAA025-001448	8/2/1989	letter from Ronald Ross, M.D. to Donna Rothman			
01311	W-MDL04782-00047398	W-MDL04782-00047398		Dear Doctor Letter signed by Marc Deitch, M.D.			
01312	NORMJ007-000123	NORMJ007-000125	2/15/1989	Premarin/MPA			
01313	CONNS014-001580	CONNS014-001597	2/10/1989	Revised Recommendations 1989 Public Relations Program Wyeth-Ayerst Laboratories/Premarin			
01314	CONNS014-001622	CONNS014-001625	1/11/1989	Recommended Action Plan, Premarin/Generics Bioequivalency Issue			
01315	PANAA023-000356	PANAA023-000357		ACOG - Media Relations Activities at a Glance			
01316	W-MCL015-01318	W-MCL015-01331		Menopause Management			
01317	DUROJ032-001294	DUROJ032-001294	12/30/1988	Wyeth-Sponsored Medical Conference; Depo: Jeanne Durocher 6/30/06 EX021: Internal Correspondence All Wyeth Regional Managers from Backstrand			
01318	PICKJ011-002928	PICKJ011-002931	2/15/1989	Letter from Eliza Parson to Dr. Virginia Upton			
01319	PICKJ011-002933	PICKJ011-002934	12/29/1988	Signature page of Letter from Eliza Parson to Dr. Virginia Upton			
01320	DUROJ033-000013	DUROJ033-000022	12/6/1988	COR Meeting Minutes: Phase IV Reproductive Endocrinology; Depo: Jeanne Durocher 6/30/06 EX022: Reproductive Nedocrinology Phase IV, Distribution List			
01321	DUROJ029-000202	DUROJ029-000202	12/1/1988	Public Relations FDA Policy			
01322	CONNS014-001601	CONNS014-001601	11/14/1988	FDA Ad Chief: Most Product-Related PR can be Regulated as Promotion			
01323	CONNS014-001602	CONNS014-001605	11/10/1988	Pharmaceutical Marketing Symposium			
01324	CONNS008-000585	CONNS008-000585	10/28/1988	Premarin DTC Advertising FDA Meeting			
01325	CONNS008-000586	CONNS008-000588	10/27/1988	FDA Meeting - 10/26/88 Premarin DTC Advertising			
01326	DUROJ032-001243	DUROJ032-001243	9/21/1988	Single Sponsored Publications; Depo: Jeanne Durocher 6/30/06 EX020: Internal Correspondence Rachelli from Those listed			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01327	CONNS008-000608	CONNS008-000609	9/15/1988	Dickinson's FDA			
01328	PANAA035-002045	PANAA035-002047	7/25/1990	Letter from Robert Kreisberg to Dr. Dan Prince			
01329	CONTA013-000914	CONTA013-000915		Womens HOPE Clinical Trial Publications: Initial 2nd Year Papers			
01330	W-MDL04782-00050731	W-MDL04782-00050732	6/19/1978	Ayerst Committee on Premarin and Breast Cancer			
01331	PICKJ009-001744	PICKJ009-001745		Breast Cancer Risk Factors in Postmenopausal Women			
01332	VICTJ001-001843	VICTJ001-001848	8/12/1998	Meeting Report FDA/Wyeth Ayerst Meeting on the Heart and Estrogen / Progestin Replacement Study (HERS)			
01333	VICTJ001-001775	VICTJ001-001780		HERS, HERS II Top-Line Summary			
01334	PANAA036-002744	PANAA036-002746	3/8/1993	Seasons Reports/Tracking			
01335	PANAA013-000593	PANAA013-000594	3/21/2001	FDA Telephone Contact NDA No. 20-527/S-017			
01336	PANAA226-003649	PANAA226-003650	8/14/2003	Telephone Contact Report between Joseph Sonk and FDA			
01337	CONTA211-000334	CONTA211-000336	7/00/2002	Premarin/Trimegestone Publication Plan Communication Messages			
01338	CONTA207-000205	CONTA207-000205		Loyalists Hope the Problem is not MPA			
01339	HRT MED LIT 2343001	HRT MED LIT 2343016	7/00/1987	British Journal of Obstetrics and Gynecology (July 1987, Vol. 94, pp. 620-635			
01340	CONNS008-000137	CONNS008-000190	9/13/1988	Premarin Presentation			
01341	DUROJ032-001242	DUROJ032-001242	9/13/1988	Premarin: Single Sponsored Publications; Depo: Jeanne Durocher 6/30/06 EX019: Internal Correspondence to Rachelli from Hurley			
01342	PICKJ011-002937	PICKJ011-002937	4/16/1988	Correspondence to E. Lewis, M.D. (7/25/88)			
01343	CONNS014-001627	CONNS014-001627	8/30/1988	Finance Committee Authorization			
01344	W-MDL04782-00014871	W-MDL04782-00014872	4/12/1988	Letter from Robert Lindsay to Dr. Hurley			
01345	PANAA026-001691	PANAA026-001692		After Menopause: Does Estrogen Protect Against Heart Disease?			
01346	PICKJ009-001581	PICKJ009-001582	11/10/1987	Premarin/Medroxyprogesterone			
01347	GPIL002-001964	GPIL002-001966	9/25/1987	Hormone Replacement: Gynecologists Consider the Heart of the Matter			
01348	W-MDL04782-00050881	W-MDL04782-00050881	11/30/1978	Dr. Robert Hoover's Report to the WHO - 11001978 Estrogens and Cancer			
01349	W-MDL04782-00050725	W-MDL04782-00050726	11/28/1978	Premarin			
01350	W-MDL04782-00057748	W-MDL04782-00057748	9/00/1978	Dear Doctor Letter signed by Dr. George Brice			
01351	W-MDL04782-00050733	W-MDL04782-00050734	6/1/1978	Ayerst Committee on PREMARIN and BREAST Cancer			
01352	W-MDL04782-00060188	W-MDL04782-00060189	8/23/1979	SAMPLE SIZE DETERMINATION ON THE PROPOSED PREMARIN - PROGESTIN STUDIES			
01353	W-MDL04782-00050673	W-MDL04782-00050673	7/9/1979	Estrogen / Breast Cancer Committee Meeting			
01354	W-MDL04782-00051276	W-MDL04782-00051276	6/19/1979	Review of Estrogens and Breast Cancer Literature Draft of Manuscript by Drs. Feinstein and Horwitz - Yale.			
01355	W-MDL04782-00050709	W-MDL04782-00050710	2/21/1979	Letter from Don Austin, M.D. to James Lamb, M.D.			
01356	W-MCL019-01256	W-MCL019-01265	9/28/1983	Do Hormones Cause Breast Cancer?			
01357	YAVUE010-000460	YAVUE010-000468	11/00/1983	Treating Menopausal Symptoms- Important New Findings			
01358	W-MDL04782-00032406	W-MDL04782-00032406	3/12/1980	Letter from Layman Gray, M.D. to John Jewell, M.D.			
01359	W-MDL04782-00032157	W-MDL04782-00032158	3/12/1980	Estrogen and Breast Cancer			
01360	W-MDL04782-00040820	W-MDL04782-00040828	3/00/1980	For Residents Only The Physiology of the Menopause: Implications for Therapy			
01361	SONKJ210-000225	SONKJ210-000225	8/8/1997	Submission to FDA on the Premarin Labeling of Cardiovascular Benefit of ERT			
01362	STRIS206-005131	STRIS206-005132	2/2/2004	Date			
01363	STRIS206-001809	STRIS206-001809	6/8/2003	Re: Prempro Video Receptionist			
01364	DUROJ010-000934	DUROJ010-000981		Alzheimer's Disease Research Possible Causes Potential Treatment; Depo: Jeanne Durocher 6/30/06 EX001: Alzheimer's Disease Research			
01365	W-MDL04782-00128934	W-MDL04782-00128937	7/6/2000	Inadequacy Letter; Depo: DelConte, Anthony 1/19/2006 EX 004: Inadequacy Letter			
01366	CONSG006-000200	CONSG006-000203	10/9/1998	Premarin Osteoporosis Indication Chronology - Major Events			
01367	DUROJ013-000412	DUROJ013-000412		Premarin Treatment of Osteoporosis			
01368	DUROJ013-000872	DUROJ013-000875	10/22/1997	Meeting Minutes			
01369	LYTTR016-013385	LYTTR016-013410		WHC Portfolio Optimization Process			
01370	LYTTR016-012581	LYTTR016-012581	3/10/1999	Talking Points for meeting between Wyeth and Lilly			
01371	STRIS206-007529	STRIS206-007530	5/12/2004	Re: Urgent need for menopause info			
01372	STRIS206-002540	STRIS206-002551		AREA 24			
01373	STRIS205-053435	STRIS205-053467	3/00/2003	Return on Investment powerpoint			
01374	STRIS205-052559	STRIS205-052559		Document re: WHI questions			
01375	STRIS205-052560	STRIS205-052560		Powerpoint Slide			
01376	STRIS206-000661	STRIS206-000664	11/14/2002	1			
01377	STRIS206-000660	STRIS206-000660	1/28/2003	Pubs list			
01378	STRIS205-008447	STRIS205-008458	6/5/2003	draft speech to sales reps for a low dose launch			
01379	STRIS205-008403	STRIS205-008446		2003 POA			
01380	STRIS202-000849	STRIS202-000857		Administrative Policy 405			
01381	STRIS205-001870	STRIS205-001906	9/22/2003	analysis of persistency amongst ERT/HRT patients post-WHI			
01382	CHOOM044-000006	CHOOM044-000017	11/12/1996	Assessment of the Impact of New Horizons on Hormone Replacement Therapy Patient Compliance Outcomes Research			
01383	CONKJ228-000590	CONKJ228-000594	9/22/2003	Simulation #2 - Draft			
01384	LOJEL038-001443	LOJEL038-001456		Bob Essner draft speech for Prempro launch; Depo: Robert Essner 6/29/06 EX 035: 4/2 new version speech notes			
01385	LOJEL038-001457	LOJEL038-001463		Bob Essner's closing speech from Prempro launch meeting			
01386	CHOOM024-000040	CHOOM024-000040	5/8/1998	Check Number 00580419			
01387	CHOOM024-000039	CHOOM024-000039	5/14/1998	Check for the Balance of the Unrestricted Educational Grant for the Association's "Women and Alzheimer's Disease" Campaign			
01388	CHOOM024-000347	CHOOM024-000349	1/12/1998	National Corporate Sponsorship Proposal			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01389	CHOOM029-000812	CHOOM029-000812		Women's Health Campaign Unrestricted Grant Designation			
01390	CHOOM029-000800	CHOOM029-000800	6/23/1999	Wyeth Ayerst's Check in the Amount of \$12,500 for Support of the Alzheimer's Association's 15th Annual Rita Hayworth Gala			
01391	CHOOM029-000801	CHOOM029-000801	5/24/1999	Use of Ketchum Public Relations Inkkind Services to the Association			
01392	CHOOM029-000802	CHOOM029-000802	5/18/1999	Support of the Women and Alzheimer's Disease Campaign			
01393	CHOOM029-000803	CHOOM029-000803	5/11/1999	Wyeth-Ayerst's Check 5038437 Represents an Unrestricted Educational Grant to the Alzheimer's Association in Support of the Women's Health Campaign			
01394	CHOOM029-000804	CHOOM029-000804	5/4/1999	Check No. 5038437			
01395	CHOOM029-000811	CHOOM029-000811	4/12/1999	Brief Summary of how we Proposed the \$2 Million Unrestricted Grant			
01396	CHOOM034-000205	CHOOM034-000212	1/20/1998	Alzheimer's Association/Wyeth-Ayerst Laboratories Agreement			
01397	CHOOM034-000364	CHOOM034-000365		National Corporate Sponsorship Proposal			
01398	CHOOM034-000358	CHOOM034-000361		Proposal to Continue the Alzheimer's Association Scientific Poster Session			
01399	CHOOM019-000575	CHOOM019-000575	2/20/1997	Request for educational grant from Wyeth-Ayerst			
01400	CHOOM019-000572	CHOOM019-000572	4/8/1997	Promotion Material Request / Assignment Number 41900			
01401	CHOOM019-000573	CHOOM019-000573	4/23/1997	Check Number 00420191			
01402	CHOOM019-000576	CHOOM019-000577	2/27/1997	Finance Committee Authorization 2-Year Unrestricted Educational Grant to AHA			
01403	CHOOM019-000595	CHOOM019-000595	9/18/1997	Check Number 00475130			
01404	CHOOM024-000003	CHOOM024-000003	7/17/1998	Second installment in the Amount of \$500,000 for Wyeth's Commitment to the Women and Heart Disease Campaign			
01405	CHOOM029-000873	CHOOM029-000873	7/30/1999	Check No. 5067384			
01406	CHOOM029-000876	CHOOM029-000876	6/9/1999	Wyeth-Ayerst Laboratories' Check 5047576 Represents the First Payment of an Unrestricted Educational Grant to Support the American Heart Association's Women and Heart Disease and Stroke Campaign			
01407	CHOOM029-000877	CHOOM029-000877	6/2/1999	Check No. 5047576			
01408	CHOOM029-000883	CHOOM029-000883	1/5/1999	Requests an Educational Grant from Wyeth-Ayerst Laboratories, Inc.			
01409	CHOOM029-000872	CHOOM029-000872	8/11/1999	Wyeth-Ayerst Laboratories' Check 5067384 Represents the Final Payment of an Unrestricted Educational Grant to Support the American Heart Association's Women and Heart Disease and Stroke Campaign			
01410	CHOOM033-001464	CHOOM033-001464	7/12/1996	American Heart Association (AHA) Brochure			
01411	CHOOM047-000193	CHOOM047-000193	9/9/1999	Requests a One-Year Educational Grant from Wyeth-Ayerst Laboratories, Inc.			
01412	CHOOM024-000411	CHOOM024-000412	3/25/1998	Update Memo			
01413	CHOOM024-000066	CHOOM024-000066	1/6/1998	Promotion Material Request / Assignment No. 32285			
01414	CHOOM024-000067	CHOOM024-000067	1/9/1998	Check Number 00526887			
01415	CHOOM024-000068	CHOOM024-000068	1/6/1998	Promotion Material Request / Assignment No. 32286			
01416	CHOOM024-000410	CHOOM024-000410	2/20/1998	Exclusive Sponsorship of NAMS Web Site in 1998			
01417	CHOOM067-000013	CHOOM067-000013	3/4/1998	Commitment to Provide a \$40,000 Grant to be the Exclusive Sponsor of the 1998 NAMS WebSite			
01418	CHOOM024-000351	CHOOM024-000351	10/28/1997	ACOG Newsletter Level of Sponsorship will Increase to \$20,000 per Issue Agreement			
01419	CHOOM027-000086	CHOOM027-000086		Finance Committee Authorization 1999 A.C.O.G. Annual Meeting			
01420	CHOOM033-001609	CHOOM033-001611		Wyeth-Ayerst Sponsored Research Awards, Grants & Fellowships			
01421	CHOOM044-000855	CHOOM044-000855	10/16/1998	Memo re ACOG Newsletter			
01422	MARRA209-020940	MARRA209-020942	7/14/2003	Re: Fwd: promotional aid for Premelle			
01423	SENDM015-020338	SENDM015-020339	5/8/2000	regarding the efficacy of the Wyeth-Ayerst products Premarin (conjugated estrogens tablets, USP), Prempro , and Premphase (conjugated estrogens/medroxyprogesterone acetate [MPA] tablets) compared to that of Fosamax (alendronate sodium, Merck & Co			
01424	LOJEL202-000226	LOJEL202-000228		Handwritten notes from Wyeth meeting-Ideas in the Workplace			
01425	SONKJ205-000463	SONKJ205-000469	5/1/1976	Treatment of the Menopause II the Anti-Osteoporosis Dose of Premarin			
01426	SONKJ205-000141	SONKJ205-000143	11/11/1981	NDA 4782 Premarin Tablets Memorandum of Meeting			
01427	CONTA213-028274	CONTA213-028274	1/8/2004	Thailand Wyeth Symposium with Wulf utian			
01428	PANAA025-001466	PANAA025-001467	8/1/1989	NEJM Study			
01429	COBBP002-000156	COBBP002-000159	3/16/1992	Premarin			
01430	CHOOM019-000466	CHOOM019-000467	9/10/1996	Finance Committee Authorization Resident Reporter Program;			
01431	SINAM009-000224	SINAM009-000229	1/12/1993	Carrie Smith Cox -- Premarin RM/DM Speech			
01432	SINAM009-000223	SINAM009-000223		FYI Copy of my script for RM/DM Meeting			
01433	CONN5010-001551	CONN5010-001551	8/5/1994	Premarin Labeling: 1992 FDA Estrogen Labeling Guidance			
01434	ESSNR001-000630	ESSNR001-000631	10/24/1994	Premarin Tablets Adoption of 1992 Estrogen Labeling Guidance			
01435	ESSNR001-000632	ESSNR001-000634	8/4/1994	1992 Estrogen Labeling Guidance Major Labeling Changes			
01436	VICTJ005-001358	VICTJ005-001359	11/8/1994	Premarin - Direction Circular Revision			
01437	VICTJ005-001356	VICTJ005-001357	11/11/1994	Premarin Labeling			
01440	PANAA031-001816	PANAA031-001842	6/23/1992	Partners in Prevention Information Kit			
01441	PANAA031-002200	PANAA031-002200	7/5/1996	Letter from National Osteoporosis foundation to Jeffrey Buchhalter			
01442	PANAA031-001816	PANAA031-001842	6/23/1992	Partners in Prevention Information Kit			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01443	SOLOJ022-000967	SOLOJ022-000983	1/24/1997	Working Toward a Partnership; Depo: Solomon, Jeffrey 1/26/2006 EX 010; AHA proposal to Wyeth			
01444	HENRL025-000847	HENRL025-000847		Budget Explanation			
01445	HENRL025-000649	HENRL025-000650		1999 Premarin Public Relations Budget Outline			
01446	HENRL001-000305	HENRL001-000311	2/8/1999	Premarin Oral 1998 Marketing Spend Reconciliation			
01447	JANEC010-000213	JANEC010-000231		Wyeth-AHA partnership launched Sept 1997			
01448	FARAN024-018459	FARAN024-018585	8/22/1997	Powerpoint slides "Premarin Pre-emptive Plan"			
01449	PAYNC201-000002	PAYNC201-000003	7/31/2000	Letter from Carl Whatley to Wyeth			
01450	PAYNC201-000004	PAYNC201-000006	7/27/2000	Letter from Cynthia Waldrup to Wyeth			
01451	PAYNC201-000009	PAYNC201-000018	1/12/1999	Letter from Charles Payne to Wyeth			
01452	PAYNC201-000001	PAYNC201-000001	3/31/2005	Letter from Charles Payne's attorney to Wyeth's attorney			
01453	DEMAE023-007243	DEMAE023-007244	4/24/2000	Prempro financial authorization			
01454	XUESO008-014857	XUESO008-014857	11/1/2002	Re: WHI, Q3, breast cancer			
01455	XUESO008-004347	XUESO008-004360	10/1/2002	Risk Management Plan for Prempro?			
01456	XUESO008-003092	XUESO008-003147		Presentation Name			
01457	XUESO008-002334	XUESO008-002337	7/25/2002	Letter from FDA to Jennifer Norman, Wyeth			
01458	XUESO008-002332	XUESO008-002332	8/14/2002	FDA requested Risk Benefit Analysis			
01459	XUESO008-002306	XUESO008-002331	8/14/2002	RISK MANAGEMENT			
01460	XUESO008-002194	XUESO008-002198	7/00/2002	Pharmaceutical Executive article "The New Era of Risk Management"			
01461	XUESO008-001614	XUESO008-001614		Email regarding thoughts from Bruce Burlington			
01462	XUESO008-001613	XUESO008-001613	7/24/2002	Risk Management for Prempro			
01463	XUESO008-001143	XUESO008-001143	6/24/2002	The UCSF Press release			
01464	XUESO008-001144	XUESO008-001146	6/19/2002	UCSF Press Release "Longer Use of Hormones Fails to Prevent Heart Attacks in Postmenopausal Women"			
01465	XUESO007-001497	XUESO007-001498		Epidemiology Highlights August 2001			
01466	XUESO007-000524	XUESO007-000526		Additional Analyses of WHI Data			
01467	XUESO002-001953	XUESO002-001989		WHI: E + P Trial Cardiovascular Findings			
01468	CONSG005-001182	CONSG005-001183	7/1/2002	Early Stopping of WHI Trial of Estrogen Plus Progestin			
01469	DUROJ046-023746	DUROJ046-023746	11/2/2001	HERS Symptom Paper; Depo: Jeanne Durocher 6/30/06 EX034: Email			
01470	VICTJ001-001775	VICTJ001-001780		HERS, HERS II Top-Line Summary			
01471	ZUCAV207-000425	ZUCAV207-000427		Breast Mass			
01472	ZUCAV217-007842	ZUCAV217-007842	10/26/2000	Fwd: HRT not to be based on cardiovascular benefits			
01473	ZUCAV217-026652	ZUCAV217-026680		FDA Letter to Joseph Sonk			
01474	ZUCAV217-026374	ZUCAV217-026415	1/7/2003	08Jan2003.PDF			
01475	ZUCAV217-026596	ZUCAV217-026619	1/8/2003	FDA letter to Wyeth			
01476	DEVAN205-021493	DEVAN205-021494	2/28/2003	Email regarding list of experts re WHI			
01477	DEVAN205-020139	DEVAN205-020139	3/19/2003	Emails regarding ductal v. lobular breast cancer			
01478	DEVAN205-020148	DEVAN205-020148	3/19/2003				
01479	DEVAN209-000771	DEVAN209-000772		Press Release "ERT Affirmed as a 1st Line Therapy for Osteoporosis"			
01480	SENDM201-000210	SENDM201-000210		Prempro or Premphase and Indemnification			
01481	SENDM203-001348	SENDM203-001348	2/12/2004	Disease State Background:			
01482	SENDM203-001360	SENDM203-001360		Disease State Background:			
01483	SENDM204-001006	SENDM204-001007	8/18/2004	Question Related to Data on Premarin Effect on BMD			
01484	SENDM205-000236	SENDM205-000259		Training document			
01485	SENDM213-007785	SENDM213-007786		Efficacy versus Fosamax for the Prevention of Osteoporosis			
01486	SENDM213-011880	SENDM213-011880	5/4/2002	Re: HERS II			
01487	SENDM213-011881	SENDM213-011915	3/18/2002	Effects of Hormone Therapy on Coronary Outcomes at 6 Years of Follow-up:			
01488	SENDM213-011916	SENDM213-011949	3/15/2002	Effects of Hormone Therapy on Coronary Outcomes at 6 Years of Follow-up:			
01489	SENDM209-001811	SENDM209-001811	1/14/2003	Stat Question (MSL)			
01490	SEIFD024-005588	SEIFD024-005589	6/3/2004	Fwd: ABC Network Clearance			
01491	BROWS001-015063	BROWS001-015064	9/9/2002	Email re BZA in Japan			
01492	OLIVS206-000993	OLIVS206-000997	2/16/2000	Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen versus Estrogen Plus Progestin			
01493	OLIVS206-000133	OLIVS206-000133		Studies Reporting Estimated Risk of Breast Cancer Associated with ERT/HRT			
01494	OLIVS206-000134	OLIVS206-000135	2/25/2000	Attached Working Group on Breast Cancer Publicity Letter to Physicians, Question and Answer Card to Address Patients' Concerns and Message Reinforcement Card for the Sales Force			
01495	VICTJ005-001704	VICTJ005-001704	2/2/1990	2/1 Advisory Committee Meeting; Depo: DeConte, Anthony 1/19/2006 EX 002; Fred Hassan 12/16/06 DEPO EX 010: Memo			
01496	W-MDL04782-00060681	W-MDL04782-00060682	00/00/1992	COUNSELING FOR THE MENOPAUSAL WOMAN PREMARIN Women's Health Program. Nothing else is PREMARIN (conjugated estrogens tablets) 0.625 mg			
01497	PANAA036-002539	PANAA036-002541		Here's the Issue of Seasons Magazine you Requested.			
01498	CONNS006-000009	CONNS006-000138		PREMARIN: Medical Information & Sales Training Program. Ayerst PREMARIN (conjugated estrogens tablets, USP)			
01499	W-MDL04782-00060322	W-MDL04782-00060324		Menopause is the reason most women start on PREMARIN (conjugated estrogens tablets, USP) Ask your doctor if osteoporosis is a reason to stay on it.			
01500	PANAA027-001024	PANAA027-001025		Wyeth-Ayerst: A Leader in Women's Health Care			
01501	PANAA036-002713	PANAA036-002740		For the Best Times of a Woman's Life. Seasons			
01502	W-MDL04782-00003131	W-MDL04782-00003144		PREMARIN QUALITY, COMMITMENT & CARING FINAL VERSION			
01503	DUROJ034-000995	DUROJ034-001000	1/9/1995	Premarin Pharmacist Announcement Letter AYP109X95; Depo: Jeanne Durocher 6/30/06 EX023: Letter Pharmacist Announcement Letter			
01504	BURRG005-001030	BURRG005-001036		Backgrounder to the media			
01505	HENRL014-000052	HENRL014-000058	2/00/1996	Understanding Hormone Replacement Therapy			
01506	BURRG005-000734	BURRG005-000736		Press release			
01507	LYTTR016-016391	LYTTR016-016392	11/1/1999	Re: IMS meeting in Yokohama			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01508	WEBEM015-006728	WEBEM015-006762		Powerpoint slides "Perspectives in ERT/HRT - Key Findings and Actions"			
01509	STRIS016-071463	STRIS016-071542	8/24/2000	Establishing Premia as Today's Optimal HRT - Draft Educational Marketing Plan			
01510	STRIS016-047196	STRIS016-047196		Memo to Women's Health Care Sales Management Team			
01511	FARAN024-083801	FARAN024-083801		Women's Thoughts on Breast Cancer			
01512	PARKA005-000591	PARKA005-000593	1/00/2000	Cardiovascular Disease Heart to Heart			
01513	WEBEM015-004927	WEBEM015-004927	5/17/2000	Wyeth Women's Health Care			
01514	CONTA025-031724	CONTA025-031727		MEDIA CONTACT:			
01515	PINIM023-028243	PINIM023-028295	5/29/2001	Premarin and Prempro			
01516				USE TRIAL EX 1516A, 1516B and 1516C			
01516A	SOLOJ027-037445	SOLOJ027-037450		Emails between Michael Gast and Pamela Highfill			
01516B	GASTM011-002277	GASTM011-002278	4/7/2002	Emails between Michael Gast and Pamela Highfill			
01516C	MARTN010-016954		7/23/2002	Emails between Michael Gast and Pamela Highfill			
01517	SOLOJ027-037445	SOLOJ027-037450		Introduction:			
01518	GASTM011-002277	GASTM011-002278	4/7/2002	Re: April 10-12 Illinois itinerary			
01519	MARTN010-016954	MARTN010-016954	7/23/2002	Message to Mike Dey, Ph.D., President, Women's Health Care			
01520	DUROJ046-006314	DUROJ046-006319	3/11/2003	IMMEDIATE RELEASE; Depo: Jeanne Durocher 6/30/06 EX033: Wyeth News Release			
01521	DEYMI206-002044	DEYMI206-002044	1/20/2003	Draft Memo to Wyeth Employees			
01522	DUROJ212-004368	DUROJ212-004375		Press release			
01523	CONSG204-023921	CONSG204-023923	7/23/2004	Your paper SRAM 54 submitted to Sexuality, Reproduction & Menopause			
01524	PANAA226-001865	PANAA226-001914		US Marketing Accruals			
01525	COBBP024-000570	COBBP024-000577	1/15/2002	Vasomotor Symptoms			
01526	COBBP026-003094	COBBP026-003144	10/16/2002	Presentation Name			
01527	CONSG015-005462	CONSG015-005471	9/16/2002	Menopausal Symptoms			
01528	PESKM002-000346	PESKM002-000414	00/00/1997	Wyeth-Ayerst Style Manual Guidelines for Preparing Promotional Materials 2nd Edition			
01529	DUROJ029-000211	DUROJ029-000284	12/31/1987	American Home Products; Depo: Jeanne Durocher 6/30/06 EX008: American Home Products, Basic Data 1987			
01530	BURKM001-000817	BURKM001-000840	3/21/2001	Premarin Intravenous (Conjugated Estrogens, USP) for Injection			
01531	DEVAN001-000479	DEVAN001-000481		Q&A on National Institute on Aging Alzheimer's Disease Cooperative Study			
01532	DUROJ012-001109	DUROJ012-001111		Premarin Studies Summary Epidemiological Program; Depo: Jeanne Durocher 6/30/06 EX002: Epidemiological Studies			
01533	JANEC011-004011	JANEC011-004024	8/1/2002	PROPOSED SATELLITE VIDEOCONFERENCE ENTITLED:			
01534	MAHAJ005-000826	MAHAJ005-000922	11/11/2002	Wyeth North America Organizational Charts			
01535	PINIM023-014503	PINIM023-014589	10/11/2002	PowerPoint Presentation			
01536	ROSSC006-001403	ROSSC006-001409	3/10/1995	NDA 20-303 Prempro / Premphase MACMIS ID 2820			
01537	ROSSC034-000798	ROSSC034-000802	1/11/1999	NDA 4-782 Premarin (Conjugated Estrogens Tablets, USP) MACMIS 7000;			
01538	SOLOJ008-000075	SOLOJ008-000154		Risk Management Communication Program			
01539	SOLOJ022-001024	SOLOJ022-001024		Abstract Form Women with Vertebral Fractures have a very Low Risk of Breast Cancer. Unless they Take Estrogen. A Prospective Study.			
01540	STEPW014-008246	STEPW014-008250	8/30/2002	Letter from Wyeth to FDA			
01541	STEPW014-008509	STEPW014-008512	9/23/2002	21-Sep-02			
01542	W-MDL04782-00026232	W-MDL04782-00026243	2/00/1990	LABELING GUIDANCE FOR ESTROGEN DRUG PRODUCTS PHYSICIAN LABELING			
01543	W-MDL04782-00026244	W-MDL04782-00026250	2/00/1990	LABELING GUIDANCE FOR ESTROGEN DRUG PRODUCTS PATIENT PACKAGE INSERT			
01544	XUESO007-002010	XUESO007-002041		Global Safety Surveillance and Epidemiology (GSSE): Successful Transformation			
01545	XUESO008-003745	XUESO008-003746	9/11/2002	RE: WHI follow up			
01546	KUSIV205-001938	KUSIV205-001944		Questions and Answers Media Relations Responses			
01547	see 05863			Doctors have Made Premarin (Conjugated Estrogens Tablets, USP) the most Prescribed Estrogen for Menopause and Osteoporosis			
01548	SENDM213-014477	SENDM213-014486	7/8/2002	Questions and Answers (as of Tuesday 1:30)			
01549	VICTJ001-000126	VICTJ001-000128		PBS Answers			
01550	JANEC004-000597			Sales Force Voice Mail JAMA "Hormone Replacement Therapy in Relation to Breast Cancer"			
01552	CONTA021-000564	CONTA021-000566	2/6/1995	Amendment VIII HERS Heart and Estrogen-Progestin Replacement Study			
01553	DUROJ042-001548	DUROJ042-001619	3/12/1998	The U.S. Market: A Case Study in the Success of Changing the HRT Paradigm; Depo: Jeanne Durocher 6/30/06 EX030: The U.S. market: A Case Study on the Success of Changing the HRT Paradigm			
01554	CONNS005-000865	CONNS005-000942		Re: Fwd: Women's Health Ongoing Projects: WLJ/Tokyo, June 02			
01555	VICTJ001-001148		5/2/2002	Packet			
01557	W-MDL04782-00051317	W-MDL04782-00051320		Contract No. No 1 CP 61057 BREAST CANCER RISK AMONG ESTROGEN USERS			
01558			00/00/2003	2003 Annual Report			
01559			00/00/2004	2004 Annual Report			
01560	CONKJ017-058276		6/27/2002	We have not received any notification about the status of the Women's Health Initiative (WHI) study from either the National I			
01561	SINAM205-000435		3/26/2004	USMT Follow-up			
01562	see 07383			DDMAC letters			
01563	PANAA015-000948	PANAA015-000950	4/22/1993	Merchandising the Understanding Menopause Program			
01564	DUROJ046-024072	DUROJ046-024086		Premarin Family Trx Trends			
01565	CONNS005-000865	CONNS005-000942		Premarin 1993 Market Plan			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01566	SOLOJ007-000053	SOLOJ007-000064	7/11/2001	Premarin Studies Summary. Additional Estrogen Benefits			
01567	GPIL009-001533	GPIL009-001534	7/17/1989	Premarin Advocate Meeting			
01568	PANAA025-001447	PANAA025-001448	8/2/1989	From Ron Ross to Wyeth			
01569	GPIL018-000067	GPIL018-000071	7/15/1991	MPA Dosage Regimens in Conjunction with CEE			
01570	W-MDL303-00000752	W-MDL303-00000970		New Drug Application (NDA 20-303); Volume 1.5 of 1.174			
01571	CONNS005-000865	CONNS005-000942		Premarin 1993 Market Plan			
01572	PANAA037-000103	PANAA037-000105	1/10/1994	Letter from NOF			
01573	PICKJ021-002474	PICKJ021-002475	1/23/1995	Womens Health Initiative (WHI) Update PEPI Influence			
01574	VICTJ006-001002	VICTJ006-001002	1/24/1995	Project Team Meeting			
01575	PANAA027-000945	PANAA027-000947	2/9/1995	Prempro VIPP Planning Meeting			
01576	PICKJ007-000270	PICKJ007-000272	2/14/1995	Breast Cancer Labeling Prempro/Premphase			
01577	PANAA033-000063	PANAA033-000080	3/16/1995	"SGI 3/16/95 Speroff & Colditz"; Speroff Transcript			
01578	PANAA033-000043	PANAA033-000062	3/16/1995	Drs. Speroff and Colditz			
01579	W-MDL04782-00002936	W-MDL04782-00002938	6/9/1995	Dear Doctor Letter			
01580	PICKJ007-001464	PICKJ007-001465	6/9/1995	Nurses' Health Study Findings Published in The New England Journal of Medicine			
01581	PICKJ007-001220	PICKJ007-001228		Nurses Health Study Breast Cancer Risk Report (Addendum to PREMPRO Mini Meeting)			
01582	PANAA025-001083	PANAA025-001083	6/15/1995	ACOG News Release			
01583	SOLOJ022-001831	SOLOJ022-001831	6/16/1995	Colditz Breast Cancer Awareness Study			
01584	STRIS004-000206	STRIS004-000207	6/19/1995	Colditz Paper			
01585	PANAA025-001122	PANAA025-001122	6/19/1995	Dr. Wile's Breast Cancer Presentation and Current Premarin Situation.			
01586	PANAA025-001027	PANAA025-001027	6/20/1995	Colditz Breast Cancer Awareness Study - Update			
01587	SOLOJ022-001780	SOLOJ022-001781	7/5/1995	Colditz Breast Cancer Report: Final Results of Patient Awareness Study			
01588	PANAA038-000319	PANAA038-000333	7/14/1995	Market Development Business Plan			
01589	PANAA016-000391	PANAA016-000396		Launch Issues/Tactics			
01590	PANAA017-000461	PANAA017-000461	10/20/1995	1996 Marketing Expense Budget Premarin Franchise			
01591	PICKJ007-001347	PICKJ007-001347	2/23/1996	Breast Cancer Working Group Meeting			
01592	DEMAE007-002654	DEMAE007-002654	2/28/1996	Third Party Support for WHI			
01593	DUROJ041-001629	DUROJ041-001630		WHC Corporate - Constituency Relations Selection Criteria for Third-Party Advocates			
01594	DUROJ005-000860	DUROJ005-000862		Wyeth-Ayerst Funds \$16 Million WHI Alzheimer's Disease Trial Studying Hormone Replacement Therapy			
01595	DUROJ037-000033	DUROJ037-000034	9/3/1996	Unbranded Candidate Strategy CV/Osteo			
01596	W-MDL04782-00106442	W-MDL04782-00106443	9/13/1996	FDA Contact Report			
01597	RHUDM007-000240	RHUDM007-000241	2/27/1997	Finance Committee Authorization 2-Year Unrestricted Educational Grant to AHA			
01598	LYTTR016-013347	LYTTR016-013378		Types of Collaborations			
01599	ZUCAV008-000062	ZUCAV008-000073	3/9/1999	TRIMEGESTONE WORKING GROUP MEETING			
01600	LYTTR015-001188	LYTTR015-001189	9/11/2002	Orlando, Fla			
01601	CORRA201-000003	CORRA201-000009	2/20/2004	Grants and Donations Policy			
01602	HUNTH012-000907	HUNTH012-000967		Preclinical Biology of Progestins			
01603	BARBM001-001442	BARBM001-001469		Preclinical Biology of Progestins			
01604	STRIS003-001239	STRIS003-001266		Preclinical Biology of Progestins			
01605	CONTA005-000453	CONTA005-000480		Preclinical Biology of Progestins			
01606	HUNTH012-000907	HUNTH012-000967		Wyeth slide show on dangers of progestins			
01607	PAYNC001-000509			Tip of iceberg marketing piece			
01609	LYTTR016-013347	LYTTR016-013378		Premarin Family Trx Trends			
01610	ESSNR001-000399	ESSNR001-000444	3/7/1997	Premarin Summit II CNS Presentation			
01611	RHUDM007-000292	RHUDM007-000295	12/2/1996	Ally List			
01650	RM_AA 0155948	RM_AA 0155950		Premarin ad			
01651	CORRA001-000204	CORRA001-000211	3/00/1995	Code of Pharm Marketing Practices			
01652	W-MCL-003-01973	W-MCL-003-01976		Panel Discussion I			
01653	PICKJ018-000054	PICKJ018-000083	12/9/1985	Clinical Summary Use of Estrogens and Calcium			
01654	CONTA025-020225	CONTA025-020226	6/6/2002	Minutes from brainstorming meeting			
01655	W-MDL04782-00059874	W-MDL04782-00059876	2/15/1984	FDA Fertility and Maternal Health Advisory Committee Memo			
01656	W-MDL04782-00021016	W-MDL04782-00021016	3/14/1978	Letter from Henry Perdue			
01657	W-IND-0000-8342	W-IND-0000-8343	8/6/1985	FDA Meeting Trip report			
01658	GPIL045-002398	GPIL045-002400	3/21/1990	Minutes of FDA Meeting			
01659	ROSSC001-000355	ROSSC001-000355	8/11/2000	Letter to Dr. Allen from Jennifer Phillips; Depo: Fontaine, Leander 5/30/06 EX 034: Letter			
01659A	ROSSC001-000356	ROSSC001-000366		FDA proposed labeling for breast cancer			
01660	PANAA023-000358	PANAA023-000358	4/18/1995	Letter from the American College of ob/gyn to Wyeth; Ralph Hale 7/25/06 DEPO EX 017: Letter			
01661	PANAA023-000360	PANAA023-000360		1996 newsletter specifications for sponsorship inserts			
01662	PANAA023-000368	PANAA023-000368	4/7/1995	Letter from Sue Leasure			
01663	CHOOM024-000351	CHOOM024-000351	10/28/1997	One page letter from Lee Gore			
01664	PANAA023-001007	PANAA023-001007	12/14/1995	Note from Jeffrey Buchalter			
01665	PANAA023-000363	PANAA023-000363	5/4/1995	One page memo from Jim Meyer			
01666	XUES0007-001595	XUES0007-001613		Application of Epidemiology to Risk Management			
01667	CONNS008-001160	CONNS008-001160	4/18/1997	Letter From Don Gambrell			
01668	HENRL001-000305	HENRL001-000311	2/8/1999	1998 Marketing Spend Reconciliation			
01669	SOLOJ022-000967	SOLOJ022-000983	1/24/1997	"Working toward a partnership"			
01670	HENRL025-000649	HENRL025-000650	3/18/1999	1999 Premarin PR Budget outline			
01671	HENRL025-000847	HENRL025-000847		Budget explanation			
01672	JANEC010-000213	JANEC010-000231		Public Affairs Women and Cardiovascular Disease			
01673	W-MDL04782-00002939	W-MDL04782-00002945		Postmenopausal HT and Breast Cancer			
01674	W-MDL04782-00012509	W-MDL04782-00012516		The estrogen deficient patient			
01675	CONTA023-002787	CONTA023-002788	2/4/2000	Breast Cancer Communication Plan Draft 2/4/00			
01676	CONNS005-000311	CONNS005-000337		Premarin historical background			
01677	FARAN005-000592	FARAN005-000595	7/22/1991	Memo re NFO consumer study			
01678	CONTA021-001661	CONTA021-001662		Update announcement to NRH Study			
01679	VICTJ001-001737	VICTJ001-001749	6/3/2002	Proposed Media Strategy HERS			
01680	PINIM002-000001	PINIM002-000044	1/10/2001	Admin Policy 405			
01681	CONTA021-001659	CONTA021-001660		Media Promotion plan for NHS study			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
01682	CONTA018-000055	CONTA018-000055	3/21/2002	HERS memo email re Gast			
01683	ESSNR001-000630	ESSNR001-000631	10/24/1994	Letter from Justin Victoria			
01684	ESSNR001-000632	ESSNR001-000634	8/4/1994	Estrogen labeling guideline			
01685	MAHAJ017-003415	MAHAJ017-003415	3/4/2004	Rhudy email re colon cancer			
01766			00/00/2007	Biology of Cancer by Robert Weinberg: Chapter 11			
03001				Depo: Ailor, Wendy 4/6/2005 EX 001: Wendy Ailor CV			
03002			2/22/2005	Depo: Ailor, Wendy 4/6/2005 EX 002: Wendy Ailor Deposition Notice			
03003	AILOW002-001874	AILOW002-001885		Depo: Ailor, Wendy 4/6/2005 EX 003			
03004	AILOW002-001700	AILOW002-001707---001755	3/24/2000	Depo: Ailor, Wendy 4/6/2005 EX 004			
03005	AILOW002-001935	AILOW002-001949	12/3/1998	Depo: Ailor, Wendy 4/6/2005 EX 005			
03006	AILOW002-001509	AILOW002-001510	2/7/2003	Depo: Ailor, Wendy 4/6/2005 EX 006			
03007	AILOW001-000012	AILOW001-000012	12/20/1996	Depo: Ailor, Wendy 4/6/2005 EX 007: Ayerst Reports			
03008	AILOW003-002255	AILOW003-002255		Depo: Ailor, Wendy 4/6/2005 EX 008: Wyeth HRT Special Issues Panel			
03009	AILOW002-001799	AILOW002-001799	12/11/1998	Depo: Ailor, Wendy 4/6/2005 EX 009			
03010	AILOW002-001647	AILOW002-001649	8/5/1999	Depo: Ailor, Wendy 4/6/2005 EX 010			
03011	AILOW003-000945	AILOW003-000945	1/31/2001	Depo: Ailor, Wendy 4/6/2005 EX 011: CLINICAL RECORDS MANAGEMENT EUROPE			
03012	AILOW003-001163	AILOW003-001164	4/17/2001	Depo: Ailor, Wendy 4/6/2005 EX 012: No Title			
03013	AILOW002-000012	AILOW002-001462---001463		Depo: Ailor, Wendy 4/6/2005 EX 013			
03014	AILOW003-000604	AILOW003-000605	11/12/1997	Depo: Ailor, Wendy 4/6/2005 EX 014			
03015	AILOW003-001842	AILOW003-001843	11/7/2001	Depo: Ailor, Wendy 4/6/2005 EX 015			
03016	AILOW002-005553	AILOW002-005554	6/3/1998	Depo: Ailor, Wendy 4/6/2005 EX 016			
03017	AILOW002-001487	AILOW002-001487	1/1/2003	Depo: Ailor, Wendy 4/6/2005 EX 017			
03018	AILOW003-001147	AILOW003-001147	4/11/2001	Depo: Ailor, Wendy 4/6/2005 EX 018: Re: Project Termination Dates			
03019	AILOW003-001181	AILOW003-001181		Depo: Ailor, Wendy 4/6/2005 EX 019: LIST OF PRODUCTIONS (COMMERCIAL DEVELOPMENT AND LEGAL)			
03020			11/16/2005	Depo: Albano , Dominic 11/22/2005 EX 001: Wyeth's Objections & Responses to Plaintiff's Second Amended Notice of Corporate Deposition of Defendant			
03021	BURLB015-000117	BURLB015-000118	8/3/1999	Depo: Albano , Dominic 11/22/2005 EX 002: No Title			
03022	KERZC009-021829	KERZC009-021830	7/8/2002	Depo: Albano , Dominic 11/22/2005 EX 003: Women s Health Leadership Team			
03023	OLIVS021-016950	OLIVS021-016954		Depo: Albano , Dominic 11/22/2005 EX 004: No Title			
03024	DUROJ020-002155	DUROJ020-002165		Depo: Albano , Dominic 11/22/2005 EX 005: Effexor vs Placebo for Treatment of Hot Flashes			
03025	WEBEM015-030986	WEBEM015-030986	11/1/2002	Depo: Albano , Dominic 11/22/2005 EX 006: Re: Effexor/ Premarin study			
03026	LYTTR015-004287	LYTTR015-004287	10/30/2002	Depo: Albano , Dominic 11/22/2005 EX 007: Re: Hot Flush Update			
03027	CONKJ017-000010	CONKJ017-000010	6/19/2002	Depo: Albano , Dominic 11/22/2005 EX 008: Switching Premarin Details to Effexor			
03028	XUESO007-001523	XUESO007-001529		Depo: Albano , Dominic 11/22/2005 EX 009: Epidemiology Highlights, March 2002			
03029	ALBAD001-000167	ALBAD001-000171	7/00/1998	Depo: Albano , Dominic 11/22/2005 EX 010			
03030	ALBAD001-000172	ALBAD001-000176	1/15/1999	Depo: Albano , Dominic 11/22/2005 EX 011			
03031			11/15/2005	Depo: Albano , Dominic 11/22/2005 EX 012: Article titled: Hot Flashes: Aetiology & Management			
03032	ALBAD001-000191	ALBAD001-000202	11/00/2002	Depo: Albano , Dominic 11/22/2005 EX 013			
03033	ALBAD001-000214	ALBAD001-000219	1/00/2005	Depo: Albano , Dominic 11/22/2005 EX 014			
03034	ALBAD001-000225	ALBAD001-000229		Depo: Albano , Dominic 11/22/2005 EX 015			
03035	ALBAD001-000224	ALBAD001-000224		Depo: Albano , Dominic 11/22/2005 EX 016			
03036			7/15/2004	Depo: Albano , Dominic 11/22/2005 EX 017: Article titled: NAMS Releases Position Statement on the Treatment of Vasomotor Symptoms Associated w/ Menopause			
03037			9/27/2005	Depo: Anderson , Garnet 10/27/2005 EX 001: Garnet Anderson Notice to Appear			
03038			10/7/2005	Depo: Anderson , Garnet 10/27/2005 EX 002: Objections to Plaintiff's Notice of 30(b)(6) Depo of WHI Coordinating Center by Videotape			
03039			9/20/2005	Depo: Anderson , Garnet 10/27/2005 EX 003: Videotaped depo of James J. Pickar MD FACOG			
03040	FHCRC-009209	FHCRC-009240		Depo: Anderson , Garnet 10/27/2005 EX 004			
03041			10/7/2003	Depo: Anderson , Garnet 10/27/2005 EX 005: Slide Presentation titled: Part I: Statistical issues in WHI Part II: Further analyses of prior hormone therapy on breast cancer The WHI Estrogen + Progestin Trial			
03042				Depo: Anderson , Garnet 10/27/2005 EX 006: Chart (?)			
03043				Depo: Anderson , Garnet 10/27/2005 EX 007: Production Log			
03044				Depo: Anderson , Garnet 10/27/2005 EX 008: WHI Core Studies			
03045			1/7/2003	Depo: Anderson , Garnet 10/27/2005 EX 009: Email from Wendy Stephenson to Garnet Anderson re: WHI Data			
03046			3/19/2003	Depo: Anderson , Garnet 10/27/2005 EX 010: Email from Songlin Xue to Garnet Anderson re: Additional subgroup analysis of the WHI Data			
03048	BRADK008-008960	BRADK008-008963	2/4/2003	Depo: Anderson , Garnet 10/27/2005 EX 012: RE: Another Tele Con on WHI Study and Data			
03049	CONKJ020-085050	CONKJ020-085050		Depo: Anderson , Garnet 10/27/2005 EX 017: No Title			
03050	DEMAE007-000666	DEMAE007-000666	7/11/2000	Depo: Anderson , Garnet 10/27/2005 EX 026: Copy of the Last Semi-Annual Progress Report of the Women's Health Initiative			
03051	DUROJ046-000030	DUROJ046-000031	9/11/2002	Depo: Anderson , Garnet 10/27/2005 EX 033: RE: WHI follow up			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03052	DUROJ046-001581	DUROJ046-001582	10/4/2002	Depo: Anderson , Garnet 10/27/2005 EX 043: RE: WHI Database			
03053	DUROJ046-001963	DUROJ046-001963	10/10/2002	Depo: Anderson , Garnet 10/27/2005 EX 044: Re: Dr Garnet Anderson			
03054	DUROJ046-006684	DUROJ046-006684	3/25/2003	Depo: Anderson , Garnet 10/27/2005 EX 057: Fracture Risk Manuscript			
03055	KUSIV009-009291	KUSIV009-009291	11/15/2002	Depo: Anderson , Garnet 10/27/2005 EX 066: HT Advisory Board			
03056	LEVIG002-009153	LEVIG002-009157	7/7/2004	Depo: Anderson , Garnet 10/27/2005 EX 067: No Title			
03057	RUFFR003-002346	RUFFR003-002347	10/9/2002	Depo: Anderson , Garnet 10/27/2005 EX 071: RE: WHI Database			
03058	STEPW014-015928	STEPW014-015928	10/9/2002	Depo: Anderson , Garnet 10/27/2005 EX 073: Re: Update on the WHI data analysis project			
03059			10/15/2003	Depo: Anderson , Garnet 10/27/2005 EX 076: Email from Songlin Xue re: Communication on some minor typographic errors in the WHI fracture paper			
03060			9/9/2004	Depo: Anderson , Garnet 10/27/2005 EX 077: WHI Extension Study Protocol Outline			
03061			7/15/2003	Depo: Anderson , Garnet 10/27/2005 EX 078: Form 130 - Cancer Surveillance Form Ver. 3			
03062			7/1/1997	Depo: Anderson , Garnet 10/27/2005 EX 079: Form 100 - Blood Collecting & Processing Ver. 1.5			
03063			1/7/2003	Depo: Anderson , Garnet 10/27/2005 EX 080: WHI Section 1-A1 Protocol Appendix 1, Baseline & Follow Up Variables			
03064			7/5/2000	Depo: Anderson , Garnet 10/27/2005 EX 081: Form 120 - Initial Notification of Death Ver. 4			
03065			4/15/2003	Depo: Anderson , Garnet 10/27/2005 EX 082: Form 121 - Report of Cardiovascular Outcome Ver. 6.2			
03066			8/15/2001	Depo: Anderson , Garnet 10/27/2005 EX 083: Form 122 - Report of Cancer Outcome Ver. 4.1			
03067			1/15/2001	Depo: Anderson , Garnet 10/27/2005 EX 084: Form 123 - Report of Fracture Outcome Ver. 4			
03068			9/15/1999	Depo: Anderson , Garnet 10/27/2005 EX 085: Form 124A - Report of Death (Preliminary) Ver. 4			
03069			2/14/2000	Depo: Anderson , Garnet 10/27/2005 EX 086: Form 125 - Summary of Hospitalization Diagnosis Ver. 2.3			
03070			5/15/2004	Depo: Anderson , Garnet 10/27/2005 EX 087: Form 126 - Report of Venous Thromboembolic Disease (HRT) Ver. 4.1			
03071			6/1/1995	Depo: Anderson , Garnet 10/27/2005 EX 088: Form 127 - Interim Report of Potential Outcome Ver. 1			
03072			3/15/1996	Depo: Anderson , Garnet 10/27/2005 EX 089: Form 131 - Report of Hysterectomy (HRT) Ver. 1			
03073			8/16/2002	Depo: Anderson , Garnet 10/27/2005 EX 090: Form 132 - Report of Stroke Outcome Ver. 2			
03074			10/3/2005	Depo: Anderson , Garnet 10/27/2005 EX 091: Report titled: Women's Health Initiative (WHI) Extension Study (ES) Organization & Management Handbook			
03075				Depo: Anderson , Garnet 10/27/2005 EX 092: NHLBI Limited Access Data Sets, Available for Research for Research Use, Data Elements by Study, WHI Data Release			
03076				Depo: Anderson , Garnet 10/27/2005 EX 093: Slide Presentation titled: Design of WHI			
03077				Depo: Anderson , Garnet 10/27/2005 EX 094: Slide Presentation titled: Hormone Therapy & the Risk of Dementia			
03078				Depo: Anderson , Garnet 10/27/2005 EX 095: Slide Presentation titled: Hormone Therapy & Cognitive Endpoints			
03079	HRT MED LIT 3704001	HRT MED LIT 3704013	12/20/2002	Depo: Anderson , Garnet 10/27/2005 EX: 171: Implementation of the Women's Health Initiative study design.			
03080	HRT MED LIT 3742001	HRT MED LIT 3742009	12/20/2002	Depo: Anderson , Garnet 10/27/2005 EX: 209: The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants.			
03081			4/25/2006	Depo: Anderson, Benjamin 5/6/2006 EX 001: Plaintiff's Notice of Discovery Depo of Benjamin Anderson, M.D.			
03082			2/18/2006	Depo: Anderson, Benjamin 5/6/2006 EX 002: Benjamin Anderson CV			
03083			2/18/2006	Depo: Anderson, Benjamin 5/6/2006 EX 003: Report of Benjamin Anderson, M.D.			
03084			00/00/2004	Depo: Anderson, Benjamin 5/6/2006 EX 005: Advanced Therapy of Breast Disease, Second Edition			
03085	HRT MED LIT 0047001	HRT MED LIT 0047012	7/18/2002	Depo: Anderson, Benjamin 5/6/2006 EX 007: Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Daling, JR, Malone, KE, Doody, DR, Voigt, LF, Bernstein, L, Coates, RJ, Marchbanks			
03086	HRT MED LIT 0017001	HRT MED LIT 0017004	3/19/2003	Depo: Anderson, Benjamin 5/6/2006 EX 016: Trends in incidence rates of invasive lobular and ductal breast carcinoma. Li, CI, Anderson, BO, Daling, JR, Moe, RE JAMA. 2003 Mar 19			
03087	HRT MED LIT 0046001	HRT MED LIT 0046011	00/00/2002	Depo: Anderson, Benjamin 5/6/2006 EX 017: Changing incidence of lobular carcinoma in situ of the breast. Li, CI, Anderson, BO, Daling, JR, Moe, RE Breast Cancer Res Treat. 2002 Oct			
03088	HRT MED LIT 0048001	HRT MED LIT 0048009	1/31/2000	Depo: Anderson, Benjamin 5/6/2006 EX 018: Changing incidence rate of invasive lobular breast carcinoma among older women. Li, CI, Anderson, BO, Porter, PL, Holt, SK, Daling, JR, Moe, RE Cancer. 2000 Oct 15			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03089			10/12/2001	Depo: Anderson, Benjamin 5/6/2006 EX 031: Article titled: The Relation of Reproductive Factors to Mortality from Breast Cancer			
03090			9/19/2005	Depo: Anderson, Benjamin 5/6/2006 EX 033: Letter from Kerry Kearney of ReedSmith to Benjamin Anderson re: Hormone Therapy Litigation			
03091			10/3/2005	Depo: Anderson, Benjamin 5/6/2006 EX 034: Email from Tina Walker-Young to Ben Anderson re: Chen - Pleomorphic apocrine lobular carcinoma in situ			
03092				Depo: Anderson, Benjamin 5/6/2006 EX 035: Handwritten notes			
03093			3/15/2001	Depo: Anderson, Benjamin 5/6/2006 EX 044: Article titled: 2000 Update of Recommendations for the Use of Tumor Markers in Breast & Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology			
03094			1/9/2001	Depo: Anderson, Benjamin 5/6/2006 EX 055: Article titled: Measures of Cell Turnover (Proliferation & Apoptosis) & Their Association w/ Survival in Breast Cancer			
03095			2/9/2006	Depo: Armstrong, Katrina 5/1/2006 EX 001: Report of Katrina Armstrong, M.D., M.S.C.E.			
03096			4/20/2006	Depo: Armstrong, Katrina 5/1/2006 EX 002: Supplemental Report of Katrina Armstrong, M.D., M.S.C.E.			
03097			11/00/2005	Depo: Armstrong, Katrina 5/1/2006 EX 003: Katrina Armstrong CV			
03098	PDF-PREMARIN-1995-01	PDF-PREMARIN-1995-04	00/00/1995	Depo: Armstrong, Katrina 5/1/2006 EX 004			
03099			00/00/1996	Depo: Armstrong, Katrina 5/1/2006 EX 005: 1996 Physicians' Desk Reference, Premarin Label			
03100	PDF-PREMPRO-1997-01	PDF-PREMPRO-1997-06	00/00/1997	Depo: Armstrong, Katrina 5/1/2006 EX 006			
03101			00/00/2002	Depo: Armstrong, Katrina 5/1/2006 EX 007: 2002 Physicians' Desk Reference, Premarin Label			
03102			7/15/2005	Depo: Armstrong, Katrina 5/1/2006 EX 008: Patient Info on Prempro & Premphase			
03103	HRT MED LIT 1623001	HRT MED LIT 1623005	4/6/2004	Depo: Armstrong, Katrina 5/1/2006 EX: 009: Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study.			
03104	HRT MED LIT 3253001	HRT MED LIT 3253004	00/00/2004	Depo: Armstrong, Katrina 5/1/2006 EX: 010: Published results on breast cancer and hormone replacement therapy in the Million Women Study are correct. Banks E, Beral V, Reeves G; The Million Women Study Collaborators. Climacteric. 2004 Dec;7(4):415-6;			
03105	HRT MED LIT 0110001	HRT MED LIT 0110026	00/00/1999	Depo: Armstrong, Katrina 5/1/2006 EX 011: Use of HRT and the subsequent risk of cancer. Beral V, Banks, E, Reeves, G, Appleby, P, J Epidemiol Biostat 1999;4(3):191-215			
03106	HRT MED LIT 2394001	HRT MED LIT 2394009	4/30/2005	Depo: Armstrong, Katrina 5/1/2006 EX: 012: Endometrial cancer and hormone-replacement therapy in the Million Women Study. Beral V, Bull D, Reeves G; Million Women Study Collaborators. Lancet. 2005 Apr 30;365(9470):1543-51.			
03107	HRT MED LIT 0600001	HRT MED LIT 0600006	8/3/1989	Depo: Armstrong, Katrina 5/1/2006 EX 013: The risk of breast cancer after estrogen and estrogen-progestin replacement. Bergkvist, L, Adami, HO, Persson, I, Hoover, R, Schairer, C N Engl J Med. 1989 Aug 3;321(5):293-7			
03108			11/1/2005	Depo: Armstrong, Katrina 5/1/2006 EX 014: Research article titled: Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva & its possible relation w/ the use of hormone replacement therapy			
03109	HRT MED LIT 2486001	HRT MED LIT 2486011	6/3/2004	Depo: Armstrong, Katrina 5/1/2006 EX: 015: Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Cancer. 2004 Oct 1;10			
03110	HRT MED LIT 0053001	HRT MED LIT 0053008	2/13/2002	Depo: Armstrong, Katrina 5/1/2006 EX 016: Hormone replacement therapy in relation to breast cancer. Chen, C-L, Weiss NS, Newcomb, P, Barlow, W, White, E, JAMA 2002;287:734-741			
03111	HRT MED LIT 0002001	HRT MED LIT 0002011	6/25/2003	Depo: Armstrong, Katrina 5/1/2006 EX 017 and Miele, Lucio 03/04/2008 EX 8: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. Chlebowski, RT, Hendrix, SL, Langer, RD, Stefanick, ML, Gass			
03112	HRT MED LIT 0022001	HRT MED LIT 0022013	10/11/1997	Depo: Armstrong, Katrina 5/1/2006 EX 018: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Ho			
03113	HRT MED LIT 3446001	HRT MED LIT 3446016	9/8/2005	Depo: Armstrong, Katrina 5/1/2006 EX: 019: Breast cancer risk with postmenopausal hormonal treatment. Collins JA, Blake JM, Crosignani PG. Hum Reprod Update. 2005 Sep 8; [Epub ahead of print]			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03114	HRT MED LIT 0866001	HRT MED LIT 0866007	6/9/1999	Depo: Armstrong, Katrina 5/1/2006 EX 020: Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. Gapstur, SM, Morrow, M, Sellers, TA JAMA. 1999 Jun 9;281(22):2091-7			
03115	HRT MED LIT 0124001	HRT MED LIT 0124003	2/3/2004	Depo: Armstrong, Katrina 5/1/2006 EX 021: HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Holmberg, L, Anderson, H, Lancet 2004, 363:453-455			
03116	HRT MED LIT 1601001	HRT MED LIT 1601007	12/00/1990	Depo: Armstrong, Katrina 5/1/2006 EX: 022: Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Hunt, K, Vessey, M, McPherson, K Br J Obstet Gynaecol. 1990 Dec;97(12):1080-6			
03117	HRT MED LIT 1918001	HRT MED LIT 1918005	1/00/2005	Depo: Armstrong, Katrina 5/1/2006 EX: 023: Risk factors for estrogen receptor-positive breast cancer. Hwang ES, Chew T, Shiboski S, Farren G, Benz CC, Wrensch M Arch Surg. 2005 Jan;140(1):58-62			
03118	HRT MED LIT 0182001	HRT MED LIT 0182008	5/5/2003	Depo: Armstrong, Katrina 5/1/2006 EX 024: A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the lund area (WHILA) study (Sweden). Jernstrom, H, Bendahl, P, Lidfeldt,			
03119	HRT MED LIT 0097001	HRT MED LIT 0097009	3/25/2002	Depo: Armstrong, Katrina 5/1/2006 EX 025: Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Kirsh, V, Krieger, N Cancer Causes Control 2002;13:583-590			
03120	HRT MED LIT 2896001	HRT MED LIT 2896003	3/24/2003	Depo: Armstrong, Katrina 5/1/2006 EX: 026: Increase in lobular breast cancer incidence in Switzerland. Levi F, Te VC, Randimbison L, La Vecchia C. , Int J Cancer. 2003 Oct 20;107(1):164-5; author reply 166.			
03121	HRT MED LIT 0018001	HRT MED LIT 0018010	6/25/2003	Depo: Armstrong, Katrina 5/1/2006 EX 027: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. Li, CI, Malone, KE, Porter, PL, Weiss, NS, Tang, MT, Cushing-Haugen, KL, Daling, JR JAMA. 2003 Jun 25			
03122	HRT MED LIT 0117001	HRT MED LIT 0117007	11/30/1998	Depo: Armstrong, Katrina 5/1/2006 EX 028: Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Magnusson, C, Baron, JA, Correia, N, Bergstrom, R, Adami, H, Persson, I Int J Cancer 1999;81:339-344			
03123	HRT MED LIT 1241001	HRT MED LIT 1241005	2/9/2001	Depo: Armstrong, Katrina 5/1/2006 EX: 029: Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Manjer, J, Malina, J, Berglund, G, Bondeson, L, Garne, JP, Janzon, L Int J C			
03124	HRT MED LIT 0079001	HRT MED LIT 0079009	8/9/2003	Depo: Armstrong, Katrina 5/1/2006 EX 030: Breast Cancer and Hormone Replacement Therapy in the Million Women Study. Million Women Study Collaborators (Beral) Lancet 2003; 362:419-27			
03125	HRT MED LIT 0041001	HRT MED LIT 0041010	3/10/1995	Depo: Armstrong, Katrina 5/1/2006 EX 031: Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Newcomb, PA, Longnecker, MP, Storer, BE, Mittendorf, R, Baron, J, Clapp, RW, Bogdan, G, Willett, WC Am J Epidemiol. 1995			
03126	HRT MED LIT 1240001	HRT MED LIT 1240007	10/15/2002	Depo: Armstrong, Katrina 5/1/2006 EX: 032: Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Olsson, HL, Ingvar, C, Bladstrom, A Cancer. 2003 Mar 15;97(6):1387-92			
03127	HRT MED LIT 1833001	HRT MED LIT 1833007	3/6/2003	Depo: Armstrong, Katrina 5/1/2006 EX: 033: The characteristics of malignant breast tumors in hormone replacement therapy users versus nonusers.			
03128	HRT MED LIT 0787001	HRT MED LIT 0787005	4/23/1997	Depo: Armstrong, Katrina 5/1/2006 EX 034: Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Persson, I, Thurfjell, E, Bergstrom, R, Holmberg, L Int J Canc			
03129			4/10/2006	Depo: Armstrong, Katrina 5/1/2006 EX 035: Article titled: A Prospective Study of Female Hormone Use & Breast Cancer Among Black Women			
03130	HRT MED LIT 3025001	HRT MED LIT 3025005	4/19/2005	Depo: Armstrong, Katrina 5/1/2006 EX: 036: Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy—a prospective observational study. Stahlberg C, Lynge E, Andersen ZJ, Keiding N, Ottesen B,			
03131	HRT MED LIT 1464001	HRT MED LIT 1464007	4/8/2004	Depo: Armstrong, Katrina 5/1/2006 EX: 037: Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Stahlberg, C, Pedersen, AT, Andersen, ZJ, Keiding, N, Hundrup, YA, Obel, EB, Moller, S, Rank			
03132	HRT MED LIT 0658001	HRT MED LIT 0658007	7/12/1995	Depo: Armstrong, Katrina 5/1/2006 EX 038: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. Stanford, JL, Weiss, NS, Voigt, LF, Daling, JR, Habel, LA, Rossing, MA JAMA. 1995 Jul 12;2			

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03133	HRT MED LIT 1098001	HRT MED LIT 1098010	2/26/2004	Depo: Armstrong, Katrina 5/1/2006 EX: 039: Hormone replacement therapy in relation to breast carcinoma incidence rate ratios. Tjonneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Mellemkjaer L Cancer. 2004 Jun 1;100(11):2328-2337			
03134	HRT MED LIT 2102001	HRT MED LIT 2102008	4/20/2005	Depo: Armstrong, Katrina 5/1/2006 EX: 040: Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE J Natl Cancer Inst.			
03135	HRT MED LIT 0033001	HRT MED LIT 0033009	2/1/2002	Depo: Armstrong, Katrina 5/1/2006 EX 041: Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer. Ursini, G, Tseng, CC, Paganini-Hill, A, Enger, S, Wan, PC, Formenti, S, Pilo, MC, Ross, RK J Clin Oncol			
03136	HRT MED LIT 0454001	HRT MED LIT 0454004	12/12/2002	Depo: Armstrong, Katrina 5/1/2006 EX 042: Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Verkooijen, HM, Fioretta, G, Fioretta, G, Vlastos, G, Morabia, A, Schubert, H, Sappino, AP, Pette, MF, Schafer, P, Kurtz, J.			
03137	HRT MED LIT 2101001	HRT MED LIT 2101003	4/6/2005	Depo: Armstrong, Katrina 5/1/2006 EX: 043: Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.			
03138	HRT MED LIT 0030001	HRT MED LIT 0030014	7/17/2002	Depo: Armstrong, Katrina 5/1/2006 EX 044: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Writing Group WHI, Writing Groups for the Women's			
03139			00/00/1993	Depo: Armstrong, Katrina 5/1/2006 EX 045: 1993 Physicians' Desk Reference, Premarin Label			
03140			00/00/1994	Depo: Armstrong, Katrina 5/1/2006 EX 046: 1994 Physicians' Desk Reference, Premarin Label			
03141			00/00/2006	Depo: Armstrong, Katrina 5/1/2006 EX 047: Editorial titled: Observational studies & clinical trials of menopausal hormone therapy: can they both be right?			
03142			00/00/2006	Depo: Armstrong, Katrina 5/1/2006 EX 048: Editorial titled: What do we think about cognition & menopause?			
03143			11/1/2005	Depo: Armstrong, Katrina 5/1/2006 EX 049: Research article titled: Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva & its possible relation w/ the use of hormone replacement therapy			
03144	HRT MED LIT 2935001	HRT MED LIT 2935005	12/2/2004	Depo: Armstrong, Katrina 5/1/2006 EX: 050: Epidemiology and prevention of breast cancer.			
03145			6/3/1998	Depo: Armstrong, Katrina 5/1/2006 EX 051: Article titled: Relationship Between Estrogen Levels, Use of Hormone Replacement Therapy, & Breast Cancer			
03146	HRT MED LIT 2070001	HRT MED LIT 2070009	1/15/2005	Depo: Armstrong, Katrina 5/1/2006 EX: 052: Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Colditz GA, Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):909s-17s			
03147	HRT MED LIT 3448001	HRT MED LIT 3448003	8/6/2005	Depo: Armstrong, Katrina 5/1/2006 EX: 053: Hormone replacement therapy and breast cancer: estimate of risk. Coombs NJ, Taylor R, Wilcken N, Boyages J. BMJ. 2005 Aug 6;331(7512):347-9.			
03148			00/00/2006	Depo: Armstrong, Katrina 5/1/2006 EX 054: Article titled: Hormone Therapy & Coronary Heart Disease: The Role of Time since Menopause & Age at Hormone Initiation			
03149	HRT MED LIT 0049001	HRT MED LIT 0049009	1/31/2000	Depo: Armstrong, Katrina 5/1/2006 EX 055: Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Li CI, Weiss NS, Stanford JL, Daling JR Cancer. 2000 Jun 1;88(11):2570-7			
03150			00/00/2006	Depo: Armstrong, Katrina 5/1/2006 EX 056: Article titled: Hormone therapy, timing of initiation, & cognition in women aged older than 60 years: the REMEMBER pilot study			
03151			00/00/2006	Depo: Armstrong, Katrina 5/1/2006 EX 057: Editorial titled: Potential importance of early initiation of hormone therapy for cognitive benefit			
03152	HRT MED LIT 0019001	HRT MED LIT 0019012	8/7/2003	Depo: Armstrong, Katrina 5/1/2006 EX 058: Estrogen plus progestin and the risk of coronary heart disease. Manson, JE, Hsia, J, Johnson, KC, Rossouw, JE, Assaf, AR, Lasser, NL, Trevisan, M, Black, HR, Heckbert, SR, Delrano, R, Strickland, OL, Wong, ND, C			
03153	HRT MED LIT 0042001	HRT MED LIT 0042010	12/30/2002	Depo: Armstrong, Katrina 5/1/2006 EX 059: Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Newcomer, LM, Newcomb, PA, Potter, JD, Yasui, Y, Trentham-Dietz, A, Storer, BE, Longnecker, MP, Baron, JA, Daling, JR			
03155			4/20/2006	Depo: Armstrong, Katrina 5/1/2006 EX 061: Plaintiff's Notice of Discovery Depo of Katrina Armstrong M.D.			
03156			4/26/2006	Depo: Armstrong, Katrina 5/1/2006 EX 062: Letter from Kerry Kearney of ReedSmith to Katrina Armstrong re: Hormone Therapy Litigation			
03157			11/00/2005	Depo: Armstrong, Katrina 5/1/2006 EX 063: Katrina Armstrong CV			
03158				Depo: Armstrong, Katrina 5/1/2006 EX 064: Chart: Armstrong Exhibits			
03159			4/30/2006	Depo: Armstrong, Katrina 5/1/2006 EX 065: Chart: Armstrong - Supplemental Potential Exhibits			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03184			4/13/2006	Depo: Bayer, Marc 4/26/2006 EX 001: Plaintiffs' Notice of Discovery Depo of Marc J. Bayer MD			
03185			2/17/2006	Depo: Bayer, Marc 4/26/2006 EX 002: Report of Marc J. Bayer MD			
03186			1/12/2006	Depo: Bayer, Marc 4/26/2006 EX 003: Invoices to Kassandra Hendrix of Kaye Scholer LLP for time spent on HRT Litigation			
03187			6/23/2005	Depo: Bayer, Marc 4/26/2006 EX 004: Letters from Kassandra Hendrix of Kaye Scholer LLP re HRT Litigation			
03205				Depo: Bluming, Avrum 5/19/2006 EX 001: Article titled: Hormone Replacement Therapy (HRT) in Women w/ Previously Treated Primary Breast Cancer: Update I (Meeting Abstract)			
03206	W-DDL-00000059	W-DDL-00000061	7/00/2002	Depo: Bluming, Avrum 5/19/2006 EX 002			
03207				Depo: Bluming, Avrum 5/19/2006 EX 003: Vital Options Sponsors			
03208			5/15/2006	Depo: Bluming, Avrum 5/19/2006 EX 004: Invoices to Shook, Hardy & Bacon			
03251				Depo: Burlington, Bruce 8/9/2005 EX 001: D. Bruce Burlington CV			
03252			00/00/1996	Depo: Burlington, Bruce 8/9/2005 EX 002: 1996 Physicians' Desk Reference. Prempro Label			
03253			00/00/2004	Depo: Burlington, Bruce 8/9/2005 EX 003: 2004 Physicians' Desk Reference. Prempro Label			
03254	BURLB015-000219	BURLB015-000219	10/18/2000	Depo: Burlington, Bruce 8/9/2005 EX 004: Update on Premarin Labeling Issues for LEC Meeting			
03255	BURLB015-000221	BURLB015-000222	10/17/2000	Depo: Burlington, Bruce 8/9/2005 EX 005: On October 16, 2000 Ms			
03256	ZUCAV008-005665	ZUCAV008-005666	7/3/2001	Depo: Burlington, Bruce 8/9/2005 EX 006: Unknown			
03257	STEPW014-005895	STEPW014-005895		Depo: Burlington, Bruce 8/9/2005 EX 007: No Title			
03258	STEPW008-000093	STEPW008-000094	7/15/1997	Depo: Burlington, Bruce 8/9/2005 EX 008: Epidemiologic Study of the Risks and Benefits of Hormone Replacement Therapy			
03259				Depo: Camardo, Joseph 6/16/2005 EX 001: Joseph Camardo CV			
03260	SOLOJ008-000366	SOLOJ008-000415	12/2/2002	Depo: Camardo, Joseph 6/16/2005 EX 002: Menopausal Health Franchise Strategic Product Review			
03261	CAMAJ002-001411	CAMAJ002-001453		Depo: Camardo, Joseph 6/16/2005 EX 003			
03262	CAMAJ002-003350	CAMAJ002-003364		Depo: Camardo, Joseph 6/16/2005 EX 004			
03263	CAMAJ002-003252	CAMAJ002-003280		Depo: Camardo, Joseph 6/16/2005 EX 005			
03264	CAMAJ002-003786	CAMAJ002-003797		Depo: Camardo, Joseph 6/16/2005 EX 006			
03265	CAMAJ002-003933	CAMAJ002-003963		Depo: Camardo, Joseph 6/16/2005 EX 007			
03266	CONKJ012-000913	CONKJ012-000943	12/00/1997	Depo: Camardo, Joseph 6/16/2005 EX 008: Raloxifene Competitive Product Backgrounder			
03267	HRT MED LIT 0008001	HRT MED LIT 0008010	5/21/2003	Depo: Camardo, Joseph 6/16/2005 EX 009: Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. Greenspan, SL, Resnick, NM, Parker, RA JAMA. 2003 May 21			
03268			5/17/2005	Depo: Camardo, Joseph 6/16/2005 EX 010: Article titled: Hormone Therapy to Prevent Chronic Conditions in Postmenopausal Women: Recommendations from the US Preventive Services Task Force			
03269			3/25/2002	Depo: Camardo, Joseph 6/16/2005 EX 011: Article titled: Bone Mass Response to Discontinuation of Long-term Hormone Replacement Therapy			
03270			2/00/2005	Depo: Clark, Robert 3/31/2005 EX 001: Rule 1.310 Notice of Videotaped Depo of a Warner Lambert Corporate Representative (Designated by Warner-Lambert as Robert Clark) and Subpoena Duces Tecum			
03271			5/13/2004	Depo: Clark, Robert 3/31/2005 EX 002: Letter re: Agreement between US Attorney & Warner-Lambert Company LLC			
03272			5/13/2004	Depo: Clark, Robert 3/31/2005 EX 003: Copy of the US District Court vs Warner-Lambert Company LLC			
03273			5/3/2004	Depo: Clark, Robert 3/31/2005 EX 004: Settlement Agreement & Release			
03274			6/7/2004	Depo: Clark, Robert 3/31/2005 EX 005: Waiver, Change of Plea & Sentence Hearing			
03275				Depo: Cobb, Pamela 11/17/2005 EX 001: Handwritten flowchart			
03276				Depo: Cobb, Pamela 11/17/2005 EX 002: Pamela Cobb CV			
03277	SENDM009-000252	SENDM009-000258	5/21/2002	Depo: Cobb, Pamela 11/17/2005 EX 003: Communication Messages: Premarin / Trimegestone Combination			
03278	COBBP004-000496	COBBP004-000496	4/2/2002	Depo: Cobb, Pamela 11/17/2005 EX 004: HRT Franchise and Phase IV Strategy Meeting			
03279	WEBEM014-003242	WEBEM014-003246	7/19/2000	Depo: Cobb, Pamela 11/17/2005 EX 005: Depo: Weber, Margaret 6/21/2005 EX 014			
03280	COBBP002-001830	COBBP002-001830	8/9/1999	Depo: Cobb, Pamela 11/17/2005 EX 006			
03281	WEBEM015-013560	WEBEM015-013584	10/19/2000	Depo: Cobb, Pamela 11/17/2005 EX 007: Shift from challenges to opportunity, the future is quite bright			
03282	WEBEM015-028512	WEBEM015-028512	10/7/2002	Depo: Cobb, Pamela 11/17/2005 EX 008: Re: Resources on women's health; Depo: Weber, Margaret 6/21/2005 EX 016: Re: Resources on women's health			
03283	WEBEM015-029876	WEBEM015-029877	10/17/2002	Depo: Cobb, Pamela 11/17/2005 EX 009: Fwd: Presentation and Meeting with Garnet Anderson; Depo: Weber, Margaret 6/21/2005 EX 015: Fwd: Presentation and Meeting with Garnet Anderson			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03284	OLIVS019-005767	OLIVS019-005767	9/6/2002	Depo: Cobb , Pamela 11/17/2005 EX 010: Review papers			
03285	COBBP026-001460	COBBP026-001465	8/27/2002	Depo: Cobb , Pamela 11/17/2005 EX 011: Vedani Nicola - biscotica			
03286	COBBP026-001443	COBBP026-001453	8/29/2002	Depo: Cobb , Pamela 11/17/2005 EX 012: Vedani Nicola - biscotica			
03287	WEBM015-022493	WEBM015-022501	11/30/2001	Depo: Cobb , Pamela 11/17/2005 EX 013			
03288	COBBP010-000154	COBBP010-000179		Depo: Cobb , Pamela 11/17/2005 EX 014: Estrogen and the Skin			
03289	SENDM009-000225	SENDM009-000235	9/3/2002	Depo: Cobb , Pamela 11/17/2005 EX 015: Preclinical and Clinical Experience with Trimegestone a Novel New Progestin			
03290	WEBEM015-007988	WEBEM015-007988	11/7/2000	Depo: Cobb , Pamela 11/17/2005 EX 016: Re: Labeling for Concomitant use with Statins; Depo: Weber, Margaret 6/21/2005 EX 030: Re: Labeling for Concomitant use with Statins			
03291	COBBP007-001289	COBBP007-001307		Depo: Cobb , Pamela 11/17/2005 EX 017: Arterial versus Venous Effects of Estrogen			
03292	COBBP007-001118	COBBP007-001123	5/20/2002	Depo: Cobb , Pamela 11/17/2005 EX 018: Metabolic Effects of Menopausal Therapies; Depo: Mittleman, Karen 5/3/2006 EX 321: Metabolic Effects of Menopausal Therapies			
03293	COBBP010-000415	COBBP010-000421		Depo: Cobb , Pamela 11/17/2005 EX 019: Mammographic Breast Density and Hormone Replacement Therapy			
03294	DUROJ046-013387	DUROJ046-013387	6/25/2002	Depo: Cobb , Pamela 11/17/2005 EX 020: PUBLICATION PLAN TRACKING REPORT; Depo: Mittleman, Karen 5/3/2006 EX 357A: PUBLICATION PLAN TRACKING REPORT			
03295	CONTA025-029486	CONTA025-029486	12/8/2000	Depo: Cobb , Pamela 11/17/2005 EX 021: Fillit's paper and Speroff's outline; Depo: Mittleman, Karen 5/2/2006 EX 017: Fillit's paper and Speroff's outline; Depo: Mittleman, Karen 5/3/2006 EX 277: Fillit's paper and Speroff's outline			
03296	CONTA025-030538	CONTA025-030539	6/15/2000	Depo: Cobb , Pamela 11/17/2005 EX 022: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EX 204, 118, 236; Alice Perrone 8/31/06 DEPO EX 040: meeting recap			
03297	COBBP007-000488	COBBP007-000492	9/4/2001	The Atherosclerotic Process and the Impact of Estrogens; Depo: Cobb , Pamela 11/17/2005 EX 023; Depo: Mittleman, Karen 5/2/2006 EX 040			
03298	OLIVS019-025780	OLIVS019-025781	12/17/2001	Depo: Cobb , Pamela 11/17/2005 EX 024: Updated grids, action items, and sexuality outline; Depo: Mittleman, Karen 5/2/2006 EX 018: Updated grids, action items, and sexuality outline			
03299	COBBP002-000560	COBBP002-000565	10/00/1998	Depo: Cobb , Pamela 11/17/2005 EX 025: Estrogen and Atherosclerosis			
03300	DUROJ023-001712	DUROJ023-001712	1/18/2000	Depo: Cobb , Pamela 11/17/2005 EX 026: Strategic Publications Development Meeting Meeting Recap			
03301	COBBP010-000427	COBBP010-000433	12/4/2000	Depo: Cobb , Pamela 11/17/2005 EX 027: Strategic Publication Plan Tracking Report; Depo: Mittleman, Karen 5/2/2006 EX 073: Strategic Publication Plan Tracking Report			
03302	COBBP010-000412	COBBP010-000414	11/9/2000	Depo: Cobb , Pamela 11/17/2005 EX 028: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EX 358: Strategic Publications Development Meeting			
03303	COBBP010-000425	COBBP010-000426	12/5/2000	Depo: Cobb , Pamela 11/17/2005 EX 029: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EXS 121, 264, 361			
03304	MARTN010-003763	MARTN010-003764	12/5/2000	Depo: Cobb , Pamela 11/17/2005 EX 030: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EX 275: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EX 338: Strategic Publications Development Meeting; Depo: Marren, Amy 5/25/06 EX 032: Strategic Publications Development Meeting Recap			
03305	WEBEM015-012037	WEBEM015-012038	2/28/2001	Depo: Cobb , Pamela 11/17/2005 EX 031: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EX 265: Strategic Publications Development Meeting			
03306	SOLOJ027-048916	SOLOJ027-048917	8/14/2001	Depo: Cobb , Pamela 11/17/2005 EX 032: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EX 122, 213, 240, 280, 365			
03307	OLIVS006-000944	OLIVS006-000945	10/16/2001	Depo: Cobb , Pamela 11/17/2005 EX 033: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EX 179, 199, 347			
03308	MARTN010-012975	MARTN010-012976	11/27/2001	Depo: Cobb , Pamela 11/17/2005 EX 034: Strategic Publications Development Meeting			
03309	SOLOJ027-037396	SOLOJ027-037405	3/29/2002	Depo: Cobb , Pamela 11/17/2005 EX 035: Women s Healthcare Initiative			
03310			6/13/2001	Depo: Cobb , Pamela 11/17/2005 EX 036: Article titled: Unmasking ghost writers			
03311			5/23/2005	Depo: Cobb , Pamela 11/17/2005 EX 037: World Association of Medical Editors			
03326			1/30/2004	Depo: Conklin, Jeffrey 4/14/2004 EX 042: Plaintiffs' Notice of Corporate Depo of Defendant Wyeth			
03327			3/2/2004	Depo: Conklin, Jeffrey 4/14/2004 EX 043: Plaintiffs' Notice of 30(b)(6) Depo of Wyeth by Video-Tape			
03328	W-30(b)(6)-12-00411	W-30(b)(6)-12-00455	3/2/2004	Depo: Conklin, Jeffrey 4/14/2004 EX 044			
03329	W-MANUAL-00284	W-MANUAL-00680		Depo: Conklin, Jeffrey 4/14/2004 EX 045			
03330	W-30(b)(6)-12-00094	W-30(b)(6)-12-00123		Depo: Conklin, Jeffrey 4/14/2004 EX 046			
03331	W-30(b)(6)-12-00241	W-30(b)(6)-12-00270		Depo: Conklin, Jeffrey 4/14/2004 EX 047			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03332	W-30(b)(6)-12-00124	W-30(b)(6)-12-00154		Depo: Conklin, Jeffrey 4/14/2004 EX 048: All about Health, Osteoporosis, Progestin, Estrogen Study			
03333	W-30(b)(6)-12-00271	W-30(b)(6)-12-00301		Depo: Conklin, Jeffrey 4/14/2004 EX 049			
03334			10/25/2005	Depo: Constantine, Ginger 11/1/2005 EX 001: Plaintiffs' Amended Notice of Depo of Ginger Constantine			
03335			11/1/2005	Depo: Constantine, Ginger 11/1/2005 EX 002: Ginger Constantine CV			
03336	W-MDL04782-00029002	W-MDL04782-00029002	7/30/1976	Depo: Constantine, Ginger 11/1/2005 EX 003			
03337	W-MDL04782-00050783	W-MDL04782-00050792	8/18/1976	Depo: Constantine, Ginger 11/1/2005 EX 004: Plan Prepared by Genesee Computer Center, Inc. for Collection and Analysis of Data from the Records of Drs. Burch and Byrd.			
03338	W-MDL04782-00029233	W-MDL04782-00029236	6/14/1976	Depo: Constantine, Ginger 11/1/2005 EX 005: Estrogens and Breast Cancer.			
03339	CONSG018-024139	CONSG018-024143	6/29/2000	Depo: Constantine, Ginger 11/1/2005 EX 006: Objective / Strategy			
03340	CONSG001-002287	CONSG001-002291		Depo: Constantine, Ginger 11/1/2005 EX 007: Heart Estrogen / Progestin Replacement Study Frequently Asked Questions			
03341	CONSG001-002236	CONSG001-002236		Depo: Constantine, Ginger 11/1/2005 EX 008: Talking Points, Draft of 8/10/97			
03342	CONSG005-000385	CONSG005-000385		Depo: Constantine, Ginger 11/1/2005 EX 009: Understanding the WHI Study: Assessing the Results			
03343			00/00/1996	Depo: Constantine, Ginger 11/1/2005 EX 010: Prempro Label			
03344	AHP-Z-00212950	AHP-Z-00212958		Depo: Constantine, Ginger 11/1/2005 EX 011			
03345	CONSG010-000860	CONSG010-000867	10/23/2002	Depo: Constantine, Ginger 11/1/2005 EX 012: Scientific Workshop Menopausal Hormone Therapy			
03346	CONSG018-010267	CONSG018-010272	12/12/2002	Depo: Constantine, Ginger 11/1/2005 EX 013: International Executive Council			
03347	CONSG017-000723	CONSG017-000729	00/00/2001	Depo: Constantine, Ginger 11/1/2005 EX 014: The Women's HOPE Study Health Osteoporosis Progestin Estrogen Premarin (Conjugated Estrogens) & Medroxyprogesterone Acetate (MPA) Hormone Replacement Therapy (HRT) Investigators' Slide Kit			
03348	CONSG018-004720	CONSG018-004721	10/11/2002	Depo: Constantine, Ginger 11/1/2005 EX 015: 10/11/2002 ACM			
03349	CONSG018-036443	CONSG018-036444	2/27/2002	Depo: Constantine, Ginger 11/1/2005 EX 016: Dear David			
03350	CONSG001-002410	CONSG001-002419		Depo: Constantine, Ginger 11/1/2005 EX 017			
03351	W-MCL004-01712	W-MCL004-01719	9/30/1991	Depo: Constantine, Ginger 11/1/2005 EX 018: Royal Society of Medicine Anglo-American Conference on Hormone Replacement Therapy and Breast Cancer Risk London, UK, 9/24-26/91			
03352			00/00/1992	Depo: Constantine, Ginger 11/1/2005 EX 019: Premarin label			
03371				Depo: Creasman, William 5/1/2006 EX 001: William Creasman CV			
03372				Depo: Creasman, William 5/1/2006 EX 002: Literature referenced in Dr. Creasman report			
03373				Depo: Creasman, William 5/1/2006 EX 003: Report of William Creasman MD			
03374				Depo: Creasman, William 5/1/2006 EX 004: Report of William Creasman MD			
03375			4/19/2006	Depo: Creasman, William 5/1/2006 EX 005: Report of William Creasman MD, Marianne Dockter v. Wyeth			
03376			1/23/2006	Depo: Creasman, William 5/1/2006 EX 006: Invoice to Clark, Thomas & Winters			
03377			2/24/1997	Depo: Creasman, William 5/1/2006 EX 007: Invoice chart			
03378				Depo: Creasman, William 5/1/2006 EX 008: Handwritten notes			
03379				Depo: Creasman, William 5/1/2006 EX 009: Report of William Creasman MD			
03380			10/00/2004	Depo: Creasman, William 5/1/2006 EX 010: Article titled: Skin			
03381			10/00/2004	Depo: Creasman, William 5/1/2006 EX 011: Article titled: Ovarian, Endometrial, & Colorectal Cancers			
03382			10/00/2004	Depo: Creasman, William 5/1/2006 EX 012: Article titled: Osteoporosis			
03383			7/17/2002	Depo: Creasman, William 5/1/2006 EX 013: Article titled: Risks & Benefits of Estrogen Plus Progestin in Healthy Menopausal Women			
03384				Depo: Creasman, William 5/1/2006 EX 014: Hormone Replacement Therapy & Breast Cancer w/ handwritten notes			
03385				Depo: Creasman, William 5/1/2006 EX 015: Summary of Opinions w/ handwritten notes			
03386			2/6/2006	Depo: Creasman, William 5/1/2006 EX 016: Article titled: Overall benefits & harms of combination hormone replacement therapy			
03387			2/10/2006	Depo: Creasman, William 5/1/2006 EX 017: Report II of Jasenka Demirovic MD, MSe, PhD			
03388				Depo: Creasman, William 5/1/2006 EX 018: page of report w/ handwritten notes			
03389			11/30/2005	Depo: Creasman, William 5/1/2006 EX 019: pages of report w/ handwritten notes			
03390				Depo: Creasman, William 5/1/2006 EX 020: pages of report w/ handwritten notes			
03391				Depo: Creasman, William 5/1/2006 EX 021: pages of report w/ handwritten notes			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03392			11/30/2005	Depo: Creasman, William 5/1/2006 EX 022: HT Breast Cancer Litigation: Expert Report of Dr. Paul Goldfarb w/ handwritten notes			
03393			12/1/2005	Depo: Creasman, William 5/1/2006 EX 023: pages of report w/ handwritten notes			
03394			4/19/2006	Depo: Creasman, William 5/1/2006 EX 024: Report of Robert Schwarting MD w/ handwritten notes			
03399	NDA-PRO 0002030	NDA-PRO 0002033	10/9/1990	Depo: Day, Kathleen 1/26/2005 EX 024; Depo: Philander, Peter 3/22/2006 EX 027; Depo: Roehl 12/13/2005 EX 005, 10/09/90 letter			
03400	NDA-PRO 0002026	NDA-PRO 0002029	10/16/1990	Depo: Day, Kathleen 1/26/2005 EX 025; Depo: Philander, Peter 3/22/2006 EX 028; Depo: Roehl 12/13/2005 EX 006, 10/16/90 Letter			
03401	NDA-PRO 0002003	NDA-PRO 0002005	11/13/1990	Depo: Day, Kathleen 1/26/2005 EX 026: None; Depo: Philander, Peter 3/22/2006 EX 030; Depo: Roehl 12/13/2005 EX 010, 11/13/90 Letter			
03402	NDA-PRO 0002002	NDA-PRO 0002002	11/14/1990	Depo: Day, Kathleen 1/26/2005 EX 027: None			
03403	NDA-PRO 0000007	NDA-PRO 0000008	9/16/1997	Depo: Day, Kathleen 1/26/2005 EX 028: Pharmacia & Upjohn Record of FDA Telephone Contact Provera Tablets			
03404	NDA-PRO 0000052	NDA-PRO 0000052	4/13/1992	Depo: Day, Kathleen 1/26/2005 EX 029: Telephone Contact Report - Provera Bulk Packaging Supplement			
03405				Depo: Day, Kathleen 1/26/2005 EX 030: Handwritten flowchart 1996-2003			
03406	NDA-PRO 0006693	NDA-PRO 0006698	9/2/1992	Depo: Day, Kathleen 1/26/2005 EX 031: NDA 11-839 Provera Tablets (Medroxyprogesterone Acetate) Supplement			
03407	W-MDL303-00079759	W-MDL303-00079762	12/30/1994	Depo: Deitch, Marc 10/26/2005 EX 001: Submission of press release (NDA 20-303)			
03408	W-MDL303-00081783	W-MDL303-00081793	6/24/1992	Depo: Deitch, Marc 10/26/2005 EX 002: Depo-Provera (NDA 20-303)			
03409	W-MDL303-00083930	W-MDL303-00083935	9/18/1995	Depo: Deitch, Marc 10/26/2005 EX 003: Prempro/Premphase Breast Cancer Study - Meeting with FDA (NDA 20-303)			
03410	W-MCL008-00935	W-MCL008-00935	11/1/1990	Depo: Deitch, Marc 10/26/2005 EX 004			
03411	SOLOJ022-001116	SOLOJ022-001116		Depo: Deitch, Marc 10/26/2005 EX 005: The Breast Cancer Mtg. with B. Essner, J. Mahady, CSC and M. Deitch is confirmed for April 2.			
03412	W-MCL004-01736	W-MCL004-01736	1/21/1990	Depo: Deitch, Marc 10/26/2005 EX 006			
03413	ROSSC002-001373	ROSSC002-001373	1/3/1990	Depo: Deitch, Marc 10/26/2005 EX 007			
03414	VICTJ005-001707	VICTJ005-001708	1/24/1990	Depo: Deitch, Marc 10/26/2005 EX 008: FDA Advisory Committee HRT/ Breast Cancer and Endometrial Cancer			
03415	VICTJ005-001705	VICTJ005-001706	1/25/1990	Depo: Deitch, Marc 10/26/2005 EX 009: FDA Advisory Committee HRT and Cancer			
03416	VICTJ005-001700	VICTJ005-001703	2/15/1990	Depo: Deitch, Marc 10/26/2005 EX 010: Fertility and Maternal Health Advisory Committee Meeting February 1, 1990			
03417	DEMAE007-000727	DEMAE007-000729	1/23/1995	Depo: Deitch, Marc 10/26/2005 EX 011: Premarin : Selection for WHI			
03418	PANAA035-000643	PANAA035-000644	10/3/1989	Depo: Deitch, Marc 10/26/2005 EX 012: Premarin Proposals			
03419	PANAA034-001796	PANAA034-001796	7/16/1991	Depo: Deitch, Marc 10/26/2005 EX 013: Premarin CBL Program			
03420	PANAA026-001571	PANAA026-001572	2/21/1990	Depo: Deitch, Marc 10/26/2005 EX 014: Premarin Cardiovascular Indication			
03421	PANAA014-001130	PANAA014-001130	1/23/1992	Depo: Deitch, Marc 10/26/2005 EX 015: Premarin Cardiovascular Labeling			
03422	W-MDL303-00081835	W-MDL303-00081836	4/26/1992	Depo: Deitch, Marc 10/26/2005 EX 016: Premarin/Cardiovascular Labeling (NDA 20-303); Depo: DelConte, Anthony 1/19/2006 EX 012: Premarin/Cardiovascular Labeling (NDA 20-303); Depo: Pickar, James 9/20/2005 EX 039: Premarin/Cardiovascular Labeling (NDA 20-303); Depo: Justin Victoria 6/30/06 EX 010: Internal Correspondence; Depo: Robert Essner 6/29/06 EX 018: Premarin/CV Labeling			
03423	W-MDL303-00081682	W-MDL303-00081687	8/27/1992	Depo: Deitch, Marc 10/26/2005 EX 017: Cardiovascular Labeling (NDA 20-303); Depo: Pickar, James 9/20/2005 EX 037: Cardiovascular Labeling (NDA 20-303)			
03424				Depo: Deitch, Marc 10/26/2005 EX 018: Marc Deitch CV			
03425	HENRL008-000280	HENRL008-000299		Depo: Deitch, Marc 10/27/2005 EX 019: Seasons			
03426	CONNS008-000473	CONNS008-000474	2/14/1991	Depo: Deitch, Marc 10/27/2005 EX 020			
03427	W-MDL04782-00002391	W-MDL04782-00002393	2/25/1991	Depo: Deitch, Marc 10/27/2005 EX 021			
03428	CONNS008-000468	CONNS008-000469	2/27/1991	Depo: Deitch, Marc 10/27/2005 EX 022: Premarin Women Health Program			
03429	CONNS008-000386	CONNS008-000386	1/2/1992	Depo: Deitch, Marc 10/27/2005 EX 023: Premarin CBL Campaign Seasons Magazine			
03430	ROSSC005-000160	ROSSC005-000161	6/3/1992	Depo: Deitch, Marc 10/27/2005 EX 024: NDA 4-782			
03431	CONNS008-000980	CONNS008-000982	6/3/1992	Depo: Deitch, Marc 10/27/2005 EX 025: Premarin Seasons Magazine			
03432	PANAA021-000192	PANAA021-000195		Depo: Deitch, Marc 10/27/2005 EX 026: Wyeth District Manager's Leader's Guide POA 2 1994			
03433	DUROJ044-003012	DUROJ044-003012		Depo: Deitch, Marc 10/27/2005 EX 027			
03434	W-MCL003-03011	W-MCL003-03012	4/6/1990	Depo: Deitch, Marc 10/27/2005 EX 028: Incidence of Breast Cancer			
03435	PANAA025-001866	PANAA025-001867	4/30/1991	Depo: Deitch, Marc 10/27/2005 EX 029			
03436	W-MDL04782-00029233	W-MDL04782-00029236	6/14/1976	Depo: Deitch, Marc 10/27/2005 EX 030: Estrogens and Breast Cancer.			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03437	W-MCL004-01712	W-MCL004-01719	9/30/1991	Depo: Deitch, Marc 10/27/2005 EX 031: Royal Society of Medicine Anglo-American Conference on Hormone Replacement Therapy and Breast Cancer Risk London, UK, 9/24-26/91			
03438	VICTJ005-001591	VICTJ005-001592	1/15/1992	Depo: Deitch, Marc 10/27/2005 EX 032			
03439	VICTJ005-001581	VICTJ005-001581	2/6/1992	Depo: Deitch, Marc 10/27/2005 EX 033: 2/14 FDA Advisory Committee Meeting			
03440	VICTJ005-001480	VICTJ005-001483	3/17/1992	Depo: Deitch, Marc 10/27/2005 EX 034: February 14 Fertility and Maternal Health Drugs Advisory Committee Meeting			
03441	CONNS010-001551	CONNS010-001551	8/5/1994	Depo: Deitch, Marc 10/27/2005 EX 035: Premarin Labeling: 1992 FDA Estrogen Labeling Guidance			
03442	BURRG005-000705	BURRG005-000707	6/12/1995	Depo: Deitch, Marc 10/27/2005 EX 036			
03443				Depo: Deitch, Marc 10/27/2005 EX 037: Handwritten notes			
03444			1/00/2006	Depo: DelConte, Anthony 1/19/2006 EX 001: Anthony DelConte III CV			
03445	VICTJ005-001704	VICTJ005-001704	2/2/1990	Depo: DelConte, Anthony 1/19/2006 EX 002			
03446	DELCA005-000565	DELCA005-000573	6/13/2001	Depo: DelConte, Anthony 1/19/2006 EX 003: Hormone Replacement Therapy and Prevention of Nonvertebral Fractures a Meta-Analysis of Randomized Trials			
03447	W-MDL04782-00128934	W-MDL04782-00128937	7/6/2000	Depo: DelConte, Anthony 1/19/2006 EX 004: Inadequacy Letter			
03448	WEBEM015-006093	WEBEM015-006113	6/9/2000	Depo: DelConte, Anthony 1/19/2006 EX 005: Perspectives in ERT/HRT			
03449	CONKJ018-056069	CONKJ018-056074	3/26/2002	Depo: DelConte, Anthony 1/19/2006 EX 006: Business Unit Name			
03450	DELCA005-000864	DELCA005-000865		Depo: DelConte, Anthony 1/19/2006 EX 007: Estrogen/HRT Use in Osteoporosis			
03451	CONSG018-032543	CONSG018-032546		Depo: DelConte, Anthony 1/19/2006 EX 008: BAZEDOXIFENE/CE Evaluation of feasibility of EU submission following completion of study 303 in 4Q05			
03452			3/25/2002	Depo: DelConte, Anthony 1/19/2006 EX 009: Article titled: Bone Mass Response to Discontinuation of Long-term Hormone Replacement Therapy			
03453	PANAA034-001426	PANAA034-001427	8/22/1990	Depo: DelConte, Anthony 1/19/2006 EX 010: Estrogen/Progestin Packaging			
03454	W-MDL04782-00027540	W-MDL04782-00027541	5/23/1973	Depo: DelConte, Anthony 1/19/2006 EX 011: PREMARIN. Retrospective Study on Thromboembolism			
03455	W-MDL303-00081835	W-MDL303-00081836	4/26/1992	Depo: DelConte, Anthony 1/19/2006 EX 012: Premarin/Cardiovascular Labeling (NDA 20-303)			
03456	DELCA017-000915	DELCA017-000946	3/7/2001	Depo: DelConte, Anthony 1/19/2006 EX 013: 2001 Program Reviews (Agenda/Content)			
03457	DELCA008-001182	DELCA008-001185	2/00/2000	Depo: DelConte, Anthony 1/19/2006 EX 014			
03458			10/27/2004	Depo: Demke, Donald 1/19/2005 EX 001: Plaintiffs' Notice of Corporate Depo of Defendant Pfizer			
03459				Depo: Demke, Donald 1/19/2005 EX 002: Donald Demke CV			
03460	P-30(b)(6)-DS-01835	P-30(b)(6)-DS-02133		Depo: Demke, Donald 1/19/2005 EX 003			
03461	P-30(b)(6)-DS-02361	P-30(b)(6)-DS-02496		Depo: Demke, Donald 1/19/2005 EX 004			
03462	P-30(b)(6)-DS-02136	P-30(b)(6)-DS-02358		Depo: Demke, Donald 1/19/2005 EX 005			
03463	P-30(b)(6)-DS-01820	P-30(b)(6)-DS-01834		Depo: Demke, Donald 1/19/2005 EX 006			
03464	P-30(b)(6)-DS-02497	P-30(b)(6)-DS-02505		Depo: Demke, Donald 1/19/2005 EX 007			
03465	P-30(b)(6)-DS-00230	P-30(b)(6)-DS-00244		Depo: Demke, Donald 1/19/2005 EX 008			
03466			12/27/2004	Depo: DeVane, Natalie 1/25/2005 EX 001: Plaintiffs' Notice of Depo of Natalie De Vane			
03467				Depo: DeVane, Natalie 1/25/2005 EX 002: Natalie De Vane CV			
03468	DEVAN019-003267	DEVAN019-003268	9/19/2002	Depo: DeVane, Natalie 1/25/2005 EX 003: FW: Wyeth Prempro: Wyeth Doesn't Know Effect Of Hormone Therapy Sales Drop			
03469	DEVAN001-000348	DEVAN001-000349	4/30/2002	Depo: DeVane, Natalie 1/25/2005 EX 004: Issues Management General HRT Soundbites and Messages			
03470	DEVAN010-000300	DEVAN010-000300	6/13/2002	Depo: DeVane, Natalie 1/25/2005 EX 005: Rosano Blood Vessel Function in Menopausal Women Study			
03471	DEVAN002-000036	DEVAN002-000038	1/9/2001	Depo: DeVane, Natalie 1/25/2005 EX 006: Changes in Breast Density Associated with Initiation, Discontinuation, and Continuing Use of Hormone Replacement Therapy			
03472	DEVAN009-000081	DEVAN009-000081	2/8/2002	Depo: DeVane, Natalie 1/25/2005 EX 007			
03473	DEVAN001-000350	DEVAN001-000350		Depo: DeVane, Natalie 1/25/2005 EX 008			
03474	DEVAN019-005828	DEVAN019-005828	11/4/2002	Depo: DeVane, Natalie 1/25/2005 EX 009: Question / Request			
03475	DEVAN001-000457	DEVAN001-000461		Depo: DeVane, Natalie 1/25/2005 EX 010: Q&A on USC Breast Cancer Study; Q&A on USC Breast Cancer Study			
03476	DEVAN001-000171	DEVAN001-000171	7/3/2002	Depo: DeVane, Natalie 1/25/2005 EX 011: Premarin Family DTC Advertising: Hiatus of Activity			
03477	DEVAN001-000120	DEVAN001-000125	7/22/2002	Depo: DeVane, Natalie 1/25/2005 EX 012: Main Message Points R. Essner Media Interviews (Following Release of Earnings on July 23, 2002)			
03478	DEVAN001-00013	DEVAN001-00013		Depo: DeVane, Natalie 1/25/2005 EX 013			
03479	DEVAN019-000770	DEVAN019-000770	10/11/2002	Depo: DeVane, Natalie 1/25/2005 EX 014: Q&A			
03480	DEVAN019-000772	DEVAN019-000779	10/11/2002	Depo: DeVane, Natalie 1/25/2005 EX 015: Draft 10/10/02			
03481	DEVAN001-000306	DEVAN001-000308		Depo: DeVane, Natalie 1/25/2005 EX 016: WHI Announcement - Medium-Term Outreach Plan, Draft; Depo: Stephenson, Wendy 3/10/2005 EX 014			
03482	DEVAN010-00124	DEVAN010-00124		Depo: DeVane, Natalie 1/25/2005 EX 017			
03483	DEVAN011-000051	DEVAN011-000051	7/23/2002	Depo: DeVane, Natalie 1/25/2005 EX 018: 9:30 Slides; Depo: Petkus, Doug 8/18/2005 EX 015: 9:30 Slides			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03484	DEVAN011-000095	DEVAN011-000096	10/22/2002	Depo: DeVane, Natalie 1/25/2005 EX 019: Worldwide Regulatory Affairs Telephone Contact Report			
03485	DEVAN019-00062	DEVAN019-00063	9/23/2002	Depo: DeVane, Natalie 1/25/2005 EX 020			
03486	DEVAN010-000072	DEVAN010-000079		Depo: DeVane, Natalie 1/25/2005 EX 021: Premarin - Baseline 50 2002			
03487				Depo: Dey, Michael 11/3/2005 EX 001: Michael Dey CV			
03488	SINAM014-000016	SINAM014-000016	1/23/2002	Depo: Dey, Michael 11/3/2005 EX 002: Re: FYI on WHC Prempro Enhancement Proposal			
03489	PANAA039-000124	PANAA039-000139		Depo: Dey, Michael 11/3/2005 EX 003			
03490	STRIS016-008854	STRIS016-008879	3/29/1999	Depo: Dey, Michael 11/3/2005 EX 004			
03491	STRIS016-009329	STRIS016-009438		Depo: Dey, Michael 11/3/2005 EX 005			
03492	PETKD003-000739	PETKD003-000740		Depo: Dey, Michael 11/3/2005 EX 006: Postmenopausal Hormone Therapy: A Valuable Treatment for the Right Women			
03493	PETKD003-000116	PETKD003-000117	4/1/2003	Depo: Dey, Michael 11/3/2005 EX 007: Postmenopausal Hormone Therapy: Focusing on the Appropriate Use and the Appropriate User			
03494	DEYMI002-000164	DEYMI002-000165		Depo: Dey, Michael 11/4/2005 EX 008			
03495	DEYMI002-000166	DEYMI002-000167	10/16/2002	Depo: Dey, Michael 11/4/2005 EX 009: WHI Scientific Advisory Board Meeting October 16, 2002 Airport Marriot Philadelphia, PA Draft Agenda			
03496	DEYMI020-001144	DEYMI020-001211	7/8/2001	Depo: Dey, Michael 11/4/2005 EX 010: 15th Annual Symposium on the Long-Term Effects of Estrogen Deprivation			
03497	DEYMI020-000195	DEYMI020-000271	6/9/1991	Depo: Dey, Michael 11/4/2005 EX 011: 5th Annual Symposium on the Long-Term Effects of Estrogen Deprivation			
03498			00/00/1996	Depo: Dey, Michael 11/4/2005 EX 012: 1996 Physicians' Desk Reference, Prempro Label			
03499	KUSIV006-010118	KUSIV006-010118		Depo: Dey, Michael 11/4/2005 EX 013: HRT Special Issues Panel			
03500	DEYMI009-000041	DEYMI009-000042		Depo: Dey, Michael 11/4/2005 EX 014			
03501	DEYMI206-019364	DEYMI206-019364	12/3/2003	Depo: Dey, Michael 11/4/2005 EX 015: OBJECTIVE CODINGS NOT AVAILABLE			
03502	DEYMI003-000013	DEYMI003-000025	1/00/1991	Depo: Dey, Michael 11/4/2005 EX 016: What Every Women Should Know About Estrogen			
03503	DEYMI033-000038	DEYMI033-000038	1/31/1994	Depo: Dey, Michael 11/4/2005 EX 017: Wyeth-Ayerst/FDA Meeting Premarin/MPA Minimum Effective Dose Discussion			
03504	DEYMI012-000009	DEYMI012-000010	11/22/2002	Depo: Dey, Michael 11/4/2005 EX 018: FDA Sponsored - Women's Health Dialog			
03505	MARRA014-013162	MARRA014-013162	11/29/2002	Depo: Dey, Michael 11/4/2005 EX 019: HRT and breastcancer- a Swedish study-abstract			
03506	LEVIG002-007764	LEVIG002-007765	12/3/2003	Depo: Dey, Michael 11/4/2005 EX 020: Fwd: EMEA HRT Announcement			
03507	DEYMI001-000115	DEYMI001-000229	2/00/1993	Depo: Dey, Michael 11/4/2005 EX 021: Premarin Issues Management System			
03508	RHUDM014-000732	RHUDM014-000737	8/19/2002	Depo: Dey, Michael 11/4/2005 EX 022			
03509	WEBEM014-002380	WEBEM014-002381	9/4/2002	Depo: Dey, Michael 11/4/2005 EX 023			
03510	MAHAJ017-002427	MAHAJ017-002495	00/00/2003	Depo: Dey, Michael 11/4/2005 EX 024: 0318 Board Book C6d			
03511	DEYMI013-000858	DEYMI013-000922	10/31/2002	Depo: Dey, Michael 11/4/2005 EX 025: U.S. Business Review			
03512				Depo: Dey, Michael 11/4/2005 EX 026: Handwritten notes			
03555	Various	Various		Depo: Durocher, Jeanne Marie 6/2/2004 EX 054			
03556	Various	Various	3/2/2004	Depo: Durocher, Jeanne Marie 6/2/2004 EX 055			
03558			10/10/2005	Depo: Engels, David 10/19/2005 EX 001: Plaintiffs' Notice of Corporate Depo of Defendant Pfizer			
03559			10/12/2005	Depo: Engels, David 10/19/2005 EX 002: Plaintiffs' Amended Cross-Notice of Depo of a Pfizer Rep			
03560	Various	Various		Depo: Engels, David 10/19/2005 EX 003			
03561				Depo: Engels, David 10/19/2005 EX 004: Black image			
03562	Various	Various		Depo: Engels, David 10/19/2005 EX 005			
03563	Various	Various		Depo: Engels, David 10/19/2005 EX 006			
03564	Various	Various		Depo: Engels, David 10/19/2005 EX 007			
03565	P-30-(B)(6)-MRKTG-010003	P-30-(B)(6)-MRKTG-010094		Depo: Engels, David 10/19/2005 EX 008			
03566	P-30-(B)(6)-MRKTG-010001	P-30-(B)(6)-MRKTG-010002		Depo: Engels, David 10/19/2005 EX 009			
03567	ENGELS-D-0000254	ENGELS-D-0000254		Depo: Engels, David 10/19/2005 EX 010			
03568	ENGELS-D-0000619	ENGELS-D-0000619		Depo: Engels, David 10/19/2005 EX 011			
03569	NDA-PRO 0027938	NDA-PRO 0027946	00/00/1982	Depo: Engels, David 10/19/2005 EX 012: Hormonal Therapy in the Menopause a Lecture Program			
03570	ENGELS-D-0000736	ENGELS-D-0000741	11/4/2003	Depo: Engels, David 10/19/2005 EX 013			
03571	ENGELS-D-0000001	ENGELS-D-0000063		Depo: Engels, David 10/19/2005 EX 014			
03572	ENGELS-D-0000064	ENGELS-D-0000073		Depo: Engels, David 10/19/2005 EX 015			
03573	ENGELS-D-0000097	ENGELS-D-0000107		Depo: Engels, David 10/19/2005 EX 016			
03574	ENGELS-D-0000074	ENGELS-D-0000075	9/27/1994	Depo: Engels, David 10/19/2005 EX 017			
03575	ENGELS-D-0000374	ENGELS-D-0000409	3/00/1994	Depo: Engels, David 10/19/2005 EX 018			
03576	ENGELS-D-0000484	ENGELS-D-0000535		Depo: Engels, David 10/19/2005 EX 019			
03577			12/27/2004	Depo: Engels, David 1/28/2005 EX 032: Plaintiffs' Notice of Corporate Depo of Defendant Pfizer			
03578	Various	Various		Depo: Engels, David 1/28/2005 EX 033			
03579	Various	Various		Depo: Engels, David 1/28/2005 EX 034			
03580	Various	Various		Depo: Engels, David 1/28/2005 EX 035			
03581	P-30(b)(6)-D8-00239	P-30(b)(6)-D8-00239		Depo: Engels, David 1/28/2005 EX 036			
03582	KENNALLY-W-0000010	KENNALLY-W-0000010	10/30/1980	Depo: Engels, David 1/28/2005 EX 037: Estrogen after the Menopause Reprint 8882-93 (Ryan)			
03583	FISHG001-000156	FISHG001-000172	5/00/1994	Depo: Fisher, Gerald 11/22/2004 EX 126: French Health Authorities Response			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03584	FISHG001-000018	FISHG001-000018	12/23/1996	Depo: Fisher, Gerald 11/22/2004 EX 128: Premarin Team Meetings			
03585	FISHG001-000037	FISHG001-000048		Depo: Fisher, Gerald 11/22/2004 EX 129: Determination of Progesterational Activity in PCUD HPLC Fractions by in Vitro Measurement of Alkaline Phosphatase Activity in T-47 D Human Breast Cancer Cell Line			
03586	FISHG001-000074	FISHG001-000096		Depo: Fisher, Gerald 11/22/2004 EX 130: Premarin Line Extension Strategy			
03587	FISHG001-000139	FISHG001-000141	12/21/1995	Depo: Fisher, Gerald 11/22/2004 EX 131: Conjugated Oestrogens			
03588	FISHG001-000153	FISHG001-000153	5/5/1994	Depo: Fisher, Gerald 11/22/2004 EX 132: Premelle (Premarin/MPA) - French Registration			
03589	FISHG001-000175	FISHG001-000175	4/6/1993	Depo: Fisher, Gerald 11/22/2004 EX 133: Premarin/MPA - Preclinical Dossier and Expert Report			
03590	FISHG001-000177	FISHG001-000182	1/22/1993	Depo: Fisher, Gerald 11/22/2004 EX 134: Premarin MPA (Project 713B) Project Team Review Meeting January 1993			
03591	FISHG001-000201	FISHG001-000220	10/9/1992	Depo: Fisher, Gerald 11/22/2004 EX 137: Medroxyprogesterone Acetate (MPA) : Interpretation of Studies in Laboratory Animals			
03592	FISHG001-000256	FISHG001-000257	9/21/1992	Depo: Fisher, Gerald 11/22/2004 EX 138: Premarin MPA			
03593	FISHG001-000267	FISHG001-000269	9/10/1992	Depo: Fisher, Gerald 11/22/2004 EX 139: Consultant Review of Ten-Day Safety Report on MPA			
03594	FISHG001-000273	FISHG001-000276		Depo: Fisher, Gerald 11/22/2004 EX 140: Medroxyprogesterone Acetate Occurrence of Pancreatic Hyperplasia and Neoplasia in Rats			
03595	FISHG001-000341	FISHG001-000341	8/25/1992	Depo: Fisher, Gerald 11/22/2004 EX 142: Premarin/MPA			
03596	FISHG001-000370	FISHG001-000375	8/13/1992	Depo: Fisher, Gerald 11/22/2004 EX 143			
03597	FISHG001-000452	FISHG001-000455	5/00/1992	Depo: Fisher, Gerald 11/22/2004 EX 144: A Report of Results on Attitudes Toward Menopause			
03598	FISHG001-000579	FISHG001-000583	00/00/1999	Depo: Fisher, Gerald 11/22/2004 EX 146: Special Clinicopharmacological Features of Conjugated Equine Oestrogens			
03599	FISHG002-000003	FISHG002-000003	1/13/2000	Depo: Fisher, Gerald 11/22/2004 EX 149: German Anti-Premarin Article			
03600			10/00/2004	Depo: Fisher, Gerald 11/22/2004 EX 150: Gerald Fisher CV			
03601				Depo: Fontaine, Leander 3/30/2005 EX 001: Dr. Alfons Leander Fontaine CV			
03602	FONTL035-000696	FONTL035-000758	12/00/2002	Depo: Fontaine, Leander 3/30/2005 EX 002: OBJECTIVE INDEX NOT AVAILABLE			
03603	FONTL004-000912	FONTL004-001025	12/13/1999	Depo: Fontaine, Leander 3/30/2005 EX 003: Gold End-to-End Labeling Implementation Labeling Simulation Workshop			
03604			00/00/2004	Depo: Fontaine, Leander 3/30/2005 EX 004: Article titled: Current Requirements & Emerging Trends for Labelling as a Tool for Communicating Pharmacovigilance Findings			
03605	FONTL035-000173	FONTL035-000182	1/2/2002	Depo: Fontaine, Leander 3/30/2005 EX 005: OBJECTIVE INDEX NOT AVAILABLE			
03606	FONTL008-000074	FONTL008-000102	11/22/1999	Depo: Fontaine, Leander 3/30/2005 EX 006: Conjugated Estrogens Tablets Core Data Sheet (CDS)			
03607	FONTL006-001070	FONTL006-001081	7/1/2009	Depo: Fontaine, Leander 3/30/2005 EX 007: Data Sheet			
03608	FONTL006-001082	FONTL006-001096	7/1/2009	Depo: Fontaine, Leander 3/30/2005 EX 008: Data Sheet			
03609	FONTL006-001097	FONTL006-001111	7/1/2009	Depo: Fontaine, Leander 3/30/2005 EX 009: Data Sheet			
03610	FONTL006-001151	FONTL006-001162	6/00/2002	Depo: Fontaine, Leander 3/30/2005 EX 010: Premelle Cycle 5.0 Conjugated Estrogens/Medroxyprogesterone Acetate			
03611	FONTL006-001168	FONTL006-001168	1/21/2002	Depo: Fontaine, Leander 3/30/2005 EX 011			
03612	FONTL006-001165	FONTL006-001166	4/30/2002	Depo: Fontaine, Leander 3/30/2005 EX 012: Conjugated Estrogens Medroxyprogesterone Acetate			
03613	FONTL009-000265	FONTL009-000274	9/00/2001	Depo: Fontaine, Leander 3/30/2005 EX 013: Premarin Vaginal Cream Text			
03614	FONTL009-000240	FONTL009-000251	9/00/2001	Depo: Fontaine, Leander 3/30/2005 EX 014: Text of Package Insert of Premarin Coated Tablets			
03615	FONTL006-000654	FONTL006-000663		Depo: Fontaine, Leander 3/30/2005 EX 015: Summary of Product Characteristics			
03616	FONTL006-001552	FONTL006-001561		Depo: Fontaine, Leander 3/30/2005 EX 016: Expert Information			
03617	FONTL006-001593	FONTL006-001605	00/00/2001	Depo: Fontaine, Leander 3/30/2005 EX 017: Expert Information			
03689			5/9/2006	Depo: Gandy, Samuel 5/11/2006 EX 001: Plaintiffs' Notice of Discovery Depo of Samuel Gandy MD			
03690				Depo: Gandy, Samuel 5/11/2006 EX 002: Sam Gandy CV			
03691				Depo: Gandy, Samuel 5/11/2006 EX 003: Dementia/Alzheimer's Bibliograpy			
03692			4/17/2006	Depo: Gandy, Samuel 5/11/2006 EX 004: Report of Samuel Gandy III, Prempro Products Liability Litigation			
03693			5/8/2006	Depo: Gandy, Samuel 5/11/2006 EX 005: work log			
03694			5/8/2006	Depo: Gandy, Samuel 5/11/2006 EX 006: Email to Jennifer Gropper from Sam Gandy re: E2 ref list			
03695				Depo: Gandy, Samuel 5/11/2006 EX 007: Bibliography of Samuel E. Gandy III, MD, PhD			
03696			6/22/2004	Depo: Gandy, Samuel 5/11/2006 EX 008: Fact sheet: About hormone replacement therapy & Alzheimer's disease			
03697			4/18/1991	Depo: Gandy, Samuel 5/11/2006 EX 009: Article titled: Effects of Estrogen on Memory Function in Surgically Menopausal Women			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03698	HRT MED LIT 0712001	HRT MED LIT 0712005	5/26/1993	Depo: Gandy, Samuel 5/11/2006 EX 010: Estrogen replacement therapy and cognitive function in older women. Barrett-Connor, E, Kritz-Silverstein, D JAMA. 1993 May 26;269(20):2637-41			
03699	HRT MED LIT 0684001	HRT MED LIT 0684006	00/00/1994	Depo: Gandy, Samuel 5/11/2006 EX 011: Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Brenner, DE, Kukull, WA, Stergachis, A, van Belle, G, Bowen, JD, McCormick, WC, Teri, L, Larson			
03700			12/00/1998	Depo: Gandy, Samuel 5/11/2006 EX 012: Article titled: Symptom Relief & Side Effects of Postmenopausal Hormones: Results from the Postmenopausal Estrogen/Progest in Interventions Trial			
03701			00/00/1998	Depo: Gandy, Samuel 5/11/2006 EX 013: Article titled: Serum Estrogen Levels, Cognitive Performance, & Risk of Cognitive Decline in Older Community Women			
03702	HRT MED LIT 0860001	HRT MED LIT 0860006	00/00/1999	Depo: Gandy, Samuel 5/11/2006 EX 014: Estrogen replacement therapy and cognitive decline in older community women. Matthews, K, Caulley, J, Yaffe, K, Zmuda, JM J Am Geriatr Soc. 1999 May;47(5):518-23			
03703			2/23/2000	Depo: Gandy, Samuel 5/11/2006 EX 015: Article titled: Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease			
03704			6/12/2000	Depo: Gandy, Samuel 5/11/2006 EX 016: Article titled: Postmenopausal Estrogen & Estrogen-Progestin Use & 2-Year Rate of Cognitive Change in a Cohort of Older Japanese American Women			
03705			6/13/2000	Depo: Gandy, Samuel 5/11/2006 EX 017: Article titled: Effects of estrogen on cognition, mood, & cerebral flow in AD: A controlled study			
03706			00/00/2000	Depo: Gandy, Samuel 5/11/2006 EX 018: Article titled: Postmenopausal Hormone Therapy & Cognitive Function in Healthy Older Women			
03707			1/25/2000	Depo: Gandy, Samuel 5/11/2006 EX 019: Article titled: Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial			
03708			00/00/2003	Depo: Gandy, Samuel 5/11/2006 EX 020: Article titled: Higher Estrogen Levels Are Not Associated w/ Larger Hippocampi & Better Memory Performance			
03709			00/00/2003	Depo: Gandy, Samuel 5/11/2006 EX 021: Article titled: Estrogen Levels Do Not Correlate w/ Improvement in Cognition			
03710			00/00/2000	Depo: Gandy, Samuel 5/11/2006 EX 022: Alzheimer's Disease by Richard Mayeux & Samuel Gandy			
03711	CONNS013-000646	CONNS013-000651	6/16/1997	Depo: Gandy, Samuel 5/11/2006 EX 023			
03712			5/28/2003	Depo: Gandy, Samuel 5/11/2006 EX 024: Article titled: Dementia Risk Increases, at Least in Those Who Start Hormone Therapy Late			
03713			00/00/1997	Depo: Gandy, Samuel 5/11/2006 EX 025: Article titled: Estrogen Replacement Therapy & Cognitive Function in Postmenopausal Women w/out Dementia			
03714			3/4/1998	Depo: Gandy, Samuel 5/11/2006 EX 026: Article titled: Estrogen Therapy in Postmenopausal Women, Effects on Cognitive Function & Dementia			
03715			00/00/1999	Depo: Gandy, Samuel 5/11/2006 EX 027: Article titled: HRT & Dementia			
03716			4/3/1998	Depo: Gandy, Samuel 5/11/2006 EX 028: Article titled: Hormone Replacement Therapy & Alzheimer's Disease			
03717			00/00/2000	Depo: Gandy, Samuel 5/11/2006 EX 029: Commentary: The Nature of the Effect of Female Gonadal Hormone Replacement Therapy on Cognitive Function in Post-Menopausal Women: A Meta-Analysis			
03718			11/19/2002	Depo: Gandy, Samuel 5/11/2006 EX 030: Article titled: Postmenopausal Hormone Replacement Therapy for Primary Prevetion of Chronic Conditions: Recommendation & Rationale			
03719			10/00/2004	Depo: Gandy, Samuel 5/11/2006 EX 031: Article titled: Cognition & Dementia			
03720			5/17/2005	Depo: Gandy, Samuel 5/11/2006 EX 032: Article titled: Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women: Recommendations from the US Preventive Services Task Force			
03721	Various	Various		Depo: Gandy, Samuel 5/11/2006 EX 033			
03743				Depo: Gieseke, Donald 10/20/2005 EX 001: Donald Gieseke CV			
03744	Demke-D-0000862	Demke-D-0000862		Depo: Gieseke, Donald 10/20/2005 EX 002			
03745	VOLPE-G-0009207	VOLPE-G-0009208	9/30/1997	Depo: Gieseke, Donald 10/20/2005 EX 003			
03746	VOLPE-G-0009209	VOLPE-G-0009209	10/8/1997	Depo: Gieseke, Donald 10/20/2005 EX 004			
03747	VOLPE-G-0009205	VOLPE-G-0009205	10/9/1997	Depo: Gieseke, Donald 10/20/2005 EX 005			
03748	RM_AA 0256462	RM_AA 0256463	12/2/1997	Depo: Gieseke, Donald 10/20/2005 EX 006			
03749	VOLPE-G-0008742	VOLPE-G-0008742	12/17/1997	Depo: Gieseke, Donald 10/20/2005 EX 007			
03750	RM_AA 0256174	RM_AA 0256203		Depo: Gieseke, Donald 10/20/2005 EX 008			
03751	VOLPE-G-0009362	VOLPE-G-0009363	2/11/1998	Depo: Gieseke, Donald 10/20/2005 EX 009			
03752	VOLPE-G-0009175	VOLPE-G-0009175	3/25/1998	Depo: Gieseke, Donald 10/20/2005 EX 010			
03753	Deters-M-0000005	Deters-M-0000005	2/23/1998	Depo: Gieseke, Donald 10/20/2005 EX 011			
03754	NDA-PRO 0001016	NDA-PRO 0001030	12/3/1990	Depo: Gieseke, Donald 10/20/2005 EX 012: Technical Report 7215/90-039 the Relative Bioavailability of Medroxyprogesterone Acetate from Upjohn Provera Tablets 10 mg Compared to Cycin Tablets 10 mg from Wyeth-Ayerst			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03755	NDA-PRO 0001013	NDA-PRO 0001014	12/7/1990	Depo: Gieseke, Donald 10/20/2005 EX 013: Bioinequivalence of Generic Medroxyprogesterone Acetate			
03756	Deters-M-0000003	Deters-M-0000003	6/29/1995	Depo: Gieseke, Donald 10/20/2005 EX 014			
03757	Deters-M-0000002	Deters-M-0000002	1/23/1998	Depo: Gieseke, Donald 10/20/2005 EX 015			
03758	NDA-PRO 0078297	NDA-PRO 0078297	7/31/1997	Depo: Gieseke, Donald 10/20/2005 EX 016			
03759	NDA-PRO 0017599	NDA-PRO 0017599	1/5/1983	Depo: Gieseke, Donald 10/20/2005 EX 017; Depo: Philander, Peter 3/22/2006 EX 014: None			
03760	NDA-PRO 0007648	NDA-PRO 0007649	1/15/1988	Depo: Gieseke, Donald 10/20/2005 EX 018: NDA 11-839/S-048; Depo: Philander, Peter 3/22/2006 EX 018: NDA 11-839/S-048			
03761	NDA-PRO 0001004	NDA-PRO 0001005	5/12/1994	Depo: Gieseke, Donald 10/20/2005 EX 019: Request for Materials to Compile IND for Ogen and Provera in HRT			
03762	VOLPE-G-0004927	VOLPE-G-0004928	8/4/1998	Depo: Gieseke, Donald 10/20/2005 EX 020			
03763	Ballinger-J-0000256	Ballinger-J-0000257		Depo: Gieseke, Donald 10/20/2005 EX 021			
03764	Ballinger-J-0000112	Ballinger-J-0000113	5/10/2004	Depo: Gieseke, Donald 10/20/2005 EX 022			
03765	NDA-PRO 0030751	NDA-PRO 0030751	8/13/1997	Depo: Gieseke, Donald 10/20/2005 EX 023			
03766	NDA-PRO 0030929	NDA-PRO 0030934		Depo: Gieseke, Donald 10/20/2005 EX 024			
03767	RM_NY_MOPS 0076971	RM_NY_MOPS 0076972	7/30/1997	Depo: Gieseke, Donald 10/20/2005 EX 025			
03768	NDA-PRO 0027456	NDA-PRO 0027470	7/00/1990	Depo: Gieseke, Donald 10/20/2005 EX 026: Issues in Menopausal Hormone Replacement Therapy; Depo: Philander, Peter 3/22/2006 EX 031; Depo: Roehl 12/13/2005 EX 002			
03769	NDA-PRO 0026710	NDA-PRO 0026711	3/00/1997	Depo: Gieseke, Donald 10/20/2005 EX 027: Tablets Provera (Medroxyprogesterone Acetate)			
03770	NDA-PRO 0002180	NDA-PRO 0002263	7/31/1997	Depo: Gieseke, Donald 10/20/2005 EX 028			
03771	NDA-PRO 0080397	NDA-PRO 0080398	9/16/1997	Depo: Gieseke, Donald 10/20/2005 EX 029			
03772	NDA-PRO 0001661	NDA-PRO 0001673	6/29/1998	Depo: Gieseke, Donald 10/20/2005 EX 030: NDA 11-839/S-068 Provera Tablets General Correspondence			
03773	NDA-PRO 0001654	NDA-PRO 0001660	7/13/1998	Depo: Gieseke, Donald 10/20/2005 EX 031: None			
03774	NDA-PRO 0001651	NDA-PRO 0001653	7/17/1998	Depo: Gieseke, Donald 10/20/2005 EX 032: None			
03775	NDA-PRO 0001638	NDA-PRO 0001649	7/21/1998	Depo: Gieseke, Donald 10/20/2005 EX 033: NDA 11-839, S-068 PI			
03776	NDA-PRO 0001622	NDA-PRO 0001637	7/22/1998	Depo: Gieseke, Donald 10/20/2005 EX 034: NDA 11-839 (Supplement 07/31/1997) Provera Tablets (Medroxyprogesterone Acetate Tablets) Amendment 02			
03777	NDA-PRO 0001619	NDA-PRO 0001621	7/24/1998	Depo: Gieseke, Donald 10/20/2005 EX 035: None			
03778	NDA-PRO 0001604	NDA-PRO 0001618	7/30/1998	Depo: Gieseke, Donald 10/20/2005 EX 036: Revised Provera Insert NDA 11-839, S-068 S-065			
03779	NDA-PRO 0001589	NDA-PRO 0001602	7/31/1998	Depo: Gieseke, Donald 10/20/2005 EX 037: Revised Package Insert for Provera Tablets			
03780	NDA-PRO 0001577	NDA-PRO 0001586	8/3/1998	Depo: Gieseke, Donald 10/20/2005 EX 038: Provera Insert			
03781	NDA-PRO 0001561	NDA-PRO 0001576	8/3/1998	Depo: Gieseke, Donald 10/20/2005 EX 039: NDA 11-839 (Supplement 07/31/1997) Provera Tablets (Medroxyprogesterone Acetate Tablets) Final Draft Labeling			
03782	NDA-PRO 0112931	NDA-PRO 0112942	8/4/1998	Depo: Gieseke, Donald 10/20/2005 EX 040			
03783				Depo: Gieseke, Donald 10/20/2005 EX 041: Handwritten note			
03784				Depo: Gieseke, Donald 10/20/2005 EX 042: Handwritten note			
03785				Depo: Gieseke, Donald 10/20/2005 EX 043: Handwritten note			
03786				Depo: Gieseke, Donald 10/20/2005 EX 044: Handwritten note			
03787				Depo: Gieseke, Donald 10/20/2005 EX 045: Handwritten note			
03788				Depo: Gieseke, Donald 10/20/2005 EX 046: Handwritten note			
03789			9/16/1997	Depo: Gieseke, Donald 10/20/2005 EX 047: Handwritten note			
03869				Depo: Goldkind, Lawrence 5/12/2006 EX 001: Lawrence Goldkind CV			
03870			4/20/2006	Depo: Goldkind, Lawrence 5/12/2006 EX 002: Background Basis for Expert Opinion by Lawrence Goldkind MD			
03871			12/10/2005	Depo: Goldkind, Lawrence 5/12/2006 EX 003: Invoices for Prempro case			
03872			00/00/2002	Depo: Goldkind, Lawrence 5/12/2006 EX 004: 2002 Physicians' Desk Reference, Premarin Label			
03873	Various	Various		Depo: Goldkind, Lawrence 5/12/2006 EX 005			
03874				Depo: Goldkind, Lawrence 5/12/2006 EX 006: Prempro Premphase Label			
03875				Depo: Goldkind, Lawrence 5/12/2006 EX 007: DDMAC Communications			
03918			5/11/2006	Depo: Harms, Steven 5/15/2006 EX 001: Plaintiffs' Notice of Discovery Depo of Steven Harms MD			
03919				Depo: Harms, Steven 5/15/2006 EX 002: Steven Harms CV			
03920			2/16/2006	Depo: Harms, Steven 5/15/2006 EX 003: Report of Steven Harms			
03921			4/19/2006	Depo: Harms, Steven 5/15/2006 EX 004: Report of Steven Harms, Helen Rush v. Wyeth			
03922			4/19/2006	Depo: Harms, Steven 5/15/2006 EX 005: Report of Steven Harms, Linda Reeves v. Wyeth			
03923			5/11/2006	Depo: Harms, Steven 5/15/2006 EX 006: Report of Steven Harms, Elizabeth Coleman v. Wyeth			
03924			4/4/2006	Depo: Harms, Steven 5/15/2006 EX 007: Letters to Steven Harms enclosing literature & expert depos			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
03925			1/00/2004	Depo: Harms, Steven 5/15/2006 EX 008: Article titled: Quantitative Assessment of Mammographic Breast Density: Relationship w/ Breast Cancer Risk			
03926	HRT MED LIT 0881001	HRT MED LIT 0881007	8/16/1999	Depo: Harms, Steven 5/15/2006 EX 009: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. Hofseth, LJ, Raafat, AM, Osuch, JR, P			
03927			00/00/2004	Depo: Harms, Steven 5/15/2006 EX 010: Editorial titled: Evidence-Based Oncology			
03928			00/00/2000	Depo: Harms, Steven 5/15/2006 EX 011: Article titled: Mammographic density changes in perimenopausal & postmenopausal women: is effect of hormone replacement therapy predictable?			
03929			3/00/2006	Depo: Harms, Steven 5/15/2006 EX 012: Article titled: Influence of Estrogen Receptor & Progesterone Receptor Polymorphisms on the Effects of Hormone Therapy on Mammographic Density			
03930			3/22/2006	Depo: Harms, Steven 5/15/2006 EX 013: Report of Steven Harms			
03942				Depo: Henry, Lesa 2/8/2005 EX 001: Lesa Henry CV			
03943			12/27/2004	Depo: Henry, Lesa 2/8/2005 EX 002: Plaintiff's Notice of Depo of Lesa Henry			
03944	HENRL002-001109	HENRL002-001109		Depo: Henry, Lesa 2/8/2005 EX 003: Premarin Historical DTC Spending \$(M)			
03945	LUDMG002-000867	LUDMG002-000871	12/22/1997	Depo: Henry, Lesa 2/8/2005 EX 004: Consumer Research: Patient Action Center Brochures - Final Report; Depo: Ludmerer, Gail 5/25/2005 EX 006: Consumer Research: Patient Action Center Brochures - Final Report			
03946	HENRL005-000103	HENRL005-000444		Depo: Henry, Lesa 2/9/2005 EX 005: Lesa Henry handwritten notes discussing direct to consumer advertising			
03947	HENRL002-001205	HENRL002-001206	9/13/1999	Depo: Henry, Lesa 2/9/2005 EX 006: Premarin Experts			
03948	HENRL005-000603	HENRL005-000617		Depo: Henry, Lesa 2/9/2005 EX 007: The Role of the Consumer			
03949	HENRL008-000280	HENRL008-000299		Depo: Henry, Lesa 2/9/2005 EX 008: Seasons			
03950	HENRL003-000878	HENRL003-000878	10/4/2001	Depo: Henry, Lesa 2/9/2005 EX 009: 60th Anniversary - Adverse Events Reporting			
03951	HENRL003-000575	HENRL003-000498		Depo: Henry, Lesa 2/9/2005 EX 009			
03952	PANAA013-000030	PANAA013-000042	10/2/2002	Depo: Henry, Lesa 2/9/2005 EX 010: Public Hearing Plan			
03953	HOLSN013-000105	HOLSN013-000119	00/00/2002	Depo: Henry, Lesa 2/9/2005 EX 011: Presenting a positive outlook on the menopause. Answers to some commonly asked questions about the menopause and hormone replacement therapy 00002002 Update			
03954	HOLSN013-000081	HOLSN013-000092		Depo: Henry, Lesa 2/9/2005 EX 012: What are issues that ask about Bleeding Breast cancer risk Cardiovascular benefits New developments in HRT			
03955	HOLSN013-001815	HOLSN013-001817	00/00/2000	Depo: Henry, Lesa 2/9/2005 EX 013: Hormone Replacement Therapy and You			
03956	SOLOJ010-000819	SOLOJ010-000825		Depo: Henry, Lesa 2/9/2005 EX 014: Product Strategy Input Template. Product: Premarin Family			
03957	HENRL011-000456	HENRL011-000462		Depo: Henry, Lesa 2/9/2005 EX 015			
03958	HENRL003-001839	HENRL003-001857	8/2/1999	Depo: Henry, Lesa 2/9/2005 EX 016			
03959	HENRL002-002201	HENRL002-002225	5/2/2000	Depo: Henry, Lesa 2/9/2005 EX 017: Managing Issues Women's Healthcare Summit May 2, 2000			
03960	HOLSN013-000354	HOLSN013-000386		Depo: Henry, Lesa 2/9/2005 EX 018: Your Body Gave You The Estrogen You Needed For 40 Years What About The Next 40? Living With Estrogen Loss			
03961	HENRL008-000396	HENRL008-000406	12/5/2000	Depo: Henry, Lesa 2/9/2005 EX 019: "Off-Label Promotion" - FDA Enforcement Actions			
03962	HENRL002-002074	HENRL002-002075	12/7/1998	Depo: Henry, Lesa 2/9/2005 EX 020: Breast Cancer			
03963	HENRL002-002169	HENRL002-002185	10/4/2000	Depo: Henry, Lesa 2/9/2005 EX 020A: Strategic public relations recommendation for the Premarin launch...			
03964	HENRL002-002020	HENRL002-002029	12/00/1998	Depo: Henry, Lesa 2/9/2005 EX 021: Issues Management			
03965	HENRL002-002012	HENRL002-002015	2/9/1999	Depo: Henry, Lesa 2/9/2005 EX 022: Advocate Development Breast Cancer Advocacy Groups 09986			
03966	HENRL003-000270	HENRL003-000273	7/15/1998	Depo: Henry, Lesa 2/9/2005 EX 023: Premarin Branded TV Ad In-Market Test - Final Report			
03967	HENRL002-000096	HENRL002-000139	8/25/1999	Depo: Henry, Lesa 2/9/2005 EX 024: Assessment of Direct-to-Consumer Advertising for Prempro "Complexities"			
03968	HENRL002-001383	HENRL002-001423	2/00/2000	Depo: Henry, Lesa 2/9/2005 EX 025: Guidelines for Counseling Women on the Management of Menopause			
03969	HENRL002-001216	HENRL002-001218	6/21/2002	Depo: Henry, Lesa 2/9/2005 EX 026: Summary of Findings: 2002 Gallup Study of Menopause			
03970	HENRL001-001957	HENRL001-002105	1/8/1998	Depo: Henry, Lesa 2/9/2005 EX 027: Premarin/Prempro Consumer Segmentation Study HRT Segmentation			
04011			6/2/2005	Depo: Jane, Carol 7/14/2005 EX 001: Plaintiffs' Second Amended Notice of Depo of Carol Jane			
04012	COBBP013-000143	COBBP013-000167		Depo: Jane, Carol 7/14/2005 EX 002: Estrogen and Progesterin, Lipoprotein(a) and the Risk of Recurrent Coronary Heart Disease Events after Menopause			
04013	JANEC002-000959	JANEC002-001014		Depo: Jane, Carol 7/14/2005 EX 003: Postmenopausal Hormone Therapy and Breast Health			
04014	JANEC004-000876	JANEC004-000876		Depo: Jane, Carol 7/14/2005 EX 004: Keeping a Balanced Perspective on Breast Cancer Risk			
04015	JANEC011-003633	JANEC011-003638	11/30/1998	Depo: Jane, Carol 7/14/2005 EX 005: No Title			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04016	JANEC004-000968	JANEC004-000973	6/00/2001	Depo: Jane, Carol 7/14/2005 EX 006: Q&A Re: Cancer Risks & HRT			
04017	W-MDL04782-00029233	W-MDL04782-00029236	6/14/1976	Depo: Jane, Carol 7/14/2005 EX 007: Estrogens and Breast Cancer.			
04018	HRT MED LIT 1866001	HRT MED LIT 1866002	9/10/1977	Depo: Jane, Carol 7/14/2005 EX: 008: Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer.			
04019	JANEC007-001244	JANEC007-001246		Depo: Jane, Carol 7/14/2005 EX 009			
04020	JANEC011-002339	JANEC011-002483	7/5/2002	Depo: Jane, Carol 7/14/2005 EX 010: Osteo TLP #26			
04021	JANEC010-006346	JANEC010-006381		Depo: Jane, Carol 7/14/2005 EX 011			
04022	JANEC011-002316	JANEC011-002319	7/00/2002	Depo: Jane, Carol 7/14/2005 EX 012: Dear Doctor			
04023	JANEC011-003343	JANEC011-003345	7/18/2002	Depo: Jane, Carol 7/14/2005 EX 013: FW: National Osteoporosis Advisory Board - WHI HRT Results - Feedback Requested			
04024	JANEC011-006347	JANEC011-006391	9/24/2002	Depo: Jane, Carol 7/14/2005 EX 014: Postmenopausal Hormone Therapy: A Review of Recent Data and Clinical Recommendations			
04025	JANEC007-000012	JANEC007-000012	8/23/2001	Depo: Jane, Carol 7/14/2005 EX 015: Task Force on HRT/ERT Perception			
04026	ROSSC005-000092	ROSSC005-000092	7/21/1992	Depo: Jane, Carol 7/14/2005 EX 016: NDA 4-782			
04027	STRIS001-000034	STRIS001-000045	7/00/1997	Depo: Jane, Carol 7/14/2005 EX 017: For Four Decades, Her Body Supplied All the Estrogen She Needed.			
04028	JANEC006-000254	JANEC006-000257	7/9/2002	Depo: Jane, Carol 7/14/2005 EX 018: Release of the Results of the Estrogen Plus Progestin Trial of the Women's Health Initiative: Study Rationale and Design			
04029	JANEC006-000246	JANEC006-000250	7/9/2002	Depo: Jane, Carol 7/14/2005 EX 019: Release of the Results of the Estrogen Plus Progestin Trial of the Women's Health Initiative: Findings and Implications			
04030	JANEC006-000251	JANEC006-000253	7/9/2002	Depo: Jane, Carol 7/14/2005 EX 020: Release of the Results of the Estrogen Plus Progestin Trial of the Women's Health Initiative			
04031	JANEC007-002011	JANEC007-002012		Depo: Jane, Carol 7/14/2005 EX 021: Hormone Replacement Therapy and the Risk of Breast Cancer			
04032	JANEC009-000690	JANEC009-000690	10/17/2002	Depo: Jane, Carol 7/14/2005 EX 022: Presentation and Meeting with Garnet Anderson			
04033	JANEC007-001518	JANEC007-001522		Depo: Jane, Carol 7/14/2005 EX 023			
04034	STEPW013-000219	STEPW013-000229	8/29/2002	Depo: Jane, Carol 7/14/2005 EX 024: Copy of Questions and Answers on the Womens Health Initiative Study Results is Attached			
04035	HENRL001-002219	HENRL001-002259	00/00/1996	Depo: Jane, Carol 7/14/2005 EX 025: APGO Educational Series on Women's Health Issues Osteoporosis: Diagnosis, Treatment, Monitoring			
04036			00/00/1999	Depo: Jane, Carol 7/14/2005 EX 026: AACE Medical Guidelines for Clinical Practice for Management of Menopause			
04037	JANEC003-000351	JANEC003-000367		Depo: Jane, Carol 7/14/2005 EX 027: If you're Approaching Menopause, Here's your First Hot Flash.			
04038	JANEC003-000047	JANEC003-000078		Depo: Jane, Carol 7/14/2005 EX 028: Take Charge! Our Guide to Fighting Stroke for Women over 35			
04039	JANEC008-000135	JANEC008-000199	6/9/2002	Depo: Jane, Carol 7/14/2005 EX 029: Scientific Update on Postmenopausal Health Abstracts & Biographies			
04040			00/00/2000	Depo: Jane, Carol 7/14/2005 EX 030: Article titled: A Clinician's Response to the Epidemiological Data Linking Post-Menopausal Estrogen-Progestin Therapy w/ an Increased Risk of Breast Cancer			
04041	HENRL001-002162	HENRL001-002191	4/00/2000	Depo: Jane, Carol 7/14/2005 EX 031: CME Activity Guiding your Patients through the Transitional Years, Menopause, and beyond; Depo: Pinizzotto, Marie 8/23/2005 EX 016; Depo: Speroff, Leon 8/16/2005 EX 228			
04042	HENRL001-002282	HENRL001-002323	6/00/1999	Depo: Jane, Carol 7/14/2005 EX 032: Managing the Menopausal Patient: Consensus Guidelines			
04043	YAVUE009-000770	YAVUE009-000810		Depo: Jane, Carol 7/14/2005 EX 033: Therapeutic Options for Menopausal Health Monograph			
04061			6/22/2004	Depo: Kany, Steven 7/15/2004 EX 085: Plaintiffs' Second Amended Notice of 30(b)(6) Depo of Pharmacia/Upjohn now Pfizer by videotape			
04062			5/00/1996	Depo: Kany, Steven 7/15/2004 EX 086: Medical Sciences Liaison, Organization Book, May 1996			
04063				Depo: Kany, Steven 7/15/2004 EX 087: handwritten notes			
04064				Depo: Kany, Steven 7/15/2004 EX 088: Organization Charts - Research			
04065				Depo: Kany, Steven 7/15/2004 EX 089: 2000 Re-Organization			
04066				Depo: Kany, Steven 7/15/2004 EX 090: Organization Charts 12/20/91-6/1/93			
04067				Depo: Kany, Steven 7/15/2004 EX 091: Re-organization 1998-1999			
04068			12/13/1999	Depo: Kany, Steven 7/15/2004 EX 092: Article titled: Organizational Appointment - Legal - Export Compliance & Kalamazoo Operations - 1999 Dec. 13			
04069				Depo: Kany, Steven 7/15/2004 EX 093: Global Pharmaceutical Operations			
04070				Depo: Kany, Steven 7/15/2004 EX 094: Corporate Organization Charts 4/1/89			
04071				Depo: Kany, Steven 7/15/2004 EX 095: The Upjohn Company Employee Letter			
04072				Depo: Kany, Steven 7/15/2004 EX 096: Organization Charts/Announcements 12/94-2/98, Volume 2			
04073				Depo: Kany, Steven 7/15/2004 EX 097: Organization Charts/Announcements 12/94-2/98, Volume 1			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04074			4/00/1996	Depo: Kany, Steven 7/15/2004 EX 098: MSL Reproductive Medicine Map			
04075			9/14/2000	Depo: Kany, Steven 7/15/2004 EX 099: Article titled: Appointments: Project Management 2000 Sept 14			
04076				Depo: Kany, Steven 7/15/2004 EX 100: Organization Charts 11/16/93			
04077				Depo: Kany, Steven 7/15/2004 EX 101: Company Directory			
04078				Depo: Kany, Steven 7/15/2004 EX 102: Australia Organizational Chart			
04079			4/1/1989	Depo: Kany, Steven 7/15/2004 EX 103: Pharm. Div. Organization Charts 1984-4/1/89			
04080			5/16/1966	Depo: Kany, Steven 7/15/2004 EX 104: Research 1966 Organization Chart			
04081			2/1/1970	Depo: Kany, Steven 7/15/2004 EX 105: Pharmaceutical R & D 1970 Organization Chart			
04082			6/10/2004	Depo: Kany, Steven 7/15/2004 EX 106: Letter from Tobias Millrood to Emily Lawrence re: Luisa Chavira v. Wyeth			
04108				Depo: Kelly, Patricia 4/11/2006 EX 001: HRT/Breast Cancer Report by Patricia Kelly			
04109			5/29/2003	Depo: Kelly, Patricia 4/11/2006 EX 002: Invoice			
04110				Depo: Kelly, Patricia 4/11/2006 EX 003: HRT/Breast Cancer Report by Patricia Kelly			
04111				Depo: Kelly, Patricia 4/11/2006 EX 004: Bibliography for Patricia Kelly - Articles to add			
04112				Depo: Kelly, Patricia 4/11/2006 EX 005: Bibliography for Patricia Kelly			
04113			9/00/2003	Depo: Kelly, Patricia 4/11/2006 EX 006: Article titled: WHI Study: One Year Later			
04114			00/00/2003	Depo: Kelly, Patricia 4/11/2006 EX 007: Editorial: Women's Health Initiative Results: Breast Cancer Risk in Perspective			
04115			00/00/2000	Depo: Kelly, Patricia 4/11/2006 EX 008: Article titled: Cancer Risk Reflections **St. Francis Hospital			
04116				Depo: Kelly, Patricia 4/11/2006 EX 009: Hormone Replacement Therapy - hindle book			
04117			7/14/1995	Depo: Kelly, Patricia 4/11/2006 EX 010: Article titled: Epidemiology Faces Its Limits			
04118				Depo: Kelly, Patricia 4/11/2006 EX 011: Presentation: Cancer Risk Assessment & Genetic Testing			
04119				Depo: Kelly, Patricia 4/11/2006 EX 012: Slides: Duration of Estrogen/Estrogen-Progestin Use & Breast Cancer Risk			
04120				Depo: Kelly, Patricia 4/11/2006 EX 013: Table: Breast Cancer (Invasive)			
04121				Depo: Kelly, Patricia 4/11/2006 EX 014: Table: Breast Cancer (Invasive), SEER Incidence Rates, Age-Adjusted & Age-Specific Rates by Race & Sex			
04122			6/22/2004	Depo: Kibbe, Laura 7/14/2004 EX 080: Plaintiffs' Second Amended Notice of 30(b)(6) depo of Pharmacia/Upjohn now Pfizer by videotape			
04123				Depo: Kibbe, Laura 7/14/2004 EX 081: Table: Database Function, Database Name			
04124			8/21/2001	Depo: Kibbe, Laura 7/14/2004 EX 082: Pfizer: Corporate Policy #403			
04125				Depo: Kibbe, Laura 7/14/2004 EX 083: Affirmation of Laura M. Kibbe			
04126			7/12/2004	Depo: Kibbe, Laura 7/14/2004 EX 084: Motion of Defendants Pharmacia & Upjohn Company, Greenstone Ltd., Pharmacia Corporation & Pfizer Inc. for Relief from the Superceding Preservation of Data Directive Regarding the Preservation of Back-up Tapes			
04127				Depo: Kusiak, Victoria 4/26&27/2005 EX 001: Victoria Kusiak CV			
04128	KUSIV009-009208	KUSIV009-009214	11/00/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 002: July 19, 2002			
04129				Depo: Kusiak, Victoria 4/26&27/2005 EX 003: Premarin: Sales Issues & Competitive Information			
04130	KUSIV001-000366	KUSIV001-000366		Depo: Kusiak, Victoria 4/26&27/2005 EX 004: PBS Answers			
04131	PANAA001-000682	PANAA001-000691	4/23/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 005: Women's Health - US Total All Products Actual Results - Year to Date 3/31/02 (\$ 000)			
04132	KUSIV002-000291	KUSIV002-000292	2/8/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 006: JAMA "Hormone Replacement Therapy in Relation to Breast Cancer" // sales force voicemail			
04133			00/00/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 007: 2002 Physicians' Desk Reference, Prempro Label			
04134	KUSIV009-002890	KUSIV009-002890	7/10/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 008: RE: USA TODAY EDITORIAL			
04135	KUSIV009-002891	KUSIV009-002891	7/10/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 009: The decision whether or not to use hormone therapy is made by a woman in consultation with her physician or health care provid			
04136				Depo: Kusiak, Victoria 4/26&27/2005 EX 010: 1993 Physicians' Desk Reference, Premarin Label			
04137			5/21/2003	Depo: Kusiak, Victoria 4/26&27/2005 EX 011: Article titled: Combination Therapy w/ Hormone Replacement & Alendronate for Prevention of Bone Loss in Elderly Women			
04138			00/00/2004	Depo: Kusiak, Victoria 4/26&27/2005 EX 012: 2004 Physicans' Desk Reference, Premarin Label			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04139				Depo: Kusiak, Victoria 4/26&27/2005 EX 013: handwritten notes			
04140	KUSIV006-007077	KUSIV006-007077	7/24/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 014: July 24, 2002 Essner Meetings Q & A			
04141	KUSIV006-007819	KUSIV006-007841	10/2/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 015: Postmenopausal Hormone Therapy: Wyeth Perspective			
04142	KUSIV006-006832	KUSIV006-006859	6/2/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 016: Menopausal Health Portfolio Positioning, 6/2/2002			
04143	KUSIV009-002828	KUSIV009-002829	7/10/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 017: Re: HRT			
04144	KUSIV009-002974	KUSIV009-003001	7/11/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 018: No Title			
04145	KUSIV006-007151	KUSIV006-007160	7/9/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 019: Questions and Answers			
04146	KUSIV009-002573	KUSIV009-002576	7/00/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 020: Dear Doctor			
04147	KUSIV009-002751	KUSIV009-002753	7/00/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 021: Dear Doctor			
04148	KUSIV009-004813	KUSIV009-004814	8/20/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 022: Wyeth Pharmaceuticals			
04149	CCC108-001806	CCC108-001611	7/11/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 023			
04150	CCC108-001086	CCC108-001095	7/11/2002	Depo: Kusiak, Victoria 4/26&27/2005 EX 024			
04151			5/8/2006	Depo: Langer, Robert 5/10/2006 EX 001: Email from Robin Jacobsohn to Kelli Owens re: Langer Supplemental pdf			
04152			2/11/2006	Depo: Langer, Robert 5/10/2006 EX 002: Report of Robert Langer			
04153			4/19/2006	Depo: Langer, Robert 5/10/2006 EX 003: Supplemental Report of Robert Langer			
04154				Depo: Langer, Robert 5/10/2006 EX 004: Robert Langer CV			
04155			4/5/2005	Depo: Langer, Robert 5/10/2006 EX 005: Report of Robert Langer			
04156				Depo: Levitt, Geoffrey 4/28/2005 EX 001: Geoffrey Levitt CV			
04157	GOLDG001-001435	GOLDG001-001499		Depo: Levitt, Geoffrey 4/28/2005 EX 002: Field Sales Promotional Policy 511; Depo: Ryan, John 5/31/06 EX 046: Policy 511			
04158			11/4/2004	Depo: Levitt, Geoffrey 4/28/2005 EX 003: Policy on Sales & Marketing Practices			
04159	LEVIG002-008356	LEVIG002-008362	11/11/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 004: SUPPORT OF INDEPENDENT EDUCATIONAL ACTIVITIES AND PUBLICATIONS			
04160	HENRL001-002199	HENRL001-002217	7/10/2001	Depo: Levitt, Geoffrey 4/28/2005 EX 005: Review and Approval of Promotional Material (Formerly Administrative Policy 420)			
04161	HENRL006-000273	HENRL006-000290	9/16/1999	Depo: Levitt, Geoffrey 4/28/2005 EX 006: Administrative Policy 420 Review and Approval of Promotional Material			
04162			12/31/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 007: Review & Approval of Promotional Material			
04163	LEVIG002-004541	LEVIG002-004551	3/20/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 008: Wyeth Pharmaceuticals			
04164	LEVIG002-008444	LEVIG002-008451	3/28/2004	Depo: Levitt, Geoffrey 4/28/2005 EX 009: Re: Fwd: Promotional Guidelines Committee			
04165	LEVIG002-008578	LEVIG002-008577	5/5/2004	Depo: Levitt, Geoffrey 4/28/2005 EX 010: Fwd: Policy 511 - Draft Revision for Review/Approval			
04166	LEVIG002-006535	LEVIG002-006541	8/27/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 011: Revisions to Draft CME Policy			
04167	LEVIG002-009462	LEVIG002-009525	10/28/2002	Depo: Levitt, Geoffrey 4/28/2005 EX 012			
04168	LEVIG002-001617	LEVIG002-001629	10/8/2002	Depo: Levitt, Geoffrey 4/28/2005 EX 013: Adverse Experience Reporting			
04169	LEVIG002-001160	LEVIG002-001168	9/30/2002	Depo: Levitt, Geoffrey 4/28/2005 EX 014: Continuing Professional Development and Compliance to Policy and Procedures			
04170	LEVIG002-005564	LEVIG002-005566	5/7/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 015: Fwd: Wyeth's breach of WHIMS data embargo			
04171	LEVIG002-005567	LEVIG002-005572	5/9/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 016: Copy Clearance Executive Committee Meeting			
04172	LEVIG002-005578	LEVIG002-005581	5/9/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 017: FDA Contact Report - WHIMS			
04173	LEVIG002-005644	LEVIG002-005648	5/21/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 018: FDA Contact Report WHIMS			
04174	LEVIG002-006716	LEVIG002-006720	9/10/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 019: FDA Letter- Prempro/Premphase-Request for Teleconference			
04175	SINAM014-000112	SINAM014-000112	7/19/2002	Depo: Levitt, Geoffrey 4/28/2005 EX 020: CCC/CCEC WHI Review			
04176	LEVIG002-000528	LEVIG002-000530	7/22/2002	Depo: Levitt, Geoffrey 4/28/2005 EX 021: June 20, 2002			
04177	LEVIG002-001633	LEVIG002-001657	10/8/2002	Depo: Levitt, Geoffrey 4/28/2005 EX 022: Risk Management Plan for Prempro?			
04178			3/15/2004	Depo: Levitt, Geoffrey 4/28/2005 EX 024: Presentation: CME: Strategies for Effective Program Implementation			
04179			9/27/2004	Depo: Levitt, Geoffrey 4/28/2005 EX 025: Presentation: Communicating Off-Label Information: The Regulatory Framework			
04180			9/28/2000	Depo: Levitt, Geoffrey 4/28/2005 EX 026: Presentation: The WLF Case: Where Does It Leave Us?			
04181	LEVIG002-006591	LEVIG002-006593	9/3/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 027: Fwd: Continuing Pharmacy Education Programs Policy Change			
04182	LEVIG002-006312	LEVIG002-006314	7/1/2003	Depo: Levitt, Geoffrey 4/28/2005 EX 028: PES GRANTS REVIEW COMMITTEE			
04183	LEVIG002-001742	LEVIG002-001750	10/11/2002	Depo: Levitt, Geoffrey 4/28/2005 EX 029: Fwd: CCEC Overview			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04184			00/00/1997	Depo: Levitt, Geoffrey 4/28/2005 EX 030: Fundamentals of Law & Regulation, An In-Depth Look at Therapeutic Products			
04185			00/00/2002	Depo: Levitt, Geoffrey 4/28/2005 EX 031: A Practical Guide to Food & Drug Law & Regulation			
04186			2/15/2006	Depo: Lobo, Rogerio 5/9/2006 EX 001: Report of Rogerio Lobo			
04187			12/14/2005	Depo: Lojewski, Linda 1/18/2006 EX 001: Plaintiffs' Amended Cross-Notice of Intention to take 30(b)(6) Depo of Wyeth by videotape re: Fosamax			
04188	PANAA016-000589	PANAA016-000613		Depo: Lojewski, Linda 1/18/2006 EX 002			
04189				Depo: Ludmerer, Gail 5/25/2005 EX 001: Gail Ludmerer CV			
04190	LUDMG003-002406	LUDMG003-002407		Depo: Ludmerer, Gail 5/25/2005 EX 002			
04191	LUDMG003-000423	LUDMG003-000426	10/15/1998	Depo: Ludmerer, Gail 5/25/2005 EX 003: Summary of HERS Data - Impact on Physicians			
04192	LUDMG001-000483	LUDMG001-000521	10/00/1998	Depo: Ludmerer, Gail 5/25/2005 EX 004: Prempro DTC Ad Evaluation - A Qualitative Report -			
04193	LUDMG001-000978	LUDMG001-000981	10/30/1998	Depo: Ludmerer, Gail 5/25/2005 EX 005: 1999 Creative Campaign: Prempro Journal Ad Test			
04194	LUDMG002-000867	LUDMG002-000871	12/22/1997	Depo: Ludmerer, Gail 5/25/2005 EX 006: Consumer Research: Patient Action Center Brochures - Final Report			
04195	LUDMG002-001711	LUDMG002-001731		Depo: Ludmerer, Gail 5/25/2005 EX 007: Executive Summary			
04196	LUDMG003-000374	LUDMG003-000375	9/25/1997	Depo: Ludmerer, Gail 5/25/2005 EX 008: Physician Perceptions of Breast Cancer and HRT Final Report			
04197	LUDMG005-001829	LUDMG005-001831		Depo: Ludmerer, Gail 5/25/2005 EX 009			
04198	LUDMG005-000059	LUDMG005-000065		Depo: Ludmerer, Gail 5/25/2005 EX 010			
04199	LUDMG005-000362	LUDMG005-000371		Depo: Ludmerer, Gail 5/25/2005 EX 011: Prempro 2.5 mg and 5 mg: The only Single Tablet for Proven Relief and Long-Term Protection			
04200	W-ADSBRO-00302	W-ADSBRO-00303	5/00/1998	Depo: Ludmerer, Gail 5/25/2005 EX 012			
04201	LUDMG006-001069	LUDMG006-001073		Depo: Ludmerer, Gail 5/25/2005 EX 013: Prempro Concepts			
04202	LUDMG006-001091	LUDMG006-001096		Depo: Ludmerer, Gail 5/25/2005 EX 014			
04203	LUDMG007-000445	LUDMG007-000451		Depo: Ludmerer, Gail 5/25/2005 EX 015: Executive Summary			
04204	LUDMG008-001281	LUDMG008-001290	4/1/1999	Depo: Ludmerer, Gail 5/25/2005 EX 016: 1998 HRT Use and Persistency Study (Yankelovich): Section VII: Attitudes and Healthcare Practices			
04205	LUDMG008-001525	LUDMG008-001535	4/27/1999	Depo: Ludmerer, Gail 5/25/2005 EX 017: 1998 HRT Use and Persistency Study (Yankelovich): Section X: Oversample Analysis			
04206	LUDMG001-000008	LUDMG001-000053	11/24/1998	Depo: Ludmerer, Gail 5/25/2005 EX 018: HRT Message Test (Prempro) Report of Findings			
04207	LUDMG001-000982	LUDMG001-001011-	5/00/1998	Depo: Ludmerer, Gail 5/25/2005 EX 019			
04208	DWRITE065764	DWRITE065812	8/12/1996	Depo: Lynch, Rosie 5/4/2006 EX 001; Depo: Mittleman, Karen 5/2/2006 EX 003			
04209	DWRITE065858	DWRITE065863	2/13/1997	Depo: Lynch, Rosie 5/4/2006 EX 002			
04210	DWRITE065923	DWRITE065941	5/15/1997	Depo: Lynch, Rosie 5/4/2006 EX 003; Depo: Mittleman, Karen 5/2/2006 EX 004; Alice Perrone 8/31/06 DEPO EX 044: publication program			
04211	DWRITE068307	DWRITE068307	1/28/1998	Depo: Lynch, Rosie 5/4/2006 EX 004; Depo: Mittleman, Karen 5/2/2006 EX 015, 296			
04212	DWRITE065987	DWRITE065993	4/9/1998	Depo: Lynch, Rosie 5/4/2006 EX 005			
04213	DWRITE066009	DWRITE066027	8/00/1998	Depo: Lynch, Rosie 5/4/2006 EX 006; Depo: Mittleman, Karen 5/2/2006 EX 005			
04214	DWRITE065952	DWRITE065968	11/20/1998	Depo: Lynch, Rosie 5/4/2006 EX 007; Depo: Mittleman, Karen 5/2/2006 EX 006			
04215	DWRITE066004	DWRITE066008	9/20/1999	Depo: Lynch, Rosie 5/4/2006 EX 008; Depo: Mittleman, Karen 5/2/2006 EX 007			
04216	DWRITE066067	DWRITE066074	9/27/1999	Depo: Lynch, Rosie 5/4/2006 EX 009; Janas, Bernadette 1/3/2008 EX 8			
04217	DWRITE066034	DWRITE066066	9/00/1999	Depo: Lynch, Rosie 5/4/2006 EX 010			
04218	DWRITE027664	DWRITE027664	10/13/1999	Depo: Lynch, Rosie 5/4/2006 EX 011; Alice Perrone 8/31/06 DEPO EX 057: Letter			
04219	DWRITE027665	DWRITE027665	10/13/1999	Depo: Lynch, Rosie 5/4/2006 EX 012			
04220	DWRITE066078	DWRITE066080	12/7/1999	Depo: Lynch, Rosie 5/4/2006 EX 013			
04221	DWRITE066081	DWRITE066085	7/7/1999	Depo: Lynch, Rosie 5/4/2006 EX 014			
04222	DWRITE066086	DWRITE066097	5/24/2001	Depo: Lynch, Rosie 5/4/2006 EX 015			
04223	DWRITE066091	DWRITE066093	1/10/2001	Depo: Lynch, Rosie 5/4/2006 EX 016; Alice Perrone 8/30/06 DEPO EX 019; Janas, Bernadette 1/03/2008 EX 11: Proposal			
04224	DWRITE066098	DWRITE066100	2/4/2002	Depo: Lynch, Rosie 5/4/2006 EX 017; Janas, Bernadette 1/03/2008 EX 14			
04225	DWRITE020992	DWRITE020994	4/14/2002	Depo: Lynch, Rosie 5/4/2006 EX 018			
04226	DWRITE020989	DWRITE020991	4/30/2002	Depo: Lynch, Rosie 5/4/2006 EX 019			
04227	DWRITE020986	DWRITE020988	5/14/2002	Depo: Lynch, Rosie 5/4/2006 EX 020			
04228	DWRITE021012	DWRITE021014	5/30/2002	Depo: Lynch, Rosie 5/4/2006 EX 021: Janas, Bernadette 1/03/2008 EX 15, EX 68			
04229	DWRITE066104	DWRITE066106	8/13/2002	Depo: Lynch, Rosie 5/4/2006 EX 022			
04230	DWRITE066110	DWRITE066112	11/7/2002	Depo: Lynch, Rosie 5/4/2006 EX 023; Janas, Bernadette 1/03/2008 EX 18			
04231	DWRITE066107	DWRITE066109	11/7/2002	Depo: Lynch, Rosie 5/4/2006 EX 024			
04232	DWRITE020773	DWRITE020775	1/3/2003	Depo: Lynch, Rosie 5/4/2006 EX 025: Janas, Bernadette 1/03/2008 EX 17			
04233	DWRITE066204	DWRITE066208	8/11/2003	Depo: Lynch, Rosie 5/4/2006 EX 026			
04234	DWRITE066131	DWRITE066149	8/00/2003	Depo: Lynch, Rosie 5/4/2006 EX 027			
04235	DWRITE066217	DWRITE066219	10/13/2003	Depo: Lynch, Rosie 5/4/2006 EX 028			
04236	DWRITE022784	DWRITE022791	1/26/2005	Depo: Lynch, Rosie 5/4/2006 EX 029			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04237	DWRITE066229	DWRITE066230		Depo: Lynch, Rosie 5/4/2006 EX 030: DEPO; Janas, Bernadette 1/03/2008 EX 23			
04238	DWRITE027012	DWRITE027015		Depo: Lynch, Rosie 5/4/2006 EX 031			
04239	DWRITE027044	DWRITE027045	12/5/2001	Depo: Lynch, Rosie 5/4/2006 EX 032			
04240	DWRITE026720	DWRITE026721	1/11/2002	Depo: Lynch, Rosie 5/4/2006 EX 033			
04241	SOLOJ027-046438	SOLOJ027-046438	10/5/2001	Depo: Lynch, Rosie 5/4/2006 EX 034: proposed members of the national hormone council			
04242	CONTA025-024637	CONTA025-024638	11/15/2001	Depo: Lynch, Rosie 5/4/2006 EX 035 & Janas, Bernadette 1/03/2008 EX 42: update on National Hormone Council			
04243	DWRITE066028	DWRITE066029	1/12/2005	Depo: Lynch, Rosie 5/4/2006 EX 036; Depo: Mittleman, Karen 5/2/2006 EX 023			
04244				Depo: Lyttle, Richard 10/28/2005 EX 001: Richard Lyttle CV			
04245			10/4/2004	Depo: Lyttle, Richard 10/28/2005 EX 002: Nuvios Names C. Richard Lyttle President & CEO			
04246			00/00/1996	Depo: Lyttle, Richard 10/28/2005 EX 003: 1996 Physicians' Desk Reference, Premarin Label			
04247	WEBEM015-013736	WEBEM015-013736	6/19/2001	Depo: Lyttle, Richard 10/28/2005 EX 004: Vedani Nicola - biscotica			
04248	LYTTR016-007801	LYTTR016-007835		Depo: Lyttle, Richard 10/28/2005 EX 005: HRT Portfolio Strategy			
04249	DEMAE007-000727	DEMAE007-000729	1/23/1995	Depo: Lyttle, Richard 10/28/2005 EX 006: Premarin : Selection for WHI			
04250	LYTTR009-000208	LYTTR009-000212		Depo: Lyttle, Richard 10/28/2005 EX 007: Q&A on USC Breast Cancer Study			
04251	W-MDL303-00083689	W-MDL303-00083805	2/16/1995	Depo: Lyttle, Richard 10/28/2005 EX 008: Premarin/MPA Separate Tablets; Medical Officer's Review (NDA 20-303)			
04252			9/3/2004	Depo: Lyttle, Richard 10/28/2005 EX 009: Nuvios in the News			
04253			00/00/2003	Depo: Lyttle, Richard 10/28/2005 EX 010: Nuvios in the News			
04254				Depo: Lyttle, Richard 10/28/2005 EX 011: Article titled: The Osteoporosis Opportunity			
04255	LYTTR016-001222	LYTTR016-001232	2/25/2000	Depo: Lyttle, Richard 10/28/2005 EX 012: Breast Cancer Issue			
04256	DUROJ017-001067	DUROJ017-001076	2/1/2001	Depo: Lyttle, Richard 10/28/2005 EX 013: Deskside Briefing Key Messages and Q&A			
04257	LYTTR010-000289	LYTTR010-000308	2/4/1998	Depo: Lyttle, Richard 10/28/2005 EX 014: Background and Strategies			
04258				Depo: Mahady, Joseph 11/16/2005 EX 001: Joseph Mahady education & work history			
04259				Depo: Mahady, Joseph 11/16/2005 EX 001: Executive Biography Joseph Mahady			
04260	MAHAJ012-000261	MAHAJ012-000274		Depo: Mahady, Joseph 11/16/2005 EX 002: Prempro/Premphase Single Tablet Launch			
04261	MAHAJ007-000707	MAHAJ007-000729		Depo: Mahady, Joseph 11/16/2005 EX 003: Premarin Line Extension Strategy, Draft			
04262			00/00/1996	Depo: Mahady, Joseph 11/16/2005 EX 004: 1996 Physicians' Desk Reference, Prempro Label			
04263	MAHAJ011-000061	MAHAJ011-000096	7/9/1997	Depo: Mahady, Joseph 11/16/2005 EX 005: American Home Products Global Presence			
04264	MAHAJ007-000502	MAHAJ007-000509	9/18/1998	Depo: Mahady, Joseph 11/16/2005 EX 006: Premarin Family Strength Update of Medical Affairs Programs			
04265	MAHAJ014-000007	MAHAJ014-000007	11/13/2000	Depo: Mahady, Joseph 11/16/2005 EX 007: American Home Products Corporation Finance Committee Authorization. WY- 5008. Studies to Support Premarin			
04266	MAHAJ014-000031	MAHAJ014-000031	7/27/1999	Depo: Mahady, Joseph 11/16/2005 EX 008: American Home Products Corporation Finance Committee Authorization. Premarin Renaissance Program			
04267	MAHAJ014-000019	MAHAJ014-000019	9/5/2001	Depo: Mahady, Joseph 11/16/2005 EX 009: American Home Products Corporation Finance Committee Authorization. Prevention of Alzheimer's Disease WHI-MS Extension			
04268	MAHAJ014-000018	MAHAJ014-000018	11/26/2001	Depo: Mahady, Joseph 11/16/2005 EX 010: American Home Products Corporation Finance Committee Authorization. Premarin Family of Products, Phase IV US Clinical Trials			
04269	MAHAJ002-000927	MAHAJ002-000945	7/9/2002	Depo: Mahady, Joseph 11/16/2005 EX 011: Growing Threat to Our HRT Business. Pharmaceuticals Strategic Business Scenarios			
04270	MAHAJ009-000353	MAHAJ009-000387	10/22/2001	Depo: Mahady, Joseph 11/16/2005 EX 012: Area 91' 2002 Business Plan			
04271	MAHAJ014-000003	MAHAJ014-000006	11/10/2000	Depo: Mahady, Joseph 11/16/2005 EX 013: American Home Products Corporation Finance Committee Authorization. WY-4922. Premia Phase IIB/IV Program			
04272	W-ADSBRO-00988	W-ADSBRO-00988	1/00/2000	Depo: Mahady, Joseph 11/17/2005 EX 015			
04273	YAVUE007-000244	YAVUE007-000309		Depo: Mahady, Joseph 11/17/2005 EX 016: Premarin: Sales Issues & Competitive Information			
04274	SOLOJ022-001040	SOLOJ022-001042	3/27/1996	Depo: Mahady, Joseph 11/17/2005 EX 017 and Buchalter, Jeff 05/29/2008 EX 25: Cummings Study: Revised Strategic Recommendations			
04275	YAVUE007-000244	YAVUE007-000486		Depo: Mahady, Joseph 11/17/2005 EX 018: Premarin: Sales Issues & Competitive Information			
04285	MARDH007-001877	MARDH007-001878		Depo: Marder, Harold 1/17/2006 EX 001: Ginger,			
04286	MARDH003-000926	MARDH003-000926	7/19/2002	Depo: Marder, Harold 1/17/2006 EX 002: Justification Document Conjugated Estrogens, Tablets Vaginitis			
04287	MARDH003-000946	MARDH003-000946	7/19/2002	Depo: Marder, Harold 1/17/2006 EX 003: Justification Document Conjugated Estrogens, Tablets Galactorrhea			
04288	MARDH003-001017	MARDH003-001017	3/19/2002	Depo: Marder, Harold 1/17/2006 EX 004: Justification Document ERT Products Postmenopausal Estrogen Replacement Therapy and Risk of Ovarian Cancer			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04289	MARDH003-001046	MARDH003-001046	3/19/2002	Depo: Marder, Harold 1/17/2006 EX 005: Justification Document Products Containing Conjugated Equine Estrogens Porphyria			
04290	MARDH003-001067	MARDH003-001067	3/19/2002	Depo: Marder, Harold 1/17/2006 EX 006: Justification Document Products Containing Conjugated Equine Estrogens Porphyria			
04291	MARDH003-001072	MARDH003-001074	3/19/2002	Depo: Marder, Harold 1/17/2006 EX 007: Justification Document Products Containing Conjugated Equine Estrogens Superficial Estrogens Thrombophlebitis			
04292	MARDH003-001094	MARDH003-001094	7/19/2002	Depo: Marder, Harold 1/17/2006 EX 008: Justification Document Conjugated Estrogens with MPA, Tablets Urticaria/Angioedema			
04293	MARDH004-000020	MARDH004-000020	7/18/2002	Depo: Marder, Harold 1/17/2006 EX 009: Consultant Meeting			
04294	MARDH007-002261	MARDH007-002261	10/22/2002	Depo: Marder, Harold 1/17/2006 EX 010: Re: Associated Press			
04295	MARDH007-001031	MARDH007-001031	7/23/2002	Depo: Marder, Harold 1/17/2006 EX 011: Consultants			
04296	MARDH007-001476	MARDH007-001482	8/22/2002	Depo: Marder, Harold 1/17/2006 EX 012: No Title			
04297			4/14/2006	Depo: Markman, Maurie 5/18/2006 EX 001: Email from Peg Hartely to Maurie Markman re: additional materials			
04298			3/13/2006	Depo: Markman, Maurie 5/18/2006 EX 002: Letter from Karl Lisiewski re: HRT Litigation			
04299			2/3/2006	Depo: Markman, Maurie 5/18/2006 EX 003: Letter from Maurie Markman to Charles Goodell			
04300			5/00/2006	Depo: Markman, Maurie 5/18/2006 EX 004: Plaintiffs' Notice of Discovery Depo of Maurie Markman MD			
04301				Depo: Markman, Maurie 5/18/2006 EX 005: Maurie Markman Testimony & Fees			
04302				Depo: Markman, Maurie 5/18/2006 EX 006: Maurie Markman CV			
04303			2/3/2006	Depo: Markman, Maurie 5/18/2006 EX 007: Invoice to Goodell, DeVries, Leech & Gray			
04304			2/3/2006	Depo: Markman, Maurie 5/18/2006 EX 008: Invoice to Kaye Scholer			
04305			2/20/2006	Depo: Markman, Maurie 5/18/2006 EX 009: Report of Dr. Maurie Markman			
04306			4/18/2006	Depo: Markman, Maurie 5/18/2006 EX 010: Supplemental Report of Dr. Maurie Markman			
04307				Depo: Markman, Maurie 5/18/2006 EX 011: References			
04308				Depo: Markman, Maurie 5/18/2006 EX 012: References			
04309			6/1/2000	Depo: Markman, Maurie 5/18/2006 EX 013: Changing incidence rate of invasive lobular breast carcinoma among older women. Li, Cl, Anderson, BO, Porter, PL, Holt, SK, Daling, JR, Moe, RE Cancer. 2000 Oct 15 89(8):1867-8.			
04310			3/19/2003	Depo: Markman, Maurie 5/18/2006 EX 014: Article titled: Trends in Incidence Rates of Invasive Lobular & Ductal Breast Carcinoma			
04311			12/15/2002	Depo: Markman, Maurie 5/18/2006 EX 015: Article titled: Relation of Regimens of Combined Hormone Replacement Therapy to Lobular, Ductal, & Other Histologic Types of Breast Carcinoma			
04312			2/26/2004	Depo: Markman, Maurie 5/18/2006 EX 016: Article titled: Hormone Replacement Therapy in Relation to Breast Carcinoma Incidence Rate Ratios			
04313			6/3/2004	Depo: Markman, Maurie 5/18/2006 EX 017: Article titled: Association of Hormone Replacement Therapy to Estrogen & Progesterone Receptor Status in Invasive Breast Carcinoma			
04314			7/17/2002	Depo: Markman, Maurie 5/18/2006 EX 018: Article titled: Menopausal Hormone Replacement Therapy & Risk of Ovarian Cancer			
04315			3/21/2001	Depo: Markman, Maurie 5/18/2006 EX 019: Article titled: Estrogen Replacement Therapy & Ovarian Cancer Mortality in a Large Prospective Study of US Women			
04316			8/15/2005	Depo: Markman, Maurie 5/18/2006 EX 020: Article titled: A Prospective Study of Brease Size & Premenopausal Breast Cancer Incidence			
04317			2/8/2006	Depo: Markman, Maurie 5/18/2006 EX 021: Report of David Purdie, Menopausal Hormone Therapy Can Cause Ovarian Cancer			
04318			10/1/2003	Depo: Markman, Maurie 5/18/2006 EX 022: Article titled: Effects of Estrogen Plus Progestin on Gynecologic Cancers & Associated Diagnostic Procedures			
04319			3/23/2004	Depo: Marren, Amy 4/15/2004 EX 050: Plaintiffs' Amended Notice of 30(b)(6) Depo of Wyeth by Videotape			
04320				Depo: Marren, Amy 4/15/2004 EX 051: Amy Marren CV			
04321	Various	Various	4/12/2004	Depo: Marren, Amy 4/15/2004 EX 052			
04336			3/2/2006	Depo: McGee, Daniel 4/7/2006 EX 001: Plaintiffs' Notice of Discovery Deposition of Daniel McGee, PH.D.			
04337			2/17/2006	Depo: McGee, Daniel 4/7/2006 EX 002: Report Of Dr. Dan McGee			
04338				Depo: McGee, Daniel 4/7/2006 EX 003: Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Health Postmenopausal Women. Article			
04379			3/23/2004	Depo: Mitrone, Diane 4/29/2004 EX 061: Amended Notice of 30(b)6 deposition			
04380	W-30(b)(6)-06-00007	W-30(b)(6)-06-00010	4/19/2004	Depo: Mitrone, Diane 4/29/2004 EX 062			
04381	W-30(b)(6)-06-00003	W-30(b)(6)-06-00005	5/20/2002	Depo: Mitrone, Diane 4/29/2004 EX 063			
04382	W-30(b)(6)-06-00001	W-30(b)(6)-06-00002		Depo: Mitrone, Diane 4/29/2004 EX 064			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04383				Depo: Mitrione, Diane 4/29/2004 EX 065: Prempro, Premphase Pharma Insert			
04384	W-30(b)(6)-06-00123	W-30(b)(6)-06-00157	10/7/2003	Depo: Mitrione, Diane 4/29/2004 EX 066			
04385				Depo: Mittleman, Karen 5/2/2006 EX 001: National Library of Medicine PubMed search details			
04386			12/18/2000	Depo: Mittleman, Karen 5/2/2006 EX 002: Article: Metabolic Habituation Following Repeated Resting Cold-Water Immersion Is Not Apparent During Low-Intensity Cold-Water Exercise			
04387	DWRITE065764	DWRITE065812	8/12/1996	Depo: Mittleman, Karen 5/2/2006 EX 003			
04388	DWRITE065923	DWRITE065941	5/15/1997	Depo: Mittleman, Karen 5/2/2006 EX 004			
04389	DWRITE066009	DWRITE066026	8/00/1998	Depo: Mittleman, Karen 5/2/2006 EX 005			
04390	DWRITE065952	DWRITE065968	11/20/1998	Depo: Mittleman, Karen 5/2/2006 EX 006			
04391	DWRITE066004	DWRITE066008	9/20/1999	Depo: Mittleman, Karen 5/2/2006 EX 007			
04392		DWRITE 066066	9/00/1999	Depo: Mittleman, Karen 5/2/2006 EX 008			
04393	DWRITE066095	DWRITE066097	5/16/2001	Depo: Mittleman, Karen 5/2/2006 EX 009; Janas, Bernadette 1/03/2008 EX 12			
04394		DWRITE 066208	8/11/2003	Depo: Mittleman, Karen 5/2/2006 EX 010			
04395	DWRITE065864	DWRITE065864		Depo: Mittleman, Karen 5/2/2006 EX 010			
04396	DWRITE065950	DWRITE065951	1/12/2005	Depo: Mittleman, Karen 5/2/2006 EX 011			
04397	DWRITE065865	DWRITE065869		Depo: Mittleman, Karen 5/2/2006 EX 012			
04398	CONTA025-020958	CONTA025-020959	6/8/2002	Depo: Mittleman, Karen 5/2/2006 EX 013: re: GBT and Publication planning			
04399	DWRITE067403	DWRITE067403	10/29/1997	Depo: Mittleman, Karen 5/2/2006 EX 014; Depo: Mittleman, Karen 5/3/2006 EX 134, 259, 287, 295			
04400	DWRITE068307	DWRITE068307	1/28/1998	Depo: Mittleman, Karen 5/2/2006 EX 015			
04401	DWRITE073304	DWRITE073304		Depo: Mittleman, Karen 5/2/2006 EX 016			
04402	CONTA025-029486	CONTA025-029486	12/8/2000	Depo: Mittleman, Karen 5/2/2006 EX 017: Fillit's paper and Speroff's outline			
04403	OLIVS019-025780	OLIVS019-025780	12/17/2001	Depo: Mittleman, Karen 5/2/2006 EX 018: Updated grids, action items, and sexuality outline			
04404	DWRITE067402	DWRITE067402	9/19/1997	Depo: Mittleman, Karen 5/2/2006 EX 019; Depo: Mittleman, Karen 5/3/2006 EX 133; Depo: Mittleman, Karen 5/3/2006 EX 286			
04405	DUROJ046-005851	DUROJ046-005852		Depo: Mittleman, Karen 5/2/2006 EX 020: Action Steps From the 12/12 Menopausal Health Publication Committee Meeting			
04406	DWRITE003394	DWRITE003396	8/4/1997	Depo: Mittleman, Karen 5/2/2006 EX 021; Depo: Mittleman, Karen 5/3/2006 EX 285			
04407	DWRITE078083	DWRITE078083		Depo: Mittleman, Karen 5/2/2006 EX 022			
04408	DWRITE066028	DWRITE066029	1/12/2005	Depo: Mittleman, Karen 5/2/2006 EX 023			
04409	DWRITE003363	DWRITE003365		Depo: Mittleman, Karen 5/2/2006 EX 024			
04410	DWRITE066312	DWRITE066314	1/24/2005	Depo: Mittleman, Karen 5/2/2006 EX 025			
04411	DWRITE003333	DWRITE003335	11/19/2001	Depo: Mittleman, Karen 5/2/2006 EX 026			
04412	OLIVS019-025416	OLIVS019-025424		Depo: Mittleman, Karen 5/2/2006 EX 027: No Title			
04413	DWRITE067758	DWRITE067758	1/31/2005	Depo: Mittleman, Karen 5/2/2006 EX 028			
04414	DWRITE074381	DWRITE074390		Depo: Mittleman, Karen 5/2/2006 EX 029			
04415	DWRITE074324	DWRITE074337	2/1/2002	Depo: Mittleman, Karen 5/2/2006 EX 030			
04416	DWRITE074346	DWRITE074380	1/31/2005	Depo: Mittleman, Karen 5/2/2006 EX 031			
04417	STRIS016-031138	STRIS016-031139	3/28/2002	Depo: Mittleman, Karen 5/2/2006 EX 032; Depo: Weber, Margaret 6/21/06 EX 067: Strategic Publication Development Meeting			
04418	DUROJ046-013385	DUROJ046-013386	5/20/2002	Depo: Mittleman, Karen 5/2/2006 EX 033: Strategic Publications Development Meeting			
04419	DWRITE074416	DWRITE074443		Depo: Mittleman, Karen 5/2/2006 EX 034			
04420	DWRITE075253	DWRITE075253	2/19/2003	Depo: Mittleman, Karen 5/2/2006 EX 035			
04421				Depo: Mittleman, Karen 5/2/2006 EX 036: NAMS Article: The impact of hormones on menopausal sexuality			
04422	DWRITE066943	DWRITE066943		Depo: Mittleman, Karen 5/2/2006 EX 037			
04423	DWRITE018579	DWRITE018579		Depo: Mittleman, Karen 5/2/2006 EX 038			
04424	DUROJ023-001701	DUROJ023-001705	9/4/2001	Depo: Mittleman, Karen 5/2/2006 EX 039: The Atherosclerotic Process and the Impact of Estrogens			
04425	COBBP007-000488	COBBP007-000492	9/4/2001	Depo: Mittleman, Karen 5/2/2006 EX 040: The Atherosclerotic Process and the Impact of Estrogens			
04426	DWRITE069922	DWRITE069926	1/18/2005	Depo: Mittleman, Karen 5/2/2006 EX 041			
04427	DUROJ046-017005	DUROJ046-017005	5/16/2002	Depo: Mittleman, Karen 5/2/2006 EX 042			
04428	SOLOJ010-002077	SOLOJ010-002105		Depo: Mittleman, Karen 5/2/2006 EX 043: The Atherosclerotic Process and the Impact of Estrogens			
04429	STRIS016-003819	STRIS016-003819	11/6/2001	Depo: Mittleman, Karen 5/2/2006 EX 044			
04430	DWRITE069506	DWRITE069506	12/28/2001	Depo: Mittleman, Karen 5/2/2006 EX 045			
04431	DUROJ046-018229	DUROJ046-018254		Depo: Mittleman, Karen 5/2/2006 EX 046: The Atherosclerotic Process and the Impact of Estrogens			
04432	DWRITE067383	DWRITE067383		Depo: Mittleman, Karen 5/2/2006 EX 047			
04433	DWRITE074193	DWRITE074200		Depo: Mittleman, Karen 5/2/2006 EX 048			
04434	DWRITE074105	DWRITE074115	1/31/2005	Depo: Mittleman, Karen 5/2/2006 EX 049			
04435	DWRITE074130	DWRITE074139	1/31/2005	Depo: Mittleman, Karen 5/2/2006 EX 050			
04436	DWRITE074019	DWRITE074032	1/31/2005	Depo: Mittleman, Karen 5/2/2006 EX 051			
04437	DWRITE074162	DWRITE074192		Depo: Mittleman, Karen 5/2/2006 EX 052			
04438	DWRITE067294	DWRITE067294		Depo: Mittleman, Karen 5/2/2006 EX 053			
04439	DWRITE074047	DWRITE074075		Depo: Mittleman, Karen 5/2/2006 EX 054			
04440	DWRITE067733	DWRITE067733	1/18/2005	Depo: Mittleman, Karen 5/2/2006 EX 055			
04441				Depo: Mittleman, Karen 5/2/2006 EX 056: Notice: Exhibit Number 56 was not marked			
04442			1/18/2005	Depo: Mittleman, Karen 5/2/2006 EX 057: International Menopause Society Article on Estrogens and the skin			
04443	DWRITE068151	DWRITE068166		Depo: Mittleman, Karen 5/2/2006 EX 058			
04444	DWRITE068303	DWRITE068303	1/11/2005	Depo: Mittleman, Karen 5/2/2006 EX 059; Depo: Mittleman, Karen 5/3/2006 EX 306			
04445	DWRITE068322	DWRITE068322	1/11/2005	Depo: Mittleman, Karen 5/2/2006 EX 060			
04446	DWRITE068144	DWRITE068144	1/11/2005	Depo: Mittleman, Karen 5/2/2006 EX 061			
04447	DWRITE068145	DWRITE068145	1/11/2005	Depo: Mittleman, Karen 5/2/2006 EX 062			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04448	DWRITE068143	DWRITE068143	1/11/2005	Depo: Mittleman, Karen 5/2/2006 EX 063			
04449	DWRITE003399	DWRITE003399	1/11/2005	Depo: Mittleman, Karen 5/2/2006 EX 064			
04450	DWRITE067788	DWRITE067788	1/18/2001	Depo: Mittleman, Karen 5/2/2006 EX 065; Depo: Mittleman, Karen 5/3/2006 EX 158			
04451	DWRITE068146	DWRITE068146	1/11/2005	Depo: Mittleman, Karen 5/2/2006 EX 066			
04452	DWRITE068148	DWRITE068148	1/11/2005	Depo: Mittleman, Karen 5/2/2006 EX 067			
04453	DWRITE068315	DWRITE068315		Depo: Mittleman, Karen 5/2/2006 EX 068			
04454	DWRITE067799	DWRITE067799	4/12/2000	Depo: Mittleman, Karen 5/2/2006 EX 069			
04455	DWRITE068312	DWRITE068312		Depo: Mittleman, Karen 5/2/2006 EX 070			
04456	DWRITE068187	DWRITE068210		Depo: Mittleman, Karen 5/2/2006 EX 071			
04457	DWRITE068310	DWRITE068310		Depo: Mittleman, Karen 5/2/2006 EX 072			
04458	COBBP010-000427	COBBP010-000433	12/4/2000	Depo: Mittleman, Karen 5/2/2006 EX 073: Strategic Publication Plan Tracking Report			
04459	DUROJ046-013297	DUROJ046-013297	5/17/2002	Depo: Mittleman, Karen 5/2/2006 EX 074; 201			
04460	DWRITE068167	DWRITE068174	00/00/2002	Depo: Mittleman, Karen 5/2/2006 EX 075			
04461	DWRITE067763	DWRITE067763	1/11/2005	Depo: Mittleman, Karen 5/2/2006 EX 076			
04462	DWRITE072032	DWRITE072047		Depo: Mittleman, Karen 5/2/2006 EX 077			
04463	DWRITE072375	DWRITE072375	12/18/2002	Depo: Mittleman, Karen 5/2/2006 EX 078			
04464	DWRITE072376	DWRITE072392	2/8/2005	Depo: Mittleman, Karen 5/2/2006 EX 079			
04465	DWRITE072141	DWRITE072141	5/19/2003	Depo: Mittleman, Karen 5/2/2006 EX 080			
04466	DWRITE072140	DWRITE072140	2/7/2005	Depo: Mittleman, Karen 5/2/2006 EX 081			
04467	DWRITE072003	DWRITE072031		Depo: Mittleman, Karen 5/2/2006 EX 082			
04468	DWRITE072462	DWRITE072527		Depo: Mittleman, Karen 5/2/2006 EX 083			
04469	DWRITE072626	DWRITE072627	8/22/2003	Depo: Mittleman, Karen 5/2/2006 EX 084			
04470	HRT MED LIT 0496001	HRT MED LIT 0496027		Depo: Mittleman, Karen 5/2/2006 EX 085: A comparative review of the risks and benefits of hormone replacement therapy regimens. Warren, M Am J Obstet Gynecol 2004;190:1141-67			
04471	DWRITE066207	DWRITE066207	4/25/2003	Depo: Mittleman, Karen 5/3/2006 EX 085A			
04472	DWRITE003368	DWRITE003369	1/18/2005	Depo: Mittleman, Karen 5/3/2006 EX 086			
04473	DWRITE069163	DWRITE069164		Depo: Mittleman, Karen 5/3/2006 EX 087			
04474	DWRITE069139	DWRITE069139	3/1/2000	Depo: Mittleman, Karen 5/3/2006 EX 088			
04475	DWRITE069167	DWRITE069167	7/10/2000	Depo: Mittleman, Karen 5/3/2006 EX 089			
04476	DWRITE069144	DWRITE069161		Depo: Mittleman, Karen 5/3/2006 EX 090			
04477	DWRITE067784	DWRITE061030	1/18/2001	Depo: Mittleman, Karen 5/3/2006 EX 091; Depo: Mittleman, Karen 5/3/2006 EX 237			
04478	COBBP006-000761	COBBP006-000778	8/21/2001	Depo: Mittleman, Karen 5/3/2006 EX 092: Hormone Replacement Therapy and Breast Cancer Risk Audioscript for Q & A Discussion			
04479	SOLOJ027-042025	SOLOJ027-042028	2/16/2002	Depo: Mittleman, Karen 5/3/2006 EX 093: PUBLICATION PLAN TRACKING REPORT			
04480	DELCA005-001304	DELCA005-001309		Depo: Mittleman, Karen 5/3/2006 EX 094: The Role of Hormone Replacement Therapy in Preventing Early Bone Loss			
04481	DWRITE073360	DWRITE073370		Depo: Mittleman, Karen 5/3/2006 EX 095			
04482	DWRITE073349	DWRITE073359		Depo: Mittleman, Karen 5/3/2006 EX 096			
04483	DWRITE073371	DWRITE073381		Depo: Mittleman, Karen 5/3/2006 EX 097			
04484	DWRITE073304	DWRITE073304		Depo: Mittleman, Karen 5/3/2006 EX 098			
04485	DUROJ046-013412	DUROJ046-013417	6/25/2002	Depo: Mittleman, Karen 5/3/2006 EX 099: PUBLICATION PLAN TRACKING REPORT			
04486	DWRITE067287	DWRITE067300	8/15/2002	Depo: Mittleman, Karen 5/3/2006 EX 100			
04487	DWRITE069284	DWRITE069308		Depo: Mittleman, Karen 5/3/2006 EX 101			
04488	DWRITE069746	DWRITE069747		Depo: Mittleman, Karen 5/3/2006 EX 102			
04489	DWRITE066519	DWRITE066519	7/7/2000	Depo: Mittleman, Karen 5/3/2006 EX 103			
04490	DWRITE069749	DWRITE069749	3/17/2000	Depo: Mittleman, Karen 5/3/2006 EX 104			
04491	DWRITE069797	DWRITE069819		Depo: Mittleman, Karen 5/3/2006 EX 105			
04492	DWRITE067796	DWRITE067796	4/12/2000	Depo: Mittleman, Karen 5/3/2006 EX 106			
04493	DWRITE067786	DWRITE067786	1/18/2001	Depo: Mittleman, Karen 5/3/2006 EX 107, 255B; 276			
04494	HRT MED LIT 0372001	HRT MED LIT 0372006	00/00/2000	Depo: Mittleman, Karen 5/3/2006 EX 108: Hormone replacement therapy in the prevention and treatment of atherosclerosis. Mosca, L Curr Atheroscler Rep 2000;2:297-302			
04495	DWRITE077463	DWRITE077476	2/8/2005	Depo: Mittleman, Karen 5/3/2006 EX 109			
04496	DWRITE077710	DWRITE077710	12/1/2003	Depo: Mittleman, Karen 5/3/2006 EX 110			
04497	DWRITE077706	DWRITE077707	12/15/2003	Depo: Mittleman, Karen 5/3/2006 EX 111			
04498	DWRITE077711	DWRITE077711	2/7/2005	Depo: Mittleman, Karen 5/3/2006 EX 111A			
04499	DWRITE077713	DWRITE077713	2/8/2005	Depo: Mittleman, Karen 5/3/2006 EX 112			
04500	DWRITE077477	DWRITE077501		Depo: Mittleman, Karen 5/3/2006 EX 113			
04501	DWRITE077462	DWRITE077462		Depo: Mittleman, Karen 5/3/2006 EX 114			
04502			3/00/2005	Depo: Mittleman, Karen 5/3/2006 EX 115: Menopausal Vasomotor Symptoms Article			
04503	DWRITE003343	DWRITE003344	1/18/2005	Depo: Mittleman, Karen 5/3/2006 EX 116			
04504	DWRITE066496	DWRITE066496	8/30/2000	Depo: Mittleman, Karen 5/3/2006 EX 117			
04505	CONTA025-030538	CONTA025-030539	6/15/2000	Depo: Mittleman, Karen 5/3/2006 EX 118: Strategic Publications Development Meeting			
04506	DWRITE066498	DWRITE066498	10/13/2000	Depo: Mittleman, Karen 5/3/2006 EX 119			
04507	DUROJ023-001774	DUROJ023-001775	11/9/2000	Depo: Mittleman, Karen 5/3/2006 EX 120: Strategic Publications Development Meeting Meeting Recap			
04508	COBBP010-000425	COBBP010-000426	12/5/2000	Depo: Mittleman, Karen 5/3/2006 EX 121: Strategic Publications Development Meeting			
04509	DWRITE067625	DWRITE067625	6/21/2002	Depo: Mittleman, Karen 5/3/2006 EX 122			
04510	DWRITE067289	DWRITE067289		Depo: Mittleman, Karen 5/3/2006 EX 122A; Depo: Mittleman, Karen 5/3/2006 EX 230			
04511	SOLOJ027-048916	SOLOJ027-048916	8/14/2001	Depo: Mittleman, Karen 5/3/2006 EX 122B: Strategic Publications Development Meeting			
04512	DWRITE071244	DWRITE071265		Depo: Mittleman, Karen 5/3/2006 EX 123			
04513	DWRITE067766	DWRITE067766	2/18/2003	Depo: Mittleman, Karen 5/3/2006 EX 124			
04514			4/18/2002	Depo: Mittleman, Karen 5/3/2006 EX 125: Article -- Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy?			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04515			4/18/2002	Depo: Mittleman, Karen 5/3/2006 EX 126: Article -- Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy?			
04516	DWRITE003370	DWRITE003371	11/1/2000	Depo: Mittleman, Karen 5/3/2006 EX 127			
04517	DUROJ023-001712	DUROJ023-001712	1/18/2000	Depo: Mittleman, Karen 5/3/2006 EX 128: Strategic Publications Development Meeting Meeting Recap			
04518	DWRITE067785	DWRITE067785	1/18/2001	Depo: Mittleman, Karen 5/3/2006 EX 129			
04519			00/00/2001	Depo: Mittleman, Karen 5/3/2006 EX 130: Article -- Comparative Tolerability of First-Generation Selective Estrogen Receptor Modulators in Breast Cancer Treatment and Prevention			
04520	DWRITE068896	DWRITE068898		Depo: Mittleman, Karen 5/3/2006 EX 131			
04521	DWRITE068886	DWRITE068886	1/12/2005	Depo: Mittleman, Karen 5/3/2006 EX 132			
04522	DWRITE067402	DWRITE067402	9/19/1997	Depo: Mittleman, Karen 5/3/2006 EX 133			
04523	DWRITE067403	DWRITE067403	10/29/1997	Depo: Mittleman, Karen 5/3/2006 EX 134			
04524	DWRITE067405	DWRITE067405	1/12/1998	Depo: Mittleman, Karen 5/3/2006 EX 135; Depo: Mittleman, Karen 5/3/2006 EX 295			
04525	DWRITE068884	DWRITE068884	1/12/2005	Depo: Mittleman, Karen 5/3/2006 EX 136			
04526	DWRITE068302	DWRITE068302	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 137, 284, 335, 306			
04527	DWRITE068894	DWRITE068894	4/13/1998	Depo: Mittleman, Karen 5/3/2006 EX 138			
04528	DWRITE068885	DWRITE068885	1/12/2005	Depo: Mittleman, Karen 5/3/2006 EX 139			
04529	DWRITE068888	DWRITE068888	1/12/2005	Depo: Mittleman, Karen 5/3/2006 EX 140			
04530	DWRITE068899	DWRITE068918		Depo: Mittleman, Karen 5/3/2006 EX 141			
04531	DWRITE068893	DWRITE068893	1/12/2005	Depo: Mittleman, Karen 5/3/2006 EX 142			
04532	DWRITE068890	DWRITE068892	6/00/1998	Depo: Mittleman, Karen 5/3/2006 EX 143			
04533			00/00/1999	Depo: Mittleman, Karen 5/3/2006 EX 144: Article -- Sex Hormone-Binding Globulin and Breast Cancer Risk			
04534	DWRITE068895	DWRITE068895	1/12/2005	Depo: Mittleman, Karen 5/3/2006 EX 145			
04535	DWRITE003388	DWRITE003388	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 146			
04536	DWRITE068310	DWRITE068310		Depo: Mittleman, Karen 5/3/2006 EX 147			
04537	DWRITE068308	DWRITE068308	6/23/1998	Depo: Mittleman, Karen 5/3/2006 EX 148			
04538	DWRITE068323	DWRITE068323	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 149			
04539	DWRITE067798	DWRITE067798	4/12/2000	Depo: Mittleman, Karen 5/3/2006 EX 150; Depo: Mittleman, Karen 5/3/2006 EX 158A, 169, 337			
04540	DWRITE068328	DWRITE068328	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 151			
04541	DWRITE003288	DWRITE003288	2/18/1999	Depo: Mittleman, Karen 5/3/2006 EX 152			
04542	DWRITE068324	DWRITE068324	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 153			
04543	DWRITE068304	DWRITE068304	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 154, 175, 368			
04544	DWRITE003287	DWRITE003287	2/26/1999	Depo: Mittleman, Karen 5/3/2006 EX 155			
04545	DWRITE077959	DWRITE077989		Depo: Mittleman, Karen 5/3/2006 EX 156			
04546	DWRITE046258	DWRITE046258	4/13/1999	Depo: Mittleman, Karen 5/3/2006 EX 157			
04547	DWRITE067788	DWRITE067788	1/18/2001	Depo: Mittleman, Karen 5/3/2006 EX 158			
04548	DWRITE067798	DWRITE067798	4/12/2000	Depo: Mittleman, Karen 5/3/2006 EX 158A			
04549	DWRITE067403	DWRITE067403	10/29/1997	Depo: Mittleman, Karen 5/3/2006 EX 159			
04550	DWRITE068308	DWRITE068308	6/23/1998	Depo: Mittleman, Karen 5/3/2006 EX 160			
04551			4/25/2006	Depo: Mittleman, Karen 5/3/2006 EX 161: Article -- The Role of Hormone Replacement Therapy in the Management of Type 2 Diabetes in Postmenopausal Women			
04552	DWRITE068302	DWRITE068302	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 162			
04553	DWRITE079049	DWRITE079091		Depo: Mittleman, Karen 5/3/2006 EX 163			
04554	DWRITE079094	DWRITE079094	11/9/1999	Depo: Mittleman, Karen 5/3/2006 EX 163A			
04555	DWRITE079118	DWRITE079118	11/4/1999	Depo: Mittleman, Karen 5/3/2006 EX 164			
04556	DWRITE079093	DWRITE079093	3/27/2000	Depo: Mittleman, Karen 5/3/2006 EX 165			
04557	DWRITE079095	DWRITE079099		Depo: Mittleman, Karen 5/3/2006 EX 166			
04558	DWRITE079098	DWRITE079099		Depo: Mittleman, Karen 5/3/2006 EX 167			
04559	DWRITE079092	DWRITE079092	4/3/2000	Depo: Mittleman, Karen 5/3/2006 EX 168			
04560	DWRITE067798	DWRITE067798	4/12/2000	Depo: Mittleman, Karen 5/3/2006 EX 169			
04561	DWRITE079097	DWRITE079097	11/15/2000	Depo: Mittleman, Karen 5/3/2006 EX 170			
04562	DWRITE068294	DWRITE068294		Depo: Mittleman, Karen 5/3/2006 EX 171			
04563			00/00/2001	Depo: Mittleman, Karen 5/3/2006 EX 172: Article -- The Use of Hormone Replacement Therapy in Postmenopausal Women with Type 2 Diabetes			
04564	SOLOJ027-023276	SOLOJ027-023277	5/24/2002	Depo: Mittleman, Karen 5/3/2006 EX 173; Depo: Warren, Amy 5/25/06 EX 039: Publication Plan Tracking Report - Completed Papers			
04565	DWRITE069003	DWRITE069007		Depo: Mittleman, Karen 5/3/2006 EX 174			
04566	DWRITE068304	DWRITE068304	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 175			
04567	DWRITE068325	DWRITE068325	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 176			
04568	CONTA023-016384	CONTA023-016445	2/11/1999	Depo: Mittleman, Karen 5/3/2006 EX 177: Premarin Preemptive Plan Feb. 11, 1999			
04569	DWRITE067815	DWRITE067816	6/26/2001	Depo: Mittleman, Karen 5/3/2006 EX 178			
04570	OLIVS006-000944	OLIVS006-000945	10/16/2001	Depo: Mittleman, Karen 5/3/2006 EX 179: Strategic Publications Development Meeting			
04571	DWRITE067821	DWRITE067821	7/26/2001	Depo: Mittleman, Karen 5/3/2006 EX 179A			
04572	DWRITE067830	DWRITE067851		Depo: Mittleman, Karen 5/3/2006 EX 180			
04573	DWRITE068047	DWRITE068055	8/26/1999	Depo: Mittleman, Karen 5/3/2006 EX 181			
04574	DWRITE068055	DWRITE068055		Depo: Mittleman, Karen 5/3/2006 EX 181A			
04575			00/00/2004	Depo: Mittleman, Karen 5/3/2006 EX 182			
04576	DWRITE067253	DWRITE067253	1/28/2002	Depo: Mittleman, Karen 5/3/2006 EX 183			
04577	DWRITE003327	DWRITE003328	1/31/2005	Depo: Mittleman, Karen 5/3/2006 EX 184			
04578	DWRITE067254	DWRITE067254	2/25/2002	Depo: Mittleman, Karen 5/3/2006 EX 185			
04579	DWRITE074957	DWRITE074957	11/26/2002	Depo: Mittleman, Karen 5/3/2006 EX 186			
04580	DWRITE068914	DWRITE068914	4/25/2002	Depo: Mittleman, Karen 5/3/2006 EX 187			
04581	DWRITE074897	DWRITE074903		Depo: Mittleman, Karen 5/3/2006 EX 188			
04582	DWRITE074936	DWRITE074945		Depo: Mittleman, Karen 5/3/2006 EX 189			
04583	DWRITE003248	DWRITE003248	4/29/2002	Depo: Mittleman, Karen 5/3/2006 EX 190			
04584	DWRITE074958	DWRITE003248	1/31/2005	Depo: Mittleman, Karen 5/3/2006 EX 191			
04585	DWRITE074877		8/26/2002	Depo: Mittleman, Karen 5/3/2006 EX 192			
04586	DWRITE003339	DWRITE003340	1/18/2005	Depo: Mittleman, Karen 5/3/2006 EX 193			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04587	DWRITE003252	DWRITE003252	6/28/2000	Depo: Mittleman, Karen 5/3/2006 EX 193A			
04588	DWRITE003255	DWRITE003255	8/25/2000	Depo: Mittleman, Karen 5/3/2006 EX 193B			
04589	DELCA033-028519	DELCA033-028520	9/11/2000	Depo: Mittleman, Karen 5/3/2006 EX 194: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EX 255: Strategic Publications Development Meeting			
04590	DWRITE003253	DWRITE003253	9/15/2000	Depo: Mittleman, Karen 5/3/2006 EX 195			
04591	DELCA033-028522	DELCA033-028522	9/27/2000	Depo: Mittleman, Karen 5/3/2006 EX 196			
04592	DUROJ023-001774	DUROJ023-001776	11/9/2000	Depo: Mittleman, Karen 5/3/2006 EX 197: Strategic Publications Development Meeting Meeting Recap			
04593	DWRITE069536	DWRITE069567		Depo: Mittleman, Karen 5/3/2006 EX 198			
04594	OLIVS006-000944	OLIVS006-000945	10/16/2001	Depo: Mittleman, Karen 5/3/2006 EX 199: Strategic Publications Development Meeting			
04595	DWRITE067291	DWRITE067291		Depo: Mittleman, Karen 5/3/2006 EX 200			
04596	DUROJ046-013297	DUROJ046-013297	5/17/2002	Depo: Mittleman, Karen 5/3/2006 EX 201			
04597	DELCA031-006863	DELCA031-006863	5/24/2002	Depo: Mittleman, Karen 5/3/2006 EX 202: Clinical Markers for Osteoporosis Outcomes			
04598	DWRITE003361	DWRITE003362	1/18/2005	Depo: Mittleman, Karen 5/3/2006 EX 203			
04599	DWRITE066502	DWRITE066502	5/4/2000	Depo: Mittleman, Karen 5/3/2006 EX 203A			
04600	CONTA025-030538	CONTA025-030539	6/15/2000	Depo: Mittleman, Karen 5/3/2006 EX 204: Strategic Publications Development Meeting			
04601	CONTA025-019965	CONTA025-019966	6/25/2002	Depo: Mittleman, Karen 5/3/2006 EX 205: FW: HRT in the Prevention of AD paper			
04602	DWRITE066503	DWRITE066503	7/27/2000	Depo: Mittleman, Karen 5/3/2006 EX 206			
04603	DWRITE066936	DWRITE066936	8/17/2000	Depo: Mittleman, Karen 5/3/2006 EX 207			
04604	DWRITE066543	DWRITE066543	10/25/2001	Depo: Mittleman, Karen 5/3/2006 EX 208			
04605	DWRITE066940	DWRITE066940	11/9/2000	Depo: Mittleman, Karen 5/3/2006 EX 209			
04606	DUROJ023-001774	DUROJ023-001776	11/9/2000	Depo: Mittleman, Karen 5/3/2006 EX 210: Strategic Publications Development Meeting Meeting Recap			
04607	DWRITE066920	DWRITE066920	1/18/2001	Depo: Mittleman, Karen 5/3/2006 EX 211			
04608	DWRITE066330	DWRITE066330	1/24/2005	Depo: Mittleman, Karen 5/3/2006 EX 212			
04609	SOLOJ027-048916	SOLOJ027-048917	8/14/2001	Depo: Mittleman, Karen 5/3/2006 EX 213: Strategic Publications Development Meeting			
04610	DWRITE069866	DWRITE069866	12/17/2001	Depo: Mittleman, Karen 5/3/2006 EX 214			
04611	DWRITE067767	DWRITE067767	2/18/2003	Depo: Mittleman, Karen 5/3/2006 EX 215; Depo: Mittleman, Karen 5/3/2006 EX 299			
04612	DWRITE066544	DWRITE066589		Depo: Mittleman, Karen 5/3/2006 EX 216			
04613			9/23/2002	Depo: Mittleman, Karen 5/3/2006 EX 217: Article -- The Role of Hormone Replacement Therapy in the Prevention of Alzheimer Disease			
04614	DWRITE067409	DWRITE067409	5/8/1998	Depo: Mittleman, Karen 5/3/2006 EX 218			
04615	DWRITE071026	DWRITE071026	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 219			
04616	DWRITE068320	DWRITE068320	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 220			
04617	DWRITE068301	DWRITE068304	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 221, 244, 294, 349			
04618	DWRITE071052	DWRITE071096		Depo: Mittleman, Karen 5/3/2006 EX 222			
04619	DWRITE068137	DWRITE068137	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 223			
04620	DWRITE068142	DWRITE068142	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 224			
04621			4/00/2000	Depo: Mittleman, Karen 5/3/2006 EX 225: Article -- Mild Cognitive Impairment: Potential Pharmacological Treatment Options			
04622	DWRITE003374	DWRITE003375	7/10/2000	Depo: Mittleman, Karen 5/3/2006 EX 226			
04623	DWRITE003250	DWRITE003250	7/7/2000	Depo: Mittleman, Karen 5/3/2006 EX 227			
04624	DWRITE003249	DWRITE003249	3/15/2001	Depo: Mittleman, Karen 5/3/2006 EX 228			
04625	DWRITE003273	DWRITE003273	2/11/2003	Depo: Mittleman, Karen 5/3/2006 EX 229			
04626	DWRITE067289	DWRITE067289		Depo: Mittleman, Karen 5/3/2006 EX 230			
04627	DWRITE067791	DWRITE067791	1/18/2001	Depo: Mittleman, Karen 5/3/2006 EX 231			
04628	DWRITE071266	DWRITE071309		Depo: Mittleman, Karen 5/3/2006 EX 232			
04629	DWRITE066952	DWRITE066952	00/00/2002	Depo: Mittleman, Karen 5/3/2006 EX 232A			
04630			00/00/2002	Depo: Mittleman, Karen 5/3/2006 EX 233: Article -- Quality of Life and Menopause:The Role of Estrogen			
04631	CONTA023-007214	CONTA023-007219		Depo: Mittleman, Karen 5/3/2006 EX 234			
04632	DWRITE003353	DWRITE003354	1/18/2005	Depo: Mittleman, Karen 5/3/2006 EX 235			
04633	CONTA025-030538	CONTA025-030539	6/15/2000	Depo: Mittleman, Karen 5/3/2006 EX 236: Strategic Publications Development Meeting			
04634	DWRITE067784	DWRITE067784	1/18/2001	Depo: Mittleman, Karen 5/3/2006 EX 237			
04635	DWRITE003258	DWRITE003258	4/24/2001	Depo: Mittleman, Karen 5/3/2006 EX 238			
04636	MARTN010-010296	MARTN010-010297	7/23/2001	Depo: Mittleman, Karen 5/3/2006 EX 239: Strategic Publications Development Meeting			
04637	SOLOJ027-048916	SOLOJ027-048917	8/14/2001	Depo: Mittleman, Karen 5/3/2006 EX 240: Strategic Publications Development Meeting			
04638	DWRITE066322	DWRITE066322	1/24/2005	Depo: Mittleman, Karen 5/3/2006 EX 240A			
04639	DWRITE071149	DWRITE071149	2/20/2002	Depo: Mittleman, Karen 5/3/2006 EX 240B			
04640	DWRITE071148	DWRITE071148	3/7/2002	Depo: Mittleman, Karen 5/3/2006 EX 240C			
04641	DWRITE066449	DWRITE066449	10/3/2000	Depo: Mittleman, Karen 5/3/2006 EX 240D			
04642	DWRITE067293	DWRITE067293		Depo: Mittleman, Karen 5/3/2006 EX 240E			
04643	DWRITE071150	DWRITE071150	10/30/2002	Depo: Mittleman, Karen 5/3/2006 EX 240F			
04644	DWRITE071118	DWRITE071147		Depo: Mittleman, Karen 5/3/2006 EX 241			
04645			9/20/2002	Depo: Mittleman, Karen 5/3/2006 EX 242: Article -- Progestins and breast cancer			
04646	DWRITE068308	DWRITE068308	6/23/1998	Depo: Mittleman, Karen 5/3/2006 EX 243			
04647	DWRITE068301	DWRITE068304	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 244			
04648	DWRITE068320	DWRITE068320	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 245			
04649	DWRITE067795	DWRITE067795	4/12/2000	Depo: Mittleman, Karen 5/3/2006 EX 246; Depo: Mittleman, Karen 5/3/2006 EX 369			
04650	DWRITE003278	DWRITE003278	12/4/2000	Depo: Mittleman, Karen 5/3/2006 EX 247			
04651	DWRITE068310	DWRITE068310		Depo: Mittleman, Karen 5/3/2006 EX 248			
04652	HRT MED LIT 0524001	HRT MED LIT 0524010	8/14/2000	Depo: Mittleman, Karen 5/3/2006 EX 249: The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Mosca, L Arch Intern Med. 2000;160:2263-72			
04653	DWRITE012117	DWRITE012132		Depo: Mittleman, Karen 5/3/2006 EX 250			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04654	DWRITE006137	DWRITE006168		Depo: Mittleman, Karen 5/3/2006 EX 251			
04655	DWRITE040385	DWRITE040419		Depo: Mittleman, Karen 5/3/2006 EX 252			
04656	DWRITE003355	DWRITE003356	1/18/2005	Depo: Mittleman, Karen 5/3/2006 EX 253			
04657	DELCA033-028521	DELCA033-028522	9/27/2000	Depo: Mittleman, Karen 5/3/2006 EX 254: PUBLICATION PLAN TRACKING REPORT			
04658	DELCA033-028519	DELCA033-028520	9/11/2000	Depo: Mittleman, Karen 5/3/2006 EX 255: Strategic Publications Development Meeting			
04659	DWRITE066521	DWRITE066521	12/4/2000	Depo: Mittleman, Karen 5/3/2006 EX 255A			
04660	DWRITE067786	DWRITE067786	1/18/2001	Depo: Mittleman, Karen 5/3/2006 EX 255B			
04661	DWRITE066922	DWRITE066922	2/28/2001	Depo: Mittleman, Karen 5/3/2006 EX 255C			
04662	DWRITE003261	DWRITE003261	8/24/2001	Depo: Mittleman, Karen 5/3/2006 EX 255D; Depo: Mittleman, Karen 5/3/2006 EX 267			
04663			5/00/2004	Depo: Mittleman, Karen 5/3/2006 EX 256: Article -- New Clinical Markers Predictive of Cardiovascular Disease: The Role of Inflammatory Mediators			
04664	DWRITE067546	DWRITE067546	2/4/2002	Depo: Mittleman, Karen 5/3/2006 EX 257			
04665	DWRITE067295	DWRITE067295		Depo: Mittleman, Karen 5/3/2006 EX 258; Depo: Mittleman, Karen 5/3/2006 EX 266			
04666	DWRITE069933	DWRITE069934	2/18/2003	Depo: Mittleman, Karen 5/3/2006 EX 259			
04667	DWRITE069935	DWRITE069961		Depo: Mittleman, Karen 5/3/2006 EX 260			
04668	DWRITE067778	DWRITE067778	1/31/2005	Depo: Mittleman, Karen 5/3/2006 EX 261; Depo: Mittleman, Karen 5/3/2006 EX 269; Depo: Mittleman, Karen 5/3/2006 EX 279			
04669	DWRITE069927	DWRITE069929	1/18/2005	Depo: Mittleman, Karen 5/3/2006 EX 262			
04670	DWRITE069930	DWRITE069932		Depo: Mittleman, Karen 5/3/2006 EX 263			
04671	COBBP010-000425	COBBP010-000425	12/5/2000	Depo: Mittleman, Karen 5/3/2006 EX 264: Strategic Publications Development Meeting			
04672	WEBEM015-012037	WEBEM015-012038	2/28/2001	Depo: Mittleman, Karen 5/3/2006 EX 265: Strategic Publications Development Meeting			
04673	DWRITE067295	DWRITE067295		Depo: Mittleman, Karen 5/3/2006 EX 266			
04674	DWRITE003261	DWRITE003261	8/24/2001	Depo: Mittleman, Karen 5/3/2006 EX 267			
04675	OLIVS013-000002	OLIVS013-000002	11/6/2001	Depo: Mittleman, Karen 5/3/2006 EX 268: Strategic Publications Development Meeting Recap			
04676	DWRITE067778	DWRITE067778	1/31/2005	Depo: Mittleman, Karen 5/3/2006 EX 269			
04677	DWRITE069927	DWRITE069932	1/18/2005	Depo: Mittleman, Karen 5/3/2006 EX 270			
04678	DWRITE070001	DWRITE070029		Depo: Mittleman, Karen 5/3/2006 EX 271			
04679	DWRITE067705	DWRITE067705		Depo: Mittleman, Karen 5/3/2006 EX 272			
04680			5/00/2004	Depo: Mittleman, Karen 5/3/2006 EX 273: Article -- New Clinical Markers Predictive of Cardiovascular Disease: The Role of Inflammatory Mediators			
04681	DWRITE003266	DWRITE003266	12/4/2000	Depo: Mittleman, Karen 5/3/2006 EX 274			
04682	MARTN010-003763	MARTN010-003763	12/5/2000	Depo: Mittleman, Karen 5/3/2006 EX 275: Strategic Publications Development Meeting			
04683	DWRITE067786	DWRITE067786	1/18/2001	Depo: Mittleman, Karen 5/3/2006 EX 276			
04684	CONTA025-029486	CONTA025-029486	12/8/2000	Depo: Mittleman, Karen 5/3/2006 EX 277: Fillit's paper and Speroff's outline			
04685	DUROJ023-001712	DUROJ023-001712	1/18/2000	Depo: Mittleman, Karen 5/3/2006 EX 278: Strategic Publications Development Meeting Meeting Recap			
04686	DWRITE067778	DWRITE067778	1/31/2005	Depo: Mittleman, Karen 5/3/2006 EX 279			
04687	SOLOJ027-048916	SOLOJ027-048917	8/14/2001	Depo: Mittleman, Karen 5/3/2006 EX 280: Strategic Publications Development Meeting			
04688	DWRITE065477	DWRITE065480		Depo: Mittleman, Karen 5/3/2006 EX 281			
04689	DWRITE003345	DWRITE003346	8/16/2001	Depo: Mittleman, Karen 5/3/2006 EX 282			
04690	DWRITE066469	DWRITE066469	8/15/2001	Depo: Mittleman, Karen 5/3/2006 EX 283			
04691	DWRITE068302	DWRITE068302	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 284			
04692	DWRITE003394	DWRITE003396	8/4/1997	Depo: Mittleman, Karen 5/3/2006 EX 285			
04693	DWRITE067402	DWRITE067402	9/19/1997	Depo: Mittleman, Karen 5/3/2006 EX 286			
04694	DWRITE067403	DWRITE067403	10/29/1997	Depo: Mittleman, Karen 5/3/2006 EX 287			
04695	DWRITE067405	DWRITE067405	1/12/1998	Depo: Mittleman, Karen 5/3/2006 EX 288			
04696	DWRITE068320	DWRITE068320	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 289			
04697			00/00/1998	Depo: Mittleman, Karen 5/3/2006 EX 290: Article -- Is There an Association between Hormone Replacement Therapy and Breast Cancer?			
04698	DWRITE067764	DWRITE067764	2/18/2003	Depo: Mittleman, Karen 5/3/2006 EX 291			
04699	DWRITE003382	DWRITE003382	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 292			
04700	DWRITE068925	DWRITE068944		Depo: Mittleman, Karen 5/3/2006 EX 293			
04701	DWRITE068301	DWRITE068304	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 294			
04702	DWRITE067403	DWRITE067403	10/29/1997	Depo: Mittleman, Karen 5/3/2006 EX 295			
04703	DWRITE068307	DWRITE068307	1/28/1998	Depo: Mittleman, Karen 5/3/2006 EX 296			
04704	DWRITE068308	DWRITE068308	6/23/1998	Depo: Mittleman, Karen 5/3/2006 EX 297			
04705	DWRITE068319	DWRITE068319	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 298			
04706	DWRITE067767	DWRITE067767	2/18/2003	Depo: Mittleman, Karen 5/3/2006 EX 299			
04707	DWRITE046262	DWRITE046262	5/11/1999	Depo: Mittleman, Karen 5/3/2006 EX 300			
04708	DWRITE003381	DWRITE003381	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 301			
04709	DWRITE067797	DWRITE067797	4/12/2000	Depo: Mittleman, Karen 5/3/2006 EX 302			
04710			4/00/1999	Depo: Mittleman, Karen 5/3/2006 EX 303: Article -- Practical Strategies for the Diagnosis and Treatment of Alzheimer's Disease			
04711	DWRITE068316	DWRITE068316		Depo: Mittleman, Karen 5/3/2006 EX 304			
04712	DWRITE068325	DWRITE068325	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 305			
04713	DWRITE068303	DWRITE068303	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 306			
04714	DWRITE068323	DWRITE068323	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 307			
04715			8/00/1999	Depo: Mittleman, Karen 5/3/2006 EX 308: Article -- Aging and Menopause: Targeting Strategies for Therapies			
04716	DWRITE073013	DWRITE073038		Depo: Mittleman, Karen 5/3/2006 EX 309			
04717	DWRITE073011	DWRITE073011	11/22/2000	Depo: Mittleman, Karen 5/3/2006 EX 310			
04718	DWRITE067531	DWRITE067531	11/11/2002	Depo: Mittleman, Karen 5/3/2006 EX 311			
04719	DWRITE072911	DWRITE072938		Depo: Mittleman, Karen 5/3/2006 EX 312			
04720	DWRITE072945	DWRITE072945		Depo: Mittleman, Karen 5/3/2006 EX 313			
04721	DWRITE072946	DWRITE072947	2/15/2001	Depo: Mittleman, Karen 5/3/2006 EX 314			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04722	DWRITE073004	DWRITE073004	3/20/2001	Depo: Mittleman, Karen 5/3/2006 EX 314A			
04723			2/17/2001	Depo: Mittleman, Karen 5/3/2006 EX 315: Article -- Is Low-dose hormone replacement therapy for postmenopausal women efficacious and desirable?			
04724	DWRITE072968	DWRITE072968	2/14/2003	Depo: Mittleman, Karen 5/3/2006 EX 316			
04725	DWRITE072638	DWRITE072639	1/17/2005	Depo: Mittleman, Karen 5/3/2006 EX 318			
04726	DWRITE072640	DWRITE072642	5/00/2002	Depo: Mittleman, Karen 5/3/2006 EX 319			
04727	DWRITE072629	DWRITE072634	5/20/2002	Depo: Mittleman, Karen 5/3/2006 EX 320			
04728	COBBP007-001118	DWRITE072637	5/20/2002	Depo: Mittleman, Karen 5/3/2006 EX 321: Metabolic Effects of Menopausal Therapies			
04729	DWRITE072645	DWRITE072649	5/00/2002	Depo: Mittleman, Karen 5/3/2006 EX 322			
04730	DWRITE072637	DWRITE072637	10/30/2002	Depo: Mittleman, Karen 5/3/2006 EX 323			
04731	DWRITE068811	DWRITE068814		Depo: Mittleman, Karen 5/3/2006 EX 324			
04732	DWRITE067407	DWRITE067407	1/12/2005	Depo: Mittleman, Karen 5/3/2006 EX 325			
04733	DWRITE068810	DWRITE068810	1/12/2005	Depo: Mittleman, Karen 5/3/2006 EX 326			
04734	DWRITE068326	DWRITE068326	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 327			
04735	DWRITE068319	DWRITE068319	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 328			
04736	DWRITE003397	DWRITE003397	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 329			
04737	DWRITE068843	DWRITE068881		Depo: Mittleman, Karen 5/3/2006 EX 330			
04738	DWRITE068317	DWRITE068317		Depo: Mittleman, Karen 5/3/2006 EX 331			
04739	DWRITE067792	DWRITE067792	1/18/2001	Depo: Mittleman, Karen 5/3/2006 EX 332			
04740			00/00/1999	Depo: Mittleman, Karen 5/3/2006 EX 333: Article -- Selective Estrogen Receptor Modulators: A Controversial Approach for Managing Postmenopausal Health			
04741	DWRITE068322	DWRITE068322	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 334			
04742	DWRITE068302	DWRITE068302	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 335			
04743	DWRITE068315	DWRITE068315		Depo: Mittleman, Karen 5/3/2006 EX 336			
04744	DWRITE067798	DWRITE067798	4/12/2000	Depo: Mittleman, Karen 5/3/2006 EX 337			
04745	MARTN010-003763	MARTN010-003764	12/5/2000	Depo: Mittleman, Karen 5/3/2006 EX 338: Strategic Publications Development Meeting			
04746	DWRITE070295	DWRITE070329	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 339			
04747	DWRITE070861	DWRITE070865		Depo: Mittleman, Karen 5/3/2006 EX 340			
04748	DWRITE068317	DWRITE068317		Depo: Mittleman, Karen 5/3/2006 EX 341			
04749	CONTA023-008846	CONTA023-008847	5/25/2000	Depo: Mittleman, Karen 5/3/2006 EX 342, 351; Depo: Speroff, Leon 6/30/2005 EX 022			
04750	DWRITE068315	DWRITE068315		Depo: Mittleman, Karen 5/3/2006 EX 343			
04751	MARTN010-003257	MARTN010-003259		Depo: Mittleman, Karen 5/3/2006 EX 344: PUBLICATION PLAN TRACKING REPORT			
04752	DWRITE070859	DWRITE070859	12/11/2000	Depo: Mittleman, Karen 5/3/2006 EX 345			
04753	DWRITE070866	DWRITE070894		Depo: Mittleman, Karen 5/3/2006 EX 346			
04754	OLIVS006-000944	OLIVS006-000945	10/16/2001	Depo: Mittleman, Karen 5/3/2006 EX 347: Strategic Publications Development Meeting			
04755	DWRITE067768	DWRITE067768	2/18/2003	Depo: Mittleman, Karen 5/3/2006 EX 348			
04756	DWRITE068301	DWRITE068301	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 349			
04757	DWRITE068319	DWRITE068319	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 350			
04758	CONTA023-008846	CONTA023-008847	5/25/2000	Depo: Mittleman, Karen 5/3/2006 EX 351			
04759	CONTA025-030538	CONTA025-030539	6/15/2000	Depo: Mittleman, Karen 5/3/2006 EX 352: Strategic Publications Development Meeting			
04760	DWRITE067808	DWRITE067808	4/12/2000	Depo: Mittleman, Karen 5/3/2006 EX 352A			
04761	DWRITE068317	DWRITE068317		Depo: Mittleman, Karen 5/3/2006 EX 353			
04762	DWRITE070957	DWRITE071012		Depo: Mittleman, Karen 5/3/2006 EX 354			
04763	DWRITE070953	DWRITE070953	1/8/2001	Depo: Mittleman, Karen 5/3/2006 EX 355			
04764	MARTN010-005742	MARTN010-005743	2/28/2001	Depo: Mittleman, Karen 5/3/2006 EX 356: Strategic Publications Development Meeting; Depo: Mittleman, Karen 5/3/2006 EX 364: Strategic Publications Development Meeting			
04765			2/00/2001	Depo: Mittleman, Karen 5/3/2006 EX 357: Article -- Role of Estrogens in the Management of Postmenopausal Bone Loss			
04766	DUROJ046-013387	DUROJ046-013387	6/25/2002	Depo: Mittleman, Karen 5/3/2006 EX 357A: PUBLICATION PLAN TRACKING REPORT			
04767	COBBP010-000412	COBBP010-000414	11/9/2000	Depo: Mittleman, Karen 5/3/2006 EX 358: Strategic Publications Development Meeting			
04768	DWRITE078677	DWRITE078695		Depo: Mittleman, Karen 5/3/2006 EX 359			
04769	DUROJ023-001774	DUROJ023-001776	11/9/2000	Depo: Mittleman, Karen 5/3/2006 EX 360: Strategic Publications Development Meeting Meeting Recap			
04770	COBBP010-000425	COBBP010-000426	12/5/2000	Depo: Mittleman, Karen 5/3/2006 EX 361: Strategic Publications Development Meeting			
04771	DWRITE066938	DWRITE066938	9/28/2000	Depo: Mittleman, Karen 5/3/2006 EX 362			
04772	DWRITE066939	DWRITE066939	10/19/2000	Depo: Mittleman, Karen 5/3/2006 EX 363			
04773	MARTN010-005742	MARTN010-005743	2/28/2001	Depo: Mittleman, Karen 5/3/2006 EX 364: Strategic Publications Development Meeting			
04774	DWRITE066926	DWRITE066926	8/14/2001	Depo: Mittleman, Karen 5/3/2006 EX 364A			
04775	SOLOJ027-048916	SOLOJ027-048917	8/14/2001	Depo: Mittleman, Karen 5/3/2006 EX 365: Strategic Publications Development Meeting			
04776			00/00/2002	Depo: Mittleman, Karen 5/3/2006 EX 366: American Society for Reproductive Medicine Newsletter			
04777	DWRITE068920	DWRITE068924		Depo: Mittleman, Karen 5/3/2006 EX 367			
04778	DWRITE068304	DWRITE068304	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 368			
04779	DWRITE067795	DWRITE067795	4/12/2000	Depo: Mittleman, Karen 5/3/2006 EX 369			
04780	DWRITE068325	DWRITE068325	1/11/2005	Depo: Mittleman, Karen 5/3/2006 EX 370			
04781	DWRITE069347	DWRITE069353		Depo: Mittleman, Karen 5/3/2006 EX 371			
04782	DWRITE069357	DWRITE069360		Depo: Mittleman, Karen 5/3/2006 EX 372			
04783	DWRITE069333	DWRITE069346		Depo: Mittleman, Karen 5/3/2006 EX 373			
04784	DWRITE069319	DWRITE069319	1/28/2002	Depo: Mittleman, Karen 5/3/2006 EX 374			
04785	DWRITE067400	DWRITE067400	5/20/2002	Depo: Mittleman, Karen 5/3/2006 EX 375			
04786	DWRITE065475	DWRITE065475		Depo: Mittleman, Karen 5/3/2006 EX 376			
04787	DWRITE069320	DWRITE069331		Depo: Mittleman, Karen 5/3/2006 EX 377			
04788	DWRITE003359	DWRITE003360	1/18/2005	Depo: Mittleman, Karen 5/3/2006 EX 378			
04789	DWRITE066231	DWRITE066232		Depo: Mittleman, Karen 5/3/2006 EX 379			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04790			1/00/2006	Depo: Morris, Louis 5/9/2006 EX 001: Morris, Louis CV			
04791			4/20/2006	Depo: Morris, Louis 5/9/2006 EX 002: Morris, Louis Summary of Qualifications			
04792			4/20/2006	Depo: Morris, Louis 5/9/2006 EX 003: Louis A. Morris & Associates Invoices			
04793				Depo: Morris, Louis 5/9/2006 EX 004: Leapfrog Report			
04794				Depo: Morris, Louis 5/9/2006 EX 005: Salesworks Report			
04795				Depo: Morris, Louis 5/9/2006 EX 006: Materials Reviewed by Louis Morris			
04796				Depo: Morris, Louis 5/9/2006 EX 007: Description of Documents			
04835				Depo: Olivier, Sophie 9/14/2005 EX 001: Olivier, Sophie CV			
04836	OLIVS021-027201	OLIVS021-027205		Depo: Olivier, Sophie 9/14/2005 EX 002: Sophie OLIVIER			
04837	OLIVS021-035288	OLIVS021-035310	10/17/2000	Depo: Olivier, Sophie 9/14/2005 EX 003			
04838	OLIVS008-001087	OLIVS008-001089	3/28/2001	Depo: Olivier, Sophie 9/14/2005 EX 004: Long-Term Benefits of HRT			
04839	OLIVS001-000953	OLIVS001-000954	7/3/2001	Depo: Olivier, Sophie 9/14/2005 EX 005: Justification Document Conjugated Estrogens and Conjugated Estrogens with Medroxyprogesterone (MPA) Breast Cancer			
04840	ZUCAV008-042745	ZUCAV008-042746	7/3/2001	Depo: Olivier, Sophie 9/14/2005 EX 006: Unknown			
04841	BURKM029-024148	BURKM029-024149	7/3/2001	Depo: Olivier, Sophie 9/14/2005 EX 007: Unknown			
04842	CONSG018-011779	CONSG018-011783	9/21/2001	Depo: Olivier, Sophie 9/14/2005 EX 008: CONFIDENTIAL			
04843	OLIVS018-011208	OLIVS018-011210		Depo: Olivier, Sophie 9/14/2005 EX 009			
04844	OLIVS014-001405	OLIVS014-001406	10/19/2001	Depo: Olivier, Sophie 9/14/2005 EX 010: EMEA Core HRT SPC: Justification for HERS Wording for all Estrogen Formulations			
04845	OLIVS019-029893	OLIVS019-029895		Depo: Olivier, Sophie 9/14/2005 EX 011: No Title			
04846	OLIVS019-024695	OLIVS019-024695	1/22/2002	Depo: Olivier, Sophie 9/14/2005 EX 012: Investigator initiated proposal of dr. Franke			
04847	BURKM029-015868	BURKM029-015868	6/28/2002	Depo: Olivier, Sophie 9/14/2005 EX 013: Premarin CDS			
04848	OLIVS012-001921	OLIVS012-001922	2/25/2000	Depo: Olivier, Sophie 9/14/2005 EX 014: Breast Cancer Issue			
04849	OLIVS019-005908	OLIVS019-005909	9/7/2002	Depo: Olivier, Sophie 9/14/2005 EX 015: Re: First stab at BC section			
04850	OLIVS014-002040	OLIVS014-002041	10/11/2002	Depo: Olivier, Sophie 9/14/2005 EX 016: 10/11/2002 Minutes			
04851	OLIVS018-003042	OLIVS018-003056		Depo: Olivier, Sophie 9/14/2005 EX 017			
04852	OLIVS021-014979	OLIVS021-014979	10/24/2002	Depo: Olivier, Sophie 9/14/2005 EX 018: HRT Meeting in Washington			
04853	BURKM029-011426	BURKM029-011453	7/25/2002	Depo: Olivier, Sophie 9/14/2005 EX 019: No Title			
04854	OLIVS014-001893	OLIVS014-001902		Depo: Olivier, Sophie 9/14/2005 EX 020: Overall WHI design Review HRT trial			
04855				Depo: Olivier, Sophie 9/14/2005 EX 021: Note -- Exhibit 21 Not Marked			
04856	OLIVS018-003057	OLIVS018-003058		Depo: Olivier, Sophie 9/14/2005 EX 022			
04857	OLIVS018-003155	OLIVS018-003159	00/00/2001	Depo: Olivier, Sophie 9/14/2005 EX 023			
04858	Various	Various	2/17/1999	Depo: Olivier, Sophie 9/14/2005 EX 024: Estrogen Replacement Therapy for the Treatment of Osteoporosis			
04859	OLIVS011-000835	OLIVS011-000834	7/00/2001	Depo: Olivier, Sophie 9/14/2005 EX 025			
04860	OLIVS006-001269	OLIVS006-001271	10/28/1999	Depo: Olivier, Sophie 9/14/2005 EX 026: Data in Three New Studies Ephasize Importance of Primary Prevention of Cardiovascular Disease in Postmenopausal Women			
04861	OLIVS014-000983	OLIVS014-000983	3/00/2000	Depo: Olivier, Sophie 9/14/2005 EX 027: Consider the Benefits of ERT and HRT			
04862			4/18/2006	Depo: Page, David 4/29/2006 EX 001: Plaintiffs' Notice of Discovery Deposition of David Page, M.D.			
04863			2/17/2006	Depo: Page, David 4/29/2006 EX 002: Expert Report of David L. Page, MD			
04864			4/20/2006	Depo: Page, David 4/29/2006 EX 003: Report on Linda Reeves by David L. Page, MD			
04865			4/20/2006	Depo: Page, David 4/29/2006 EX 004: Report on Helene Rush by David L. Page, MD			
04866			4/20/2006	Depo: Page, David 4/29/2006 EX 005: Expert Report of David L. Page, MD			
04867			3/23/2006	Depo: Page, David 4/29/2006 EX 006: Pathology slides on Helene Rush			
04868			3/30/2006	Depo: Page, David 4/29/2006 EX 007: Jeanie B. Nelson Index of Records			
04869			3/22/2006	Depo: Page, David 4/29/2006 EX 008: Dr.Peterson Transcript.pdf			
04870			12/21/2005	Depo: Page, David 4/29/2006 EX 009: Vanderbilt university medical center/ bill on 12/19/05			
04871			00/00/2001	Depo: Page, David 4/29/2006 EX 010: Histlological and biological evolution of human premalignant breast disease. Article			
04872	HRT MED LIT 0881001	HRT MED LIT 0881007	8/16/1999	Depo: Page, David 4/29/2006 EX 011 and Winneker, Rick 03/31/2009 EX 99: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. Hofseth, LJ, Raafat, AM, Osuch, JR, Pat			
04873			00/00/2000	Depo: Page, David 4/29/2006 EX 012: Mammographic Density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable. Article			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04874			3/22/2006	Depo: Page, David 4/29/2006 EX 013: Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. BIOMED Article			
04875				Depo: Panagy, Andrew 3/30/2004 EX 001: Plaintiffs' Notice of Corporate Deposition of Defendant WYETH Pursuant to P.A.R.C.P. 4007.1(e)			
04876				Depo: Panagy, Andrew 3/30/2004 EX 002: Plaintiffs' Notice of Corporate Deposition of Defendant WYETH Pursuant to P.A.R.C.P. 4007.1(e)			
04877				Depo: Panagy, Andrew 3/30/2004 EX 003: Plaintiffs' Notice of Corporate Deposition of Defendant WYETH Pursuant to P.A.R.C.P. 4007.1(e)			
04878			3/29/2004	Depo: Panagy, Andrew 3/30/2004 EX 004: WYETH'S Cross Notice of Intention to Take Deposition of WYETH by Videotape			
04879			3/29/2004	Depo: Panagy, Andrew 3/30/2004 EX 005: WYETH'S Cross Notice of Intention to Take Deposition of WYETH by Videotape			
04880			3/29/2004	Depo: Panagy, Andrew 3/30/2004 EX 006: WYETH'S Cross Notice of Intention to Take Deposition of WYETH by Videotape			
04881	W-ORGCHA-000009	W-ORGCHA-000009	11/8/2002	Depo: Panagy, Andrew 3/30/2004 EX 007			
04882	W-ORGCHA-000008	W-ORGCHA-000008	11/8/2002	Depo: Panagy, Andrew 3/30/2004 EX 008			
04883				Depo: Panagy, Andrew 3/30/2004 EX 009: Material Redacted			
04884				Depo: Panagy, Andrew 3/30/2004 EX 010: Handwritten chart			
04885	W-ADSBRO-01735	W-ADSBRO-01767		Depo: Panagy, Andrew 3/30/2004 EX 011			
04886	W-ADSBRO-002291	W-ADSBRO-002296	1/00/2004	Depo: Panagy, Andrew 3/30/2004 EX 012			
04887	W-ADSBRO-002241	W-ADSBRO-002260	11/00/2003	Depo: Panagy, Andrew 3/30/2004 EX 013			
04888	PANAA001-001308	PANAA001-001311	3/29/2001	Depo: Panagy, Andrew 3/30/2004 EX 014: Issues Management Plan for HERS Clinical Fractures and Height Loss Study			
04889	PANAA011-000424	PANAA011-000458		Depo: Panagy, Andrew 3/30/2004 EX 015: Draft Version (R1) for June 18th Presentation Pharmaceuticals Strategic Business Scenarios Growing Threat to our HRT Business			
04890	PANAA010-000917	PANAA010-000919	7/00/2002	Depo: Panagy, Andrew 3/30/2004 EX 016			
04891	PANAA007-001216	PANAA007-001217		Depo: Panagy, Andrew 3/30/2004 EX 017			
04892	PANAA003-000655	PANAA003-000656	7/22/2002	Depo: Panagy, Andrew 3/30/2004 EX 018			
04893	PANAA008-001219	PANAA008-001220	00/00/2001	Depo: Panagy, Andrew 3/30/2004 EX 019: Premarin Family Strategic Initiatives 2001			
04894	PANAA008-001272	PANAA008-001275	00/00/2001	Depo: Panagy, Andrew 3/30/2004 EX 020: 2001 Premarin Brand Team (In-Line) Tactical Rollout			
04895	PANAA008-001459	PANAA008-001461		Depo: Panagy, Andrew 3/30/2004 EX 021: Proposed First Quarter 2001 Premarin Public Relations Tactics			
04896	PANAA003-001001	PANAA003-001012		Depo: Panagy, Andrew 3/30/2004 EX 022			
04897	PANAA001-000270	PANAA001-000270	5/10/2001	Depo: Panagy, Andrew 3/30/2004 EX 023: Premarin Print Year 2001			
04898	PANAA010-000005	PANAA010-000005		Depo: Panagy, Andrew 3/30/2004 EX 024: LaBelle Live			
04899	PANAA010-000006	PANAA010-000008		Depo: Panagy, Andrew EX 024CNTD			
04900	PANAA010-000509	PANAA010-000509	5/00/2001	Depo: Panagy, Andrew 3/30/2004 EX 025: Hot Flash			
04901	PANAA003-000816	PANAA003-000821		Depo: Panagy, Andrew 3/30/2004 EX 026			
04902	PANAA010-000493	PANAA010-00494	11/00/2001	Depo: Panagy, Andrew 3/30/2004 EX 027: Premfact 1 Prempro (Conjugated Estrogens / Medroxyprogesterone Acetate Tablets) Reduces Osteoporosis-Related Hip and Wrist Fractures By Approximately 60%!			
04903	PANAA004-000514	PANAA004-000516		Depo: Panagy, Andrew 3/30/2004 EX 028: Core Messages - Premarin Benefits Packages; Depo: Ryan, John 6/14/2005 EX 029; Depo: DelConte, Anthony 6/20/06 EX 025; DEPO: Andrew Panagy 7/13/06 EX 012; Robert Essner 9/20/06 DEPO EX 056			
04930			4/13/2006	Depo: Peck, Carl 5/12/2006 EX 001: Report of Carl C. Peck, MD.			
04931			00/00/2006	Depo: Peck, Carl 5/12/2006 EX 002: NDA Partners about us, Firm Profile			
04932				Depo: Peck, Carl 5/12/2006 EX 003: Defence Produced Documents For Carl Peck Deposition			
04933				Depo: Peck, Carl 5/12/2006 EX 004: Exhibit Peck-4 is a CD			
04934			3/00/2006	Depo: Peck, Carl 5/12/2006 EX 005: GAO Highlights			
04935			3/24/1993	Depo: Peck, Carl 5/12/2006 EX 006: Editorials understanding consequences of concurrent therapies. Article			
04936	W-MDL303-00083689	W-MDL303-00083805	2/16/1995	Depo: Peck, Carl 5/12/2006 EX 007: Premarin/MPA Separate Tablets; Medical Officer's Review (NDA 20-303)			
04940			6/22/2005	Depo: Petkus, Doug 8/18/2005 EX 001: Plaintiffs' Amended Notice of Deposition of Doug Petkus			
04941				Depo: Petkus, Doug 8/18/2005 EX 002: Petkus, Doug CV			
04942	PETKD001-000077	PETKD001-000079	5/22/1996	Depo: Petkus, Doug 8/18/2005 EX 003: Wyeth-Ayerst Funds \$16 Million WHI Alzheimer's Disease Trial Studying Hormone Replacement Therapy			
04943			11/18/2002	Depo: Petkus, Doug 8/18/2005 EX 004: The menopausal marketplace: Why do we treat change of life as a medical disorder? The answer lies in the interplay of science and marketing. Article			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04944			00/00/2002	Depo: Petkus, Doug 8/18/2005 EX 005: Research Funding, Conflicts of Interest, and the "Meta-methodology" of Public Relations. Article			
04945			4/7/2000	Depo: Petkus, Doug 8/18/2005 EX 006: Wyeth-Ayerst Laboratories:Womens Health Initiative Study to Continue. Article			
04946	PETKD002-000050	PETKD002-000054		Depo: Petkus, Doug 8/18/2005 EX 007: Q&A on USC Breast Cancer Study Journal of the National Cancer Institute			
04947	PETKD003-001102	PETKD003-001102	6/26/2002	Depo: Petkus, Doug 8/18/2005 EX 008: Draft WHI Standby Statement as of June 26, 2002			
04948			7/13/2002	Depo: Petkus, Doug 8/18/2005 EX 009: Estrogen study has some women uneasy. Article			
04949			3/00/2003	Depo: Petkus, Doug 8/18/2005 EX 010: In The Media: Reasearchers find HRT does not improve quality of life. Article			
04950			11/15/2002	Depo: Petkus, Doug 8/18/2005 EX 011: OB GYN News:National Institutes of Health hands over WHI data to WYETH.(Data on Combination Therapy).Article			
04951	PETKD003-001472	PETKD003-001473	10/19/2002	Depo: Petkus, Doug 8/18/2005 EX 012: WHI Investigators Concerns about the Way in which Data from the E+P Trial may be Used by Wyeth			
04952			00/00/2005	Depo: Petkus, Doug 8/18/2005 EX 013: Madison, N.J. based Wyeth resumes ads for controversial drugs. Article			
04953	DEVAN019-000770	DEVAN019-000779	10/11/2002	Depo: Petkus, Doug 8/18/2005 EX 014: Q&A			
04954	DEVAN011-000051	DEVAN011-000051	7/23/2002	Depo: Petkus, Doug 8/18/2005 EX 015: 9:30 Slides			
04955	PETKD003-000367	PETKD003-000370	7/25/2002	Depo: Petkus, Doug 8/18/2005 EX 016: Teleconference Call with Simon Bryceson on Media Management..			
04956	PETKD003-000293	PETKD003-000294	7/11/2002	Depo: Petkus, Doug 8/18/2005 EX 017: Media Overview			
04957	PETKD003-000564	PETKD003-000565	6/00/2002	Depo: Petkus, Doug 8/18/2005 EX 018: WHI HRT Update			
04958	PETKD003-001133	PETKD003-001134	6/25/2002	Depo: Petkus, Doug 8/18/2005 EX 019: Initial Recommendations for WHI			
04959	PETKD003-000390	PETKD003-000390	7/9/2002	Depo: Petkus, Doug 8/18/2005 EX 020: Society for Women's Health Research Statement on Recent Findings from the Women's Health Initiative			
04960	PETKD003-000830	PETKD003-000836	1/8/2003	Depo: Petkus, Doug 8/18/2005 EX 021: Hot Flash, Cold Cash how a Once-Respected Women's Group Went through the Change-With the Help of Drug Industry Money.			
04961	PETKD003-001389	PETKD003-001389		Depo: Petkus, Doug 8/18/2005 EX 022: Key Messages			
04962	PETKD003-000371	PETKD003-0000379	7/8/2002	Depo: Petkus, Doug 8/18/2005 EX 023: Premarin Oral Family - Briefing Document			
04963				Depo: Philander, Peter 3/22/2006 EX 001: Philander, Peter Work History			
04964			11/18/1980	Depo: Philander, Peter 3/22/2006 EX 002: Information on Provera			
04965			7/27/1972	Depo: Philander, Peter 3/22/2006 EX 003: Medroxyprogesterone Acetate Drugs for human use; Drug efficacy Study Implementation. Article			
04966				Depo: Philander, Peter 3/22/2006 EX 004: Info on Medroxyprogesterone Acetate Tablets			
04967	RM_AA 0156179	RM_AA 0156187	11/9/1981	Depo: Philander, Peter 3/22/2006 EX 005			
04968	NDA-PRO 0070099	NDA-PRO 0070099	9/4/1985	Depo: Philander, Peter 3/22/2006 EX 006			
04969	NDA-PRO 0000185	NDA-PRO 0000185	9/26/1985	Depo: Philander, Peter 3/22/2006 EX 007: Trip Report - 09/26/1985 FDA, Div of Drug Advertising			
04970	RM_AA 0156196	RM_AA 0156197	9/27/1985	Depo: Philander, Peter 3/22/2006 EX 008			
04971	RM_NY_MOPS 0103384	RM_NY_MOPS 0103390		Depo: Philander, Peter 3/22/2006 EX 009			
04972	NDA-PRO 0020242	NDA-PRO 0020242	4/28/1981	Depo: Philander, Peter 3/22/2006 EX 010: Provera Tablets (Medroxyprogesterone Acetate Tablets, USP)			
04973	NDA-PRO 0020243	NDA-PRO 0020259	4/28/1981	Depo: Philander, Peter 3/22/2006 EX 011: New Drug Application (Drugs for Human Use) Provera Tablets (Medroxyprogesterone Acetate Tablets, USP)			
04974	NDA-PRO 0027869	NDA-PRO 0027869		Depo: Philander, Peter 3/22/2006 EX 012: The other Half of Estrogen Replacement Therapy. Provera 10 mg Tablets (Medroxyprogesterone Acetate Tablets)			
04975	NDA-PRO 0000200	NDA-PRO 0000200	9/20/1984	Depo: Philander, Peter 3/22/2006 EX 013: Provera Tablets FDA Telecon			
04976	NDA-PRO 0017599	NDA-PRO 0017599	1/5/1984	Depo: Philander, Peter 3/22/2006 EX 014: None			
04977			00/00/1984	Depo: Philander, Peter 3/22/2006 EX 015: Product info on Provera			
04978	NDA-PRO 0027815	NDA-PRO 0027815		Depo: Philander, Peter 3/22/2006 EX 016: The other Half of Estrogen Replacement Therapy. Provera 10 mg Tablets (Medroxyprogesterone Acetate Tablets)			
04979	NDA-PRO 0011994	NDA-PRO 0011994	9/10/1985	Depo: Philander, Peter 3/22/2006 EX 017: None			
04980	NDA-PRO 0007648	NDA-PRO 0007649	1/15/1988	Depo: Philander, Peter 3/22/2006 EX 018: NDA 11-839/S-048			
04981	NDA-PRO 0011628	NDA-PRO 0011629	7/8/1986	Depo: Philander, Peter 3/22/2006 EX 019: NDA 11-839 Provera Tablets (Medroxyprogesterone Acetate Tablets, USP)			
04982	NDA-DE-0000363	NDA-DE-0000364	4/4/1986	Depo: Philander, Peter 3/22/2006 EX 020: NDA's 16-649 17-968			
04983	NDA-PRO 0011608	NDA-PRO 0011608	5/29/1987	Depo: Philander, Peter 3/22/2006 EX 021: NDA 11-839/S-048			
04984	NDA-PRO 0011591	NDA-PRO 0011592	7/1/1987	Depo: Philander, Peter 3/22/2006 EX 022: NDA 11-839 / S-048 Provera Tablets (Medroxyprogesterone Acetate Tablets, USP)			
04985	NDA-PRO 0002106	NDA-PRO 0002106	10/25/1989	Depo: Philander, Peter 3/22/2006 EX 023			
04986	NDA-PRO 0002025	NDA-PRO 0002025	10/30/1990	Depo: Philander, Peter 3/22/2006 EX 024; Depo: Roehl 12/13/2005 EX 007, 11/06/90 Letter			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
04987	CHIRBY-D 0000931	CHIRBY-D 0000933	11/8/1990	Depo: Philander, Peter 3/22/2006 EX 025 (duplicate of EX 10187, 10253, 10483)			
04988	NDA-PRO 0002006	NDA-PRO 0002006	11/9/1990	Depo: Philander, Peter 3/22/2006 EX 026: None			
04989	NDA-PRO 0002030	NDA-PRO 0002033	10/9/1990	Depo: Philander, Peter 3/22/2006 EX 027: None			
04990	NDA-PRO 0002026	NDA-PRO 0002029	10/16/1990	Depo: Philander, Peter 3/22/2006 EX 028: None			
04991	NDA-PRO 0002021	NDA-PRO 0002023	10/31/1990	Depo: Philander, Peter 3/22/2006 EX 029: None			
04992	NDA-PRO 0002003	NDA-PRO 0002005	11/13/1990	Depo: Philander, Peter 3/22/2006 EX 030: None			
04993	NDA-PRO 0027456	NDA-PRO 0027466		Depo: Philander, Peter 3/22/2006 EX 031: Issues in Menopausal Hormone Replacement Therapy			
04994	CHIRBY-D 0000935	NDA-PRO-0027470	10/18/1990	Depo: Philander, Peter 3/22/2006 EX 032			
04995			8/30/2005	Depo: Pickar, James 9/20/2005 EX 001: Plaintiffs' Amended Notice of Deposition of James Pickar			
04996				Depo: Pickar, James 9/20/2005 EX 002: James Pickar CV			
04997	PANAA028-000467	PANAA028-000536	9/19/1995	Depo: Pickar, James 9/20/2005 EX 018: In Vitro Activities of Defined Premarin Components and Analyses of Samples from Fractionation of Premarin and Preserved Condensed Urine Desiccated (PCUD)			
04998	PANAA034-001426	PANAA034-001427	8/22/1990	Depo: Pickar, James 9/20/2005 EX 019: Estrogen/Progestin Packaging			
04999	PICKJ025-000013	PICKJ025-000014	4/5/1999	Depo: Pickar, James 9/20/2005 EX 020: HERS Resources			
05000	PICKJ009-001654	PICKJ009-001667		Depo: Pickar, James 9/20/2005 EX 023: P.M. Meeting			
05001	W-MDL303-00081415	W-MDL303-00081423	9/1/1995	Depo: Pickar, James 9/20/2005 EX 036: Request for meeting (NDA 20-303)			
05002	W-MDL303-00081682	W-MDL303-00081687	8/27/1992	Depo: Pickar, James 9/20/2005 EX 037: Cardiovascular Labeling (NDA 20-303)			
05003	W-MDL303-00081835	W-MDL303-00081836	4/26/1992	Depo: Pickar, James 9/20/2005 EX 039: Premarin/Cardiovascular Labeling (NDA 20-303)			
05004	W-MDL303-00083463	W-MDL303-00083465	12/2/1994	Depo: Pickar, James 9/20/2005 EX 041: Telephone Contact; FDA Request for Clinical Data Analysis (NDA 20-303)			
05005	W-MDL303-00083691	W-MDL303-00083804	12/30/1994	Depo: Pickar, James 9/20/2005 EX 043			
05006	W-MDL303-00083808	W-MDL303-00083823	2/13/1995	Depo: Pickar, James 9/20/2005 EX 044: Prempro/Premphase Labeling Meeting (NDA 20-303)			
05007	PICKJ004-000163	PICKJ004-000163		Depo: Pickar, James 9/20/2005 EX 046: "The Lowest of Progestin Required for Endometrial Protection should be Prescribed."			
05008	PICKJ004-000668	PICKJ004-000711	5/19/1992	Depo: Pickar, James 9/20/2005 EX 047			
05009	PICKJ007-000036	PICKJ007-000039	2/22/2000	Depo: Pickar, James 9/20/2005 EX 054			
05010	PICKJ007-000159	PICKJ007-000161	4/25/1996	Depo: Pickar, James 9/20/2005 EX 058 and Buchalter, Jeff 05/29/2008 EX 26; ASGO Meeting - Strategic Recommendations			
05011	PICKJ007-000182	PICKJ007-000184	9/25/1997	Depo: Pickar, James 9/20/2005 EX 059: Phase IV Commitment			
05012	PICKJ007-000280	PICKJ007-000281	1/24/1995	Depo: Pickar, James 9/20/2005 EX 062: Premarin/MPA Breast Cancer Phase IV Commitment			
05013	PICKJ007-000568	PICKJ007-000568	10/1/1991	Depo: Pickar, James 9/20/2005 EX 063: Epidemiologic Breast Cancer Study of Dr Ronald Ross			
05014			5/3/2004	Depo: Pickar, James 5/26/2004 EX 067: Plaintiffs' First Amended Notice of 30(b)(6) Deposition of WYETH by Video-tape			
05015	W-30(b)(6)-09-03582	W-30(b)(6)-09-03655	3/12/2004	Depo: Pickar, James 5/26/2004 EX 068			
05016	W-30(b)(6)-09-03656	W-30(b)(6)-09-03738	3/18/2004	Depo: Pickar, James 5/26/2004 EX 069			
05017	W-30(b)(6)-09-03739	W-30(b)(6)-09-03812	12/30/1994	Depo: Pickar, James 5/27/2004 EX 070			
05018			5/3/2004	Depo: Pickar, James 5/27/2004 EX 071: Plaintiffs' First Amended Notice of 30(b)(6) Deposition of WYETH by Video-tape and Subpoena Duces Tecum Requesting Production of Documents			
05019				Depo: Pickar, James 5/27/2004 EX 072: Planned Studies			
05020	PICKJ007-001349	PICKJ007-001349	1/31/1996	Depo: Pickar, James 9/20/2005 EX 073: Breast Cancer Task Force Meeting 1/31/96			
05021	PICKJ017-000082	PICKJ017-000096	12/10/1998	Depo: Pickar, James 9/20/2005 EX 080: Premarin and Premarin/MPA in Alzheimer's Disease Task Force Recommendation			
05022	PICKJ019-000045	PICKJ019-000045	1/12/1999	Depo: Pickar, James 9/20/2005 EX 082: Funding Discussion			
05023	PICKJ020-003693	PICKJ020-003693	4/13/1999	Depo: Pickar, James 9/20/2005 EX 087: HERS Analysis Task Force Minutes			
05024	PICKJ023-002677	PICKJ023-002680	5/7/1999	Depo: Pickar, James 9/20/2005 EX 099: Post-HERS Publication Strategy			
05025			7/15/2005	Depo: Pickar, James 9/20/2005 EX 177: Prempro, Premphase Pharma Description			
05026			6/22/2005	Depo: Pinizzotto, Marie 8/23/2005 EX 001: Plaintiffs' Notice of Deposition of Marie Pinizzotto			
05027				Depo: Pinizzotto, Marie 8/23/2005 EX 002: Maria Pinizzotto CV			
05028			00/00/1996	Depo: Pinizzotto, Marie 8/23/2005 EX 003: PDR			
05029			00/00/1997	Depo: Pinizzotto, Marie 8/23/2005 EX 004: PDR			
05030			00/00/1998	Depo: Pinizzotto, Marie 8/23/2005 EX 005: PDR			
05031			00/00/1999	Depo: Pinizzotto, Marie 8/23/2005 EX 006: PDR			
05032			00/00/2000	Depo: Pinizzotto, Marie 8/23/2005 EX 007: PDR			
05033			00/00/2001	Depo: Pinizzotto, Marie 8/23/2005 EX 008: PDR			
05034			8/23/2005	Depo: Pinizzotto, Marie 8/23/2005 EX 009: Exhibit 9 unmarked			
05035			00/00/2002	Depo: Pinizzotto, Marie 8/23/2005 EX 010: PDR			
05036			8/23/2005	Depo: Pinizzotto, Marie 8/23/2005 EX 011: Exhibit 11 unmarked			
05037	PINIM001-000576 Thru 000588	PINIM004-000001 Thru 000002	8/22/2002	Depo: Pinizzotto, Marie 8/23/2005 EX 012			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05038	PINIM020-000522	PINIM020-000538	8/2/2002	Depo: Pinizzotto, Marie 8/23/2005 EX 013: Adverse Event Count for Conjugated Estrogens/Medroxyprogesterone Acetate			
05039	PINIM020-000539	PINIM020-000558	8/14/2002	Depo: Pinizzotto, Marie 8/23/2005 EX 013A: Adverse Event Count for Conjugated Estrogens			
05040	PINIM017-000457	PINIM017-000457	00/00/1984	Depo: Pinizzotto, Marie 8/23/2005 EX 014			
05041	PINIM003-000001	PINIM003-000069		Depo: Pinizzotto, Marie 8/23/2005 EX 015: The Boorum & Pease Quality Guarantee			
05042	HENRL001-002162	HENRL001-002191	4/00/2000	Depo: Pinizzotto, Marie 8/23/2005 EX 016: CME Activity Guiding your Patients through the Transitional Years, Menopause, and beyond			
05043	PETKD001-000069	PETKD001-000070	6/19/1997	Depo: Pinizzotto, Marie 8/23/2005 EX 017: Wyeth-Ayerst Statement on NEJM Article			
05044	PETKD002-000055	PETKD002-000058	2/22/2000	Depo: Pinizzotto, Marie 8/23/2005 EX 018: Journal of the American Medical Association (JAMA) and Journal of the National Cancer Institute (J Natl Cancer Inst); Depo: Robert Essner 6/29/06 EX 052: Dear Doctor Letter; DEPO: Andrew Panagy 7/13/06 EX 021: Dear Doctor Letter			
05045			1/23/2003	Depo: Pinizzotto, Marie 8/23/2005 EX 019: Prempro, Premphase Pharma Description			
05065			4/13/2006	Depo: Ratain, Mark 4/21/2006 EX 001: Plaintiffs' Notice of Discovery Deposition of Mark J. Ratain, M.D.			
05066			2/17/2006	Depo: Ratain, Mark 4/21/2006 EX 002: Report of Mark J. Ratain, M.D.			
05067			2/7/2006	Depo: Ratain, Mark 4/21/2006 EX 003: Rough Draft of Report			
05068			2/12/2006	Depo: Ratain, Mark 4/21/2006 EX 004: Another Rough Draft of Report			
05069			2/16/2006	Depo: Ratain, Mark 4/21/2006 EX 005: Final Pre-Draft copy of Report			
05070			11/30/2005	Depo: Ratain, Mark 4/21/2006 EX 006: Payment from KAYE SCHOLER LLP			
05071			1/25/2006	Depo: Ratain, Mark 4/21/2006 EX 007: Invoices from Mark Ratain			
05072			12/6/2005	Depo: Ratain, Mark 4/21/2006 EX 008: Notes on Plaintiffs Expert Report			
05073			2/14/2006	Depo: Ratain, Mark 4/21/2006 EX 009: Letter from INDEX Challenges Reserch Department			
05074	HRT MED LIT 0454001	HRT MED LIT 0454004	12/12/2002	Depo: Ratain, Mark 4/21/2006 EX 010: Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Verkooijen, HM, Fioretta, G, Fioretta, G, Vlastos, G, Morabia, A, Schubert, H, Sappino, AP, Pette, MF, Schafer, P, Kurtz, J, Bouchardy, C Int J Cancer 2003;104:778-81			
05075	HRT MED LIT 0881001	HRT MED LIT 0881007	8/16/1999	Depo: Ratain, Mark 4/21/2006 EX 011: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. Hofseth, LJ, Raafat, AM, Osuch, JR, Pathak, DR, Slomski, CA, Haslam, SZ J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65			
05076			4/21/2005	Depo: Ratain, Mark 4/21/2006 EX: 012: Proliferation of Endothelial and Tumor Epithelial Cells by Progestin-Induced VEGF from Human Breast Cancer Cells: Paracrine and Autocrine Effects. Liang Y, Hyder SM. Endocrinology. 2005 Apr 21; [Epub ahead of print]			
05077			3/22/2006	Depo: Ratain, Mark 4/21/2006 EX 013: Remarkable change in age-specific breast cancer incidence in the Swiss of Geneva and its possible relation with the use of hormone replacement therapy. Article			
05078			4/5/2006	Depo: Ratain, Mark 4/21/2006 EX 014: Mark J. Ratain CV			
05079			4/25/2006	Depo: Riggs, B. Lawrence 5/4/2006 EX 001: Plaintiffs' Notice of Discovery Deposition of B. Lawrence Riggs.MD			
05080				Depo: Riggs, B. Lawrence 5/4/2006 EX 002: Riggs, B. Lawrence CV			
05081				Depo: Riggs, B. Lawrence 5/4/2006 EX 003: Time spent on WYETH			
05082				Depo: Riggs, B. Lawrence 5/4/2006 EX 004: Expert Report of Dr. John Gueriguian			
05083			4/4/2006	Depo: Riggs, B. Lawrence 5/4/2006 EX 005: Comments and Listing of Publications Relevant to Expert Report of Dr. Stuart Weinerman Regarding Estrogen Administration			
05084				Depo: Riggs, B. Lawrence 5/4/2006 EX 006: Expert Report of B. Lawrence Riggs, M.D., M.S.			
05085			9/00/2001	Depo: Riggs, B. Lawrence 5/4/2006 EX 007: Hormone Replacement Therapy and Breast Cancer: A Qualitative Review. Article			
05086			4/00/1994	Depo: Riggs, B. Lawrence 5/4/2006 EX 008: Guidelines for Preclinical and Clinical Evaluation of Agents used in the Prevention or Treatment of Postmenopausal Osteoporosis			
05087				Depo: Roehl 12/13/2005 EX 001: Sharon Roehl CV			
05088	NDA-PRO 0027456	NDA-PRO 0027470	7/00/1990	Depo: Roehl 12/13/2005 EX 002: Issues in Menopausal Hormone Replacement Therapy			
05089	Breed-K-0007226	Breed-K-0007235	6/00/1993	Depo: Roehl 12/13/2005 EX 003, Provera Generic Strategy June 1993			
05090	CHIRBY-D 0001033	CHIRBY-D 0001034	9/10/1990	Depo: Roehl 12/13/2005 EX 004, Interoffice Memo			
05091	NDA-PRO 0002030	NDA-PRO 0002033	10/9/1990	Depo: Roehl 12/13/2005 EX 005, 10/09/90 letter			
05092	NDA-PRO 0002026	NDA-PRO 0002029	10/16/1990	Depo: Roehl 12/13/2005 EX 006, 10/16/90 Letter			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05093	NDA-PRO 0002025	NDA-PRO 0002025	10/30/1990	Depo: Roehl 12/13/2005 EX 007, 11/06/90 Letter			
05094	CHIRBY-D 0001019	CHIRBY-D 0001021	10/31/1990	Depo: Roehl 12/13/2005 EX 008, 10/31/90 Letter			
05095	NDA-PRO 0002010	NDA-PRO 0002011	11/9/1990	Depo: Roehl 12/13/2005 EX 009: NDA 11-839/S-055 Provera Tablets (Medroxyprogesterone Acetate)			
05096	NDA-PRO 0002003	NDA-PRO 0002005	11/13/1990	Depo: Roehl 12/13/2005 EX 010, 11/13/90 Letter			
05097	NDA-PRO 0027233	NDA-PRO 0027233	12/9/1991	Depo: Roehl 12/13/2005 EX 011, 12/09/91 Letter			
05098	NDA-PRO 0027444	NDA-PRO 0027447	9/00/1990	Depo: Roehl 12/13/2005 EX 012: Use these Little Holes to Fill in Hormone Replacement Therapy (HRT)			
05099	Breed-K-0007327	Breed-K-0007330	2/13/1991	Depo: Roehl 12/13/2005 EX 013, 02/13/91 Interoffice Memo			
05100	CHIRBY-D 0000992	CHIRBY-D 0000992	3/00/1991	Depo: Roehl 12/13/2005 EX 014, 03/91 Upjohn Dear Doctor Letter			
05101	CHIRBY-D 0000929	CHIRBY-D 0000929	11/9/1990	Depo: Roehl 12/13/2005 EX 015, 11/09/90 Letter			
05102			2/00/1991	Depo: Roehl 12/13/2005 EX 016: The Provera Press Newsletter 02/91			
05103				Depo: Roehl 12/13/2005 EX 017: Hormone Repacement Therapy Newsletter			
05140	ROSSC041-000027	ROSSC041-000027		Depo: Rosser, Christine 9/2/2004 EX 107			
05141	ROSSC041-000115	ROSSC041-000115		Depo: Rosser, Christine 9/2/2004 EX 108			
05142	ROSSC041-000118	ROSSC041-000118		Depo: Rosser, Christine 9/2/2004 EX 109			
05143	ROSSC041-000091	ROSSC041-000091		Depo: Rosser, Christine 9/2/2004 EX 110			
05144	ROSSC041-000001	ROSSC041-000001		Depo: Rosser, Christine 9/2/2004 EX 111			
05145	ROSSC041-000006	ROSSC041-000006		Depo: Rosser, Christine 9/2/2004 EX 112			
05146	ROSSC012-001496	ROSSC012-001496		Depo: Rosser, Christine 9/2/2004 EX 113: NDA 20-303 Conjugated Estrogens Tablets and Medroxyprogesterone Acetate Tablets			
05147	ROSSC012-001739	ROSSC012-001739	12/20/1996	Depo: Rosser, Christine 9/2/2004 EX 114			
05148	DUROJ003-001573	DUROJ003-001573		Depo: Rosser, Christine 9/2/2004 EX 115: Nurses Study (Post-Survey) Final Report			
05149			00/00/1996	Depo: Rosser, Christine 9/2/2004 EX 116: PDR			
05150			00/00/1997	Depo: Rosser, Christine 9/2/2004 EX 117: PDR			
05151				Depo: Ruffolo 11/14/2005 EX 001: Robert Ruffolo CV			
05152	RUFFR003-001849	RUFFR003-001849	9/10/2002	Depo: Ruffolo 11/14/2005 EX 002			
05153	CONSG010-001341	CONSG010-001342	9/13/2002	Depo: Ruffolo 11/14/2005 EX 003: Formal Request for Representatives from Wyeth Pharmaceuticals to be Included as Speakers at the Specific Workshop on Menopausal Hormone Therapy			
05154	CONSG010-001343	CONSG010-001343	9/16/2002	Depo: Ruffolo 11/14/2005 EX 004: Interpretation by the Group of Manufacturers which Produce Various Estrogen and Progesterone Products			
05155	MAHAJ008-000249	MAHAJ008-000542	10/15/2001	Depo: Ruffolo 11/14/2005 EX 005: 2002 Budget Presentation Collegeville October 15, 2001			
05156	RUFFR001-000819	RUFFR001-000821	7/13/2002	Depo: Ruffolo 11/14/2005 EX 006: WHI			
05157	RUFFR003-002220	RUFFR003-002221	9/27/2002	Depo: Ruffolo 11/14/2005 EX 007: Bob Essner; Depo: Ruffolo 11/14/2005 EX 014: Bob Essner			
05158	RUFFR003-002083	RUFFR003-002086	9/16/2002	Depo: Ruffolo 11/14/2005 EX 008: Conclusion			
05159	RUFFR003-001745	RUFFR003-001745	8/8/2002	Depo: Ruffolo 11/14/2005 EX 009: No Title			
05160	RUFFR003-001826	RUFFR003-001827	9/4/2002	Depo: Ruffolo 11/14/2005 EX 010: Business Unit Name			
05161	RUFFR003-001688	RUFFR003-001689	8/5/2002	Depo: Ruffolo 11/14/2005 EX 011: No Title			
05162	RUFFR002-007023	RUFFR002-007142	4/00/2001	Depo: Ruffolo 11/14/2005 EX 012			
05163	MAHAJ006-000171	MAHAJ006-000180		Depo: Ruffolo 11/14/2005 EX 013: Wyeth			
05164	RUFFR003-002220	RUFFR003-002221	9/27/2002	Depo: Ruffolo 11/14/2005 EX 014: Bob Essner			
05165	RUFFR003-002458	RUFFR003-002459	10/21/2002	Depo: Ruffolo 11/14/2005 EX 015: Re: Phone calls with Drs. Alving and Anderson			
05166	RUFFR003-000093	RUFFR003-000093	11/8/2002	Depo: Ruffolo 11/14/2005 EX 016: Re: My Continuing Skepticism; DEPO: Robert Ruffolo 7/27/06 EX 006: Email			
05167			4/18/2005	Depo: Ryan, John 6/14/2005 EX 001: Plaintiffs' Notice of Deposition of John Ryan			
05168			1/00/2001	Depo: Ryan, John 6/14/2005 EX 002: Letter from President of WYETH			
05169				Depo: Ryan, John 6/14/2005 EX 003: Wyeth Ayerst Overall Compensation and Benefits Program			
05170			2/27/2000	Depo: Ryan, John 6/14/2005 EX 004: E-mails from Mike Ceppi			
05171	RYANJ004-000013	RYANJ004-000014	3/20/2003	Depo: Ryan, John 6/14/2005 EX 005: Prempro Call Simulation; Robert Essner 9/20/06 DEPO EX 057: Prempro Call Simulations			
05172				Depo: Ryan, John 6/14/2005 EX 006: Handwritten Notes			
05173				Depo: Ryan, John 6/14/2005 EX 007: Premarin Product Information			
05174			2/18/1994	Depo: Ryan, John 6/14/2005 EX 008: Seasons Circulation Bounds Past Popular Consumer Mags. Article			
05175			8/27/1992	Depo: Ryan, John 6/14/2005 EX 009: Seasons			
05176	PANAA036-002450	PANAA036-002471	00/00/1991	Depo: Ryan, John 6/14/2005 EX 010: For the Best Times of a Woman's Life. Seasons			
05177	PANAA036-001536	PANAA036-001559	5/14/1992	Depo: Ryan, John 6/14/2005 EX 011: Seasons Subscribers Tracking; Fred Hassan 12/16/06 DEPO EX 013			
05178	RYANJ002-000495	RYANJ002-000524	00/00/1990	Depo: Ryan, John 6/14/2005 EX 012			
05179	RYANJ003-000464	RYANJ003-000513		Depo: Ryan, John 6/14/2005 EX 013			
05180	RYANJ003-000183	RYANJ003-000216		Depo: Ryan, John 6/14/2005 EX 014			
05181			5/00/2000	Depo: Ryan, John 6/14/2005 EX 015: Response to Objections About MPA			
05182	RYANJ003-001152	RYANJ003-001259	00/00/2001	Depo: Ryan, John 6/14/2005 EX 016			
05183	RYANJ004-000105	RYANJ004-000105	3/20/2003	Depo: Ryan, John 6/14/2005 EX 017: Prempro Information			
05184	RYANJ004-000106	RYANJ004-000107		Depo: Ryan, John 6/14/2005 EX 018: Prempro Information			
05185			2/00/1993	Depo: Ryan, John 6/14/2005 EX 019: American Druggist Magazine			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05186			8/26/1994	Depo: Ryan, John 6/14/2005 EX 020: Premarin: Powerhouse of the 90's. Article			
05187	RYANJ001-000001 thru 000062	RYANJ001-000069 thru 000151		Depo: Ryan, John 6/14/2005 EX 021			
05188			00/00/1992	Depo: Ryan, John 6/14/2005 EX 022: PDR			
05189			00/00/1994	Depo: Ryan, John 6/14/2005 EX 023: PDR			
05190	RYANJ003-001580	RYANJ003-001814		Depo: Ryan, John 6/14/2005 EX 024			
05191	RYANJ001-000152	RYANJ001-000152		Depo: Ryan, John 6/14/2005 EX 025: Premarin Family (Conjugated Estrogens Tablets, USP) Training Program Book 2			
05192	RYANJ001-000154	RYANJ001-000206	3/00/1998	Depo: Ryan, John 6/14/2005 EX 026: Hormone Replacement Therapy (HRT)			
05193	PANAA002-000247	PANAA002-000271	9/4/2002	Depo: Ryan, John 6/14/2005 EX 027: ERT/HRT Update			
05194	YAVUE007-000244	YAVUE007-000486		Depo: Ryan, John 6/14/2005 EX 028: Premarin: Sales Issues & Competitive Information			
05195	PANAA004-000514	PANAA004-000516		Depo: Ryan, John 6/14/2005 EX 029: Core Messages - Premarin Benefits Packages			
05196				Depo: Ryan, John 6/14/2005 EX 030: Cycrin Training Program			
05197	RYANJ003-000360	RYANJ003-000374		Depo: Ryan, John 6/14/2005 EX 031			
05198	HENRL001-001235	HENRL001-001236	10/00/1997	Depo: Ryan, John 6/14/2005 EX 032: Answers to some of your Questions about Estrogen; Depo: Stephenson, Wendy 3/10/2005 EX 016: Answers to some of your Questions about Estrogen			
05199	YAVUE001-001604	YAVUE001-001637	00/00/1990	Depo: Ryan, John 6/14/2005 EX 033: Osteoporosis the only Cure is Prevention; Depo: Yavuz, Ed 1/14/2005 EX 003: Osteoporosis the only Cure is Prevention			
05200	RYANJ001-000001	RYANJ001-000035	00/00/1992	Depo: Ryan, John 6/14/2005 EX 034: Premarin Family (Conjugated Estrogens Tablets, USP) Training Program Book 1			
05201	YAVUE001-001216	YAVUE001-001267	00/00/1995	Depo: Ryan, John 6/14/2005 EX 035: Hormone Replacement Therapy (HRT)			
05202	YAVUE005-000188	YAVUE005-000215	00/00/1996	Depo: Ryan, John 6/14/2005 EX 036			
05203	RYANJ003-000001	RYANJ003-000039		Depo: Ryan, John 6/14/2005 EX 037			
05204	YAVUE005-000170	YAVUE005-000187		Depo: Ryan, John 6/14/2005 EX 038			
05205	RYANJ002-000473	RYANJ002-000473		Depo: Ryan, John 6/14/2005 EX 039			
05206	RYANJ002-000329	RYANJ002-000364		Depo: Ryan, John 6/14/2005 EX 040			
05207	RYANJ203-000037	RYANJ203-000075		Depo: Ryan, John 6/14/2005 EX 041: Progestins and Hormone Replacement Therapy (HRT): Issues and Implications			
05208	RYANJ002-000502	RYANJ002-000531		Depo: Ryan, John 6/14/2005 EX 042: Premarin (Conjugated Estrogens, U.S.P.) ...Still Ahead of its Time.			
05209			10/23/2000	Depo: Ryan, John 6/14/2005 EX 043: Marketing and Promotion of Pharmaceuticals			
05210			6/10/2005	Depo: Ryan, John 6/14/2005 EX 044: Patricia Beeman-FWD: RE:Deposition of John Ryan			
05211	PANAA019-000589	CHOOM011-001232	8/26/1994	Depo: Ryan, John 6/14/2005 EX 045: Premarin - Powerhouse of the '90s!			
05262				Depo: Sinapi 8/29/2005 EX 001: BIO For Michael Sinapi			
05263	CONKJ011-000499	CONKJ011-000504	8/16/2002	Depo: Sinapi 8/29/2005 EX 002: Summary Statistics Report			
05264	SINAM013-000602	SINAM013-000612		Depo: Sinapi 8/29/2005 EX 003			
05265	SINAM203-000020	SINAM203-000020		Depo: Sinapi 8/29/2005 EX 004: No Title			
05266	SINAM013-002532	SINAM013-002572	7/31/2002	Depo: Sinapi 8/29/2005 EX 005			
05267	SINAM005-000286	SINAM005-000294	1/17/2000	Depo: Sinapi 8/29/2005 EX 006: Finance Committee Authorization 2000 Awards and Grants			
05268	SINAM001-000012	SINAM001-000051	8/12/2002	Depo: Sinapi 8/29/2005 EX 007: Prempro (Conjugated Estrogens / Medroxyprogesterone Acetate Tablets) Premphase (Conjugated Estrogens / Medroxyprogesterone Acetate Tablets)			
05269	SINAM004-000494	SINAM004-000494	1/7/2002	Depo: Sinapi 8/29/2005 EX 008: Finance Committee Authorization 2002 Awards and Grants			
05270	SINAM007-000288	SINAM007-000300		Depo: Sinapi 8/29/2005 EX 009: VSB Honoraria Negotiation			
05271	SINAM013-002087	SINAM013-002087		Depo: Sinapi 8/29/2005 EX 010			
05272	SINAM004-000464	SINAM004-000466	2/11/2002	Depo: Sinapi 8/29/2005 EX 011: Finance Committee Authorization Visiting Speakers Bureau - Performance Effectiveness Tracking & Return on Investment (ROI) Analysis			
05273	HOLSN013-000354	HOLSN013-000386		Depo: Sinapi 8/29/2005 EX 012: Your Body Gave You The Estrogen You Needed For 40 Years What About The Next 40? Living With Estrogen Loss			
05274	W-ADSBRO-00981	W-ADSBRO-00988	1/00/2000	Depo: Sinapi 8/29/2005 EX 013			
05275	SOLOJ027-050742	SOLOJ027-050742	11/1/2002	Depo: Sinapi 8/29/2005 EX 014: Re: CONFIDENTIAL - 30 WEST			
05276	SINAM002-000839	SINAM002-000840	11/29/1993	Depo: Sinapi 8/29/2005 EX 015: Sales Presentation - Premarin versus Estrace			
05277	SINAM002-000873	SINAM002-000876		Depo: Sinapi 8/29/2005 EX 016: Limited Use: Vasomotor Symptoms/Short Term; Depo: Sinapi 8/29/2005 EX 017: Limited Use: Vasomotor Symptoms/Short Term			
05278	SINAM002-000768	SINAM002-000774		Depo: Sinapi 8/29/2005 EX 017: Limited Use: Vasomotor Symptoms/Short Term			
05279	LUDMG002-001710	LUDMG002-001710	10/20/1997	Depo: Sinapi 8/29/2005 EX 018: Summary Report on Hormone Replacement Therapy, Market Measures; Depo: Jeanne Durocher 6/30/06 EX052: Memo from Allonsi			
05280	SINAM002-000762	SINAM002-000765	4/00/1994	Depo: Sinapi 8/29/2005 EX 019: Estrogen Replacement Therapy in Women with Previously Treated Breast Cancer			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05281	SINAM014-000186	SINAM014-000186	1/23/2002	Depo: Sinapi 8/29/2005 EX 020: Re: FYI on WHC Prempro Enhancement Proposal			
05282	PANAA019-000537	PANAA019-000539	4/22/1993	Depo: Sinapi 8/29/2005 EX 021: Extending Compliance Increases Sales			
05283	HENRL008-000280	HENRL008-000299		Depo: Sinapi 8/29/2005 EX 022: Seasons			
05284			12/30/2005	Depo: Solomon, Jeffrey 1/26/2006 EX 001: Plaintiffs' Second Amended Notice of Deposition of Jeff Solomon			
05285			1/12/2006	Depo: Solomon, Jeffrey 1/26/2006 EX 002: WYETH'S Cross Notice of Plaintiffs' Second Amended Notice of Deposition of Jeff Solomon			
05286			12/30/2005	Depo: Solomon, Jeffrey 1/26/2006 EX 003A: Plaintiffs' Request for Admissions to Defendant Wyeth, Inc.			
05287				Depo: Solomon, Jeffrey 1/26/2006 EX 004: Jeff Solomon's Background Info			
05288			00/00/1996	Depo: Solomon, Jeffrey 1/26/2006 EX 005A: Handwritten Notes			
05289			00/00/1998	Depo: Solomon, Jeffrey 1/26/2006 EX 005B: Handwritten Notes			
05290	SOLOJ022-003052	SOLOJ022-003096		Depo: Solomon, Jeffrey 1/26/2006 EX 006: ERT/HRT Franchise Three Year Strategic Plan 1996 - 1998			
05291	SOLOJ025-000286	SOLOJ025-000355	3/10/1998	Depo: Solomon, Jeffrey 1/26/2006 EX 007: The US Market: A Case Study in the Success of Changing the HRT Paradigm			
05292	SOLOJ028-002307	SOLOJ028-002413		Depo: Solomon, Jeffrey 1/26/2006 EX 008			
05293	SOLOJ027-027445	SOLOJ027-027543	5/14/2002	Depo: Solomon, Jeffrey 1/26/2006 EX 009: Contraceptive Team			
05294	SOLOJ022-000967	SOLOJ022-000983	1/24/1997	Depo: Solomon, Jeffrey 1/26/2006 EX 010: Working Toward a Partnership			
05295	SOLOJ012-001377	SOLOJ012-001403	3/20/2002	Depo: Solomon, Jeffrey 1/26/2006 EX 011: 2002 Public Relations. Flexible Strategies for a Changed World. Ketchum Wyeth Strategic Planning Meeting March 20, 2002			
05296	SOLOJ021-000019	SOLOJ021-000021		Depo: Solomon, Jeffrey 1/26/2006 EX 012: Core Messages - Premarin Benefits Packages Draft			
05297	SOLOJ028-006270	SOLOJ028-006271		Depo: Solomon, Jeffrey 1/26/2006 EX 013			
05298	SOLOJ027-027331	SOLOJ027-027337	5/2/2002	Depo: Solomon, Jeffrey 1/26/2006 EX 014: No Slide Title			
05299	SOLOJ022-000272	SOLOJ022-000406	5/11/1998	Depo: Solomon, Jeffrey 1/26/2006 EX 015: Therapeutic Options for Menopausal Health			
05300	SOLOJ002-000001	SOLOJ002-000112	12/12/2001	Depo: Solomon, Jeffrey 1/26/2006 EX 016: Premarin Advocate Directory. Investigator List			
05301	SOLOJ011-000129	SOLOJ011-000129	9/14/2001	Depo: Solomon, Jeffrey 1/26/2006 EX 017: Top Paid VSB Speakers			
05302	SOLOJ020-000420	SOLOJ020-000424	12/7/1999	Depo: Solomon, Jeffrey 1/26/2006 EX 018: Premarin Family of Products Medical Communication Plan			
05303	SOLOJ013-000059	SOLOJ013-000060	6/6/2001	Depo: Solomon, Jeffrey 1/26/2006 EX 031: Strategic Publications Development Meeting June 6, 2001 Meeting Recap			
05304	SOLOJ027-046945	SOLOJ027-046958	9/26/2001	Depo: Solomon, Jeffrey 1/26/2006 EX 033: PUBLICATION PLAN TRACKING REPORT			
05305	SOLOJ027-050513	SOLOJ027-050513	8/14/2001	Depo: Solomon, Jeffrey 1/26/2006 EX 034: Strategic Publications Development Meeting			
05306	SOLOJ028-000847	SOLOJ028-000853	4/22/2004	Depo: Solomon, Jeffrey 1/26/2006 EX 085			
05307	SOLOJ010-001982	SOLOJ010-001987	11/25/2002	Depo: Solomon, Jeffrey 1/26/2006 EX 086: Premarin Family Tactics 2003 A&P Budget as of 11/25/02			
05308	SOLOJ010-001959	SOLOJ010-001959		Depo: Solomon, Jeffrey 1/26/2006 EX 087: Continuing Medical Education Grid 2002 & 2003			
05309	SOLOJ022-001302	SOLOJ022-001323	00/00/1996	Depo: Solomon, Jeffrey 1/26/2006 EX 088: Guide to Understanding Studies on ERT/HRT and Breast Cancer Risk			
05310				Depo: Solomon, Jeffrey 1/26/2006 EX 089: Article: Get the Facts on..... Cardiovascular Disease and Women			
05311				Depo: Solomon, Jeffrey 1/26/2006 EX 090: Article: Get the Facts on.....Osteoporosis and Women			
05312	Various	Various	12/13/1999	Depo: Solomon, Jeffrey 1/26/2006 EX 091			
05313	SOLOJ022-001929	SOLOJ022-001929		Depo: Solomon, Jeffrey 1/26/2006 EX 092: regarding Premarin...			
05314	SOLOJ003-000183	SOLOJ003-000191		Depo: Solomon, Jeffrey 1/26/2006 EX 093A: Premarin Family Label Changes			
05315	SOLOJ003-000197	SOLOJ003-000198		Depo: Solomon, Jeffrey 1/26/2006 EX 093B: Key Guidelines for Discussing Revised Labeling with Doctors			
05316	SONKJ013-000389	SONKJ013-000408	12/00/1996	Depo: Sonk 1/24/2006 EX 001: The Effects of Hormone Replacement Therapy on the Cardiovascular System			
05317	SONKJ016-000425	SONKJ016-000426	9/28/1998	Depo: Sonk 1/24/2006 EX 002: Premarin Family Tacticals Presentation			
05318	SONKJ028-000239	SONKJ028-000246	10/5/1993	Depo: Sonk 1/24/2006 EX 003: Memorandum of Meeting Premarin/MPA Refusal to File NDA No. 20-303			
05319	SONKJ020-000776	SONKJ020-000779		Depo: Sonk 1/24/2006 EX 006: Fosamax Concomitant Use with Conjugated Estrogens (Progestine) in the Treatment of Osteoporosis			
05320	SONKJ019-000164	SONKJ019-000165	3/17/2000	Depo: Sonk 1/24/2006 EX 007: Fosamax Concomitant Use with Conjugated Estrogens			
05321	SONKJ027-001217	SONKJ027-001217	1/2/1997	Depo: Sonk 1/24/2006 EX 009: Medguide Action Plan HRT Reference			
05322	MDL527-00039695	MDL527-00039698	11/19/1998	Depo: Sonk 1/24/2006 EX 010			
05323	SONKJ016-000029	SONKJ016-000031	2/12/1999	Depo: Sonk 1/24/2006 EX 014: Comments on "Labeling Guidance for Non-Contraceptive Estrogen Drug Products - Physician and Patient Labeling" Docket No. 98D-0834			
05324				Depo: Sonk 1/24/2006 EX 016: Joseph S. Sonk CV			
05325				Depo: Sonk 1/24/2006 EX 017: Joseph S. Sonk Resume			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05326	SONKJ030-000641	SONKJ030-000642	5/19/1998	Depo: Sonk 1/24/2006 EX 018			
05327	SONKJ016-000466	SONKJ016-000468	5/20/1998	Depo: Sonk 1/24/2006 EX 020: NDA 4-782 Premarin (Conjugated Estrogens) Tablets MACMIS 6663			
05328	W-MDL527-00044579	W-MDL527-00044580	7/10/2002	Depo: Sonk 1/24/2006 EX 020A: FDA Telephone Contact Report (NDA 20-527)			
05329	SONKJ028-000459	SONKJ028-000463		Depo: Sonk 1/24/2006 EX 021: 12/5 Team			
05330	SONKJ030-001466	SONKJ030-001466	5/5/1997	Depo: Sonk 1/24/2006 EX 022			
05331	SONKJ030-002872	SONKJ030-002872		Depo: Sonk 1/24/2006 EX 023			
05332			4/18/2006	Depo: Sorrentino, Matthew 5/3/2006 EX 001: Plaintiffs' Notice of Discovery Deposition of Matthew Sorrentino, M.D.			
05333			1/00/2003	Depo: Sorrentino, Matthew 5/3/2006 EX 002: Matthew Sorrentino, M.D., F.A.C.C. Curriculum Vitae			
05334			4/18/2006	Depo: Sorrentino, Matthew 5/3/2006 EX 003: Report of Matthew Sorrentino, M.D.			
05335				Depo: Sorrentino, Matthew 5/3/2006 EX 004: Bill From Matthew Sorrentino			
05336			8/23/2004	Depo: Sorrentino, Matthew 5/3/2006 EX 005: Verified Statement of Matthew Sorrentino, M.D.			
05337	STRIS001-000034	STRIS001-000045	7/00/1997	Depo: Sorrentino, Matthew 5/3/2006 EX 006: For Four Decades, Her Body Supplied All the Estrogen She Needed.			
05338	W-ADSBRO-00185	W-ADSBRO-00185		Depo: Sorrentino, Matthew 5/3/2006 EX 007: When Considering Menopause and the Consequences of its Associated Estrogen loss, Consider the Entire Body of Evidence. Article			
05339	W-ADSBRO-01410	W-ADSBRO-01411	6/10/1998	Depo: Sorrentino, Matthew 5/3/2006 EX 008			
05340	W-ADSBRO-00006	W-ADSBRO-00007	1/00/1999	Depo: Sorrentino, Matthew 5/3/2006 EX 009			
05341	W-ADSBRO-00068	W-ADSBRO-00070	1/00/1999	Depo: Sorrentino, Matthew 5/3/2006 EX 010			
05342			5/00/2000	Depo: Sorrentino, Matthew 5/3/2006 EX 011			
05343	W-ADSBRO-01244	W-ADSBRO-01255	3/00/2001	Depo: Sorrentino, Matthew 5/3/2006 EX 012			
05344	W-ADSBRO-00981	W-ADSBRO-00988	1/00/2000	Depo: Sorrentino, Matthew 5/3/2006 EX 013			
05345				Depo: Sorrentino, Matthew 5/3/2006 EX 014: Observational Studies of CVD Risk and Hormone Therapy			
05346			2/25/2004	Depo: Sorrentino, Matthew 5/3/2006 EX 015: The Womens Health Initiative Could Not Have Detected Cardioprotective Effects of Starting Hormone Therapy During the Menopausal Transition. Article			
05347			2/17/1999	Depo: Sorrentino, Matthew 5/3/2006 EX 016: Postmenopausal Hormone Therapy and risk of Cardiovascular Disease and Hip Fracture in a Cohort of Swedish Women. Article			
05348			12/19/2000	Depo: Sorrentino, Matthew 5/3/2006 EX 017: A Prospective Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease. Article			
05349			00/00/2006	Depo: Sorrentino, Matthew 5/3/2006 EX 018: Hormone Therapy and Coronary Heart Disease:The role of time Since Menopause and Age at Hormone Initiation. Article			
05350			9/16/2004	Depo: Sorrentino, Matthew 5/3/2006 EX 019: AJE Article: Combined Postmenopausal Hormone Therapy and Cardiovascular Disease.....			
05351			12/16/1999	Depo: Sorrentino, Matthew 5/3/2006 EX 020: Hormone Replacement Therapy and Incidence of Acute Myocardial Infraction. Article			
05352			2/14/2006	Depo: Sorrentino, Matthew 5/3/2006 EX 021: Conjugated Equine Estrogens and Coronary Heart Disease. Article			
05353	HRT MED LIT 0440001	HRT MED LIT 0440004	9/13/1993	Depo: Sorrentino, Matthew 5/3/2006 EX 022: Coronary heart disease and estrogen replacement therapy can compliance bias explain the results of observational studies? Petitti, DB Ann Epidemiol 1994;4:115-8			
05354			10/30/1980	Depo: Sorrentino, Matthew 5/3/2006 EX 023: NEJM Article:Influence of Adherence to Treatment and Response of Cholesterol on Mortality in the Coronary Drug Project			
05355			11/9/2004	Depo: Sorrentino, Matthew 5/3/2006 EX 024: Postmenopausal Hormone Therapy: Critical Reappraisal and a Unified Hypothesis. Article			
05356			9/13/1997	Depo: Sorrentino, Matthew 5/3/2006 EX 025: BMJ Article: Impact of Postmenopausal Hormone Therapy on Cardiovascular Events and Cancer			
05357			1/31/2005	Depo: Speroff, Leon 6/30/2005 EX 003: OHSU School of Medicine letter to Jeff Gibson			
05358	BARBM022-006614	BARBM022-006634		Depo: Speroff, Leon 6/30/2005 EX 004			
05359	BRADK006-001383	BRADK006-001383	7/22/1999	Depo: Speroff, Leon 6/30/2005 EX 005: HERS Meeting			
05360	BURRG005-000690	BURRG005-000733		Depo: Speroff, Leon 6/30/2005 EX 006			
05361	CHOOM001-002318	CHOOM001-002323	10/26/2000	Depo: Speroff, Leon 6/30/2005 EX 007			
05362	CHOOM001-002325	CHOOM001-002326	10/5/2000	Depo: Speroff, Leon 6/30/2005 EX 008			
05363	COBBP006-001648	COBBP006-001659-		Depo: Speroff, Leon 6/30/2005 EX 010: Postmenopausal Estrogen-Progestin Therapy and Breast Cancer a Clinical Response to Epidemiological Reports			
05364	COBBP006-001680	COBBP006-001691	2/9/2000	Depo: Speroff, Leon 6/30/2005 EX 011: Postmenopausal Estrogen-Progestin Therapy and Breast Cancer a Clinical Response to Epidemiological Reports			
05365	COBBP006-001692	COBBP006-001704		Depo: Speroff, Leon 6/30/2005 EX 012: Postmenopausal Estrogen-Progestin Therapy and Breast Cancer a Clinical Response to an Epidemiological Report			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05366	COBBP026-000121	COBBP026-000121	1/9/2001	Depo: Speroff, Leon 6/30/2005 EX 013: Hi Jamie			
05367	COBBP026-000813	COBBP026-000819	2/14/2002	Depo: Speroff, Leon 6/30/2005 EX 014: Fwd: Re: JAMA Breast Cancer Article			
05368	CONKJ019-016267	CONKJ019-016270	10/3/2001	Depo: Speroff, Leon 6/30/2005 EX 015: Fwd: Notes from talk by Leon Speroff M.D.			
05369	CONSG018-015904	CONSG018-015910	6/14/2001	Depo: Speroff, Leon 6/30/2005 EX 016: Fwd: Comment from Speroff re: USA Today			
05370	CONTA004-002205	CONTA004-002205	2/7/2002	Depo: Speroff, Leon 6/30/2005 EX 018			
05371	CONTA016-000455	CONTA016-000470--	7/2/2002	Depo: Speroff, Leon 6/30/2005 EX 019			
05372	CONTA019-000734	CONTA019-000734	8/22/2000	Depo: Speroff, Leon 6/30/2005 EX 020: August 24 NEJM: HRT and CVD			
05373	CONTA023-008846	CONTA023-008847---	5/25/2000	Depo: Speroff, Leon 6/30/2005 EX 022			
05374	CONTA023-014454	CONTA023-014460	2/23/2000	Depo: Speroff, Leon 6/30/2005 EX 023			
05375	CONTA025-015780	CONTA025-015795-	12/12/2002	Depo: Speroff, Leon 6/30/2005 EX 024: PUBLICATION PLAN TRACKING REPORT			
05376	CONTA025-019407	CONTA025-019407	7/2/2002	Depo: Speroff, Leon 6/30/2005 EX 025: Important Evaluation			
05377	CONTA025-020240	CONTA025-020240	6/21/2002	Depo: Speroff, Leon 6/30/2005 EX 026: HERS II			
05378	CONTA025-026089	CONTA025-026092	6/29/2001	Depo: Speroff, Leon 6/30/2005 EX 027: WHI Issues Management Plan			
05379	CONTA025-030907	CONTA025-030912	6/10/2000	Depo: Speroff, Leon 6/30/2005 EX 028: Perspectives in ERT/HRT			
05380	CONTA025-030913	CONTA025-030914	6/9/2000	Depo: Speroff, Leon EX 029: Advisory Bd. Friday June 9, 2000			
05381	CONTA025-032042	CONTA025-032042	3/19/2001	Depo: Speroff, Leon 6/30/2005 EX 030: No Title			
05382	CONTA026-001101	CONTA026-001103-	7/7/2003	Depo: Speroff, Leon 6/30/2005 EX 033: Requesting to Closely Review the Terms and Conditions of Agreement			
05383	DELCA011-000001	DELCA011-000001	3/13/2000	Depo: Speroff, Leon 6/30/2005 EX 034			
05384	DEYMI021-000197	DEYMI021-000198-----	8/21/2001	Depo: Speroff, Leon 6/30/2005 EX 035			
05385	DUROJ0006-000470	DUROJ0006-000471		Depo: Speroff, Leon 6/30/2005 EX 036			
05386	DUROJ017-000813	DUROJ017-000819	6/29/2001	Depo: Speroff, Leon 6/30/2005 EX 038: Interview with Leon Speroff, M.D.			
05387	DUROJ019-000753	DUROJ019-000754	7/20/2001	Depo: Speroff, Leon 6/30/2005 EX 039			
05388	DUROJ021-002084	DUROJ021-002090	10/12/1998	Depo: Speroff, Leon 6/30/2005 EX 040: Abstract			
05389	DUROJ024-001426	DUROJ024-001426	6/22/2001	Depo: Speroff, Leon 6/30/2005 EX 043: Points for Dr. Speroff			
05390	DUROJ024-001499	DUROJ024-001819	7/2/2001	Depo: Speroff, Leon 6/30/2005 EX 044: Responses to the USA Today Article			
05391	DUROJ027-000181	DUROJ027-000190	6/13/2001	Depo: Speroff, Leon 6/30/2005 EX 045			
05392	DUROJ027-000311	DUROJ027-000313	3/20/2001	Depo: Speroff, Leon 6/30/2005 EX 046: JAMA Article			
05393	DUROJ027-000314	DUROJ027-000320----	3/19/2001	Depo: Speroff, Leon 6/30/2005 EX 047: JAMA Article on ERT			
05394	DUROJ027-000733	DUROJ027-000736-	1/8/2001	Depo: Speroff, Leon 6/30/2005 EX 048: JAMA Article			
05395	DUROJ027-000969	DUROJ027-000980	9/26/2000	Depo: Speroff, Leon 6/30/2005 EX 049			
05396	DUROJ032-000210	DUROJ032-000218	1/7/1994	Depo: Speroff, Leon 6/30/2005 EX 050: Premarin			
05397	DUROJ036-002615	DUROJ036-002622	6/2/1995	Depo: Speroff, Leon 6/30/2005 EX 051: Draft for Client Review			
05398	DUROJ034-000396	DUROJ034-000397-	8/26/2002	Depo: Speroff, Leon 6/30/2005 EX 052			
05399	DUROJ046-005405	DUROJ046-005417--	11/15/2002	Depo: Speroff, Leon 6/30/2005 EX 056: Fwd: Response from Leon			
05400	DUROJ046-007197	DUROJ046-007197	9/16/2002	Depo: Speroff, Leon 6/30/2005 EX 057: Leon			
05401	DUROJ046-007641	DUROJ046-007641	9/2/2002	Depo: Speroff, Leon 6/30/2005 EX 058: Hi Jamie			
05402	DUROJ046-010671	DUROJ046-010678-	7/18/2002	Depo: Speroff, Leon 6/30/2005 EX 059: Hi Jamie			
05403	DUROJ046-013137	DUROJ046-013140-	6/27/2002	Depo: Speroff, Leon 6/30/2005 EX 060: HERS II			
05404	DUROJ046-013581	DUROJ046-013586	6/24/2002	Depo: Speroff, Leon 6/30/2005 EX 061: Hi Jamie			
05405	DUROJ046-015650	DUROJ046-015654	5/25/2002	Depo: Speroff, Leon 6/30/2005 EX 062: Hi Jamie			
05406	DUROJ046-015872	DUROJ046-015873--	5/28/2002	Depo: Speroff, Leon 6/30/2005 EX 063: Re: Fwd: HERS II			
05407	DUROJ046-015932	DUROJ046-015932	5/24/2002	Depo: Speroff, Leon 6/30/2005 EX 064: Re: A Bad Sequel to a 1998 Feature			
05408	DUROJ046-018080	DUROJ046-018086-	5/1/2002	Depo: Speroff, Leon 6/30/2005 EX 065: A Response to the Critics			
05409	DUROJ046-019009	DUROJ046-019013	4/13/2002	Depo: Speroff, Leon 6/30/2005 EX 066: Hi Jamie			
05410	DUROJ046-020819	DUROJ046-020820	3/13/2002	Depo: Speroff, Leon 6/30/2005 EX 067: Re: Thank You			
05411	DUROJ046-022734	DUROJ046-022738	2/1/2002	Depo: Speroff, Leon 6/30/2005 EX 069: Hi Jamie			
05412	DUROJ046-024620	DUROJ046-024624	10/22/2002	Depo: Speroff, Leon 6/30/2005 EX 071: Hi Jamie			
05413	DUROJ046-025099	DUROJ046-025105	10/29/2002	Depo: Speroff, Leon 6/30/2005 EX 072: Re: Fwd: Fw: question on WHI results			
05414	DUROJ046-025859	DUROJ046-025874-	10/4/2002	Depo: Speroff, Leon 6/30/2005 EX 073: Fwd: NAMS Report on Hormone Therapy			
05415	DUROJ046-026505	DUROJ046-026505	9/16/2002	Depo: Speroff, Leon 6/30/2005 EX 074: Leon			
05416	DUROJ046-027492	DUROJ046-027492	7/12/2002	Depo: Speroff, Leon 6/30/2005 EX 075: Half Moon Bay			
05417	DUROJ046-029484	DUROJ046-029489--	5/30/2002	Depo: Speroff, Leon 6/30/2005 EX 076: Fwd			
05418	DUROJ046-029961	DUROJ046-029966		Depo: Speroff, Leon 6/30/2005 EX 077			
05419	DUROJ046-032647	DUROJ046-032647	11/19/2001	Depo: Speroff, Leon 6/30/2005 EX 078: Re			
05420	GASTM0009-000654	GASTM0009-000660	9/8/1998	Depo: Speroff, Leon 6/30/2005 EX 079			
05421	GASTM011-022805	GASTM011-022810	12/20/2000	Depo: Speroff, Leon 6/30/2005 EX 080: Hi Jamie			
05422	PANAA023-001092	PANAA023-001094	1/13/1994	Depo: Speroff, Leon 6/30/2005 EX 083: News Release - Estrogen Therapy & Cardiovascular Disease			
05423	PANAA026-001324	PANAA026-001325-	12/22/1992	Depo: Speroff, Leon 6/30/2005 EX 084			
05424	PANAA037-001010	PANAA037-001184	1/19/1995	Depo: Speroff, Leon 6/30/2005 EX 085			
05425	PANAA040-029642	PANAA040-029644	4/29/2002	Depo: Speroff, Leon 6/30/2005 EX 086: Fwd: Re			
05426	PICKJ035-001075	PICKJ035-001078	9/5/1997	Depo: Speroff, Leon 6/30/2005 EX 087: Fwd: Re			
05427	SOLOJ022-001066	SOLOJ022-001107		Depo: Speroff, Leon 6/30/2005 EX 088: Call Leon			
05428	WEBEM015-006528	WEBEM015-006528	6/30/2000	Depo: Speroff, Leon 6/30/2005 EX 089: PUBLICATION PLAN TRACKING REPORT			
05429			00/00/1985	Depo: Speroff, Leon 8/16/2005 EX 093: Estrogen Replacement Therapy: Current Thinking and Practice. Article			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05430			7/22/1993	Depo: Speroff, Leon 6/30/2005 EX 095: Cardiovascular Health and Disease in Women. Article			
05431			00/00/1999	Depo: Speroff, Leon 6/30/2005 EX 107: Women's Healthcare in the 21st Century. Article			
05432			00/00/2000	Depo: Speroff, Leon 6/30/2005 EX 110: It's Time to Stop Using the Word "Replacement". Article			
05433			10/00/2003	Depo: Speroff, Leon 6/30/2005 EX 124: HT: A Clinician Demurs. Article			
05434			6/21/2005	Depo: Speroff, Leon 6/30/2005 EX 135: Leon Speroff's CV			
05435			12/00/1986	Depo: Speroff, Leon 6/30/2005 EX 141: OB/GYN Clinical Alert/ Comments Made by Dr.Speroff			
05436			6/00/2000	Depo: Speroff, Leon 6/30/2005 EX 142: The Promise of HRT. Article			
05437			4/00/2000	Depo: Speroff, Leon 6/30/2005 EX 143: Guiding Your Patients Through the Transitional Years, Menopause, and Beyond. Article			
05438			00/00/2003	Depo: Speroff, Leon 6/30/2005 EX 144: Menopausal Medicine Newsletter			
05439			00/00/1997	Depo: Speroff, Leon 6/30/2005 EX 145: Menopausal Medicine Newsletter			
05440			7/00/2001	Depo: Speroff, Leon 6/30/2005 EX 146: The Impact of Low-Dose HRT. Article			
05441			10/00/2001	Depo: Speroff, Leon 6/30/2005 EX 147: HRT: Putting the Latest Data into Practice. Article			
05442			00/00/2005	Depo: Speroff, Leon 6/30/2005 EX 149: NAMS: When Choosing the Right Hormone Therapy for Her GO LOW. Article			
05443			6/00/2002	Depo: Speroff, Leon 6/30/2005 EX 150: Preventing CV In Women: A Work in Progress			
05444			9/00/2000	Depo: Speroff, Leon 6/30/2005 EX 151: Transdermal HRT: The Female Perspective. Article			
05445			12/00/2001	Depo: Speroff, Leon 6/30/2005 EX 152: The Human Genome Project and Postmenopausal Hormone Replacement. Article			
05446			5/18/1988	Depo: Speroff, Leon 6/30/2005 EX 158: Letter to Ms. Kathleen Welsh From Leon Speroff			
05447			5/00/1988	Depo: Speroff, Leon 6/30/2005 EX 160: 1970's Research info			
05448			2/18/1988	Depo: Speroff, Leon 6/30/2005 EX 164: Letter to Ms. Diane Harri From Leon Speroff			
05449			2/5/1988	Depo: Speroff, Leon 6/30/2005 EX 165: Letter to Sanford B. Gaffin From Leon Speroff			
05450			2/17/1998	Depo: Speroff, Leon 6/30/2005 EX 174: Letter to Pat Iverson From Leon Speroff			
05451			11/5/1991	Depo: Speroff, Leon 6/30/2005 EX 178: Letter to Mark Deitch From Leon Speroff			
05452			12/24/1991	Depo: Speroff, Leon 6/30/2005 EX 179: Letter to Marc W. Deitch, M.D. From Leon Speroff			
05453			12/14/1992	Depo: Speroff, Leon 6/30/2005 EX 180: Letter to David A. Colasante,M.D. From Leon Speroff			
05454			8/4/1993	Depo: Speroff, Leon 6/30/2005 EX 181: Letter to Mark Deitch From Leon Speroff			
05455			4/8/1993	Depo: Speroff, Leon 6/30/2005 EX 182: Letter to Justin M. McCarthy From Leon Speroff			
05456			11/8/1993	Depo: Speroff, Leon 6/30/2005 EX 183: Letter to James H. Pickar, M.D. From Leon Speroff			
05457			5/19/1994	Depo: Speroff, Leon 6/30/2005 EX 184: Letter to Justin M. McCarthy From Leon Speroff			
05458			8/25/1994	Depo: Speroff, Leon 6/30/2005 EX 185: Letter to James H. Pickar, M.D. From Leon Speroff			
05459			3/11/1996	Depo: Speroff, Leon 6/30/2005 EX 186: Letter to James H. Pickar, M.D. From Leon Speroff			
05460			2/25/1997	Depo: Speroff, Leon 6/30/2005 EX 187: Letter to Jeff Buchalter From Leon Speroff			
05461			7/29/1997	Depo: Speroff, Leon 6/30/2005 EX 188: Letter to David R. Downey From Leon Speroff			
05462			10/2/1997	Depo: Speroff, Leon 6/30/2005 EX 189: Letter to Donna S. Duvall, R.N.,M.N. From Leon Speroff			
05463			9/4/2001	Depo: Speroff, Leon 6/30/2005 EX 190: Letter to James H. Pickar, M.D. From Leon Speroff			
05464			5/17/2001	Depo: Speroff, Leon 6/30/2005 EX 191: Letter to James H. Pickar, M.D. From Leon Speroff			
05465			5/23/2002	Depo: Speroff, Leon 6/30/2005 EX 192: Letter to James H. Pickar, M.D. From Leon Speroff			
05466			10/19/1991	Depo: Speroff, Leon 6/30/2005 EX 193: Parke-Davis Endocrine Advisory Panel Meeting- October 19, 1991			
05467			5/1/1991	Depo: Speroff, Leon 6/30/2005 EX 194: Parke-Davis Endocrine Advisory Panel Meeting- March 21, 1991			
05468			10/13/1990	Depo: Speroff, Leon 6/30/2005 EX 195: Parke-Davis Endocrine Advisory Panel Meeting- October 13, 1990			
05469			5/5/1990	Depo: Speroff, Leon 6/30/2005 EX 196: Parke-Davis Endocrine Advisory Panel Meeting- May 5, 1990			
05470	VARIOUS	VARIOUS	4/19/2005	Depo: Speroff, Leon 8/16/2005 EX 202			
05471				Depo: Speroff, Leon 8/16/2005 EX 205: Clinical Gynecologic Endocrinology and Infertility- Seventh Edition			
05472				Depo: Speroff, Leon 8/16/2005 EX 206: Menopause and the Perimenopausal Transition. Article			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05473	HRT MED LIT 0048001	HRT MED LIT 0048009	1/31/2000	Depo: Speroff, Leon 8/16/2005 EX 209: Changing incidence rate of invasive lobular breast carcinoma among older women. Li, Ci, Anderson, BO, Porter, PL, Holt, SK, Daling, JR, Moe, RE Cancer. 2000 Oct 15			
05474	HRT MED LIT 0192001	HRT MED LIT 0192004	4/18/1990	Depo: Speroff, Leon 8/16/2005 EX 216: Rising incidence of breast cancer: relationship to stage and receptor status. Glass, A, Hoover, R J Nat Cancer Inst 1990; 82			
05475			00/00/2005	Depo: Speroff, Leon 8/16/2005 EX 219: Effect of Reproductive Factors and Postmenopausal Hormone Use on the Risk of Parkinson Disease. Article			
05476	HRT MED LIT 1357001	HRT MED LIT 1357006	11/00/2002	Depo: Speroff, Leon 8/16/2005 EX: 220: Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cerhan, JR, Vachon, CM, Habermann, TM, Ansell, SM, Witzig, TE, Kurtin, PJ, Janney, CA, Zheng, W, Potter, JD, Sellers, T			
05477			3/00/2000	Depo: Speroff, Leon 8/16/2005 EX 225: Postmenopausal Estrogen-Progestin Therapy and Breast Cancer: A Clinical Response to an epidemiologic Report			
05478			8/1/2003	Depo: Speroff, Leon 8/16/2005 EX 226: Is Tibolone a Viable Alternative to HT?			
05479			00/00/1992	Depo: Speroff, Leon 8/16/2005 EX 227: The Risk of Breast Cancer Associated with Oral Contraception and Hormone Replacement Therapy. Article			
05480	HENRL001-002162	HENRL001-002191	00/00/2000	Depo: Speroff, Leon 8/16/2005 EX 228: CME Activity Guiding your Patients through the Transitional Years, Menopause, and beyond			
05481			6/1/2004	Depo: Speroff, Leon 8/16/2005 EX 229: What I've Learned From the Emotional and Political Response to WHI. Article			
05482			7/27/2004	Depo: Speroff, Leon 8/16/2005 EX 230: Postmenopausal Hormone Therapy A Clinician's Response to the WHI - By Leon Speroff			
05483			6/20/2005	Depo: Speroff, Leon 8/16/2005 EX 231: HRT and Female Health: From Randomized Clinical Trials to Clinical Practice			
05484			3/00/2004	Depo: Stephenson, Wendy 3/10/2005 EX 001: Wendy P. Stephenson CV			
05485			00/00/1996	Depo: Stephenson, Wendy 3/10/2005 EX 002: PDR			
05486			00/00/1997	Depo: Stephenson, Wendy 3/10/2005 EX 003: PDR			
05487			00/00/1998	Depo: Stephenson, Wendy 3/10/2005 EX 004: PDR			
05488			00/00/1999	Depo: Stephenson, Wendy 3/10/2005 EX 005: PDR			
05489			00/00/2000	Depo: Stephenson, Wendy 3/10/2005 EX 006: PDR			
05490			00/00/2001	Depo: Stephenson, Wendy 3/10/2005 EX 007: PDR			
05491			00/00/2004	Depo: Stephenson, Wendy 3/10/2005 EX 008: PDR			
05492	STEPW008-00093	STEPW008-00095	7/15/1997	Depo: Stephenson, Wendy 3/10/2005 EX 009			
05493	STEPW008-00092	STEPW008-00092	8/22/1997	Depo: Stephenson, Wendy 3/10/2005 EX 010			
05494	PICKJ043-005192	PICKJ043-005192	10/16/2002	Depo: Stephenson, Wendy 3/10/2005 EX 011: Presentation and Meeting with Garnet Anderson			
05495	STEPW014-010872	STEPW014-010872	10/18/2002	Depo: Stephenson, Wendy 3/10/2005 EX 012: Re: Revised: October 17th HRT Core Team Agenda- 555 LL- A			
05496	STEPW014-01697	STEPW014-01697	7/8/2002	Depo: Stephenson, Wendy 3/10/2005 EX 013			
05497	DEVAN001-000306	DEVAN001-000308		Depo: Stephenson, Wendy 3/10/2005 EX 014: WHI Announcement - Medium-Term Outreach Plan, Draft			
05498	STEPW014-01040	STEPW014-01041	10/11/2002	Depo: Stephenson, Wendy 3/10/2005 EX 015			
05499	HENRL001-001235	HENRL001-001236	10/00/1997	Depo: Stephenson, Wendy 3/10/2005 EX 016: Answers to some of your Questions about Estrogen			
05500	STEPW013-000441	STEPW013-000445	2/22/2000	Depo: Stephenson, Wendy 3/10/2005 EX 017: ERT HRT and the Risk of Breast Cancer			
05501			7/17/2002	Depo: Stephenson, Wendy 3/10/2005 EX 018: Risks and Benefits of Estrogen Plus Progestin In Healthy Postmeopausal Women.Article			
05502				Depo: Stephenson, Wendy 3/11/2005 EX 019: Handwritten Notes			
05503	STEPW014-008624	STEPW014-008627	9/23/2002	Depo: Stephenson, Wendy 3/11/2005 EX 020: September 21, 2002			
05504				Depo: Strickland 9/8/2005 EX 001: Steven R. Strickland CV			
05505	STRIS018-003045	STRIS018-003045		Depo: Strickland 9/8/2005 EX 002			
05506	SOLOJ025-000286	SOLOJ025-000355	3/10/1998	Depo: Strickland 9/8/2005 EX 003: The US Market: A Case Study in the Success of Changing the HRT Paradigm			
05507	STRIS001-000034	STRIS001-000045	7/00/1997	Depo: Strickland 9/8/2005 EX 004: For Four Decades, Her Body Supplied All the Estrogen She Needed.			
05508	STRIS004-000183	STRIS004-000184	12/20/1996	Depo: Strickland 9/8/2005 EX 005: Business Brief - December			
05509	STRIS004-000185	STRIS004-000186	9/16/1996	Depo: Strickland 9/8/2005 EX 006: Business Brief - September			
05510	STRIS002-000398	STRIS002-000402	1/2/1998	Depo: Strickland 9/8/2005 EX 007: Premarin Role Play Physician Needing Assurance			
05511	STRIS002-000403	STRIS002-000408	1/2/1998	Depo: Strickland 9/8/2005 EX 008: Premarin Role Play Approved Early Adopter			
05512	STRIS016-068583	STRIS016-068632		Depo: Strickland 9/8/2005 EX 009			
05513	PANAA040-027590	PANAA040-027670	6/2/2000	Depo: Strickland 9/8/2005 EX 010: Example slides for segmentation analysis			
05514	STRIS003-000708	STRIS003-000727	11/13/2001	Depo: Strickland 9/8/2005 EX 011: Final Report of Findings: Consumer Evaluation of HRT Benefit Messages			
05515				Depo: Strickland 9/8/2005 EX 012: Risk VS Reality/ Handwritten Notes			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05516	STRIS016-009280	STRIS016-009328		Depo: Strickland 9/8/2005 EX 013			
05517				Depo: Victoria, Justin 6/4/2004 EX 073: Blank Page			
05518			11/10/1994	Depo: Victoria, Justin 6/4/2004 EX 074: Citizen Petition			
05519			5/5/1997	Depo: Victoria, Justin 6/4/2004 EX 075: Approvability of a synthetic Generic Version of Premarin			
05520			2/23/1990	Depo: Victoria, Justin 6/4/2004 EX 076: Citizen Petition			
05521			12/15/1994	Depo: Victoria, Justin 6/4/2004 EX 077: Petition for Stay 94P-0430			
05522			9/9/2002	Depo: Victoria, Justin 6/4/2004 EX 078: Letter to Dockets Management Branch From Donald O.Beers			
05523			6/25/1996	Depo: Victoria, Justin 6/4/2004 EX 079: Citizen Petition			
05524			3/17/2006	Depo: Warren, Michelle 3/24/2006 EX 001: Plaintiffs' Notice of Discovery Deposition of Michelle Warren, M.D.			
05525			2/17/2006	Depo: Warren, Michelle 3/24/2006 EX 002: Report of Michelle P. Warren, M.D.			
05526			8/1/2005	Depo: Warren, Michelle 3/24/2006 EX 003: Michelle P. Warren, M.D. Curriculum Vitae			
05527				Depo: Warren, Michelle 3/24/2006 EX 004: Attachment B-References			
05528			3/21/2006	Depo: Warren, Michelle 3/24/2006 EX 005: E-mail from Gita F. Rothschild to Tobias Mirood March 21, 2006			
05529				Depo: Warren, Michelle 3/24/2006 EX 006: Handwritten Notes			
05530			2/24/2006	Depo: Warren, Michelle 3/24/2006 EX 007: Invoice to Kay Scholer.LLP Feb/24/2006			
05531				Depo: Warren, Michelle 3/24/2006 EX 008: Department of Obstetrics and Gynecology			
05532			1/00/1999	Depo: Warren, Michelle 3/24/2006 EX 009: Benefits and Drawbacks of Hormone Replacement Therapy. Article			
05533			8/26/2003	Depo: Warren, Michelle 3/24/2006 EX 010: A Comparative Review Of the Risks and Benefits of Hormone Replacement therapy Regimens. Article			
05534			00/00/2004	Depo: Warren, Michelle 3/24/2006 EX 011: Hormone Replacement Therapy: Controversies, Pros and Cons. Article			
05535			3/3/2006	Depo: Warren, Michelle 3/24/2006 EX 012: A Readers Guide to Menopause			
05536				Depo: Weber, Margaret 6/21/2005 EX 001: Margaret E. Weber CV			
05537			00/00/2005	Depo: Weber, Margaret 6/21/2005 EX 002: Handwritten Notes			
05538			00/00/2002	Depo: Weber, Margaret 6/21/2005 EX 003: Handwritten Notes			
05539	WEBEM015-013556	WEBEM015-013557	5/00/2001	Depo: Weber, Margaret 6/21/2005 EX 004: WYETH-AYERST			
05540	WEBEM015-014047	WEBEM015-014048	9/00/2001	Depo: Weber, Margaret 6/21/2005 EX 005: WYETH-AYERST			
05541	WEBEM015-031026	WEBEM015-031026	7/00/2002	Depo: Weber, Margaret 6/21/2005 EX 006: WYETH-AYERST			
05542	WEBEM015-023255	WEBEM015-023256	8/00/2002	Depo: Weber, Margaret 6/21/2005 EX 007: WYETH-AYERST			
05543	WEBEM015-012948	WEBEM015-012948	5/18/2001	Depo: Weber, Margaret 6/21/2005 EX 008: cardiovascular info; Depo: Cobb, Pamela 6/23/06 EX 002: Email			
05544	WEBEM014-003252	WEBEM014-003273		Depo: Weber, Margaret 6/21/2005 EX 010			
05545	WEBEM015-020791	WEBEM015-020792	7/31/2002	Depo: Weber, Margaret 6/21/2005 EX 011: HRT Advisory Committee Meeting			
05546	WEBEM015-006093	WEBEM015-006113		Depo: Weber, Margaret 6/21/2005 EX 012: Perspectives in ERT/HRT			
05547			00/00/2000	Depo: Weber, Margaret 6/21/2005 EX 013: PDR			
05548	WEBEM014-003242	WEBEM014-003246	7/19/2000	Depo: Weber, Margaret 6/21/2005 EX 014			
05549	WEBEM015-029876	WEBEM015-029877	10/17/2002	Depo: Weber, Margaret 6/21/2005 EX 015: Fwd: Presentation and Meeting with Garnet Anderson			
05550	WEBEM015-028512	WEBEM015-028512	10/7/2002	Depo: Weber, Margaret 6/21/2005 EX 016: Re: Resources on women's health			
05551	WEBEM015-027388	WEBEM015-027431		Depo: Weber, Margaret 6/21/2005 EX 017: Postmenopausal Hormone Therapy: A Review of Recent Data and Clinical Recommendations			
05552	BURRG002-000096	BURRG002-000140	10/11/2002	Depo: Weber, Margaret 6/21/2005 EX 018: Postmenopausal Hormone Therapy: Scientific Review and Position			
05553	WEBEM015-022502	WEBEM015-022502	9/6/2002	Depo: Weber, Margaret 6/21/2005 EX 019: First stab at BC section			
05554	WEBEM015-021517	WEBEM015-021525	8/22/2002	Depo: Weber, Margaret 6/21/2005 EX 020: Vedani Nicola - biscotica			
05555	WEBEM015-026702	WEBEM015-026756		Depo: Weber, Margaret 6/21/2005 EX 021: Postmenopausal Hormone Therapy: A Review of Recent Data and Clinical Recommendations			
05556	WEBEM015-028761	WEBEM015-028761	10/9/2002	Depo: Weber, Margaret 6/21/2005 EX 022: Postmenopausal Hormone Therapy: A Review of Recent Data and Clinical Recommendations			
05557	WEBEM015-014397	WEBEM015-014399	1/12/2002	Depo: Weber, Margaret 6/21/2005 EX 023: FW: Agenda for Jan 18th meeting - Council on Hormone Education			
05558	WEBEM015-008331, 008334	WEBEM015-008341	12/4/2000	Depo: Weber, Margaret 6/21/2005 EX 024			
05559	WEBEM015-022493	WEBEM015-022501	11/30/2001	Depo: Weber, Margaret 6/21/2005 EX 025: Estrogen and the Skin			
05560	SENDM009-000225	SENDM009-000235	9/3/2002	Depo: Weber, Margaret 6/21/2005 EX 026: Preclinical and Clinical Experience with Trimegestone a Novel New Progestin			
05561	STRIS011-000118	STRIS011-000142		Depo: Weber, Margaret 6/21/2005 EX 027: TSE424 Pre-Launch Template			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05562	WEBEM015-013083	WEBEM015-013086	5/24/2001	Depo: Weber, Margaret 6/21/2005 EX 029: Ethan Frome			
05563	WEBEM015-007988	WEBEM015-007988	11/7/2000	Depo: Weber, Margaret 6/21/2005 EX 030: Re: Labeling for Concomitant use with Statins			
05564	WEBEM015-016154	WEBEM015-016158		Depo: Weber, Margaret 6/21/2005 EX 031: No Title			
05565	WEBEM015-013782	WEBEM015-013786	10/2/2001	Depo: Weber, Margaret 6/21/2005 EX 032: Ethan Frome			
05566	WEBEM015-022423	WEBEM015-022423	9/6/2002	Depo: Weber, Margaret 6/21/2005 EX 033: Review papers			
05567	WEBEM015-016410	WEBEM015-016417	4/23/2002	Depo: Weber, Margaret 6/21/2005 EX 034: Women s Healthcare Initiative			
05568	SENDM009-000252	SENDM009-000258	5/21/2002	Depo: Weber, Margaret 6/21/2005 EX 035: Communication Messages: Premarin / Trimegestone Combination			
05569			6/00/2004	Depo: Weber, Margaret 6/21/2005 EX 036: Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results			
05570			5/23/2005	Depo: Weber, Margaret 6/21/2005 EX 037: WAME News letter			
05571	PANAA009-000178	PANAA009-000554	6/9/2000	Depo: Weber, Margaret 6/21/2005 EX 038: Perspective in ERT/HRT: Advisory Board Meeting			
05572	YAVUE002-000906	YAVUE002-000906	5/3/1996	Depo: Yavuz, Ed 1/14/2005 EX 002: Estrogen Replacement Therapy Issues			
05573	YAVUE001-001604	YAVUE006-001637	00/00/1990	Depo: Yavuz, Ed 1/14/2005 EX 003: Osteoporosis the only Cure is Prevention			
05574	YAVUE001-001622	YAVUE006-001650	00/00/1994	Depo: Yavuz, Ed 1/14/2005 EX 004			
05575	YAVUE006-001546	YAVUE006-001637		Depo: Yavuz, Ed 1/14/2005 EX 005: Premarin Family (Conjugated Estrogens Tablets, USP) Training Program			
05576	W-ADSBRO-00717	W-ADSBRO-00717		Depo: Yavuz, Ed 1/14/2005 EX 006			
05577	COBBP016-001240	COBBP016-001275	9/00/1998	Depo: Yavuz, Ed 1/14/2005 EX 007: Cardiovascular Disease/Lipids Backgrounder			
05578	ROSSC006-001359	ROSSC006-001360	6/30/1995	Depo: Yavuz, Ed 1/14/2005 EX 008: NDA 20-303 Prempro / Premphase (Conjugated Estrogens / Medroxyprogesterone) MACMIS ID 2820			
05579	COBBP002-000510	COBBP002-000515		Depo: Yavuz, Ed 1/14/2005 EX 009: HERS Backgrounder			
05580	YAVUE006-001697	YAVUE006-001750	3/00/1998	Depo: Yavuz, Ed 1/14/2005 EX 013: Premarin Family (Conjugated Estrogens Tablets, USP) Training Program			
05581	YAVUE009-002064	YAVUE009-002064	00/00/2002	Depo: Yavuz, Ed 1/14/2005 EX 014			
05582	W-ADSBRO-00718	W-ADSBRO-00718	8/00/1998	Depo: Yavuz, Ed 1/14/2005 EX 015			
05583			1/12/2005	Depo: Yavuz, Ed 1/14/2005 EX A: Plaintiffs' Notice of Deposition of Wendy Stephenson, Plaintiffs' Notice of Deposition Ed Yavuz			
05588				Depo: Zucal, Vincent 7/28/2005 EX 001: Vincent P. Zucal CV			
05589			6/14/1976	Depo: Zucal, Vincent 7/28/2005 EX 002: Estrogens and Breast Cancer. Article			
05590	SOLOJ022-001373	SOLOJ022-001374	4/23/1996	Depo: Zucal, Vincent 7/28/2005 EX 003 and Buchalter, Jeff 05/29/2008 EX 28: Bone Mineral Density Predicts the Risk of Breast Cancer in Older Women. The Study of Osteoporotic Fractures.			
05591	ZUCAV001-000069	ZUCAV001-000077	11/25/1992	Depo: Zucal, Vincent 7/28/2005 EX 004: Wyeth-Ayerst Premarin Tablets Conjugated Estrogens International Corporate Direction Circular			
05592	ZUCAV002-001078	ZUCAV002-001099	9/27/1999	Depo: Zucal, Vincent 7/28/2005 EX 005: Guidance for Industry Labeling Guidance for Noncontraceptive Estrogen Drug Products Prescribing Information for Healthcare Providers and Patient Labeling			
05593	ZUCAV005-000823	ZUCAV005-000826	6/5/2001	Depo: Zucal, Vincent 7/28/2005 EX 006: Protocol Number 07132D2-309US CSF-41303 Synopsis			
05594	ZUCAV006-000684	ZUCAV006-000698	7/31/2001	Depo: Zucal, Vincent 7/28/2005 EX 007: Conjugated Estrogens-Cardioprotection			
05595	ZUCAV007-012845	ZUCAV007-012863	4/4/2003	Depo: Zucal, Vincent 7/28/2005 EX 010			
05596	ZUCAV007-012864	ZUCAV007-012881	4/4/2003	Depo: Zucal, Vincent 7/28/2005 EX 011			
05597	ZUCAV007-012900	ZUCAV007-012917	10/21/2002	Depo: Zucal, Vincent 7/28/2005 EX 012			
05598	ZUCAV008-005222	ZUCAV008-005234	3/20/2003	Depo: Zucal, Vincent 7/28/2005 EX 013: Core SPC HRT			
05599	ZUCAV008-005665	ZUCAV008-005666	7/3/2001	Depo: Zucal, Vincent 7/28/2005 EX 014: Unknown			
05600	ZUCAV008-007243	ZUCAV008-007243	10/24/2002	Depo: Zucal, Vincent 7/28/2005 EX 015: EU Core			
05601	ZUCAV008-008682	ZUCAV008-008682	12/13/2002	Depo: Zucal, Vincent 7/28/2005 EX 016: Re: New Federal "Report on Carcinogens" Lists Estrogen Therapy			
05602	ZUCAV008-011874	ZUCAV008-011878		Depo: Zucal, Vincent 7/28/2005 EX 017: No Title			
05603	ZUCAV008-014210	ZUCAV008-014213	10/27/1999	Depo: Zucal, Vincent 7/28/2005 EX 018: No Title			
05604	ZUCAV008-016647	ZUCAV008-016648	10/26/2000	Depo: Zucal, Vincent 7/28/2005 EX 019: No Title			
05605	ZUCAV008-029295	ZUCAV008-029295	6/9/2003	Depo: Zucal, Vincent 7/28/2005 EX 020: Re: Fwd: Progestin only non-contraceptive			
05606	ZUCAV008-042690	ZUCAV008-042691	7/3/2001	Depo: Zucal, Vincent 7/28/2005 EX 021: No Title			
05607	ZUCAV008-066544	ZUCAV008-066546	7/00/2002	Depo: Zucal, Vincent 7/28/2005 EX 022: Dear Doctor			
05608	CHOOM002-002197	CHOOM002-002483	12/00/1997	When Considering Menopause and its Associated Estrogen Loss. Consider the Entire Body of Evidence			
05609	CHOOM011-001222	CHOOM011-001222	1/6/1995	New Premarin DTC Advertising Campaign			
05610	CHOOM011-001232	CHOOM011-001233	8/26/1994	Premarin - Powerhouse of the '90s!			
05611	CHOOM011-001257	CHOOM011-001259	6/17/1994	"S.T.O.P." Gets Things Started! New Campaign Targets Substitution of Premarin			
05612	CHOOM022-000928	CHOOM022-001114	2/00/1997	For Four Decades, your Body Supplied All the Estrogen you Needed.			
05613	CHOOM022-001673	CHOOM022-001776	8/00/1996	POA II 1996 Discussion Guide			
05614	CONKJ017-008141	CONKJ017-008171	8/23/2002	Effexor ViPP			
05615	CONNS001-000654	CONNS001-000656	3/18/1993	Draft of Dear Doctor Letter			
05616			10/00/1993	Diana Blanton memo to sales force re: Seasons Magazine			
05617			12/13/1989	Premarin Success Stories			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05618			12/18/1990	Memo from Dave Swingle to sales force announcing new promotional program			
05619			12/2/1988	Wyeth memo re: newly organized sales team			
05620			12/00/1987	Premarin POA 1			
05621				1991 Premarin Label			
05622			2/8/1990	Memo from Ernst Zobel outlining key action areas			
05623			3/20/1989	Sales Force memo giving review of Dr. Robert G. Wells article, Six Advantages of Estrogen Replacement Therapy			
05624			4/00/1987	Premarin: A Long-Term Treatment Strategy			
05625			5/6/1994	Memo from Mike Sinapi re: Wyeth's participation in American College of Obstetricians and Gynecologists Annual Clinical Meeting			
05626			7/2/1993	Memo from Barbara Vallotton re: Seasons Magazine			
05627			12/13/1989	Wyeth memo: "we are not selling Season's Magazines, but long-term Premarin therapy"			
05628			9/24/1993	Memo to sales staff on OBG Management Article -- "2 Benefits vs A Risk of Estrogen Replacement Therapy"			
05629			9/00/1993	Memo from Dave Swingle to sales force re: New Premarin direct to consumer advertising			
05630	BARBM001-000065	BARBM001-000066		Zone Vice President Voice Mail on WHI			
05631	BARBM001-000069	BARBM001-000070	3/24/2000	WHI HRT Update What you Should Know About Hormones and Cardiovascular Health			
05632				BUCHALTER PREMPRO SPEECH			
05633	BURKM001-000273	BURKM001-000276		NDA 20-527/S-017			
05634	BURKM005-000711	BURKM005-000712	8/23/2002	NDA 04-782 Premarin (Conjugated Estrogens Tablets, USP) Special Supplement - Changes being Effected Effective Immediately			
05635	BURKM006-001090	BURKM006-001093		Totelle 1mg Continuous Combined Labelling Proposed HERS/WHI Modification for Labelling Executive Committee Consideration			
05636	BURKM007-000200	BURKM007-000328	9/7/2001	Prempro Premphase (Conjugated Estrogens Medroxyprogesterone Acetate Tablets) NDA 20-527. Special Supplement - Changes Being Effected September 7, 2001 Volume 1 of 1			
05637	BURKM010-000723	BURKM010-000764	5/5/1997	Approvability of a Synthetic Generic Version of Premarin			
05638	BURKM020-000997	BURKM020-000997	6/10/1999	SPC Wording for Estrogen Containing Medicinal Products Used for Hormone Replacement Therapy with Regard to Increased Risk of Breast Cancer as Agreed by the PhVWP in April 1999			
05639	BURKM029-024261	BURKM029-024262	7/3/2001	Unknown			
05640	BURKM029-024941	BURKM029-024944	6/29/2001	TO:			
05641	BURKM029-026891	BURKM029-026891	3/16/2001	Labeling Executive Committee Meeting			
05642				Carrie Cox-Smith Speech -- "Women's Health Care #1 area for Wyeth Ayerst and for American Home Products"			
05643	CONNS005-000193	CONNS005-000196	11/29/1989	1990 Premarin Public Relations Media Program			
05644	CONNS008-000731	CONNS008-000734	7/00/1997	Guidance for Industry Consumer-Directed Broadcast Advertisements			
05645	CONNS017-000113	CONNS017-000116	2/15/1990	Fertility and Maternal Health Advisory Committee Meeting February 1, 1990			
05646	CONSG005-000016	CONSG005-000044		The New Science of Premarin			
05647	CONSG005-000388	CONSG005-000401	8/9/2002	HRT "Where do we Go from here" an Educational Initiative of the Endocrine Society			
05648	CONSG010-000366	CONSG010-000369	7/25/2002	NDA 21-396			
05649	CONSG017-000723	CONSG017-000783	00/00/2001	The Women's HOPE Study Health Osteoporosis Progestin Estrogen Premarin (Conjugated Estrogens) & Medroxyprogesterone Acetate (MPA) Hormone Replacement Therapy (HRT) Investigators' Slide Kit			
05650	CONTA020-000012	CONTA020-000012	11/1/2001	Letter from William Andrews to Carolyn Schatz			
05651	CONTA023-005597	CONTA023-005703	10/15/2002	Global Publication Plan 2002 Bazedoxifene; Alice Perrone 8/31/06 dEPO EX 024: publication plan			
05652	CONTA023-006750	CONTA023-006762		Powerpoint re: Publication Planning and Management			
05653	CONTA023-022826	CONTA023-022827		2001 Grants from Premarin Budget			
05654	CONTA023-027511	CONTA023-027588		Depo: Jana, Bernadette 1/3/2008 EX 31; DesignWrite Wyeth-Ayerst National Hormone Council			
05655	CONTA025-026308	CONTA025-026309	5/3/2002	FW: The Empire Strikes back			
05656	CORRA001-000163	CORRA001-000167	4/21/2001	Release and Settlement Agreement			
05657			11/00/1993	Clinician's Guide for Women at Menopause			
05658			5/3/1989	Internal correspondence from Rich Etter to District W-4500 re: District Sales & Training Conference Re-Cap			
05659			8/8/1989	Letter from Ernst Zobel to Wyeth Sales Representatives "Our POA 3 Sales Conference is over..."			
05660			2/8/1990	Letter from Ernst Zobel to All members of the Wyeth Sales Group "My video message to you at the recent POA District Sales Conference contained five key actions areas..."			
05661			9/13/2001	Draft Skin Messages for Skin Platform; Depo: DelConte, Anthony 6/20/06 EX 022: Memo to Solomon from Roark			
05662	DELCA014-000218	DELCA014-000220		Leon Speroff Comments on White Paper			
05663	DELCA028-000493	DELCA028-000494	9/21/1999	Premarin Renaissance II Meeting			
05664	DELCA031-000482	DELCA031-000484		2002 Womens' Health Care Budget			
05665	DELCA032-001648	DELCA032-001660		Incidence and Persistency Study			
05666	DELCA033-030442	DELCA033-030445		Objective / Strategy			
05667	DEVAN001-000129	DEVAN001-000133		Report on Wyeth's respond to the release of the WHI study			
05668	DEVAN001-000457	DEVAN001-000461		Q&A on USC Breast Cancer Study			
05669	DEVAN011-000778	DEVAN011-000780	8/8/2002	Bruce Burlington Interview with the Washington Post Talking Points			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05670	DEYMI018-000244	DEYMI018-000259	9/29/1976	Department of Health Education and Welfare. Food and Drug Administration (21 CFR Part 310) (Doc 76N-0384). Estrogens for General Use. Requirement for Labeling Directed to the Patient			
05671	DEYMI202-000082	DEYMI202-000084		Handwritten note on Robert Becker stationery			
05672	DUROJ017-000990	DUROJ017-000990		New Survey Findings Highlight Spokane-Area Women's Greatest Fears about Aging			
05673	DUROJ019-000642	DUROJ019-000680	9/00/2001	AHA Issue Tracking Key Findings: Physicians & Consumers			
05674	DUROJ030-001792	DUROJ030-001794	2/22/1993	Ogen Osteoporosis			
05675	DUROJ034-002367	DUROJ034-002370	1/31/1997	DTC Ad Evaluation - Final Report			
05676	DUROJ037-001704	DUROJ037-001713	8/00/1992	DTC Marketing of Premarin: 1993-1995 a White Paper			
05677	DUROJ040-000093	DUROJ040-000098	12/22/1997	Repositioning the Breast Cancer Issue			
05678	DUROJ042-000027	DUROJ042-000064	4/3/1996	Consumer Magazines Seminar and Overview of DTC Competitive Advertising Spending			
05679	DUROJ042-000974	DUROJ042-000975	9/2/1997	Finance Committee Authorization Unrestricted Educational Grants; Finance Committee Authorization Unrestricted Educational Grants			
05680	DUROJ044-002415	DUROJ044-002422		Premarin HCP 1999 Budget; Jeannemarie Durocher 8/2/06 DEPO EX 065: Premarin HCP 1999 Budget			
05681	DUROJ046-006364	DUROJ046-006365		FDA Approval Letter for Prempro .45/1.5mg			
05682	DUROJ046-007650	DUROJ046-007653	9/13/2002	Wyeth Ayerst Grants and Awardees 2003			
05683	DUROJ046-024072	DUROJ046-024086		Premarin Family Rx Trends 1942-1999			
05684	DWRITE026890	DWRITE26909	1/26/2005	New Business Presentation 1: DEPO; Janas, Bernadette 1/03/2008 EX 30			
05685	DWRITE026967	DWRITE26976	10/22/2001	CME Poster Receptions			
05686	DWRITE027055	DWRITE27055	12/13/2001	Letter from Rosie Lynch to Gail Goldsmith			
05687	DWRITE027125	DWRITE27126	10/23/2001	National Hormone Council Estimated Budget			
05688	DWRITE027138	DWRITE27139		Timeline for initial meeting of leadership board of NHCE: DEPO; Janas, Bernadette 1/03/2008 EX 33			
05689	DWRITE033394	DWRITE03396	8/4/1997	Memo from K Mittleman @ Design Write to J Solomon @ Wyeth re: Premarin Publication Plan			
05690	DWRITE033397	DWRITE03397	1/11/2005	Memo from K Mittleman @ Design Write to J Solomon @ Wyeth re: Premarin Publication Plan			
05691	DWRITE046248	DWRITE46250	12/14/1999	Minutes of WHC Publication / Presentation Planning Meeting			
05692	DWRITE065864	DWRITE65864	6/20/1997	Document from A Infranco to K Mittleman re: Premarin Campaign			
05693	DWRITE065942	DWRITE65942	1/4/1999	Letter from Donnica Moore, MD President Sapphire Women's Health Group to Editorial Desk of Consumer Reports Magazine			
05694	DWRITE065943	DWRITE65949		Agreement between Wyeth-Ayerst Laboratories and DesignWrite, Inc.			
05695	DWRITE066110	DWRITE66112	11/7/2002	Women's HealthCare Strategic Publication Development Proposal 2003 for Alice Conti submitted by DesignWrite, Inc.			
05696	DWRITE066229	DWRITE66232		2005 Strategic Publication Development Brainstorm Session			
05697	DWRITE066315	DWRITE66318		Strategic Publications Development (objectives and core message)			
05698	DWRITE068301	DWRITE68304	1/11/2005	Publication Plan Tracking Report			
05699	DWRITE020773	DWRITE20775	1/3/2003	Proposal from Thomson / Medical Economics to Wyeth re: Continuing Medical Education			
05700	DWRITE022902	DWRITE22905	11/14/2003	Proposal of CME activities for 2004 from Council on Hormone Education to Wyeth			
05701	DWRITE022916	DWRITE22917		Council on Hormone Education paperwork summary			
05702	DWRITE022918	DWRITE22919	1/6/2004	Letter from Wyeth to University of Wisconsin Medical School			
05703	DWRITE027012	DWRITE027022	1/26/2005	National Hormone Council proposed steering committee: DEPO; Janas, Bernadette 1/03/2008 EX 38			
05704	DWRITE027077	DWRITE27087	12/5/2001	draft of procedures for Council on Hormone Education activities			
05705	DWRITE065764	DWRITE65812	8/12/1996	DesignWrite proposal - Medical Education and Communications Plan for Premarin Product Line			
05706	DWRITE065814	DWRITE65820	8/6/1996	DesignWrite proposal for Speaker's Bureau Meeting			
05707	DWRITE065821	DWRITE65831	8/6/1996	DesignWrite proposal for National Consensus Meeting			
05708	DWRITE065923	DWRITE65941	5/15/1997	DesignWrite Publication Plan Proposal			
05709	DWRITE065950	DWRITE65951	1/12/2005	DesignWrite letter to Jeff Solomon confirming Premarin publication plan			
05710	DWRITE065952	DWRITE65968	11/20/1998	DesignWrite Premarin Family of Products Study Management Plan (proposal)			
05711	DWRITE066004	DWRITE66008	9/20/1999	DesignWrite Publication Plan proposal to increase awareness of benefits			
05712	DWRITE066032	DWRITE66033	00/00/2000	DesignWrite typical work flow plan for developing a manuscript			
05713	DWRITE066034	DWRITE66066	9/00/1999	DesignWrite proposal to Wyeth re Medical and Scientific Communications Plan for 2000			
05714	DWRITE066091	DWRITE66093	1/10/2001	DesignWrite Strategic Publication Plan			
05715	DWRITE066095	DWRITE66097	5/16/2001	DesignWrite Low-Dose Hormone Replacement Therapy 2001 Publication Plan Proposal			
05716	DWRITE066107	DWRITE66109	11/7/2002	DesignWrite proposal for Publication Management 2003			
05717	DWRITE066150	DWRITE66153		DesignWrite proposal - Publication Plan 2003			
05718	DWRITE066168	DWRITE66199		DesignWrite - Council on Hormone Education tactics			
05719	DWRITE066214	DWRITE66216	10/13/2003	DesignWrite proposal - Publication Management and Strategic Publication Planning 2004: DEPO; Janas, Bernadette 1/03/2008 EX 20			
05720	DWRITE068298	DWRITE68298	8/27/1997	Memo recapping publication plan meeting			
05721	DWRITE068884	DWRITE68885	1/12/2005	Letters from DesignWrite to Dr. Lila Nachtigall			
05722				Robert Essner launch speech for Prempro			
05723	FARAN024-083474	FARAN024-083487	9/00/1999	Body of Evidence DTC AD Evaluation - A Qualitative Report - Prepared for Wyeth Ayerst by Zimerman Associates			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05724	FARAN024-083456	FARAN024-083473	12/00/1999	New Premarin direct to consumer advertising			
05725			11/00/1976	Article "Informing Patients About Estrogen" in Food and Drug Administration Consumer			
05726			11/1977	Update in Food and Drug Administration Consumer regarding Estrogen, Progestin labeling			
05727			00/00/1966	Femine Forever Book by Robert Wilson			
05728	GASTM008-000249	GASTM008-000293	8/25/1995	Comprehensive Estrogen Replenishment Therapy: The Uniqueness of Premarin			
05729	GPIL005-001774	GPIL005-001777	3/15/1990	Estrogen-Progestogen Replacement and Cancer Risk; Estrogen-Progestogen Replacement and Cancer Risk			
05730	GPIL008-002293	GPIL008-002295	9/20/1985	General Discussion - Ogen Advertising Follow-Up Notice of Violation NOV Letter 8/28/85			
05731	GPIL044-002229	GPIL044-002230	10/4/1990	Premarin (Conjugated Estrogens, USP) NDA 4-782/S-084			
05732	HENRL001-000145	HENRL001-000154	11/17/1997	Finance Committee Authorization 1998 Awards & Grants			
05733	HENRL001-000293	HENRL001-000301	3/4/1999	1999 Awards & Grants			
05734	HENRL001-000501	HENRL001-000516	1/17/2000	2000 Awards and Grants			
05735	HENRL001-000583	HENRL001-000586	6/28/2000	Premarin Family Strategic Options Executive Summary June 28, 2000			
05736	HENRL001-000620	HENRL001-000620		PBM Targeted DTC			
05737	HENRL003-001543	HENRL003-001543	1/11/1999	NDA 4-782 Premarin (Conjugated Estrogens Tablets, USP) MACMIS 7000			
05738	HENRL005-000103	HENRL005-000104		Lesa Henry handwritten notes discussing direct to consumer advertising			
05739	HENRL005-000441	HENRL005-000444	4/2/1998	Lesa Henry handwritten notes			
05740	HENRL008-000001	HENRL008-000142	7/13/1999	Wyeth-Ayerst Marketing Seminar: Optimizing Direct-to-Consumer Marketing			
05741	HENRL011-000470	HENRL011-000491	6/00/2000	Consequences of Menopause			
05742	HENRL018-000887	HENRL018-000889	12/2/1999	Natural Alternatives Approach Plan 2000			
05743	HENRL025-000094	HENRL025-000148		Mission Vision Values - Premarin Family			
05744	HENRL025-000427	HENRL025-000428		Maximizing the Current Growth Opportunities for the Premarin Franchise			
05745	HENRL025-000795	HENRL025-000797	7/9/1998	Memo from Lesa Henry to Joseph Mahady			
05746	HENRL025-001146	HENRL025-001150	6/16/1999	Wyeth internal memo describing DTC advertising			
05747	HENRL025-001657	HENRL025-001689		Womens' Health Care DTC Experience and Perspective			
05748	HOLSN003-001161	HOLSN003-001406	1/19/2001	Premarin (Conjugated Estrogen, USP) for Injection NDA 10-402/S-035 Special Supplement - Changes Being Effected Volume 1 of 1			
05749	HOLSN003-001636	HOLSN003-001661	11/24/1999	Wyeth Ayerst Comments to 1999 Draft Guidance Entitled Labeling Guidance for Noncontraceptive Estrogen Drug Products Prescribing Information for Healthcare Providers and Patient Labeling			
05750	HOLSN004-000254	HOLSN004-000256	10/1/1999	Special Regulatory Update "Labeling Guidance for Noncontraceptive Estrogen Drug Products-Prescribing Information for Healthcare Providers and Patient Labeling"			
05751	HOLSN004-000258	HOLSN004-000279	9/00/1999	Guidance for Industry Labeling Guidance for Noncontraceptive Estrogen Drug Products -Prescribing Information for Healthcare Providers and Patient Labeling			
05752	HOLSN004-000716	HOLSN004-000838		Table of Updates Volume 1			
05753	HOLSN004-001113	HOLSN004-001115	9/8/1998	Food and Drug Administration approves Supplemental New Drug Application S93			
05754	HOLSN005-000721	HOLSN005-000731		Fertility and maternal Health Drugs Advisory Committee Open Session			
05755	HOLSN005-000972	HOLSN005-000972	1/26/1984	NDA 4-782/S-049			
05756	HOLSN013-000388	HOLSN013-000394		IS THE FEAR OF BREAST CANCER STOPPING YOUR PATIENTS FROM ENJOYING THE BENEFITS OF HRT?			
05757	HOLSN015-000988	HOLSN015-000989	6/19/2000	PRIOR APPROVAL SUPPLEMENT			
05758	HOLSN016-002290	HOLSN016-002291		Aetna Formulary Utilization			
05759	HOLSN016-002298	HOLSN016-002298	4/4/2002	PROMOTION REQUEST / ASSIGNMENT / PURCHASE ORDER. PURCHASE ORDER NUMBER AGY - 83735. PREMPRO			
05762			8/27/2002	Food and Drug Administration withdraws 1999 draft labeling guidance			
05763	KUSIV006-001088	KUSIV006-001091	9/23/2002	Letter			
05764	KUSIV009-002573	KUSIV009-002576	7/00/2002	Dear Doctor:			
05765	KUSIV009-002751	KUSIV009-002753	7/00/2002	Dear Doctor:			
05766	LAWT021-009874	LAWT021-009918	11/8/2001	Affiliate Brand Plan			
05767	LEVIG002-005733	LEVIG002-005735		FDA Approval Letter for Prempro .3/1.5mg			
05768	LEVIG002-006089	LEVIG002-006090		FDA Approval Letter for Prempro .45mg			
05769	LEVIG002-009465	LEVIG002-009525	10/18/2002	Presentation Name			
05770	LUDMG001-000845	LUDMG001-000852	11/12/1998	Physician HRT Awareness and Use - Final Report			
05771	LUDMG002-001710	LUDMG002-001710	10/20/1997	Summary Report on Hormone Replacement Therapy, Market Measures			
05772	LUDMG008-000182	LUDMG008-000184	4/27/1998	Premarin Fastape; Depo: Jeanne Durocher 6/30/06 EX045:Memo from Breckenridge			
05773	LUDMG008-000612	LUDMG008-000619	5/6/1999	January 1999 ERT/HRT Consumer A&U Study - Final Report			
05774	LYTTR016-001222	LYTTR016-001223	2/25/2000	Breast Cancer Issue			
05775	LYTTR016-001224	LYTTR016-001228	2/22/2000	Document			
05776	LYTTR016-013347	LYTTR016-013378		Types of Collaborations			
05778	MAHAJ007-000510	MAHAJ007-000578	5/7/1997	Premarin Tablets Analysis: Gross Sales Gross Units Gross ASP January 1989 - December 1996			
05779	MAHAJ017-003270	MAHAJ017-003272		EMBARGOED FOR RELEASE			
05780	MARTN008-001743	MARTN008-001808	1/00/2000	Premarin: the new science			
05781	MITRD007-000527	MITRD007-000527	1/6/2003	FDA Approves Prescribing Information for Postmenopausal Hormone Therapies			
05782	NDA-PRO 0000186	NDA-PRO 0000187	9/26/1985	Handwritten Notes			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05783	NDA-PRO 0000929	NDA-PRO 0000930		New Provera Effective in 95% of Amenorrhea			
05784	NDA-PRO 0001168	NDA-PRO 0001169	10/22/1980	Oral Estrogen Market Profile			
05785	NDA-PRO 0001475	NDA-PRO 0001475	11/19/1970	Dear Doctor Letter from Upjohn			
05786	NDA-PRO 0001545	NDA-PRO 0001546	8/4/1998	NDA 11-839/S-068			
05787	NDA-PRO 0002167	NDA-PRO 0002167	7/31/1997	NDA 11-839, Provera Tablets			
05788	NDA-PRO 0007371	NDA-PRO- 0007371	8/11/1989	NDA 11-839 / S-044 / S-045			
05789			6/00/2005	National Institutes of Health Publication "Facts About Menopausal Hormone Therapy"			
05790	NORMJ003-000842	NORMJ003-000843	10/30/1992	ANDA 81-239 (2.5 mg) 81-240 (5 mg)			
05791	OLIVS018-004785	OLIVS018-004787		Report in USA Today by Leon Speroff			
05792	OLIVS018-033070	OLIVS018-033087		Womens' Health Care Strategic Planning Presentation			
05793	PANAA001-000010	PANAA001-000013	11/8/2001	Finance Committee Authorization Low-Dose Domestic Introductory Pricing and Contracting Strategy			
05794	PANAA001-000750	PANAA001-000750	10/19/2001	Question on 2002 Budget COGs			
05795	PANAA001-001255	PANAA001-001256		Draft Tactical Outline for WHI; Depo: Andrew Panagy 3/31/04 EX 037: Draft Tactical Outline for WHI			
05796	VICTJ005-001768	VICTJ005-001768	4/14/1986	Letter from Food and Drug Administration to Ayerst re: New Drug Application 4-782			
05797	W_ANNREP01-001	W_ANNREP01-074		Wyeth Annual Report 2001			
05798	W_ANNREP94-001	W_ANNREP94-067		American Home Products Annual Report 1994			
05799	W-MDL303-0083037	W_MDL303-0083097	8/18/1994	Food and Drug Administration issues Estrogen Drug Products Labeling Guideline			
05800	W-30(b)(6)-12-00124	W-30(b)(6)-12-00154		All about Health, Osteoporosis, Progestin, Estrogen Study			
05801	W-30(b)(6)-06-00123	W-30(b)(6)-06-00157	10/7/2003	Food and Drug Administration Endocrine and Metabolic Drugs Advisory Committee: Wyeth			
05802	W-ADSBRO-000006	W-ADSBRO-000007	1/00/1999	Body of Evidence Brochure			
05803	W-ADSBRO-000302	W-ADSBRO-000303	5/00/1998	Body of Evidence poster			
05804	W-ADSBRO-000485	W-ADSBRO-000500	7/23/2001	Seasons Magazine and Direct to Consumer Advertising			
05805	W-ADSBRO-001369	W-ADSBRO-001369	1/00/1998	Body of Evidence tear sheet			
05806	W-ANDA-00000252	W-ANDA-00000297	4/23/1998	Apr 23 1998 NDA - 81 - 239			
05807	W-DDL-00000001	W-DDL-00000012	2/22/2000	Dear Doctor Letter			
05808	PANAA003-000810	PANAA003-000824	8/19/2002	Premarin Family Area Management Meeting			
05809	PANAA003-000991	PANAA003-001021	4/00/2000	Guiding your Patients Through the Transitional Years, Menopause, and Beyond			
05810	PANAA004-000607	PANAA004-000609	8/30/2002	Prempro 2.5mg Physician Journal Ad Testing Findings - August 27 & 28, 2001			
05811	PANAA010-000005	PANAA010-000008	3/2002	LaBelle Live			
05812	PANAA010-000493	PANAA010-000494	00/00/2001	Premfact 1 Prempro (Conjugated Estrogens / Medroxyprogesterone Acetate Tablets) Reduces Osteoporosis-Related Hip and Wrist Fractures By Approximately 60%!			
05813	PANAA010-000509	PANAA010-000532	5/00/2001	Hot Flash:			
05814	PANAA010-000717	PANAA010-000722		I. Understanding the Need; Depo: Andrew Panagy 3/31/04 EX 029: Message Statements			
05815	PANAA011-000820	PANAA011-000822	7/5/2001	Summary Recommendations; Depo: Andrew Panagy 3/31/04 EX 035			
05816	PANAA013-000044	PANAA013-000061		Wyeth Women's Health Care Draft; Depo: Andrew Panagy 3/31/04 EX 038: Wyeth WHC			
05817	PANAA013-000614	PANAA013-000619		Wyeth Opinion Leader and Advocacy Relations (OLAR); Depo: Andrew Panagy 3/31/04 EX 034: Wyeth OLAR			
05818	PANAA013-000744	PANAA013-000745	7/24/2002	Pattonium Inc. f/s/o Patti Labelle - W - Bates Advertising As Agent for Wyeth-Ayerst			
05819	PANAA014-000014	PANAA014-000014	3/24/1994	Pharmaceutical Products Division Forecast Net Sales Analysis			
05820	PANAA019-000583	PANAA019-000583	2/18/1994	Seasons Circulation Bounds Past Popular Consumer Mags			
05821	PANAA024-001244	PANAA024-001246	6/28/1991	CRTL Radiodensitometry of the Hand for Evaluation of Osteoporosis Risk			
05822	PANAA024-001249	PANAA024-001250	10/22/1990	Clinical Radiology Testing Laboratory			
05823	PANAA027-000657	PANAA027-000657	1/19/1995	Correspondence from Max Borten, M.D., J.D. to Muury Greene			
05824	PANAA027-000658	PANAA027-000660		Protocol Medicolegal Implications of the Failure to Prophylactically Prescribe Hormone Replacement Therapy in the Postmenopausal Patient.			
05825	PANAA027-000925	PANAA027-000925	1/19/1995	Correspondence from Max Borten, M.D., J.D. to Muury Greene			
05826	PANAA030-001465	PANAA030-001490	9/12/1990	The GTFH Proposal for Premarin Brand Loyalty			
05827	PANAA031-000770	PANAA031-000774		Third Annual Meeting			
05828	PANAA033-002676	PANAA033-002707	5/11/1990	Osteoporosis Strategic Plan			
05829	PANAA034-001272	PANAA034-001273	1/2/1992	Premarin Labeling Estrogen/Progestogen Use			
05830	PANAA036-001536	PANAA036-001536	5/14/1992	Seasons Subscribers Tracking			
05831	PANAA036-002499	PANAA036-002500	2/14/1992	Premarin Women's Health Program Monthly Reports			
05832	PANAA038-000160	PANAA038-000160		To the National Women's Political Caucus			
05833	PARKA007-001080	PARKA007-001082	12/20/2002	NDA 20-527 Prempro/Premphase (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets) Prior Approval Supplement			
05834	PESKM003-000428	PESKM003-000430		Address patient questions about ERT and Breast Cancer			
05835	PESKM003-000441	PESKM003-000452	1/00/1999	Prempro (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets) 0.625 mg / 5 mg			
05836	PICKJ011-003007	PICKJ011-003008	1/22/1988	Letter from Penny Budoff, MD @ Women's Medical Center to James Pickar, MD			
05837	PINIM023-044633	PINIM023-044634	4/1/2002	Email from Marie Pinizzotto to Ian Ballard			
05838			4/29/1991	Pink Sheet regarding Food and Drug Administration's Fertility and Maternal Health Advisory Committee meeting in June 1991			
05839				Administration and Dosage			
05840				Premarin 1957			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05841	RHUM007-000033	RHUM007-000059	11/30/1994	Citizen Petition to Establish the Proper Composition of Conjugated Estrogens and Conjugated Estrogens Tablets			
05842	RIGGB007-002005	RIGGB007-002007	4/24/1992	Memorandum of Meeting			
05843	RIGGB007-002008	RIGGB007-002010	6/23/1992	Premarin / MPA FDA Meeting Results of Clinical Study Osteoporosis Indication Proposed Cardiovascular Clinical Study Proposed Labeling with Study Status of Labeling Supplement			
05844	ROSSC002-000117	ROSSC002-000124	1/00/1979	Breast Cancer Risk Factors Among Screening Program Participants			
05845	ROSSC002-000128	ROSSC002-000135	11/00/1978	Illegible of Exogenous Female Hormones in Altering the Risk of Benign and Malignant Neoplasms in Humans			
05846	ROSSC002-000198	ROSSC002-000203	8/19/1976	Menopausal Estrogens and Breast Cancer			
05847	ROSSC005-000011	ROSSC005-000013	8/4/1994	NDA 04-782 Premarin MACMIS 2195			
05848	ROSSC005-001018	ROSSC005-001078	5/00/2002	Welcome POA 2 2002 Say Yes to the Science and Women of Premarin			
05849	ROSSC005-001079	ROSSC005-001119	5/00/2002	Premarin Family POA Leader's Guide - POA 2			
05850	ROSSC007-000188	ROSSC007-000189	8/13/2001	Medwatch 8-93234-004R			
05851	ROSSC012-001044	ROSSC012-001044	7/31/1997	NDA 20-527/S-004			
05852	ROSSC012-001743	ROSSC012-001745	11/17/1995	NDA 20-527			
05853	ROSSC012-002074	ROSSC012-002075	11/10/1995	NDA 20-527 CE / MPA Combination Tablets Phase IV Biopharm Commitment			
05854	ROSSC012-002095	ROSSC012-002097	11/18/1994	Conjugated Estrogens and Medroxyprogesterone Acetate Combination Tablets NDA No. 20-527			
05855	ROSSC015-000948	ROSSC015-000950	12/30/1993	Conjugated Estrogens and Medroxyprogesterone Acetate NDA No. 20-303			
05856	ROSSC017-001471	ROSSC017-001492	9/8/1998	Guidance for Industry Labeling Guidance for Non-Contraceptive Estrogen Drug Products - Physician and Patient Labeling			
05857	ROSSC018-000631	ROSSC018-000632	1/9/1998	NDA 20-527/S-006			
05858	ROSSC021-001995	ROSSC021-002001	2/00/1972	Suggested Labeling Guidelines for Estrogens			
05859	ROSSC022-000001	ROSSC022-000002	2/15/1994	Wyeth submits Supplemental New Drug Application S93			
05860	ROSSC022-000012	ROSSC022-000021	2/22/1995	Letter from Food and Drug Administration to Wyeth re: New Drug Application 4-782/S-093			
05861	ROSSC026-000606	ROSSC026-000609	7/18/1995	IND No. 21,696 Serial No. 122			
05862	ROSSC026-000624	ROSSC026-000627	9/24/2001	N021396 Prempro (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets) Premphase (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets)			
05863	ROSSC034-000798	ROSSC034-000802	1/11/1999	NDA 4-782 Premarin (Conjugated Estrogens Tablets, USP) MACMIS 7000			
05864	ROSSC036-002251	ROSSC036-002252		NDA 04-782/S-129 Supplemental New Drug Application Submitted under Section 505(b) of the Federal Food, Drug, and Cosmetic Act for the Premarin (Conjugated Estrogens Tablets USP)			
05865	SALESTR003-000330	SALESTR003-000533		Premarin Rally 2000 -- Topics and Agenda (Power Point presentation)			
05866	SINAM002-000726	SINAM002-000754	9/4/1996	Guide to Understanding Studies on ERT/HRT and Breast Cancer Risk			
05867	SINAM002-000755	SINAM002-000760		Breast Cancer-Physician			
05868	SINAM002-000840	SINAM002-000840		Selling Presentation: Premarin vs Estrace			
05869	SOLOJ002-000312	SOLOJ002-000345		Low Dose Premarin/MPA US Commercial Launch Plan			
05870	SOLOJ002-000352	SOLOJ002-000355	7/24/2000	Launch of Lower Dose ERT/HT Public Relations Plan			
05871	SOLOJ005-000359	SOLOJ005-001097	00/00/2002	Scientific Update on Hormones and Postmenopausal Health. 2002 Edition			
05872	SOLOJ005-001243	SOLOJ005-001376	00/00/2002	Scientific Update on Hormones and Postmenopausal Health			
05873	SOLOJ007-000053	SOLOJ007-000064	7/11/2001	Premarin Studies Summary. Additional Estrogen Benefits			
05874	SOLOJ007-000096	SOLOJ007-000097		Publications and Presentations Summary			
05875	SOLOJ008-000417	SOLOJ008-000417	11/13/2002	Correspondence from Synavant to Jeff Soloman at Wyeth			
05876	SOLOJ010-001157	SOLOJ010-001157	8/21/2001	Women's Health Premarin Family Actual Results - Year to Date July 31, 2001			
05877	SOLOJ010-001226	SOLOJ010-001228		Income Statement Total Premarin Family Actual Results - Year to Date 12/31/01			
05878	SOLOJ010-001229	SOLOJ010-001230	3/29/2002	Women's Health-US Total Premarin Actual Results - Year to Date 2/28/02			
05879	SOLOJ010-001250	SOLOJ010-001282		ERT/HRT Team Strategic Options 2002-2004			
05880	SOLOJ010-001383	SOLOJ010-001400		Major US Pharmaceuticals. The Lehman Brothers Soap Box: The Future of HRT a Survey of 102 Physicians			
05881	SOLOJ010-001821	SOLOJ010-001827	8/26/2002	Wyeth Ayerst 2003 Awards and Grants AHT - Confidential			
05882	SOLOJ012-000339	SOLOJ012-000344	6/21/2002	Prempro Premphase NDA 20-527 FDA Approvable Letter Dated June 7, 2002			
05883	SOLOJ012-001132	SOLOJ012-001145	00/00/2001	Patient Enrollment Package. Patient Adherence/Education & Disease Management Program			
05884	SOLOJ020-000598	SOLOJ020-000600	3/16/1994	Finance Committee Authorization the North American Menopause Society Fellowship			
05885	SOLOJ020-000666	SOLOJ020-000766	5/14/2002	Roller Coaster of Menopausal Counseling HRG Strategic Planning			
05886	SOLOJ022-001040	SOLOJ022-001042	3/27/1996	Cummings Study: Revised Strategic Recommendations			
05887	SOLOJ026-000521	SOLOJ026-000556		Premarin Family. Lederle Sales Force Maximizing It's Potential			
05888	SOLOJ027-046439	SOLOJ027-046442		The National Hormone Council; DEPO: Janas, Bernadette 1/03/2008 EX 37			
05889	SONKJ007-000001	SONKJ007-000003	12/9/2002	NDA 04-782/S-128			
05890	SONKJ007-000004	SONKJ007-000032	12/9/2002	NDA 20-527/S-029			
05891	SONKJ012-000861	SONKJ012-000862	5/3/1942	NDA 4782			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05892	SONKJ012-001276	SONKJ012-001280	10/27/1997	Premarin; / Prempro / Premphase FDA Meeting - 10/22/97; Minutes			
05893	SONKJ016-000489	SONKJ016-000491	5/20/1998	NDA 4-782 Premarin (Conjugated Estrogens) Tablets MACMIS 6663			
05894	SONKJ023-001742	SONKJ023-001747	12/22/1992	Conjugated Estrogens and Medroxyprogesterone Acetate NDA No. 20-303			
05896	STEPW014-007867	STEPW014-007869	9/3/2002	Correspondence from FDA to Jennifer Norman			
05897	STEPW014-008128	STEPW014-008128	9/15/2002	Re: (no subject)			
05898	STEPW014-008654	STEPW014-008654	9/25/2002	Dr Gentile and WHI			
05899	STEPW014-009108	STEPW014-009109	9/27/2002	Bob Essner			
05900	STEPW014-009141	STEPW014-009141	9/27/2002	Fwd: MedWatch - new safety info on Prempro/Premphase and Premarin			
05901	STRIS003-000711	STRIS003-000713		Core Messages - Premarin Benefits Packages			
05902	STRIS003-001526	STRIS003-001554	00/00/1996	Guide to Understanding Studies on ERT/HRT and Breast Cancer Risk			
05903	STRIS003-001594	STRIS003-001596	2/3/2000	Feedback Teleconference Thursday February 3, 2000 JAMA Article Ayerst Lederle & Wyeth Field Trainers			
05904	STRIS004-000203	STRIS004-000203	8/9/1995	Williams and Wilkins			
05905	STRIS004-000214	STRIS004-000214	5/8/1995	Prempro			
05906	STRIS004-000221	STRIS004-000226	7/1/1999	Marketing Plan for the Transitional Patient			
05907	STRIS004-000228	STRIS004-000243	6/00/1986	Promoting Premarin: Tactical Reps			
05908	STRIS012-000097	STRIS012-000100	12/17/2001	NDA No. 21-417 Premarin (Conjugated Estrogens Tablets, USP)			
05909	STRIS013-000185	STRIS013-000186		Premarin and Indemnification			
05910	STRIS013-000187	STRIS013-000188		Prempro or Premphase and Indemnification			
05911	STRIS013-000250	STRIS013-000251	7/1/2002	Early Stopping of WHI Trial of Estrogen Plus Progestin			
05912	STRIS013-000297	STRIS013-000300		Handwritten charts			
05913	STRIS013-000311	STRIS013-000311	7/9/2002	Member Alert: NIH Halts WHI Study on Estrogen and Progestin			
05914	STRIS013-000318	STRIS013-000326	7/8/2002	Premarin Oral Family - Briefing Document			
05915	STRIS014-000146	STRIS014-000152		Prempro Q1 and Q2 2002 Incentive Enhancement			
05916	STRIS014-000580	STRIS014-000581		Body Copy for Prempro .45/1.5 AD			
05917	STRIS016-004644	STRIS016-004645	12/1/2000	Pre launch Direct Mail Concepts			
05918	STRIS016-018740	STRIS016-018741		Premarin Finance Proposed Marketing Budget 1999			
05919	STRIS016-019072	STRIS016-019073		Premarin Franchise = Budget Reduction Implication			
05920	STRIS016-068583	STRIS002-068632		Promoting Intervention			
05921	W-MDL04782-00097066	W-MDL04782-00097094	4/9/1997	Submission of Data			
05922	W-MDL04782-00100468	W-MDL04782-00100470	10/27/1997	Submission of Requested Materials			
05923	W-MDL04782-00119713	W-MDL04782-00119724		Ross Paper			
05924	W-MDL04782-00127749	W-MDL04782099127756	3/24/1999	Submission of Meeting Minutes			
05925	W-MDL04782-00140916	W-MDL04782-00140917	6/28/1994	Labeling Guidance			
05926	W-MDL04782-00141573	W-MDL04782-00141576	4/14/1992	Proposed DTC Advertisement			
05927	W-MDL303-00079350	W-MDL303-00079357	2/19/1993	Notice of insufficient filing (NDA 20-303)			
05928	W-MDL303-00081182	W-MDL303-00081186	3/7/1995	List of teleconference participants (NDA 20-303)			
05929	W-MDL303-00081734	W-MDL303-00081738	8/7/1992	FDA meeting minutes (NDA 20-303)			
05930	W-MDL303-00081887	W-MDL303-00081906	7/13/1990	Estrogen Drug Products Labeling Guidance - Premarin Labeling Revision (NDA 20-303)			
05931	STRIS019-004234	STRIS019-004320	10/11/2002	PowerPoint Presentation			
05932	VICTJ001-000008	VICTJ001-000010	8/10/1992	Premarin (Conjugated Estrogens,USP) Tablets NDA 4- 782			
05933	VICTJ005-001521	VICTJ005-001522	8/19/1991	Ron Ross Breast Cancer Data			
05934	W-DDL-00000035	W-DDL-00000042	3/17/2000	Dear Doctor Letter regarding label change			
05935	W-DDL-00000102	W-DDL-00000112	8/28/2002	Dear Doctor Letter re: Prempro/Premphase labeling change			
05936	WEBEM014-003238	WEBEM014-003241		HRT Summit: Strategic Implications - Medical / Marketing Sub-team Objective and Strategies			
05937	WEBEM015-016138	WEBEM015-016138		Email from Joe to Bob			
05938	WEBEM015-018824	WEBEM015-018827		Questions and Answers (as of Tuesday 1:30)			
05939	W-IND-01000003	W-IND-01000179	2/14/1978	IND 14, 189			
05940	W-IND-02000180	W-IND-02000246	3/18/1986	IND 13, 146			
05941	W-MCL001-01869	W-MCL001-01916		Alzheimer's Disease Research: Possible Causes. Potential Treatment			
05942	W-MCL004-01720	W-MCL004-01723	3/17/1992	February 14 Fertility and Maternal Health Drugs Advisory Committee Meeting			
05943	W-MCL011-01011	W-MCL011-01014	12/4/1975	Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens			
05944	W-MCL011-01022	W-MCL011-01025	12/4/1975	Association of Exogenous Estrogen and Endometrial Carcinoma			
05945	W-MCL017-00292	W-MCL017-00295	2/00/1990	Mammographic Changes Associated with Postmenopausal Hormone Replacement Therapy: A Longitudinal Study			
05946	W-MCL017-00322	W-MCL017-00324	1/00/1990	Hormonal Replacement Therapy: Mammographic Manifestations			
05947	W-MDL04782-00000028	W-MDL04782-00000029	1/2/1990	FDA Approval of Premarin Tablet Labeling			
05948	W-MDL04782-00000201	W-MDL04782-00000202	11/27/1989	Premarin Cardioprotection Claim			
05949	W-MDL04782-00000281	W-MDL04782-00000285		Now. Help women grow old gracefully			
05950	W-MDL04782-00000296	W-MDL04782-00000298	10/26/1989	Premarin Cardioprotection Claim			
05951	W-MDL04782-00001550	W-MDL04782-00001552	5/22/1990	SPECIAL REGULATORY UPDATE. Prescription Estrogen Drug Products: Patient Package Insert Requirement. Final Rule			
05952	W-MDL04782-00009642	W-MDL04782-00009644	7/15/1986	Premarin FDA Meeting			
05953	W-MDL04782-00009642	W-MDL04782-00009644	7/15/1986	Premarin Food and Drug Administration Meeting			
05954	W-MDL04782-00013800	W-MDL04782-00013803	00/00/1987	ESTROGEN DEFICIENCY: SHORT-TERM SYMPTOMS, LONG-TERM CONSEQUENCES. PREMARIN (conjugated estrogens tablets)			
05955	W-MDL04782-00014926	W-MDL04782-00014928	3/20/1942	Ayerst letter to Carson Frailey of the American Drug Manufacturers Association			
05956	W-MDL04782-00014934	W-MDL04782-00014934	2/20/1942	Document listing procedure steps from The Amer Company			
05957	W-MDL04782-00014959	W-MDL04782-00014960	4/27/1942	Pending NDA 4782 Premarin Tablets			
05958	W-MDL04782-00014962	W-MDL04782-00014964	5/8/1942	Letter to Ayerst from the Food and Drug Administration			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
05959	W-MDL04782-00014967	W-MDL04782-00014969	5/16/1942	Letter to Mr. Carson Frailey @ American Drug Manufacturers Association; Depo: Robert Essner 6/29/06 EX 003: Letter			
05960	W-MDL04782-00014976	W-MDL04782-00014977	3/21/1947	NDA 4782			
05961	W-MDL04782-00014992	W-MDL04782-00014993	9/1/1966	NDA 4782, Premarin Tablets			
05962	W-MDL04782-00015081	W-MDL04782-00015083		PREMARIN TABLETS NDA 4782 LOG 00001938. Panel on Antineoplastic Drugs			
05963	W-MDL04782-00015084	W-MDL04782-00015085		PREMARIN TABLETS NDA 4782 LOG 00001938. Panel on Drugs Used in Disturbances of the Reproductive System			
05964	W-MDL04782-00015124	W-MDL04782-00015130	00/00/1972	PREMARIN BRAND OF CONJUGATED ESTROGENS TABLETS, U.S.P.			
05965	W-MDL04782-00015151	W-MDL04782-00015152	9/25/1972	NDA 4782, PREMARIN (Conjugated Estrogens, U.S.P.) Tablets, DESI 1543			
05966	W-MDL04782-00015154	W-MDL04782-00015155	10/18/1972	NDA 4782, PREMARIN Tablets (Conjugated estrogens tablets USP)			
05967	W-MDL04782-00015164	W-MDL04782-00015165	2/15/1973	NDA 4782 Premarin (Conjugated estrogens Tablets U.S.P.)			
05968	W-MDL04782-00015184	W-MDL04782-00015185	3/30/1973	NDA 4782, Premarin Tablets			
05969	W-MDL04782-00015201	W-MDL04782-00015202		PREMARIN (Conjugated Estrogens Tablets, U.S.P.)			
05970	W-MDL04782-00015239	W-MDL04782-00015245		Estrogens and Emotions			
05971	W-MDL04782-00015494	W-MDL04782-00015494	7/24/1973	NDA 4-782, PREMARIN (conjugated estrogens U.S.P.) Tablets:			
05972	W-MDL04782-00015981	W-MDL04782-00015981	12/10/1973	NDA 4-782, PREMARIN (conjugated estrogens, U.S.P.) Tablets			
05973	W-MDL04782-00015982	W-MDL04782-00016002		PREMARIN AND THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS			
05974	W-MDL04782-00016708	W-MDL04782-00016715		WHY STOP ESTROGEN REPLACEMENT THERAPY AFTER THE HOT FLUSHES HAVE SUBSIDED. WHEN THE DEFICIENCY IS STILL THERE?			
05975	W-MDL04782-00017144	W-MDL04782-00017151	7/8/1974	SUGGESTED LABELING GUIDELINES FOR ESTROGENS			
05976	W-MDL04782-00025944	W-MDL04782-00025944	8/28/1992	Division of Drug Marketing, Advertising, and Communications letter			
05977	W-MDL04782-00026470	W-MDL04782-00026472	10/26/1987	New FDA Text of Estrogen Package Insert and PPI			
05978	W-MDL04782-00026508	W-MDL04782-00026511	6/25/1992	Premarin Osteoporosis Labeling Ayerst / FDA Chronology - Major Events			
05979	W-MDL04782-00026817	W-MDL04782-00026828	8/25/1992	FDA Letter to Wyeth			
05980	W-MDL04782-00027029	W-MDL04782-00027334	10/1/1976	TRANSCRIPT OF PROCEEDINGS FOOD AND DRUG ADMINISTRATION OBSTETRICS AND GYNECOLOGY ADVISORY COMMITTEE			
05981	W-MDL04782-00027343	W-MDL04782-00027513	12/16/1975	TRANSCRIPT OF PROCEEDINGS, OBSTETRICS AND GYNECOLOGY ADVISORY COMMITTEE			
05982	W-MDL04782-00027520	W-MDL04782-00027522	2/19/1975	PREMARIN (Conjugated Estrogens, U.S.P.) Conference with officials of the FDA on proposed revisions of the U.S.P. monograph of 02191975			
05983	W-MDL04782-00027548	W-MDL04782-00027557		SUGGESTED LABELING GUIDELINES FOR ESTROGENS			
05984	W-MDL04782-00027564	W-MDL04782-00027565	3/13/1973	PREMARIN (conjugated estrogens) Tablets			
05985	W-MDL04782-00028448	W-MDL04782-00028470	4/24/1978	DIFFERENT BIOLOGICAL PROFILES IN RESPONSE TO VARIOUS ESTROGENS			
05986	W-MDL04782-00032315	W-MDL04782-00032316	3/10/1980	Consultation with Dr. Brian Macmahon Harvard School of Public Health			
05987	W-MDL04782-00033898	W-MDL04782-00033899	4/00/1990	Nothing else is PREMARIN (conjugated estrogens tablets) Exclusively from natural sources 0.625 mg			
05988	W-MDL04782-00035523	W-MDL04782-00035525	11/9/1989	NDA No. 4-782			
05989	W-MDL04782-00035526	W-MDL04782-00035546		CLINICAL STUDIES SUPPORTING THE USE OF PREMARIN TO DECREASE THE RISK OF CORONARY HEART DISEASE IN POSTMENOPAUSAL WOMEN			
05990	W-MDL04782-00037054	W-MDL04782-00037055	8/7/1992	NDA 4-782			
05991	W-MDL04782-00047468	W-MDL04782-00047495	00/00/1995	PREMARIN Product Training Program			
05992	W-MDL04782-00047601	W-MDL04782-00047617	2/00/1992	A DOCTOR'S GUIDE FOR WOMEN AT MENOPAUSE MAKING A CHOICE ABOUT ESTROGEN			
05993	W-MDL04782-00050222	W-MDL04782-00050223	7/16/1991	Premarin Cardiovascular Labeling			
05994	W-MDL04782-00059874	W-MDL04782-00059876	2/15/1984	FDA Fertility and Maternal Health Advisory Committee Meeting 02091984 - 02101984			
05995	W-MDL04782-00059877	W-MDL04782-00059888	2/9/1984	OPEN SESSION			
05996	W-MDL04782-00060469	W-MDL04782-00060481	3/00/1993	What a Man Should Know About Menopause			
05997	W-MDL04782-00064017	W-MDL04782-00064024		When Women outlive their Ovaries			
05998	W-MDL04782-00064630	W-MDL04782-00064631	1/9/1976	Dear Doctor Letter communicating the results of the advisory committee meeting			
05999	W-MDL04782-00067561	W-MDL04782-00067573	2/19/1986	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
06000	W-MDL04782-00082263	W-MDL04782-00082567	10/1/1976	Transcript of Proceedings - Obstetrics and Gynecology Advisory Committee			
06001	W-MDL04782-00082568	W-MDL04782-00082575	1/12/1976	FDA's Memoranda of Conferences with Ayerst's Representatives on January 7 and 12, 1976			
06002	W-MDL04782-00082750	W-MDL04782-00082755	2/27/1975	Commentary			
06003	W-MDL04782-00094079	W-MDL04782-00094081	1/13/1998	FDA Contact			
06004	W-MDL04782-00095312	W-MDL04782-00095314	4/30/1998	FDA Contact Report			
06005	W-MDL04782-00095525	W-MDL04782-00095527	8/7/1998	Notice of Inadequacy			
06006	W-MDL04782-00095886	W-MDL04782-00095889	11/19/1998	FDA Telephone Contact; Conjugated Estrogens Standards FDA Contact			
06007	W-MDL303-00082550	W-MDL303-00082560	3/16/1994	Minutes from the February 2, 1994 Meeting with FDA Regarding the 8-Arm Osteoporosis Study (NDA 20-303)			
06008	W-MDL303-00082574	W-MDL303-00082577	2/14/1994	Memorandum of Meeting (of resubmission) (NDA 20-303)			
06009	W-MDL303-00082597	W-MDL303-00082607	1/13/1994	Premarin/MPA 8 Arm Osteoporosis Study (NDA 20-303)			
06010	W-MDL303-00082810	W-MDL303-00082811	10/26/1994	Premarin/MPA NDA Review (NDA 20-303)			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06011	W-MDL303-00083112	W-MDL303-00083113	1/24/1995	Premarin/MPA Breast Cancer Phase IV Commitment (NDA 20-303)			
06012	W-MDL303-00083689	W-MDL303-00083862	2/16/1995	Premarin/MPA Separate Tablets; Medical Officer's Review (NDA 20-303)			
06013	W-MDL303-00084282	W-MDL303-00084283	2/14/1997	FDA Contact Report - Prempro Premphase (NDA 20-303)			
06014	W-MDL303-00084429	W-MDL303-00084695	9/25/1997	Phase IV Commitment (NDA 20-303)			
06015	W-MDL303-00084713	W-MDL303-00084714	11/12/1997	Correspondence re: NDA and investigation of breast cancer risk (NDA 20-303)			
06016	W-MDL527-00035136	W-MDL303-00085237	5/2/1985	FDA Contact Report (NDA 20-527)			
06017	W-MDL527-00035879	W-MDL527-00036806	1/8/1997	Supplemental Application (NDA 20-527)			
06018	W-MDL527-00037299	W-MDL527-00037301	8/8/1997	FDA Telephone Contact Report (NDA 20-527)			
06019	W-MDL527-00039707	W-MDL527-00039713	12/1/1998	FDA Contact Report (NDA 20-527)			
06020	W-MDL527-00039728	W-MDL527-00039731	1/4/1999	Prempro/Premphase Tablets MACMIS #6819 (NDA 20-527)			
06021	W-MDL527-00044383	W-MDL527-00044428	4/30/2002	Labeling Supplement (NDA 20-527)			
06022			10/6/2005	Wyeth Citizen Petition			
06023	YAVUE006-000690	YAVUE006-000756	4/6/2001	Prempro 0.45mg/1.5mg Training System Module 4: Selling Skills			
06024	ALIVJ003-000817	ALIVJ003-000819	9/8/1998	NDA 4-782/S-093			
06025	CHOOM010-000656	CHOOM010-000670	7/22/1977	Progestational Drug Products for Human Use Requirements for Labeling Directed to the Patient			
06026	CHOOM023-001619	CHOOM023-001665	11/20/1997	Endocrinologic and Metabolic Drugs Advisory Committee Clinical Review			
06027	CONNS017-000037	CONNS017-000037	2/28/1990	FDA Letter to Barr			
06028	CONTA025-026426	CONTA025-026426	5/1/2002	JAMA - request to meet with editor			
06029	CONTA025-026427	CONTA025-026427	5/1/2002	24-Apr-02			
06030	DUROJ017-000947	DUROJ017-000949		Hello. This is Dr. Pamela Cobb from Global Medical Affairs			
06031	DUROJ042-000027	DUROJ042-000064	4/3/1996	Consumer Magazines Seminar and Overview of DTC Competitive Advertising Spending			
06032	DUROJ042-000974	DUROJ042-000975	9/2/1997	Finance Committee Authorization Unrestricted Educational Grants			
06033	DUROJ044-002415	DUROJ044-002422		Premarin HCP 1999 Budget			
06034	ESSNR001-000513	ESSNR001-000517		Chronology of the Major Events Related to Premarin/MPA			
06035	FARAN024-083474	FARAN024-083487	9/00/1999	Body of Evidence DTC AD Evaluation for Wyeth Ayerst prepared by Zimmerman & Associates			
06036			12/1/1999	FDA Approval of ANDA 40-311			
06037			2/4/2004	Guidance For Industry -- Labeling Guidance for Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms -- Prescribing Information for Health Care Providers and Patient Labeling			
06038	FDAGUIDE-00000008	FDAGUIDE-00000015	10/29/1976	Federal Register, Vol. 41, No. 210, p. 47573			
06039	FDAGUIDE-00000195	FDAGUIDE-00000207	9/00/1998	FDA Labeling Guidance for MPA			
06040	HENRL005-000110	HENRL005-000148	5/15/1998	Premarin Franchise Strategic Options 1999 - 2003			
06041	HENRL005-000554	HENRL005-000587	3/20/2002	2002 Public Relations Flexible Strategies for a Changed World			
06042	HENRL006-000589	HENRL006-000590	6/15/1998	FDA Ad Letters			
06043	HOLSN005-000735	HOLSN005-000737	4/11/1988	Oral Estrogens for Postmenopausal Osteoporosis Drug Efficacy Study Implementation Reevaluation			
06044	KERZC007-000212	KERZC007-000232	5/00/1998	Premarin			
06045	LEVIG001-000540	LEVIG001-000567	10/22/2002	Bridging what is Known and what is not Known FDA Perspective and Response			
06046	MARTN009-001298	MARTN009-001320	7/10/2001	Review and Approval of Promotional Material (Formerly Administrative Policy 420)			
06047	MOORK016-000002	MOORK016-000464	6/20/1991	Fertility and Maternal Health Drugs Advisory Committee Workshop of current status of combined Hormone Replacement Therapy Volume I (FDA)			
06048	NORMJ003-000842	NORMJ003-000843	10/30/1992	ANDA 81-239 (2.5 mg) 81-240 (5 mg)			
06049	PANAA028-000237	PANAA028-000239	7/25/1972	Notices			
06050	PARKA012-001751	PARKA012-001752	2/3/2003	Document			
06051	POUSB002-000229	POUSB002-000230		NDA 20-527/S-030			
06052	ROSSC002-000055	ROSSC002-000076	12/22/1976	Labeling for Estrogens for General Use, 41 Fed. Reg. 43108-23 (Sept. 29, 1976) and 41 Fed. Reg. 47573-78 (Oct. 29, 1976) ; FDA Docket Nos. 76N-0384; 76N-0261; DESI 2238; 76N-0377; DESI 7661- Docket Nos. 76N-0381; DESI Nos. 740,1543, 2238, and 7661			
06053	ROSSC023-000496	ROSSC023-000498	10/14/1991	NDA No. 4-782 Premarin (Conjugated Estrogens) Tablets			
06055	ROSSC023-000607	ROSSC023-000611	11/21/1995	Prempro/Premphase (Conjugated Estrogens/Medroxyprogesterone Acetate) Single Combination Tablets NDA 20-257 MACMIS 3671			
06056	ROSSC040-002303	ROSSC040-002303	9/10/2002	Document			
06057	SONKJ028-000239	SONKJ028-000246	10/5/1993	Memorandum of Meeting Premarin /MPA Refusal to File NDA No. 20-303			
06058	SONKJ207-000333	SONKJ207-000334		Approval Letter from Daniel Shames @ FDA to Jennifer Norman at Wyeth			
06059	STRIS012-000151	STRIS012-000151	3/20/2001	FDA Telephone Contact: NDA No. 20-527 / S-017			
06060	STRIS016-070468	STRIS016-070470		Agenda for 2/28 Strat Ops Discussion			
06061	STRIS019-006776	STRIS019-006792	5/30/2002	Contraceptive Team			
06062			10/00/2002	USPTF 10-02: Hormone Replacement Therapy for Primary Prevention of Chronic Conditions			
06063	VICTJ005-000616	VICTJ005-000621	5/27/1992	FDA Advisory Committee: Osteoporosis			
06064	WEBEM015-016137	WEBEM015-016137	4/23/2002	Additional thoughts about continuous use sales line			
06065	W-LABELS-000218	W-LABELS-000221	00/00/1991	PDR 1991 - Premarin			
06066	W-MDL04782-00009652	W-MDL04782-00009653	12/20/1978	Workshop on Estrogen and Endometrial Cancer			
06067	W-MDL04782-00009973	W-MDL04782-00009974	9/10/1981	OPEN SESSION			
06068	W-MDL04782-00015184	W-MDL04782-00015185	3/30/1973	NDA 4782, Premarin Tablets			
06069	W-MDL04782-00026232	W-MDL04782-00026243	2/00/1990	LABELING GUIDANCE FOR ESTROGEN DRUG PRODUCTS PHYSICIAN LABELING			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06070	W-MDL04782-00026470	W-MDL04782-00026472	10/26/1987	New FDA Text of Estrogen Package Insert and PPI			
06071	W-MDL04782-00027562	W-MDL04782-00027563	4/5/1973	PREMARIN TABLETS			
06072	W-MDL04782-00027685	W-MDL04782-00027827	2/18/1977	TRANSCRIPT OF PROCEEDINGS, ENDOCRINOLOGY AND METABOLISM ADVISORY COMMITTEE			
06073	W-MDL04782-00032623	W-MDL04782-00032649	4/26/1984	FERTILITY AND MATERNAL HEALTH DRUGS ADVISORY COMMITTEE, VOLUME I			
06074	W-MDL04782-00034653	W-MDL04782-00034656	6/14/1991	Premarin (Conjugated Estrogens, USP) NDA 4-782/S-084			
06075	W-MDL04782-00038769	W-MDL04782-00038770	8/24/1984	NDA 4-782. Premarin (R) (Conjugated Estrogens, U.S.P.)			
06076	W-MDL04782-00062830	W-MDL04782-00062830	3/14/1978	NDA 4-782: PREMARIN (Conjugated Estrogens Tablets, U.S.P.)			
06077	W-MDL04782-00062831	W-MDL04782-00062848	3/1/1978	THE ROLE OF PROGESTINS IN ESTROGEN REPLACEMENT THERAPY			
06078	W-MDL04782-00064016	W-MDL04782-00064016	7/7/1975	TRANSMITTAL OF ADVERTISEMENTS AND PROMOTIONAL LABELING FOR DRUGS FOR HUMAN USE. NDA NUMBER N04782. PREMARIN (Conjugated Estrogens, U.S.P.) Tablets			
06079	W-MDL303-00081663	W-MDL303-00081664	9/9/1992	Cardiovascular Labeling (NDA 20-303)			
06080	W-MDL303-00081988	W-MDL303-00081989	6/2/1993	FDA Letter Regarding Osteoporosis Issues (NDA 20-303)			
06081	W-MDL303-00083037	W-MDL303-00083097	8/18/1994	Premarin/MPA Separate Tablets Direction Circulars (NDA 20-303)			
06082	W-MDL303-00085231	W-MDL303-00085234	9/29/2000	Response to FDA request for revised labeling (NDA 20-303)			
06083	ROSSC002-000117	ROSSC002-000124	4/25/1978	Breast Cancer Risk Factors Among Screen Program Participants			
06084	GPIL005-001774	GPIL005-001777	3/15/1990	Estrogen-Progestogen Replacement and Cancer Risk			
06085	CONNS008-001160	CONNS008-001160	4/18/1997	Letter from Gambrell to Rofsky			
06086	PICKJ009-001232	PICKJ009-001233	12/3/1996	Memo from Michaelis to File Re: Breasts Cancer and Hormone Therapy			
06087	DUROJ005-000860	DUROJ005-000862		Press Release Re: Wyeth funding of Alzheimer study			
06088	PANAA016-000391	PANAA016-000396		Launch Issues / Tactics			
06089	FISHG001-000345	FISHG001-000349	8/13/1992	Letter from Hoyle to Hite			
06090	FISHG001-000267	FISHG001-000269	9/10/1992	Memo from Victoria to Wetzal			
06091	FISHG001-000270	FISHG001-000272	8/26/1992	Memo from Wetzal to Victoria			
06092	YAVUE001-001045	YAVUE001-001198	00/00/1988	Premarin Family training manual			
06093	CONTA003-000623	CONTA003-000672	00/00/1995	Women's health issues and hormones; Alice Perrone 8/30/06 DEPO EX 001: Sales Training Material			
06094	CONNS005-000311	CONNS005-000337		Premarin Historical Backgrounder			
06095	COBBP002-000136	COBBP002-000140	6/14/1991	Memo Colsante to Rofsky			
06096	PANAA033-000063	PANAA033-000080	3/16/1995	Speroff Transcript			
06097	GPIL009-001533	GPIL009-001534	7/17/1989	Memo from Joyner to Christie			
06098	PANAA025-001447	PANAA025-001448	8/2/1989	Letter from Ross to Rothman			
06099	GPIL018-000067	GPIL018-000071	7/15/1991	Memo from Fructman to Michaelis			
06100	GPIL018-000072	GPIL018-000074	6/15/1991	MPA/ CEE Dose Regimens			
06101	GPIL018-000075	GPIL018-000077		Lipid Profile Effects			
06102	GPIL018-000078	GPIL018-000078		Lipid Profile Effects			
06103	GPIL018-000079	GPIL018-000079		Clinical Trials: Effects of Hormones			
06104	GPIL018-000080	GPIL018-000080		Effects of ERT or HRT			
06105	GPIL018-000081	GPIL018-000081		Effects of Hormone Replacement Therapy			
06106	COBBP016-001047	COBBP016-001097	00/00/1995	Hormone Replacement Therapy (HRT)			
06258	CHOOM007-000956	CHOOM007-000956	3/5/1998	W-A check request for unrestricted education grant : Amount \$152,500.00			
06259	CHOOM007-000957	CHOOM007-000957	3/5/1998	W-A check request for 1998 Annual Corporate Advisory Dues : Amount \$10,000.00			
06260	CHOOM007-000968	CHOOM007-000968	1/23/1998	W-A check request for unrestricted grant to support the Indiana Osteoporosis Prevention Initiative : Amount \$20,000.00			
06261	CHOOM007-000970	CHOOM007-000970	3/13/1998	Copy of check to IN State Dept. of Health : Amount \$20,000.00			
06262	CHOOM007-000972	CHOOM007-000972	11/18/1997	1998 CME Activities Budget : Amount \$775,000.00			
06263	CHOOM007-000973	CHOOM007-000973	11/18/1997	1998 CME Activities - marketing fund : Amount \$7,902,010.00			
06264	CHOOM007-000974	CHOOM007-000974	12/18/1997	Wyeth check request for NYLCare HRT mailing to members and MDs : Amount \$14,707.00			
06265	CHOOM007-000985	CHOOM007-000985	10/27/1997	Wyeth check request for PPFA menopause program (2nd payment of 3) : Amount \$166,666.00			
06266	CHOOM007-000995	CHOOM007-000995	7/29/1997	W-A check request for grant to fund AMWA's Advanced Curriculum on Women's Health International Conference : Amount \$50,000.00			
06267	CHOOM007-001015	CHOOM007-001016	6/18/1997	Wyeth check request for funding 2nd, 3rd and 4th Annual symposia : Amount \$1,530,000.00			
06268	CHOOM007-001019	CHOOM007-001020	11/21/1994	Wyeth check request for funding for 9th, 10th and 11th annual symposia : Amount \$1,503,000.00			
06269	CHOOM007-001073	CHOOM007-001073	3/12/1998	Wyeth check request for AHA Women's Health Initiative - year 2 : Amount \$1,500,000.00			
06270	CHOOM007-001074	CHOOM007-001074	1/7/1998	Wyeth request for sponsorship fee for ACOG annual meeting newspaper ACM News Preview : Amount \$42,000.00			
06271	CHOOM007-001076	CHOOM007-001076	12/1/1998	Letter to W-A confirming agreement to sponsor ACOG newspaper ACM News Post : Amount \$42,000.00			
06272	CHOOM007-001079	CHOOM007-001079	1/30/1998	Wyeth request for ACOG pocket planner for 1998 ACOG meeting : Amount \$33,150.00			
06273	CHOOM019-000306	CHOOM019-000309	8/6/1997	Letter from WHRG to W-A detailing activities and requesting donation to support fourth annual fall conference : Amount \$25,000.00			
06274	CHOOM019-000338	CHOOM019-000338	11/7/1996	Wyeth request for 1998 Fellowship Brochure for NAMS : Amount \$4,000.00			
06275	CHOOM019-000341	CHOOM019-000341	12/20/1995	1996 CME Budget : Amount \$2,858,543.00			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06276	CHOOM019-000379	CHOOM019-000379	10/8/1996	Burston-Marstellar services and expenses for public relations programs in 1997 : Amount \$3,000,000.00			
06277	CHOOM019-000443	CHOOM019-000443	2/28/1996	consultant services from APCO Associates for regulatory and crisis management issues for 1996 : Amount \$36,000.00			
06278	CHOOM019-000466	CHOOM019-000467	9/10/1996	Wyeth request for funding participation of over 800 residents at various key medical societies during their 1997 meetings : Amount \$2,575,000.00			
06279	CHOOM019-000482	CHOOM019-000482	1/24/1997	Request for unrestricted grant : Amount \$350,000.00			
06280	CHOOM019-000483	CHOOM019-000483	1/31/1997	Wyeth request for Fellowship grant : Amount \$25,000.00			
06281	CHOOM019-000575	CHOOM019-000575	2/20/1997	AHA letter requesting educational grant for 1997 and 1998 : Amount \$3,230,000.00			
06282	CHOOM019-000576	CHOOM019-000577	2/27/1997	Wyeth check request for AHA 2-year educational grant : Amount \$3,000,000.00			
06283	CHOOM019-000595	CHOOM019-000595	9/18/1997	Check to AHA : Amount \$500,000.00			
06284	CHOOM019-000602	CHOOM019-000602	11/22/1996	Wyeth request for funding APGO-CREOG Resident Reporter Program at 1997 meeting : Amount \$56,203.00			
06285	CHOOM019-000605	CHOOM019-000605	8/21/1996	Wyeth request for ASRM Resident Reporter Program : Amount \$405,364.00			
06286	CHOOM019-000609	CHOOM019-000609	11/22/1996	Funding for ACOOG Resident Reporter Program : Amount \$66,741.00			
06287	CHOOM019-000617	CHOOM019-000617	11/22/1996	Wyeth request for funding ACOG Resident Reporter Program at 1997 meeting : Amount \$440,439.00			
06288	CHOOM019-000622	CHOOM019-000622	1/14/1997	Wyeth request to sponsor special supplement to Resident Reporter Journal : Amount \$57,600.00			
06289	CHOOM019-000645	CHOOM019-000645	9/3/1997	unrestricted grant for HRT brochure : Amount \$34,000.00			
06290	CHOOM019-000646	CHOOM019-000646	9/3/1997	unrestricted educational grant : Amount \$200,000.00			
06291	CHOOM019-000653	CHOOM019-000653	9/3/1997	unrestricted educational grant : Amount \$52,500.00			
06292	CHOOM019-000654	CHOOM019-000654	10/14/1997	Wyeth check request for grant in support of fourth annual fall conference : Amount \$25,000.00			
06293	CHOOM019-000687	CHOOM019-000687	11/11/1997	Wyeth check request for unrestricted educational grant to be distributed between University of MD at Baltimore and Johns Hopkins University Women's Research Core to be headed by Trudy Bush, MD : Amount \$475,000.00			
06294	CHOOM019-000707	CHOOM019-000707	6/10/1997	Wyeth check request for unrestricted grant to fund research fellowship in Women's Health Care : Amount \$35,000.00			
06295	CHOOM019-000729	CHOOM019-000729	4/16/1997	Wyeth check request for educational grant to support BPW "Understanding Menopause" annual program : Amount \$15,000.00			
06296	CHOOM019-000784	CHOOM019-000784	8/7/1997	Wyeth request to sponsor Resident Reporter Journal with ASRM. : Amount \$50,000.00			
06297	CHOOM019-000797	CHOOM019-000797	3/7/1997	Requested funding of awards and grants for 1997 : Amount \$8,706,275.00			
06298	CHOOM019-000803	CHOOM019-000803	6/30/1997	Wyeth check request for unrestricted grant to fund 4 issues of Menopausal Medicine for 1998 : Amount \$155,000.00			
06299	CHOOM023-000524	CHOOM023-000524	12/20/1996	Letter to Trudy Bush, MD enclosing gift to support Women's Health Research Group conference on 10/25/96 : Amount \$25,000.00			
06300	CHOOM024-000003	CHOOM024-000003	7/17/1998	Wyeth letter enclosing 2nd installment for Women and Heart Disease campaign : Amount \$500,000.00			
06301	CHOOM024-000039	CHOOM024-000039	5/14/1998	Letter to AA enclosing Wyeth check for "Women and Alzheimer's Disease" campaign : Amount \$2,453,900.00			
06302	CHOOM024-000066	CHOOM024-000066	1/6/1998	Wyeth check request for NAMS Consensus conference in 1998 : Amount \$60,000.00			
06303	CHOOM024-000067	CHOOM024-000067	1/9/1998	Copy of check to NAMS : Amount \$85,000.00			
06304	CHOOM024-000068	CHOOM024-000068	1/6/1998	Wyeth check request for NAMS Clinical Research Fellowship Grant : Amount \$25,000.00			
06305	CHOOM024-000070	CHOOM024-000070	1/7/1998	Wyeth check request for symposia fee "Prevention and Management of CV Disease" : Amount \$112,500.00			
06306	CHOOM024-000073	CHOOM024-000073	1/7/1998	Wyeth check request for lecture series fee : Amount \$18,000.00			
06307	CHOOM024-000076	CHOOM024-000076	3/2/1998	Wyeth check request for symposia fee "Prevention and Management of CV Disease" : Amount \$100,000.00			
06308	CHOOM024-000080	CHOOM024-000080	3/6/1998	W-A letter to AAFP enclosing checks for Chapter Lecture Series "Effect of HRT in CV Disease Risk in Postmenopausal Women" and Regional Symposia "Women and Heart Disease" : Amount \$130,500.00			
06309	CHOOM024-000101	CHOOM034-000102	11/13/1997	Wyeth check request for funding for Endowed Professorship at Columbia University : Amount \$1,500,000.00			
06310	CHOOM024-000129	CHOOM024-000129	4/22/1998	Wyeth check request for funding to administer 8th Annual ASRM Resident/Fellow Reporter Program. : Amount \$400,000.00			
06311	CHOOM024-000130	CHOOM024-000131	12/18/1997	Wyeth request to fund 1998 Resident and Fellow Reporter Programs. : Amount \$3,554,000.00			
06312	CHOOM024-000132	CHOOM024-000132	4/21/1998	Wyeth check request for funding to sponsor Resident Reporter Journal for 8th Annual ASRM Resident Reporter Program : Amount \$51,000.00			
06313	CHOOM024-000135	CHOOM024-000135	4/30/1998	Wyeth check request for funding for ob/gyn resident textbook grant : Amount \$162,000.00			
06314	CHOOM024-000147	CHOOM024-000147	2/19/1998	C : Amount \$1,200,000.00			
06315	CHOOM024-000148	CHOOM024-000148	3/3/1998	Letter of Agreement b/t DU and W-A (development of 1 slide kit, 1 printed monograph, 4 regional meetings)			
06316	CHOOM024-000149	CHOOM024-000149	4/10/1998	Agreement for CME : Amount \$516,250.00			
06317	CHOOM024-000150	CHOOM024-000150	3/13/1998	Agreement for CME : Amount \$716,628.00			
06318	CHOOM024-000153	CHOOM024-000153	5/4/1998	Copy of check to DU for clinical research grant : Amount \$500,000.00			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06319	CHOOM024-000154	CHOOM024-000154	3/18/1998	Copy of check to DU for medical grant : Amount \$500,000.00			
06320	CHOOM024-000160	CHOOM024-000161	8/19/1998	Copy of check to DU : Amount \$200,000.00			
06321	CHOOM024-000164	CHOOM024-000164	11/17/1998	Copy of check to DU : Amount \$120,000.00			
06322	CHOOM024-000214	CHOOM024-000219	11/12/1997	Wyeth check request for support of Women's Health Care Internet program : Amount \$190,000.00			
06323	CHOOM024-000338	CHOOM024-000338	3/18/1998	Wyeth check to AMWA : Amount \$50,000.00			
06324	CHOOM024-000347	CHOOM024-000349	1/12/1998	Wyeth Request for Check to AA : Amount \$150,000.00			
06325	CHOOM024-000351	CHOOM024-000351	10/28/1997	ACOG letter re cost of sponsorship of the ACOG newsletter for 1998 (references 1981 agreement) : Amount \$20,000 per issue			
06326	CHOOM024-000383	CHOOM024-000383	3/25/1998	Wyeth check request for increased grant amount for public service announcement re Osteoporosis : Amount \$25,000.00			
06327	CHOOM024-000384	CHOOM024-000385	2/19/1998	Wyeth check request for NOF 1998 contribution and 1997 Symposium exhibit fee : Amount \$400,000.00			
06328	CHOOM024-000389	CHOOM024-000390	8/26/1997	NOF letter requesting grant : Amount \$400,000.00			
06329	CHOOM024-000397	CHOOM024-000397	3/27/1998	Copy of check to NOF : Amount \$400,000.00			
06330	CHOOM024-000410	CHOOM024-000410	2/20/1998	NAMS letter inviting Wyeth to be exclusive sponsor of NAMS website for 1998 : Amount \$40,000.00			
06331	CHOOM024-000411	CHOOM024-000412	3/25/1998	NAMS letter re update on issues affecting W-A and NAMS : Amount \$153,000.00			
06332	CHOOM026-000081	CHOOM026-000084	6/29/1998	Wyeth request for funds to complete commitment to Women's Health Care Curriculum : Amount \$50,000.00			
06333	CHOOM026-000114	CHOOM026-000115	11/4/1998	Wyeth check request for PR Design Write created for NAMS slides for Dr. Nachtigall : Amount \$42,000.00			
06334	CHOOM026-000123	CHOOM026-000126	2/25/1998	Wyeth request for funds to administer 12th Annual ACOG Resident Reporter Program : Amount \$450,000.00			
06335	CHOOM026-000127	CHOOM026-000130	2/25/1998	Wyeth request for funds to administer 3rd Annual CREOG Resident Reporter Program : Amount \$70,000.00			
06336	CHOOM026-000131	CHOOM026-000131	3/2/1998	Wyeth Request for funds to administer 3rd Annual ACOG Resident Reporter Program : Amount \$70,000.00			
06337	CHOOM026-000132	CHOOM026-000135	3/20/1998	Wyeth request for funds to sponsor Resident Reporter Journal in conjunction with ACOG Annual Clinical Meeting : Amount \$41,000.00			
06338	CHOOM026-000136	CHOOM026-000137	3/20/1998	Wyeth request for funds to sponsor Resident Reporter Magazine at ACOG Meeting : Amount \$51,000.00			
06339	CHOOM027-000056	CHOOM027-000057	5/12/1997	W-A Request for funding for 12th, 13th and 14th Annual symposia : Amount \$1,503,000.00			
06340	CHOOM027-000075	CHOOM027-000085	10/15/1997	W-A Request for funding 1998 CME budget for national events for all products : Amount \$31,563,155.00			
06341	CHOOM027-000086	CHOOM027-000086		Wyeth request for 1999 ACOG Annual Meeting funds : Amount \$250,000.00			
06342	CHOOM027-000087	CHOOM027-000093	11/17/1997	Requested funding of awards and grants for 1998 : Amount \$27,461,175.00			
06343	CHOOM027-000144	CHOOM027-000145	9/2/1997	Requested funding for various organization's DTC initiatives : Amount \$9,150,000.00			
06344	CHOOM027-000195	CHOOM027-000198	10/22/1996	Wyeth request to continue funding Wyeth scholarship for women in graduate medical and health science programs through BPW (1997-1998) : Amount \$100,000 over 2 years			
06345	CHOOM027-000203	CHOOM027-000205	1/15/1996	Wyeth check request for funding for three year alliance with Mayo Clinic : Amount \$1,225,000.00			
06346	CHOOM027-000209	CHOOM027-000209	9/27/1995	Wyeth check request to sponsor quarterly newsletter publication under ASRM : Amount \$148,000.00			
06347	CHOOM029-000022	CHOOM029-000030	3/4/1999	Requested funding of awards and grants for 1999 : Amount \$18,114,725.00			
06348	CHOOM029-000331	CHOOM029-000331	4/14/1999	Wyeth check request for 1999 Annual Corporate Advisory Dues : Amount \$10,000.00			
06349	CHOOM029-000694	CHOOM029-000694	2/24/1999	W-A Endowed Chair PR Opportunities			
06350	CHOOM029-000784	CHOOM029-000784	5/6/1999	Wyeth letter enclosing check for sponsorship of Family Circle/AMWA Women's Health program for 1999 : Amount \$224,000.00			
06351	CHOOM029-000793	CHOOM029-000795		Description of alliance b/t AMWA, Family Circle and Wyeth			
06352	CHOOM029-000800	CHOOM029-000800	6/23/1999	Letter to AA enclosing Wyeth check for 15th Annual Rita Hayworth Gala : Amount \$12,500.00			
06353	CHOOM029-000801	CHOOM029-000801	5/24/1999	AA letter thanking Wyeth for the use of Ketchum services to advance public relations for the Women's Health campaign : Amount \$65,000.00			
06354	CHOOM029-000802	CHOOM029-000802	5/18/1999	AA letter thanking Wyeth for recent contribution : Amount \$2,000,000.00			
06355	CHOOM029-000803	CHOOM029-000803	5/11/1999	Letter to AA enclosing Wyeth check for unrestricted educational grant in support of the Women's Health Campaign : Amount \$2,000,000.00			
06356	CHOOM029-000811	CHOOM029-000811	4/12/1999	AA letter summarizing how the proposed \$2M grant would be divided			
06357	CHOOM029-000819	CHOOM029-000819	5/11/1999	Wyeth letter enclosing check for unrestricted educational grant for women's educational campaign on menopausal treatment options : Amount \$75,000.00			
06358	CHOOM029-000872	CHOOM029-000872	8/11/1999	Wyeth letter enclosing check for second installment of unrestricted educational grant to AHA : Amount \$750,000.00			
06359	CHOOM029-000876	CHOOM029-000876	6/9/1999	Wyeth letter enclosing check for first installment of unrestricted educational grant to AHA : Amount \$750,000.00			
06360	CHOOM029-000883	CHOOM029-000883	1/5/1999	AHA letter requesting educational grant for 1999 : Amount \$1,500,000.00			
06361	CHOOM029-000908	CHOOM029-000908	6/11/1999	ACSH letter thanking Wyeth for contribution : Amount \$150,000.00			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06362	CHOOM029-000912	CHOOM029-000912	6/9/1999	Wyeth letter enclosing check for unrestricted educational grant : Amount \$150,000.00			
06363	CHOOM029-000925	CHOOM029-000925	6/15/1999	Wyeth letter enclosing unrestricted educational grant to co-sponsor AMA Fifth Annual Menopause Symposium : Amount \$5,000.00			
06364	CHOOM029-000937	CHOOM029-000937	7/22/1999	Wyeth letter enclosing check for 2nd and final payment of unrestricted education grant for support of Women's Educational Campaign : Amount \$100,000.00			
06365	CHOOM029-000945	CHOOM029-000945	4/14/1999	Progress Report			
06366	CHOOM029-000949	CHOOM029-000949	6/7/1999	Wyeth letter enclosing check for 1st payment of unrestricted educational grant in support of Women's Educational Campaign : Amount \$100,000.00			
06367	CHOOM029-001014	CHOOM029-001014	6/15/1999	Wyeth letter enclosing check : Amount \$10,000.00			
06368	CHOOM029-001029	CHOOM029-001029	8/25/1999	U of MD letter thanking Wyeth for gift : Amount \$50,000.00			
06369	CHOOM029-001157	CHOOM029-001157	9/30/1999	Wyeth letter enclosing check for unrestricted educational grant : Amount \$150,000.00			
06370	CHOOM029-001160	CHOOM029-001160	9/27/1999	Copy of check to NOF : Amount \$150,000.00			
06371	CHOOM029-001176	CHOOM029-001176	11/15/1999	Wyeth letter enclosing check for unrestricted grant to cosponsor NOF World Congress on Osteoporosis in 2000 : Amount \$25,000.00			
06372	CHOOM029-001179	CHOOM029-001179	10/28/1999	Copy of check to NOF : Amount \$25,000.00			
06373	CHOOM029-001261	CHOOM029-001261	1/4/2000	Wyeth letter enclosing check for educational grant for printing costs of booklet "What's Right for Me?" : Amount \$6,095.28			
06374	CHOOM031-002038	CHOOM019-002038	6/17/1998	W-A letter enclosing check for unrestricted educational grant : Amount \$200,000.00			
06375	CHOOM032-000143	CHOOM032-000144	2/25/1997	Agreement b/t Eden Communications Group and Wyeth to develop, implement and execute PPFA Menopause/Mid-Life services program : Amount \$250,000.00			
06376	CHOOM032-001068	CHOOM032-001068	4/6/1998	Letters of Agreement with Drs. Cyr, Landau and Moulton for writing "What's Right for Me" booklet : Amount \$75,000.00			
06377	CHOOM033-000795		9/22/1999	Fax to Wyeth from AHA requesting approval of newsletter			
06378	CHOOM033-001609	CHOOM033-001611		List of W-A sponsored ACOG Research awards, grants and fellowships			
06379	CHOOM034-000205	CHOOM034-000212		AA and Wyeth Agreement : Amount \$2,603,900.00			
06380	CHOOM034-000358	CHOOM034-000361		AA Scientific Poster Session proposal from AA (references earlier agreements in 1995-1997) : Amount \$1,040,000.00			
06381	CHOOM034-000364	CHOOM034-000365		Corporate Sponsorship Fee proposal from AA : Amount \$150,000.00			
06382	CHOOM034-000366	CHOOM034-000375	10/13/1997	AA Partnership proposal			
06383	CHOOM034-000376	CHOOM034-000383		AA proposal to Wyeth to sponsor AA national educational conference			
06384	CHOOM034-000521	CHOOM034-000522	9/10/1997	Memo re AHA Media Event/coverage			
06385	CHOOM034-000624	CHOOM034-000624	10/31/1997	Memo re suggestion to include AHA logo on field sales business cards			
06386	CHOOM034-001672	CHOOM034-001673	7/16/1997	Dr. Lobo is requesting gift from Wyeth to establish professorship in Dept. of OB/GYN at Columbia University : Amount \$1,500,000.00; Ralph Hale 7/25/06 DEPO EX 022: Memo			
06387	CHOOM034-001760	CHOOM034-001760	10/20/2000	Grants for 2001 : Amount \$7,420,000.00			
06388	CHOOM044-000552	CHOOM044-000554	9/27/2000	Wyeth request for sponsoring 5th, 6th and 7th Annual Frontiers in Estrogen Action Symposium : Amount \$1,650,000.00			
06389	CHOOM044-000555	CHOOM044-000565	9/19/2000	W-A Request for funding for 15th, 16th and 17th Annual symposia : Amount \$2,273,400.00			
06390	CHOOM044-000855	CHOOM044-000855	10/16/1998	ACOG letter re cost of sponsorship of the ACOG newsletter for 1999 : Amount \$24,000 per issue			
06391	CHOOM047-000193	CHOOM047-000193	9/9/1999	AHA letter requesting educational grant for 2000 : Amount \$1,000,000.00			
06392	CHOOM047-000195	CHOOM047-000195	3/23/2000	WCOA request for grant for delivery of comprehensive women's health and wellness initiative : Amount \$150,000.00			
06393	CHOOM047-000197	CHOOM047-000197	1/14/2000	AHRP letter requesting unrestricted educational grant for 2000 ARHP consumer education speakers panel program : Amount \$343,000.00			
06394	CHOOM047-000199	CHOOM047-000199	1/12/2000	AA letter w/ revised recommendations for symposia and public relations need : Amount \$250,000.00			
06395	CHOOM047-000203	CHOOM047-000203	3/6/2000	AHA letter thanking Wyeth for support for Professional Development Luncheon : Amount \$5,000.00			
06396	CHOOM047-000262	CHOOM047-000262	8/24/2000	Wyeth check request for grant for 4 issues of Menopausal Medicine for 2000 & Menopausal Medicine on ASRM Website (1996, 1997, 1998, 1999) : Amount \$176,000.00			
06397	CHOOM047-000421	CH00M047-000421	3/30/2000	Wyeth check request for Resident Grant 1999-2000 : Amount \$70,000.00			
06398	CHOOM047-000479	CHOOM047-000479	11/23/1999	NOF invoice to Wyeth for Congress+D78 sponsor fee : Amount \$75,000.00			
06399	CHOOM047-000653	CHOOM047-000655	12/00/1999	Wyeth request for funds to create card for NOF outlining osteoporosis risk factors : Amount \$13,200			
06400	CHOOM047-000656	CHOOM047-000656	3/17/2000	Wyeth request for funding for NAMS Nurse Practitioner Report program : Amount \$25,000.00			
06401	CHOOM047-000669	CHOOM047-000670		Wyeth request for funding to support 2000 ADRM Resident Reporter Program : Amount \$390,000.00			
06402	CHOOM047-000681	CHOOM047-000681	6/22/2000	AHA letter thanking Wyeth for support of Women in Cardiology : Amount \$18,750.00			
06403	CHOOM047-000685	CHMOOM047-00688		AHA Travel Grant Program Schedule of Payments 1998-2001			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06404	CHOOM047--000715	CHOOM047-000715	6/26/2000	DU letter to W-A enclosing letter of agreement for "Therapeutic Options for Menopausal Health Slide Kit, Vol. 3" : Amount \$241,502.00			
06405	CHOOM047-000716	CHOOM047-000721	5/30/2000	W-A Check Request for Slide Kit : Amount \$241,502.00			
06406	CHOOM047-000729	CHOOM047-000730	7/5/2000	Wyeth check request for NAMS Symposia Highlights Publication : Amount \$19,000.00			
06407	CHOOM047-000759	CHOOM047-000769	8/7/2000	Wyeth check request for costs incurred for NAMS Symposium 9/6/00 : Amount \$49,290.00			
06408	CHOOM047-000782	CHOOM047-000787	8/14/2000	Wyeth check request for sponsorship of ADBMR/NAMS joint symposium : Amount \$20,000.00			
06409	CHOOM047-000818	CHOOM047-000819	10/27/2000	Wyeth request to fund Endowed Professorship in Women's Health with Columbia University for 1999 and 2000 : Amount \$612,500.00			
06410	CHOOM047-000820	CHOOM047-000820	4/1/1998	Wyeth request for year 1 installment for Endowed Professorship : Amount \$325,000.00			
06411	CHOOM047-000835	CHOOM047-000841	6/22/2000	Wyeth request for funds to disseminate information from NOF World Congress : Amount \$133,825.00			
06412	CHOOM047-000958	CHOOM047-000959	9/28/2000	Wyeth request for funding for Celebration Health - joint venture between Florida Hospital Association and Disney : Amount \$1,425,000.00			
06413	CHOOM047-001058	CHOOM047-001059	4/27/2000	Wyeth check request for sponsorship of First International Conference of Women, Heart Disease and Stroke : Amount \$222,000.00			
06414	CHOOM047-001267	CHOOM047-001267	3/9/2000	Wyeth check request for funding to fulfill contract with Celebration Health : Amount \$275,000.00			
06415	CHOOM067-000013	CHOOM067-000013	3/4/1998	NAMS letter thanking Wyeth for commitment to be sponsor of NAMS website : Amount \$40,000.00			
06416	CHOOM067-000340	CHOOM067-000340	4/10/1998	NOF letter thanking Wyeth for 1998 grant and 1997 Symposium exhibit fee and additional monies for public service announcement : Amount \$425,000.00			
06417	CHOOM067-000341	CHOOM067-000341	4/5/1998	Wyeth letter enclosing check for NOF osteo public service announcement campaign : Amount \$25,000.00			
06418	CHOOM067-000697	CHOOM067-000697	6/26/1996	Wyeth request for unrestricted educational grant to develop, implement and evaluate success of WHPCCP : Amount \$295,150.00			
06419	JANEC010-000213	JANEC010-000231		Wyeth ppt re AHA and Wyeth partnership			
06420	PANAA001-000017	PANAA001-000029	11/16/2000	Request for local funding for CME, VSB, unrestricted grants, peer selling : Amount \$74,900,000.00			
06421	PANAA031-001645	PANAA031-001645	5/17/1990	Wyeth wish list involving the NOF			
06422	PANAA031-001816	PANAA031-001842	6/23/1992	proposal to Wyeth for NOF requesting 1993 grant support : Amount \$1,428,000.00			
06423	PANAA031-002200	PANAA031-002200	7/5/1996	NOF letter thanking Wyeth for 1996 grant : Amount \$300,000.00			
06424	PANAA037-000103	PANAA037-000105	1/10/1994	NOF letter to Wyeth concerning NOF commitment			
06425	SOLOJ020-000598	SOLOJ020-000600	3/16/1994	Wyeth request to support Fellowship with Wolf Utian, MD, President of NAMS : Amount \$75,000 over three years			
06426	SOLOJ022-000967	SOLOJ022-000983	1/24/1997	AHA proposal to Wyeth			
06427				1942 Premarin Label			
06428				1943 Premarin Label			
06429				1944 Premarin Label			
06430				1945 Premarin Label			
06431				1946 Premarin Label			
06432				1947 Premarin Label			
06433				1948 Premarin Label			
06434			00/00/1949	1949 Premarin Label			
06435				1950 Premarin Label			
06436				1951 Premarin Label			
06437				1952 Premarin Label			
06438			00/00/1953	1953 Premarin Label			
06439				1954 Premarin Label			
06440				1955 Premarin Label			
06441				1956 Premarin Label			
06442			00/00/1957	1957 Premarin Label			
06443			00/00/1958	1958 Premarin Label			
06444			00/00/1959	1959 Premarin Label			
06445			00/00/1960	1960 Premarin Label			
06446			00/00/1961	1961 Premarin Label			
06447			00/00/1962	1962 Premarin Label			
06448				1963 Premarin Label			
06449				1964 Premarin Label			
06450			00/00/1965	1965 Premarin Label			
06451			00/00/1966	1966 Premarin Label			
06452			00/00/1967	1967 Premarin Label			
06453			00/00/1968	1968 Premarin Label			
06454				1969 Premarin Label			
06455				1970 Premarin Label			
06456				1971 Premarin Label			
06457	W-LABELS-000320	W-LABELS-000323	00/00/1974	1972 Premarin Label			
06458	W-LABELS-000324	W-LABELS-000325	00/00/1973	1973 Premarin Label			
06459			00/00/1974	1974 Premarin Label			
06460	W-LABELS-000329	W-LABELS-000331	00/00/1975	1975 Premarin Label			
06461	W-LABELS-000332	W-LABELS-000334	00/00/1976	1976 Premarin Label			
06462	W-LABELS-000335	W-LABELS-000337	00/00/1977	1977 Premarin Label			
06463	W-LABELS-000338	W-LABELS-000342	00/00/1978	1978 Premarin Label			
06464	W-LABELS-000343	W-LABELS-000348	00/00/1979	1979 Premarin Label			
06465	W-LABELS-000349	W-LABELS-000354	00/00/1980	1980 Premarin Label			
06466	W-LABELS-000355	W-LABELS-000359	00/00/1981	1981 Premarin Label			
06467	W-LABELS-000360	W-LABELS-000365	00/00/1982	1982 Premarin Label			
06468	W-LABELS-000366	W-LABELS-000371	00/00/1983	1983 Premarin Label			
06469	W-LABELS-000372	W-LABELS-000377	00/00/1984	1984 Premarin Label			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06470	W-LABELS-000378	W-LABELS-000382	00/00/1985	1985 Premarin Label			
06471	W-LABELS-000383	W-LABELS-000387	00/00/1986	1986 Premarin Label			
06472	W-LABELS-000388	W-LABELS-000392	00/00/1987	1987 Premarin Label			
06473	W-LABELS-000393	W-LABELS-000396	00/00/1988	1988 Premarin Label			
06474	W-LABELS-000397	W-LABELS-000401	00/00/1989	1989 Premarin Label			
06475	W-LABELS-000402	W-LABELS-000405	00/00/1990	1990 Premarin Label			
06476	W-LABELS-000406	W-LABELS-000409	00/00/1991	1991 Premarin Label			
06477	W-LABELS-000410	W-LABELS-000413	00/00/1992	1992 Premarin Label			
06478	W-LABELS-000414	W-LABELS-000417	00/00/1993	1993 Premarin Label			
06479	W-LABELS-000418	W-LABELS-000421	00/00/1994	1994 Premarin Label			
06480	W-LABELS-000422	W-LABELS-000425	00/00/1995	1995 Premarin Label			
06481	W-LABELS-000426	W-LABELS-000429	00/00/1996	1996 Premarin Label			
06482	W-LABELS-000430	W-LABELS-000433	00/00/1997	1997 Premarin Label			
06483	W-LABELS-000498	W-LABELS-000498	00/00/1998	1998 Premarin Label			
06484	W-LABELS-000438	W-LABELS-000441	00/00/1999	1999 Premarin Label			
06485	W-LABELS-000442	W-LABELS-000446	00/00/2000	2000 Premarin Label			
06486			00/00/2001	2001 Premarin Label			
06487			00/00/2002	2002 Premarin Label			
06488			00/00/2003	2003 Premarin Label			
06489			00/00/2004	2004 Premarin Label			
06490			4/00/2005	2005 Premarin Label			
06491	W-LABELS-000001	W-LABELS-000008	00/00/1996	1996 Prempro Label			
06492	W-LABELS-000009	W-LABELS-000017	00/00/1997	1997 Prempro Label			
06493	W-LABELS-000018	W-LABELS-000025	00/00/1998	1998 Prempro Label			
06494	W-LABELS-000026	W-LABELS-000035	00/00/1999	1999 Prempro Label			
06495	W-LABELS-000036	W-LABELS-000042	00/00/2000	2000 Prempro Label			
06496			00/00/2001	2001 Prempro Label			
06497			00/00/2002	2002 Prempro Label			
06498			00/00/2002	2003 Prempro Label			
06499			00/00/2004	2004 Prempro Label			
06500	W-LABELS-000547	W-LABELS-000555	00/00/2005	2005 Prempro Label			
06501	ALIVJ002-001965	ALIVJ002-001967	8/6/1992	Letter from Morrison to Feather			
06502	BURLB013-001804	BURLB013-001807	1/11/1999	Letter from Peterson to Sonk; Depo: Robert Essner 6/29/06 EX 047:			
06503	CCC093-000061	CCC093-000064	8/5/1999	Menopause and Your Risk of Colon Cancer Patient Brochure			
06504	CONKJ003-000400	CONKJ003-000402	2/27/2001	Physician HRT Awareness and Use - Final Report			
06505	CONKJ003-000403	CONKJ003-000408	2/27/2001	ERT/HRT Consumer A&U Study Final Report			
06506	CONNS005-001254	CONNS005-001257	2/2/1998	BOE Ad - Message Track and Q&A			
06507	CONNS009-000833	CONNS009-00844		1992 article on FDA policy			
06508	CONNS019-000007	CONNS019-000008	6/10/1993	Letter from Rose to Beers			
06509	DAVIJ004-000928	DAVIJ004-000930		Remarks from David Colasante			
06510	DAVIJ004-004437	DAVIJ004-004495		Women, Cognition & Alzheimer's Disease			
06511	DEANE 241	DEANE 246		Antune and Stolley Reprint - Explanation of Table 5			
06512	DEANE 826	DEANE 827	4/00/1987	Premarin: A Long Term Treatment Strategy			
06513	DEANE 834	DEANE 836	12/00/1987	Premarin POA I			
06514	DEANE 927	DEANE 928	3/20/1989	Article			
06515	DEANE 977	DEANE 978	5/3/1989	District Sales and Training Conference Recap			
06516	DEANE 989	DEANE 990	8/8/1989	Memo to Wyeth Sales Reps			
06517	DEANE 1028	DEANE 1028	12/13/1989	Premarin Success Story			
06518	DEANE 1145	DEANE 1146	2/8/1990	Memo			
06519	DEANE 1202	DEANE 1205	12/18/1990	Memo			
06520	DEANE 1294	DEANE 1294	8/27/1992	Memo to Territory Representatives			
06521	DEANE 1515	DEANE 1518	7/2/1993	Memo			
06522	DEANE 1525	DEANE 1525	9/00/1993	New Premarin DTC Advertising Campaign			
06523	DEANE 1534	DEANE 1535	9/24/1993	Article			
06524	DEANE 1547	DEANE 1548	10/00/1993	Seasons Clipboard			
06525	DEANE 1596	DEANE 1604	11/00/1993	Pamphlet			
06526	DEANE 1687	DEANE 1688	5/6/1994	Memo			
06527	DEANE 2029	DEANE 2038	12/2/1988	Memo to Wyeth Field Sales Force			
06528	DUROJ018-000258	DUROJ018-000305	5/8/1998	PPT "Strategic Options"			
06529	DUROJ023-000888	DUROJ023-000947	1/19/1998	PPT "Consumer Segmentation Study"			
06530	DUROJ035-000223	DUROJ035-000239		Premarin Franchise Summary Marketing Plan			
06531	DUROJ035-000829	DUROJ035-000830	9/25/1997	Physician Perceptions of Breast Cancer and HRT; Depo: Jeanne Durocher 6/30/06 EX051: Memo from Alfonsi			
06532	DUROJ037-000025	DUROJ037-000027		PPT "Grow Market: ERT/HRT"			
06533	DUROJ037-000271	DUROJ037-000314		ERT/HRT Franchise Three Year Strategic Plan			
06534	DUROJ037-000919	DUROJ037-000936		PPT "Premarin"			
06535	DUROJ039-000256	DUROJ039-000260	9/4/1997	Raloxifene War Games Final Report			
06536	DUROJ041-002116	DUROJ041-002119	10/22/1998	Nurse Practitioner Estrogen/Hormone Replacement Study			
06537	FARAN002-002334	FARAN002-002335		Premarin Market Share 1976-1990			
06538	FARAN024-034691	FARAN024-034692	5/5/1998	Market Research Proposal			
06539	FARAN024-034930	FARAN024-034930		Premarin Brand Image			
06540	FARAN024-039648	FARAN024-039649	11/12/1997	Market Research Proposal			
06541	FARAN024-041076	FARAN024-041077	1/12/1998	Market Research Proposal			
06542	FARAN025-015185	FARAN025-015186	3/3/1998	Market Research Proposal			
06543	FARAN025-028320	FARAN025-028322	11/5/1999	Internal Memo from Johansen			
06544	FISHG004-000542	FISHG004-000546	9/28/2001	Memo to DSM Management Board			
06545	GOLDG004-000225	GOLDG004-000240		Premarin Family DTC Tactics 2000			
06546	HENRL001-001108	HENRL001-001109	9/16/1999	Report of Body of Evidence Development Research			
06547	HENRL005-001308	HENRL005-001308	11/11/1998	Internal Memo to Sales Force Managers			
06548	HENRL006-000618	HENRL006-000625	12/3/1997	FDA Guidance for industry-supported Scientific and Education Activities			
06549	KUSIV203-002042	KUSIV203-002353	9/4/2002	ERT/HRT Update - Presentation			
06550	LAWT022-009719	LAWT022-009720	7/10/2002	WSJ Article "Wyeth CEO: Concerned But Hopeful"			
06551	LAWT022-036537	LAWT022-036538	9/18/2001	Todd Law Accomplishments			
06552	LEVIG002-005125	LEVIG002-005126		Letter from Wendy			
06553	LUDMG003-000376	LUDMG003-0000378	9/10/1997	Breast Cancer Q&A Research Final Report			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06554	MAHAJ007-000654	MAHAJ007-000654	5/5/1997	FDA contact Conjugated Estrogens			
06555	MAHAJ012-000291	MAHAJ012-000304	1/15/1996	Internal Weyth Memo			
06556	MAHAJ016-000216	MAHAJ016-000224	00/00/2000	Essner speech			
06557	MKTAR078-001238	MKTAR078-001245	11/12/1998	Physician HRT Awareness and Use - Final Report			
06558	MMSVC001-000001	MMSVC001-000012	4/2/1995	Essner Prempro Launch Speech Opening			
06559	MMSVC001-000013	MMSVC001-000018	4/4/1995	Essner Prempro Launch Speech Closing			
06560	PANAA025-001462	PANAA025-001462	8/8/1989	Letter from The Rowland Company			
06561	PANAA027-000893	PANAA027-000894		Legal Implications			
06562	PANAA027-000895	PANAA027-000895		Protocol			
06563	ROSSC034-000357	ROSSC034-000358	7/14/1998	Letter from Stockbridge to Sonk			
06564	ROSSC034-001102	ROSSC034-001104	5/20/1998	Letter from Stockbridge to Sonk			
06565	ROSSC036-0001923	ROSSC036-0001924	3/24/1992	Wyeth Internal Memo regarding FDA meeting			
06566	SINAM002-000871	SINAM002-000872	11/18/1993	RM Conference Call Outline			
06567	SINAM002-000873	SINAM002-000876	12/3/1993	Defend the brand program			
06568	SINAM002-000877	SINAM002-000878		Facsimile			
06569	SINAM010-000033	SINAM010-00047	2/2/1997	Smith Cox Speech			
06570	SOLOJ022-003052	SOLOJ022-003096		ERT/HRT Franchise			
06571	SOLOJ025-000437	SOLOJ025-000439	12/14/1993	Letter from James Thomson to Nancy Driver			
06572	SONKJ017-000360	SONKJ017-000417	1/00/1997	Premarin White Paper			
06573	SONKJ019-000305	SONKJ019-000306	4/30/1998	Contact Report Premarin			
06574	SONKJ030-000476	SONKJ030-000477	1/14/1998	Summary of FDA Advisory Committee Meeting			
06575	SONKJ030-001528	SONKJ030-001531	11/18/1999	Internal Correspondence from Joseph Sonk			
06576	SONKJ030-001562	SONKJ030-001564	7/31/1997	Letter from Sonk to Rarick			
06577	SONKJ030-003169	SONKJ030-003173		Draft List of Committee and Chairs			
06578	SONKJ030-003427	SONKJ030-003427		Memo to Robert Essner from Bathish			
06579	STRIS016-008909	STRIS016-009064	9/4/2002	ERT/HRT Update - Presentation			
06580	W-MCL004-01421	W-MCL004-1423	11/3/1989	Letter from Goldzieher to Bergkvist			
06581	W-MDL04782-00009301	W-MDL04782-00009302	6/27/1985	Ogen Promotion Memo			
06582	W-MDL04782-00033523	W-MDL04782-00033526		Narrative of Action Taken			
06583	W-MDL04782-00035765	W-MDL04782-00035769	4/16/1991	Letter from Victoria to Feather			
06584	W-MDL04782-00094079	W-MDL-4782-00094081	1/13/1998	FDA Contact			
06585	W-MDL04782-00095886	W-MDL04782-00095889	11/19/1998	Conjugated Estrogens Standards FDA Contact			
06586	W-MDL527-00039785	W-MDL527-00039791	2/22/1999	Meeting Minutes			
06587	W-MDL527-00039792	W-MDL527-00039798	2/22/1999	Memorandum of Meeting			
06588	SALESTR001-000113	SALESTR001-000155		Training Manual- Estrogen Replacement Therapy			
06589	SALESTR001-000157	SALESTR001-000207	00/00/1995	Training Manual- Hormone Replacement Therapy			
06590	SALESTR001-000209	SALESTR001-000236	00/00/1995	Training Manual- Prempro & Premphase; Lawrence Kessler 8/28/06 DEPO EX 001; Product Training Manual; Alice Perrone 8/30/06 DEPO EX 003; Product Training Manual			
06591	SALESTR001-000261	SALESTR001-000289	00/00/1996	Training Manual- ERT/HRT and Breast Cancer Risk			
06592	SALESTR001-000290	SALESTR001-000317	2/00/1998	Training Manual- ERT/HRT and Breast Cancer Incidence, Detection and Mortality			
06593	SALESTR001-000438	SALESTR001-000471		Training Manual- Cardiovascular Disease/ Lipids Backgrounder			
06594	SALESTR001-001707	SALESTR001-001741	7/00/1990	Training Manual- Osteoporosis			
06595	SALESTR001-001743	SALESTR001-001773	8/00/1999	Memo- Premarin			
06596	CONNS005-001254	CONNS005-001257	2/2/1998				
06597	SALESTR002-000582	SALESTR002-000589		Training Guide and Notes			
06598	SALESTR002-000600	SALESTR002-000633		PPT- Prempro/Premphase			
06599	SALESTR002-000714	SALESTR002-000755		Tutorial- Prempro/Premphase			
06600	SALESTR002-000796	SALESTR002-000954	3/16/2001	Premia Training System			
06601	SALESTR002-000955	SALESTR002-001193	7/30/2001	Training System Proof- Prempro LD			
06602	SALESTR002-001291	SALESTR002-001509	10/23/2001	Approved Proof Sales Training Learning System Module 1			
06603	SALESTR002-001521	SALESTR002-001695	5/25/2001	Proof of Fertility & Sterility			
06604	SALESTR002-001702	SALESTR002-001799		Training Tutorial- Small Wonder Module 2			
06605	SALESTR002-001986	SALESTR002-002155	4/25/2001	Premia Training System- Prempro			
06606	SALESTR003-000348	SALESTR003-000365		Training Manual- Promotion Intervention			
06607	SALESTR003-000366	SALESTR003-000370		Training Manual- Driving Consumer Demand			
06608	SALESTR003-000466	SALESTR003-000473		Training Manual- Marketing Workshop			
06609	SALESTR003-000486	SALESTR003-000493	12/00/1999	Training Manual- Leaders' Guide			
06610	SALESTR003-000495	SALESTR003-000529		PPT- Promoting Intervention			
06611	SALESTR003-000535	SALESTR003-000737	00/00/1988	Training Manual- Premarin Family			
06612	SALESTR003-000769	SALESTR003-000770	2/00/1998	Training Guide- Answers to Some Questions			
06613	SALESTR004-000004	SALESTR004-000050	00/00/1996	Training Manual- Osteoporosis: Diagnosis, Treatment and Monitoring			
06614	SALESTR004-000308	SALESTR004-000327	12/00/1988	Training Manual- Cardiovascular Changes after Menopause			
06615	SALESTR004-000328	SALESTR004-000332		Training Manual- You're the key to improving			
06616	SALESTR004-000333	SALESTR004-000348	7/00/1991	A Doctors Guide for Women at Menopause			
06617	SALESTR004-000391	SALESTR004-000477	00/00/1995	PPT- Hormone Replacement Therapy Benefits and Risks			
06618	SALESTR004-000532	SALESTR004-000551	12/00/1992	Training Manual- Instructor's Guide			
06619	SALESTR004-001106	SALESTR004-001167	5/3/1996	M.A.I.L.- Estrogen Replacement Therapy Issues			
06620	SALESTR004-001203	SALESTR004-001209	00/00/1995	Women's Health Journal- Women and Breast Cancer			
06621	SALESTR004-001216	SALESTR004-001216	7/15/1995	Article HRT's Weak Breast Cancer Link			
06622	SALESTR004-001237	SALESTR004-001243	7/12/1995	Article- JAMA Combined Estrogen and Progestin HRT			
06623	SALESTR004-001253	SALESTR004-001254	3/00/1996	M.A.I.L.- Premarin			
06624	SALESTR004-001287	SALESTR004-001293	8/00/1995	Article- Estrogen and Coronary Artery Disease in Postmenopausal Women			
06625	SALESTR004-001494	SALESTR004-001528		Training Manual- The Economics of Hormone Replacement Therapy			
06626	SALESTR004-001529	SALESTR004-001532	10/00/1997	Training Manual- Addressing Patients Questions about ERT and Breast Cancer			
06627	SALESTR004-001548	SALESTR004-001552		Training Manual- You're the key to improving			
06628	SALESTR004-001569	SALESTR004-001572	7/21/1989	Article - Estrogen Replacement Therapy			
06629	SALESTR004-001577	SALESTR004-001583		Patient Information- Preparing for Menopause			
06630	SALESTR004-001615	SALESTR004-001645	9/00/1998	Patient Information- Discover more about Menopause, Estrogen and HRT			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06631	SALESTR004-001661	SALESTR004-001691	5/00/1992	Brochure- Osteoporosis and Estrogen Deprivation			
06632	SALESTR005-000032	SALESTR005-000033	12/15/1992	Clinical Guidelines- Guidelines for Counseling Postmenopausal Women			
06633	SALESTR005-000153	SALESTR005-000156	8/00/1998	Results of the Heart Estrogen/progestin Replacement Study			
06634	SALESTR005-000157	SALESTR005-000162		HERS Backgrounder			
06635	SALESTR005-000163	SALESTR005-000165		Heart Estrogen/progestin Replacement Study FAQ's			
06636	SALESTR007-000278	SALESTR007-000297	5/00/1998	Training Manual-Therapeutic Options in Hormone Replacement Therapy			
06637	SALESTR007-000945	SALESTR007-000979	00/00/1995	Training Manual- Women's Health Issues and Hormones			
06638	SALESTR007-001033	SALESTR007-001082	00/00/1995	Training Manual- Prempro/Premphase Product Training			
06639	SALESTR007-001118	SALESTR007-001173	00/00/1995	Training Manual- Marketing Strategy and Selling Issues			
06640	SALESTR007-001189	SALESTR007-001202		Patient Information- Introducing the first and only hormone replacement therapy....			
06641	SALESTR007-001216	SALESTR007-001239		Training Manual- Premarin Family Book 3			
06642	SALESTR007-001583	SALESTR007-001590	10/00/1997	Article- Latest news in Geriatric medicine			
06643	SALESTR007-001670	SALESTR007-001678		Training Manual- Breast Cancer- Physician			
06644	SALESTR007-001679	SALESTR007-001698		Training Manual- Premarin: Sales Issues and Competitive Information			
06645	SALESTR007-001729	SALESTR007-001738		Training Manual- Endometrial Cancer			
06646	SALESTR007-001880	SALESTR007-001882		Training Manual- The Meaning of Relative Risk			
06647	YAVUE012-001163	YAVUE012-001187	10/15/2002	Wyeth draft policy on sales and marketing practices			
06648			1/16/2006	Depo: Sendi, Mary 5/19/06 EX 001: Curriculum vitae			
06649	SENDM015-008848	SENDM015-008875		Depo: Sendi, Mary 5/19/06 EX 002: The Global Medical Communications Department			
06650	SENDM015-008374	SENDM015-008439	6/4/2002	Depo: Sendi, Mary 5/19/06 EX 003: Global Publication Plan 2002 Bazedoxifene acetate			
06651	DWRITE065923	DWRITE065941	5/15/1997	Depo: Sendi, Mary 5/19/06 EX 004 & Jana, Bernadette 1/03/2008 EX 5: Premarin Publication Program			
06652	DWRITE065952	DWRITE065967	11/20/1998	Depo: Sendi, Mary 5/19/06 EX 005 & Janas, Bernadette 1/03/2008 EX 6: Premarin Family of Products Study Management Plan			
06653	SENDM015-005150	SENDM015-005152		Depo: Sendi, Mary 5/19/06 EX 006: WHY Therapy Area Development Plan			
06654	SENDM008-001358	SENDM008-001359	5/20/2002	Depo: Sendi, Mary 5/19/06 EX 007: Strategic Publications Development Meeting			
06655	SENDM008-001118		4/24/2002	Depo: Sendi, Mary 5/19/06 EX 008: Strategic Publication Plan Tracking Report - Papers Proposed for 2002			
06656	SENDM008-001116		4/24/2002	Depo: Sendi, Mary 5/19/06 EX 009: Strategic Publication Plan Tracking Report - Papers Proposed for 2002			
06657	SENDM009-000223	SENDM009-000224	7/26/2002	Depo: Sendi, Mary 5/19/06 EX 010: Meeting Minutes			
06658	SENDM014-005251	SENDM014-005254	9/20/2002	Depo: Sendi, Mary 5/19/06 EX 011: Meeting Minutes			
06659	SENDM015-008226	SENDM015-008226	6/10/2002	Depo: Sendi, Mary 5/19/06 EX 012: Email from Durocher			
06660	SENDM009-000225	SENDM009-000235	9/3/2002	Depo: Sendi, Mary 5/19/06 EX 013: Preclinical and Clinical Experience with Trimegestone			
06661	SENDM008-001222	SENDM008-001247		Depo: Sendi, Mary 5/19/06 EX 014: The Impact of Timing of Initiation on the CV Effects of Postmenopausal HRT			
06662	SENDM008-001551	SENDM008-001576		Depo: Sendi, Mary 5/19/06 EX 015: Estrogens and the Skin			
06663	SENDM008-001577	SENDM008-001586		Depo: Sendi, Mary 5/19/06 EX 016: The Role of HRT in Preventing Early Bone Loss			
06664	SENDM008-001346	SENDM008-001357		Depo: Sendi, Mary 5/19/06 EX 017: The Effects of Tibolone on Breast Tissue			
06665	SENDM008-001363	SENDM008-001387		Depo: Sendi, Mary 5/19/06 EX 018: The Role of HRT in Preventing Early Bone Loss			
06666	SENDM008-001321	SENDM008-001344		Depo: Sendi, Mary 5/19/06 EX 019: Comparative Vascular Effects of HRT and Raloxifene in Women at Increased CV Risk			
06667	SENDM008-001248	SENDM008-001253	5/20/2002	Depo: Sendi, Mary 5/19/06 EX 020: Metabolic Effects of Menopausal Therapies			
06668	SENDM008-001267	SENDM008-001291		Depo: Sendi, Mary 5/19/06 EX 021: Sexuality at Menopause			
06669	SENDM008-001524	SENDM008-001550	3/27/2002	Depo: Sendi, Mary 5/19/06 EX 022: Menopause, Sexuality and HRT			
06670	SENDM008-001140	SENDM008-001162		Depo: Sendi, Mary 5/19/06 EX 023: Mammographic Breast Density and HT			
06671	SENDM008-001173	SENDM008-001191		Depo: Sendi, Mary 5/19/06 EX 024: Arterial Versus Venous Effects of Estrogen			
06672	SENDM009-000283	SENDM009-000292	6/27/2002	Depo: Sendi, Mary 5/19/06 EX 025: 2002 Media Outreach			
06673	SENDM008-001163	SENDM008-001164	3/28/2002	Depo: Sendi, Mary 5/19/06 EX 026: Strategic Publications Development Meeting			
06674	SENDM015-008067	SENDM015-008067		Depo: Sendi, Mary 5/19/06 EX 027: M.A.I.L. Prograqm Global Medical Communications Product Responsibility List			
06675	SENDM015-003972	SENDM015-003972		Depo: Sendi, Mary 5/19/06 EX 028: M.A.I.L. Target Sales Force			
06676	SENDM008-001111	SENDM008-001114	4/24/2002	Depo: Sendi, Mary 5/19/06 EX 029: Strategic Publication Plan Tracking Report			
06677	SENDM009-000306	SENDM009-000310		Depo: Sendi, Mary 5/19/06 EX 030: Premarin, Prempro, prephase Standard Letter Index			
06678			9/10/1999	Depo: Sendi, Mary 5/19/06 EX 035: Approved RPI form Reference No.161027			
06679			9/10/1999	Depo: Sendi, Mary 5/19/06 EX 036: Approved RPI form, JH-82499-15499			
06680			9/10/1999	Depo: Sendi, Mary 5/19/06 EX 037: Approved RPI Form, TG-62499-16015			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06681			4/12/1996	Depo: Sendi, Mary 5/19/06 EX 038: Madira Intake Form, DE-4996-10190			
06682			7/25/1996	Depo: Sendi, Mary 5/19/06 EX 039: Madira RPI Intake Form, HF-72296-16410			
06683			10/21/1997	Depo: Sendi, Mary 5/19/06 EX 040: Madira Intake Form, DS-102197-154630			
06684			8/3/1998	Depo: Sendi, Mary 5/19/06 EX 041: Madira Approved RPI Form, MH-72898-113818			
06685			3/18/1999	Depo: Sendi, Mary 5/19/06 EX 042: Madira Approved RPI Form, MP-12988-111955			
06686			1/17/1997	Depo: Sendi, Mary 5/19/06 EX 043: Madira Intake Form, DE-11697-113626			
06687			10/26/1998	Depo: Sendi, Mary 5/19/06 EX 044: Madira Approved RPI Form, MH-102198-12365			
06688			7/27/1999	Depo: Sendi, Mary 5/19/06 EX 045: Madira Intake Form, CF-72799-124642			
06689			9/17/1999	Depo: Sendi, Mary 5/19/06 EX 046: Madira Approved RPI Form, MP-52599-103755			
06690			9/16/1999	Depo: Sendi, Mary 5/19/06 EX 047: Madi+F166ra Approved RPI Form, TG-72299-1566+F19851			
06691			9/30/1998	Depo: Sendi, Mary 5/19/06 EX 048: Madira Approved RPI Form, MP-92998-11827			
06692			8/13/1999	Depo: Sendi, Mary 5/19/06 EX 049: Madira Approved RPI Form, PS-8699-93531			
06693			10/30/1997	Depo: Sendi, Mary 5/19/06 EX 050: Madira Intake Form, DV-103097-10813			
06694			11/23/1998	Depo: Sendi, Mary 5/19/06 EX 051: Madira Approved RPI Form, MH-112398-11943			
06695			6/21/1999	Depo: Sendi, Mary 5/19/06 EX 052: Madira Approved RPI Form, DL-61799-74535			
06696			5/24/1999	Depo: Sendi, Mary 5/19/06 EX 053: Madira Approved RPI Form, MP-52099-121426			
06697			3/3/1999	Depo: Sendi, Mary 5/19/06 EX 054: Madira Approved RPI Form, MP-3299-84416			
06698			5/13/1996	Depo: Sendi, Mary 5/19/06 EX 055: Madira Intake Form, KD-51096-152620			
06699			8/28/1998	Depo: Sendi, Mary 5/19/06 EX 056: Madira Approved RPI Form, MP-82798-154155			
06700			5/13/1999	Depo: Sendi, Mary 5/19/06 EX 057: Madira Approved RPI Form, MP-51199-14112			
06701			12/23/1998	Depo: Sendi, Mary 5/19/06 EX 058: Madira Intake Form, MP-122398-83126			
06702	ROSSC006-001118	ROSSC006-001121	1/00/1998	Depo: Sendi, Mary 5/19/06 EX 059: Menopause and Your Risk of Osteoporosis			
06703	CHOOM006-000106	CHOOM006-000109	1/00/1998	Depo: Sendi, Mary 5/19/06 EX 060: Treatment Options for the Symptoms of Menopause			
06704	ROSSC006-001137	ROSSC006-001141	1/00/1998	Depo: Sendi, Mary 5/19/06 EX 061: Menopause and Sexuality			
06705				Depo: Sendi, Mary 5/19/06 EX 062: Package insert			
06706			00/00/1998	Depo: Sendi, Mary 5/19/96 EX 063: 1998 PDR Excerpt			
06707	MARRA009-000047	MARRA009-000052		Depo: Marren, Amy 5/25/06 EX 001: Organization chart			
06708				Depo: Marren, Amy 5/25/06 EX 002: Printout of Access database windows			
06709			12/23/1998	Depo: Marren, Amy 5/25/06 EX 003: Madira Intake Form, MP-122398-83126			
06710	ROSSC006-001118	ROSSC006-001121	1/00/1998	Depo: Marren, Amy 5/25/06 EX 004: Menopause and Your Risk of Osteoporosis			
06711	MARRA014-024412	MARRA014-024417	5/18/2000	Depo: Marren, Amy 5/25/06 EX 005: Health Policy Report - Uneasy Alliance			
06712	MARRA014-001886		8/19/2002	Depo: Marren, Amy 5/25/06 EX 006: Email from Marren to Stromelo			
06713	MARRA014-016190	MARRA014-016201	5/17/2002	Depo: Marren, Amy 5/25/06 EX 007: Minutes from Menopausal Health Publication Management Meeting			
06714	MARRA014-025415	MARRA014-025423	12/12/2001	Depo: Marren, Amy 5/25/06 EX 008: Minutes from Menopausal Health Publication Management Meeting			
06715	MARRA209-017913	MARRA209-017976		Depo: Marren, Amy 5/25/06 EX 009: Comparative Review of the Risks and Benefits of HRT Regimens			
06716	MARRA209-017912	MARRA209-017912	8/20/2003	Depo: Marren, Amy 5/25/06 EX 010: Email from Marren to Sendi			
06717	MARRA014-012234	MARRA014-012234	11/20/2002	Depo: Marren, Amy 5/25/06 EX 011: GMA WHC Assignments			
06718	MARRA014-001887	MARRA014-001887	8/19/2002	Depo: Marren, Amy 5/25/06 EX 012: Email from Mittleman to Marren			
06719	MARRA014-001888	MARRA014-001930		Depo: Marren, Amy 5/25/06 EX 013: The Role of HRT in the Prevention of Postmenopausal Heart Disease			
06720	DWRITE068301	DWRITE068304	1/11/2005	Depo: Marren, Amy 5/25/06 EX 014: Publication Plan Tracking Report			
06721	DWRITE003278	DWRITE003278	12/4/2000	Depo: Marren, Amy 5/25/06 EX 015: Letter from Mittleman to Wesselcouch			
06722	MARRA014-001931	MARRA014-001953		Depo: Marren, Amy 5/25/06 EX 016: HRT in the Prevention and Treatment of Atherosclerosis			
06723	HRT MED LIT 0372001	HRT MED LIT 0372006	00/00/2000	Depo: Marren, Amy 5/25/06 EX 017: Article			
06724	DWRITE069746	DWRITE 069747		Depo: Marren, Amy 5/25/06 EX 018: Manuscript Outline			
06725	DWRITE066519	DWRITE066519	7/7/2000	Depo: Marren, Amy 5/25/06 EX 019: Letter from Mittleman to Tozzi			
06726			5/16/2003	Depo: Marren, Amy 5/25/06 EX 020: Letter from Wang to Adlaka			
06727			5/15/2003	Depo: Marren, Amy 5/25/06 EX 021: Letter from Wang to Wachen			
06728			5/15/2003	Depo: Marren, Amy 5/25/06 EX 022: Correspondence from Global Medical Affairs			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06729			11/10/1998	Depo: Marren, Amy 5/25/06 EX 023: Review "Is there an association between hrt and breast cancer?"			
06730	DWRITE068302	DWRITE068302	1/11/2005	Depo: Marren, Amy 5/25/06 EX 024: Publication Plan Tracking Report; Depo: Marren, Amy 5/25/06 EX 025:			
06731	DWRITE068320	DWRITE068320	1/11/2005	Depo: Marren, Amy 5/25/06 EX 025:			
06732			4/14/2006	Depo: Marren, Amy 5/25/06 EX 026: CD-ROM "Designations"			
06733			7/1/2002	Depo: Marren, Amy 5/25/06 EX 027: Screen Shot			
06734			5/25/2006	Depo: Marren, Amy 5/25/06 EX 028: Document			
06735	DWRITE068302	DWRITE068302	1/11/2005	Depo: Marren, Amy 5/25/06 EX 029: Publication Plan Tracking Report; Depo: Marren, Amy 5/25/06 EX 038: Publication Plan Tracking Report; Depo: Weber, Margaret 6/21/06 EX 063: Publication Plan Tracking Report			
06736	DWRITE068322	DWRITE068322	1/11/2005	Depo: Marren, Amy 5/25/06 EX 030: Document			
06737	MARTN010-003763	MARTN010-003764	12/5/2000	Depo: Marren, Amy 5/25/06 EX 032: Strategic Publications Deveopment Meeting Recap			
06738			10/18/2001	Depo: Marren, Amy 5/25/06 EX 033: Screen Shots			
06739			5/25/2006	Depo: Marren, Amy 5/25/06 EX 034: Documen t+F248			
06740			00/00/2001	Depo: Marren, Amy 5/25/06 EX 035: Review "The Use of HRT in Postmenopausal Women with Type 2 Diabetes"			
06741	DWRITE068308	DWRITE068308	6/23/1998	Depo: Marren, Amy 5/25/06 EX 036: Premarin Publication Plan Meeting Recap; Depo: Weber, Margaret 6/21/06 EX 062: Premarin Publication Plan Meeting Recap			
06742			4/25/2006	Depo: Marren, Amy 5/25/06 EX 037: Abstract "The Role of HRT in the Management of Type 2 Diabetes in Postmenopausal Women"			
06743	DWRITE068302	DWRITE068302	1/11/2005	Depo: Marren, Amy 5/25/06 EX 038: Publication Plan Tracking Report			
06744	SOLOJ027-023276	SOLOJ027-023276	5/24/2002	Depo: Marren, Amy 5/25/06 EX 039: Publication Plan Tracking Report - Completed Papers			
06745	BURKM006-000507	BURKM006-000549	8/8/2000	Depo: Fontaine, Leander 5/30/06 EX 018: Global Medical Labeling Decision-Making and Implementation for Marketed Products Procedure			
06746	ROSSC039-001916	ROSSC039-001918	9/00/2000	Depo: Fontaine, Leander 5/30/06 EX 019: Wyeth Core Labeling Teams Charter			
06747	ROSSC008-000770	ROSSC003-000782	5/00/2001	Depo: Fontaine, Leander 5/30/06 EX 020: CEE with MPA Core Data Sheet Version 2.0			
06748				Depo: Fontaine, Leander 5/30/06 EX 021: 21 CFR 201, 314, 601			
06749	DUROJ024-001212	DUROJ024-001213	4/00/2000	Depo: Fontaine, Leander 5/30/06 EX 022: WHI HRT Update			
06750	HUNTH006-000529		4/28/2000	Depo: Fontaine, Leander 5/30/06 EX 023: Labeling Executive Committee Meeting Minutes			
06751	W-MDL04782-00128945	W-MDL04782-00128978	7/12/2000	Depo: Fontaine, Leander 5/30/06 EX 024: Letter "Premarin NDA 04-782/S-114"			
06752	ROSSC007-000141	ROXXC007-000142		Depo: Fontaine, Leander 5/30/06 EX 025: WHI HRT Update Excerpt			
06753	LECMI001-000043		7/17/2001	Depo: Fontaine, Leander 5/30/06 EX 026: Labeling Executive Committee Meeting Minutes			
06754	W-MDL527-00043063	W-MDL527-00043067	9/7/2001	Depo: Fontaine, Leander 5/30/06 EX 027: CBE Letter			
06755	W-MDL527-00043449	W-MDL527-00043464	10/26/2001	Depo: Fontaine, Leander 5/30/06 EX 028: CBE Letter			
06756	DELCA007-000060	DELCA007-000062	1/29/2002	Depo: Fontaine, Leander 5/30/06 EX 029: Revised US Direction Circular			
06757	W-MDL04782-00078856	W-MDL04782-00078860	8/30/2001	Depo: Fontaine, Leander 5/30/06 EX 030: CBE Letter			
06758	W-MDL04782-00079054	W-MDL04782-00079081	10/26/2001	Depo: Fontaine, Leander 5/30/06 EX 031: CBE Letter			
06759	W-MDL527-00044496	W-MDL527-00044533	6/7/2002	Depo: Fontaine, Leander 5/30/06 EX 032: Letter			
06760	W-MDL527-00040692	W-MDL527-00040693	8/10/2000	Depo: Fontaine, Leander 5/30/06 EX 033 & Allen, Susan 4/24/2007 EX 19: Letter			
06761	ROSSC001-000355	ROSSC001-000366	4/11/2000	Depo: Fontaine, Leander 5/30/06 EX 034: Letter			
06762	LECMI001-000039		10/20/2000	Depo: Fontaine, Leander 5/30/06 EX 035: Labeling Executive Committee Meeting Minutes			
06763	W-MDL527-00041128	W-MDL527-00041156	1/19/2001	Depo: Fontaine, Leander 5/30/06 EX 036: CBE Letter			
06764	W-MDL527-00041214	W-MDL527-00041271	1/22/2001	Depo: Fontaine, Leander 5/30/06 EX 037: CBE Letter			
06765	ROSSC003-001812	ROSSC003-001841	3/6/2001	Depo: Fontaine, Leander 5/30/06 EX 038: Letter			
06766	ROSSC003-001843	ROSSC003-001875		Depo: Fontaine, Leander 5/30/06 EX 039: Letter			
06767	W-MDL527-00042665	W-MDL527-00042877	5/17/2001	Depo: Fontaine, Leander 5/30/06 EX 040: Letter			
06768	W-DDL-0000058	W-DDL-0000068	7/00/2002	Depo: Fontaine, Leander 5/30/06 EX 041:			
06769	W-MDL527-00044657	W-MDL527-00044683	7/19/2002	Depo: Fontaine, Leander 5/30/06 EX 042: letter			
06770	W-MDL527-00045485	W-MDL527-00045489	8/23/2002	Depo: Fontaine, Leander 5/30/06 EX 043: Letter			
06771	W-MDL04782-00138923	W-MDL04782-00139157	8/23/2002	Depo: Fontaine, Leander 5/30/06 EX 044: Letter			
06772	MOORK004-000561	MOORK004-000613	8/28/2002	Depo: Fontaine, Leander 5/30/06 EX 045: Letter			
06773	LECMI001-000041		3/16/2001	Depo: Fontaine, Leander 5/30/06 EX 046: Labeling Executive Committee Meeting Minutes			
06774	GOLDG001-001435	GOLDG001-001499		Depo: Ryan, John 5/31/06 EX 046: Policy 511			
06775			00/00/2002	Depo: Ryan, John 5/31/06 EX 047: PDR excerpts			
06776				Depo: Ryan, John 5/31/06 EX 048: Transcript of Bob Essner speech			
06777	SOLOJ027-023007	SOLOJ027-023016		Depo: Ryan, John 5/31/06 EX 049: Box Warning on Prempro/Premphase			
06778			12/2/1988	Depo: Ryan, John 5/31/06 EX 050: Letter			
06779			2/8/1990	Depo: Ryan, John 5/31/06 EX 051: Letter			
06780			4/00/1987	Depo: Ryan, John 5/31/06 EX 052: Premarin: A Long-Term Treatment Strategy			
06781			3/20/1989	Depo: Ryan, John 5/31/06 EX 053: Memo			
06782			9/00/1993	Depo: Ryan, John 5/31/06 EX 054: Memo			
06783			1/6/1995	Depo: Ryan, John 5/31/06 EX 055: New Premarin DTC Advertising Campaign			
06784			12/13/1989	Depo: Ryan, John 5/31/06 EX 056: Premarin Success Stories			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06785				Depo: Ryan, John 5/31/06 EX 057: Sales Call Notes			
06786				Depo: Ryan, John 5/31/06 EX 058: Sales Call Notes			
06787	SOLOJ027-022996		6/28/2002	Depo: Ryan, John 5/31/06 EX 059: Email			
06788			5/5/2006	Depo: Poussot, Bernard 5/31/06 EX 001: NOD			
06789			5/00/2006	Depo: Poussot, Bernard 5/31/06 EX 002: Executive biography			
06790			5/5/2006	Depo: Poussot, Bernard 5/31/06 EX 003: WHI Study			
06791	LEVIG002-005135	LEVIG002-005140	5/13/2003	Depo: Poussot, Bernard 5/31/06 EX 004: Remarks to Society of Women's Health Society			
06792	KERZC009-018718	KERZC009-018719	10/7/2002	Depo: Poussot, Bernard 5/31/06 EX 005: Email from Brown to Kerzner			
06793	POUSB004-000382		6/3/2003	Depo: Poussot, Bernard 5/31/06 EX 006: Email from Lyttle			
06794	DUROJ006-000938		9/5/2001	Depo: Poussot, Bernard 5/31/06 EX 007: Email from Durocher			
06795				Depo: Poussot, Bernard 5/31/06 EX 008: Premarin Product Informatin			
06796	POUSB003-000369			Depo: Poussot, Bernard 5/31/06 EX 009: Handwritten note			
06797	POUSB003-000370	POUSB003-000415	12/2/2002	Depo: Poussot, Bernard 5/31/06 EX 010: Menopausal Franchise Strategic Product Review Presentation			
06798			00/00/2002	Depo: Poussot, Bernard 5/31/06 EX 011: Premarin Product information			
06799	SONKJ019-000355		3/26/1998	Depo: Poussot, Bernard 5/31/06 EX 012: Internal memo from Victoria			
06800	BURRG007-009404		9/25/2002	Depo: Poussot, Bernard 5/31/06 EX 013: Email from Burr to Crow			
06801	WEBEM204-015447	WEBEM204-015462		Depo: Poussot, Bernard 5/31/06 EX 014: Wyeth Sales Training and Management Development			
06802	MARRA209-032687	MARRA209-032691	3/14/2003	Depo: Poussot, Bernard 5/31/06 EX 015: Premarin Media Highlights			
06803			3/13/2003	Depo: Poussot, Bernard 5/31/06 EX 016: Philadelphia Business Journal article			
06804	DEYMI030-000116		4/4/2001	Depo: Poussot, Bernard 5/31/06 EX 017: Email from Burlington to Poussot			
06805	DEYMI030-000117	DEYMI030-000122		Depo: Poussot, Bernard 5/31/06 EX 018: Handwritten letter from Dey to Poussot			
06806	STRIS206-000690	STRIS206-000692	1/28/2003	Depo: Poussot, Bernard 5/31/06 EX 019: AHP Finance Committee Authorizatio			
06807	MAHAJ017-003031	MAHAJ017-003032	12/2/2003	Depo: Poussot, Bernard 5/31/06 EX 020: Email from Sonk			
06808	POUSB003-000426	POUSB003-000458	8/15/2000	Depo: Poussot, Bernard 5/31/06 EX 021: Perspectives in ERT/HRT			
06809	CONKJ003-000150		2/7/2002	Depo: Poussot, Bernard 5/31/06 EX 022: Email from Petkus			
06810	Various	Various	1/10/2000	Depo: Poussot, Bernard 5/31/06 EX 023: Email from Hunter			
06811	POUSB003-000041	POUSB003-000042	8/8/2003	Depo: Poussot, Bernard 5/31/06 EX 024: News Release			
06812			4/00/2005	Depo: Minkin, Mary Jane 6/1/06 EX 001: Curriculum vitae			
06813			10/30/2003	Depo: Minkin, Mary Jane 6/1/06 EX 002: NAMS position statement			
06814				Depo: Minkin, Mary Jane 6/1/06 EX 003: Greendale/Cauley Chapter 6 Estrogens			
06815			2/13/2006	Depo: Minkin, Mary Jane 6/1/06 EX 004: CEE and Coronary Heart Disease			
06816			4/10/2006	Depo: Minkin, Mary Jane 6/1/06 EX 005: A Prospective Study of Female Hormone Use and Breast Cancer Among Black Women			
06817			4/17/2002	Depo: Minkin, Mary Jane 6/1/06 EX 006: Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women			
06818			8/21/2004	Depo: Minkin, Mary Jane 6/1/06 EX 007: Menopausal HT			
06819			1/18/2005	Depo: Minkin, Mary Jane 6/1/06 EX 008: Estrogens and the Skin			
06820				Depo: Minkin, Mary Jane 6/1/06 EX 009: Managing Menopausal Symptoms in 2005			
06821			5/00/2004	Depo: Minkin, Mary Jane 6/1/06 EX 010: Use of HRT after Treatment of Breast Cancer			
06822				Depo: Minkin, Mary Jane 6/1/06 EX 011: Considerations in the Choice of Oral v. Transdermal Hormone Therapy			
06823			10/24/2005	Depo: Minkin, Mary Jane 6/1/06 EX 012: Estrogen therapy back in the lab			
06824			00/00/1996	Depo: Minkin, Mary Jane 6/1/06 EX 013: 1996 PDR Excerpt			
06825			00/00/1998	Depo: Minkin, Mary Jane 6/1/06 EX 014: 1998 PDR Excerpt			
06826				Depo: Minkin, Mary Jane 6/1/06 EX 015: Handwritten notes			
06827			5/31/2006	Depo: Kopans, Daniel 6/7/06 EX 001: NOD			
06828			2/15/2006	Depo: Kopans, Daniel 6/7/06 EX 002: Kopans Expert Report (Generic)			
06829			4/6/2006	Depo: Kopans, Daniel 6/7/06 EX 003: Kopans Expert Report (Docker)			
06830				Depo: Kopans, Daniel 6/7/06 EX 004: Draft of First Report			
06831			2/15/2006	Depo: Kopans, Daniel 6/7/06 EX 005: Miscellaneous correspondence and emails			
06832			3/21/2006	Depo: Kopans, Daniel 6/7/06 EX 006: Index of Documents from Docker case			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06833	DUROJ027-000717	DUROJ027-000720	1/9/2001	Depo: Kopans, Daniel 6/7/06 EX 007: Talking points document			
06834			3/25/2005	Depo: Kopans, Daniel 6/7/06 EX 008: Erin Aiello article			
06835			8/5/1999	Depo: Kopans, Daniel 6/7/06 EX 009: Atkinson paper			
06836			12/8/1988	Depo: Kopans, Daniel 6/7/06 EX 010: Berkowitz paper			
06837			5/18/1989	Depo: Kopans, Daniel 6/7/06 EX 011: Berkowitz paper			
06838			5/3/1995	Depo: Kopans, Daniel 6/7/06 EX 012: Boyd paper, 1995			
06839			9/19/2002	Depo: Kopans, Daniel 6/7/06 EX 013: Boyd paper, 2002			
06840			00/00/2001	Depo: Kopans, Daniel 6/7/06 EX 014: Boyd paper, 2001			
06841			10/00/2005	Depo: Kopans, Daniel 6/7/06 EX 015: Boyd paper, 2005			
06842			7/25/2002	Depo: Kopans, Daniel 6/7/06 EX 016: Boyd paper, 2002			
06843			12/1998	Depo: Kopans, Daniel 6/7/06 EX 017: Boyd paper, 1998			
06844			9/00/2000	Depo: Kopans, Daniel 6/7/06 EX 018: Chow paper, 2000			
06845			3/27/2001	Depo: Kopans, Daniel 6/7/06 EX 019: Colourcl paper, 2001			
06846			7/24/2000	Depo: Kopans, Daniel 6/7/06 EX 020: El-Bastawissi paper			
06847			9/21/2005	Depo: Kopans, Daniel 6/7/06 EX 021: Greendale paper, 2005			
06848			00/00/1999	Depo: Kopans, Daniel 6/7/06 EX 022: Greendale paper, 1999			
06849			1/1/2003	Depo: Kopans, Daniel 6/7/06 EX 023: Greendale paper, 2003			
06850			00/00/1999	Depo: Kopans, Daniel 6/7/06 EX 024: Hofseth paper			
06851				Depo: Kopans, Daniel 6/7/06 EX 025: Kaufman paper			
06852			00/00/1998	Depo: Kopans, Daniel 6/7/06 EX 026: Dr. Kopans book Chapter 3			
06853			5/5/1999	Depo: Kopans, Daniel 6/7/06 EX 027: Lundswtrom paper			
06854			10/11/1996	Depo: Kopans, Daniel 6/7/06 EX 028: Marugg paper			
06855			4/1/1994	Depo: Kopans, Daniel 6/7/06 EX 029: McNicholas paper			
06856			4/13/2005	Depo: Kopans, Daniel 6/7/06 EX 030: Noh paper			
06857			10/13/1978	Depo: Kopans, Daniel 6/7/06 EX 031: Peck paper			
06858			1/10/2001	Depo: Kopans, Daniel 6/7/06 EX 032: Rutter paper			
06859			00/00/2000	Depo: Kopans, Daniel 6/7/06 EX 033: Stearns paper			
06860			1/00/1998	Depo: Kopans, Daniel 6/7/06 EX 034: Ursin paper, 1998			
06861			6/8/2005	Depo: Kopans, Daniel 6/7/06 EX 035: Ursin paper, 2005			
06862			7/00/2005	Depo: Kopans, Daniel 6/7/06 EX 036: Yaffe paper			
06863			4/19/2006	Depo: Brenner, Leonard 6/7/06 EX 001: Subpoena			
06864	W-MDL017-01461	W-MDL017-01464	4/00/1968	Depo: Brenner, Leonard 6/7/06 EX 002: WRF Bulletin April 1968 Vol. 2 No.2			
06865	W-MDL017-01457	W-MDL017-01460	00/00/1968	Depo: Brenner, Leonard 6/7/06 EX 003: The Medical Folio Summer 1968			
06866			8/15/1966	Depo: Brenner, Leonard 6/7/06 EX 004: Washington Post article			
06867			1/13/1967	Depo: Brenner, Leonard 6/7/06 EX 005: Washington Post article			
06868			11/16/1966	Depo: Brenner, Leonard 6/7/06 EX 006: Washington Post article			
06869				Depo: Brenner, Leonard 6/7/06 EX 007: Menopause pamphlet excerpt			
06870			7/8/1963	Depo: Brenner, Leonard 6/7/06 EX 008: Certificate of Incorporation and Certificate of Name Change			
06871			6/2/2006	Depo: Brenner, Leonard 6/7/06 EX 009: NY Dept of State Certification Letter			
06872				Depo: Brenner, Leonard 6/7/06 EX 010: Washington Post article			
06873	W-MCL017-01465	W-MCL017-01466		Depo: Brenner, Leonard 6/7/06 EX 011: brochure excerpt			
06874			6/2/2006	Depo: Brenner, Leonard 6/7/06 EX 012: Letter			
06875	XUESO007-0001571	XUESO007-001594	6/12/2002	Depo: Xue, Songlin 6/8/06 EX 001: PPT "Epidemiology and Its Application in Pharmacovigilance and Risk Management			
06876	XUESO007-001595	XUESO007-001613		Depo: Xue, Songlin 6/8/06 EX 002: PPT "Application of Epidemiology to Risk Management			
06877	W-MCL003-03011	W-MCL003-03012	4/6/1990	Depo: Xue, Songlin 6/8/06 EX 003: Memo to Marc Deitch from M. Weber			
06878			4/18/1990	Depo: Xue, Songlin 6/9/06 EX 005: Reports, Rising Incidence of Breast Cancer			
06879	XUESO007-001424	XUESO007-001432	12/16/2002	Depo: Xue, Songlin 6/9/06 EX 006: Epidemiology in GSSE			
06880			6/25/2003	Depo: Xue, Songlin 6/9/06 EX 007: Influence of Estrogen Plus progestin on Breast Cancer and Mammography			
06881	BRADK001-001261	BRADK001-001573		Depo: Xue, Songlin 6/9/06 EX 009: Additional Analyses of WHI Data			
06882			1/28/2004	Depo: Xue, Songlin 6/9/06 EX 010: Letter from Lane Heard to Michael Mills			
06883			10/14/2005	Depo: Xue, Songlin 6/9/06 EX 011: Letter to Andrew Trevelise from S&B			
06884	XUESO208-000201	XUESO208-000424	5/27/2003	Depo: Xue, Songlin 6/9/06 EX 012: Additional Analyses of WHI Data			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06885				Depo: Xue, Songlin 6/9/06 EX 013: Curriculum vitae			
06887	XUESO002-001481	XUESO002-001485		Depo: Xue, Songlin 6/9/06 EX 022: Risk Management Plan for Prempro			
06888	XUESO007-001631	XUESO007-001641	4/30/2002	Depo: Xue, Songlin 6/9/06 EX 052: Ongoing/Completed Epidemiologic Projects			
06889	CONTA013-000420	CONTA013-000433	6/27/2002	Depo: Xue, Songlin 6/9/06 EX 058: Menopausal Health Publication Management Meeting Minutes			
06890	CORRA001-000153	CORRA001-000157	4/20/2001	Depo: Payne, Charles 6/10/06 EX 001: Release and Settlement Agreement			
06891	PAYNC201-000010	PAYNC201-000011	7/18/2000	Depo: Payne, Charles 6/10/06 EX 002: Correspondence to AHP from Payne			
06892	PAYNC201-000161	PAYNC201-000162		Depo: Payne, Charles 6/10/06 EX 003: Consider the Entire Body of Evidence			
06893	PAYNC201-000660	PAYNC201-000718	1/7/1999	Depo: Payne, Charles 6/10/06 EX 004: W-A Combo District Fast Start Meeting			
06894	PAYNC002-000032	PAYNC002-000036	12/8/2000	Depo: Payne, Charles 6/10/06 EX 005: Payne performance Planning and Appraisal			
06895	CORRA301-000013	CORRA301-000013	5/30/2000	Depo: Payne, Charles 6/10/06 EX 006: Correspondence to Payne from Richards			
06896	PAYNC201-000016	PAYNC201-000017	6/14/2000	Depo: Payne, Charles 6/10/06 EX 007: Correspondence to Richards from Payne			
06897	PAYNC201-000012	PAYNC201-000015	6/12/2000	Depo: Payne, Charles 6/10/06 EX 008: Correspondence to Richards from Payne			
06898	PAYNC201-001158	PAYNC201-000068		Depo: Payne, Charles 6/10/06 EX 009: Premarin Message			
06899	PAYNC201-000616	PAYNC201-000659		Depo: Payne, Charles 6/10/06 EX 010: Breast Cancer, Know the Facts			
06900	CORRA302-000055	CORRA302-000056		Depo: Payne, Charles 6/10/06 EX 011: Bama Slammers			
06901	PAYNC201-001171	PAYNC201-001174	10/13/1998	Depo: Payne, Charles 6/10/06 EX 012: Memo to Steel City District Members			
06902	PAYNC201-001154	PAYNC201-001154		Depo: Payne, Charles 6/10/06 EX 013: Tip of the Iceberg			
06903	PAYNC001-000431	PAYNC001-000431		Depo: Payne, Charles 6/10/06 EX 014: Estrogen improves overall cholesterol levels			
06904	PAYNC001-000464	PAYNC001-000464	7/00/1993	Depo: Payne, Charles 6/10/06 EX 015: Two Benefits and a Risk			
06905	PAYNC001-000001	PAYNC001-000002	2/00/2000	Depo: Payne, Charles 6/10/06 EX 016: Q&A			
06906	PAYNC201-000831	PAYNC201-000905		Depo: Payne, Charles 6/10/06 EX 017: Focus on Growth			
06907	PAYNC001-000688	PAYNC001-000696	6/00/1996	Depo: Payne, Charles 6/10/06 EX 018: HRT and your Health pamphlet			
06908	PAYNC201-001148	PAYNC201-001148		Depo: Payne, Charles 6/10/06 EX 019: Premarin presentation			
06909	PAYNC201-001149	PAYNC201-001149		Depo: Payne, Charles 6/10/06 EX 020: Premarin message			
06910	PAYNC201-001151	PAYNC201-001151		Depo: Payne, Charles 6/10/06 EX 021: Premarin growth objectives			
06911	PAYNC201-001175	PAYNC201-001177	2/4/2000	Depo: Payne, Charles 6/10/06 EX 022: VM to the Field			
06912	PAYNC001-000110	PAYNC001-000114	12/00/1997	Depo: Payne, Charles 6/10/06 EX 023: Consider the Entire Body of Evidence			
06913	PAYNC001-000061	PAYNC001-000065	8/24/2000	Depo: Payne, Charles 6/10/06 EX 024: VM to the field			
06914	PAYNC001-000047	PAYNC001-000047		Depo: Payne, Charles 6/10/06 EX 025: Premarin components			
06915	CORRA001-000227	CORRA001-000230	10/31/2000	Depo: Payne, Charles 6/10/06 EX 026: Territory Representative Rules of Conduct			
06916	CORRA001-000212	CORRA001-000226	3/5/2001	Depo: Payne, Charles 6/10/06 EX 027: Sustainable Commercial Compliance			
06917	PAYNC001-000040	PAYNC001-000040	3/00/1993	Depo: Payne, Charles 6/10/06 EX 028: page from NEJM article			
06918	PAYNC001-000090	PAYNC001-000090		Depo: Payne, Charles 6/10/06 EX 029: Sex, Happiness and Hormones			
06919	CORRA001-000204	CORRA001-000211	3/00/1995	Depo: Payne, Charles 6/10/06 EX 030: PhRMA Code of Marketing Practices			
06920	PAYNC201-000002	PAYNC201-000003	7/31/2000	Depo: Payne, Charles 6/10/06 EX 031: Correspondence to Wyeth from Whatley			
06921	PAYNC201-000004	PAYNC201-000006	7/27/2000	Depo: Payne, Charles 6/10/06 EX 032: Correspondence to Wyeth from Waldrep			
06922	PAYNC002-000046	PAYNC002-000046	6/15/1999	Depo: Payne, Charles 6/10/06 EX 033: AHP Code of Conduct			
06923			1/1/1999	Depo: Payne, Charles 6/10/06 EX 033A: AHP Code of Conduct			
06924	CORRA001-000192	CORRA001-000193	2/28/2001	Depo: Payne, Charles 6/10/06 EX 034: Correspondence from Brady			
06925	CORRA301-000099	CORRA301-000099	3/13/2001	Depo: Payne, Charles 6/10/06 EX 035: Wyeth Senior Management Forum program			
06926	LAWT023-042874	LAWT023-042880	4/6/2001	Depo: Payne, Charles 6/10/06 EX 036: Email			
06927	ALIVJ010-001081	ALIVJ010-001144		Depo: Payne, Charles 6/10/06 EX 037: Wyeth Sales and Marketing Policies and Guidelines			
06928			6/00/2006	Depo: Acs, Geza 6/12/06 EX 001: Curriculum vitae			
06929			4/11/2006	Depo: Acs, Geza 6/12/06 EX 002: Expert Report Dockter			
06930				Depo: Acs, Geza 6/12/06 EX 003: Expert Report Nelson			
06931				Depo: Acs, Geza 6/12/06 EX 004: Nelson color slides			
06932				Depo: Acs, Geza 6/12/06 EX 005: Dockter color slides			
06933			8/12/2003	Depo: Acs, Geza 6/12/06 EX 006: Prasad article			
06934			8/16/1999	Depo: Acs, Geza 6/12/06 EX 007: Hofseth article			
06935			6/9/2006	Depo: Arias, Raquel 6/14/06 EX 001: NOD			
06936			2/2/2006	Depo: Arias, Raquel 6/14/06 EX 002: Expert Report			
06937			4/13/2006	Depo: Arias, Raquel 6/14/06 EX 003: Supplemental Report			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06938				Depo: Arias, Raquel 6/14/06 EX 004: Expert Report Coleman			
06939			4/5/2005	Depo: Arias, Raquel 6/14/06 EX 005: Expert Report			
06940			8/18/2004	Depo: Arias, Raquel 6/14/06 EX 006: McCormack depo			
06941			5/25/2006	Depo: Arias, Raquel 6/14/06 EX 007: Invoice			
06942			1/18/2005	Depo: Arias, Raquel 6/14/06 EX 008: Estrogens and the Skin			
06943			00/00/2001	Depo: Arias, Raquel 6/14/06 EX 009: The Use of HRT in Postmenopausal Women with Type 2 Diabetes			
06944			00/00/1998	Depo: Arias, Raquel 6/14/06 EX 010: Is there an association between hrt and breast cancer			
06945			8/14/2000	Depo: Arias, Raquel 6/14/06 EX 011: The Role of HRT in the Prevention of Postmenopausal Heart Disease			
06946			00/00/2000	Depo: Arias, Raquel 6/14/06 EX 012: HRT in the Prevention and Treatment of Atherosclerosis			
06947			00/00/1996	Depo: Arias, Raquel 6/14/06 EX 013: 1996 PDR Excerpt			
06948			00/00/1997	Depo: Arias, Raquel 6/14/06 EX 014: 1997 PDR Excerpt			
06949			00/00/1998	Depo: Arias, Raquel 6/14/06 EX 015: 1998 PDR Excerpt			
06950			00/00/1999	Depo: Arias, Raquel 6/14/06 EX 016: 1999 PDR Excerpt			
06951			00/00/2000	Depo: Arias, Raquel 6/14/06 EX 017: 2000 PDR Excerpt			
06952			00/00/2001	Depo: Arias, Raquel 6/14/06 EX 018: 2001 PDR Excerpt			
06953			00/00/2002	Depo: Arias, Raquel 6/14/06 EX 019: 2002 PDR Excerpt			
06954			7/15/2005	Depo: Arias, Raquel 6/14/06 EX 020: Patient information re Prempro and Premphase			
06955			2/12/2004	Depo: Arias, Raquel 6/14/06 EX 021: Menstrual Factors and Risk of Breast Cancer			
06956			6/25/2003	Depo: Arias, Raquel 6/14/06 EX 022: Influence of Estrogen Plus Progestin			
06957			7/17/2003	Depo: Arias, Raquel 6/14/06 EX 023: WHI: Now that the dust has settled			
06958			9/4/2002	Depo: Arias, Raquel 6/14/06 EX 024: Article from NCBI website			
06959			2/28/1995	Depo: Arias, Raquel 6/14/06 EX 025: Reproductive factors and family history of breast cancer			
06960			7/3/2002	Depo: Arias, Raquel 6/14/06 EX 026: Article from NCBI website			
06961			8/22/2005	Depo: Arias, Raquel 6/14/06 EX 027: Impact of teenage oral contraceptive use			
06962			9/00/2005	Depo: Arias, Raquel 6/14/06 EX 028: Antibiotics and the Risk of Breast Cancer			
06963			3/23/2005	Depo: Arias, Raquel 6/14/06 EX 029: An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk			
06964			8/3/2005	Depo: Arias, Raquel 6/14/06 EX 030: SERMs: Mechanism of anticarcinogenesis and drug resistance			
06965			6/1/2005	Depo: Arias, Raquel 6/14/06 EX 031: Nonsteroidal Anti-Inflammatory Drug Use and Breast Cancer Risk			
06966			8/9/2003	Depo: Arias, Raquel 6/14/06 EX 032: Breast Cancer and HRT in MWS			
06967			10/5/2004	Depo: Arias, Raquel 6/14/06 EX 033: The NAMS Updates Position Statement on Estrogen and Progestogen Use			
06968			5/28/2003	Depo: Arias, Raquel 6/14/06 EX 034: Effect of Estrogen Plus Progestin			
06969			5/28/2003	Depo: Arias, Raquel 6/14/06 EX 035:			
06970			12/29/1997	Depo: Arias, Raquel 6/14/06 EX 036: WHIMS			
06971			2/18/2004	Depo: Arias, Raquel 6/14/06 EX 037: Antibiotic Use in Relation to Risk of Breast Cancer			
06972			4/14/2004	Depo: Arias, Raquel 6/14/06 EX 038: Effects of CEE in Postmenopausal Women with Hysterectomy			
06973			7/17/2002	Depo: Arias, Raquel 6/14/06 EX 039: Article from NCBI website			
06974			00/00/2002	Depo: Fontaine, Leander 6/14/06 EX 047: Prempro 2002 PDR			
06975			00/00/2001	Depo: Fontaine, Leander 6/14/06 EX 048: Prempro 2001 PDR			
06976	SOLOJ010-000224		10/11/2001	Depo: Fontaine, Leander 6/14/06 EX 049: Removal of Indication for CV Protection			
06977	W-MDL527-00043186		9/27/2001	Depo: Fontaine, Leander 6/14/06 EX 050: Telephone Contact Report			
06978			6/9/2006	Depo: Chodosh, Lewis 6/16/06 EX 001: NOD			
06979			1/00/2005	Depo: Chodosh, Lewis 6/16/06 EX 002: Curriculum vitae			
06980			2/17/2006	Depo: Chodosh, Lewis 6/16/06 EX 003: Expert Report			
06981			4/19/2006	Depo: Chodosh, Lewis 6/16/06 EX 004: Supplemental Expert Report			
06982			5/27/2005	Depo: Chodosh, Lewis 6/16/06 EX 005: Billing Information			
06983			6/9/2006	Depo: Chodosh, Lewis 6/16/06 EX 006: Article			
06984			11/30/2005	Depo: Chodosh, Lewis 6/16/06 EX 007: Expert Report of Carole Banka			
06985				Depo: Chodosh, Lewis 6/16/06 EX 008: Expert report of Dr. Bundred			
06986				Depo: Chodosh, Lewis 6/16/06 EX 009: Expert report of Dr. Gabrielson			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
06987			5/9/2006	Depo: Chodosh, Lewis 6/16/06 EX 010: Expert Report in Coleman			
06988	DELCA008-001174	DELCA008-001185	2/00/2000	Depo: DelConte, Anthony 6/20/06 EX 015: Dear Doctor Letter			
06989			00/00/2000	Depo: DelConte, Anthony 6/20/06 EX 016: 2000 PDR Prempro/ Premphase			
06990	DELCA008-000355	DELCA008-000356		Depo: DelConte, Anthony 6/20/06 EX 017: Medical Affairs VM			
06991	CONKJ018-039166	CONKJ018-039167	2/24/2002	Depo: DelConte, Anthony 6/20/06 EX 018: WHI Grand Rounds Report			
06992	DELCA028-000005	DELCA028-000008	5/16/2000	Depo: DelConte, Anthony 6/20/06 EX 019: Meeting Minutes			
06993	VICTJ005-001696	VICTJ005-001699	2/1/1990	Depo: DelConte, Anthony 6/20/06 EX 020: Advisory Committee Minutes			
06994	W-MDL303-0083689	W-MDL303-0083700	2/16/1995	Depo: DelConte, Anthony 6/20/06 EX 021: Internal Memo from Bissinger			
06995	DELCA001-000271	DELCA001-000273	9/13/2001	Depo: DelConte, Anthony 6/20/06 EX 022: Memo to Solomon from Roark			
06996	DELCA031-001695		8/27/2001	Depo: DelConte, Anthony 6/20/06 EX 023: Email			
06997	DELCA001-000278			Depo: DelConte, Anthony 6/20/06 EX 024: Emotional Impact of Estrogen's Effects on Skin			
06998	PANAA004-000514	PANAA004-000516		Depo: DelConte, Anthony 6/20/06 EX 025: Core Messages - Premarin Benefits Packages			
06999	DELCA004-000222			Depo: DelConte, Anthony 6/20/06 EX 026: Handwritten Note			
07000	DELCA020-000132			Depo: DelConte, Anthony 6/20/06 EX 027: Handwritten Note			
07001	BRADK001-001134		9/25/2002	Depo: DelConte, Anthony 6/20/06 EX 028: Email from DelConte			
07002	DELCA008-000627	DELCA008-000631	4/25/1980	Depo: DelConte, Anthony 6/20/06 EX 029: Case-Control Study of Menopausal ET and Breast Cancer			
07003	DELCA028-000021	DELCA028-000022	7/17/1996	Depo: DelConte, Anthony 6/20/06 EX 030: AHP Finance Committee Authorization			
07004	DELCA008-000554		2/16/2000	Depo: DelConte, Anthony 6/20/06 EX 031: RR of Breast Cancer with ERT/HRT			
07005	W-MDL042782-0015317	W-MDL042782-0015325		Depo: DelConte, Anthony 6/20/06 EX 032: At Her Age Are Tranquilizers Really Enough			
07006	DELCA201-004008		10/16/2001	Depo: DelConte, Anthony 6/20/06 EX 034: Comments			
07007	DUROJ027-000876	DUROJ027-000894	10/6/2000	Depo: Weber, Margaret 6/21/06 EX 050: Policy 420			
07008	CCC084-000698	CCC084-001095	10/26/1999	Depo: Weber, Margaret 6/21/06 EX 051: Documents			
07009				Depo: Weber, Margaret 6/21/06 EX 052: Curriculum vitae			
07010	HENRL002-000657		11/11/1998	Depo: Weber, Margaret 6/21/06 EX 053: Internal correspondence			
07011	CHOOM034-000407		12/2/1997	Depo: Weber, Margaret 6/21/06 EX 054: Internal correspondence			
07012	DWRITE065923	DWRITE 065941	5/15/1997	Depo: Weber, Margaret 6/21/06 EX 055: Premarin Publication program			
07013	DWRITE065952	DWRITE 065968	11/20/1998	Depo: Weber, Margaret 6/21/06 EX 056: Premarin Family Study Management Plan			
07014	DWRITE066081	DWRITE 066085	12/7/1999	Depo: Weber, Margaret 6/21/06 EX 057: Premarin Family ; Jeannemarie Durocher 8/2/06 DEPO EX 068: Premarin Family of Products Publication Plan Proposal			
07015	DWRITE067383		1/28/2002	Depo: Weber, Margaret 6/21/06 EX 058: Strategic Publication Plan Tracking Report			
07016	DWRITE074105	DWRITE 074115	1/31/2005	Depo: Weber, Margaret 6/21/06 EX 059: Estrogens and Skin draft outline			
07017			3/29/2005	Depo: Weber, Margaret 6/21/06 EX 060: Estrogens and the Skin			
07018	SOLOJ028-016914	SOLOJ028-016920		Depo: Weber, Margaret 6/21/06 EX 061: Role of HRT In the Management of Type 2 Diabetes			
07019	DWRITE068308		6/23/1998	Depo: Weber, Margaret 6/21/06 EX 062: Premarin Publication Plan Meeting Recap			
07020	DWRITE068302		1/11/2005	Depo: Weber, Margaret 6/21/06 EX 063: Publication Plan Tracking Report			
07021			11/3/2001	Depo: Weber, Margaret 6/21/06 EX 064: The Use of HRT in Postmenopausal Women with type 2 Diabetes			
07022	DWRITE0003333	DWRITE 003335	11/19/2001	Depo: Weber, Margaret 6/21/06 EX 065: Project Assignment Form			
07023	DWRITE677658		1/31/2005	Depo: Weber, Margaret 6/21/06 EX 066: Strategic Publication Plan Tracking Report			
07024	STRIS016-031138	STRIS016-031139	3/28/2002	Depo: Weber, Margaret 6/21/06 EX 067: Strategic Publication Development Meeting			
07025	DWRITE074346	DWRITE 074380	1/31/2005	Depo: Weber, Margaret 6/21/06 EX 068: Menopause, Sexuality and HRT			
07026			11/14/2002	Depo: Weber, Margaret 6/21/06 EX 069: The Impact of Hormones on Menopausal Sexuality			
07027	DELCA008-001182	DELCA008-001185	2/00/2000	Depo: Weber, Margaret 6/21/06 EX 070: Q&A document and card			
07028				Depo: Cobb, Pamela 6/23/06 EX 001: Curriculum vitae			
07029	WEBEM015-012948		5/18/2001	Depo: Cobb, Pamela 6/23/06 EX 002: Email			
07030	STRIS202-001106	STRIS202-001112	4/8/2003	Depo: Cobb, Pamela 6/23/06 EX 003: Article			
07031			11/14/2002	Depo: Cobb, Pamela 6/23/06 EX 004: Article			
07032	DWRITE065923	DWRITE 065941	5/15/1997	Depo: Cobb, Pamela 6/23/06 EX 005: Dwrite proposal to Solomon			
07033	DWRITE065952	DWRITE065968	11/20/1998	Depo: Cobb, Pamela 6/23/06 EX 006: Dwrite proposal			
07034	COBBP007-001118	COBBP007-001123	5/20/2002	Depo: Cobb, Pamela 6/23/06 EX 007:			
07035	DWRITE072638	DWRITE072639	1/17/2005	Depo: Cobb, Pamela 6/23/06 EX 008:			
07036	DWRITE003361	DWRITE003362	1/18/2005	Depo: Cobb, Pamela 6/23/06 EX 009: Email to Cobb			
07037	DWRITE066502		5/4/2000	Depo: Cobb, Pamela 6/23/06 EX 010: Letter from Mittleman			
07038			9/23/2002	Depo: Cobb, Pamela 6/23/06 EX 011:			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07039	DWRITE000333	DWRITE000335	11/19/2001	Depo: Cobb, Pamela 6/23/06 EX 012:			
07040	DWRITE067757	DWRITE067763	1/31/2005	Depo: Cobb, Pamela 6/23/06 EX 013:			
07041	DWRITE074346	DWRITE074380	1/31/2005	Depo: Cobb, Pamela 6/23/06 EX 014:			
07042			00/00/1996	Depo: Dey, Michael 6/26/06 EX 027: Prempro 1996 PDR			
07043			00/00/2006	Depo: Dey, Michael 6/26/06 EX 028: Prempro 2006 PDR			
07044	W-MDL04782-00032460	W-MDL04782-00032462	5/5/1981	Depo: Dey, Michael 6/26/06 EX 029: Memo			
07045	W-MDL04782-00030691	W-MDL04782-00030693	9/15/1983	Depo: Dey, Michael 6/26/06 EX 030: Memo			
07046			6/12/2006	Depo: Philipson, James 6/26/06 EX 001: NOD			
07047	MRK-HRT-0085	MRK-HRT-0168	6/2/1995	Depo: Philipson, James 6/26/06 EX 002: Co-Promotion Agreement; DEPO: Jean Meaney 7/11/06 EX 002: Co-Promotion Agreement			
07048	MRK-HRT-0253	MRK-HRT-0257	2/15/1995	Depo: Philipson, James 6/26/06 EX 003: Letter Agreement			
07049	MRK-HRT-0067	MRK-HRT-0071	7/9/1996	Depo: Philipson, James 6/26/06 EX 004: Second Amendment to Letter Agreement			
07050	MRK-HRT-0263	MRK-HRT-0268	11/13/1996	Depo: Philipson, James 6/26/06 EX 005: Third Amendment to Letter Agreement			
07051	MRK-HRT-0054	MRK-HRT-0066	3/14/1997	Depo: Philipson, James 6/26/06 EX 006: Letter from Esch to Dugan			
07052	MRK-HRT-0081	MRK-HRT-0084	11/1/1995	Depo: Philipson, James 6/26/06 EX 007: Memo			
07053	MRK-HRT-0072	MRK-HRT-0077	7/18/1996	Depo: Philipson, James 6/26/06 EX 008: Letter from Esch to Smith Cox			
07054	MRK-HRT-0337	MRK-HRT-0339	5/18/2006	Depo: Philipson, James 6/26/06 EX 009: Graphs			
07055	MRK-HRT-0049	MRK-HRT-0053	4/6/1999	Depo: Philipson, James 6/26/06 EX 010: Letter from Miller to Hunter			
07056	MRK-HRT-0046	MRK-HRT-0048	10/8/1999	Depo: Philipson, James 6/26/06 EX 011: Letter from Miller to Hunter			
07057	MRK-HRT-0042	MRK-HRT-0045	10/13/1999	Depo: Philipson, James 6/26/06 EX 012: Letter from Hunter to Miller			
07058	MRK-HRT-0028	MRK-HRT-0029	11/12/1999	Depo: Philipson, James 6/26/06 EX 013: Letter from Miller to Hunter			
07059	MRK-HRT-0022	MRK-HRT-0024		Depo: Philipson, James 6/26/06 EX 014: Letter from Dixon to Mahady			
07060	MRK-HRT-0020	MRK-HRT-0021	12/8/1999	Depo: Philipson, James 6/26/06 EX 015: Letter			
07061	MRK-HRT-0001		12/13/2001	Depo: Philipson, James 6/26/06 EX 016: Letter from Patel to Lojewski			
07062	MRK-HRT-0013	MRK-HRT-0019	12/21/1999	Depo: Philipson, James 6/26/06 EX 017: Letter from Cohn to Hartman			
07063	ESSNR202-000380	ESSNR202-000390	11/7/2003	Depo: Robert Essner 6/29/06 EX 001: Simulcast Draft 2			
07064	ESSNR202-000531	ESSNR202-000536	6/26/2001	Depo: Robert Essner 6/29/06 EX 002: Essner corporate address			
07065	W-MDL04782-00014967	W-MDL04782-00014969	5/16/1942	Depo: Robert Essner 6/29/06 EX 003: Letter			
07066	BURRG002-000049	BURRG002-000053	10/31/1994	Depo: Robert Essner 6/29/06 EX 004: History of Premarin			
07067			7/00/1973	Depo: Robert Essner 6/29/06 EX 005: Contemp OB/GYN July 1973 excerpts			
07068			7/15/2005	Depo: Robert Essner 6/29/06 EX 006: Prempro label			
07069			00/00/1996	Depo: Robert Essner 6/29/06 EX 007: 1996 Prempro PDR Excerpts			
07070	W-MDL04782-00064632	W-MDL04782-00064633	12/00/1975	Depo: Robert Essner 6/29/06 EX 008: Dear Doctor Letter			
07071	W-MDL04782-00027339	W-MDL04782-00027342	1/12/1976	Depo: Robert Essner 6/29/06 EX 009: Memo of Conference			
07072			6/14/1979	Depo: Robert Essner 6/29/06 EX 010: Premarin Challenge Program			
07073	CONNS014-001645	CONNS014-001646	10/1987	Depo: Robert Essner 6/29/06 EX 011: Dear Doctor Letter			
07074	YAVUE007-000244	YAVUE007-000486		Depo: Robert Essner 6/29/06 EX 012: Premarin Sales Issues & Competitive Information			
07075	W-MDL04782-00000931		1/26/1990	Depo: Robert Essner 6/29/06 EX 013: Premarin CV Promotion			
07076	W-MDL04782-00002391	W-MDL04782-00002393	2/25/1991	Depo: Robert Essner 6/29/06 EX 014: Letter			
07077	DEYMI003-000013	DEYMI003-000025	1/00/1991	Depo: Robert Essner 6/29/06 EX 015: Patient brochure			
07078	PANAA034-001796		7/16/1991	Depo: Robert Essner 6/29/06 EX 016: Premarin CBL Program			
07079	PANAA014-001130		1/23/1992	Depo: Robert Essner 6/29/06 EX 017: Premarin/CV Labeling			
07080	W-MDL303-00081836		4/26/1992	Depo: Robert Essner 6/29/06 EX 018: Premarin/CV Labeling			
07081	CHOOM018-000033	CHOOM018-000043	1/00/1997	Depo: Robert Essner 6/29/06 EX 019: Growth Through Intervention POA I 1997			
07082	ESSNR202-000651	ESSNR202-000663		Depo: Robert Essner 6/29/06 EX 020: speech notes			
07083	STRIS004-000183	STRIS004-000184	12/20/1996	Depo: Robert Essner 6/29/06 EX 021: Memo			
07084			3/10/1998	Depo: Robert Essner 6/29/06 EX 022: PPT "The U.S. Market"			
07085	W-MDL04782-00094080	W-MDL04782-00094081	1/14/1998	Depo: Robert Essner 6/29/06 EX 023 & Allen, Susan 4/24/2007 EX 11: Memo			
07086	W-ADSBRO-000068	W-ADSBRO-000070	1/00/1999	Depo: Robert Essner 6/29/06 EX 024: Brochure excerpts			
07087	W-ADSBRO-000981	W-ADSBRO-0000988	1/00/2000	Depo: Robert Essner 6/29/06 EX 025: Brochure			
07088	W-MCL004-01712	W-MCL004-1719	9/30/1991	Depo: Robert Essner 6/29/06 EX 026: memo to Deitch			
07089			00/00/1991	Depo: Robert Essner 6/29/06 EX 027: Premarin label PDR			
07090			00/00/1992	Depo: Robert Essner 6/29/06 EX 028: Premarin Label PDR			
07091			00/00/1993	Depo: Robert Essner 6/29/06 EX 029: Premarin Label PDR			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07092			00/00/1994	Depo: Robert Essner 6/29/06 EX 030: Premarin Label PDR			
07093			00/00/1995	Depo: Robert Essner 6/29/06 EX 031: Premarin Label PDR			
07094	W-MDL303-00083689	W-MDL303-00083892	2/16/1995	Depo: Robert Essner 6/29/06 EX 032: Memo			
07095	W-MDL303-00083214	W-MDL303-00083220	12/30/1994	Depo: Robert Essner 6/29/06 EX 033: Memo			
07096				Depo: Robert Essner 6/29/06 EX 034: 4/4 Essner close speech notes			
07097	LOJEL038-001443	LOJEL038-001456		Depo: Robert Essner 6/29/06 EX 035: 4/2 new version speech notes			
07098	W-MDL527-00048273	W-MDL527-00048281	7/12/2001	Depo: Robert Essner 6/29/06 EX 036: ACOG Newsletter; Depo: Jeanne Durocher 6/30/06 EX039: transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use			
07099			7/17/2002	Depo: Robert Essner 6/29/06 EX 037: Risks and Benefits of Estrogen Plus Progestin			
07100			2/9/2006	Depo: Robert Essner 6/29/06 EX 038: ACS statement			
07101				Depo: Robert Essner 6/29/06 EX 039: NCI web pages			
07102			7/29/2005	Depo: Robert Essner 6/29/06 EX 040: IARC web pages			
07103			5/00/2005	Depo: Robert Essner 6/29/06 EX 041: USPSTF statement			
07104			6/00/2005	Depo: Robert Essner 6/29/06 EX 042: NHLBI brochure			
07105			1/10/2006	Depo: Robert Essner 6/29/06 EX 043: Letter from Reed Smith			
07106			4/27/2006	Depo: Robert Essner 6/29/06 EX 044: NOD			
07107			8/3/1989	Depo: Robert Essner 6/29/06 EX 045A: Boston Globe Article			
07108			11/28/1990	Depo: Robert Essner 6/29/06 EX 045B: AP article			
07109			6/28/2006	Depo: Robert Essner 6/29/06 EX 046: Letter from Williams & Connolly			
07110	BURLB013-001804	BURLB013-001807	1/11/1999	Depo: Robert Essner 6/29/06 EX 047: Letter			
07111	CORRA001-000204	CORRA001-000241		Depo: Robert Essner 6/29/06 EX 048: PhRMA Code of Pharmaceutical Marketing Practices; DEPO: Andrew Panay 7/13/06 EX 002: Code of Pharmaceutical Marketing Practices			
07112	CONNS017-000118		2/2/1990	Depo: Robert Essner 6/29/06 EX 049: Memo			
07113	PICKJ016-000912		6/19/1990	Depo: Robert Essner 6/29/06 EX 050: Memo			
07114	PETKD002-000055	PETKD002-000058	2/22/2000	Depo: Robert Essner 6/29/06 EX 052: Dear Doctor Letter			
07115	DELCA008-001182	DELCA008-001185	2/00/2000	Depo: Robert Essner 6/29/06 EX 053: Q&A Card			
07116	ROSSC0021-002254	ROSSC021-002255	11/9/1989	Depo: Justin Victoria 6/30/06 EX 001: Letter			
07117	ROSSC022-000828	ROSSC022-000844	1/3/1990	Depo: Justin Victoria 6/30/06 EX 002: Letter			
07118	W-MDL04782-00032460	W-MDL04782-00032463	5/5/1981	Depo: Justin Victoria 6/30/06 EX 003: Internal Memo			
07119	W-MDL04782-00000930	W-MDL04782-00000931	1/26/1990	Depo: Justin Victoria 6/30/06 EX 004: Internal Correspondence			
07120	VICTJ005-001700	VICTJ005-001703	2/15/1990	Depo: Justin Victoria 6/30/06 EX 005: Internal Memo			
07121	W-MDL04782-00000354	W-MDL04782-00000355	5/16/1990	Depo: Justin Victoria 6/30/06 EX 006: Internal Correspondence			
07122	PANAA026-001749		5/17/1990	Depo: Justin Victoria 6/30/06 EX 007: Internal Correspondence			
07123	PANAA025-000820	PANAA025-000823	3/17/1992	Depo: Justin Victoria 6/30/06 EX 008: Internal Correspondence			
07124	CONNS005-000070	CONNS005-000072	3/24/1992	Depo: Justin Victoria 6/30/06 EX 009: Internal Correspondence; DEPO: Nick Marmontello 7/28/06 EX 006: Memo			
07125	W-MDL303-00081835	W-MDL303-00081836	4/26/1992	Depo: Justin Victoria 6/30/06 EX 010: Internal Correspondence			
07126	W-MDL303-00081682	W-MDL303-00081687	8/25/1992	Depo: Justin Victoria 6/30/06 EX 011: Letter			
07127	PANAA026-001453		9/9/1992	Depo: Justin Victoria 6/30/06 EX 012: Internal Memo			
07128	VICTJ001-001013	VICTJ001-001039	7/31/2002	Depo: Justin Victoria 6/30/06 EX 013: Market Research Update			
07129	CONNS005-000396	CONNS005-000397	6/29/1989	Depo: Justin Victoria 6/30/06 EX 0014: Internal Correspondence			
07130	W-MDL04782-00001932	W-MDL04782-00001933	5/30/1990	Depo: Justin Victoria 6/30/06 EX 015: Memo			
07131	PANAA014-001130		1/23/1992	Depo: Justin Victoria 6/30/06 EX 016: Internal Correspondence			
07132	PANAA034-001426	PANAA034-001427	8/22/1990	Depo: Justin Victoria 6/30/06 EX 017: Internal Correspondence			
07133	ROSSC005-000083	ROSSC005-000084	8/14/1992	Depo: Justin Victoria 6/30/06 EX 018: Internal Correspondence			
07134	ROSSC023-000521		9/5/1991	Depo: Justin Victoria 6/30/06 EX 019: Internal Correspondence			
07135	FISHG002-000003		1/13/2000	Depo: Justin Victoria 6/30/06 EX 020: Internal Correspondence			
07136	VICTJ007-000225		5/1/2002	Depo: Justin Victoria 6/30/06 EX 021: Investor Relation Messages			
07137	DUROJ010-000934	DUROJ010-000961		Depo: Jeanne Durocher 6/30/06 EX001: Alzheimer's Disease Research			
07138	DUROJ012-001109	DUROJ012-001111		Depo: Jeanne Durocher 6/30/06 EX002: Epidemiological Studies			
07139	DUROJ013-000412			Depo: Jeanne Durocher 6/30/06 EX003: Premarin Treatment of Osteoporosis			
07140	DUROJ013-000872	DUROJ013-000875	10/22/1997	Depo: Jeanne Durocher 6/30/06 EX004: Meeting Minutes			
07141	DUROJ018-000058			Depo: Jeanne Durocher 6/30/06 EX005: Facts about Wyeth- Ayerst/ AHP			
07142	DUROJ021-002436	DUROJ021-002439	6/26/1992	Depo: Jeanne Durocher 6/30/06 EX006: Internal Correspondence to Distribution from Marani			
07143	DUROJ029-000202		12/1/1988	Depo: Jeanne Durocher 6/30/06 EX007: Internal Correspondence to Distributionfrom Victoria			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07144	DUROJ029-000211	DUROJ029-00284	12/31/1987	Depo: Jeanne Durocher 6/30/06 EX008:American Home Products, Basic Data 1987			
07145	DUROJ030-000383	DUROJ030-000385	4/14/1992	Depo: Jeanne Durocher 6/30/06 EX009: Internal Correspondence to marmontello from Westerfield			
07146	DUROJ030-000446		3/5/1992	Depo: Jeanne Durocher 6/30/06 EX010: Detail Verbatims for Estraderm			
07147	DUROJ030-000471	DUROJ030-000472	2/19/1992	Depo: Jeanne Durocher 6/30/06 EX011:Internal Correspondence to Hassan from Westerfield/Chen			
07148	DUROJ030-001375	DUROJ030-001377	1/23/1992	Depo: Jeanne Durocher 6/30/06 EX012:Internal Correspondence to Distribution from Victoria			
07149	DUROJ030-001544	DUROJ030-001545	1/10/1991	Depo: Jeanne Durocher 6/30/06 EX013:Letter to Birch from Cavanaugh			
07150	DUROJ030-001660	DUROJ030-001661	8/5/1993	Depo: Jeanne Durocher 6/30/06 EX014: Wyeth- Ayerst Laboratories, Regulatory Affairs Distribution List Advertising-- Promotion			
07151	DUROJ030-001679	DUROJ030-001680	2/9/1994	Depo: Jeanne Durocher 6/30/06 EX015: Letter to Zimney from Barton			
07152	DUROJ030-002197	DUROJ030-002198	6/15/1990	Depo: Jeanne Durocher 6/30/06 EX016: Internal Correspondence to Hertel from Morrison			
07153	DUROJ031-000126	DUROJ031-000131	4/10/1991	Depo: Jeanne Durocher 6/30/06 EX017: Estrogen and Coronary Heart Disease in Women			
07154	DUROJ032-000211	DUROJ032-000212	12/14/1993	Depo: Jeanne Durocher 6/30/06 EX018:Letter to Sasson from Bush			
07155	DUROJ032-001242		9/13/1988	Depo: Jeanne Durocher 6/30/06 EX019: Internal Correspondence to Rachelli from Hurley			
07156	DUROJ032-001243		12/21/1988	Depo: Jeanne Durocher 6/30/06 EX020: Internal Correspondence Rachelli from Those listed			
07157	DUROJ032-001294		12/30/1988	Depo: Jeanne Durocher 6/30/06 EX021: Internal Correspondence All Wyeth Regional Managers from Backstrand			
07158	DUROJ033-000013	DUROJ033-000022	12/6/1988	Depo: Jeanne Durocher 6/30/06 EX022: Reproductive Nedocrinology Phase IV, Distribution List			
07159	DUROJ034-000995	DUROJ034-001000	1/31/1995	Depo: Jeanne Durocher 6/30/06 EX023: Letter Pharmacist Announcement Letter			
07160	DUROJ035-000120		6/30/1994	Depo: Jeanne Durocher 6/30/06 EX024: Detailing Reporting Form			
07161	DUROJ039-002167	DUROJ039-002206	7/31/1992	Depo: Jeanne Durocher 6/30/06 EX025: Public Relations Recommendation to Support Wyeth- Ayerst/ EPICH Trial NIH/ Women's Health Initiative			
07162	DUROJ041-000765	DUROJ041-000767	9/11/1992	Depo: Jeanne Durocher 6/30/06 EX026: Pending AHT Status			
07163	DUROJ041-001008	DUROJ041-001009	3/31/1992	Depo: Jeanne Durocher 6/30/06 EX027:Internal Correspondence to Distribution from Colasante			
07164	DUROJ041-001011		4/7/1992	Depo: Jeanne Durocher 6/30/06 EX028: Internal Correspondence to Distribution from Colasante			
07165	DUROJ042-000403		12/15/1992	Depo: Jeanne Durocher 6/30/06 EX029: Dear Colleague Letter			
07166	DUROJ042-001548	DUROJ042-001619	3/12/1998	Depo: Jeanne Durocher 6/30/06 EX030:The U.S. market: A Case Study on the Success of Changing the HRT Paradigm			
07167	DUROJ043-001053	DUROJ043-001058	00/00/1994	Depo: Jeanne Durocher 6/30/06 EX031:Premarin 1994 Strategic Options			
07168	DUROJ046-004837	DUROJ046-004842	10/31/2002	Depo: Jeanne Durocher 6/30/06 EX032:Women's Health Care Pharmacy Advisory Board Executive Summary			
07169	DUROJ046-006314	DUROJ046-006319	3/11/2003	Depo: Jeanne Durocher 6/30/06 EX033: Wyeth News Release			
07170	DUROJ046-023746		11/2/2001	Depo: Jeanne Durocher 6/30/06 EX034: Email			
07171	DUROJ212-0004368	DUROJ212-0004375	4/5/2004	Depo: Jeanne Durocher 6/30/06 EX035: Wyeth News Release			
07172				Depo: Jeanne Durocher 6/30/06 EX036:Resume			
07173			00/00/1990	Depo: Jeanne Durocher 6/30/06 EX037: Physicians' Desk Reference 1990 Excerpt			
07174	DUROJ037-000019		9/9/1996	Depo: Jeanne Durocher 6/30/06 EX038:Fax Memo to Geisel from Hone			
07175	W-MDL527-00048273	W-MDL527-00048274	7/12/2001	Depo: Jeanne Durocher 6/30/06 EX039: transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use			
07176	CONNS014-001645	CONNS014-001646	10/1987	Depo: Jeanne Durocher 6/30/06 EX040:Dear Doctor letter			
07177	DUROJ012-001113	DUROJ012-001126	7/11/2001	Depo: Jeanne Durocher 6/30/06 EX041: Additional Estrogen Benefits			
07178	DUROJ010-000201	DUROJ010-00204	11/00/1999	Depo: Jeanne Durocher 6/30/06 EX042:The body of evidence			
07179	DUROJ010-000322	DUROJ010-000324	00/00/2000	Depo: Jeanne Durocher 6/30/06 EX043: Advertisement			
07180	DUROJ042-001419	DUROJ042-001422	11/18/1997	Depo: Jeanne Durocher 6/30/06 EX044: Premarin Life Cycle			
07181	LUDMG008-000182	LUDMG008-000184	4/27/1998	Depo: Jeanne Durocher 6/30/06 EX045:Memo from Breckenridge			
07182	SOLOJ025-000286	SOLOJ025-000355	3/10/1998	Depo: Jeanne Durocher 6/30/06 EX046: The US Market: A Case Study in the Success of Changing the HRT Paradigm			
07183	DUROJ037-0001790	DUROJ037-0001814		Depo: Jeanne Durocher 6/30/06 EX047: Franchise Optimization			
07184	DUROJ013-000246	DUROJ013-000263	2/4/1998	Depo: Jeanne Durocher 6/30/06 EX048: Background & Strategies			
07185			3/20/1989	Depo: Jeanne Durocher 6/30/06 EX049: Memo to All Members of the Wyeth Sales Force and All Members of the Wyeth- Ayerst Hospital Sales Force from Rothman			
07186			4/00/1987	Depo: Jeanne Durocher 6/30/06 EX050: Letter Re Premarin: A long term Treatment Strategy			
07187	DUROJ035-000829	DUROJ035-000830	9/25/1997	Depo: Jeanne Durocher 6/30/06 EX051: Memo from Alfonsi			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07188	LUDMG002-001710		10/20/1997	Depo: Jeanne Durocher 6/30/06 EX052: Memo from Alfonsi			
07189	DUROJ035-000831	DUROJ035-000839		Depo: Jeanne Durocher 6/30/06 EX053: Ill Market Climate			
07190	MKTAR978-001238	MKTAR978-001245	11/12/1998	Depo: Jeanne Durocher 6/30/06 EX054: Memo from Johansen			
07191	DUROJ043-000211	DUROJ043-000212		Depo: Jeanne Durocher 6/30/06 EX055: Development of Advocates and Initiatives November 1997 to Present; Ralph Hale 7/25/06 DEPO EX 025; Jeannemarie Durocher 8/2/06 DEPO EX 092			
07192	DUROJ046-015207		6/4/2002	Depo: Jeanne Durocher 6/30/06 EX056: E-mail from Durocher			
07193	DUROJ008-001058			Depo: Jeanne Durocher 6/30/06 EX057: Advocate Intergration			
07194	DUROJ044-004206	DUROJ044-004223		Depo: Jeanne Durocher 6/30/06 EX058: Global Women's Health Care Advocacy Issues Management and Medical Communication			
07195	DUROJ046-020694	DUROJ046-020699	3/13/2002	Depo: Jeanne Durocher 6/30/06 EX059: Memo from Stevens			
07196	DUROJ208-000008	DUROJ208-000011	11/19/2003	Depo: Jeanne Durocher 6/30/06 EX060:2003-2004 Publications Medical Plans			
07197	DUROJ212-000677	DUROJ212-000678	00/00/2003	Depo: Jeanne Durocher 6/30/06 EX061: Letter			
07198	DUROJ213-045895	DUROJ213-045896	4/21/2003	Depo: Jeanne Durocher 6/30/06 EX062: Letter to Archer from Conti			
07199	DUROJ213-0044300	DUROJ213-0044300	5/00/2003	Depo: Jeanne Durocher 6/30/06 EX063: Letter			
07200	PANAA010-000717	PANAA010-000722		Depo: Andrew Panagy 3/31/04 EX 029: Message Statements			
07201	PANAA008-001186	PANAA008-001197		Depo: Andrew Panagy 3/31/04 EX 030: Seven Decades that Changed Women's Health			
07202	PANAA007-001548	PANAA007-001548	3/23/2001	Depo: Andrew Panagy 3/31/04 EX 031: Memo			
07203	PANAA008-001613	PANAA008-001614	1/22/2001	Depo: Andrew Panagy 3/31/04 EX 032: List of Organizations			
07204	PANAA013-000062	PANAA013-000063		Depo: Andrew Panagy 3/31/04 EX 033: Proposal			
07205	PANAA013-000614	PANAA013-000619		Depo: Andrew Panagy 3/31/04 EX 034: Wyeth OLAR			
07206	PANAA011-000820	PANAA011-000822	1/5/2001	Depo: Andrew Panagy 3/31/04 EX 035:			
07207	PANAA002-000824	PANAA002-000829		Depo: Andrew Panagy 3/31/04 EX 036: A Risk Management Strategy			
07208	PANAA001-001255	PANAA001-001256		Depo: Andrew Panagy 3/31/04 EX 037: Draft Tactical Outline for WHI			
07209	PANAA013-000044	PANAA013-000061		Depo: Andrew Panagy 3/31/04 EX 038: Wyeth WHC			
07210	Various	Various		Depo: Andrew Panagy 3/31/04 EX 039: various promotional, marketing, advertising to the public			
07211	Various	Various		Depo: Andrew Panagy 3/31/04 EX 040: various promotional, marketing, advertising to physicians			
07212	Various	Various		Depo: Andrew Panagy 3/31/04 EX 041: various promotional, marketing advertising after 7/02			
07213			4/20/2006	Depo: Lisa Rarick 5/10/06 EX 001: Expert Report			
07214			4/00/2006	Depo: Lisa Rarick 5/10/06 EX 002: Curriculum vitae			
07215				Depo: Lisa Rarick 5/10/06 EX 003: List of previous testimony			
07216				Depo: Lisa Rarick 5/10/06 EX 004: Invoices			
07217				Depo: Lisa Rarick 5/10/06 EX 005: FDA Guidances Binder			
07218	MEDIABUY-000001	MEDIABUY-000042		Media Buys			
07219	MEDIABUY-000043	MEDIABUY-000133		Media Buys			
07220	MEDIABUY-000134	MEDIABUY-000134		Media Buys			
07221	MEDIABUY-000135	MEDIABUY-000146		Media Buys			
07222				AHPR3097 - TV Ad "Menopause"			
07223				AHPR6099 - TV Ad "Every day prevention"			
07224				BAHW0021 - TV Ad "Walk on"			
07225				AHPR6076 - TV Ad "Complexities"			
07226				AHPR3078 - TV Ad "Lauren"			
07227				AHPR6078 - TV Ad "Lauren"			
07228				AHPR1582 - TV Ad "Care Revised"			
07229				AHPR1583 - TV Ad "Change revised"			
07230				AHPR1584 - TV Ad "Important revised"			
07231				AHPR3098 - TV Ad "Diary 8774694732"			
07232				AHPR6106 - TV Ad "Diary 8774694732"			
07233				AHPR1585 - TV Ad "New attitude revised tm"			
07234				AHPR3109 - TV Ad "New attitude 8004983170:			
07235				AHPR6120 - TV Ad "New attitude 800-4804419:			
07236				UJPR3119 - TV Ad "Luaren says yes 30"			
07237				UJPR6204 - TV Ad "Lauren says yes 620260"			
07238	W-ADSBRO-00003	W-ADSBRO-00005	00/00/1995	Patient Ad			
07239	W-ADSBRO-00035	W-ADSBRO-00039	5/4/1998	Patient Brochure			
07240	W-ADSBRO-00138	W-ADSBRO-00138	1/00/2002	Patient Ad			
07241	W-ADSBRO-00185	W-ADSBRO-00185	00/00/1998	Patient Ad			
07242	W-ADSBRO-00306	W-ADSBRO-00309	5/00/2000	Menopause and Sexuality Patient Brochure			
07243	W-ADSBRO-00310	W-ADSBRO-00311	5/00/2000	Menopause and Your Risk of Osteoporosis Patient Brochure			
07244	W-ADSBRO-00312	W-ADSBRO-00315	12/00/1999	Treatment Options for the Symptoms of Menopause Patient Brochure			
07245	W-ADSBRO-00316	W-ADSBRO-00319	3/00/2000	A Medical Context for Understanding Breast Cancer Risk			
07246	W-ADSBRO-00412	W-ADSBRO-00413	12/00/1999	Menopause and Your Risk of Alzheimer's Disease Patient Brochure			
07247	W-ADSBRO-00414	W-ADSBRO-00415	12/00/1999	Menopause and Your Risk of Heart Disease Patient Brochure			
07248	W-ADSBRO-00528	W-ADSBRO-00529	4/00/2000	Assessing Your Health at Menopause			
07249	W-ADSBRO-00530	W-ADSBRO-00531	7/00/1999	Menopause and Your Vision Patient Brochure			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07250	W-ADSBRO-01119	W-ADSBRO-01139	8/00/2001	Patient Action Guide - Taking Charge of Your Menopause			
07251	W-ADSBRO-01165	W-ADSBRO-001165	1/00/1999	Consequences of Menopause			
07252	W-ADSBRO-01267	W-ADSBRO-01345	00/00/2001	Profiles in Menopause			
07253	W-ADSBRO-01348	W-ADSBRO-01349	00/00/2002	Patient Ad			
07254	W-ADSBRO-01350	W-ADSBRO-01350	00/00/2001	Patient Ad			
07255	W-ADSBRO-01351	W-ADSBRO-01351	00/00/2001	Patient Ad			
07256	W-ADSBRO-01352	W-ADSBRO-01353	00/00/2000	Patient Ad			
07257	W-ADSBRO-01354	W-ADSBRO-01355	00/00/2000	Patient Ad			
07258	W-ADSBRO-01356	W-ADSBRO-01357	00/00/2000	Patient Ad			
07259	W-ADSBRO-01358	W-ADSBRO-01360	00/00/2000	Patient Ad			
07260	W-ADSBRO-01361	W-ADSBRO-01361	00/00/2000	Patient Ad			
07261	W-ADSBRO-01365	W-ADSBRO-01365	00/00/1999	Patient Ad			
07262	W-ADSBRO-01366	W-ADSBRO-01368	00/00/1998	Patient Ad			
07263	W-ADSBRO-01370	W-ADSBRO-01372	00/00/1997	Patient Ad			
07264	W-ADSBRO-01373	W-ADSBRO-01375	00/00/1997	Patient Ad			
07265	W-ADSBRO-01382	W-ADSBRO-01383		Patient Ad			
07266	W-ADSBRO-01384	W-ADSBRO-01386	00/00/1995	Patient Ad			
07267	W-ADSBRO-01387	W-ADSBRO-01389	00/00/1995	Patient Ad			
07268	W-ADSBRO-01390	W-ADSBRO-01392	00/00/1994	Patient Ad			
07269	W-ADSBRO-01393	W-ADSBRO-01395	00/00/1993	Patient Ad			
07270	W-ADSBRO-01396	W-ADSBRO-01398	00/00/1993	Patient Ad			
07271	W-ADSBRO-01399	W-ADSBRO-01400	00/00/1992	Patient Ad			
07272	W-ADSBRO-01507	W-ADSBRO-01509	00/00/1997	Patient Ad			
07273	W-ADSBRO-01603	W-ADSBRO-01604	00/00/1997	Patient Ad			
07274	W-ADSBRO-01610	W-ADSBRO-01612	00/00/1997	Patient Ad			
07275	W-ADSBRO-01676	W-ADSBRO-01688	1/23/2003	Physician Ad			
07276	W-ADSBRO-02065	W-ADSBRO-02067	5/00/2001	Patient Ad			
07277	W-ADSBRO-02177	W-ADSBRO-02180	1/00/2002	Patient Brochure			
07278	W-ADSBRO-03851	W-ADSBRO-03880	5/4/1998	Seasons Magazine			
07279				CME Presentation by Rowan Chlobowski, MD "Inside Breast Cancer: The evolution of HT"			
07280			9/16/2005	American Cancer Society "What Causes Breast Cancer"			
07281			9/00/2005	IARC Monograph, Vol. 91, Section 5 draft			
07282			10/00/2002	USPSTF "Recommendations and Rationale - HRT for Primary Prevention of Chronic Conditions			
07283			5/23/2006	National Cancer Institute "Breast Cancer Prevention"			
07284			6/00/2005	NIH "Facts About Menopausal Hormone Therapy"			
07287				Selected Sales Call Notes previously provided to Defendants with Expert Reports			
07288			7/11/2006	Estimated Sales Data provided by Melissa Oretsky on 7/11/06			
07289				Madira database			
07290				Magic database			
07291			7/22/1996	Madira RPI Intake Form, HF-72296-16410			
07292			10/21/1997	Madira Intake Form, DS-102197-154630			
07293			9/29/1998	Madira Approved RPI Form, MP-92998-11827			
07294			7/28/1998	Madira Approved RPI Form, MH-72898-113818			
07295			10/21/1998	Madira Approved RPI Form, MH-102198-12365			
07296			5/25/1999	Madira Approved RPI Form, MP-52599-103755			
07297			8/6/1999	Madira Approved RPI Form, PS-8699-93531			
07298	W-MCL003-1429	W-MCL003-1430	10/00/2001	VM to Sales Force			
07299	W-MDL04782-00059870	W-MDL04782-00059872	9/22/1983	Memo re Prem-pak			
07320			6/21/2006	DEPO: Jean Meaney 7/11/06 EX 001: Notice of Deposition			
07321	MRK-HRT-0085	MRK-HRT-0167	6/2/1995	DEPO: Jean Meaney 7/11/06 EX 002: Co-Promotion Agreement			
07322	LOJEL011-000083	LOJEL011-000084		DEPO: Jean Meaney 7/11/06 EX 003: Fosamax Sales Issues			
07323			00/00/1997	DEPO: Jean Meaney 7/11/06 EX 004: Prempro label			
07324			00/00/1997	DEPO: Jean Meaney 7/11/06 EX 005: Premarin 1997 label			
07325			00/00/1998	DEPO: Jean Meaney 7/11/06 EX 006: Fosamax label			
07326	PICKJ018-000150	PICKJ018-00152	3/16/1994	DEPO: Jean Meaney 7/11/06 EX 007: Internal correspondence			
07327	LOJEL202-000745	LOJEL202-000809	9/00/1997	DEPO: Jean Meaney 7/11/06 EX 008: PPT "Fosamax PPA I"			
07328	LOJEL044-001477	LOJEL044-001490	00/00/1998	DEPO: Jean Meaney 7/11/06 EX 009: Marketing Plan			
07329	LOJEL044-000429	LOJEL044-000429	10/29/1996	DEPO: Jean Meaney 7/11/06 EX 010: Internal Memo			
07330	PANAA016-000512	PANAA016-000513	9/29/1995	DEPO: Jean Meaney 7/11/06 EX 011: Internal Memo			
07331	STRIS004-000197	STRIS004-000197	10/13/1995	DEPO: Jean Meaney 7/11/06 EX 012: Internal Memo			
07332	BURRG002-000049	BURRG002-000053	10/31/1994	DEPO: Jean Meaney 7/11/06 EX 013: History of Premarin			
07333	LOJEL008-001110	LOJEL008-001110	2/26/1997	DEPO: Jean Meaney 7/11/06 EX 014: Internal Memo			
07334				DEPO: Robert W. Wilson, Jr. 7/13/06 EX 001: Excerpts from Feminine Forever			
07335			6/5/2006	DEPO: Robert W. Wilson, Jr. 7/13/06 EX 002: Subpoena			
07336	W-MCL017-01461	W-MCL017-01464	4/00/1968	DEPO: Robert W. Wilson, Jr. 7/13/06 EX 003: WRF Bulletin			
07337	W-MCL017-01457	W-MCL017-01460	00/00/1968	DEPO: Robert W. Wilson, Jr. 7/13/06 EX 004: Medical Folio			
07338				DEPO: Robert W. Wilson, Jr. 7/13/06 EX 005: Washington Post article			
07339			11/16/1966	DEPO: Robert W. Wilson, Jr. 7/13/06 EX 006: Washington Post article			
07340			1/13/1967	DEPO: Robert W. Wilson, Jr. 7/13/06 EX 007: Washington Post Article			
07341				DEPO: Robert W. Wilson, Jr. 7/13/06 EX 008: Article			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07342			5/23/1963	DEPO: Robert W. Wilson, Jr. 7/13/06 EX 009: Certificate of Incorporation			
07343				DEPO: Robert W. Wilson, Jr. 7/13/06 EX 010: Article			
07344			6/30/1976	DEPO: Robert W. Wilson, Jr. 7/13/06 EX 011: Washington Post article			
07345	FARAN009-000353	FARNA009-000353	1/31/1964	DEPO: Robert W. Wilson, Jr. 7/13/06 EX 012: Letter			
07346	W-MCL017-01456	W-MCL017-01466		DEPO: Robert W. Wilson, Jr. 7/13/06 EX 013: Brochure			
07347				DEPO: Robert W. Wilson, Jr. 7/13/06 EX 014: Handwritten notes			
07348			7/10/2002	DEPO: Robert W. Wilson, Jr. 7/13/06 EX 015: Website			
07349				DEPO: Andrew Panagy 7/13/06 EX 001: Resume			
07350	CORRA001-000204	CORRA001-000211	3/00/1995	DEPO: Andrew Panagy 7/13/06 EX 002: Code of Pharmaceutical Marketing Practices			
07351	W-MDL04782-00065632	W-MDL04782-00065633	12/00/1975	DEPO: Andrew Panagy 7/13/06 EX 003: Letter			
07352	W-MDL04782-00027339	W-MDL04782-00027342	1/12/1976	DEPO: Andrew Panagy 7/13/06 EX 004: Memo			
07353	W-MDL04782-00015343	W-MDL04782-00015347		DEPO: Andrew Panagy 7/13/06 EX 005: Advertisement			
07354	PANAA026-001571	PANAA026-001572	2/21/1990	DEPO: Andrew Panagy 7/13/06 EX 006: Internal Correspondence			
07355	PANAA026-001750	PANAA026[-001751	5/15/1990	DEPO: Andrew Panagy 7/13/06 EX 007: Letter			
07356	PANAA034-001693	PANAA034-001694	8/22/1990	DEPO: Andrew Panagy 7/13/06 EX 008: Internal Correspondence			
07357	PANAA025-001950	PANAA025-001951	5/31/1990	DEPO: Andrew Panagy 7/13/06 EX 009: Internal Correspondence			
07358	PANAA002-000247	PANAA002-000271	9/4/2002	DEPO: Andrew Panagy 7/13/06 EX 010: PPT "ERT/HRT Update"			
07359	PANAA004-000511	PANAA004-000513	11/13/2001	DEPO: Andrew Panagy 7/13/06 EX 011: Final Report on HRT Benefit Messages			
07360	PANAA004-000514	PANAA004-000516		DEPO: Andrew Panagy 7/13/06 EX 012: Core Messages - Premarin Benefits Packages			
07361	PANAA040-027590	PANAA040-027670	6/2/2000	DEPO: Andrew Panagy 7/13/06 EX 013: PPT "Global ERT/HRT Strategy"			
07362	W-ADSBRO-00981	W-ADSBRO-00988	1/00/2000	DEPO: Andrew Panagy 7/13/06 EX 014: Advertisement			
07363	W-ADSBRO-00068	W-ADSBRO-00070	1/00/1999	DEPO: Andrew Panagy 7/13/06 EX 015: Advertisement			
07364	PANAA013-000299	PANAA013-000299	10/8/2002	DEPO: Andrew Panagy 7/13/06 EX 016: Fax Cover Sheet			
07365	W-MDL04782-00002391	W-MDL04782-00002393	2/25/1991	DEPO: Andrew Panagy 7/13/06 EX 017: Letter			
07366	PANAA011-000986	PANAA011-000988		DEPO: Andrew Panagy 7/13/06 EX 018: African-American Analysis			
07367	PANAA011-000983	PANAA011-000985	6/12/2001	DEPO: Andrew Panagy 7/13/06 EX 019: Memo			
07368	LOJEL027-001550	LOJEL027-001564		DEPO: Andrew Panagy 7/13/06 EX 020: Doctor's Guide for Women in Menopause			
07369	PETKD002-000055	PETKD002-000057	2/22/2000	DEPO: Andrew Panagy 7/13/06 EX 021: Dear Doctor Letter			
07370	DELCA008-001182	DELCA008-001185	2/00/2000	DEPO: Andrew Panagy 7/13/06 EX 022: Q&A			
07371	HENRL018-000214	HENRL018-000222	7/8/2002	DEPO: Lesa Henry 7/21/06 EX 001: Premarin Oral Family Briefing Document			
07372	HENRL001-000350	HENRL001-000360	00/00/1999	DEPO: Lesa Henry 7/21/06 EX 002: Premarin Family HCP Budget			
07373	HENRL001-000112	HENRL001-000121		DEPO: Lesa Henry 7/21/06 EX 003: Key Campaigns and Message Tracks			
07374	HENRL011-000450	HENRL011-000469		DEPO: Lesa Henry 7/21/06 EX 004: PPT "Power of Consumer Communications"			
07375	HENRL001-000459	HENRL001-000459	12/8/1999	DEPO: Lesa Henry 7/21/06 EX 005: Ketchum document			
07376	HENRL001-001208	HENRL001-001208	4/30/1999	DEPO: Lesa Henry 7/21/06 EX 006: Internal Correspondence			
07377	HENRL001-001200	HENRL001-001204	5/19/1999	DEPO: Lesa Henry 7/21/06 EX 007: Draft document			
07378	HENRL018-000994	HENRL018-000994	11/10/1999	DEPO: Lesa Henry 7/21/06 EX 008: Ketchum document			
07379	HENRL018-000995	HENRL018-000995	12/2/1999	DEPO: Lesa Henry 7/21/06 EX 009: draft breast cancer template response letter			
07380	DAVIJ004-000928	DAVIJ004-000930		Colasante email			
07381	DEYMI015-000644	DEYMI015-000644	1/00/2001	Letter from Joseph Mahady			
07382	SOLOJ025-000228	SOLOJ025-000245	00/00/1997	AAFP Video CME Program			
07383	W-MDL04782-00150933	W-MDL04782-00150992	2/11/1991	DDMAC letters			
07384	W-MDL303-00083889	W-MDL303-00083892	11/8/1995	Internal Memo			
07385	PINIM002-000001	PINIM002-000044	1/10/2001	Policy 405			
07386			7/22/2003	Statement by Janet Woodcock, M.D. before the Senate Special Committee on Aging			
07387				DEPO: Robert Ruffolo 7/27/06 EX 001: C.V.			
07388	RUFFR003-001835	RUFFR003-001842	9/10/2002	DEPO: Robert Ruffolo 7/27/06 EX 002: PPT "Fall 2002 R&D All Hands Meeting"			
07389	RUFFR003-000984	RUFFR003-001002		DEPO: Robert Ruffolo 7/27/06 EX 003:			
07390	RUFFR003-000519	RUFFR003-000520		DEPO: Robert Ruffolo 7/27/06 EX 004: PPT			
07391	CONSG010-001341	CONSG010-001343	9/13/2002	DEPO: Robert Ruffolo 7/27/06 EX 005: Letter			
07392	RUFFR003-000093	RUFFR003-000093	11/8/2002	DEPO: Robert Ruffolo 7/27/06 EX 006: Email			
07393	RUFFR003-003480	RUFFR003-003481	11/22/2002	DEPO: Robert Ruffolo 7/27/06 EX 007: Email			
07394	RUFFR001-000637	RUFFR001-000637	8/00/2002	DEPO: Robert Ruffolo 7/27/06 EX 008: Questions and Answers on HRT			
07395	RUFFR001-000636	RUFFR001-000636	8/30/2002	DEPO: Robert Ruffolo 7/27/06 EX 009: Email			
07396	RUFFR001-000638	RUFFR001-000646	8/00/2002	DEPO: Robert Ruffolo 7/27/06 EX 010: Background on WHI Study Results			
07397	RUFFR001-000704	RUFFR001-000717	8/7/2002	DEPO: Robert Ruffolo 7/27/06 EX 011: draft resposne to WHI Study Results by ACOG			
07398	CONNS005-000396	CONNS005-000397	6/29/1989	DEPO: Nick Marmontello 7/28/06 EX 001: Internal Correspondence			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07399	W-MDL04782-00000931	W-MDL04782-00000931	1/26/1990	DEPO: Nick Marmontello 7/28/06 EX 002: Internal Correspondence			
07400	PANAA034-001426	PANAA034-001427	8/22/1990	DEPO: Nick Marmontello 7/28/06 EX 003: Internal Correspondence			
07401	ROSSC023-000521	ROSSC023-000521	9/5/1991	DEPO: Nick Marmontello 7/28/06 EX 004: Internal Correspondence			
07402	PANAA014-0001130	PANAA014-0001130	1/23/1992	DEPO: Nick Marmontello 7/28/06 EX 005: Internal Correspondence			
07403	CONNS005-000070	CONNS005-000072	3/24/1992	DEPO: Nick Marmontello 7/28/06 EX 006: Memo			
07404	W-MDL303-00081862	W-MDL303-00081867	8/27/1992	DEPO: Nick Marmontello 7/28/06 EX 007: Letter			
07405	STRIS004-000183	STRIS004-000184	12/20/1996	DEPO: Nick Marmontello 7/28/06 EX 008: Letter			
07406	MARMN014-000150	MARMN014-000181		DEPO: Nick Marmontello 7/28/06 EX 009: Business Planning & Analysis			
07407	MARMN014-000295	MARMN014-000308	6/18/2002	DEPO: Nick Marmontello 7/28/06 EX 010: Growing Threat to Our HRT Business			
07408	MARMN001-000330	MARMN001-000342	5/20/2002	DEPO: Nick Marmontello 7/28/06 EX 011: Premarin Diagnostic Report			
07409	MARMN012-000015	MARMN012-000037		DEPO: Nick Marmontello 7/28/06 EX 012: Conference Call Q&As			
07410	MARMN013-000652	MARMN013-000684	9/24/2003	DEPO: Nick Marmontello 7/28/06 EX 013: Wyeth Diagnostic Review			
07411	MARMN012-000019	MARMN012-000029	4/00/2003	DEPO: Nick Marmontello 7/28/06 EX 014: Briefing Document			
07412	MARMN013-000721	MARMN013-000722	6/00/1998	DEPO: Nick Marmontello 7/28/06 EX 015: Premarin News Net			
07413	MARMN016-000090	MARMN016-000092	10/29/1999	DEPO: Nick Marmontello 7/28/06 EX 016: POA Portfolio Worksheet			
07414	STRIS004-000197	STRIS004-000197	10/13/1995	DEPO: Nick Marmontello 7/28/06 EX 017: Memo			
07415	PANAA016-000500	PANAA016-000507	5/31/1995	DEPO: Nick Marmontello 7/28/06 EX 018: Fosamax Press Release			
07416			6/22/2006	Ralph Hale 7/25/06 DEPO EX 001: Subpoena and NOD of ACOG			
07417			4/00/1998	Ralph Hale 7/25/06 DEPO EX 002: ACOG Educational Bulletin Number 246 April 1998 "Osteoporosis"			
07418			5/00/1998	Ralph Hale 7/25/06 DEPO EX 003: ACOG Educational Bulletin Number 247 May 1998 "Hormone Replacement Therapy"			
07419			8/00/1991	Ralph Hale 7/25/06 DEPO EX 004: ACOG Technical Bulletin Number 158 August 1991 "Carcinoma of the Breast"			
07420			4/00/1986	Ralph Hale 7/25/06 DEPO EX 005: ACOG Technical Bulletin Number 93 April 1996 "Estrogen Replacement Therapy"			
07421			4/00/1992	Ralph Hale 7/25/06 DEPO EX 006: ACOG Technical Bulletin Number 166 April 1992 "Hormone Replacement Therapy"			
07422			9/00/1997	Ralph Hale 7/25/06 DEPO EX 007: ACOG Committee Opinion Number 185 September 1997 "Routine Cancer Screening"			
07422 A	HENRL001-000112	HENRL001-000121		Raise awareness and concern			
07423			4/00/1994	Ralph Hale 7/25/06 DEPO EX 008: ACOG Committee Opinion Number 135 April 1994 "Estrogen Replacement Therapy in Women with Previously Treated Breast Cancer"			
07423 A	LYTRR016-001231	LYTRR016-001232	2/00/2000	Working Group on Breast Cancer publicity			
07423 B	LYTRR016-001229	LYTRR016-001230	2/00/2000	Card for sales rep to memorize on how to respond to the breast cancer issue			
07423 C	LYTRR016-001224	LYTRR016-001228	2/22/2000	Card for doctors to use with patients to reassure them that there is no breast cancer issue			
07424			11/00/1999	Ralph Hale 7/25/06 DEPO EX 009: ACOG Committee Opinion Number 226 November 1999 "Hormone Replacement Therapy in Women with Previously Treated Breast Cancer"			
07425			12/00/2001	Ralph Hale 7/25/06 DEPO EX 010: ACOG Committee Opinion Number 262 December 2001 "Risk of Breast Cancer with Estrogen-Progestin Replacement Therapy"			
07426			10/1992	Ralph Hale 7/25/06 DEPO EX 011: ACOG Patient Education pamphlet October 1992 "Hormone Replacement Therapy"			
07427			5/00/1986	Ralph Hale 7/25/06 DEPO EX 012: ACOG Patient Education pamphlet May 1986 "Estrogen Use"			
07428			10/1992	Ralph Hale 7/25/06 DEPO EX 013: ACOG Patient Education pamphlet October 1992 "Preventing Osteoporosis"			
07429			8/00/1984	Ralph Hale 7/25/06 DEPO EX 014: ACOG Patient Education pamphlet August 1984 "Preventing Osteoporosis"			
07430			8/00/1984	Ralph Hale 7/25/06 DEPO EX 015: ACOG Patient Education pamphlet August 1984 "Preventing Osteoporosis"			
07431			10/1992	Ralph Hale 7/25/06 DEPO EX 016: ACOG Patient Education pamphlet October 1992 "The Menopause Years"			
07432	PANAA023-000358	PANAA023-000360	9/18/1995	Ralph Hale 7/25/06 DEPO EX 017: Letter			
07433	CHOOM024-000355		7/18/1998	Ralph Hale 7/25/06 DEPO EX 018: Letter			
07434	CHOOM024-000351	CHOOM024-000352	10/28/1997	Ralph Hale 7/25/06 DEPO EX 019: Letter			
07435			12/8/2003	Ralph Hale 7/25/06 DEPO EX 020: ACOG Postgraduate Course "Controversies in Menopause" (Archer) excerpts 25274; 25276-25278			
07436	DUROJ204-002134	DUROJ204-002163		Ralph Hale 7/25/06 DEPO EX 021: Financial documents			
07437	CHOOM034-001672	CHOOM034-001673	1/16/1997	Ralph Hale 7/25/06 DEPO EX 022: Memo			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07438			12/00/2002	Ralph Hale 7/25/06 DEPO EX 023: "Perspectives on the Women's Health Initiative Trial of Hormone Replacement Therapy" (Grimes, et al) ACOG reprint			
07439			3/12/2003	Ralph Hale 7/25/06 DEPO EX 024: Memo			
07440	DUROJ043-000211	DUROJ043-000212		Ralph Hale 7/25/06 DEPO EX 025: "Development of Advocates and Initiatives November 1997 to Present"			
07441			12/4/2003	Ralph Hale 7/25/06 DEPO EX 026: "Osteoporosis" 46704 - 46751			
07442			8/11/2004	Ralph Hale 7/25/06 DEPO EX 027: Letter			
07443			3/8/2005	Ralph Hale 7/25/06 DEPO EX 28: Email			
07444			5/00/1986	Ralph Hale 7/25/06 DEPO EX 29: ACOG Patient Education pamphlet "Estrogen Use" May 1986			
07445			7/00/1997	Ralph Hale 7/25/06 DEPO EX 30: ACOG Patient Education pamphlet "Preventing Osteoporosis" July 1997			
07446			10/00/2004	Ralph Hale 7/25/06 DEPO EX 031: "Frequently Asked questions about Hormone Therapy" October 2004 ACOG website excerpt			
07447			10/00/2004	Ralph Hale 7/25/06 DEPO EX 032: "Hormone Therapy" Obstetrics & Gynecology Vol. 104, No. 4, Supplement October 2004 excerpts			
07448	DUROJ044-002415	DUROJ044-002422	00/00/1999	Jeannemarie Durocher 8/2/06 DEPO EX 064: IM AD proposed Department Budget			
07449	DUROJ206-000066	DUROJ206-000068	9/25/2003	Jeannemarie Durocher 8/2/06 DEPO EX 065: Premarin HCP 1999 Budget			
07450	DUROJ020-000649	DUROJ020-000652	00/00/2001	Jeannemarie Durocher 8/2/06 DEPO EX 066: Premarin In-Line Budget 2001			
07451	CONTA025-020958	CONTA025-020959	1/8/2002	Jeannemarie Durocher 8/2/06 DEPO EX 067: Email			
07452	DWRITE066081	DWRITE 066085	12/7/1999	Jeannemarie Durocher 8/2/06 DEPO EX 068 & Janas, Bernadette 1/03/2008 EX 9: Premarin Family of Products Publication Plan Proposal			
07453	DWRITE066034	DWRITE 066066	9/00/1999	Jeannemarie Durocher 8/2/06 DEPO EX 069 & Janas, Bernadette 1/03/2008 EX10: Medical and Scientific Communications Plan			
07454	DWRITE066067	DWRITE 066074	9/27/1999	Jeannemarie Durocher 8/2/06 DEPO EX 070: Symposia Topics 2000			
07455	DWRITE065952	DWRITE 065968	11/20/1998	Jeannemarie Durocher 8/2/06 DEPO EX 071: Study Management Plan			
07456	DWRITE065764	DWRITE 065812	8/12/1996	Jeannemarie Durocher 8/2/06 DEPO EX 072 & Janas, Bernadette 1/3/2008 EX 4: Medical Education and Communications Plan			
07457	DWRITE065923	DWRITE065941	5/15/1997	Jeannemarie Durocher 8/2/06 DEPO EX 073: Premarin Publication Program			
07458	DUROJ206-000246	DUROJ206-000248	11/7/2002	Jeannemarie Durocher 8/2/06 DEPO EX 074: WHC Strategic Publication Development Proposal			
07459	DUROJ206-000249	DUROJ206-000251	11/7/2002	Jeannemarie Durocher 8/2/06 DEPO EX 075: Publication Management			
07460	DUROJ206-000177	DUROJ206-000179	8/11/2003	Jeannemarie Durocher 8/2/06 DEPO EX 076: Publication Management and Strategic Publication Planning			
07461	DWRITE066028	DWRITE 066029	1/12/2005	Jeannemarie Durocher 8/2/06 DEPO EX 077: Memo			
07462	Various	Various	1/19/1999	Jeannemarie Durocher 8/2/06 DEPO EX 078: Group of documents			
07463				Jeannemarie Durocher 8/2/06 DEPO EX 079: CD-ROM of documents			
07464	DUROJ022-000042	DUROJ022-000043		Jeannemarie Durocher 8/2/06 DEPO EX 080: Memo			
07465	DUROJ023-002046	DUROJ023-002047	3/29/2002	Jeannemarie Durocher 8/2/06 DEPO EX 081: Tibolone Global Initiative Agenda			
07466	DUROJ046-019452	DUROJ046-019460	3/29/2002	Jeannemarie Durocher 8/2/06 DEPO EX 082: Tibolone Global Initiative Meeting Minutes			
07467	DUROJ026-000385	DUROJ026-000396		Jeannemarie Durocher 8/2/06 DEPO EX 083: Draft Outline			
07468	KUSIV009-009208	KUSIV009-009214	11/00/2002	Jeannemarie Durocher 8/2/06 DEPO EX 084: Letter			
07469	DUROJ001-000854	DUROJ001-000854	8/15/2002	Jeannemarie Durocher 8/2/06 DEPO EX 085: Guidelines for Promoting Research and Discovery			
07470	DUROJ020-000399	DUROJ020-000401	2/00/2000	Jeannemarie Durocher 8/2/06 DEPO EX 086: Letter			
07471	DUROJ024-002467	DUROJ024-002469	2/8/2002	Jeannemarie Durocher 8/2/06 DEPO EX 087: Media Release			
07472	DUROJ017-001011	DUROJ001-001011		Jeannemarie Durocher 8/2/06 DEPO EX 088: New Survey Findings			
07473	DUROJ017-001010	DUROJ017-001010	2/21/2001	Jeannemarie Durocher 8/2/06 DEPO EX 089: Dr. Waldrep Dallas Media Tour			
07474	DUROJ017-001012	DUROJ017-001013	2/21/2001	Jeannemarie Durocher 8/2/06 DEPO EX 090 - Document			
07475	DUROJ017-001020	DUROJ017-001022		Jeannemarie Durocher 8/2/06 DEPO EX 091: New Survey Findings			
07476	DUROJ043-000211	DUROJ043-000212		Jeannemarie Durocher 8/2/06 DEPO EX 092: Development of Advocates and Initiatives			
07477	LUDMG003-00423	LUDMG003-00426	10/15/1998	Jeannemarie Durocher 8/2/06 DEPO EX 093: Memo			
07478	DUROJ039-000644	DUROJ039-000644	1/26/1998	Jeannemarie Durocher 8/2/06 DEPO EX 094: Letter			
07479	PANAA016-000465	PANAA016-000487		Carrie Smith Cox 8/10/06 DEPO EX 001:			
07480	SINAM009-000224	SINAM009-000229	1/12/1993	Carrie Smith Cox 8/10/06 DEPO EX 002:			
07481	PANAA031-001645	PANAA031-001645	5/17/1990	Carrie Smith Cox 8/10/06 DEPO EX 003:			
07482	PANAA026-001749	PANAA026-001749	5/17/1990	Carrie Smith Cox 8/10/06 DEPO EX 004:			
07483	PANAA034-001426	PANAA034-001427	8/22/1990	Carrie Smith Cox 8/10/06 DEPO EX 005:			
07484	PANAA014-001130	PANAA014-001130	1/23/1992	Carrie Smith Cox 8/10/06 DEPO EX 006:			
07485	VICTJ005-001581	VICTJ005-001581	2/6/1992	Carrie Smith Cox 8/10/06 DEPO EX 007:			
07486	CONNS005-000070	CONNS005-000072	3/24/1992	Carrie Smith Cox 8/10/06 DEPO EX 008:			
07487	W-MDL303-00081835	W-MDL303-00081836	4/26/1992	Carrie Smith Cox 8/10/06 DEPO EX 009:			
07488	ROSSC005-000083	ROSSC005-000084	8/14/1992	Carrie Smith Cox 8/10/06 DEPO EX 010:			
07489	W-MDL303-00081683	W-MDL303-00081687	8/27/1992	Carrie Smith Cox 8/10/06 DEPO EX 011:			
07490	W-MDL303-00081654	W-MDL303-00081654	9/9/1992	Carrie Smith Cox 8/10/06 DEPO EX 012:			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07491				Carrie Smith Cox 8/10/06 DEPO EX 013:			
07492	SINAM010-000033	SINAM010-000047	2/2/1997	Carrie Smith Cox 8/10/06 DEPO EX 014:			
07493	DUROJ044-002415	DUROJ044-002422	00/00/1999	Carrie Smith Cox 8/10/06 DEPO EX 015:			
07494	PANAA023-000358	PANAA023-000358	8/18/1995	Carrie Smith Cox 8/10/06 DEPO EX 016:			
07495	CHOOM024-000355	CHOOM024-000355	7/18/1998	Carrie Smith Cox 8/10/06 DEPO EX 017:			
07496	DUROJ020-000632	DUROJ020-000635	00/00/2001	Carrie Smith Cox 8/10/06 DEPO EX 018:			
07497			2/9/1994	Carrie Smith Cox 8/10/06 DEPO EX 019:			
07498			7/27/2006	Justin Victoria 8/15/06 DEPO EX 001: Statement			
07498A			8/17/2006	Justin Victoria 8/15/06 DEPO EX 002: Statement			
07499			7/27/2006	Ginger Constantine 8/16/06 DEPO EX 001: Statement			
07500			7/27/2006	James Pickar 8/16/06 DEPO EX 001: Statement			
07501			7/27/2006	JeanneMarie Durocher 8/18/06 DEPO EX 001: Statement			
07502	W-MDL04782-00030694	W-MDL04782-00030703	9/13/1983	Estrogen Workshop			
07503	W-ADSBRO-00771	W-ADSBRO-00786	11/17/1995	Patient Brochure			
07504	STRIS005-000090	STRIS005-000109	08/00/1998	Sales aids			
07505	PESKM001-000004	PESKM001-000004	09/00/1998	Memo to Sales force			
07506	YAVUE002-001526	YAVUE002-001528	00/00/1999	Premarin family brand strategy			
07507	DUROJ042-000781	DUROJ042-000826	3/1/1998	Premarin 3 Year Strategic Plan 1995-1997			
07508	PANAA017-000480	PANAA017-000498	12/00/1995	1996 Marketing Plan			
07509	SINAM002-000850	SINAM002-000851	12/2/1993	Premarin v. Estrace Presentation			
07510	W-MDL04782-00014933	W-MDL04782-00014933	3/21/1942	Wyeth letter to FA submitting NDA for Premarin			
07511	W-MDL04782-00082823	W-MDL04782-00082834	7/28/1977	Ayerst summary of OB/GYN Advisory Committee Meeting			
07512	W-MDL04782-00067638	W-MDL04782-00067642	2/11/1986	Ayerst letter to FDA			
07513	W-IND-00007054	W-IND-00007056	2/3/1992	Internal Correspondence re Premarin CV labeling			
07514	W-MDL04782-00141601	W-MDL04782-00141603	3/27/1992	FDA letter re supplemental NDA for Premarin			
07515	W-MDL527-00037492	W-MDL527-00037541	12/12/1997	Wyeth letter enclosing draft labeling			
07516	CONNS015-000295	CONNS015-000295	11/8/1988	Wyeth memo re Premarin Substitution Data			
07517	VICTJ005-000096	VICTJ005-000096	2/1/1989	Wyeth memo re Premarin Tablets			
07518	W-MDL04782-00000388	W-MDL04782-00000389	12/6/1989	Wyeth memo re HRT & Protective Benefits			
07519	W-MDL04782-00000392	W-MDL04782-00000394	3/21/1990	FDA Meeting Minutes			
07520	DUROJ039-002017	DUROJ039-0002019	7/23/1991	FDA Meeting Minutes			
07521	VICTJ005-001580	VICTJ005-001580	2/16/1992	Wyeth Memo re Trip Report			
07522	ROSSC012-002098	ROSSC012-002099	1/12/1995	FDA Memo 45 day meeting			
07523	ROSSC008-001897	ROSSC008-001897	7/13/1995	FDA Memo re Material for July meeting			
07524	GPIL044-002259	GPIL044-002274	3/9/1990	draft Premarin label			
07526				Edward DeAngelo 9/7/06 TRIAL EX 7526			
07527				Edward DeAngelo 9/7/06 TRIAL EX 7527			
07529	W-MDL04782-00000392	W-MDL04782-00000394	3/21/1990	Philip Corfman 9/8/06 TRIAL EX 7529			
07532				Philip Corfman 9/8/06 TRIAL EX 7532			
07535			7/12/2006	Patricia Franklin 8/23/06 DEPO EX 001: NOD			
07536	SDRVE002-0013636	SDRVE002-0013673	1/00/2000	Patricia Franklin 8/23/06 DEPO EX 002: Incentive Plan			
07536A	DUROJ043-000992	DUROJ043-000994		Robert Essner 9/20/06 DEPO EX 005: Strategic Plan			
07537	W-ADSBRO-00070	W-ADSBRO-00070	1/00/1999	Patricia Franklin 8/23/06 DEPO EX 003: PAC ad			
07538	FRANP002-035810	FRANP002-035817		Patricia Franklin 8/23/06 DEPO EX 004: suggested sales presentations			
07539	REYNJ003-000584	REYNJ003-000584	3/00/2002	Patricia Franklin 8/23/06 DEPO EX 005: Brag Report			
07540	FRANP001-036274	FRANP001-036274	2/5/2005	Patricia Franklin 8/23/06 DEPO EX 006: Email			
07541	FRANP002-029640	FRANP002-029641		Patricia Franklin 8/23/06 DEPO EX 007: Memo			
07542	SALESTR001-000209	SALESTR001-000236	00/00/1995	Lawrence Kessler 8/28/06 DEPO EX 001: Product Training Manual			
07543	CONTA003-000728	CONTA003-000785	00/00/1995	Lawrence Kessler 8/28/06 DEPO EX 002: Product Training Manual; Alice Perrone 8/30/06 DEPO EX 002: Product Training Manual			
07544	CCC060-000476	CCC060-000499	8/1/1995	Lawrence Kessler 8/28/06 DEPO EX 004: Understanding Hormone Replacement Therapy			
07545	CCC054-000526	CCC054-000528	00/00/1996	Lawrence Kessler 8/28/06 DEPO EX 005: Premarin POA I			
07546	PAYN001-000688	PAYN001-000696	6/00/1996	Lawrence Kessler 8/28/06 DEPO EX 006: Ad			
07547	SALESTR001-001586	SALESTR001-001612	00/00/1996	Lawrence Kessler 8/28/06 DEPO EX 007: Guide to Understanding Studies			
07548	CCC060-000565	CCC060-000564	00/00/1997	Lawrence Kessler 8/28/06 DEPO EX 008: POA I			
07549	CCC023-000004	CCC023-000015	1/00/1997	Lawrence Kessler 8/28/06 DEPO EX 009: POA I			
07550	CCC079-001680	CCC079-001686; CCC079-001697;CCC023-000002	7/00/1997	Lawrence Kessler 8/28/06 DEPO EX 010: Ad			
07551	PAYN001-000110	PAYN001-000114	12/00/1997	Lawrence Kessler 8/28/06 DEPO EX 011: Ad			
07552	CCC004-000024	CCC004-000041	2/00/1997	Lawrence Kessler 8/28/06 DEPO EX 012: Ad			
07553	CCC079-000245	CCC079-000248	00/00/1997	Lawrence Kessler 8/28/06 DEPO EX 013: POA II			
07554	CCC087-001894	CCC087-001895	10/00/1997	Lawrence Kessler 8/28/06 DEPO EX 014: Tear Sheet			
07555	CCC087-001892	CCC087-001895; CCC053-000632		Lawrence Kessler 8/28/06 DEPO EX 015: Addressing Patient Questions			
07556	CCC046-001274	CCC046-001274		Lawrence Kessler 8/28/06 DEPO EX 016: Consequences of Aging			
07557	CCC093-000063	CCC093-000064	1/00/1998	Lawrence Kessler 8/28/06 DEPO EX 018: PAC piece			
07558	CCC051-001444	CCC051-001445; CCC093-000061-CCC093-000062	10/00/1999	Lawrence Kessler 8/28/06 DEPO EX 018A: PAC piece			
07559	CCC053-001637	CCC053-001642	1/00/1998	Lawrence Kessler 8/28/06 DEPO EX 019: Ask Your Doctor			
07560	CCC051-000965	CCC051-000966	12/00/1999	Lawrence Kessler 8/28/06 DEPO EX 019A: Ask Your Doctor			
07561	CCC059-000458	CCC059-000459	3/00/2000	Lawrence Kessler 8/28/06 DEPO EX 019B: Ask Your Doctor			
07562	CCC087-002122	VARIOUS	1/00/1998	Lawrence Kessler 8/28/06 DEPO EX 020: Menopause and Your Vision			
07563	CCC093-000026	VARIOUS	1/00/1998	Lawrence Kessler 8/28/06 DEPO EX 021: Ask Your Doctor			
07564	SALETR001-001560	SALETR001-001583		Lawrence Kessler 8/28/06 DEPO EX 022: Guide to Understanding Recent Studies			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07565	CONTA004-000871	CONTA004-000902		Lawrence Kessler 8/28/06 DEPO EX 023: CV Disease/Lipids Backgrounder; Alice Perrone 8/30/06 DEPO EX 004: CV/Lipids Backgrounder			
07566	CONTA012-001895	CONTA012-001929		Lawrence Kessler 8/28/06 DEPO EX 024: slide show persentation; Alice Perrone 8/30/06 DEPO EX 005: Slide presentation			
07567	CCC093-000104	CCC093-000134	5/4/1998	Lawrence Kessler 8/28/06 DEPO EX 025: Discover More			
07568	CONTA004-000857	CONTA004-000859	08/00/1998	Lawrence Kessler 8/28/06 DEPO EX 026: Evaluating HRT			
07569	CONTA004-000867	CONTA004-000869		Lawrence Kessler 8/28/06 DEPO EX 027: Frequently Asked Questions; Alice Perrone 8/30/06 DEPO EX 007: Heart Estrogen/Progestin Replacement Study			
07570	CCC072-000142	CCC072-000150	00/00/1999	Lawrence Kessler 8/28/06 DEPO EX 028: Draft of POA II			
07571	CCC093-000082	VARIOUS	3/00/1999	Lawrence Kessler 8/28/06 DEPO EX 029: Menopause and Sexuality			
07572	CCC093-001416	CCC093-001419	6/00/1999	Lawrence Kessler 8/28/06 DEPO EX 030: Putting Estrogen and Risk for Breast Cancer in Perspective			
07573	CCC011-001037	CCC011-001038	1/00/1999	Lawrence Kessler 8/28/06 DEPO EX 031: Menopause Isn't Gone in a Flash			
07574	PAYNC201-000831	PAYNC201-000905		Lawrence Kessler 8/28/06 DEPO EX 032: Focus on Growth			
07575	SALESTR001-001742	SALESTR001-001773	8/00/1999	Lawrence Kessler 8/28/06 DEPO EX 033: Resource Guide			
07576	CONTA012-000514	CONTA012-000530		Lawrence Kessler 8/28/06 DEPO EX 034: POA 2K			
07577	PAYNC201-001175	PAYNC201-001177	2/4/2000	Lawrence Kessler 8/28/06 DEPO EX 036: Voice Mail			
07578	CONTA003-000623	CONTA003-000670	00/00/1995	Alice Perrone 8/30/06 DEPO EX 001: Sales Training Material			
07579	CONTA003-000728	CONTA003-000785	00/00/1995	Alice Perrone 8/30/06 DEPO EX 002: Product Training Manual			
07579A	BECK002-000551			Product Training Manual Beck 5			
07580	SALESTR001-000209	SALESTR001-000236	00/00/1995	Alice Perrone 8/30/06 DEPO EX 003: Product Training Manual			
07581	CONTA004-000871	CONTA004-000902		Alice Perrone 8/30/06 DEPO EX 004: CV/Lipids Backgrounder			
07582	CONTA012-001895	CONTA012-001929		Alice Perrone 8/30/06 DEPO EX 005: Slide presentation			
07583	CONTA012-000514	CONTA012-000530		Alice Perrone 8/30/06 DEPO EX 006: POA slide presentation			
07584	CONTA004-000867	CONTA004-000869		Alice Perrone 8/30/06 DEPO EX 007: Heart Estrogen/Progestin Replacement Study			
07585	CONTA023-000540	CONTA023-000575		Alice Perrone 8/30/06 DEPO EX 008: ERT/HRT Update			
07586	CONTA023-002258	CONTA023-002358	2/9/2002	Alice Perrone 8/30/06 DEPO EX 009: CHE Slide presentation			
07587	CONTA014-000103	CONTA014-000110	1/4/2001	Alice Perrone 8/30/06 DEPO EX 010: Slide presentation			
07588	CONTA014-000168	CONTA014-000173	12/13/2000	Alice Perrone 8/30/06 DEPO EX 011: Slide presentation			
07589				Alice Perrone 8/30/06 DEPO EX 012: CV			
07590	CONTA002-001187	CONTA002-001187	12/14/2000	Alice Perrone 8/30/06 DEPO EX 013: Letter			
07591	CONTA023-006750	CONTA023-006762		Alice Perrone 8/30/06 DEPO EX 014: PPT presentation			
07592	DWRITE076355	DWRITE076355	5/13/2002	Alice Perrone 8/30/06 DEPO EX 015: Email			
07593	DWRITE076334	DWRITE076334	6/6/2002	Alice Perrone 8/30/06 DEPO EX 016: Meeting minutes			
07594	CONTA213-014481	CONTA213-014481	8/12/2003	Alice Perrone 8/30/06 DEPO EX 017: Memo			
07595	DURQJ046-024041	DURQJ046-024041	10/3/2001	Alice Perrone 8/30/06 DEPO EX 018: Memo			
07596	DWRITE066091	DWRITE066093	1/10/2001	Alice Perrone 8/30/06 DEPO EX 019: Proposal			
07597	CONTA213-022294	CONTA213-022295	5/16/2001	Alice Perrone 8/31/06 DEPO EX 020: Publication plan			
07598	CONTA213-005382	CONTA213-005384	11/7/2002	Alice Perrone 8/31/06 DEPO EX 021: proposal			
07599	CONTA213-014395	CONTA213-014398	8/4/2003	Alice Perrone 8/31/06 DEPO EX 022: proposal			
07600	CONTA213-021510	CONTA213-021512	10/13/2003	Alice Perrone 8/31/06 DEPO EX 023: publication planning			
07601	CONTA023-005597	CONTA023-005703	10/15/2002	Alice Perrone 8/31/06 dEPO EX 024: publication plan			
07602	DWRITE066590	DWRITE066603	6/15/1998	Alice Perrone 8/31/06 DEPO EX 025: document			
07603	CONTA204-000882	CONTA204-000882		Alice Perrone 8/31/06 DEPO EX 026: review manuscripts			
07604	CONTA013-001035	CONTA013-001044		Alice Perrone 8/31/06 DEPO EX 027: PPT presentation			
07605	CONTA204-000807	CONTA204-000808	6/11/2003	Alice Perrone 8/31/06 DEPO EX 028: journal suggestions			
07606	CONTA023-011184	CONTA023-011207		Alice Perrone 8/31/06 DEPO EX 029: publication strategy			
07607	CONTA213-000647	CONTA213-000648	9/14/2000	Alice Perrone 8/31/06 DEPO EX 030: Email			
07608	CONTA213-003673	CONTA213-003681		Alice Perrone 8/31/06 DEPO EX 031: manuscript outline			
07609	CONTA213-000710	CONTA213-000717		Alice Perrone 8/31/06 DEPO EX 032: manuscript outline			
07610	CONTA025-030466	CONTA025-030475		Alice Perrone 8/31/06 DEPO EX 033: Role of Estrogens			
07611	DWRITE016061	DWRITE016079		Alice Perrone 8/31/06 DEPO EX 034: Efficacy and Safety of Low-Dose HT			
07612	DWRITE015749	DWRITE015769		Alice Perrone 8/31/06 DEPO EX 035: Efficacy and Safety of Low-Dose HT			
07613	DWRITE012863	DWRITE012885	7/10/1999	Alice Perrone 8/31/06 DEPO EX 036: HRT positive effects			
07614	DWRITE077463	DWRITE077476	2/8/2005	Alice Perrone 8/31/06 DEPO EX 037: Importance of Treating Vasomotor Symptoms			
07615	DWRITE077477	DWRITE077501		Alice Perrone 8/31/06 DEPO EX 038: Manopausal Vasomotor Symptoms			
07616	CONTA025-030228	CONTA025-030228		Alice Perrone 8/31/06 DEPO EX 039: Manuscript			
07617	CONTA025-030538	CONTA025-030539	6/15/2000	Alice Perrone 8/31/06 DEPO EX 040: meeting recap			
07618	CONTA017-000754	CONTA017-000761		Alice Perrone 8/31/06 DEPO EX 041: M.A.I.L.			
07619	CONTA025-024777	CONTA025-024783	9/13/2001	Alice Perrone 8/31/06 DEPO EX 042: document			
07620	CONTA023-007120	CONTA023-007124	3/24/2003	Alice Perrone 8/31/06 DEPO EX 043: tracking report			
07621	DWRITE065923	DWRITE065941	5/15/1997	Alice Perrone 8/31/06 DEPO EX 044: publication program			
07622	CONTA023-007125	CONTA023-007138	3/24/2003	Alice Perrone 8/31/06 DEPO EX 045: tracking report			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07623	CONTA023-007139	CONTA023-007145	3/24/2003	Alice Perrone 8/31/06 DEPO EX 046: tracking report			
07624	CONTA023-007113	CONTA023-007119	3/24/2003	Alice Perrone 8/31/06 DEPO EX 047: tracking report			
07625	CONTA013-000573	CONTA013-000574	11/27/2001	Alice Perrone 8/31/06 DEPO EX 048: tracking report			
07626	CONTA006-000091	CONTA006-000108	11/00/1998	Alice Perrone 8/31/06 DEPO EX 049: Consequences of Menopause			
07627	CONTA006-000109	CONTA006-000124		Alice Perrone 8/31/06 DEPO EX 050: Consequences of Menopause			
07628	OLIVS020-006156	OLIVS020-006158	6/26/2002	Alice Perrone 8/31/06 DEPO EX 051: Meeting minutes			
07629	SENDM015-005841	SENDM015-005843	10/23/2002	Alice Perrone 8/31/06 DEPO EX 052: Meeting minutes			
07630	CONTA019-001579	CONTA019-001581	12/6/2000	Alice Perrone 8/31/06 DEPO EX 053: Effect of HRT			
07631	CONTA019-001578	CONTA019-001578	12/7/2000	Alice Perrone 8/31/06 DEPO EX 054: Fax			
07632	CONTA020-000021	CONTA020-000022	10/30/2001	Alice Perrone 8/31/06 DEPO EX 055: Fax			
07633	CONTA020-000012	CONTA020-000013	11/1/2001	Alice Perrone 8/31/06 DEPO EX 056: Letter			
07634	DWRITE027664	DWRITE027665	10/13/1999	Alice Perrone 8/31/06 DEPO EX 057: Letter			
07635	MARQM015-000062	MARQM015-000065	2/17/1998	Robert Essner 9/20/06 DEPO EX 054: Letter			
07637	PANAA004-000514	PANAA004-000516		Robert Essner 9/20/06 DEPO EX 056: Core Message			
07638	RYANJ004-000013	RYANJ004-000014	3/20/2003	Robert Essner 9/20/06 DEPO EX 057: Prempro Call Simulations			
07639			10/7/2003	Garnet Anderson 11/28/06 DEPO EX 002: 10/7/03 PPT slides			
07640			10/30/2006	Garnet Anderson 11/28/06 DEPO EX 010: Clark paper			
07641			5/5/2006	Garnet Anderson 11/28/06 DEPO EX 017: 2006 Maturitas paper			
07642			7/17/2002	Garnet Anderson 11/28/06 DEPO EX 018: "Risks and Benefits of E + P in Healthy Postmenopausal Women"			
07643				Garnet Anderson 11/28/06 DEPO EX 020: Chart of E+P Never Users, Former Users, Placebo 1 and 2			
07644				Garnet Anderson 11/28/06 DEPO EX 021A: Chart showing rate of breast cancer, signed			
07645				Garnet Anderson 11/28/06 DEPO EX 021B: Chart showing rate of breast cancer, not signed			
07646			11/16/2006	Fred Hassan 12/16/06 DEPO EX 001: NOD of Fred Hassan			
07647			11/16/2006	Fred Hassan 12/16/06 DEPO EX 002: Cross-Notice of Depo			
07648			00/00/2005	Fred Hassan 12/16/06 DEPO EX 003: AHP Proxy Statement			
07649			00/00/2005	Fred Hassan 12/16/06 DEPO EX 004: AHP Proxy Statement			
07650	PICKJ016-000912	PICKJ016-000913	6/19/1990	Fred Hassan 12/16/06 DEPO EX 005: Memo			
07651				Fred Hassan 12/16/06 DEPO EX 006: Handwritten sheet			
07652				Fred Hassan 12/16/06 DEPO EX 007: Handwritten page			
07653			8/00/2005	Fred Hassan 12/16/06 DEPO EX 008: Biography			
07654			10/12/2006	Fred Hassan 12/16/06 DEPO EX 009: Fred Hassan Remarks			
07655	VICTJ005-001704		2/2/1990	Fred Hassan 12/16/06 DEPO EX 010: Memo			
07656	W-LABELS-000226	W-LABELS-000229	00/00/1993	Fred Hassan 12/16/06 DEPO EX 011: 1993 PDR excerpt			
07657	W-LABELS-000222	W-LABELS-000225	00/00/1992	Fred Hassan 12/16/06 DEPO EX 012: 1992 PDR excerpt			
07658	PANAA036-001536		5/14/1992	Fred Hassan 12/16/06 DEPO EX 013: Memo			
07660	ALIVJ002-000714		3/11/1991	Fred Hassan 12/16/06 DEPO EX 015: Memo			
07661	COBBP002-002728		5/16/1995	Fred Hassan 12/16/06 DEPO EX 016: Fax			
07662	W-MCL004-01712	W-MCL004-01719	9/30/1991	Fred Hassan 12/16/06 DEPO EX 017: Memo			
07663	W-LABELS-000230	W-LABELS-000233	00/00/1994	Fred Hassan 12/16/06 DEPO EX 018: 1994 PDR excerpt			
07664	W-LABELS-000234	W-LABELS-000237	00/00/1995	Fred Hassan 12/16/06 DEPO EX 019: 1995 PDR excerpt			
07665	PANAA023-00632		9/16/1994	Fred Hassan 12/16/06 DEPO EX 020: Letter			
07666	PANAA030-001795	PANAA030-001796	3/13/1992	Premarin Working Group			
07667	BROWS002-002576	BROWS002-002576	12/18/1998	OBJECTIVE DATA NOT AVAILABLE			
07668	BURKM016-000512	BURKM016-000512	6/9/1992	Application to Market a New Drug for Human Use or an Antibiotic Drug for Human Use ANDA No. 89-386 Cycrin			
07669	BURKM016-000971	BURKM016-000973	1/17/1997	NDA No. 04-782 Premarin Tablets			
07670	CHOOM004-000002	CHOOM004-000004		Prometrium Oral Micronized Progesterone			
07671	CHOOM006-002296	CHOOM006-002298	11/23/1998	MPA Defense Action Items			
07672	COBBP026-000185	COBBP026-000223		PROGESTINS AND HRT: ISSUES AND IMPLICATIONS			
07673	COBBP026-000730	COBBP026-000768		PROGESTINS AND HRT: ISSUES AND IMPLICATIONS			
07674	CONN5014-002112	CONN5014-002127	3/9/1990	Premarin/Cycrin (Conjugated Estrogens Tablets, Medroxyprogesterone Acetate Tablets)			
07675	DELCA032-002620	DELCA032-002658		PROGESTINS AND HRT: ISSUES AND IMPLICATIONS			
07676	DUROJ021-002085	DUROJ021-002090	10/12/1998	Do Progestins Attenuate Estrogen's Benefits against Cardiovascular Disease?			
07677	DUROJ023-001227	DUROJ023-001227	5/1/1998	Prometrium Meeting Outcome			
07678	DUROJ039-001958	DUROJ039-001958	2/28/1995	Schering-Plough			
07679	DUROJ041-001848	DUROJ041-001850	9/24/1998	Prometrium War Games			
07680	DUROJ041-001851	DUROJ041-001909	8/24/1998	Prempro/Premphase War Games - Final Report -			
07681	DUROJ044-004108	DUROJ044-004110		frequently asked questions re: HERS			
07682	FARAN016-001534	FARAN016-001551	6/3/1998	Prometrium War Games June 3, 1998 Voorhees, NJ			
07683	FARAN016-001553	FARAN016-001578	6/15/1998	Prometrium War Games June 15, 1998 Atlanta, GA			
07684	FISHG002-000004	FISHG002-000009	00/00/1999	Special Clinicopharmacological Features of Conjugated Equine Oestrogens is there Nowadays any Justifications for their Continuing Use for Postmenopausal Hormone Replacement Therapy?			
07685	MARTN010-008460	MARTN010-008484	4/12/2001	1996 HRT Budget			
07686	OLIVS018-018986	OLIVS018-018988	1/00/2002	Objectives			
07687	PANAA034-001673	PANAA034-001674	2/27/1990	letter from J Victoria to D Michels re: combination packaging for premarin & cycrin			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07688	PANAA034-001701	PANAA034-001701	5/23/1990	letter from J Hamilton to J Victoria re: combination packaging for premarin & cyrin			
07689	PANAA036-000201	PANAA036-000201	10/29/1991	Prometrium and Estrogel (Schering Plough)			
07690	PANAA036-000205	PANAA036-000205	10/21/1991	letter from A Baker to D Poorvin re: estrogel & prometrium			
07691	PANAA036-000206	PANAA036-000206	7/12/1991	Hormone Replacement Products (Schering-Plough)			
07692	PANAA036-000207	PANAA036-000207	7/3/1991	Hormone Replacement Products (Schering-Plough)			
07693	PANAA036-000208	PANAA036-000208		Prometrium (Oral Micronized Progesterone)			
07694	PANAA036-000209	PANAA036-000209	8/16/1991	Hormone Replacement Products from Schering Plough			
07695	PANAA036-000210	PANAA036-000210	10/14/1991	Terms of Secrecy Agreement (Schering Plough)			
07696	PANAA036-000213	PANAA036-000213	7/2/1991	Hormone Replacement Products (Schering-Plough)			
07697	PANAA036-000218	PANAA036-000218	9/22/1994	Prometrium (Schering Plough)			
07698	PANAA036-000219	PANAA036-000219	9/13/1994	Prometrium (Schering Plough)			
07699	PANAA036-000220	PANAA036-000220	6/3/1991	letter from D Poorvin to A Baker at Wyeth re: strategic objectives for their HRT			
07700	PANAA036-000226	PANAA036-000226	10/24/1991	letter from D Poorvin to A Baker re: prometrium			
07701	PANAA036-000227	PANAA036-000260		Utrogestan II. Application Summary			
07702	PANAA036-000296	PANAA036-000296	11/12/1991	Prometrium and Estrogel (Schering-Plough)			
07703	PANAA036-000297	PANAA036-000297	12/23/1991	Results, Meeting No.4 (December 16, 1991)			
07704	PANAA036-000298	PANAA036-000299	1/21/1992	Meeting with Schering Plough (S-P)			
07705	PANAA036-000300	PANAA036-000300	3/17/1992	hand written note to A Baker			
07706	PANAA036-000303	PANAA036-000303	4/21/1992	Schering's Prometrium			
07707	PANAA036-000307	PANAA036-000307	5/27/1993	Estrogel and Prometrium (Schering Plough)			
07708	PANAA036-000317	PANAA036-000317	5/28/1993	Telephone Conversation with Mark Wiggins (Schering Plough)			
07709	PANAA036-000330	PANAA036-000331	5/3/1995	Potential Co-Promotion Agreement with Schering-Plough for Prometrium			
07710	PANAA036-000336	PANAA036-000336	4/5/1995	Prometrium Schering Plough			
07711	PANAA036-000337	PANAA036-000337	5/5/1995	Prometrium Document			
07712	PANAA036-000338	PANAA036-000339		Wyeth-Ayerst World Leaders in Women Health Care			
07713	PANAA036-000342	PANAA036-000343	9/14/1995	Prometrium(TM) to Make Hormone Therapy more Appealing for Menopausal Women			
07715	W-MDL303-00084725	W-MDL303-00084852	1/27/1998	Form 2253 - Summary of Significant New Information tab; Manufacturing and Control Changes tab; Nonclinical Laboratory Studies tab; Clinical Data tab (NDA 20-303)			
07716	W-MDL527-00036112	W-MDL527-00036171	1/15/1997	Annual Report (NDA 20-527)			
07717	DUROJ039-001922	DUROJ039-001923	5/3/1995	email re: potential co-promotion agreement with Schering-Plough on prometrium			
07718	SOLOJ027-035699		4/11/2002	email re: MPA sales ad			
07719	LYTTR016-015553	LYTTR016-015557		letter from Wyeth to M Baylor-Henry at DDMAC re: solvay ads			
07721	CONTA213-020564	CONTA213-020565	10/7/2003	email re: micronized progesterone in KEEPS study			
07723	Various	Various	9/19/1997	Meeting Agenda - various designwrite and published articles			
07725	CHOOM024-000352	CHOOM024-000352	12/6/1997	Newsletter specs for ACOG Sponsorship Inserts			
07726	CHOOM024-000350	CHOOM024-000350	1/7/1998	Promotional Material request/assignment			
07727	BARBM013-000153	BARBM013-000568	10/27/1992	General Medical Report a Prospective Double-Blind, Randomized, Parallel Study of the Safety and Efficacy of Premarin (AY-11,152) and Medroxyprogesterone Acetate (AX-11,236) for Postmenopausal Hormone Replacement Therapy: Final Report		Land, Harriette - Wyeth Ayerst McCloud, Shirley - Wyeth Ayerst Snyder, Carolyn - Wyeth Ayerst Nadelmann, Judith - Wyeth Ayerst Doyle, Robert - Wyeth Ayerst Kuhnert, B - Wyeth Ayerst Littman, G - Wyeth Ayerst Pickar, J - Wyeth Ayerst Korba, V - Wyeth Ayerst	
07728	BURKM010-000647	BURKM010-000655	5/10/1995	Protocol No. 713-B-309-US Clinical Protocol Synopsis			
07729	BURKM017-001012	BURKM017-001014		hand written notes			
07731	CONSG018-024135	CONSG018-024138	6/29/2000	Health Care Providers		willocj1	
07732	CONTA021-002023	CONTA021-002057	9/29/1988	Study Protocol Postmenopausal Estrogen/Progestin Intervention Trial		PEPI	
07733	DELCA007-000094	DELCA007-000102	3/20/2000	Talking Points to Address DSMB Recommendations			
07734	DEYMI031-000372	DEYMI031-000374	3/19/1993	Hormonal Agents and Matching Placebos Needed for the Conduct		Levy, Bob - Wyeth-Ayerst Research Healy, Bernadine - National Institute of Health	
07736	DUROJ027-000916	DUROJ027-000917	3/00/2000	Keeping a Balanced Perspective on Breast Cancer Risk		Wyeth-Ayerst Laboratories	
07737	FARAN024-018459	FARAN024-018585	8/22/1997	premarin pre-emptive plan		FARAKLAN	
07738	HENRL001-000305	HENRL001-000311	2/8/1999	Premarin Oral 1998 Marketing Spend Reconciliation			
07739	HENRL025-000847	HENRL025-000847		budget explanation		HENRYL	
07740	JANEC010-000213	JANEC010-000231		women and cardiovascular disease		JANEC	
07741	LAWT021-031386	LAWT021-031420	5/22/2001	Wyeth-Ayerst Laboratories		Jordan Levinson	
07742	MARRA014-025211	MARRA014-025212	4/10/2001	Use in Women with a Family History of Breast Cancer		Wyeth-Ayerst User	
07743	NORMJ006-000169	NORMJ006-000223	10/5/1988	A Prospective Double-Blind, Randomized, Parallel Study of the Safety and Efficacy of Premarin and Medroxyprogesterone Acetate Evaluating Metabolic Effects during Postmenopausal Hormone Replacement Therapy Protocol No. 713B-301		Wyeth-Ayerst Research	
07744	NORMJ006-000224	NORMJ006-000277	10/5/1988	A Prospective Double-Blind, Randomized, Parallel Study of the Safety and Efficacy of Premarin and Medroxyprogesterone Acetate for Postmenopausal Hormone Replacement Therapy Protocol No. 713B-300		Wyeth-Ayerst Research	
07745	PANAA038-000807	PANAA038-000808	9/10/1992	Women's Health Initiative (WHI) Drug Supply (Ref. 92-052-MA)		Colasante, David A - Wyeth-Ayerst Laboratories	
07746	PICKJ002-001357	PICKJ002-001365	3/14/1995	Finance Committee Authorization			
07747	PICKJ007-001349	PICKJ007-001349	1/31/1996	Breast Cancer Task Force meeting			
07748	PICKJ043-001918	PICKJ043-001928	9/9/2002	Breast Cancer Analysis Clinical Studies			
07749	PINIM020-000240	PINIM020-000261		Premarin/MPA			
07750	RIGGB006-001418	RIGGB006-001454	11/10/1992	Heart & Estrogen/Progestin Replacement Study		Wyeth Ayerst Clinical Research	EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07751	ROSSC003-000378	ROSSC003-000532	12/17/1999	Heart and Estrogen / Progestin Replacement Study (HERS): Final Report		Blackman,Beatrice C - Wyeth-Ayerst Research Graepel,G - Wyeth-Ayerst Research Shields,Kathleen M - Wyeth-Ayerst Research Levner,Mark H - Wyeth-Ayerst Research Littman,Gary S - Wyeth-Ayerst Research Richards,Cynthia H - Wyeth-Ayerst Research Pickar,J	
07752	SENDM009-000305	SENDM009-000305		Menopause Study Group Publications			
07753	SOLOJ022-000967	SOLOJ022-000983	1/24/1997	Working Toward a Partnership			
07754	SOLOJ022-001019	SOLOJ022-001019		DEPO: Buchalter, Jeff 05/29/2008 EX 27; Breast CA			
07755	SOLOJ022-001022	SOLOJ022-001022		DEPO: Buchalter, Jeff 05/29/2008 EX 39; BCA Working Group		Buchalter,Jeff	
07756	SOLOJ022-001040	SOLOJ022-001042	3/27/1996	Cummings Study: Revised Strategic Recommendations		Winkler,Shellie Stone,Gloria	
07757	SOLOJ025-000286	SOLOJ025-000355	3/10/1998	The US Market: A Case Study in the Success of Changing the HRT Paradigm		Durocher,Jamie	
07758	SONKJ023-001742	SONKJ023-001747	12/22/1992	Conjugated Estrogens and Medroxyprogesterone Acetate NDA No. 20-303		Sasson,Stephen B - Wyeth Ayerst Laboratories	
07759	W-MCL003-03011	W-MCL003-03012	4/6/1990	Incidence of Breast Cancer		Weber,Margaret E - Wyeth Ayerst	
07760	W-MDL04782-00029233	W-MDL04782-00029236	6/14/1976	Estrogens and Breast Cancer.		Stern,M - Ayerst Lab	
07762	BECKK002-000148	BECKK002-000154		Just the Facts Sales Trainer			
07763	CHENK001-002958	CHENK001-002959		Mid-POA Assignments			
07764	DAVIJ004-001516	DAVIJ004-001516	00/00/1999	Prempro POA, Davis Depo 7/11/2006 Exh: 12			
07765	DAVIJ006-001159	DAVIJ006-001160	6/00/2001	Answering Tough Questions - Sales trainer; Davis Depo Exhibit #29			
07766	MARLM004-001420	MARLM004-001425	12/00/2001	Incentive Compensation Report			
07767	MARLM004-008031	MARLM004-008034		WHI Trial Arm With E/P Find An Increase In Breast Cancer (Draft editorial)			
07768	MARLM004-008114	MARLM004-008145		Breast Health and Menopause			
07769	MONND401-000922	MONND401-000922	4/00/1999	AD: Prempro can help			
07770	PAYNC201-001158	PAYNC201-001168	8/15/2000	Premarin Message Sales Trainer piece			
07771	PAYNC201-001148	PAYNC201-001148		Premarin Presentation-Detail Piece			
07772	HUBST001-031288	HUBST001-031289		Area 72 Manager's Meeting Outline - Detailer prep			
07773	ROSSC012-001497	ROSSC012-001587	12/30/1994	Medical Officer's Review of Original and Resubmitted NDA Submissions			
07774	MARMN009-000329	MARMN009-000332	11/28/2001	2002 Wyeth Field Sales Incentives Plan EAN - Authorization request to fund bonus plan \$104.7 million			
07775	COBBP002-001423	COBBP002-001423	10/8/1997	Approved Voice Mail Script Lancet Meta-analysis 10/8/1997 (45358-05)			
07776	MICHR001-000014	MICHR001-000028		Premarin AERs			
07777	CONNS014-002190	CONNS014-002190	1/7/1992	HRT Research Team Day 17 Beta-Estradiol/Progesterone SR (Project 810A)			
07778	CONNS020-000401	CONNS020-000401	9/20/1990	17 Beta Estradiol/Slow Release Natural Progesterone			
07779	DUROJ046-018050	DUROJ046-018050	5/2/2002	Fwd: JAMA - request to meet with editor			
07780	DUROJ046-018051	DUROJ046-018051	5/2/2002	Fwd: JAMA - request to meet with editor			
07781	DUROJ046-018052	DUROJ046-018052	4/24/2002	Wyeth Advertising expenditures in JAMA 01/02			
07782	DUROJ046-018053	DUROJ046-018053	5/1/2002	JAMA - request to meet with editor			
07783	DUROJ046-018054	DUROJ046-018054	5/1/2002	letter from Wyeth to C DeAngelis at JAMA			
07784	DUROJ046-018428	DUROJ046-018429	4/24/2002	Just in case you don't have this info...			
07785	DUROJ046-018563	DUROJ046-018563	4/23/2002	Re: NEJM, JAMA, Lancet - former editors - follow-up			
07786	DUROJ046-025265	DUROJ046-025269	10/24/2002	Statement of Susan Wysocki, President and CEO			
07787	HENRL026-001723	HENRL026-001731		Working With Global			
07788	PANAA038-000032	PANAA038-000033	10/9/1991	17 Beta-Estradiol/Progesterone (Project 810A) Project Team Review Meetings of September 4, 1991 & October 3,1991			
07789	RIGGB007-001889	RIGGB007-001890	5/27/1992	HRT Research Team Day Premarin/MPA (Project 713B) 17 Beta Estradiol Progesterone/SR (Project 810A) Estrogen Wrinkle Cream (Project 713H) HRT Patch 17-Estradiol (Project 802A) HRT Patch Combination (Project 802B)			
07790	RIGGB007-001891	RIGGB007-001894	5/27/1992	HRT Research Team Day Agenda			
07791	SOLOJ027-046965	SOLOJ027-047117	9/25/2001	HRT Satisfaction Campaign			
07792	W-MDL04782-00051892	W-MDL04782-00051892		SAN FRANCISCO - OAKLAND BAY AREA			
07793	W-MDL04782-00059028	W-MDL04782-00059029	1/12/1984	Protocol Synopsis. Efficacy of Prem-Pak in Reducing Bone Loss in Postmenopausal Women.			
07794	W-MDL04782-00059624	W-MDL04782-00059624	9/1/1981	PREM-PAK. Need for Bioequivalence Data.			
07795	W-MDL04782-00059629	W-MDL04782-00059632		PATIENT CONSENT FOR PREM-PAK PROTOCOL			
07796	W-MDL04782-00059687	W-MDL04782-00059689	8/19/1982	Minutes of Prem-Pak Subcommittee Meeting			
07797	W-MDL04782-00059979	W-MDL04782-00059980	10/28/1983	PREM-PAK. Meeting With FDA on Rationale for Approval of Product Containing PREMARIN 0.625mg.			
07798	W-MDL04782-00059996	W-MDL04782-00059996	6/20/1983	PREM-PAK, etc.			
07799	W-MDL04782-00060011	W-MDL04782-00060012	12/13/1982	PREM-PAK NY Meeting			
07800	W-MDL04782-00060080	W-MDL04782-00060081	9/16/1982	Consultations on Prem-Pak Protocol			
07801	W-MDL04782-00060082	W-MDL04782-00060085	8/27/1982	Prem-Pak New York Team Meeting 08241982			
07802	W-MDL04782-00060105	W-MDL04782-00060107	3/30/1982	MINUTES OF THE PREM-PAK MEETING			
07803	W-MDL04782-00060132	W-MDL04782-00060132	9/21/1981	Prem-Pak Minutes of 09181981 Meeting			
07804	BURKM010-000720	BURKM010-000722	4/25/2000	FDA Backgrounder on Conjugated Estrogens			
07805	CONKJ008-000129	CONKJ008-000144	9/25/2001	Visiting Speakers Bureau Premarin Reports			
07806	CONSG007-000079	CONSG007-000104		Effects of Hormone Replacement Therapy on Clinical Fractures and Height Loss: The Heart and Estrogen/Progestin Replacement Study (HERS)			
07807	CONSG007-000117	CONSG007-000118		NDA 20-527 Prempro/Premphase (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets)			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07808	CONTA012-001534	CONTA012-001552		Prempro/Premphase Planning for New Competitive Challenges			
07809	CONTA012-001554	CONTA012-001555	7/30/1999	Final Report of Findings: Prempro/Activelle War Games			
07810	CONTA012-001686	CONTA012-001722		Progestins and Hormone Replacement Therapy			
07811	DUROJ034-000439	DUROJ034-000441	7/31/1997	NDA No. 04-782 Premarin Tablets			
07812	DUROJ039-001945	DUROJ039-001954		Premarin Franchise Three Year Strategic Plan			
07813	DUROJ039-002000	DUROJ039-002000		Schering's Prometrium			
07814	DUROJ039-002021	DUROJ039-002021	7/12/1991	Hormone Replacement Products (Schering-Plough)			
07815	DUROJ039-002022	DUROJ039-002022	7/3/1991	Hormone Replacement Products (Schering-Plough)			
07816	DUROJ039-002024	DUROJ039-002024	10/14/1991	Terms of Secrecy Agreement (Schering Plough)			
07817	DUROJ039-002026	DUROJ039-002026	8/26/1991	Letter from Alan Baker to David Poorvin re: estrogen & prometrium			
07818	DUROJ039-002032	DUROJ039-002038		Why AN Alliance			
07819	FISHG001-000037	FISHG001-000048		Determination of Progestational Activity in PCUD HPLC Fractions by in Vitro Measurement of Alkaline Phosphatase Activity in T-47 D Human Breast Cancer Cell Line			
07820	FISHG001-000200	FISHG001-000200	10/9/1992	Letter from Francis Roe to Jon Wetzel re: MPA			
07821	FISHG001-000258	FISHG001-000261	9/17/1992	From the Meeting Held on the 14 September 1992 with Dr Roe and Dr Prentice to Discuss the MPA Two-Year Rat Carcinogenicity Study			
07822	FISHG001-000331	FISHG001-000332	6/26/1992	Letter from Laurence Demers to Jame Inhelder re: rat study			
07823	FISHG001-000333	FISHG001-000334		MPA and various body systems			
07824	FISHG001-000353	FISHG001-000354	9/8/1989	Premarin/MPA Two-Year Rat Carcinogenicity Study Minutes of FDA Meeting of September 1, 1989			
07825	FISHG001-000355	FISHG001-000357	6/23/1992	Preliminary Toxicologic and Histologic Findings in MPA Two Year Oral (Diet) Toxicity Study in Rat (Illegible-11,236)			
07826	FISHG001-000358	FISHG001-000358	6/23/1992	Table 1 Preliminary Incidence Summary with (%) of Microscopic Observations AK-11, 236 (Protocol 89094)			
07827	FISHG001-000387	FISHG001-000392	12/22/1992	Conjugated Estrogens and Medroxyprogesterone Acetate NDA No. 20-303			
07828	FISHG001-000393	FISHG001-000393	12/16/1992	Premarin/MPA Labeling			
07829	FISHG001-000402	FISHG001-000417	3/11/1993	Conjugated Estrogens and Medroxyprogesterone Acetate NDA No. 20-303			
07830	FISHG001-000510	FISHG001-000573	12/13/2000	Report on Carcinogens Background Document for Steroidal Estrogens			
07831	HENRL005-001314	HENRL005-001314	11/11/1998	New Unbranded Direct-to-Consumer (DTC) Advertising Campaign Video Tapes			
07832	PANAA019-000679	PANAA019-000684	5/4/1995	Overview: Premarin and Women's Health			
07833	PICKJ004-000667	PICKJ004-000667	8/00/1991	ACOG Technical Bulletin			
07834	ROSSC001-000336	ROSSC001-000336	9/29/2000	NDA No. 04-782 Premarin (Conjugated Estrogens Tablets, USP) NDA No. 10-402 Premarin Intravenous (Conjugated Estrogens, USP) for Injection NDA No. 10-971 PMB (Conjugated Estrogens / Meproamate) Tablets NDA No. 11-074 Premarin H-C (Conjugated Estrogens / Hydrocortisone) Vaginal Cream NDA No. 20-126 Premarin (Conjugated Estrogens) Vaginal Cream NDA No. 20-303 Prempro / Premphase (Conjugated Estrogens / Medroxyprogesterone Acetate Tablets) NDA No. 20-527 Prempro / Premphase (Conjugated Estrogens / Medroxyprogesterone Acetate Tablets)			
07835	ROSSC001-000367	ROSSC001-000368	7/13/2000	FDA Telephone Contact, Premarin (Conjugated Estrogens Tablets, USP)			
07836	ROSSC001-000371	ROSSC001-000373	5/1/2000	Premarin (Conjugated Estrogens Tablets, USP) NDA No. 04-782 Special Supplement - Changes Being Effectuated			
07837	SONKJ024-001753	SONKJ024-001753	11/12/1998	HERS Poster Presentation			
07838	VICTJ005-001658	VICTJ005-001665	00/00/1988	The Dose-Effect Relationship between 'Unopposed' Oestrogens and Endometrial Mitotic Rate: Its Central Role in Explaining and Predicting Endometrial Cancer Risk			
07839	W-MDL04782-00009303	W-MDL04782-00009305	6/25/1985	Endocrinologic and Metabolic Drugs Advisory Committee Meeting 06241985			
07840	W-MDL04782-00059890	W-MDL04782-00059892	3/16/1983	Telephone Conversation with Dr. Whitehead, 04161983			
07841	W-MDL04782-00059895	W-MDL04782-00059897	2/6/1983	Letter from Malcolm Whitehead at King's College Hospital Medical School, London to Dr. A Kapadia at Ayerster re: continuous/combined protocol			
07842	W-MDL04782-00059898	W-MDL04782-00059903	1/20/1983	REPORT ON MEETING WITH MR. MALCOLM WHITEHEAD ON 12091982			
07843	W-MDL04782-00059904	W-MDL04782-00059905	2/28/1983	Letter from Malcolm Whitehead at King's College Hospital Medical School, London to Dr. A Kapadia at Ayerster re: continuous/combined protocol			
07844	W-MDL04782-00059906	W-MDL04782-00059922	1/28/1983	CONTINUOUS PREMARIN / PROGESTIN STUDY PHASE I: - EFFECTS ON BLEEDING PATTERNS, AND THE ENDOMETRIAL, PHYSICAL AND PSYCHOLOGICAL STATUS OF POSTMENOPAUSAL WOMEN. MENOPAUSE CLINICS			
07845	W-MDL04782-00059954	W-MDL04782-00059954	12/6/1983	PREM-PAK Protocol for Study on Effects on Bone Loss (Protocol 83-14 MD)			
07846	W-MDL04782-00059959	W-MDL04782-00059966	11/9/1983	Protocol Outline Prem-Pak: Osteoporosis - Efficacy of Prem-Pak in Reducing Bone Loss in Postmenopausal Women			
07847	W-MDL303-00084698	W-MDL303-00084699	11/6/1997	Prempro/Premphase FDA Contact - Phase IV Commitment Breast Cancer Study (NDA 20-303)			
07848	W-MDL527-00035054	W-MDL527-00035074	11/21/1995	Prempro Labeling (NDA 20-527)			
07849	W-MDL527-00035128	W-MDL527-00035129	10/23/1995	FDA Breast Cancer Study (NDA 20-527)			
07850	W-MDL527-00038634	W-MDL527-00039022	6/26/1998	Proposed launch materials (NDA 20-527)			
07851	WEBEM015-001202	WEBEM015-001204	2/4/2000	voicemail to the field re: recent breast cancer publications			
07852	BARBM001-001106	BARBM001-001109	5/15/2000	Response to Objections About MPA			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07853	LYTTR017-003272	LYTRR017-003273	12/18/2001	Wyeth letter to Dr. Handelin			
07854	W-MDL04782-00000207	W-MDL04782-00000208	11/17/1989	Wyeth memo re Dingell hearing on generic drugs			
07855	W-MDL04782-00000719	W-MDL04782-00000722	2/13/1990	Wyeth memo re Dingell inquiry			
07856	HENRL011-000741	HENRL011-001160	6/9/2000	Official Transcript of Advisory Board Meeting			
07857			10/25/2001	Premia patent application			
07858	63 FR 66378 (Simon P142)		12/1/1998	FDA rules & regulations for prescription drug labeling			
07859	WINNR002-000284	WINNR002-000310	10/27/1998	TMG cardio studies see bate WINNR002-000291			
07860	W-PUBLIC-004136		1/5/1998	Medical Officers Review for new bleeding efficacy indication			
07861	PANAA008-000347	PANAA008-000348	8/23/2000	Survey of potential users			
07862	BRADK006-000441	BRADK006-000442	2/4/2003	HRT labeling change – a qualitative report			
07863	BECKK002-000502	BECKK002-000549	00/00/1995	Deposition Ex 6			
07864			8/00/2006	Human Drug Program			
07865				Medical officer's Position at the FDA			
07866			10/24/2007	Current CDER set up			
07867			10/28/2004	DMEDP medical team			
07868			10/24/2007	CDER medical staff			
07869				FDA in your neighborhood			
07871	BUCHJ002-001265	BUCHJ002-001265	6/8/1995	fax from Pickar re: mammographic study of Dr Gilbert			
07872	BUCHJ002-001266	BUCHJ002-001266	6/8/1995	memo from Pickar re: mammographic study of Dr Fiona Gilbert			
07873	BUCHJ002-001267	BUCHJ002-001267	6/8/1995	fax from Julio Casoy to James Pickar re: Dr Gilbert			
07874	BUCHJ002-001268	BUCHJ002-001269	6/6/1995	fax from James Pickar to Julio Casoy re: Dr Gilbert; DEPO: Buchalter, Jeff 05/29/2008 EX 29			
07875	BUCHJ002-001270	BUCHJ002-001276	1/26/1995	Study info re: qualitative evaluation of mammographic density from digitized mammograms in premenopausal women receiving HRT			
07876	PAYNC201-000002	PAYNC201-000003	7/31/2000	letter from Carl Whatley to Wyeth			
07877	PAYNC201-000004	PAYNC201-000006	7/27/2000	Waldrep Letter			
07878	PAYNC201-000010	PAYNC201-000011	7/18/2000	Wyeth-Ayerst Letter Re Redux			
07879			8/00/2007	Updated Causality Report of Donald F. Austin, MD, MPH (Part I and Part II attachments)			
07880	HRT MED LIT 0551001	HRT MED LIT 0551009	5/7/1976	Dog Study			
07881	BUCHJ001-000001	BUCHJ001-000001	1/3/1997	Wyeth Internal Correspondence RE: Crinone AHT WY9365			
07882	BUCHJ001-000002	BUCHJ001-000002	7/26/1996	AHP Finance Committee Authorization RE: Crinone (Progesterone Vaginal Gel), Pre-Launch AHT			
07883	BUCHJ001-000003	BUCHJ001-000003	1/7/1997	Wyeth Internal Correspondence RE: Crinone Package Insert			
07884	BUCHJ001-000004	BUCHJ001-000004	12/20/1996	Wyeth Internal Correspondence RE: Crinone Labeling			
07885	BUCHJ001-000005	BUCHJ001-000005	12/15/1996	Facsimile to Jamie Durocher from Howard Levine, Ph.D. RE: Crinone Package Insert Indications			
07886	BUCHJ001-000021	BUCHJ001-000021	1/17/1997	Crinone Advisory Board Meeting - Faculty List			
07887	BUCHJ001-000022	BUCHJ001-000024	1/24/1997	Crinone IND Treatment Protocol			
07888	BUCHJ001-000162	BUCHJ001-000162	7/24/1995	Note from Jeff Buchalter RE: Mack/Frist Bill			
07889	BUCHJ001-000163	BUCHJ001-000163		Note from Carrie Smith-Cox			
07890	BUCHJ001-001110	BUCHJ001-001110	6/8/1995	Interoffice Memorandum RE: Micronized Progesterone			
07891	BUCHJ001-001111	BUCHJ001-001114		Letter to Stephanie Gray, FDA			
07892	BUCHJ001-001115	BUCHJ001-001115	6/8/1995	Interoffice Memorandum			
07893	BUCHJ001-001116	BUCHJ001-001122	05/00/1995	Micronized Progesterone Backgrounder, Wyeth Sales Training & Development			
07894	BUCHJ001-001520	BUCHJ001-001520	8/29/1997	Internal Correspondence re: TheraTech Female T: AHT			
07895	BUCHJ001-001521	BUCHJ001-001535	8/29/1997	AHP Finance Committee Authorization RE: Transdermal Testosterone-Only Product for Females			
07896	BUCHJ001-001536	BUCHJ001-001537	9/2/1997	Status of Negotiations			
07897	BUCHJ001-001538	BUCHJ001-001538	8/28/1997	Correspondence from Alan J. Howarth (Esq.) to Dr. Charles D. Ebert RE: Certificate of Correction - U.S. Patent No. 5,460,820			
07898	BUCHJ001-001540	BUCHJ001-001540	8/28/1997	Financial Summary, TheraTech - Female Transdermal Testosterone Patch - Global			
07899	BUCHJ001-001544	BUCHJ001-001547	8/29/1997	U. S. Forecast Assumptions, Female Testosterone Patch			
07900	BUCHJ001-001548	BUCHJ001-001555		TheraTech Female Testosterone Patch Information			
07901	BUCHJ001-001557	BUCHJ001-001558	6/11/1997	Note from Ted to Carrie RE: Testosterone Patch			
07902	BUCHJ001-001559	BUCHJ001-001559		Concerns Expressed by W-AR at 06/10/1997 Meeting RE: TheraTech's Ongoing Phase II Trial of Transdermal Testosterone in Females			
07903	BUCHJ001-001560	BUCHJ001-001560		Correspondence from Deborah Eppstein, Ph.D. with TheraTech to Ted Kozin re: Female Testosterone and Estradiol/Testosterone Combination Patches			
07904	BUCHJ001-001563	BUCHJ001-001564	3/17/1997	Initial Terms: Female Testosterone Products (Transdermal T-Only and E2/T)			
07905	BUCHJ001-001565	BUCHJ001-001570	5/31/1997	Female Testosterone Transdermal Products (T-Only and E2/T) Proposed Terms			
07906	BUCHJ001-001571	BUCHJ001-001571	6/9/1997	Correspondence from Deborah Eppstein, Ph.D. with TheraTech to David Chase, Ph.D. RE: T Patch Developments			
07907	BUCHJ001-001577	BUCHJ001-001577	4/28/1997	TheraTech 3.5 Day Testosterone Patch - Product Forecast			
07908	BUCHJ001-001578	BUCHJ001-001579		Forecast Assumptions, Female Testosterone Patch			
07909	BUCHJ001-001580	BUCHJ001-001585	4/28/1997	Female Testosterone Market Size Projections			
07910	BUCHJ001-001586	BUCHJ001-001587	4/22/1997	Correspondence from Deborah Eppstein, Ph.D. with TheraTech to Theodore Kozio, Ph.D. re: P&L Model			
07911	BUCHJ001-001592	BUCHJ001-001592	4/29/1997	Wyeth Internal Correspondence RE: TheraTech's Male Transdermal Testosterone for Parts of Europe, Australia, New Zealand			

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07912	BUCHJ001-001593	BUCHJ001-001593	4/28/1997	Correspondence from Deborah Eppstein, Ph.D. with TheraTech to Theodore Koziol, Ph.D. re: Exclusive Rights to Testosterone Patch for men from SmithKline Beecham in Countries Outside of North America			
07913	BUCHJ001-001599	BUCHJ001-001599	4/28/1997	TheraTech 3.5 Day Testosterone Patch - Product Forecast			
07914	BUCHJ001-001600	BUCHJ001-001601		Forecast Assumptions, Female Testosterone Patch			
07915	BUCHJ001-001602	BUCHJ001-001607	4/28/1997	Female Testosterone Market Size Projections			
07916	BUCHJ001-001609	BUCHJ001-001610		Draft Forecast Assumptions, Female Testosterone Patch with Handwritten Notes			
07917	BUCHJ001-001611	BUCHJ001-001611		TheraTech 3.5 Day Testosterone Patch - Product Forecast with Handwritten Notes			
07918	BUCHJ001-001612	BUCHJ001-001617	10/29/1996	Female Testosterone Market Size Projections			
07919	BUCHJ001-001653	BUCHJ001-001655	8/17/1990	NDA 19-781 Prometrium Capsules (August 17, 1990 Deficiency Letter), FDA Meeting 07/23/1991 (Confidential)			
07920	BUCHJ001-001678	BUCHJ001-001681	4/25/1995	Micronized Progesterone Backgrounder			
07921	BUCHJ001-001736	BUCHJ001-001788	7/9/1996	Clinical Affairs Project Review			
07922	BUCHJ001-001789	BUCHJ001-001790	7/1/1996	Premarin Alzheimer's Study Status Reports Ongoing Studies			
07923	BUCHJ001-001791	BUCHJ001-001791	7/1/1996	Premarin Arthritis Study Status Reports Ongoing Studies			
07924	BUCHJ001-001792	BUCHJ001-001792	7/1/1996	Premarin CNS Study Status Reports Ongoing Studies			
07925	BUCHJ001-001793	BUCHJ001-001794	7/1/1996	Premarin Cardiovascular Study Status Reports Ongoing Studies			
07926	BUCHJ001-001795	BUCHJ001-001795	7/1/1996	Premarin Data Base Study Status Reports Ongoing Studies			
07927	BUCHJ001-001796	BUCHJ001-001796	7/1/1996	Premarin Dental Study Status Reports Ongoing Studies			
07928	BUCHJ001-001797	BUCHJ001-001797	7/1/1996	Premarin Metabolic Study Status Reports Ongoing Studies			
07929	BUCHJ001-001798	BUCHJ001-001799	7/1/1996	Premarin Miscellaneous Study Status Reports Ongoing Studies			
07930	BUCHJ001-001800	BUCHJ001-001801	7/1/1996	Premarin Osteoporosis Study Status Reports Ongoing Studies			
07931	BUCHJ001-001802	BUCHJ001-001802	7/1/1996	Premarin Urinary Tract Study Status Reports Ongoing Studies			
07932	BUCHJ001-001803	BUCHJ001-001806	7/1/1996	Premarin Study Status Reports Planned & Completed Studies			
07933	BUCHJ001-001808	BUCHJ001-001808	5/10/1996	Wyeth-Ayerst Laboratories Media Statement for Responsive Use Only - Draft with Handwritten Notes			
07934	BUCHJ001-001813	BUCHJ001-001814	7/15/1996	Facsimile Cover Pages RE: Revised PMT Letter			
07935	BUCHJ001-001815	BUCHJ001-001815	5/17/1996	AHP Finance Committee Authorization RE: Discontinuance of Premarin with Methyltestosterone Tabs			
07936	BUCHJ001-001816	BUCHJ001-001817		Premarin with Methyltestosterone (PMT), Brief Regulatory History			
07937	BUCHJ001-001818	BUCHJ001-001818	3/4/1996	Facsimile from Roberta Michaelis to Jeff Buchalter RE: PMT			
07938	BUCHJ002-001277	BUCHJ002-001278	4/4/1995	Internal Correspondence re: Premarin Studies Review Committee Meeting - March 31, 1995			
07939	BUCHJ002-001279	BUCHJ002-001281	12/15/1994	Internal Correspondence re: Premarin Studies Review Committee Meeting - December 14, 1994			
07940	BUCHJ002-001282	BUCHJ002-001284	1/24/1995	Internal Correspondence re: Premarin Studies Review Committee Meeting - January 20, 1995			
07941	BUCHJ002-001285	BUCHJ002-001286	10/7/1994	Internal Correspondence re: Premarin Studies Review Committee Meeting - October 6, 1994			
07942	BUCHJ002-001287	BUCHJ002-001287	8/8/1994	Correspondence from Chris P. Morath to Nick Marmatello with Handwritten Notes			
07943	BUCHJ002-001288	BUCHJ002-001290	8/11/1994	Internal Correspondence re: Premarin Studies Review Committee Meeting - August 9, 1994			
07944	BUCHJ002-001291	BUCHJ002-001292	6/28/1994	Internal Correspondence re: Premarin Studies Review Committee Meeting - June 27, 1994			
07945	BUCHJ002-001293	BUCHJ002-001293	5/13/1994	Correspondence from John Steege with The University of North Carolina to Dr. Raymond Klein with Wyeth with attached Brief Summary of Proposal			
07946	BUCHJ002-001301	BUCHJ002-001301	6/15/1994	Internal Correspondence re: Premarin Studies Review Committee Meeting - June 27, 1994			
07947	BUCHJ002-001302	BUCHJ002-001302	5/27/1994	Correspondence from Victor Henderson with University of Southern California to Dr. Raymond Klein with Wyeth RE: Therapeutic Trial of Premarin in Women with Alzheimer's Disease			
07948	BUCHJ002-001303	BUCHJ002-001312	05/00/1994	Randomized Double-Blind, Placebo-Controlled Trial of Conjugated Equine-Estrogen for Alzheimer's Disease: A Preliminary Proposal to Wyeth-Ayerst			
07949	BUCHJ002-001313	BUCHJ002-001314		Biographical Sketch of Victor W. Henderson, Professor of Neurology, Gerontology and Psychology			
07950	BUCHJ002-001315	BUCHJ002-001333		Oestrogens and Alzheimer's Disease			
07951	BUCHJ002-001334	BUCHJ002-001334	6/23/1994	Internal Correspondence RE: Premarin Studies Review Committee with attached second item to be reviewed at the next Premarin Studies Review Committee Meeting to be held Monday, June 27, 1994			
07952	BUCHJ002-001346	BUCHJ002-001346	6/24/1994	Internal Correspondence RE: Premarin Studies Review Committee with attached third item to be reviewed at the next Premarin Studies Review Committee Meeting to be held Monday, June 27, 1994			
07953	BUCHJ002-001366	BUCHJ002-001366	6/27/1994	Internal Correspondence RE: Premarin Studies Review Committee with attached fourth item to be reviewed at the next Premarin Studies Review Committee Meeting to be held Monday, June 27, 1994			
07954	BUCHJ002-001368	BUCHJ002-001372	6/27/1994	Internal Correspondence RE: Proposed Synthetic vs. Natural CE Article attaching the proposed letter /communication planned to be submitted to the NEJM			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07955	BUCHJ002-001373	BUCHJ002-001374	5/27/1994	Internal Correspondence RE: Premarin Studies Review Committee Meeting - May 27, 1994			
07956	BUCHJ002-001375	BUCHJ002-001375	11/2/1994	Internal Correspondence RE: Proposed MRC Hormone Replacement Therapy Trial with attached proposal			
07957	BUCHJ002-001505	BUCHJ002-001509	6/8/1995	Interoffice Memorandum RE: Micronized Progesterone with attached draft of a letter to Mike Peskoe for review at the Competitive Task Force meeting			
07958	BUCHJ002-001510	BUCHJ002-001510	6/8/1995	Interoffice Memorandum RE: Voice Mail Transcript from Howard Rofsky's call to Health Pharmacy RE: Micronized Progestin			
07959	BUCHJ002-001511	BUCHJ002-001513	3/13/1995	Internal Correspondence: Minutes from Premarin Competitive Task Froce Meeting of March 9, 1995			
07960	BUCHJ002-001519	BUCHJ002-001519	3/20/1995	Internal Correspondence RE: Competitive Task Force with Attached Communication from Health Pharmacies in Madison, Wisconsin			
07961	BUCHJ002-001521	BUCHJ002-001524	10/00/1989	Absorption of Oral Progesterone is Influenced by Vehicle and Particle Size			
07962	BUCHJ002-001525	BUCHJ002-001525		Dear Doctor letter from Health Pharmacies RE: Menopausal Hormone Replacement Therapy with Continuous Daily Oral Natural Micronized Estradiol and Natural Micronized Progesterone in the Same Capsule			
07963	BUCHJ002-001526	BUCHJ002-001533	04/00/1989	Menopausal Hormone Replacement Therapy with Continuous Daily Oral Natural Micronized Estradiol and Progesterone (Hargrove, et al - Estrogen Replacement Therapy, Vol. 73, No. 4, April 1989)			
07964	BUCHJ002-001534	BUCHJ002-001537	11/00/1994	Hormone Replacement Therapy: You Have Other Options by Jane Heimlich, Associate Editor for Health & Healing, Tomorrow's Medicine Today, November 1994 Supplement			
07965	BUCHJ002-001689	BUCHJ002-001695	1/21/1994	Natural Progesterone (Educational Materials Only)			
07966	BUCHJ002-001837	BUCHJ002-001837		Premarin Support Team (Objective & Plan of Action)			
07967	BUCHJ002-001838	BUCHJ002-001838		Handwritten Notes on paper from The Ritz-Carlton			
07968	BUCHJ002-001839	BUCHJ002-001841	2/6/1995	Premarin Support Group Proposal (Draft)			
07969	BUCHJ002-001842	BUCHJ002-001843	5/4/1995	Premarin Meeting at the Ritz-Carlton Hotel, Philadelphia, PA			
07970	BUCHJ002-001844	BUCHJ002-001845	1/11/1995	DEPO: Buchalter, Jeff 05/29/08 EX 13Correspondence from Robert Knopp, MD with Northwest Lipid Research Clinic to Dr. Michael Jordan, Medical Center Manager RE: their investigations of the antioxidant effects of estrogen			
07971	BUCHJ002-001847	BUCHJ002-001847		Estrogen use in women is associated with a reduction in cardiovascular disease.E5642			
07972	BUCHJ002-001848	BUCHJ002-001853		Figure Legends			
07973	BUCHJ002-001854	BUCHJ002-001855	2/10/1995	Correspondence from Gautam Chaudhuri, MD with the University of California, Los Angeles to Andres Negro-Vilar, MD with Wyeth			
07974	BUCHJ002-001856	BUCHJ002-001860		The Effect of Premarin on Myocardial Blood Flow in Postmenopausal Women			
07975	BUCHJ002-001861	BUCHJ002-001890		Research Plan			
07976	BUCHJ002-001891	BUCHJ002-001895	2/16/1995	Internal Correspondence RE: Summary of January 25 Meeting			
07977	BUCHJ002-001896	BUCHJ002-001897	11/1/1994	Correspondence from William H. Barr, Ph.D. with VCU MCV Campus to Andres Negro-Vilar with Wyeth RE: Review of Current Developments in Estrogen Research and Premarin Support			
07978	BUCHJ002-001898	BUCHJ002-001898	11/4/1994	Internal Correspondence RE: Investigator (Dr. Mendelsohn)			
07979	BUCHJ002-001899	BUCHJ002-001899		Correspondence from Claudia Diotalevi with Wyeth to Jim Meyer with Wyeth RE: Dr. Mendelsohn			
07980	BUCHJ002-001900	BUCHJ002-001900	10/4/1994	Correspondence from Micahel Mendelsohn, MD with the New England Medical Center to Claudia Diotalevi with Wyeth RE: the Molecular Effects of Estrogen Compounds on Vascular Tissue			
07981	BUCHJ002-001901	BUCHJ002-001908	05/00/1994	Human Vascular Smooth Muscle Cells Contain Functional Estrogen Receptor (Karas, et al - Circulation Vol. 89, No. 5, May 1994)			
07982	BUCHJ002-001909	BUCHJ002-001913	00/00/1994	Estrogen and the Blood Vessel Wall (Mendelsohn, et al - 1994 Current Science ISBN 1-85922-604-3 ISSN 0268-4705)			
07983	BUCHJ002-001914	BUCHJ002-001925	9/19/1994	CV of Dr. Michael Mendelsohn			
07984	BUCHJ002-001926	BUCHJ002-001930	12/001991	The 29-kDa proteins phosphorylated in thrombin-activated human platelets are forms of the estrogen receptor-related 27-kDa heat shock protein (Mendelsohn, et al - Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 11212-11216, December 1991, Cell Biology)			
07985	BUCHJ002-001931	BUCHJ002-001931	11/4/1994	Internal Correspondence RE: Financial Support			
07986	BUCHJ002-001932	BUCHJ002-001932	10/25/1994	Correspondence from Curtis Robinson with Wyeth to Jim Meyer, Medical Center Group RE: Research Funding			
07987	BUCHJ002-001933	BUCHJ002-001933		Correspondence from UCLA to Curtis Robinson with Wyeth with Spinal Curvature Study Budget and Research Project No. P-8068-01 entitled, Abnormal Spinal Curvature and its Relation to Genital Tract Prolaspe attached			
07988	BUCHJ002-001967	BUCHJ002-001991		Antioxidant Potential of Premarin in Menopause, a Proposal to Wyeth-Ayerst (Confidential)			
07989	BUCHJ002-001992	BUCHJ002-001993		Handwritten Notes RE: Premarin Support Team			
07990	BUCHJ002-001994	BUCHJ002-001994	7/20/1994	Internal Correspondence RE: Dr. Michael Belfort's Visit with his proposal and CV attached			
07991	BUCHJ002-002033	BUCHJ002-002033	6/21/1994	Premarin Support Group Distribution List			
07992	BUCHJ002-002034	BUCHJ002-002034	5/15/1994	Internal Correspondence RE: Premarin Studies - Dr. Bruce Kessel with handwritten notes			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
07993	BUCHJ002-002035	BUCHJ002-002036	9/9/1993	Internal Correspondence RE: Premarin Proposal: Dr. Bruce Kessel			
07994	BUCHJ002-002037	BUCHJ002-002037		Handwritten Note from Carrie Smith-Cox			
07995	BUCHJ002-002038	BUCHJ002-002038		Handwritten Note from Nick Marmontello			
07996	BUCHJ002-002039	BUCHJ002-002039	6/16/1994	Internal Correspondence RE: Lon Schneider, MD, Meeting in CA - CNS/Premarin			
07997	BUCHJ002-002040	BUCHJ002-002040		Handwritten Note from Linda to Nick			
07998	BUCHJ002-002041	BUCHJ002-002041		Address List			
07999	BUCHJ002-002042	BUCHJ002-002042	6/24/1994	Handwritten Note from Diane Brodsky			
08000	FISHG002-000004	FISHG002-000009		Facsimile from Rose Shayeghi with Wyeth's Women's Health Research Institute to Linda with address list			
08001	BUCHJ002-002045	BUCHJ002-002045	6/14/1994	Premarin Support Group Distribution List			
08002	BUCHJ002-002046	BUCHJ002-002046	6/8/1994	Handwritten Note from Dave Bluey to Carrie Smith-Cox			
08003	BUCHJ002-002047	BUCHJ002-002047	5/15/1994	Internal Correspondence RE: Premarin Studies - Dr. Bruce Kessel with CV of Bruce Kessel, MD and Antioxidant Potential of Premarin in Menopause, a Proposal to Wyeth-Ayerst (Confidential)			
08004	BUCHJ002-002086	BUCHJ002-002086		Handwritten Note titled Strategic Objections			
08005	BUCHJ002-002124	BUCHJ002-002125	3/26/1996	DEPO: Buchalter, Jeff 05/29/2008 EX 30; Premarin/Prempro Market Research Proposal, Market Planning Department			
08006	BUCHJ003-000017	BUCHJ003-000049	07/00/1996	Crinone - Pre-Launch U. S. Marketing Plan			
08007	BUCHJ003-000050	BUCHJ003-000067	07/00/1996	Crinone - Pre-Launch U. S. Marketing Plan with handwritten notes			
08008	BUCHJ003-000068	BUCHJ003-000139	9/13/1996	The Crinone Opportunity (Klemtnier Advertising, Inc.)			
08009	BUCHJ003-000140	BUCHJ003-000159	7/25/1996	Crinone - New Products, Commerical Review Committee			
08010	W-MDL04782-00028106	W-MDL04782-00028107	9/7/1977	agreement to share Kaiser database			
08010A	BUCHJ003-000160	BUCHJ003-000161	8/12/1996	Internal Correspondence RE: Crinone Issues			
08011	W-MDL04782-00021016	W-MDL04782-00021016	3/14/1978	Leter from Ayerst to DMEDP re: E+P therapy			
08011A	BUCHJ003-000162	BUCHJ003-000172	4/30/1996	Crinone Clinical Study Update			
08012	W-MDL04782-00043054	W-MDL04782-00043091	9/23/1982	Evaluation of Safety and Efficacy of Fixed Doses of Premarin and MPA			
08012A	BUCHJ003-000173	BUCHJ003-000173	5/23/1996	Facsimile to Sid Mazel, Ph.D. from Sophie LaLou RE: Slides of Last Presentation			
08013	PICKJ027-000869	PICKJ027-000870	2/24/1987	Memo re: NHLBI study on estrogens and progestins			
08013A	BUCHJ003-000174	BUCHJ003-000175	10/23/1996	Correspondence from David Olive, MD with Yale University to Raymond A. Klein, MD RE: Ideas regarding clinical trials for the progesterone gel			
08014	W-MDL303-00083350	W-MDL303-00083363	12/29/1994	Fax from Wyeth to the FDA agreement with the proposed changes			
08014A	BUCHJ003-000176	BUCHJ003-000176	11/15/1996	Crinone Memo RE: Preliminary Crinone Forecast			
08015	GMAAR080-000049	GMAAR080-000049	3/3/1997	Finance Committee Authorization			
08015A	BUCHJ003-000177	BUCHJ003-000178		Crinone Preliminary Unit Forecast			
08016	HENRL025-001036	HENRL001-001045	10/00/1998	Ketchum: Premarin News Bureau	Ketchum: Premarin News Bureau		
08016A	BUCHJ003-000179	BUCHJ003-000180	11/20/1996	AHP Finance Committee Authorization RE: Crinone (Progesterone Gel) Launch Stock			
08017	W-MDL04782-00060080	W-MDL04782-00060081	9/16/1982	PremPak study	PremPak study		
08017A	BUCHJ003-000181	BUCHJ003-000182	11/25/1996	Letter from Department of Health & Human Service to Dr. Howard Levine RE: Crinone FDA Drug Application			
08018	RIGGB004-001483	RIGGB004-001507	4/1/1998	HERS Study - Wyeth used their 1983 IND for the HERS study	HERS Study - Wyeth used their 1983 IND for the HERS study		
08018A	BUCHJ003-000183	BUCHJ003-000224	12/00/1996	Crinone Product Monograph			
08019	W-MDL04782-00059998		4/11/1983	Finance Committee- nurses health study PPT			
08019A	BUCHJ003-001905	BUCHJ003-001933	6/6/1994	DEPO: Buchalter, Jeff 05/29/08 EX 20; Premarin & Wyeth-Ayerst Women's Health Account Overview			
08020	DEMAE023-005377	DEMAE023-005378	11/26/2001	Finance Committee- nurses health study			
08020A	BUCHJ004-000133	BUCHJ004-000134	10/21/1993	DEPO: Buchalter, Jeff 05/29/08 EX 21; Internal Correspondence RE: Premarin Speakers			
08020A	DEMAE023-005377	DEMAE023-005378	11/26/2001	Finance Committee- nurses health study			
08021	DUROJ020-000014	DUROJ020-000014	11/1/2000	Finance Committee- Lexus			
08021A	DUROJ020-000014	DUROJ020-000014	11/1/2000	Correspondence from Jeff Buchalter to Carrie Smith-Cox RE: Proposed Activities for Premarin and Premarin MPA			
08022A	BUCHJ004-000455	BUCHJ004-000455	12/1/1994	DEPO: Buchalter, Jeff 05/29/08 EX 22; Correspondence from Libby Brown to Jeff Buchalter RE: Consultants' Meeting			
08023			7/00/2003	GO low with Prempro Color ad			
08023A	BUCHJ004-000456	BUCHJ004-000458	2/10/1995	DEPO: Buchalter, Jeff 05/29/08 EX 22; "Cutting Edge" Consultant Conference on Hormone Replacement Therapy; "Advances in Hormone Replacement Therapy"			
08024	W-MDL04782-00059996		6/20/1983	PremPak Study			
08024A	BUCHJ004-000459	BUCHJ004-000461	12/2/1994	DEPO: Buchalter, Jeff 05/29/08 EX 23; Correspondence from Libby Brown to Jeff Buchalter RE: Agenda Changes, Consultant Meeting			
08025	W-MDL04782-00058954	W-MDL04782-00058955	9/21/1984	Choosing MPA as the P for E+P - based on market share			
08025A			7/13/2007	Cardone Depo Ex. 19: Correspondence from ReedSmith to Williams, Cuker & Berezofsky			
08026	NORMJ001-000649		3/18/1985	Ayerst Brazil			
08026A	PAYNC201-000009	PAYNC201-000018	7/18/2000	Payne Depo Ex. 2: Correspondence from Charles H. Payne to AHP Office of Ethics and Business Conduct			
08027	W-MCL003-02713	W-MCL003-02715	11/00/1986	Editorial by Cummings			
08027A	PAYNC201-000002	PAYNC201-000003	7/31/2000	Payne Depo Ex. 31: Correspondence from Carl Whatley, Jr. to Wyeth's Office of Ethics & Business Conduct			
08028A	PAYNC201-000004	PAYNC201-000006	7/27/2000	Payne Depo Ex. 32: Correspondence from Cynthia Waldrep, Territory Specialist			
08029A	PAYNC002-000046	PAYNC002-000046	6/15/1999	Payne Depo Ex. 33: AHP Code of Conduct Certificate of Compliance RE: Charles H. Payne			
08030A	see M04533		3/1/1999	Sex Hormone-Binding Globulin and Breast Cancer Risk (Oncology Update, Vol. 6, Number 2, 1999)			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08031			3/22/2005		Guidance for Industry - Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment		
08031A	DWRITE067402	DWRITE 067402	9/19/1997	Meeting Agenda			
08032A	DWRITE067403	DWRITE 067403	10/29/1997	Meeting Agenda			
08033A	DWRITE067405	DWRITE 067405	1/12/1998	Meeting Agenda			
08034				Various DesignWrite documents.			
08034A	DWRITE068302	DWRITE 068302	1/11/2005	Publication Plan Tracking Report			
08034J				Nachtigall article re: sex hormone-binding globulin and brca risk			
08035A	DWRITE068884	DWRITE 068884	1/12/2005	Correspondence from Karen D. Mittleman, Ph.D. to Lila E. Nachtigall, MD RE: Development of a manuscript concerning breast cancer and sex hormone-binding globulin			
08036A	DWRITE068885	DWRITE 068885	1/12/2005	Correspondence from Karen D. Mittleman, Ph.D. to Lila E. Nachtigall, MD RE: SHBG Paper - Reference missing #81			
08037A	DWRITE068886	DWRITE 068886	1/12/2005	Fax Cover Sheet RE: SHBG Outline			
08038A	DWRITE068890	DWRITE068890	06/00/1998	Draft Letter and revised article "Sex Hormone-Binding Globulin and Breast Cancer			
08039A	DWRITE068896	DWRITE068896		Role of Sex Hormone Binding Globulin (SHBG) in Modulating Breast Cancer Risk, Manuscript Outline Prepared for Wyeth-Ayerst by DesignWrite, Inc., Target Journal: Obstetrics and Gynecology			
08052			1/3/2007	Thompson StreetEvents: WYE - Wyeth at Morgan Stanley Pharmaceutical CEOs Unplugged Conference - TRANSCRIPT			
08053	W-MDL04782-00065039	W-MDL04782-00065055		ENDOMETRIAL CANCER, ESTROGENS, AND THE MENOPAUSE A SUMMARY OF PRELIMINARY OBSERVATIONS			
08054	W-MDL04782-00051891	W-MDL04782-00051892	12/22/1975	PREMARIN Letter Thomas, Norman J - Ayerst Lab Roberts, HK			
08055	W-MDL04782-00051979	W-MDL04782-00051981	11/20/1975	Memo re: Recent Lay Press Publicity Concerning the Possible Increased Incidence of Cancer of the Endometrium With Long Term Estrogen Therapy Bustamante, Robert - Ayerst Intl			
08056	W-MDL04782-00051847	W-MDL04782-00051871		Transcript of recorded meeting with Kirsch, Jewell and Purdue			
08057			3/00/2006	GAO Report 06-402 March 2006 - DRUG SAFETY: Improvement Needed in FDA's Postmarket Decision-making and Oversight Process			
08058	PANAA029-000103			Fred Hassan 12/16/06 DEPO EX 014: Handwritten note			
08059	W-MDL303-00079034	W-MDL303-00079160	9/30/1994	Submission of revised labeling and CMC (NDA 20-303)			
08060	DUROJ020-000786	DUROJ020-000789	2/4/2000	Finance Committee Authorization - Premarin additional marketing budget draft			
08061			1/10/2007	Dear Health Care Professional letter from Wyeth re SAN Antonio Breast Cancer Symposium and Dr. Ravdin's findings			
08061A			00/00/2007	print out from University of Maryland Medical Center website re: Breast Cancer			
08062	HENRL001-000400	HENRL001-000404	3/27/2000	Finance Committee Authorization Premarin - Additional Marketing Budget			
08063	DUROJ019-000054	DUROJ019-000054	1/13/1999	Finance Committee Authorization - High speed printing equipment to add icon to Premarin pills			
08064	W-MDL303-00084307	W-MDL303-00084426	4/7/1997	NDA annual report Premarin and Premphase			
08065	W-MDL303-00084726	W-MDL303-00084852	1/27/1998	NDA annual reports Prempro and Premphase			
08066	W-MDL303-00084859	W-MDL303-00084966	12/30/1998	NDA annual reports Prempro and Premphase			
08067	W-MDL527-00036113	W-MDL527-00036171	1/15/1997	NDA Annual report submission			
08068			03/00/2006	GOA - Drug Safety Improvement Needed in FDA's Postmarket Decision-making and Oversight Process			
08068A				webpage-- about the GAO			
08069			3/00/2003	DHHS Office of Inspector General: FDA's Review Process for New Drug Applications			
08070			00/00/2007	The Future of Drug Safety: Promoting and Protecting the Health of the Public Committee on the Assessment of the US Drug Safety System, Alina Baci, Kathleen Stratton, Sheila P. Burke, Editors ISBN: 0-309-66600-7, 350 pages, 6 x 9, (2006)			
08071			9/00/2002	GAO-02-958 FOOD AND DRUG ADMINISTRATION Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities			
08072	W-MDL303-00083904	W-MDL303-00083907	10/5/1995	memo from Joan Barton re: Prempro Labeling Supplement: FDA Requires User Fee			
08073	W-MDL303-00083283	W-MDL303-00083345	12/29/1994	Package insert revisions			
08074	W-MDL303-00083349	W-MDL303-00083363	12/29/1994	Wyeth's agreement with changes proposed (NDA 20-303)		Bissinger, JoAnne; Victoria, Justin	
08075	FOLDR003-000641	FOLDR003-000656	4/28/1994	Corporate Direction Circular: Premarin/MPA Continuous Combined Tablet			
08076	GPIL018-001401	GPIL018-001409	8/14/1991	Direction Circular: Wyeth MPA Tablets			
08077	ZUCAV008-011718	ZUCAV008-011722		DRAFT: Justification for changes to he EU Core SPC for HT products			
08078			12/18/2006	More Answers to Your Questions on Breast Cancer and Hormone Therapy: Q&A With Dr. Clifford A. Hudis http://abcnews.go.com/WNT/printid 2734429 Accessed 1/23/2007	More Answers to Your Questions on Breast Cancer and Hormone Therapy: Q&A With Dr. Clifford A. Hudis		http://abcnews.go.com/WNT/printid 2734429 Accessed 1/23/2007
08078A				Hudis Transcript			
08078B				Norton Transcript			
08078C				Norton Website			
08078D				Hudis Website			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08079			00/00/2006	Mainline Health Services: Breast Health Partnership (Thomas Frazier, Director) Patient Information Page www.mainlinehealth.org/mlh/wellness/whs/article_10337.asp			
08080			00/00/2007	Chapters 11.13 and 11.14 Multistep Tumorigenesis" pp 435-441; 454			
08081	w-mdl303-00083350	w-mdl303-00083363	12/29/1994	Letter to Kish w/ eclosure: Package insert changes (DX 221)		Bissenger	
08082	COBBP002-000644	COBBP002-000652	6/25/1992	Hormone Replacement (Premarin-MPA) in Women with CHD AHT, Phase III		Riggs,Betty S - American Home Products Levy,Robert - American Home Products DeVane,Philip J - American Home Products Hassan,Fred - American Home Products Illegible,B - American Home Products	
08083	DUROJ020-000730	DUROJ020-000732	12/8/1999	Finance Committee Authorization HERS		Pickar,James H - American Home Products Gage,L - American Home Products Hunter,Heidi - American Home Products Mahady,J - American Home Products Illegible,B - American Home Products	
08084			03/00/2005	Guidance for Industry: Premarketing Risk Assessment			
08085	ROSSC005-000167	ROSSC005-000167	8/19/1991	Letter to J Morrison from R Hassell, FDA			
08086			1/10/2007	Wyeth Dear Doctor Letter			
08087	HUBST001-031288	HUBST001-031289		Managers Meeting Product Workshop			
08088	WHERS171-000971		11/9/1992	Vasomometer symptoms			
08089	PSCAR015-001805	PSCAR015-001807	5/4/1992	PREM MPA Correspondence email from Bissett to Pickar and Dey			
08090			11/00/2007	FDA Science and Mission at Risk Report			
08095	W-SALES-000016	W-SALES-000017		Marketing Budget by year 2004 to 2008			
08096	W-SALES-000018	W-SALES-000022		Premarin Sales January 2004 to Dec. 2008			
08097	W-SALES-000023	W-SALES-000030		Prempro Gross and Net profit starting in 1994			
08098	W-SALES-000031	W-SALES-000031		Share of estrogen containing market for Prempro, Premarin and Premphase 1992-2008			
08150	HENRL001-000219	HENRL001-000223	1/22/1998	Finance Committee			
08151	DUROJ020-000722	DUROJ020-000726	4/28/2000	Finance Committee			
08152	DEMAE023-007243	DEMAE023-007244	4/24/2000	Finance Committee for Viagra study			
08153	DUROJ019-000054		1/13/1999	Finance Committee for printing press			
08154	CONNS008-000915		12/00/1993	New Premarin Ad campaign memo			
08155			7/9/2002	NIH Press Release on stopping the WHI study			
08155A	Various	Various	10/29/1997	Trudy Bush compilation exhibit			
08155B				various DesignWrite and Martin docs			
08155G				various Martin docs: tables about publications			
08155Z				Composite exhibit - Bush			
08159	PANAA035-000498	PANAA035-000499	3/6/1991	Premarin Extramural			
08160			8/14/2007	Kerlikowske 8/14/07 Press Release			
08161			9/13/2007	American Cancer Reference Information - What Are The Risk Factors for Breast Cancer?			
08164	CONTA003-000623	CONTA003-000672	00/00/1995	Women's Health Issues and Hormones			
08165			10/00/2001	September 2001: Supplement to Women's Health in Primary Care			
08166	DEMAE021-00169		5/16/2001	Memo re: endowment for Dr. DiSaia			
08167	PICKJ013-000611		6/27/1998	List of studies and investigators			
08168	HENRL001-000092		6/25/1998	PR change notice to Burson Marsteller			
08169	HENRL001-000122		10/15/1997	Burson Marsteller memo to Lisa Henry			
08170	PANAA035-00001967		6/26/1990	Letter from University of California to Wyeth			
08171	HENRL001-000103	HENRL001-000111		1998 Premarin Public Relations Budget			
08171A	HENRL001-000111	HENRL001-000111		Burson Marsteller Premarin Budget			
08172	DEYMI213-016699	DEYMI213-016942	5/12/2004	EMT strategy off-site			
08173	CONKJ005-000436	CONKJ005-000437	7/1/2002	Wyeth letter to FDA re: WHI study			
08174			12/00/2006	1997 ACOG pamphlet on Menopause			
08175			12/00/2006	2006 Wyeth Pamphlet: Menopause treatment - Making a Decision that's right for you			
08175A							
08176	W-30(b)(6)-12-00411	W-30(b)(6)-12-00455	1/1/2003	IMS contract			
08177	GPIL009-000760		7/31/1990	Premarin memo			
08190	FHCRC084617	FHCRC084621	9/24/2007	Robert Langer email to Ross Prentice			
08191	FHCRC084622	FHCRC084628	9/25/2007	Robert Langer email to Ross Prentice			
08192	FHCRC084629	FHCRC084636	9/27/2007	Robert Langer email to Ross Prentice and Mary Pettinger			
08193	FHCRC084637	FHCRC084646	9/28/2007	Robert Langer email to Ross Prentice			
08194	FHCRC084647	FHCRC084648	11/3/2007	Robert Langer email to Ross Prentice			
08195	FHCRC084649	FHCRC084652	11/5/2007	Robert Langer email to Ross Prentice			
08196	FHCRC084653	FHCRC084658	1/21/2008	Robert Langer email to Ross Prentice and Sheri Greaves			
08197	FHCRC084659	FHCRC084665	1/21/2008	Robert Langer email to Ross Prentice			
08198	FHCRC084666	FHCRC084668	1/23/2008	Robert Langer email to Ross Prentice			
08199	FHCRC084669	FHCRC084672	1/24/2008	Robert Langer email to Ross Prentice			
08200	FHCRC084673	FHCRC084679	1/29/2008	Robert Langer email to Ross Prentice			
08201	FHCRC084680	FHCRC084681	1/29/2008	Robert Langer email to Ross Prentice			
08202	FHCRC084604	FHCRC084606	8/8/2007	Robert Langer email to Ross Prentice			
08203	FHCRC084607	FHCRC084612	8/9/2007	Robert Langer email to Ross Prentice			
08204	FHCRC084613	FHCRC084616	8/30/2007	Robert Langer email to Ross Prentice			
08211			11/7/2003	CONVINCE: Equivalence trial ended prematurely			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08212			12/00/2007	ACOG 2007 guidelines			
08213			10/7/2003	ACOG 2003 guidelines on osteo			
08214			2/1/1990	1990 FDA Advisory Committees			
08215	RM_AA 0102328	RM_AA 0102575	6/21/1991	1991 FDA Advisory Committees vol II			
08215A	RM_AA 0102111	RM_AA 0102325	06/20/1991	1991 FDA Advisory Committees vol I			
08216			2/14/2002	1992 FDA Advisory Committees			
08217	GMAAR086-000312	GMAAR086-000312	12/11/1998	Additional Listing 4 Mammogram Results for Subjects having an Abnormal Mammogram			
08218	SOLOJ020-000618	SOLOJ020-000620	10/2/1996	Finance Committee Authorization Premarin Cardiovascular Labeling Submission			
08219	DEYMI206-000372	DEYMI206-000380	00/00/2002	FINANCE COMMITTEE AUTHORIZATION-- Premarin primer			
08220	PANAA029-000104	PANAA029-000109	1/1/1989	Menopause Estrogen Deficiency and Estrogen Replacement Therapy			
08221	CHOOM202-001679	CHOOM202-001683					
08222	ROSSC034-000919	ROSSC034-000920	6/30/1995	DDMAC- NDA 20-303 Prempro/Premphase (Conjugated Estrogens/Medroxyprogesterone)			
08229	STEPW014-004505	STEPW014-004505	7/8/2002	Email re WHI and smoking			
08230	SINAM012-001131	SINAM012-001144	2/2/1999	Bernard Poussot powerpoint			
08231	DEMAE202-007316	DEMAE202-007323		Informed Consent- Asian women study			
08232	PANAA029-000382	PANAA029-000383		Wyeth Internal - Nick Marmontello - Premarin crisis preparedness			
08233	NORMJ225-021432	NORMJ225-021826		Hope Protocols			
08234				Pepi Consent			
08235	W-MDL-30300058150	W-MDL-30300058150		CRF			
08236	W-MDL-30300057150	W-MDL-30300058149					
08245	BeckKK002-000042			Icebreakers and introductions Beck Exh 10			
08246	BeckKK002-000163			Beck Exh 17 powerpoint slides			
08246c				Onolink breast cancer prevention			
08247	BeckKK002-0000332			Q & A heart disease data Beck Exh 27			
08248	BeckKK002-0001096			Beck Exh 13 Body of Evidence			
08249	BeckKK002-0000096			Beck Exh 12			
08250	BeckKK002-0000023			Osteo Self Assessment Beck Exh 9			
08251	BeckKK002-0000525			Product training manuel Beck Exh 6			
08252				Just the facts: Beck Exh 16			
08270							
08301				Susan Allen Review			
08302	BURKM014-001854	BURKM014-001857	7/27/2000	ATTL Agreement			
08302B	BURKM029-030769	BURKM029-030782		ATTL draft: Medical Literature Substantiation for 07/30/00 Recommended Revisions to FDA's Proposed Breast Cancer Warning Verbiage			
08306				Jeff Buchalter voice mail to sales force			
08306A				Breast Health Resource Guide			
08306				investigator list			
08311				women's health care sales			
08330							
08348	W-MDL303-00083278		12/30/1994	Memo from Kish to victoria re phase 4 commitments			
08400	N/A	N/A	9/21/2006	FDA Amicus Brief" Re Andrea Perry et al. v. Novartis Pharmaceuticals et al. Civ. No. 05-5350 to Hon. Stewart Dalzell"		Swingle, S	
08402			11/13/2003	SEC Filing 8-K 11/13/2003 Pfizer			
08403			2/26/2007	Wyeth Annual report 2006			
08404			2/27/2006	SEC Filing Wyeth 10-K Period 12/31/2005			
08405			11/16/2006	Wyeth 10-Q Period 9/30/2006			
08406			12/18/2006	Breast Cancer News Brings range of reactions	Breast Cancer News Brings Range of Reactions	Kolata, G	NY Times 12/18/2006
08407			12/15/2006	Reversing Trend article	Reversing Trend, Big Drop in Breast Cancer	Kolata, G	NY Times 12/15/2006
08408			3/1/2005	S. Hrg. 109-67 HEARING OF THE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS UNITED STATES SENATE "FDA's Drug Approval Process, Up to the Challenge?"			
08409			4/10/2007	Dear Health Care Professional letter			
08410			12/2/2004	How to improve drug safety	How to Improve Drug Safety	Schultz	Wash. Post A35
08411			6/9/2006	TRANSCRIPT: Doherty v. Merck - Superior Court of New Jersey -pp581-586 - Judge Higbee rules on FDA preamble			
08412	N/A		1/6/1998	FDA/CDER Prempro NDA 20-527/S-006 - Administrative Documents			
08413			2/25/1997	FDA/CDER Prempro NDA 20-527/S-006 - Administrative Documents 2			
08414			1/9/1998	FDA/CDER Prempro NDA 20-527/S-006 - Approval Letter			
08415				FDA/CDER Prempro NDA 20-527/S-006 Pharmacology Reviews			
08416				FDA/CDER Prempro NDA 20-527/S-006 - Correspondence			
08417			7/1/2006	Video file - C-SPAN: [109 Senate Hearings][DOCID: f99761.wais] S. Hrg. 109-67 EXCERPT			
08418	H00017470	H00017470		Timeline poster tracking examples of Prempro promotion, DTC, 3rd party, etc.			
08419			1/00/2007	2006 Prempro Label (Prescribing Information)			
08420			1/00/2007	2007 Prempro Label			
08421			9/26/2006	The future of drug safety: promoting and protecting the health of the public.		Bacin et al, Es. (Institute of Medicine)	
08422			4/18/2007	Wyeth press Release re: Ravdin Article NEJM - decline of Breast Cancer			http://www.wyeth.com/news?nav=display&navTo=wyeth_html/home/news/pressreleases/2007/1176930028193.html

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08423				Unbranded ad for HRT - Woman's Day 3/10/1998			
08424				Premarin			
08425			00/00/2001	Patti LaBelle Woman's day ad 4/23/2002			
08425A				Lauren Hutton Woman's Day ad			
08425B				IARC structure			
08425C				IARC Board			
08426				IARC Mission			
				List of studies finding RR 2.0 opr greater with combo HRT			
08426A			11/1/2007	National Cancer Institute - Additional Tests			
08426B			10/27/2002	Oncolink.Com			
08426B+A5656				Oncolink			
08426c				NCI			
08500			4/19/2006	Generic Expert Report - Jolson, Heidi M.		Jolson, Heidi M.	
08501			2/16/2006	Generic Expert Report - Acs, Geza		Acs, Geza	
08502			2/18/2006	Generic Expert Report - Anderson, Benjamin O.		Anderson, Benjamin O.	
08503				Generic Expert Report - Archer, David F.		Archer, David F.	
08504			2/2/2006	Generic Expert Report - Arias, Raquel D.		Arias, Raquel D.	
08505			2/9/2006	Generic Expert Report - Armstrong, Katrina		Armstrong, Katrina	
08506			2/17/2006	Generic Expert Report - Bayer, Marc J.		Bayer, Marc J.	
08507			2/17/2006	Generic Expert Report - Bluming, Avrum Z.		Bluming, Avrum Z.	
08508			2/17/2006	Generic Expert Report - Chodosh, Lewis A.		Chodosh, Lewis A.	
08509			4/19/2006	Generic Expert Report - Creasman, William T.		Creasman, William T.	
08510			2/13/2006	Generic Expert Report - Disaia, Philip J.		Disaia, Philip J.	
08511			2/15/2006	Generic Expert Report - Edwards, Michael		Edwards, Michael	
08512			2/20/2006	Generic Expert Report - Elmore, Joann G.		Elmore, Joann G.	
08513			2/16/2006	Generic Expert Report - Fuqua, Suzanne A.W.		Fuqua, Suzanne A.W.	
08514			4/17/2006	Generic Expert Report - Gandy, Samuel E.		Gandy, Samuel E.	
08515			2/16/2006	Generic Expert Report - Harms, Steven E.		Harms, Steven E.	
08516			2/17/2006	Generic Expert Report - Hollingsworth, Alan		Hollingsworth, Alan	
08517			2/13/2006	Generic Expert Report - Jensen, Roy A.		Jensen, Roy A.	
08518			2/16/2006	Generic Expert Report - Kelly, Patricia T.		Kelly, Patricia T.	
08519			2/15/2006	Generic Expert Report - Kopans, Daniel B.		Kopans, Daniel B.	
08520			2/11/2006	Generic Expert Report - Langer, Robert D.		Langer, Robert D.	
08521			2/16/2006	Generic Expert Report - Ling, Frank W.		Ling, Frank W.	
08522			2/15/2006	Generic Expert Report - Lobo, Rogerio A.		Lobo, Rogerio A.	
08523			2/16/2006	Generic Expert Report - McDonnell, Donald P.		McDonnell, Donald P.	
08524			2/17/2006	Generic Expert Report - McGee, Daniel L.		McGee, Daniel L.	
08525			2/16/2006	Generic Expert Report - Minkin, Mary Jane		Minkin, Mary Jane (Gynecology Yale University School of Medicine)	
08526			2/17/2006	Generic Expert Report - Page, David L.		Page, David L.	
08527			2/17/2006	Generic Expert Report - Ratain, Mark J.		Ratain, Mark J.	
08528				Generic Expert Report - Riggs, B. Lawrence		Riggs, B. Lawrence	
08529			4/18/2006	Generic Expert Report - Sorrentino, Matthew		Sorrentino, Matthew	
08530			2/16/2006	Generic Expert Report - Stovall, Thomas G.		Stovall, Thomas G.	
08531			2/17/06	Generic Expert Report - Warren, Michelle P.		Warren, Michelle P.	
08532			1/20/2006	Generic Expert Report - Westbrook, Kent C.		Westbrook, Kent C.	
08533			2/16/2006	Generic Expert Report - Abramson, John David		Abramson, John David	
08534			2/14/2006	Generic Expert Report - Austin, Donald F.; Buckley David		Austin, Donald F.; Buckley David Buckley, David I.	
08534A			1/21/2007	Austin CV			
08535			11/30/2005	Generic Expert Report - Banka, Carole L.		Banka, Carole L.	
08536			12/15/2005	Generic Expert Report - Beck, James F.		Beck, James F.	
08537			2/15/2006	Generic Expert Report - Blume, Cheryl D.		Blume, Cheryl D.	
08537A				CV for Dr. Cheryl Blume		Blume, Cheryl D.	
08538				Generic Expert Report - Bundred, N.J.		Bundred, N.J.	
08539			2/15/2006	Generic Expert Report - Cope, Dennis E.		Cope, Dennis E. (Olive View UCLA Medical Center)	
08540			12/13/2005	Generic Expert Report - Fincher, Robert L.		Fincher, Robert L.	
08541			2/1/2006	Generic Expert Report - Frisina, Robert D.		Frisina, Robert D.	
08542			2/16/2006	Generic Expert Report - Fugh-Berman, Adriane J.		Fugh-Berman, Adriane J.	
08543			2/15/2006	Generic Expert Report - Fuller, David N.		Fuller, David N.	
08544			11/21/2005	Generic Expert Report - Gabrielson, Edward		Gabrielson, Edward	
08545			5/19/2006	Generic Expert Report - Gann, Peter H.		Gann, Peter H.	
08546			2/14/2006	Generic Expert Report - Gill, George M.		Gill, George M.	
08547			11/30/2005	Generic Expert Report - Goldfarb, Paul		Goldfarb, Paul	
08548			2/15/2006	Generic Expert Report - Gueriguan, John		Gueriguan, John	
08549			2/15/2006	Generic Expert Report - Hartman, Raymond S.		Hartman, Raymond S.	
08550			2/14/2006	Generic Expert Report - Hawkes, Kristen		Hawkes, Kristen	
08551			12/16/2005	Generic Expert Report - Henry-Tillman, Ronda S.		Henry-Tillman, Ronda S.	
08552			2/15/2006	Generic Expert Report - Hollon, Matthew F.		Hollon, Matthew F.	
08552A				CV for Dr. Matthew Hollon		Hollon, Matthew F.	
08553			12/1/2005	Generic Expert Report - Jordan, V. Craig		Jordan, V. Craig	
08554			2/16/2006	Generic Expert Report - Keegan, Warren J.		Keegan, Warren J.	
08555			12/15/2005	Generic Expert Report - Klimberg, V. Suzanne		Klimberg, V. Suzanne	
08556			2/13/2006	Generic Expert Report - Maloney, Michael T.		Maloney, Michael T.	
08557			2/16/2006	Generic Expert Report - Metzl, Jonathan M.		Metzl, Jonathan M.	
08558			2/16/2006	Generic Expert Report - Munro, Malcolm G.		Munro, Malcolm G.	
08559				Generic Expert Report - Parisian, Suzanne		Parisian, Suzanne	
08559A			7/17/2009	Parisian, Suzanne- CV			
08560			2/8/2006	Generic Expert Report - Purdie, David M.		Purdie, David M.	
08561			2/10/2006	Generic Expert Report - Sackett, David L.		Sackett, David L.	
08562			11/30/2005	Generic Expert Report - Schwarting, Roland		Schwarting, Roland	
08563			12/15/2005	Generic Expert Report - Waldron, James A.		Waldron, James A.	
08564			2/1/2006	Generic Expert Report - Weirnerman, Stuart		Weirnerman, Stuart	
08565			2/20/2006	Generic Expert Report - Markman, Maurie		Markman, Maurie	
08566			2/16/2006	Generic Expert Report - Munro, Malcolm G.		Munro, Malcolm G.	

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08567			5/12/2006	Generic Expert Report - Austin, Donald F.; Buckley, David I.		Austin, Donald F. Buckley, David I.	
08568			5/5/2006	Generic Expert Report - Gaughan, Patrick		Gaughan, Patrick	
08569			4/20/2006	Generic Expert Report - Goldkind, Lawrence		Goldkind, Lawrence	
08570			4/20/2006	Generic Expert Report - Rarick, Lisa		Rarick, Lisa	
08571			4/13/2006	Generic Expert Report - Peck, Carl		Peck, Carl	
08572			4/20/2006	Generic Expert Report - Morris, Louis		Morris, Louis	
08573			4/20/2006	Generic Expert Report - Mazis, Michael		Mazis, Michael	
08574			12/21/2006	Generic Expert Report - Stolley, Paul		Stolley, Paul	
08575			1/11/2007	Generic Expert Report - Clarke, Christina		Clarke, Christina	
08576				Generic Expert Report - Addendum - Bundred, Nigel		Bundred, Nigel	
08577				Generic Expert Report - - Causality - Austin, Donald		Austin, Donald	
08578			12/00/2006	Generic Expert Report - - Supp - Austin, Donald		Austin, Donald	
08579			11/7/2005	Generic Expert Report - -BC- Colditz, Graham A.		Colditz, Graham A.	
08579A			11/9/2010	CV for Dr. Graham Colditz		Colditz, Graham A.	
08580			2/10/2006	Generic Expert Report - -BC-Demirovic, Jasenka		Demirovic, Jasenka	
08581			12/19/2005	Generic Expert Report - -BC-Lewis, Cora E.		Lewis, Cora E.	
08582			2/15/2006	Generic Expert Report - -BC-McPherson, Klim		McPherson, Klim	
08583			4/18/2006	Generic Expert Report - -Supplemental-Markman, Maurie		Markman, Maurie	
08584			4/13/2006	Generic Expert Report - -Supplemental-Arias, Raquel D.		Arias, Raquel D.	
08585			4/20/2006	Generic Expert Report - -Supplemental-Armstrong, Katrina		Armstrong, Katrina	
08586			4/19/2006	Generic Expert Report - -Supplemental-Bluming, Avrum Z.		Bluming, Avrum Z.	
08587			4/19/2006	Generic Expert Report - -Supplemental-Chodosh, Lewis A.		Chodosh, Lewis A.	
08588			4/13/2006	Generic Expert Report - -Supplemental-Disaia, Philip J.		Disaia, Philip J.	
08589			4/19/2006	Generic Expert Report - -Supplemental-Langer, Robert D.		Langer, Robert D.	
08590			2/6/2006	Generic Expert Report - -Supplemental-Colditz, Graham A.		Colditz, Graham A.	
08591			2/10/2006	Generic Expert Report - -Supplemental-Demirovic, Jasenka		Demirovic, Jasenka	
08592				Generic Expert Report - -Supplemental-Lewis, Cora E.		Lewis, Cora E.	
08593			2/15/2006	Generic Expert Report - -Supplemental-McPherson, Klim		McPherson, Klim	
08594			8/21/2006	Generic Expert Report - - Supp-Hartman, Raymond S		Hartman, Raymond S	
08595			4/18/2006	Generic Expert Report - - Supp-Lobo, Roogerio A.		Lobo, Roogerio A.	
08596			2/16/2006	Generic Expert Report - Minkin, Mary Jane		Minkin, Mary Jane	
08597				Generic Expert Report - Creasman, William T.		Creasman, William T.	
08599				Expert Report of Kurt Barnhart, MD			
08600			3/23/2007	Generic Expert Report - Pommier, Rodney		Pommier, Rodney	
08601			4/9/2007	Affidavit of Paul Stolley re: Design Defect		Stolley, Paul	
08602			4/12/2007	Supplemental Expert Report of Paul Stolley			
08603			7/2/2007	Report of Dr. Parisian - Generic (Wyeth)			
08604	CHOOM004-000020	CHOOM004-000020		Vaginal Progesterone: A Natural Alternative for Progesterone Intolerant Women on Hormone Replacement Therapy			
08605	COBBP008-000014	COBBP008-000018		Natural Progesterone Information Service			
08606	CONKJ002-000028	CONKJ002-000029		Natural Progesterone the Multiple Roles of a Remarkable Hormone			
08607	CONKJ009-000217	CONKJ009-000220	00/00/2000	The Benefits of Prometrium (Progesterone, USP) Capsules as Proven in the PEPI Papers			
08608	CONKJ019-009016	CONKJ019-009124	8/00/2001	Mosaic Study #30 Hormone Replacement Therapy			
08609	CONNS010-001462	CONNS010-001473	1/21/1994	Natural Progesterone Usage & Instructions			
08610	CONSG001-001157	CONSG001-001162	11/27/1998	Table1 Effects Of Oral Conjugated Equine Estrogen Combined with Micronized Progesterone or Medroxyprogesterone Acetate on Endothelial Function			
08611	CONSG015-007257	CONSG015-007257	10/28/2002	Constantine RSVP to 2nd Annual Progestins Symposium			
08612	CONSG015-007361	CONSG015-007390	11/00/2002	Clinical Experience with Trimegeston PPT			
08613	CONSG018-019374	CONSG018-019375	2/20/2001	Email from R. Lyttle re vascular effect of TMG			
08614	CONSG206-000245	CONSG206-000246	4/25/2003	Email from R. Lyttle re Position Paper on WHI HRT Trial			
08615	DELCA033-030523	DELCA033-030543		Internal Memo: Perspectives in ERT/HRT			
08616	DEMAE007-000719	DEMAE007-000720	1/25/1995	Follow-Up Discussion of Various Aspects of Micronized Progesterone (MP) and Oral Medroxyprogesterone Acetate (MPA)			
08617	DEMAE007-002451	DEMAE007-002452	1/25/1995	Micronized Progesterone (MP) and of Oral Medroxyprogesterone Acetate (MPA) as Contained in cyclin 2.5mg Tablets and in the Premarin 0.625 mg/MPA 2.5mg Combination Tablets			
08618	DEMAE019-001583	DEMAE019-001584		Metabolism of Progesterone			
08619	DUROJ044-004675	DUROJ044-004676	11/13/1997	DRAFT letter to Medispan re Crinone			
08620	DUROJ046-003347	DUROJ046-003347	10/22/2002	Fwd: Update: Million Women Study			
08621	DUROJ212-001913	DUROJ212-001913	5/14/2004	VM to WHC Sales Team re Million Women Fracture Data			
08622	GPIL007-000147	GPIL007-000148		Colprosterone 25 mg (Progesterone)			
08623	GPIL014-000088	GPIL014-000130	12/00/1996	Crinone Product Monograph			
08624	KREBS002-012987	KREBS002-012988	6/00/2004	M.A.I.L. re Banks Beral article			
08625	KUSIV201-000046	KUSIV201-000047		DRAFT Estrogen/Progestin Talking Points	DRAFT		
08626	KUSIV201-000072	KUSIV201-000074		Reference Material:	Reference Material:		
08627	LYTTR017-001933	LYTTR017-001951	11/19/1997	Types of Collaborations	Types of Collaborations		
08628	MARRA209-013808	MARRA209-013808	11/4/2003	Email from A. Marren re Brand Name Tid Bits			
08629	MARRA209-031889	MARRA209-031889		p2p Alert	p2p Alert		
08630	PANAA036-000187	PANAA036-000187		Utrogestan Micronized Progesterone	Utrogestan Micronized Progesterone		
08631	PANAA036-000188	PANAA036-000188		Utrogestan Progesterone (DCI) Oestrogel Estradiol 17 (D.C.I.)	Utrogestan Progesterone (DCI) Oestrogel Estradiol 17 (D.C.I.)		

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08632	PANAA036-000200	PANAA036-000200	11/8/1991	Schering-Plough HRT: Prometrium (Oral Micronized Progesterone) and Estrogel (Topical Estradiol - 17 -E Gel)	Schering-Plough HRT: Prometrium (Oral Micronized Progesterone) and Estrogel (Topical Estradiol - 17 -E Gel)		
08633	PANAA036-000272	PANAA036-000291		Progesterone NDA Clinical Program Proposal	Progesterone NDA Clinical Program Proposal		
08634	PCSAR001-000457	PCSAR001-000461	11/00/1995	Hulka: Hormones and Breast and Endometrial Cancers			
08635	PCSAR003-001701	PCSAR003-001702	12/10/1993	Letter from Dr. Jusko to Steven Troy			
08636	PCSAR005-002078	PCSAR005-002078	10/17/1994	Internal Memo from Suzanne Joyner re Premarin MPA			
08637	PCSAR005-002086	PCSAR005-002086	11/11/1994	Internal Memo from Beat Leber re Premarin/MPA			
08638	PCSAR005-002087	PCSAR005-002087	10/17/1994	Internal Memo from Suzanne Joyner re Premarin MPA			
08639	PCSAR005-002173	PCSAR005-002175	12/8/1992	Internal Memo from James Pickar re Premarin/MPA Study - Breast Carcinoma			
08640	PCSAR005-002176	PCSAR005-002176		Table of Annual Average Cancer Incidence Rates			
08641	PCSAR005-002177	PCSAR005-002177		1987 Annual Cancer Statistics Review			
08642	PICKJ009-000940	PICKJ009-000940	4/10/1987	Micronized Progesterone and Estradiol Menopause Formulations	Micronized Progesterone and Estradiol Menopause Formulations		
08643	PICKJ009-000941	PICKJ009-000941	3/31/1989	Use of Micronized Progesterone in the Menopause	Use of Micronized Progesterone in the Menopause		
08644	PICKJ009-000943	PICKJ009-000955		Natural Micronized Progesterone	Natural Micronized Progesterone		
08645	PICKJ009-000980	PICKJ009-000981	9/23/1986	Micronized Progesterone	Micronized Progesterone		
08646	SINAM002-001085	SINAM002-001091	05/00/1995	Micronized Progesterone Backgrounder	Micronized Progesterone Backgrounder		
08647	W-MCL003-00078	W-MCL003-00084	05/00/1995	Micronized Progesterone Backgrounder	Micronized Progesterone Backgrounder		
08648	DEANE 1771	DEANE 1772	8/26/1994	Women's Health Care News: Premarin Powerhouse of the '90s! From Carrie Smith Cox			
08649	DEANE 2055		1/6/1995	Women's Health Care News: New Premarin DTC Advertising Campaign from Carrie Smith Cox			
08650	FARAN025-011665	FARAN025-011686		Slide Presentation / slide #10 Importance of Physician Recommendations and what is needed to convince women to take HRT			
08651			5/25/2008	print out from Oncolink.com website re: Receptor Quotes			
08652			2/19/2008	Order in Rowatt			
08653			8/7/2008	Order from Hill			
08654			6/19/2007	Judge Bryan Garruto's order and memorandum re: Wyeth's challenges to Dr. Austin in Deutsch v. Wyeth (6-19-07)			
08655			9/27/2006	Order, McCreary v. Wyeth, et al., Second Judicial District Court of State of Nevada (September 27, 2006), Exhibit 3			
08656			9/27/2006	Order in Rowatt			
08657			6/14/2006	Supplemental Affidavit of Michael T. Maloney			
08658				Supplemental Disclosure of Cheryl Blume			
08659				Supplemental Disclosure of Cheryl Blume - Labeling Supplement			
08660				Austin Chart re articles and conclusions re Ductal Breast Cancer			
08661			8/24/2007	Affidavit of Jenq-Sheng Liu, MD			
08662	GOLDG001-001435	GOLDG001-001499		Field Sales Promotional Policy 511			
08663				Cheryl Blume PhD Curriculum Vitae			
08664			9/13/2007	Schwartz Supplemental. Report 9/13/07			
08665			4/18/2007	NIH Press Release: Decrease in Breast Cancer Rates Related to Reduction in Use of Hormone Replacement Therapy			
08666				National Cancer Institute, Tamoxifen: Questions & Answers			
08667			1/27/1997	1997 Prempro Patient Insert			
08668				National Cancer Institute, Breast Cancer Risk Assessment Tool			
08669			9/13/2006	Order in Rush			
08670			7/16/2003	Premarin conjugated estrogens tablets PDR April 2004 approved_labeling			
08671	DEVAN207-002612	DEVAN207-002617	5/14/2002	Broadcast Transcript for "The Other Half" syndicated, co-hosted by Dick Clark, Mario Lopez, Hutton			
08672	PARKA001-000143	PARKA001-000145	2/28/2001	Bates Healthworld unbranded "Diary" :30 ad stills			
08673	KET-161516	KET-161516	3/12/2001	Cox News Service article - After seeing the world, Hutton not interested in Full-Time Work			
08674	KET-074330	KET-074334		Newspaper articles where Hutton discusses Hormone Replacement Therapy			
08675	HENRL213-000228	HENRL213-000235	6/17/2003	Transcript of "The Flipside" program hosted by V. Morris. Guest Lauren Hutton talks about ageless beauty			
08676	HENRL211-008488	HENRL211-008488		2001/2002 DTC Summary			
08677	HENRL002-002185	HENRL002-002185	9/25/2000	Memo from L. Henry to Baldwin re Lauren Fees 2000			
08678	ROSSC030-000457	ROSSC030-000469	5/24/2002	FPO Leading the way: a guide to using well-known spokesperson in Women's Health Care			
08679			00/00/2004	Height Change and Bone Mineral Density (Exhibit 9 to Hollon depo); Orthopaedic nursing, Sept/Oct. 2004, Vol. 23, No. 5:315-20; Diagnosis and Management of Vertebral Fractures in Elderly Adults, Am J Med. 2002;113:220-228; Vertebral Fracture Epidemiology, Wasnich, Bone, Vol. 18, No. 3, Supplement, March 1996:179S-183S			
08680	ROSSC025-001279	ROSSC025-001287		Phases Online			
08681	SOLOJ027-047419	SOLOJ027-047440	8/21/2001	2002 Premarin Family Consumer Tactics - Slide show presentation			
08682	ROSSC025-001203	ROSSC025-001204	00/00/2001	One Woman's Story, written by Hutton - with handwritten notes editing article			
08683	ROSSC025-001347	ROSSC025-001347		Staying Young - Letter from Hutton to enclose in menopause management kit			
08684	DUROJ004-002057	DUROJ004-002114	2/00/2001	Consumers' Reactions to an unbranded DTC Communications Program regarding Hormone Replacement Therapy			
08685	DEVAN009-000090	DEVAN009-000090		Hutton commercial stills from "Diary" :60 - Comm'l No.: AHPR-6087			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08686	CCC160-000196	CCC160-000196	2/20/2001	Note by Dr. Nash stating Ms. Huttons height changed from 5'7 1/2" to 5' 6 1/2" from 1990-1991			
08687	Various	Various	11/1/1999	Letter to Hutton enclosing agreement with Ehrental for Hormone Replacement Therapy ads			
08688	CCC160-000103	CCC160-000208	8/00/2001	Bates Healthworld Journal Ad - Lauren "Hot Flash" unbranded Ad for Premarin;			
08689	SOLOJ022-001055	SOLOJ022-001056	2/13/1996	Burson-Marsteller confidential memo from Winkler & Stone to Smith-Cox, Buchalter, Geisler re Positioning Trudy Bush to deflect Susan Love			
08690	FARAN009-000650	FARAN009-000651	11/00/1990	Events used in Impact Analysis.			
08691	DUROJ040-000093	DUROJ040-000098	12/22/1997	Highly Confidential memo from Barritt re Repositioning the breast cancer issue			
08692	DUROJ039-000256	DUROJ039-000260	9/4/2007	Internal Memo from Ludmerer re Raloxifene War Games - Final Report			
08693	DEVAN206-008617	DEVAN206-008618	8/8/2003	Internal Memo from Whiting re Lancet 8/8/03 - Hormone Replacement Therapy and Breast Cancer			
08694	DEVAN206-016445	DEVAN206-016455	00/00/2002	Global Women's Health Care Communications Strategy			
08695	BRADK008-005684	BRADK008-005726	11/19/2002	Executive Summary and full report - Registration Decision Point Document - Premarin (0.625mg)/Trimegestone Continuous Combined & Sequential Regiments			
08696	WHERS171-000971	WHERS171-000972	11/9/1992	Wyeth, Inc. internal document re estradiol and progesterone combination product; DEPO: Nagi, Arwinder 8/11/2009 EX 12			
08697	DEVAN206-016445	DEVAN206-016455		Global Women's Health Care Communications Strategy			
08698	DEVAN206-008617	DEVAN206-008618	8/8/2003	Internal Memo from Whiting re Lancet 8/8/03 - Hormone Replacement Therapy and Breast Cancer			
08699	FARAN009-000650	FARAN009-000651	11/00/1990	Events used in Impact Analysis.			
08700	SOLOJ022-001055	SOLOJ022-001056	2/13/1996	Burson-Marsteller confidential memo from Winkler & Stone to Smith-Cox, Buchalter, Geisler re Positioning Trudy Bush to deflect Susan Love			
08701	DEVAN207-002612	DEVAN207-002617	5/14/2002	Broadcast Transcript for "The Other Half" syndicated, co-hosted by Dick Clark, Mario Lopez, Hutton			
08702	SOLOJ027-047419	SOLOJ027-047440	8/21/2001	2002 Premarin Family Consumer Tactics - Slide show presentation			
08703	ROSSC025-001203	ROSSC025-001204	00/00/2001	One Woman's Story, written by Hutton - with handwritten notes editing article			
08704	ROSSC025-001347	ROSSC025-001347		Staying Young - Letter from Hutton to enclose in menopause management kit			
08705	BRADK008-005684	BRADK008-005726	11/19/2002	Executive Summary and full report - Registration Decision Point Document - Premarin (0.625mg)/Trimegestone Continuous Combined & Sequential Regiments			
08706	DEVAN009-000090	DEVAN009-000090		Hutton commercial stills from "Diary" :60 - Comm1 No.: AHPR-6087			
08707	ROSSC030-000457	ROSSC030-000469	5/24/2002	FPO Leading the way: a guide to using well-known spokesperson in Women's Health Care			
08708	CCC160-000196	CCC160-000196	2/20/2001	Note by Dr. Nash stating Ms. Huttons height changed from 5'7 1/2" to 5' 6 1/2" from 1990-1991			
08709	CCC160-000103	CCC160-000103	8/00/2001	Bates Healthworld Journal Ad - Lauren "Hot Flash" unbranded Ad for Premarin;			
08710	Various	Various	11/1/1999	Letter to Hutton enclosing agreement with Ehrental for Hormone Replacement Therapy ads			
08711	ROSSC025-001279	ROSSC025-001344	11/8/2001	Phases Online			
08712	HENRL002-002185	HENRL002-002185	9/25/2000	Memo from L. Henry to Baldwin re Lauren Fees 2000			
08713	HENRL211-008488	HENRL211-008488	00/00/2002	2001/2002 DTC Summary			
08714	HENRL213-000228	HENRL213-000235	6/17/2003	Transcript of "The Flipside" program hosted by V. Morris. Guest Lauren Hutton talks about ageless beauty			
08715	KET-074330	KET-074334		Newspaper articles where Hutton discusses Hormone Replacement Therapy			
08716	KET-161516	KET-161516	3/12/2001	Cox News Service article - After seeing the world, Hutton not interested in Full-Time Work			
08717	PARKA001-000143	PARKA001-000145	2/23/2001	Bates Healthworld unbranded "Diary" :30 ad stills			
08718	DUROJ004-002057	DUROJ004-002114	2/00/2001	Consumers' Reactions to an unbranded DTC Communications Program regarding Hormone Replacement Therapy			
08719	W-MDL527-00040876	W-MDL527-00040879	9/29/2000	Letter from Phillips to Allen at FDA re NDAs and breast cancer language			
08720				Austin Powerpoint Slides re SEER			
08721				austin ductal chart with additional columns			
08722			2/27/2007	Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Fournier A, Breast Cancer Res Treat (2008) 107:103-111			
08723	DUROJ039-001964	DUROJ039-001964	4/10/1987	Internal Memo from Pickar to Agersborg re Micronized Progesterone and Estradiol Menopause Formulations			
08724	DEMAE007-000719	DEMAE007-000720	1/25/1995	Letter from Colasante to Rossouw at WHI re micronized progesterone and MPA			
08725	DUROJ039-001905	DUROJ039-001911	5/00/1995	Micronized Progesterone			
08726	BURKM001-000528	BURKM001-000529	2/21/2001	Letter from FDA to Wyeth, Inc. re supplemental NDA for Premarin			
08727	BURKM029-026718	BURKM029-026723	10/27/1999	Internal Memo from Weber re 10/18/99 FDA advisory committee meeting			
08728			00/00/2007	American Cancer Society Breast Cancer Facts & Figures 2007 to 2008			
08729	W-MDL527-00040875	W-MDL527-00040875	9/29/2000	Letter from Phillips to Allen at FDA re Premarin, Prempro, Premphas NDAs			
08730	SOLOJ027-035083	SOLOJ027-035088	4/15/2002	Internal Memo from Ng to Henry and Solomon re Integrated Summary of Findings: Wave II Lauren Hutton DRTV re-contact Study			
08731	W-MDL527-00040888	W-MDL527-00040889	10/17/2000	Internal Memo from Phillips to Premarin Labeling List re FDA telephone Contact			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08732	W-ADSBRO-02527	W-ADSBRO-02531	1/00/1999	Menopause Gone in a Flash - color Blume Ex. 14			
08733			9/13/2007	Exhibit 19 - Stovall 9/4/08 depo - What are the Risk Factors for Breast Cancer?			
08734			10/00/2004	Exhibit 20 - Stovall 9/4/08 depo - Executive Summary - History of HT in ACOG Vol. 104, No. 4 (supplement) 10/04			
08735	FARAN024-020105	FARAN024-020146		Durocher depo ex. 27 - slides re Integrated Perspective on DRTV Lauren Hutton Campaign			
08736	HENRL002-002112	HENRL002-002144	2/27/2001	Exhibit 29 Durocher - Premarin 2001 Program Recommendations			
08737	STRIS003-000608	STRIS003-000616	12/21/2001	Exhibit 34 - Durocher depo - Consumer Hormone Replacement Therapy A&U Study 4th Quarter 2001			
08738	HENRL205-000106	HENRL205-000110	3/22/2001	Exhibit 36 - Durocher depo - Grassroots Programs - objectives and opportunities			
08739	BURKM029-031326	BURKM029-031326	7/14/2000	Internal Memo re FDA Contact Report on Premarin			
08740	SOLOJ207-000977	SOLOJ207-001020	7/1/1999	Klemtner Advertising - Editorial Guide & Claim Structure for Premarin			
08741	BURRG005-000737	BURRG005-000744	6/17/1997	Final Q&A -- CCC/CCEC changes incorporated // NEJM			
08742	BURRG005-001224	BURRG005-001224	3/19/2003	email coversheet from G Burr re: SERMs article			
08743	CHOOM057-000802	CHOOM057-000803	3/4/1996	Confidential Cummings Data Task Force Meeting Minutes			
08744	CHOOM057-000817	CHOOM057-000817	6/2/1995	memorandum from N Marmontello re: NEJM Breast Cancer Strategy -- Refinements to Plan Based on 5/30/95 meeting			
08744A	CHOOM057-000833	CHOOM057-000837	6/2/1995	memorandum from N Marmontello re: NEJM Breast Cancer Strategy -- Refinements to Plan Based on 5/30/95 meeting			
08745	CHOOM057-000818	CHOOM057-000818	6/2/1995	email coversheet to C Smith-Cox from Burson Marsteller re: revised strategy Speroff			
08746	CHOOM057-000819	CHOOM057-000822	6/2/1995	Revised strategy: Speroff from Burson Marsteller			
08747	CHOOM057-000823	CHOOM057-000823	6/2/1995	Draft for Client Review: Speroff from Burson Marsteller			
08748	CHOOM057-000824	CHOOM057-000830	6/2/1995	Postmenopausal Hormone Therapy and Breast Cancer: Speroff			
08749	CHOOM057-000831	CHOOM057-000831	6/5/1995	fax coversheet to P Lacante re: Premarin			
08750	CONSG018-002509	CONSG018-002520	9/13/2002	Breast Cancer Analysis Wyeth Clinical Studies			
08751	CONSG018-011769	CONSG018-011773	9/27/2001	Executive Safety Review of Conjugated Estrogen (CE)/Trimegestone (TMG) meeting agenda			
08752	CONSG018-017416	CONSG018-017509	3/27/2001	Bolt Due Diligence: SERM Thought Leader Panel #22			
08753	DEYMI206-000801	DEYMI206-000801	12/31/2002	email from M Dey re: FDA contact report WHI and Low Dose			
08754	DEYMI206-006542	DEYMI206-006559	8/29/2002	DRAFT Breast Cancer-Relative Risk 1996-Present, randomized & observational			
08755	DUROJ020-000641	DUROJ020-000642	9/12/1997	AHP Finance Committee Authorization: Studies to Support Premarin			
08756	DUROJ020-001091	DUROJ020-001095	10/23/1996	AHP Finance Committee Authorization: Celebration Health			
08757	DUROJ027-000742	DUROJ027-000754	11/16/2000	AHP Finance Committee Authorization: Local CME, VSB, Unrestricted Grants, Peer Selling			
08758	DUROJ027-000947	DUROJ027-000948	9/27/2000	AHP Finance Committee Authorization: Resident/Fellow Reporter Program			
08759	DUROJ041-001139	DUROJ041-001151	2/21/1995	AHP Finance Committee Personnel Authorization: Prempro/Premphase Sales Incentive Plan			
08760	DUROJ041-001161	DUROJ041-001162	11/7/1995	AHP Finance Committee Authorization: Prempro/Premphase Sales Incentive Plan			
08761	DUROJ041-001247	DUROJ041-001254	4/10/1996	AHP Finance Committee Authorization: Prempro/Premphase Special Sales Incentive			
08762	HENRL001-000098	HENRL001-000100		Burson Marsteller preliminary budget for 1988			
08763	HUBST001-025375	HUBST001-025375	5/9/2003	email from T Hubsch re: Premarin Family WHC Nation RX weekly reports for area 72000			
08764	LYTTR016-007525	LYTTR016-007545	12/18/2000	G Constantine 2000 Year End Review			
08765	LYTTR016-012062	LYTTR016-012069	3/26/1999	TSE-424 Wrap up correspondence			
08766	PANAA015-000896	PANAA015-000903	3/7/1997	AHP Finance Committee Authorization: 1997 Awards & Grants			
08767	ROSSC009-002205	ROSSC009-002237	03/00/1993	Stratos Communication: Premarin/Medroxyprogesterone Acetate Clinical Expert Report			
08768	SOLOJ015-000002	SOLOJ015-000012	9/19/2000	AHP Finance Committee Authorization: 15, 16, 17 Annual Symposia on the Long Term Effects of Estrogen Deprivation			
08769	SOLOJ022-001117	SOLOJ022-001120	2/9/1996	draft memo to J Buchalter re: 1996 World Congress on Osteoporosis: Breast Cancer Data Preliminary Plan			
08770	SOLOJ022-001417	SOLOJ022-001435		Breast Cancer, ERT & the Media			
08771	STEPW014-001341	STEPW014-001341	9/27/2001	email from W Stephenson re: CE/TMG Exec Safety Rev Slides			
08772	STRIS205-007933	STRIS205-007934	10/21/2003	AHT 6263 Low Dose Launch Costs			
08773	WEBEM015-003321	WEBEM015-003321	2/11/2000	email re: Premarin Advocate program at Renaissance meeting			
08774	YAVUE012-000033	YAVUE012-000071					
08775	W-MDL303-00081690	W-MDL303-00081725	8/26/1992	List of FDA meetings for Premarin/MPA NDA			
08776	ALTOC018-018520		3/17/2008	email from J Bobula re: Kanis article on OSTEO			
08777	BURRG005-000949	BURRG005-000955	12/7/1998	Outline & Budget for Breast Cancer 1 pager from Ketchum			
08777B	COBBP002-001304	COBBP002-001304	11/5/1997	HRT Breast Cancer Warning - Sweden			
08778	DUROJ020-000626	DUROJ020-000626	2/5/1998	Dispelling the estrogen myth			
08779	ALIVJ002-000029	ALIVJ002-000030	4/15/1994	Health & Healing letter			
08779B	PANAA027-000628	PANAA027-000631	1/00/1994	Health & Healing letter			
08780	COBBP013-001482	COBBP013-001483	12/14/2000	Wyeth-Ayerst Statement on the NIH Report on Carcinogens			
08781	HUNTH006-000830	HUNTH006-000831	2/2/2000	Brast Cancer Containment & Communication (draft w/ hand writing)			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08782			8/15/2006	Actavis Totowa, LLC Warning Letter from FDA re: reporting & recordkeeping requirements			
08783	see M0130		7/24/2001	AHA Science Advisory: Hormone Replacement Therapy and Cardiovascular Disease (Lori Mosca et al)			
08784				AMA website: Continuing Medical Education			
08785				AMA website: Gifts to Physicians from Industry			
08786			7/9/2009	Wyeth, Inc website 07/09/2009: Breast Cancer Definition			
08786A			7/9/2009	Wyeth, Inc website 07/09/2009: Breast Cancer Definition (in color)			
08787	BURKM005-000263	BURKM005-000265	1/22/2001	Letter from Wyeth to FDA re: Premarin Special Supplement - Changes being effected 30 Day Implementation			
08788	CHOOM047-000423		3/21/2000	Letter from ACOG to Wyeth re: \$70,000 for support of K White/Wyeth Resident Grant			
08789			7/29/2005	IARC Press Release No 167			
08790	JANEC209-001419	JANEC209-001449		A Current Assessment of Hormone Therapy for the Management of Menopause			
08791			12/00/1996	Action Plan for the Provision of Useful Prescription Medicine Information			
08792	MARLM001-000948	MARLM001-000949	08/00/2002	Understanding the WHI Study: Assessing the Results			
08793			9/25/2005	Nephron Pharmaceuticals Corp Warning letter from FDA re: postmarketing safety surveillance			
08794				Schering-Plough Research Institute: Prometrium Labeling			
08795			12/12/2008	Senator Grassley's letter to Poussot			
08796	SOLOJ027-014209	SOLOJ027-014215	11/11/2002	Premarin Family Tactics 2003 Estimated Budget as of 11/11/2002			
08797			5/26/2004	Vintage Pharmaceuticals, Inc Warning letter from FDA re: safety surveillance & postmarketing adverse drug events			
08798			7/29/2005	IARC Press Release No 167			
08799	MARTN010-002503	MARTN010-002600	11/00/1999	Mosaic Study #17 Hormone Replacement Therapy			
08800	ALTOC018-017218	ALTOC018-017222	3/4/2008	Wyeth News Release -- WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy			
08801	BARBM017-000001	BARBM017-000003; BARBM017-000270-000343	00/00/2002	DEPO: Janas, Bernadette 1/04/2008 EX 111			
08802	BARBM023-004422	BARBM023-004422	4/17/2002	DEPO: Janas, Bernadette 1/04/2008 EX 59			
08803	BARBM023-004436	BARBM023-004436	4/19/2002	DEPO: Janas, Bernadette 1/04/2008 EX 60			
08804	BUCHJ001-001116	BUCHJ001-001122		DEPO: Buchalter, Jeff 5/29/2008 EX 12			
08805	BUCHJ001-001622	BUCHJ001-001624	6/2/1997	DEPO: Buchalter, Jeff 5/29/2008 EX 10			
08806	BUCHJ002-000509	BUCHJ002-000552		DEPO: Buchalter, Jeff 5/29/2008 EX 8			
08807	BUCHJ002-000553	BUCHJ002-000635	00/00/1995	DEPO: Buchalter, Jeff 5/29/2008 EX 9			
08808	BUCHJ002-000637	BUCHJ002-000641	00/00/1997	DEPO: Buchalter, Jeff 5/29/2008 EX 11			
08809	BUCHJ003-001734	BUCHJ003-001738		DEPO: Buchalter, Jeff 5/29/2008 EX 14			
08810	BUCHJ003-001739	BUCHJ003-001742	5/00/1996	DEPO: Buchalter, Jeff 5/29/2008 EX 15			
08811	BUCHJ003-001743	BUCHJ003-001745	8/00/1995	DEPO: Buchalter, Jeff 5/29/2008 EX 16			
08812	BUCHJ003-001782	BUCHJ003-001783	5/25/1995	DEPO: Buchalter, Jeff 5/29/2008 EX 17			
08813	BUCHJ003-001790	BUCHJ003-001792		DEPO: Buchalter, Jeff 5/29/2008 EX 18			
08814	BUCHJ003-001858	BUCHJ003-001858	2/27/1995	DEPO: Buchalter, Jeff 5/29/2008 EX 19			
08815	BUCHJ004-000032	BUCHJ004-000032	12/15/1993	DEPO: Buchalter, Jeff 5/29/2008 EX 4			
08816	BUCHJ004-000138	BUCHJ004-000139	10/8/1993	DEPO: Buchalter, Jeff 5/29/2008 EX 5			
08817	BUCHJ004-000143	BUCHJ004-000165		DEPO: Buchalter, Jeff 5/29/2008 EX 6			
08818	BUCHJ004-000733	BUCHJ004-000737		DEPO: Buchalter, Jeff 5/29/2008 EX 7			
08819	COBBP024-000414	COBBP024-000462	1/00/2002	DEPO: Janas, Bernadette 1/03/2008 EX 52			
08820	CONSG204-010712	CONSG204-010712	7/23/2003	DEPO: Winneker, Rick 3/31/2009 EX 129			
08821	CONSG204-010713	CONSG204-010713	7/23/2003	DEPO: Winneker, Rick 3/31/2009 EX 130			
08822	DELCA004-000591	DELCA004-000591	11/1/2001	DEPO: Janas, Bernadette 1/03/2008 EX 34			
08823	DELCA004-000592	DELCA004-000592		DEPO: Janas, Bernadette 1/03/2008 EX 35			
08824	DUROJ017-001102	DUROJ017-001103		DEPO: Janas, Bernadette 1/03/2008 EX 87			
08825	DUROJ021-001896	DUROJ021-001904	4/13/2001	DEPO: Buchalter, Jeff 5/29/2008 EX 34			
08826	DUROJ046-023933	DUROJ046-023933	10/10/2001	DEPO: Janas, Bernadette 1/03/2008 EX 39			
08827	DUROJ046-024195	DUROJ046-024195	8/28/2001	DEPO: Janas, Bernadette 1/03/2008 EX 86			
08828	DUROJ213-036670	DUROJ213-036674	7/2/2003	DEPO: Montgomery-Rice 1/05/2007 EX 9			
08829	DWRITE022824	DWRITE 022827	4/8/2004	DEPO: Janas, Bernadette 1/03/2008 EX 105			
08830	DWRITE022855	DWRITE 022857	4/21/2004	DEPO: Janas, Bernadette 1/03/2008 EX 106			
08831	DWRITE022860	DWRITE 022863	3/9/2004	DEPO: Janas, Bernadette 1/03/2008 EX 104			
08832	DWRITE022906	DWRITE 022915	12/31/2004	DEPO: Janas, Bernadette 1/03/2008 EX 109			
08833	DWRITE025722	DWRITE 025725	3/12/2002	DEPO: Janas, Bernadette 1/03/2008 EX 56			
08834	DWRITE025860	DWRITE 025863	3/12/2002	DEPO: Janas, Bernadette 1/03/2008 EX 58			
08835	DWRITE027669	DWRITE 027930	3/12/2002	DEPO: Janas, Bernadette 1/03/2008 EX 16, EX 57			
08836	DWRITE078512	DWRITE 078513		DEPO: Janas, Bernadette 1/03/2008 EX 96			
08837	DWRITE035083	DWRITE 035136	1/2/2002	DEPO: Janas, Bernadette 1/03/2008 EX 50			
08838	DWRITE038986	DWRITE 038989	9/20/1999	DEPO: Janas, Bernadette 1/03/2008 EX 7			
08839	DWRITE040906	DWRITE 040992		DEPO: Janas, Bernadette 1/03/2008 EX 91			
08840	DWRITE041522	DWRITE 041540	5/24/2001	DEPO: Janas, Bernadette 1/03/2008 EX 78			
08841	dwrite046551	DESIGN046551		DEPO: Winneker, Rick 3/31/2009 EX 131			
08842	DWRITE065813	DWRITE 065813	8/5/1996	DEPO: Janas, Bernadette 1/03/2008 EX 1			
08843	DWRITE066162	DWRITE 066191		DEPO: Janas, Bernadette 1/03/2008 EX 22			
08844	DWRITE078142	DWRITE 078144		DEPO: Janas, Bernadette 1/03/2008 EX 81			
08845	DWRITE078245	DWRITE 078257		DEPO: Janas, Bernadette 1/03/2008 EX 93			
08846	DWRITE078370	DWRITE 078370	5/18/2001	DEPO: Janas, Bernadette 1/03/2008 EX 95			
08847	GOLDG005-000900	GOLDG005-000901	10/16/2001	DEPO: Janas, Bernadette 1/03/2008 EX 79			
08848	GOLDG005-000904	GOLDG005-000904		DEPO: Janas, Bernadette 1/03/2008 EX 92			
08849	HENRL211-007358	HENRL211-007361	12/23/2003	DEPO: Montgomery-Rice 1/05/2007 EX 7			
08850	HENRL211-007630	HENRL211-007630	12/00/2003	DEPO: Montgomery-Rice 1/05/2007 EX 8			
08851	LEWDO001-032042	LEWDO001-032055		DEPO: Lewis, Don 7/31/2009 EX 56			
08852	LEWDO001-040072	LEWDO001-040072	5/30/2008	DEPO: Lewis, Don 7/31/2009 EX 55			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08853	LEWDO001-043446	LEWDO001-043508	7/1/2008	DEPO: Lewis, Don 7/31/2009 EX 54			
08854	LEWDO001-043539	LEWDO001-043559	6/13/2008	DEPO: Lewis, Don 7/31/2009 EX 50			
08855	LEWDO001-044817	LEWDO001-044846	6/13/2008	DEPO: Lewis, Don 7/31/2009 EX 49			
08856	LEWDO002-007013	LEWDO002-007013	10/3/2008	DEPO: Lewis, Don 7/31/2009 EX 51			
08857	LEWDO002-007510	LEWDO002-007510	10/10/2008	DEPO: Lewis, Don 7/31/2009 EX 52			
08858	LEWDO002-007847	LEWDO002-007908	8/00/2006	DEPO: Lewis, Don 7/31/2009 EX 53			
08859	LEWDO002-011242	LEWDO002-011248	11/14/2008	DEPO: Lewis, Don 7/31/2009 EX 57			
08860	LEWDO002-011776	LEWDO002-011778	11/18/2008	DEPO: Lewis, Don 7/31/2009 EX 48			
08861	LEWDO002-014709	LEWDO002-014721	12/15/2008	DEPO: Lewis, Don 7/31/2009 EX 25			
08862	LEWDO002-015018	LEWDO002-015018	12/17/2008	DEPO: Lewis, Don 7/31/2009 EX 26			
08863	LEWDO002-015031	LEWDO002-015031	12/17/2008	DEPO: Lewis, Don 7/31/2009 EX 27			
08864	LEWDO002-015032	LEWDO002-015032	12/17/2008	DEPO: Lewis, Don 7/31/2009 EX 28			
08865	LEWDO002-015033	LEWDO002-015046	1/21/1998	DEPO: Lewis, Don 7/31/2009 EX 29			
08866	LEWDO002-015131	LEWDO002-015131	12/21/2008	DEPO: Lewis, Don 7/31/2009 EX 32			
08867	LEWDO002-015132	LEWDO002-015134	1/5/2009	DEPO: Lewis, Don 7/31/2009 EX 33			
08868	LEWDO002-015233	LEWDO002-015233	12/23/2008	DEPO: Lewis, Don 7/31/2009 EX 30			
08869	LEWDO002-015531	LEWDO002-015531	1/5/2009	DEPO: Lewis, Don 7/31/2009 EX 34			
08870	LEWDO002-015534	LEWDO002-015541	1/6/2009	DEPO: Lewis, Don 7/31/2009 EX 31			
08871	LEWDO002-015544	LEWDO002-015544	1/6/2009	DEPO: Lewis, Don 7/31/2009 EX 35			
08872	LEWDO002-016006	LEWDO002-016006	1/9/2009	DEPO: Lewis, Don 7/31/2009 EX 36			
08873	LEWDO002-016108	LEWDO002-016119	10/00/2007	DEPO: Lewis, Don 7/31/2009 EX 37			
08874	LEWDO002-016266	LEWDO002-016266	1/13/2009	DEPO: Lewis, Don 7/31/2009 EX 38			
08875	LEWDO002-016267	LEWDO002-016279	1/13/2009	DEPO: Lewis, Don 7/31/2009 EX 39			
08876	LEWDO002-036898	LEWDO002-036898	2/19/2009	DEPO: Lewis, Don 7/31/2009 EX 40			
08877	LEWDO002-036899	LEWDO002-036916		DEPO: Lewis, Don 7/31/2009 EX 41			
08878	LEWDO002-036938	LEWDO002-036939		DEPO: Lewis, Don 7/31/2009 EX 42			
08879	LEWDO002-040303	LEWDO002-040303	3/11/2009	DEPO: Lewis, Don 7/31/2009 EX 43			
08880	LEWDO002-040307	LEWDO002-040307	3/12/2009	DEPO: Lewis, Don 7/31/2009 EX 44			
08881	LEWDO003-000395	LEWDO003-000395	4/6/2006	DEPO: Lewis, Don 7/31/2009 EX 45			
08882	LEWDO003-011604	LEWDO003-011608	1/18/2006	DEPO: Lewis, Don 7/31/2009 EX 46			
08883	LEWDO003-013337	LEWDO003-013364		DEPO: Lewis, Don 7/31/2009 EX 47			
08884	LOMOL002-000152	LOMOL002-000153	1/00/2003	DEPO: Janas, Bernadette 1/03/2008 EX 55			
08885	LOMOL005-000173	LOMOL005-000174	4/00/2002	DEPO: Janas, Bernadette 1/03/2008 EX 61			
08886	OLIVS019-002848	OLIVS019-002848	8/16/2002	DEPO: Winneker, Rick 3/31/2009 EX 126			
08887	OLIVS019-002849	OLIVS019-002868	8/16/2002	DEPO: Winneker, Rick 3/31/2009 EX 127			
08888	OLIVS019-019363	OLIVS019-019366	4/25/2002	DEPO: Winneker, Rick 3/31/2009 EX 125			
08889	PANAA037-001206	PANAA037-001258	7/21/1996	DEPO: Buchalter, Jeff 5/26/2008 EX 32			
08890	PANAA040-020548	PANAA040-020548	11/19/2001	DEPO: Janas, Bernadette 1/03/2008 EX 43			
08891	PEARL002-000013	PEARL002-000016	1/19/1990	DEPO: Nagi, Arwinder 8/11/2009 EX 4			
08892	PEARL002-000017	PEARL002-000017	10/11/1990	DEPO: Nagi, Arwinder 8/11/2009 EX 5			
08893	PEARL002-000045	PEARL002-000045	12/27/1990	DEPO: Nagi, Arwinder 8/11/2009 EX 7			
08894	PEARL002-000200	PEARL002-000200	7/6/1992	DEPO: Nagi, Arwinder 8/11/2009 EX 8			
08895	PEARL002-000208	PEARL002-000213	9/29/1992	DEPO: Nagi, Arwinder 8/11/2009 EX 9			
08896	PEARL002-000214	PEARL002-000214	9/29/1992	DEPO: Nagi, Arwinder 8/11/2009 EX 10			
08897	PEARL002-000217	PEARL002-000217	9/14/1992	DEPO: Nagi, Arwinder 8/11/2009 EX 11			
08898	PEARL002-000253	PEARL002-000254	12/15/1994	DEPO: Nagi, Arwinder 8/11/2009 EX 14			
08899	PEARL002-000266	PEARL002-000266	4/3/1995	DEPO: Nagi, Arwinder 8/11/2009 EX 15			
08900	PEARL002-000269	PEARL002-000269	5/15/1995	DEPO: Nagi, Arwinder 8/11/2009 EX 17			
08901	PEARL002-000270	PEARL002-000270	5/1/1995	DEPO: Nagi, Arwinder 8/11/2009 EX 16			
08902	PEARL002-000274	PEARL002-000275	7/20/1995	DEPO: Nagi, Arwinder 8/11/2009 EX 18			
08903	PEARL002-000276	PEARL002-000276	7/31/1995	DEPO: Nagi, Arwinder 8/11/2009 EX 19			
08904	PEARL002-000277	PEARL002-000278	8/1/1995	DEPO: Nagi, Arwinder 8/11/2009 EX 20			
08905	PEARL002-000356	PEARL002-000358	3/2/1993	DEPO: Nagi, Arwinder 8/11/2009 EX 13			
08906	PEARL007-000001	PEARL007-000008	12/20/1989	DEPO: Nagi, Arwinder 8/11/2009 EX 3			
08907	PEARL021-000002	PEARL021-000002	10/26/1981	DEPO: Nagi, Arwinder 8/11/2009 EX 2			
08908	PEARL022-000001	PEARL022-000005	11/8/1990	DEPO: Nagi, Arwinder 8/11/2009 EX 6			
08909	PICKJ042-004545	PICKJ042-004547	3/29/2000	DEPO: Janas, Bernadette 1/03/2008 EX 100			
08910	ROSSC023-000543	ROSSC023-000545	7/30/1999	DEPO: Allen, Susan 4/24/2007 EX 17			
08911	SENDM001-001147	SENDM001-001273		DEPO: Janas, Bernadette 1/03/2008 EX 51			
08912	SINAM014-000260	SINAM014-000276	00/00/2001	DEPO: Montgomery-Rice 1/05/2007 EX 5			
08913	SOLOJ022-001846	SOLOJ022-001846	12/17/1996	DEPO: Buchalter, Jeff 5/26/2008 EX 31			
08914	SOLOJ027-044521	SOLOJ027-044521	1/14/2002	DEPO: Janas, Bernadette 1/03/2008 EX 54			
08915	SOLOJ027-046058	SOLOJ027-046058	10/23/2001	DEPO: Janas, Bernadette 1/03/2008 EX 40			
08916	SOLOJ027-046059	SOLOJ027-046059	10/23/2001	DEPO: Janas, Bernadette 1/03/2008 EX 41			
08917	SOLOJ027-047483	SOLOJ027-047539	00/00/2002	DEPO: Janas, Bernadette 1/03/2008 EX 32			
08918	SONKJ204-001747	SONKJ204-001747	10/2/2003	DEPO: Montgomery-Rice 1/05/2007 EX 4			
08919	STRIS014-000675	STRIS014-000679	5/24/2000	DEPO: Janas, Bernadette 1/03/2008 EX 99			
08920	WEBEM015-014397	WEBEM015-014399	1/12/2002	DEPO: Janas, Bernadette 1/03/2008 EX 46			
08921	WINNR001-000404	WINNR001-000410	7/1/2000	DEPO: Winneker, Rick 3/31/2009 EX 110			
08922	WINNR001-000424	WINNR001-000425		DEPO: Winneker, Rick 3/31/2009 EX 114			
08923	WINNR001-000441	WINNR001-000442		DEPO: Winneker, Rick 3/31/2009 EX 115			
08924	WINNR001-000748	WINNR001-000748	9/3/1996	DEPO: Winneker, Rick 3/31/2009 EX 116			
08925	WINNR201-003761	WINNR201-003927	11/00/1999	DEPO: Winneker, Rick 3/31/2009 EX 100			
08926	WINNR201-004710	WINNR201-004727	7/2/1999	DEPO: Winneker, Rick 3/31/2009 EX 106			
08927	WINNR201-005179	WINNR201-005189		DEPO: Winneker, Rick 3/31/2009 EX 107			
08928	WINNR201-006381	WINNR201-006381	7/9/2001	DEPO: Winneker, Rick 3/31/2009 EX 111			
08929	WINNR201-006382	WINNR201-006392	7/4/2001	DEPO: Winneker, Rick 3/31/2009 EX 112			
08930	WINNR201-006910	WINNR201-006948		DEPO: Winneker, Rick 3/31/2009 EX 108			
08931	WINNR201-007992	WINNR201-008006		DEPO: Winneker, Rick 3/31/2009 EX 95			
08932	WINNR201-009428	WINNR201-009457	11/00/2001	DEPO: Winneker, Rick 3/31/2009 EX 109			
08933	WINNR201-011222	WINNR201-011222	9/20/2002	DEPO: Winneker, Rick 3/31/2009 EX 133			
08934	WINNR201-011223	WINNR201-011223	9/18/2002	DEPO: Winneker, Rick 3/31/2009 EX 134			
08935	WINNR201-011224	WINNR201-011234	9/3/2002	DEPO: Winneker, Rick 3/31/2009 EX 135			
08936	WINNR201-014825	WINNR201-014890		DEPO: Winneker, Rick 3/31/2009 EX 104			
08937	WINNR201-018942	WINNR201-018942	3/15/2007	DEPO: Winneker, Rick 3/31/2009 EX 124			
08938	WINNR201-019386	WINNR201-019386	1/30/2003	DEPO: Winneker, Rick 3/31/2009 EX 119			
08939	WINNR301-009309	WINNR301-009321		DEPO: Winneker, Rick 3/31/2009 EX 101			
08940	WINNR301-011801	WINNR301-011803	10/22/1999	DEPO: Winneker, Rick 3/31/2009 EX 118			
08941	WINNR301-012522	WINNR301-012534	3/17/2000	DEPO: Winneker, Rick 3/31/2009 EX 97			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
08942	WINNR301-016762	WINNR301-016778		DEPO: Winneker, Rick 3/31/2009 EX 123			
08943	WINNR301-018354	WINNR301-018376		DEPO: Winneker, Rick 3/31/2009 EX 103			
08944	WINNR401-005630	WINNR401-005631		DEPO: Winneker, Rick 3/31/2009 EX 117			
08945	WINNR401-012287	WINNR401-012306		DEPO: Winneker, Rick 3/31/2009 EX 102			
08946	WINNR401-012903	WINNR401-012985	12/9/2002	DEPO: Winneker, Rick 3/31/2009 EX 105			
08947	WINNR401-013709	WINNR401-013719		DEPO: Winneker, Rick 3/31/2009 EX 113			
08948	WINNR401-017119	WINNR401-017120		DEPO: Winneker, Rick 3/31/2009 EX 96			
08949	CONTA023-002318	CONTA023-002318		DEPO: Janas, Bernadette 1/03/2008 EX 24			
08950	DWRITE001062	DWRITE001129		DEPO: Janas, Bernadette 1/03/2008 EX 82, EX 76			
08951	DWRITE001130	DWRITE001252		DEPO: Janas, Bernadette 1/03/2008 EX 97, EX 98, EX 88, EX 70			
08952	DWRITE001848	DWRITE002023		DEPO: Janas, Bernadette 1/03/2008 EX 77, EX 69, EX 75, EX 73, EX 74			
08953	DWRITE019240	DWRITE019597	2/10/2005	DEPO: Janas, Bernadette 1/03/2008 EX 21, EX 48, EX 102, EX 103			
08954	DWRITE024541	DWRITE024556		DEPO: Janas, Bernadette 1/03/2008 EX 53, EX 49			
08955	DWRITE025733	DWRITE025738	1/15/2002	DEPO: Janas, Bernadette 1/03/2008 EX 47			
08956	DWRITE026777	DWRITE026960		DEPO: Janas, Bernadette 1/03/2008 EX 25, EX 26, EX 27, EX 28, EX 29			
08957	DWRITE026962	DWRITE027342		DEPO: Janas, Bernadette 1/03/2008 EX 45, EX 44			
08958	DWRITE040906	DWRITE040992		DEPO: Janas, Bernadette 1/03/2008 EX 72			
08959	DWRITE041228	DWRITE041329		DEPO: Janas, Bernadette 1/03/2008 EX 85, EX 83			
08960	DWRITE041541	DWRITE041577	9/5/2001	DEPO: Janas, Bernadette 1/03/2008 EX 80			
08961	DWRITE046005	DWRITE046017		DEPO: Winneker, Rick 3/31/2009 EX 128			
08962	DWRITE046692	DWRITE046940		DEPO: Winneker, Rick 3/31/2009 EX 132			
08963	DWRITE058358	DWRITE058729		DEPO: Janas, Bernadette 1/03/2008 EX 94			
08964	DWRITE078151	DWRITE078244	10/00/2001	DEPO: Janas, Bernadette 1/03/2008 EX 84			
08965	DWRITE078814	DWRITE078861		DEPO: Janas, Bernadette 1/03/2008 EX 89, EX 90			
08966	dwrite250271	DESIGN250272; DWRITE022915	11/27/2001	DEPO: Janas, Bernadette 1/03/2008 EX 110			
08967	HRT MED LIT 0080001	HRT MED LIT 0080004		DEPO: Allen, Susan 4/24/2007 EX 15			
08968	PICKJ042-013231	PICKJ042-013236	12/9/1996	DEPO: Buchalter, Jeff 5/26/2008 EX 38			
08969	UW 000014	UW 000015		DEPO: Janas, Bernadette 1/03/2008 EX 107			
08970	UW 004626	UW 004640	4/15/2004	DEPO: Janas, Bernadette 1/03/2008 EX 66			
08971	UW 005417	UW 005419; UW 005424		DEPO: Janas, Bernadette 1/03/2008 EX 64			
08972	UW 005575	UW 005583	5/18/2002	DEPO: Janas, Bernadette 1/03/2008 EX 65			
08973	Various	Various	1/00/2001	Also: W-ADSBRO-01244-01255; FARAN024-083477-083487; HENRL001-001108-001109; FARAN025-028320-028322; KONJ017-008141-008171; LAWT022-036537; SOLOJ027-047251; FARAN024-034930			
08974	W-IND-00006702	W-IND-00006726	6/6/1989	DEPO: Buchalter, Jeff 5/29/2008 EX 36			
08975	ROSSC023-000534	ROSSC023-000535	2/27/1991	DEPO: Allen, Susan 4/24/2007 EX 9			
08976	ROSSC023-000706	ROSSC023-000708		DEPO: Allen, Susan 4/24/2007 EX 10			
08977	ROSSC023-001026	ROSSC023-001027	2/6/1991	DEPO: Allen, Susan 4/24/2007 EX 8			
08978	W-MDL527-00039695	W-MDL527-00039698	11/19/1998	DEPO: Allen, Susan 4/24/2007 EX 12			
08979	FREYM014-062988	FREYM014-062988	7/24/2002	DEPO: Janas, Bernadette 1/03/2008 EX 62			
08980	FREYM014-062989	FREYM014-063061		DEPO: Janas, Bernadette 1/03/2008 EX 63			
08981	GOLDG201-004412	GOLDG201-004416		DEPO: Janas, Bernadette 1/03/2008 EX 101			
08982	DELCA032-014956	DELCA032-014956	10/5/2001	DEPO: Janas, Bernadette 1/03/2008 EX 36			
08983	DEYMI201-001408	DEYMI201-001410	10/13/2003	DEPO: Janas, Bernadette 1/03/2008 EX 19			
08984				What is breast cancer- American Cancer Society			
08985				NCI website- clinical trials PDQ-			
08986	DELCA032-019946			Graphic re premarin from Dunton			
08987				Estrogen, Progesterone, and Menopause Bryn Mawr			
08988	webem204-001889		1/9/2003	Email regarding Commercial Advisory Board re Dunton			
08989	CONTA025-000163			Consultant list Dunton			
10001				David Archer 6/13/06 DEPO EX 1: Dr. Archer Report			
10002			4/20/2006	David Archer 6/13/06 DEPO EX 2: Dr. Archer Report Re: Helene Rush			
10003				David Archer 6/13/06 DEPO EX 3: Dr. Archer Invoice			
10004				David Archer 6/13/06 DEPO EX 4: Dr. Archer Curriculum Vitae			
10005			1/21/2005	David Archer 6/13/06 DEPO EX 5: Thomas Clarkson Article: Controversies about HRT - lessons from monkey models			
10006			00/00/2002	David Archer 6/13/06 DEPO EX 6: Cline article: Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys			
10007				David Archer 6/13/06 DEPO EX 7: Conner article Hormone Therapy (HT) and Breast Response In Postmenopausal Women			
10008			12/00/2002	David Archer 6/13/06 DEPO EX 8: Archer article Hormone Replacement Therapy: Effect of Progestin Dose and Time Since Menopause on Endometrial Bleeding			
10009			00/00/2005	David Archer 6/13/06 DEPO EX 9: Menopausal Medicine article			
10010			12/6/2000	David Archer 6/13/06 DEPO EX 10: Journal of the National Cancer Institute article Re: Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin			
10011			7/31/1996	David Archer 6/13/06 DEPO EX 11: Soderqvist article Proliferation of breast epithelial cells in healthy women during the menstrual cycle			
10012			00/00/2005	David Archer 6/13/06 DEPO EX 12: Menopausal Medicine article			
10018			5/15/2006	Joann Elmore 05/23/06 DEPO EX 1: Deposition Notice			
10019			2/16/2006	Joann Elmore 05/23/06 DEPO EX 2: CV of Dr. Elmore			
10020			2/20/2006	Joann Elmore 05/23/06 DEPO EX 3: Report of Dr. Elmore			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10021	PDF PREMARIN 1995 01	PDF PREMARIN 1995 04	00/00/1995	Joann Elmore 05/23/06 DEPO EX 4: PDR 49 Edition 1995			
10022			00/00/1996	Joann Elmore 05/23/06 DEPO EX 5: PDR 50 Edition 1996			
10023	PDF PREMPRO 1997 01	PDF PREMPRO 1997 06	00/00/1997	Joann Elmore 05/23/06 DEPO EX 6: PDR 51 Edition 1997			
10024			00/00/2002	Joann Elmore 05/23/06 DEPO EX 7: PDR 56 Edition 2002			
10025			7/15/2005	Joann Elmore 05/23/06 DEPO EX 8: Prempro/Premphase Patient Information updated 07/15/05			
10026			6/2/2004	Joann Elmore 05/23/06 DEPO EX 9: Hormone Replacement Therapy and Incidence of Hormone-Dependent Cancers in the Norwegian Women and Cancer Study			
10027			00/00/2004	Joann Elmore 05/23/06 DEPO EX 10: Climacteric 2004; 7:415-417 Letters to the Editors			
10028			00/00/1999	Joann Elmore 05/23/06 DEPO EX 11: Use of HRT and the subsequent risk of cancer			
10029			4/30/2005	Joann Elmore 05/23/06 DEPO EX 12: Endometrial cancer and hormone-replacement therapy in the Million Women Study			
10030			8/3/1989	Joann Elmore 05/23/06 DEPO EX 13: The Risk of Breast Cancer After Estrogen and Estrogen-Progestin Replacement			
10031			3/22/2006	Joann Elmore 05/23/06 DEPO EX 14: Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy			
10032			8/13/2004	Joann Elmore 05/23/06 DEPO EX 15: Association of Hormone Replacement Therapy to Estrogen and Progesterone Receptor Status in Invasive Breast Carcinoma			
10033			2/13/2002	Joann Elmore 05/23/06 DEPO EX 16: Hormone Replacement Therapy in Relation to Breast Cancer			
10034			6/25/2003	Joann Elmore 05/23/06 DEPO EX 17: Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women			
10035			10/11/1997	Joann Elmore 05/23/06 DEPO EX 18: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer			
10036			9/8/2005	Joann Elmore 05/23/06 DEPO EX 19: Breast cancer risk with postmenopausal hormonal treatment			
10037			6/9/1999	Joann Elmore 05/23/06 DEPO EX 20: Hormone Replacement Therapy and Risk of Breast Cancer with a Favorable History			
10038			2/3/2004	Joann Elmore 05/23/06 DEPO EX 21: HABITS			
10039			12/00/1990	Joann Elmore 05/23/06 DEPO EX 22: Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis			
10040			01/00/2005	Joann Elmore 05/23/06 DEPO EX 23: Risk Factors for Estrogen Receptor-Positive Breast Cancer			
10041			5/5/2003	Joann Elmore 05/23/06 DEPO EX 24: A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area study			
10042			3/25/2002	Joann Elmore 05/23/06 DEPO EX 25: Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada			
10043			4/25/2003	Joann Elmore 05/23/06 DEPO EX 26: Int. J. Cancer 107, 164-165 (2003) Letter to the Editor			
10044			6/25/2003	Joann Elmore 05/23/06 DEPO EX 27: Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer			
10045			11/30/1998	Joann Elmore 05/23/06 DEPO EX 28: Breast-Cancer Risk Following Long-Term Oestrogen and Oestrogen-Progestin Replacement Therapy			
10046			2/9/2001	Joann Elmore 05/23/06 DEPO EX 29: Increased Incidence of Small and Well-Differentiated Breast Tumours in Post-Menopausal Women Following Hormone-Replacement Therapy			
10047			8/9/2003	Joann Elmore 05/23/06 DEPO EX 30: Breast cancer and hormone-replacement therapy in the Million Women Study			
10048			00/00/1995	Joann Elmore 05/23/06 DEPO EX 31: Long-term Hormone Replacement Therapy and Risk of Breast Cancer in Postmenopausal Women			
10049			3/15/2003	Joann Elmore 05/23/06 DEPO EX 32: Hormone Replacement Therapy Containing Progestins and Given Continuously Increases Breast Carcinoma Risk in Sweden			
10050			00/00/2003	Joann Elmore 05/23/06 DEPO EX 33: The Characteristics of Malignant Breast Tumors in Hormone Replacement Therapy Users Versus Nonusers			
10051			4/23/1997	Joann Elmore 05/23/06 DEPO EX 34: Hormone replacement therapy and the risk of breast cancer			
10052			4/10/2006	Joann Elmore 05/23/06 DEPO EX 35: A Prospective Study of Female Hormone Use and Breast Cancer Among Black Women			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10053			5/24/2005	Joann Elmore 05/23/06 DEPO EX 36: Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy - a prospective observational study			
10054			00/00/2004	Joann Elmore 05/23/06 DEPO EX 37: Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy			
10055			7/12/1995	Joann Elmore 05/23/06 DEPO EX 38: Combined Estrogen and Progestin Hormone Replacement Therapy in Relation to Risk of Breast Cancer in Middle-aged Women			
10056			00/00/2004	Joann Elmore 05/23/06 DEPO EX 39: Hormone Replacement Therapy in Relation to Breast Carcinoma Incidence Rate Ratios			
10057			4/20/2005	Joann Elmore 05/23/06 DEPO EX 40: Plasma Sex Hormone Concentrations and Subsequent Risk of Breast Cancer Among Women Using Postmenopausal Hormone			
10058			2/1/2002	Joann Elmore 05/23/06 DEPO EX 41: Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?			
10059			12/18/2002	Joann Elmore 05/23/06 DEPO EX 42: Important Increase of Invasive Lobular Breast Cancer Incidence in Geneva, Switzerland			
10060			4/6/2005	Joann Elmore 05/23/06 DEPO EX 43: Menopausal Hormone Therapy After Breast Cancer: The Stockholm Randomized Trial			
10061			7/17/2002	Joann Elmore 05/23/06 DEPO EX 44: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial			
10062			00/00/1993	Joann Elmore 05/23/06 DEPO EX 45: PDR 47 Edition, 1993			
10063			00/00/1994	Joann Elmore 05/23/06 DEPO EX 46: PDR 48 Edition, 1994			
10064			00/00/2006	Joann Elmore 05/23/06 DEPO EX 47: Observational studies and clinical trial of menopausal hormone therapy: can they both be right?			
10065			00/00/2006	Joann Elmore 05/23/06 DEPO EX 48: Editorial: What do we think about cognition and menopause?			
10066			6/22/2006	Joann Elmore 05/23/06 DEPO EX 49: Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy			
10067			4/00/2005	Joann Elmore 05/23/06 DEPO EX 50: Epidemiology and Prevention of Breast Cancer			
10068			6/3/1998	Joann Elmore 05/23/06 DEPO EX 51: Relationship Between Estrogen Levels, Use of Hormone Replacement Therapy, and Breast Cancer			
10069			1/15/2005	Joann Elmore 05/23/06 DEPO EX 52: Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer			
10070			8/6/2005	Joann Elmore 05/23/06 DEPO EX 53: Hormone Replacement Therapy and Breast Cancer: Estimate of risk.			
10071			11/1/2006	Joann Elmore 05/23/06 DEPO EX 54: Hormone Therapy and Coronary Heart Disease: The Role of Time Since Menopause and age at Hormone Initiation			
10072			6/1/2000	Joann Elmore 05/23/06 DEPO EX 55: Hormone Replacement Therapy in Relation to Risk of Lobular and Ductal Breast Carcinoma in Middle-Aged Women			
10073			00/00/2006	Joann Elmore 05/23/06 DEPO EX 56: Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study			
10074			00/00/2006	Joann Elmore 05/23/06 DEPO EX 57: Potential importance of early initiation of hormone therapy for cognitive benefit			
10075			8/7/2003	Joann Elmore 05/23/06 DEPO EX 58: Estrogen plus Progestin and the Risk of Coronary Heart Disease			
10076			12/30/2002	Joann Elmore 05/23/06 DEPO EX 59: Postmenopausal hormone therapy and risk of breast cancer by histologic type			
10077			00/00/2001	Joann Elmore 05/23/06 DEPO EX 60: Risk of Breast Cancer with Progestins in Combination with Estrogen as Hormone Replacement Therapy			
10078			00/00/2001	Joann Elmore 05/23/06 DEPO EX 61: Histological and biological evolution of human premalignant breast disease			
10079			7/00/2005	Joann Elmore 05/23/06 DEPO EX 62: Is mammographic density, as currently measured, a robust surrogate marker for breast cancer?			
10080			00/00/1993	Joann Elmore 05/23/06 DEPO EX 63: Consult 1993 Supplements for revisions, Physicians' Desk Reference			
10081			00/00/1994	Joann Elmore 05/23/06 DEPO EX 64: Consult 1994 Supplements for revisions, Physicians' Desk Reference			
10082			00/00/1995	Joann Elmore 05/23/06 DEPO EX 65: 2576/Physicians' Desk Reference - 1995 Provera			
10083			00/00/1996	Joann Elmore 05/23/06 DEPO EX 66: 2836/Physicians' Desk Reference - 1996 Provera			
10084			00/00/1997	Joann Elmore 05/23/06 DEPO EX 67: 2110/Physicians' Desk Reference - 1997 Provera			
10085			00/00/1998	Joann Elmore 05/23/06 DEPO EX 68: Pharmacia & Upjohn/2287 - 1998 Provera			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10086			00/00/1999	Joann Elmore 05/23/06 DEPO EX 69: 2506/Pharmacia & Upjohn, Physicians' Desk Reference - 1999 Provera			
10087			00/00/2000	Joann Elmore 05/23/06 DEPO EX 70: Provera-Cont. - 2000 Provera			
10088			5/19/2006	Joann Elmore 05/23/06 DEPO EX 71: E-mail to Michael Williams from Shella Anderson			
10089			5/19/2006	Joann Elmore 05/23/06 DEPO EX 72: E-mail to Jacqueline Caza from Pamela Yates			
10090			5/17/2006	Joann Elmore 05/23/06 DEPO EX 73: E-mail to Dr. Elmore from Kassandra Hendrix			
10091			5/16/2006	Joann Elmore 05/23/06 DEPO EX 74: Request for Taxpayer Identification Number and Certification			
10092			5/22/2006	Joann Elmore 05/23/06 DEPO EX 75: E-mail string			
10093			00/00/2006	Joann Elmore 05/23/06 DEPO EX 76: Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study			
10094				Heidi M. Jolson 05/30/06 DEPO EX 1: Curriculum Vitae			
10095			5/18/2006	Heidi M. Jolson 05/30/06 DEPO EX 2: Plaintiffs' Amended Notice of Discovery Deposition of Heidi Jolson, M.D.			
10096			5/1/2006	Heidi M. Jolson 05/30/06 DEPO EX 3: Invoice			
10097			5/1/2006	Heidi M. Jolson 05/30/06 DEPO EX 4: Invoice			
10098			5/8/2006	Heidi M. Jolson 05/30/06 DEPO EX 5: Cumulative Invoice			
10099				Heidi M. Jolson 05/30/06 DEPO EX 6: E-mails			
10100			4/14/2006	Heidi M. Jolson 05/30/06 DEPO EX 7: Provera Chronology			
10101				Heidi M. Jolson 05/30/06 DEPO EX 8: Draft Report			
10102			4/10/2006	Heidi M. Jolson 05/30/06 DEPO EX 9: Draft Report			
10103			4/14/2006	Heidi M. Jolson 05/30/06 DEPO EX 10: Draft Report			
10104				Heidi M. Jolson 05/30/06 DEPO EX 11: Handwritten Notes			
10105			4/19/2006	Heidi M. Jolson 05/30/06 DEPO EX 12: Expert Report			
10106				Heidi M. Jolson 05/30/06 DEPO EX 13: Materials Reviewed			
10107			2/00/1999	Heidi M. Jolson 05/30/06 DEPO EX 14: Article: Endometrial cancer incidence: a long-term perspective			
10108	NDA-PRO 0011989	NDA-PRO 0011990	9/4/1985	Heidi M. Jolson 05/30/06 DEPO EX 15: Letter			
10109	NDA-PRO 0000185	NDA-PRO 0000185	9/26/1985	Heidi M. Jolson 05/30/06 DEPO EX 16: Memo-Trip Report - September 26, 1985 FDA, Division of Drug Advertising; DONALD B. ANDERSON 12/08/06 DEPO EX. 15: Memo			
10110	NDA-PRO 0011628	NDA-PRO 0011633	7/8/1986	Heidi M. Jolson 05/30/06 DEPO EX 17: Letter with attachments			
10111	NDA-PRO 0011608	NDA-PRO 0011608	5/29/1987	Heidi M. Jolson 05/30/06 DEPO EX 18: Letter			
10112	NDA-PRO 0026059	NDA-PRO 0026059	9/16/1994	Heidi M. Jolson 05/30/06 DEPO EX 20: Letter			
10113			10/3/2006	Rodney Carlson 10/18/06 DEPO EX 1: Notice of Deposition			
10114	RM_AA 0101745	RM_AA 0101752	8/2/1990	Rodney Carlson 10/18/06 DEPO EX 3: Degge Group August 2, 1990 proposal			
10115	RM_AA 0101742	RM_AA 0101742	8/3/1990	Rodney Carlson 10/18/06 DEPO EX 4: E-Mail JSGARDNE to SMNOWAK			
10116			12/17/1990	Rodney Carlson 10/18/06 DEPO EX 5: Degge Group Final Report December 17, 1990			
10117			3/00/1992	Rodney Carlson 10/18/06 DEPO EX 6: Progestins and Breast Cancer: An Epidemiologic Review			
10118	RM_AA 0102049	RM_AA 0102069	6/18/1991	Rodney Carlson 10/18/06 DEPO EX 7 & Schoenfeld, Michael 8/03/2007 EX 19: The Upjohn Company Position Paper			
10119	RM_AA 0101486	RM_AA 0101488	4/25/1991	Rodney Carlson 10/18/06 DEPO EX 8: Interoffice memo, Halvorson to List			
10120			8/28/2004	Rodney Carlson 10/18/06 DEPO EX 11: CV of Rodney Frederick Carlson, M.D.			
10121			03/00/1992	Rodney Carlson 10/18/06 DEPO EX 12: Progestins, Breast Cancer, and the Limitations of Epidemiology			
10122			7/12/1995	Rodney Carlson 10/18/06 DEPO EX 13: Combined Estrogen and Progestin Hormone Replacement Therapy in Relation to Risk of Breast Cancer in Middle-Aged Women			
10123			00/00/1995	Rodney Carlson 10/18/06 DEPO EX 14: American Journal of Epidemiology			
10124	RM_AA 0154266	RM_AA 0154269	6/23/1991	Rodney Carlson 10/18/06 DEPO EX 15 & Schoenfeld, Michael 8/03/2007 EX 20: Summary Minutes of June 20-21, 1991 FDA Committee Meeting			
10125	RM_AA 0101489	RM_AA 0101491	6/20/1991	Rodney Carlson 10/18/06 DEPO EX 16: Provisional Agenda FDA June 20, 1991			
10126	NDA-PRO 0023643	NDA-PRO 0023756	00/00/1961	Brook Lodge Symposium: Progesterone, 1961			
10127			00/00/1965	Provera label			
10128			7/27/1972	DESI 11839			
10129				DESI Panel on Drugs Used in Disturbances to the Reproductive System			
10130			10/13/1973	DESI 11839 Follow-up, Federal Register 27917-27920; Federal Register 47178-47181			
10131			7/22/1977	Federal Register 37613-37618, Progestational Drug Products for Human Use			
10132	NDA-PRO 0000929	NDA-PRO 0000929		Dear Doctor Letter re Provera			
10133	NDA-PRO 0029068	NDA-PRO 0029068		Promotional material: the benefits			
10134	NDA-PRO 0029078	NDA-PRO 0029082		Promotional material: Estrogen and Provera			
10135	NDA-PRO 0000631	NDA-PRO 0000633		The Glamorous Grandmother			
10136	NDA-PRO 0028917	NDA-RPO 0028918	00/00/1970	Promotional material: the "Upjohn Plan"			
10138	NDA-PRO 0001167	NDA-PRO 0001167	12/8/1980	Upjohn memo			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10140	NDA-PRO 0001166	NDA-PRO 0001166	12/19/1980	Internal Upjohn letter			
10141	NDA-PRO 0020242	NDA-PRO 0020259	4/28/1981	Upjohn to FDA Labeling Format Insert Revision			
10142	NDA-PRO 0020252	NDA-PRO 0020256		Upjohn's proposed draft revised package insert			
10143	NDA-PRO 0020257	NDA-PRO 0020259		Upjohn's proposed draft revised package insert			
10144	NDA-PRO 0000200	NDA-PRO 0000200	9/20/1984	Upjohn memo			
10145	KENNALLY-W 0000147	KENNALLY-W 0000147	10/27/1981	Upjohn internal memo/letter			
10146	RM_AA 0156179	RM_AA 00156187	11/9/1981	Corporate Product Statement			
10147	RM_NY_MOPS 0234095	RM_NY_MOPS 0234102		Promotion Plan I, Sales Training Notes			
10147A	RM_NY_MOPS 0234090	RM_NY_MOPS 0234093	8/25/1982	Advertising Notes: Provera Tablets Prototype Plan I			
10148	RM_NY_MOPS 0234089	RM_NY_MOPS 0234089	8/25/1982	Upjohn letter to recipients of Promotion Plan I			
10149	NDA-PRO 0027938	NDA-PRO 0027946	00/00/1982	Hormonal Therapy in the Menopause - A Lecture Program			
10150	RM_AA 0156146	RM_AA 0156153	10/00/1983	Proposal for product line extension			
10151	RM_AA 0156145	RM_AA 0156145	10/00/1983	Coversheet for proposal for produce line extension			
10152	NDA-PRO 0027869	NDA-PRO 0027869	00/00/1983	The other half of estrogen replacement therapy			
10153	NDA-PRO 0027815	NDA-PRO 0027815	00/00/1984	The other half of estrogen replacement therapy			
10154	NDA-PRO 0017599	NDA-PRO 0017599	1/5/1984	FDA letter to Upjohn			
10155	NDA-PRO 0011994	NDA-PRO 0011994	9/10/1985	FDA letter to Upjohn			
10156	RM_NY_MOPS 0103384	RM_NY_MOPS 0103390	03/00/1985	The other half of estrogen replacement therapy			
10157	NDA-PRO 0070099	NDA-PRO 0070099	9/4/1985	Upjohn letter to FDA			
10158	RM_AA 0156196	RM_AA 015697	9/27/1985	Upjohn memo			
10159	NDA-PRO 0000185	NDA-PRO 0000185	9/26/1985	Upjohn memo			
10160	NDA-PRO 0000186	NDA-PRO 0000187	9/26/1985	Upjohn executive's handwritten notes			
10161	NDA-DE 0000363	NDA-DE 0000364	4/4/1986	FDA letter to Upjohn			
10162	NDA-PRO 0011628	NDA-PRO 0011629	7/8/1986	Upjohn letter to FDA			
10163	NDA-PRO 0011608	NDA-PRO 0011608	5/29/1987	FDA letter to Upjohn			
10164	NDA-PRO 0011591	NDA-PRO 0011592	7/1/1987	Upjohn letter to FDA			
10165	NDA-PRO 0002106	NDA-PRO 0002106	10/25/1989	Upjohn letter to FDA			
10166	NDA-PRO 0007648	NDA-PRO 0007649	1/15/1988	FDA letter to Upjohn			
10167	RM_NY_MOPS 0102637	RM_NY_MOPS 0102651	00/00/1988	Current Medical Topics, Management of the Menopausal Patient			
10168	RM_NY_MOPS 0234458	RM_NY_MOPS 0234463	12/00/1989	Upjohn Sales Information Notes			
10169	NDA-PRO 0007375	NDA-PRO 0007379	5/26/1989	Upjohn Statistical Review and Evaluation			
10170	NDA-PRO 0007222	NDA-PRO 0007223	9/28/1989	Upjohn letter to FDA			
10171	NDA-PRO 0007227	NDA-PRO 0007227	9/14/1989	Upjohn letter to FDA			
10172	NDA-PRO 0027456	NDA-PRO 0027470	7/00/1990	Upjohn promotion: Issues in Menopausal Hormone Therapy			
10173	NDA-PRO 0011608	NDA-PRO 0011608	5/29/1987	FDA letter to Upjohn			
10174	NDA-PRO 0027466	NDA-PRO 0027470	7/00/1990	In menopausal therapy: When unscheduled bleeding occurs with estrogen...make Provera the other half of HRT; DONALD B. ANDERSON 12/08/06 DEPO EX. 10: Advertisement			
10175			02/00/1993	Ryan Depo Exhibit 19: American Druggist: Annual Survey The Top 200 Drugs			
10176	NDA-PRO 0002030	NDA-PRO 0002033	10/9/1990	FDA letter to Upjohn			
10177	NDA-PRO 0002026	NDA-PRO 0002029	10/16/1990	FDA letter to UpjohnDONALD B. ANDERSON 12/08/06 DEPO EX. 9: Letter from J.R. Assenzo with Upjohn to Thomas W. Cavanaugh with FDA			
10178	NDA-PRO 0011994	NDA-PRO 0011994	9/10/1985	FDA letter to Upjohn			
10179	NDA-PRO 0002021	NDA-PRO 0002023	10/31/1990	FDA letter to Upjohn			
10180	NDA-PRO 0002025	NDA-PRO 0002025	10/30/1990	FDA letter to Upjohn			
10181	CHIRBY-D 0000952	CHIRBY-D 0000953		Provera Chronology			
10182	NDA-PRO 0002012	NDA-PRO 0002012	11/9/1990	Upjohn Dear Doctor Letter			
10183	NDA-PRO 0027444	NDA-PRO 0027447	09/00/1990	Advertisement: Provera Convenience Pack			
10184	NDA-PRO 0002006	NDA-PRO 0002006	11/9/1990	Upjohn letter to FDA			
10185	CHIRBY-D 0000992	CHIRBY-D 0000992	03/00/1991	Upjohn Dear Doctor Letter			
10186	BREED-K 0007327	BREED-K 0007330	2/13/1991	Upjohn Interoffice memo; DONALD B. ANDERSON 12/08/06 DEPO EX. 13:			
10187	CHIRBY-D 0000931	CHIRBY-D 0000933	11/8/1990	Upjohn Interoffice memo; DONALD B. ANDERSON 12/08/06 DEPO EX. 12: Upjohn Interoffice memo (duplicate of EX 10253, 10483, 04987)			
10188	NDA-PRO 0002003	NDA-PRO 0002005	11/13/1990	FDA letter to Upjohn; DONALD B. ANDERSON 12/08/06 DEPO EX. 11: Letter from Thomas W. Cavanaugh with FDA to Peter Philander with Upjohn			
10189	NDA-PRO 0027233	NDA-PRO 0027233	12/9/1991	FDA letter to Upjohn			
10190	CHIRBY-D 0001022	CHIRBY-D 0001022	11/1/1990	Upjohn Interoffice memo			
10191			02/00/1991	Roehl Depo Exhibit 16: Upjohn internal newsletter: The Provera Press			
10192	RM_NY_MOPS 0102854	RM_NY_MOPS 0102857	11/00/1992	Upjohn document: Strategy & Tactics			
10193	RM_AA 0154204	RM_AA 0154204	8/16/1994	Upjohn Interoffice memo			
10194	RM_AA 0154207	RM_AA 0154208	4/27/1993	FDA letter to medical and profession organizations			
10195	RM_AA 0154240	RM_AA 0154240	6/3/1993	Upjohn Interoffice memo			
10196	RM_AA 0154205	RM_AA 0154205	5/17/1993	Upjohn Interoffice memo			
10197	RM_AA 0154206	RM_AA 0154206	5/11/1993	Upjohn Interoffice memo			
10198	RM_AA 0154219	RM_AA 0154225		Upjohn internal document: Provera - Unlabeled Use Requested by FDA			
10199	RM_AA 0154241	RM_AA 0154241	5/10/1993	Washington Drug Letter			
10200	RM_AA 0154217	RM_AA 0154217	6/17/1993	Upjohn Interoffice memo			
10201	RM_AA 0154226	RM_AA 0154227	7/12/1993	Upjohn Interoffice memo			
10202	RM_AA 0154216	RM_AA 0154216	7/30/1993	Upjohn interoffice e-mail			
10203	RM_AA 0154228	RM_AA 0154236	8/25/1993	Upjohn Interoffice memo			
10204	RM_NY_MOPS 0168668	RM_NY_MOPS 0168674		Upjohn promotion: Prempro and Premphase Sales Notes			
10222	CHIRBY-D 0000139	CHIRBY-D 0000143	1/31/1995	Amendment M5410/0336, Amendment 2			
10223	CHIRBY-D 0000935	CHIRBY-D 0000935	10/18/1990	Upjohn Interoffice Memo			
10224	CHIRBY-D 0001701	CHIRBY-D 0001755		Provera Toxicology and Pharmacology Expert Report			
10225	NDA-OGEN 0000827	NDA-OGEN 0000833	02/00/1990	Labeling Guidance for Estrogen Drug Products, Patient Package Insert			
10226	NDA-PRO 0001867	NDA-PRO 0001872	1/28/1992	FDA letter to Upjohn			
10227	NDA-PRO 0004246	NDA-PRO 0004255	12/27/1993	Upjohn letter to FDA			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10228	VOLPE-G 0005012	VOLPE-G 0005015	1/30/1991	Fax from FDA to Upjohn			
10229	NDA-PRO 0027401	NDA-PRO 0027417	2/6/1991	Upjohn letter to FDA with attachment			
10230	NDA-PRO 0027786	NDA-PRO 0027786	01/00/1985	Provera ad			
10231	NDA-PRO 0049766	NDA-PRO 0049770	9/27/1985	Drug Experience Report			
10232	NDA-PRO 0058854	NDA-PRO 0058859	3/6/1975	FDA letter to Upjohn			
10233	NDA-PRO 0058869	NDA-PRO 0058878	6/19/1974	Upjohn letter to FDA			
10234	NDA-PRO 0058880	NDA-PRO 0058886	3/12/1974	Upjohn letter to FDA			
10235	NDA-PRO 0059017	NDA-PRO 0059022	5/5/1972	Upjohn letter to FDA			
10236	NDA-PRO 0059033	NDA-PRO 0059036	3/28/1972	Upjohn letter to FDA			
10237	NDA-PRO 0059155	NDA-PRO 0059164	5/11/1970	Upjohn New Drug Application Tablets Provera			
10238	NDA-PRO 0059286	NDA-PRO 0059341	4/28/1981	Upjohn letter to FDA and attachments			
10239	NDA-PRO 0070537	NDA-PRO 0070538	2/24/1989	Upjohn letter to FDA			
10240	NDA-PRO 0070616	NDA-PRO 0070617	3/1/1988	Upjohn letter to FDA			
10241	NDA-PRO 0075641	NDA-PRO 0075642	7/26/1990	FDA letter to Upjohn			
10242	NDA-PRO 0075718	NDA-PRO 0075724	10/25/1989	Upjohn letter to FDA			
10243	NDA-PRO 0075991	NDA-PRO 0075992	3/28/1997	FDA letter to Pharmacia & Upjohn			
10244	NDA-PRO 0076092	NDA-PRO 0076094	2/12/1997	Pharmacia & Upjohn letter to FDA			
10245	NDA-PRO 0114442	NDA-PRO 0114447	2/20/2004	FDA letter to Pfizer			
10246	NDA-PRO 0113701	NDA-PRO 0113703	4/5/2004	Pfizer Global Pharmaceuticals letter to FDA			
10247	NDA-PRO 0113704	NDA-PRO 0113707	3/30/2004	FDA letter to Pharmacia & Upjohn			
10248	VOLPE-G 0004823	VOLPE-G 0004837	1/4/2000	Pharmacia & Upjohn letter to FDA			
10249	CHIRBY-D 0000009	CHIRBY-D 0000009	1/4/1994	Internal Upjohn memorandum			
10250	CHIRBY-D 0000126	CHIRBY-D 0000128	10/31/1994	FDA Letter to Upjohn			
10251	CHIRBY-D 0000129	CHIRBY-D 0000138		Upjohn's response to FDA letter dated October 31, 1994			
10252	CHIRBY-D 0000144	CHIRBY-D 0000145	12/2/1994	Internal Upjohn memorandum			
10253	CHIRBY-D 0000931	CHIRBY-D 0000933	11/8/1990	Upjohn Interoffice memo (duplicate of EX 10187, 10483, 04987)			
10254	CHIRBY-D 0000964	CHIRBY-D 0000966	1/31/1991	FDA letter to Upjohn			
10255	CHIRBY-D 0000971	CHIRBY-D 0000972	1/10/1991	Internal Upjohn memorandum			
10256	CHIRBY-D 0000986	CHIRBY-D 0000986	5/1/1991	Upjohn letter to FDA			
10257	CHIRBY-D 0001017	CHIRBY-D 0001018	11/5/1990	Internal Upjohn memorandum; DONALD B. ANDERSON 12/08/06 DEPO EX. 14: Email			
10258	CHIRBY-D 0001811	CHIRBY-D 0001817	2/22/1982	MPA Animal Toxicology - Toxicology Expert Opinion for Germany			
10259	CHIRBY-D 0002215	CHIRBY-D 0002297	04/00/1993	RF Carlson, MD Clinical Expert Report			
10260	CHIRBY-D 0003387	CHIRBY-D 0003387	4/5/1996	Upjohn letter to FDA			
10261	CHIRBY-D 0003493	CHIRBY-D 0003495	12/30/1994	FDA letter to Wyeth-Ayerst			
10262	CHIRBY-D 0003596	CHIRBY-D 0003684	12/30/1994	Medical Officer's Review of Original and Resubmitted NDA Submissions			
10264	CHIRBY-D 0003685	CHIRBY-D 0003695	12/29/1994	Interoffice Memorandum			
10265	CHIRBY-D 0003744	CHIRBY-D 0003824		Clinical Studies			
10266	CHIRBY-D 0003951	CHIRBY-D 0003952	9/27/1993	Wyeth-Ayerst letter to FDA			
10267	CHIRBY-D 0003976	CHIRBY-D 0003977	10/5/1993	Memorandum of Meeting			
10268	CHIRBY-D 0003978	CHIRBY-D 0003979	2/16/1993	Addendum to Memorandum of Meeting			
10269	LEWIS-R 0000288	LEWIS-R 0000290	8/23/2002	FDA letter to Pharmacia & Upjohn			
10270	NDA-GEN 0001522	NDA-GEN 0001523	10/9/2002	FDA letter to Pharmacia & Upjohn			
10271	NDA-PRO 0000003	NDA-PRO 0000005	8/18/1999	Pharmacia & Upjohn Record of FDA Telephone Contact			
10272	NDA-PRO 0000007	NDA-PRO 0000008	9/16/1997	Pharmacia & Upjohn Record of FDA Telephone Contact			
10273	NDA-PRO 0000011	NDA-PRO 0000011	8/25/1997	Pharmacia & Upjohn Record of FDA Telephone Contact			
10274	NDA-PRO 0000013	NDA-PRO 0000014	6/27/1997	Pharmacia & Upjohn Record of FDA Telephone Contact			
10275	NDA-PRO 0000015	NDA-PRO 0000015	3/3/1997	Interoffice Memorandum			
10276	NDA-PRO 0000016	NDA-PRO 0000016	3/3/1997	Pharmacia & Upjohn Record of FDA Telephone Contact			
10277	NDA-PRO 0000019	NDA-PRO 0000019	1/22/1997	Pharmacia & Upjohn Record of FDA Telephone Contact			
10278	NDA-PRO 0000021	NDA-PRO 0000022	10/2/1996	Pharmacia & Upjohn Record of FDA Telephone Contact			
10279	NDA-PRO 0000031	NDA-PRO 0000031	10/7/1993	Interoffice Memorandum			
10280	NDA-PRO 0000057	NDA-PRO 0000057	12/19/1985	Upjohn Interoffice memo			
10281	NDA-PRO 0000063	NDA-PRO 0000068	11/26/1985	Mocked-up Provera insert			
10282	NDA-PRO 0000070	NDA-PRO 0000070	11/26/1985	Upjohn Interoffice memo			
10283	NDA-PRO 0000132	NDA-PRO 0000132	11/26/1985	Upjohn Interoffice memo			
10284	NDA-PRO 0000185	NDA-PRO 0000185	9/26/1985	Upjohn Interoffice memo			
10285	NDA-PRO 0001004	NDA-PRO 0001005	5/12/1994	Upjohn letter to Abbott Laboratories			
10286	NDA-PRO 0001013	NDA-PRO 0001014	12/7/1990	Upjohn letter to FDA			
10287	NDA-PRO 0001016	NDA-PRO 0001030	12/3/1990	Upjohn Technical Report			
10288	NDA-PRO 0001513	NDA-PRO 0001515	12/5/2002	FDA letter to Pharmacia & Upjohn			
10289	NDA-PRO 0001516	NDA-PRO 0001517	11/14/2002	Pharmacia & Upjohn letter to FDA			
10291	NDA-PRO 0000042	NDA-PRO 0000042	11/23/1992	Upjohn internal memo			
10292	NDA-PRO 0001522	NDA-PRO 0001524	11/11/2002	Pharmacia fax cover to FDA			
10293	NDA-PRO 0001547	NDA-PRO 0001555	8/4/1998	Provera Tablets Proposed Package Insert approved			
10294	NDA-PRO 0001679	NDA-PRO 0001679	1/8/1998	Pharmacia & Upjohn letter to FDA			
10295	NDA-PRO 0001721	NDA-PRO 0001721	12/18/1991	FDA letter to Upjohn			
10296	NDA-PRO 0001881	NDA-PRO 0001882	12/18/1991	FDA letter to Upjohn			
10297	NDA-PRO 0001883	NDA-PRO 0001883	12/9/1991	FDA letter to Upjohn			
10298	NDA-PRO 0001884	NDA-PRO 0001884	11/20/1991	Upjohn letter to FDA			
10299	NDA-PRO 0001891	NDA-PRO 0001893	10/10/1991	FDA Notice of W/D of Approval of a Supplemental New Drug App			
10300	NDA-PRO 0001894	NDA-PRO 0001895	10/11/1991	Upjohn letter to FDA			
10301	NDA-PRO 0001936	NDA-PRO 0001937	8/14/1991	Upjohn letter to FDA			
10302	NDA-PRO 0001970	NDA-PRO 0001970	5/31/1991	Upjohn letter to FDA			
10303	NDA-PRO 0001973	NDA-PRO 0001974	5/24/1991	Upjohn letter to FDA			
10304	NDA-PRO 0001976	NDA-PRO 0001977	4/11/1991	Upjohn letter to FDA			
10305	NDA-PRO 0001989	NDA-PRO 0001989	2/18/1991	Upjohn letter to FDA			
10306	NDA-PRO 0001997	NDA-PRO 0001997	2/13/1991	FDA letter to Upjohn			
10307	NDA-PRO 0002002	NDA-PRO 0002002	11/14/1990	FDA letter to Upjohn			
10308	NDA-PRO 0002003	NDA-PRO 0002005	11/13/1990	FDA letter to Upjohn			
10309	NDA-PRO 0002006	NDA-PRO 0002006	11/9/1990	Upjohn letter to FDA			
10310	NDA-PRO 0002007	NDA-PRO 0002007		Upjohn memo to sales reps			
10311	NDA-PRO 0002008	NDA-PRO 0002009		Provera ad info for September-November 1990 - unable to cancel insertions			
10313	NDA-PRO 0002010	NDA-PRO 0002011	11/9/1990	Upjohn letter to FDA			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10314	NDA-PRO 0002014	NDA-PRO 0002014	11/7/1990	Upjohn letter to FDA			
10315	NDA-PRO 0002018	NDA-PRO 0002020	07/00/1990	Provera insert			
10316	NDA-PRO 0002021	NDA-PRO 0002023	10/31/1990	FDA letter to Upjohn			
10317	NDA-PRO 0002025	NDA-PRO 0002025	10/30/1990	FDA letter to Upjohn			
10318	NDA-PRO 0002026	NDA-PRO 0002029	10/16/1990	FDA letter to Upjohn			
10319	NDA-PRO 0002030	NDA-PRO 0002033	10/9/1990	FDA letter to Upjohn			
10320	NDA-PRO 0002041	NDA-PRO 0002041	7/5/1990	FDA letter to Upjohn			
10321	NDA-PRO 0002068	NDA-PRO 0002069	11/9/1989	Upjohn letter to FDA			
10322	NDA-PRO 0002148	NDA-PRO 0002150	3/4/2003	Pharmacia & Upjohn letter to FDA			
10323	NDA-PRO 0002155	NDA-PRO 0002157	1/8/2003	FDA letter to Pharmacia & Upjohn			
10324	NDA-PRO 0002164	NDA-PRO 0002165	1/3/2003	Recommended labeling changes			
10325	NDA-PRO 0004305	NDA-PRO 0004324	3/8/1994	Upjohn internal document - Technical Report			
10326	NDA-PRO 0004374	NDA-PRO 0004584	6/17/1993	Upjohn Project No. P-5410-0227, Analytical Study Report			
10327	NDA-PRO 0005399	NDA-PRO 0005400	3/26/1997	FDA letter to Pharmacia & Upjohn			
10328	NDA-PRO 0005401	NDA-PRO 0005402	3/4/1997	Pharmacia & Upjohn letter to FDA			
10329	NDA-PRO 0005507	NDA-PRO 0005507	9/10/1996	Pharmacia & Upjohn letter to FDA			
10330	NDA-PRO 0005523	NDA-PRO 0005524	5/21/1996	Upjohn letter to FDA			
10331	NDA-PRO 0005527	NDA-PRO 0005536	4/15/1996	Review of MPA and Cerebrovascular Thromboembolic Disorders			
10332	NDA-PRO 0006634	NDA-PRO 0006634		FDA letter to Upjohn			
10333	NDA-PRO 0006693	NDA-PRO 0006698	9/2/1992	Upjohn letter to FDA			
10334	NDA-PRO 0007222	NDA-PRO 0007223	9/28/1989	Upjohn letter to FDA			
10335	NDA-PRO 0007227	NDA-PRO 0007227	9/14/1989	Upjohn letter to FDA			
10336	NDA-PRO 0007370	NDA-PRO 0007370	8/29/1989	FDA letter to Upjohn			
10337	NDA-PRO 0007374	NDA-PRO 0007374	6/20/1989	FDA letter to Upjohn			
10338	NDA-PRO 0007375	NDA-PRO 0007379	5/26/1989	Statistical Review and Evaluation			
10339	NDA-PRO 0007472	NDA-PRO 0007473	3/23/1989	FDA Regulatory Affairs Minutes of Meeting; DONALD B. ANDERSON 12/08/06 DEPO EX. 5: The Upjohn Company Regulatory Affairs, Minutes, Meeting with Division of Metabolism and Endocrine Drug Products on Provera and Conjugated Estrogens			
10340	NDA-PRO 0007481	NDA-PRO 0007484	3/9/1989	FDA Regulatory Affairs Minutes of Meeting			
10341	NDA-PRO 0007537	NDA-PRO 0007538	2/1/1989	Upjohn letter to FDA; DONALD B. ANDERSON 12/08/06 DEPO EX. 4: Letter from D.J. Mason with Upjohn to Solomon Sobel with FDA			
10342	NDA-PRO 0007548	NDA-PRO 0007548	7/10/1986	Memorandum of Meeting			
10343	NDA-PRO 0007561	NDA-PRO 0007561	11/11/1988	Upjohn letter to FDA			
10344	NDA-PRO 0007648	NDA-PRO 0007649	1/15/1988	FDA Letter to Upjohn			
10345	NDA-PRO 0007650	NDA-PRO 0007651	1/12/1988	FDA Letter to Upjohn			
10346	NDA-PRO 0007652	NDA-PRO 0007652	12/28/1987	FDA Letter to Upjohn			
10347	NDA-PRO 0008764	NDA-PRO 0008765	2/1/1989	Upjohn letter to FDA			
10348	NDA-PRO 0008876	NDA-PRO 0008876	2/1/1988	Upjohn letter to FDA			
10349	NDA-PRO 0011591	NDA-PRO 0011592	7/1/1987	Upjohn letter to FDA			
10350	NDA-PRO 0011608	NDA-PRO 0011608	5/29/1987	FDA Letter to Upjohn			
10351	NDA-PRO 0011628	NDA-PRO 0011629	7/8/1986	Upjohn letter to FDA			
10352	NDA-PRO 0011639	NDA-PRO 0011640	6/20/1986	US Pharmaceutical Regulatory Affairs letter to FDA			
10353	NDA-PRO 0011671	NDA-PRO 0011671	4/7/1986	Upjohn letter to FDA			
10354	NDA-PRO 0011995	NDA-PRO 0011996	9/4/1985	Upjohn letter to FDA			
10355	NDA-PRO 0011994	NDA-PRO 0011994	9/10/1985	FDA letter to Upjohn			
10356	NDA-PRO 0017582	NDA-PRO 017582	5/21/1984	FDA letter to Upjohn			
10357	NDA-PRO 0017590	NDA-PRO 0017590	3/29/1984	Upjohn letter to FDA			
10358	NDA-PRO 0017599	NDA-PRO 0017599	1/5/1983	FDA letter to Upjohn			
10359	NDA-PRO 0017771	NDA-PRO 0017771	8/16/1983	Upjohn letter to FDA			
10360	NDA-PRO 0017796	NDA-PRO 0017796	2/28/1983	Upjohn letter to FDA			
10361	NDA-PRO 0020293	NDA-PRO 0020297	5/16/1980	Federal Register 32550-32554, Vol. 45, No. 97			
10362	NDA-PRO 0020301	NDA-PRO 0020301	3/16/1981	FDA letter to Upjohn			
10363	NDA-PRO 0020439	NDA-PRO 0020439	11/17/1978	Upjohn letter to FDA			
10364	NDA-PRO 0020451	NDA-PRO 0020451	10/27/1978	Upjohn letter to FDA			
10365	NDA-PRO 0020479	NDA-PRO 0020479	8/12/1977	Upjohn letter to FDA			
10366	NDA-PRO 0020487	NDA-PRO 0020499	7/22/1977	Federal Register Vol. 42, No. 141, 37637-37648			
10367	NDA-PRO 0020546	NDA-PRO 0020546	11/30/1973	Upjohn letter to FDA			
10368	NDA-PRO 0020621	NDA-PRO 0020621	1/31/1974	Upjohn letter to FDA			
10369	NDA-PRO 0020638	NDA-PRO 0020648	10/4/1973	FDA Follow-up			
10370	NDA-PRO 0020671	NDA-PRO 0020673	4/18/1973	Federal Register, Vol. 38, No. 74, 9612-9613 and Vol. 28, No. 25, 3534			
10371	NDA-PRO 0020702	NDA-PRO 0020702	10/6/1972	Upjohn letter to FDA			
10372	NDA-PRO 0020707	NDA-PRO 0020707	8/31/1972	Upjohn letter to FDA			
10373	NDA-PRO 0020750	NDA-PRO 0020750	7/27/1972	Federal Register, Vol. 37, No. 145, 15033			
10374	NDA-PRO 0020751	NDA-PRO 0020751	7/14/1972	FDA letter to Upjohn			
10375	NDA-PRO 0020786	NDA-PRO 0020787	9/10/1971	FDA letter to Upjohn			
10376	NDA-PRO 0020816	NDA-PRO 0020817	8/14/1971	Upjohn letter to FDA			
10377	NDA-PRO 0020830	NDA-PRO 0020832	2/9/1971	FDA letter to Upjohn			
10378	NDA-PRO 0020833	NDA-PRO 0020834	2/9/1971	FDA letter to Upjohn			
10379	NDA-PRO 0020901	NDA-PRO 0020901	8/5/1970	Upjohn letter to FDA			
10380	NDA-PRO 0022864	NDA-PRO 0022864	2/8/1965	Upjohn letter to FDA			
10381	NDA-PRO 0023463	NDA-PRO 0023463	1/17/1964	Upjohn letter to FDA			
10382	NDA-PRO 0023467	NDA-PRO 0023467	10/28/1963	Upjohn letter to FDA			
10383	NDA-PRO 0023952	NDA-PRO 0023952	11/22/1968	Upjohn letter to FDA			
10384	NDA-PRO 0023971	NDA-PRO 0023971	7/31/1968	FDA letter to Upjohn			
10385	NDA-PRO 0023977	NDA-PRO 0023978	7/31/1968	FDA letter to Upjohn			
10386	NDA-PRO 0024027	NDA-PRO 0024027	10/25/1967	Upjohn letter to FDA			
10387	NDA-PRO 0024061	NDA-PRO 0024061	9/28/1966	Upjohn letter to FDA			
10388	NDA-PRO 0024066	NDA-PRO 0024066	8/10/1966	FDA letter to Upjohn			
10389	NDA-PRO 0024068	NDA-PRO 0024094	2/1/1966	Upjohn letter to FDA; DONALD B. ANDERSON 12/08/06 DEPO EX. 16: Letter from Upjohn to FDA			
10390	NDA-PRO 0024485	NDA-PRO 0024486	00/00/1959	FDA letter to Upjohn			
10391	NDA-PRO 0024493	NDA-PRO 0024500	5/8/1959	Interoffice Memorandum			
10392	NDA-PRO 0026059	NDA-PRO 0026059	9/16/1994	FDA letter to Upjohn			
10393	NDA-PRO 0026141	NDA-PRO 0026141	3/4/1994	Upjohn letter to FDA			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10394	NDA-PRO 0026142	NDA-PRO 0026142	1/30/1991	FDA letter to Upjohn			
10395	NDA-PRO 0026961	NDA-PRO 0026961	1/29/1993	FDA letter to Upjohn			
10396	NDA-PRO 0026963	NDA-PRO 0026963	1/27/1993	Upjohn letter to FDA			
10397	NDA-PRO 0027233	NDA-PRO 0027233	12/9/1991	FDA letter to Upjohn			
10398	NDA-PRO 0027241	NDA-PRO 0027251	11/18/1991	Upjohn letter to FDA			
10399	NDA-PRO 0027272	NDA-PRO 0027272	10/21/1991	FDA letter to Upjohn			
10400	NDA-PRO 0027273	NDA-PRO 0027285	9/24/1991	Upjohn letter to FDA			
10401	NDA-PRO 0027307	NDA-PRO 0027309	6/13/1991	FDA letter to Upjohn			
10402	NDA-PRO 0027310	NDA-PRO 0027312	5/28/1991	FDA letter to Upjohn			
10403	NDA-PRO 0027318	NDA-PRO 0027319	5/24/1991	Upjohn letter to FDA			
10404	NDA-PRO 0027345	NDA-PRO 0027351	4/15/1991	Upjohn letter to FDA			
10405	NDA-PRO 0027352	NDA-PRO 0027354	4/19/1991	Upjohn letter to FDA			
10406	NDA-PRO 0027368	NDA-PRO 0027368	5/9/1991	Certified Card			
10407	NDA-PRO 0027373	NDA-PRO 0027374	3/29/1991	Upjohn letter to FDA			
10408	NDA-PRO 0027396	NDA-PRO 0027397	2/12/1991	FDA letter to Upjohn			
10409	NDA-PRO 0027398	NDA-PRO 0027398	2/13/1991	Upjohn Interoffice Memo			
10410	NDA-PRO 0027724	NDA-PRO 0027732	7/16/1985	Upjohn Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
10411	NDA-PRO 0027733	NDA-PRO 0027769	5/00/1985	Nathan Kase, MD, Perimenopausal Dysfunctional Uterine Bleeding, Diagnosis and Management			
10412	NDA-PRO 0055676	NDA-PRO 0055679	6/10/1963	Upjohn letter to FDA			
10413	VOLPE-G 0004870	VOLPE-G 0004870	1/23/1998	Pharmacia & Upjohn Record of FDA Telephone Contact			
10415	NDA-PRO 0002168	NDA-PRO 0002168	8/1/1997	Certified Card			
10416	NDA-PRO 0002170	NDA-PRO 0002171	7/31/1997	Application to Market a New Drug			
10417	NDA-PRO 0002173	NDA-PRO 0002174	7/31/1997	User Fee Cover Sheet			
10418	NDA-PRO 0002175	NDA-PRO 0002338	7/31/1997	NDA Provera Supplement, Volume 1			
10419	NDA-PRO 0002339	NDA-PRO 0002813	7/31/1997	NDA Provera Supplement, Volume 2			
10420	NDA-PRO 0002814	NDA-PRO 0003283	7/31/1997	NDA Provera Supplement, Volume 3			
10421	NDA-PRO 0003285	NDA-PRO 0003605	7/31/1997	NDA Provera Supplement, Volume 4			
10422	NDA-PRO 0003607	NDA-PRO 0004062	7/31/1997	NDA Provera Supplement, Volume 5			
10423	NDA-PRO 0004064	NDA-PRO 0004237	7/31/1997	NDA Provera Supplement, Volume 6			
10424	VOLPE-G 0006053	VOLPE-G 0006054	8/16/2000	FDA letter to Pharmacia & Upjohn; DEPO: Allen, Susan 4/24/2007 EX20			
10425	BURKM015-000087	BURKM015-000089	11/7/2000	Arnold & Porter letter to FDA; DEPO: Allen, Susan 4/24/2007 EX 21			
10426	CHIRBY-D 0000991	CHIRBY-D 0000991		Upjohn memo to sales reps (duplicate of EX 10657)			
10427	CHIRBY-D 0000078	CHIRBY-D 0000080	7/17/1989	J. William Hendrix, M.D. Clinical Expert Report			
10428	RM_AA 0156173	RM_AA 0156176	11/5/1985	Upjohn internal memo			
10429	CHIRBY-D 0001036	CHIRBY-D 0001036	4/25/1990	Upjohn internal memo			
10430	CHIRBY-D 0001015	CHIRBY-D 0001015	11/8/1990	Upjohn Interoffice Memo			
10431	NDA-PRO 0075451	NDA-PRO 0075454	10/17/1991	FDA letter to Upjohn			
10432	NDA-PRO 0075568	NDA-PRO 0075585	2/18/1991	Upjohn letter to FDA			
10433	CHIRBY-D 0000012	CHIRBY-D 0000013	11/23/1992	Upjohn letter to FDA; DONALD B. ANDERSON 12/08/06 DEPO EX. 7: Letter from J.R. Assenzo with Upjohn to FDA (duplicate of EX 10478)			
10434	CHIRBY-D 0000010	CHIRBY-D 0000010	7/30/1992	Interoffice Memorandum			
10435	CHIRBY-D 0000007	CHIRBY-D 0000007	5/29/1990	Upjohn Interoffice Memo; DONALD B. ANDERSON 12/08/06 DEPO EX. 6: Upjohn Interoffice memo (duplicate of EX 10477)			
10436	CHIRBY-D 0000016	CHIRBY-D 0000016	10/8/1993	Upjohn Interoffice Memo			
10437	CHIRBY-D 0000019	CHIRBY-D 0000019	10/8/1993	Upjohn internal memo			
10438	CHIRBY-D 0000026	CHIRBY-D 0000030	9/7/1993	Upjohn letter to FDA			
10439	CHIRBY-D 0000156	CHIRBY-D 0000157		Clinical Protocol Summary; DONALD B. ANDERSON 12/08/06 DEPO EX. 8: Protocol Summary, Protocol Number M5410/0336 (duplicate of EX 10479)			
10440	CHIRBY-D 0000121	CHIRBY-D 0000121	8/20/1996	Weekly Report to Management			
10441	CHIRBY-D 0000120	CHIRBY-D 0000120	8/23/1996	Pharmacia & Upjohn Interoffice Memo			
10442	CHIRBY-D 0000114	CHIRBY-D 0000114	6/15/1995	Internal Memo			
10443	CHIRBY-D 0000044	CHIRBY-D 0000044	7/13/1993	Upjohn Interoffice Memo			
10444	CHIRBY-D 0000403	CHIRBY-D 0000407	9/9/1993	Upjohn Interoffice Memo			
10445	CHIRBY-D 0000158	CHIRBY-D 0000158	10/8/1993	Upjohn Interoffice Memo			
10446	NDA-PRO 0001557	NDA-PRO 0001558	8/4/1998	FDA letter to Pharmacia & Upjohn			
10447	CHIRBY-D 0005768	CHIRBY-D 0005770	06/00/1991	Upjohn Current Trends in Medicine and Therapy			
10448	CHIRBY-D 0005751	CHIRBY-D 0005753	2/12/1992	Upjohn Interoffice Memo			
10449	RM_AA 0101787	RM_AA 0101788	6/22/1990	Upjohn Interoffice Memo			
10450	RM_NY_MOPS 0167124	RM_NY_MOPS 0167140	10/00/1992	Proposal for Provera Tablets for Hormone Replacement Therapy			
10451	RM_NY_MOPS 0235920	RM_NY_MOPS 0235992	12/00/1994	Provera Training Manual			
10452	CHIRBY-D 0005339	CHIRBY-D 0005341	12/5/1996	Pharmacia & Upjohn Interoffice Memo			
10453	CHIRBY-D 0000221	CHIRBY-D 0000222	07/00/1992	Clinical Protocol Summary			
10454	CHIRBY-D 0000183	CHIRBY-D 0000187	6/21/1994	Upjohn Interoffice Memo			
10455	CHIRBY-D 0000002	CHIRBY-D 0000005	6/15/1993	Internal memos			
10456	NDA-PRO 0001526	NDA-PRO 00001526	10/30/2002	FDA letter to Pharmacia & Upjohn			
10457	VOLPE-G 0006205	VOLPE-G 0006206	9/26/2000	University of MD School of Medicine letter to FDA			
10458	RM_NY_MOPS 0070752	RM_NY_MOPS 0070791	8/14/1991	Upjohn Internal Technical Report			
10459	RM_AA 0156129	RM_AA 0156131	1/7/1986	Upjohn Internal Memo			
10460	RM_AA 0155877	RM_AA 0155904		Index of Appendices			
10461	RM_AA 0155833	RM_AA 0155843	3/12/1993	Upjohn Interoffice memo			
10462	NDA-PRO 0080680	NDA-PRO 0080684	1/8/2003	FDA letter to Pharmacia & Upjohn			
10463	NDA-PRO 0080673	NDA-PRO 0080677	3/4/2003	Pharmacia & Upjohn letter to FDA			
10464	de Koning Gans-H 0000023	de Koning Gans-H 0000040	8/2/1995	Upjohn Interoffice Memo			
10465	de Koning Gans-H 0000011	de Koning Gans-H 0000021	8/4/1995	Handwritten memo from R.F. Carlson to Gans			
10466	RM_AA 0156136	RM_AA 0156144		Marketing Information			
10467	CHIRBY-D 0000011	CHIRBY-D 0000011	12/14/1993	Internal memo			
10468	CHIRBY-D 0000122	CHIRBY-D 0000122	07/00/1996	Monthly Report, Project: Provera Tablets HRT			
10469	NDA-PRO 0027399	NDA-PRO 27400	2/12/1991	FDA letter to Upjohn			
10470	CHIRBY-D 0003916	CHIRBY-D 0003917	12/15/1994	Wyeth-Ayerst letter to FDA			
10471	CHIRBY-D 0003970	CHIRBY-D 0003975	12/22/1992	Wyeth-Ayerst letter to FDA			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10472			11/9/2006	DONALD B. ANDERSON 12/08/06 DEPO EX. 1: Plaintiff's Amended Notice of Deposition of Donald Anderson			
10473			01/00/2006	DONALD B. ANDERSON 12/08/06 DEPO EX. 2: CV/Profile			
10474			4/12/1989	DONALD B. ANDERSON 12/08/06 DEPO EX. 3: 1990 Budget Reproductive Medicine and Oncology F.B.G.			
10475	NDA-PRO 0007537	NDA-PRO 0007538	2/1/1989	DONALD B. ANDERSON 12/08/06 DEPO EX. 4: Letter from D.J. Mason with Upjohn to Solomon Sobel with FDA			
10476	NDA-PRO 0007472	NDA-PRO 0007479	3/23/1989	DONALD B. ANDERSON 12/08/06 DEPO EX. 5: The Upjohn Company Regulatory Affairs, Minutes, Meeting with Division of Metabolism and Endocrine Drug Products on Provera and Conjugated Estrogens			
10477	CHIRBY-D 0000007	CHIRBY-D 0000007	5/29/1990	DONALD B. ANDERSON 12/08/06 DEPO EX. 6: Upjohn Interoffice memo (duplicate of EX 10435)			
10478	CHIRBY-D 0000012	CHIRBY-D 0000013	11/23/1992	DONALD B. ANDERSON 12/08/06 DEPO EX. 7: Letter from J.R. Assenzo with Upjohn to FDA (duplicate of EX 10433)			
10479	CHIRBY-D 0000156	CHIRBY-D 0000157		DONALD B. ANDERSON 12/08/06 DEPO EX. 8: Protocol Summary, Protocol Number M5410/0336 (duplicate of EX 10439)			
10480	NDA-PRO 0002026	NDA-PRO 0002029	10/16/1990	DONALD B. ANDERSON 12/08/06 DEPO EX. 9: Letter from J.R. Assenzo with Upjohn to Thomas W. Cavanaugh with FDA			
10481	NDA-PRO 0027466	NDA-PRO 0027466		DONALD B. ANDERSON 12/08/06 DEPO EX. 10: Advertisement			
10482	NDA-PRO 0002003	NDA-PRO 0002005	11/13/1990	DONALD B. ANDERSON 12/08/06 DEPO EX. 11: Letter from Thomas W. Cavanaugh with FDA to Peter Philander with Upjohn			
10483	CHIRBY-D 0000931	CHIRBY-D 0000933	11/8/1990	DONALD B. ANDERSON 12/08/06 DEPO EX. 12: Upjohn Interoffice memo (duplicate of EX 10187, 10253, 04987)			
10484	BREED-K 0007327	BREED-K 0007330	2/13/1991	DONALD B. ANDERSON 12/08/06 DEPO EX. 13: Upjohn Interoffice memo			
10485	CHIRBY-D 0001017	CHIRBY-D 0001018	11/5/1990	DONALD B. ANDERSON 12/08/06 DEPO EX. 14: Email			
10486	NDA-PRO 0000185	NDA-PRO 0000185	9/26/1985	DONALD B. ANDERSON 12/08/06 DEPO EX. 15: Memo			
10487	NDA-PRO 0024068	NDA-PRO 0024094	2/1/1966	DONALD B. ANDERSON 12/08/06 DEPO EX. 16: Letter from Upjohn to FDA			
10488				Assenzo, Joseph R., M.D. - Exh. 1: Curriculum Vitae			
10489	NDA-PRO 0075661	NDA-PRO 0075661	11/21/1989	Assenzo, Joseph R., M.D. - Exh. 4: Upjohn letter- 11/21/89			
10490	NDA-PRO 0002040	NDA-PRO-0002040	7/26/1990	Assenzo, Joseph R., M.D. - Exh. 5: Letter of Solomon Sobel			
10491	NDA-PRO 0027320	NDA-PRO 0027321	4/11/1991	Assenzo, Joseph R., M.D. - Exh. 10: Letter-4/11/91			
10492	N/A			Assenzo, Joseph R., M.D. - Exh. 15: Low dose Provera tablets document			
10493	RM_AA 0155608	RM_AA 0155646	9/29/1992	Assenzo, Joseph R., M.D. - Exh. 19 & Schoenfeld, Michael 8/03/2007 EX 21: Interoffice memo-9/29/92			
10494	RM_AA 0155566	RM_AA 0155567	1/5/1994	Assenzo, Joseph R., M.D. - Exh. 23: Interoffice memo- 1/5/1994			
10495	KENNALLY-W-0000045	KENNALLY-W-0000052	8/3/1977	Ventilatory Response to Medroxyprogesterone Acetate in Normal Subjects: Time Course and Mechanism			
10496	KENNALLY-W-0000147	KENNALLY-W-0000147	10/27/1981	Memo to Sales Personnel			
10497	NDA-PRO 0000167	NDA-PRO 0000171	10/31/1985	Provera Brand of Medroxyprogesterone Acetate Tablets, USP			
10498	NDA-PRO 0001166	NDA-PRO 0001166	12/19/1980	Upjohn letter to sales force re: estrogen market information			
10499	NDA-PRO 0001167	NDA-PRO 0001167	12/8/1980	Premarin Sales and Daily Dosage			
10500	NDA-PRO 0001499	NDA-PRO 0001509	8/6/1970	Bleeding According to Plan Two Phases of Menopause Management Feminone 0.05 mg (Ethinyl Estradiol Upjohn, U.S.P.) Helps Manage Menopausal Symptoms Provera 10 mg. (Medroxyprogesterone Acetate [Upjohn], U.S.P.) Modifies Estrogen Effects on the Endometrium			
10501	NDA-PRO 0002166	NDA-PRO 0002166	7/31/1997	NDA No. 11-839 Provera Brand of Medroxyprogesterone Acetate Tablets			
10502	NDA-PRO 0002167	NDA-PRO 0002167	7/31/1997	NDA 11-839, Provera Tablets			
10503	NDA-PRO 0002168	NDA-PRO 0002168	8/1/1997	2278366425 M839 Suppl			
10504	NDA-PRO 0027815	NDA-PRO 0027815	00/00/1984	The other Half of Estrogen Replacement Therapy. Provera 10 mg Tablets (Medroxyprogesterone Acetate Tablets)			
10505	NDA-PRO 0028888	NDA-PRO 0028901	2/00/1971	Provera 10 mg. Tablets (Medroxyprogesterone Acetate [Upjohn], U.S.P.) to Help Modify Estrogen-Related Irregular Bleeding			
10506	NDA-PRO 0028917	NDA-PRO 0028938	1/1/1970	She may be in for a Pleasant Change .with your Help, and the Upjohn Plan for Managing the Newly Menopausal Patient			
10507	NDA-PRO 0029025	NDA-PRO 0029028		The Case of the Glamorous Grandmother			
10508	NDA-PRO 0029053	NDA-PRO 0029056	1/1/1969	Estrogen. Helps Manage Symptoms of Menopause.			
10509	NDA-PRO 0029063	NDA-PRO 0029069	00/00/1969	The Case of the Glamorous Grandmother			
10510	NDA-PRO 0029078	NDA-PRO 0029082	00/00/1969	Provera (Medroxyprogesterone Acetate, Upjohn) Helps Control Irregular Menses. Modifies the Effect of Unopposed Estrogen on the Endometrium.			
10511	NDA-PRO 0029099	NDA-PRO 0029103		The Case of the Glamorous Grandmother			
10512	NDA-PRO 0029111	NDA-PRO 0029117		Symptomatic Relief to Manage the Menopause			
10513	NDA-PRO 0029124	NDA-PRO 0029130		Symptomatic Relief to Manage the Menopause			
10514	RM_AA 0156136	RM_AA 0156157		Marketing Information re: Provera			
10515	RM_AA 0156177	RM_AA 0156187	11/9/1981	Corporate Product Statement re: Provera			
10516	RM_AA 0156193	RM_AA 0156197		Regulatory Summary for Provera			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10517	NDA-PRO 0008775	NDA-PRO 0008775	7/10/1986	Memorandum of Meeting: FDA and Upjohn			
10518	RM_NY_MOPS 0103192	RM_NY_MOPS 0103193	4/10/1990	Educational Service Ideas for the MSR: management of the Menopausal Woman (Job No. 7553.1) Description and Order Form			
10519	RM_NY_MOPS 0103181	RM_NY_MOPS 0103191	00/00/1990	Management of the Menopausal Woman - OB/GYN Clinical Update monograph			
10520	NDA-PRO 0024462	NDA-PRO 0024462	6/17/1959	Cover Letter Upjohn to FDA re NDA 11839 - attaching 5 copies of Provera materials carton, label and leaflet From WF Werner to MW Sandmeyer			
10521	NDA-PRO 0024465	NDA-PRO 0024471		Copy of package insert attached to NDA 11839 (Exh 10520)			
10522	N/A	N/A		2004 Provera Label			
10523				2001 Provera Label (PDR)			
10524				2002 provera label			
10525	RM_AA 0155906	RM_AA 0155956	10/1/1986	Provera Tablets Situation Analysis Year-to-Date October/November 1986			
10526	Chirby-D 0003402	Chirby-D 0003405	10/4/1995	Letter from the Upjohn Company to Division of Metabolism and Endocrine Drug Products			
10527	Chirby-D 0003435	Chirby-D 0003436	3/11/1996	Letter from Clinical Research Institutional Review Committee to Louis Cohen, M.D.			
10528	Chirby-D 0000118	Chirby-D 0000119		Ogen/Provera Study. MTRA Incremental Study Grant Changes.			
10529	Chirby-D 0000146	Chirby-D 0000149	10/4/1994	Letter from Upjohn Company to Division of Metabolism and Endocrine Drug Products			
10530	Chirby-D 0003056	Chirby-D 0003057	11/3/1992	The Use of Sequential Sex Steroids in the Treatment of Climacteric Women - An Open Label Comparative Trial; DEPO: Schoenfeld, Michael 8/03/2007 EX 7 & Carlson, Rodney 2/20/2007 EX 35			
10531	Deters-M 0001357	Deters-M 0001362	12/16/1994	Letter from the Upjohn Company to Division of Metabolism and Endocrine Drug Products			
10532	Deters-M 0001405	Deters-M 0001466	3/26/1993	The Upjohn Company Clinical Protocol - The Effects of Post Menopause Estrogen / PROVERA Hormone Replacement Therapy (HRT) on Endometrial Histology and Bone Mineral Density; DEPO: Carlson, Rodney 2/20/2007 EX 23			
10533	Deters-M 0001941	Deters-M 0002006	1/20/1993	The Upjohn Company Clinical Protocol - Investigation of Possible Genetic Determinants of Lipoprotein Changes Induced by Post-Menopausal Hormone Replacement Therapy (HRT); DEPO: Carlson, Rodney 2/20/2007 EX 22			
10534	Deters-M 0002143	Deters-M 0002148	7/9/1993	The Upjohn Clinical Protocol Amendment - The Effects of Post-Menopausal Estrogen/PROVERA Hormone Replacement Therapy (HRT) an Endometrial Histology and Bone Mineral Density.			
10535	Deters-M 0004320	Deters-M 0004330	10/1/1980	Menopausal Treatment Study - The Upjohn Company Medical Endocrinology Protocol; Carlson, Rodney 2/20/2007 EX 4			
10536	Deters-M 0004496	Deters-M 0004524	10/27/1982	C.T. Provera Osteoporosis Study - The Upjohn Company Medical Endocrinology Protocol; DEPO: Carlson, Rodney 2/20/2007 EX 5			
10537	Deters-M 0004525	Deters-M 0004534	6/6/1984	Combined Premarin Plus C.T. Provera For the Treatment of the Menopause; DEPO: Carlson, Rodney 2/20/2007 EX 6			
10538	Deters-M 0004535	Deters-M 0004549	6/28/1984	Combined Premarin Plus C.T. Provera For the Treatment of the Menopause; DEPO: Carlson, Rodney 2/20/2007 EX 7			
10539	Deters-M 0004550	Deters-M 0004554	12/12/1984	Combined Premarin Plus C.T. Provera For the Treatment of the Menopause			
10540	Deters-M 0004556	Deters-M 0004575	9/16/1985	The Effects of Estrogen and a Progestogen on Coagulation and Lipid Profiles in Postmenopausal Women; DEPO: Carlson, Rodney 2/20/2007 EX 9			
10541	Deters-M 0004595	Deters-M 0004627		The Treatment of Menopausal Patients with Sequential and Combined Estrogen and Progestin Therapy; DEPO: Carlson, Rodney 2/20/2007 EX 10			
10542	Deters-M 0004633	Deters-M 0004653		The Treatment of Menopausal Patients with Sequential and Combined Estrogen and Progestin Therapy			
10543	DETERS-M 0005187	DETERS-M 0005194	6/9/1992	Letter from Upjohn Company to Division of Metabolism and Endocrine Drug Products; DEPO: Carlson, Rodney 2/20/2007 EX 21			
10544	FEINER-C 0015861	FEINER-C 0015892	5/16/1995	The Upjohn Company Clinical Protocol - OGEN/PROVERA, Efficacy of Continuous Hormone Replacement Therapy (HRT) on the Relief of Symptoms of Menopause; DEPO: Carlson, Rodney 2/20/2007 EX 28			
10545	FEINER-C 0016719	FEINER-C 0016720	3/10/2004	Memo from Elyse Shapiro RE Ogen/Provera Studies; DEPO: Carlson, Rodney 2/20/2007 EX 29			
10546	FEINER-C 0027909	FEINER-C 0027909	5/31/2004	Invoice from Data & Inference Inc. to Pfizer Inc.			
10547	FEINER-C 0027899	FEINER-C 0027899	3/2/2004	Invoice from Data & Inference Inc. to Pfizer Inc.			
10548	HUGHES-J 0000300	HUGHES-J 0000322		The Effect of Low-Dose Conjugated Estrogens and Cyclic Medroxyprogesterone Acetate on Bone Mineral Density; DEPO: Carlson, Rodney 2/20/2007 EX 34			
10549	LEWIS-R 0000699	LEWIS-R 0000699	6/4/2003	Progress Overview Per Protocol; DEPO: Carlson, Rodney 2/20/2007 EX 31			
10550	RM_AA 0151363	RM_AA 0151365	3/7/1995	SUMMARY TABLE - Product Support Projects to Start in 1995 The Upjohn Company; DEPO: Schoenfeld, Michael 8/03/2007 EX 10 & Carlson, Rodney 2/20/2007 EX 37			
10551	NDA-PRO 0027273	NDA-PRO 0027273	9/24/1991	Letter from the Upjohn Company to Attn Rita Hassall Division of Drug Marketing, Advertising, and Communications Food and Drug Administration			
10553	NDA-PRO 0032641	NDA-PRO 0032647	10/24/1991	The New England Journal of Medicine - Prevention of Post Menopausal Osteoporosis; DEPO: Carlson, Rodney 2/20/2007 EX 39			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10554	PATEL-M 0007989	PATEL-M 0007993	07/00/1991	A Randomized, Double Blind, Placebo-Controlled Cross Over Trial to Assess the Side Effects of Medroxyprogesterone Acetate in Hormone Replacement Therapy; DEPO: Carlson, Rodney 2/20/2007 EX 38			
10555	RAY-A 0009335	RAY-A 0009346	6/00/2004	Pfizer - WW Medical Submissions and Diversified Products Monthly Highlights June 2004			
10555A				Wyeth Website - Breast Cancer			
10556	RAY-A 0011065	RAY-A 0011074	5/00/2004	Pfizer - WW Medical Submissions and Diversified Products Monthly Highlights May 2004			
10556A				Wyeth Website - Menopause			
10556C			00/00/2010	Pfizer Website - Menopause and Breast Cancer			
10557	RAY-A 0011385	RAY-A 0011390		WW DVP Mecical Budget			
10558	RM_AA 0013056	RM_AA 0013063	6/15/1995	Clinical Investigator Grant			
10559	RM_AA 0009203	RM_AA 0009258	3/24/1994	The Upjohn Clinical Protocol - Evaluation of Endometrial Histology and Bone Mineral Density in Post Menopausal Women Receiving OGEN/PROVERA Hormone Replacement Therapy; DEPO: Schoenfeld, Michael 8/03/2007 EX 12 & Carlson, Michael 2/20/2007 EX 25			
10560	RM_AA 0009429	RM_AA 0009431	5/7/1994	Letter from the Upjohn Company to Attn Mabel P. Smith Administrator Academic Affairs Department of Pathology Johns Hopkins Medical Institute.			
10561	RM_AA 0010465	RM_AA 0010473	6/30/1998	Interoffice Memo Pharmacia & Upjohn Company - Subject: Contract/Project for Ogen Provera Protocol.			
10562	RM_AA 0010691	RM_AA 0010726	9/8/1995	Interoffice Memo Pharmacia & Upjohn Company - Subject: Agreement for File			
10563	RM_AA 0010798	RM_AA 0010801	1/9/1995	Letter from Medical & Technical Research Associates, Inc.			
10564	RM_AA 0010906	RM_AA 0010906	1/9/1995	MTRA - Amendment #1 to the Agreement of July 1, 1994 between the Upjohn Company & Medical & Technical Research Associates, Inc.			
10565	RM_AA 0013168	RM_AA 0013169	4/13/1995	Letter from Clinical Research Institutional Review Committee John David Hoff, M.D.			
10566	RM_AA 0013657	RM_AA 0013660	8/25/1994	Letter from Clinical Research Institutional Review Committee to Saeeda Khairi M.D.			
10567	RM_AA 0013820	RM_AA 0013820	10/9/1995	Letter from MTRA to James Jacobs, M.D. Re: Upjohn Ogen/Provera Protocol.			
10568	RM_AA 0013821	RM_AA 0013821	10/9/1995	Letter from MTRA to James Jacobs, M.D. Re: Upjohn Ogen/Provera Protocol.			
10569	RM_AA 0014820	RM_AA 0014820	5/4/1995	Letter from MTRA to Donald Middleton, M.D. Re: Upjohn Company Protocol			
10570	RM_AA 0014965	RM_AA 0014966	4/18/1995	Letter from Clinical Research Institutional Review Committee to Donald Middleton, M.D.			
10571	RM_AA 0015613	RM_AA 0015736	8/25/1994	Letter from Clinical Research Institutional Review Committee to Stephen Phillips, M.D.			
10572	RM_AA 0015793	RM_AA 0015802	2/10/1997	Letter from MTRA to Michael Schoenfeld Re: Upjohn OGEN Protocol.			
10573	RM_AA 0015873	RM_AA 0015875	8/24/1994	Letter from Clinical Research Institutional Review Committee to Irwin Kerber, M.D.			
10574	RM_AA 0016598	RM_AA 0016599	4/3/1995	Letter from Clinical Research Institutional Review Committee to Sid Rosenblatt, M.D.			
10575	RM_AA 0017182	RM_AA 0017184	8/25/1994	Letter from Clinical Research Institutional Review Committee to Carl E. Schwenker, M.D.			
10576	RM_AA 0018355	RM_AA 0018357	2/9/1995	Letter from MTRA to Louis Weinstein, M.D. RE: The Upjohn Company "Evaluation of Endometrial Histology and Bone Mineral Density in Post Menopausal Women Receiving OGEN/PROVERA Hormone Replacement Therapy.			
10577	RM_AA 0019518	RM_AA 0019521	4/3/1986	South Southern Regional Meeting of ASBMR High Hampton Inn and Country Club; DEPO: Carlson, Rodney 2/20/2007 EX 41			
10578	RM_AA 0020004	RM_AA 0020006	11/15/1990	Letter from The Upjohn Company to Howard Judd, M.D.			
10579	RM_AA 0020052	RM_AA 0020066	2/6/1990	Upjohn - A Study of the Effect of Less Frequent Cyclin Progestin Administration during Estrogen Replacement Therapy To Determine if Protection Against Endometrial Hyperplasia is Adequate; DEPO: Carlson, Rodney 2/20/2007 EX 18			
10580	RM_AA 0020181	RM_AA 0020202	5/8/1986	Upjohn Confidential: The Effect of Estrogen and Progestin on Coagulation and Liquid Profiles and Osteocalcin in Postmenopausal Women; DEPO: Carlson, Rodney 2/20/2007 EX 11			
10581	RM_AA 0021026	RM_AA 0021032	10/14/1993	The Upjohn Company Clinical Protocol Amendment 1: "Genetic Determinates of Lipoprotein Changes Post-Menopausal Hormone Replacement."			
10582	RM_AA 0021080	RM_AA 0021084		Correspondence between Upjohn and Dr. H. Robert Superko-Sequoia Hospital/Lipid Institute			
10583	RM_AA 0021140	RM_AA 0021140	10/31/1991	Sequoia Hospital Clinical Laboratory report			
10584	RM_AA 0021288	RM_AA 0021289		Letter from Lipid Institute requesting study payment from Upjohn			
10585	RM_AA 0021320	RM_AA 0021321	12/7/1995	Letter from Upjohn to Dr. H. Robert Superko re: study payment			
10586	RM_AA 0021356	RM_AA 0021356	2/14/1995	Letter from Upjohn to Dr. H. Robert Superko re: study payment			
10587	RM_AA 0021359	RM_AA 0021361		Letter from Upjohn re: funding of Dr. H. Robert Superko's study			
10588	RM_AA 0021377	RM_AA 0021378	12/15/1994	Letter from Upjohn to Dr. H. Robert Superko re: study payment			
10589	RM_AA 0021410	RM_AA 0021410	12/21/1993	Letter from Upjohn to Sequoia Hospital Lipid Institute re: payment for Dr. H. Robert Superko's study			
10590	RM_AA 0021472	RM_AA 0021473	9/1/1994	Reports of Payments			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10591	RM_NY_MOPS 0077250	RM_NY_MOPS 0077252	11/22/1994	Upjohn letter to FDA re: Amendment No. 010 Re: Ind 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment Amendment #1 T			
10592	RM_NY_MOPS 0077256	RM_NY_MOPS 0077318	10/27/1994	Upjohn letter to FDA re: Amendment No. 009 Re: Ind 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment Amendment #1 T			
10593	RM_NY_MOPS 0077319	RM_NY_MOPS 0077450	10/4/1994	Upjohn letter to FDA re: Amendment No. 008 Re: Ind 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment Amendment #1 To Protocol M15410/0336 New Investigators (Protocol M5410/0336)			
10594	RM_AA 0105799	RM_AA 0105856	9/28/1995	Ogen/Premarin/Provera A Study of the Effects of Three Different Regimens of Continuous Hormone Replacement Therapy (HRT); DEPO: Carlson, Rodney 2/20/2007 EX 26			
10595	RM_AA 0149785	RM_AA 0149837	10/31/1994	Pilot Study of Effect of Harmogen/Provera Combination Hormone Replacement Therapy on Plasma Lipid Profile; DEPO: Carlson, Rodney 2/20/2007 EX 24			
10596	RM_AA 0149841	RM_AA 0149841	7/29/1996	Protocol Status Report: Harmogen/Provera HRT, Effect on Plasma Lipids			
10597	RM_AA 0149913	RM_AA 0149968	9/16/1994	Pilot Study of Effect of Harmogen/Provera Combination Hormone Replacement Therapy on Plasma Lipid Profile			
10598	RM_AA 0150049	RM_AA 0150066	7/26/1989	Protocol No.: 54N/3170 continuous oestrone sulphate and medroxyprogesterone acetate hormonal replacement therapy -- a study of endometrial, lipid, bone density and bleeding pattern response over 2 years; DEPO: Carlson, Rodney 2/20/2007 EX 14			
10599	RM_AA 0150934	RM_AA 0150994	9/28/1995	The Upjohn Company Clinical Protocol 70.2111 7/92 Protocol Title: Ogen/Premarin/Provera A Study Of The Effects Of Three Different Regimens Of Sequential Hormone Replacement Therapy (HRT) Protocol Number: M15410/0367; DEPO: Carlson, Rodney 2/20/2007 EX 27			
10600	RM_AA 0209200	RM_AA 0209208	8/00/1983	August, '83 Protocol N° Prov./Be N° '39 Upjohn Belgium Trial N° '39 Comparative Hormone Therapy In The Menopausal Syndrome. Provera Versus Combination Therapy ; DEPO: Schoenfeld, Michael 8/03/2007 EX 6 & Carlson, Rodney 2/20/2007 EX 8			
10601	RM_AA 0210829	RM_AA 0210829	1/4/1985	Letter to Upjohn from Kenneth Ryan, M.D. acknowledging payment for Provera osteoporosis study			
10602	RM_AA 0210836	RM_AA 0210843		Correspondence re: Upjohn's funding of studies			
10603	RM_AA 0210853	RM_AA 0210853	12/31/1984	Letter from Veronica Ravnika, M.D. to Upjohn re: osteoporosis study payment			
10604	RM_AA 0210855	RM_AA 0210858		Correspondence re: payment by Upjohn for grants and studies			
10605	RM_AA 0211277	RM_AA 0211278	4/13/1995	Letter from Clinical Research Review Committee to J. Davila, M.D. re: study: Evaluation of Endometrial Histology and Bone Mineral Density (BMD) in Post Menopausal Women Receiving Ogen®/Provera® Hormone Replacement Therapy (HRT)", Protocol M5410/0336, dated March 24, 1994.			
10606	RM_AA 0211319	RM_AA 0211320	4/28/1995	Letter from Clinical Research Review Committee to Frances Fisk, M.D. re: study: Evaluation of Endometrial Histology and Bone Mineral Density (BMD) in Post Menopausal Women Receiving Ogen®/Provera® Hormone Replacement Therapy (HRT)", Protocol M5410/0336, dated March 24, 1994.			
10607	RM_AA 0212765	RM_AA 0212766	3/8/1995	Letter from Clinical Research Review Committee to Marcia Montgomery, M.D. re: study: Evaluation of Endometrial Histology and Bone Mineral Density (BMD) in Post Menopausal Women Receiving Ogen®/Provera® Hormone Replacement Therapy (HRT)", Protocol M5410/0336, dated March 24, 1994.			
10608	RM_AA 0212947	RM_AA 0212948	8/25/1994	Letter from Clinical Research Review Committee to Morris Notelovitz, M.D. re: approval of Evaluation of Endometrial Histology and Bone Mineral Density (BMD) in Post Menopausal Women Receiving Ogen®/Provera® Hormone Replacement Therapy (HRT)", Protocol M5410/0336, dated March 24, 1994.			
10609	RM_AA 0318455	RM_AA 0318456	12/2/1986	Letter from Upjohn to Betty Roof, M.D. re: Provera Osteoporosis study			
10610	RM_AA 0318457	RM_AA 0318457	3/17/1986	Letter from Upjohn re: funding Betty Roof, M.D.'s study for Provera and osteoporosis			
10611	RM_AA 0318470	RM_AA 0318471		Letters from Upjohn to Betsy Roof, M.D. re: funding IND Study No. 21,160			
10612	RM_AA 0318675	RM_AA 0318679	12/00/1987	Continuous Estrogen/Progestin Therapy In Menopause			
10613	RM_AA 0325350	RM_AA 0325352		Letters from Upjohn to J.C. Gallagher, M.D. re: funding CT scan portion of bone loss study			
10614	RM_AA 0325380	RM_AA 0325380	3/15/1984	Letter from Upjohn to J.C. Gallagher, M.D. re: funding CT scan portion of bone loss study			
10615	RM_AA 0325385	RM_AA 0325385	1/23/1984	Letter from J.C. Gallagher, M.D. to Upjohn re: adding more women to "The Effects of Hormone Therapy on Postmenopausal Bone Loss" study			
10616	RM_AA 0325402	RM_AA 0325402	5/3/1983	Letter from Upjohn to J.C. Gallagher re: funding for study			
10617	RM_AA 0325406	RM_AA 0325406	12/2/1982	Letter from J.C. Gallagher, M.D. to Upjohn re: adding CT spine to study			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10618	RM_AA 0325412	RM_AA 0325412	9/10/1982	Letter from Upjohn to J.C. Gallagher, M.D. re: financing computed tomographic assessment in study			
10619	RM_AA 0325421	RM_AA 0325421	3/30/1982	Letter from Upjohn to J.C. Gallagher, M.D. re: payment for study			
10620	RM_AA 0325452	RM_AA 0325454	2/26/1982	Pharmaceutical Grant Proposal of J.C. Gallagher, M.D.			
10621	RM_AA 0325456	RM_AA 0325456	9/21/1981	Letter from J.C. Gallagher, M.D. to Upjohn requesting financial assistance for study of hormones on post-menopausal bone loss			
10622	RM_AA 0350451	RM_AA 0350451	1/6/1982	Letter to Richard Worley, M.D. re: payment for Menopausal Treatment Study			
10623	RM_AA 0210845	RM_AA 0210850		Letters re: payment by Upjohn for grants and studies			
10624	RM_NY_MOPS0077746	RM_NY_MOPS0077822	9/7/1994	Regulatory Summary - IND Number 45,949 Protocol Number M5410/0336			
10625	RM_NY_MOPS 0077028	RM_NY_MOPS 0077030	6/13/1995	Amendment No. 012 Re: IND 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment			
10626	RM_NY_MOPS 0077031	RM_NY_MOPS 0077038	5/5/1995	Amendment No. 017 Re: IND 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment			
10627	RM_NY_MOPS 0077039	RM_NY_MOPS 0077067	5/1/1995	Correction to Cover Letter for Amendment No. 016 Re: IND 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment			
10628	RM_NY_MOPS 0077068	RM_NY_MOPS 0077094	5/1/1995	Amendment No. 016 Re: IND 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment			
10629	RM_NY_MOPS 0077095	RM_NY_MOPS 0077104	4/13/1995	Amendment No. 015 Re: IND 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment			
10630	RM_NY_MOPS 0077105	RM_NY_MOPS 0077143	4/4/1995	Amendment No. 014 Re: IND 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment			
10631	RM_NY_MOPS 0077144	RM_NY_MOPS 0077146	2/21/1995	Amendment No. 013 Re: IND 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment			
10632	RM_NY_MOPS 0077236	RM_NY_MOPS 0077244	1/25/1995	Amendment No. 012 Re: IND 45,949 Provera® Tablets Hormone Replacement Therapy Protocol Amendment			
10633	RM_NY_MOPS 0068960	RN_NY_MOPS 0068974	1/8/1987	The Treatment of Menopausal Patients with Combined Estrogen and Progestin Therapy; DEPO: Carlson, Rodney 2/20/2007 EX 12			
10634	RM_NY_MOPS 0068977	RM_NY_MOPS 0068997	10/15/1987	An Evaluation of Premenstrual-Like Symptoms in Menopausal Women Treated with .625 mg/day of Conjugated Equine Estrogen (Premarin) and 10 mg/day of Oral Medroxyprogesterone Acetate (PROVERA® Tablets) for One Week; DEPO: Carlson, Rodney 2/20/2007 EX 15			
10636	RM_NY_MOPS 0069600	RM_NY_MOPS 0069619	4/24/1989	ND #13,530 DEPO—PROVERA® Sterile Aqueous Suspension (Use in Menopause) Miscellaneous Studies; DEPO: Carlson, Rodney 2/20/2007 EX 16			
10637	RM_NY_MOPS 0069812	RM_NY_MOPS 0069844	8/8/1988	IND #13,530 DEPO—PROVERA® Sterile Aqueous Suspension (Use in Menopause) Miscellaneous Studies; DEPO: Carlson, Rodney 2/20/2007 EX 13			
10638	RM_NY_MOPS 0070160	RM_NY_MOPS 0070199	6/27/1990	Provera tablets - Final Protocol version 1. 5 Infrequent Cyclic Estrogen/Progestin Therapy for Treatment of Menopausal Patients: Endometrial and Lipid Effects; DEPO: Carlson, Rodney 2/20/2007 EX 17			
10639	RM_NY_MOPS 0070568	RM_NY_MOPS 0070632	7/16/1992	Letter to FDA re: Amendment #031 of IND 13,530; DEPO: Carlson, Rodney 2/20/2007 EX 33			
10640	RM_NY_MOPS 0070803	RM_NY_MOPS 0070886	12/30/1991	Clinical Protocol - Title: Effect Of Estrogen Alone Or Estrogen Plus Progestin On The Lipoprotein Composition M41) Plasma Enzyme Activities In Postmenopausal Women With NIDDM; DEPO: Carlson, Rodney 2/20/2007 EX 19			
10652	NDA-PRO 0007209	NDA-PRO 0007209	10/10/1989	Upjohn's letter to FDA re essential changes to professional insert Provera tablets NDA 11-839			
10653	NDA-PRO 0008834	NDA-PRO 0008834	2/29/1988	Upjohn's response to FDA letter dated December 28, 1987 re: insufficient evidence of efficacy and safety for use of Provera tablets in endometriosis NDA 11-839			
10654	CHIRBY-D 0002880	CHIRBY-D 0002904	3/30/1989	Expert Report prepared by Dr. C. H. Burton for Upjohn Limited on the use of medroxyprogesterone acetate as adjunctive therapy with oestrogens in postmenopausal women			
10655	VOLPE-G 0004852	VOLPE-G 0004862	6/24/1999	Tabulated Study Report re: Medroxyprogesterone acetate USP and Estropipate tablets			
10656	NDA-PRO 0001530	NDA-PRO 0001531	10/15/2002	Letter from FDA re: invitation to Women's Health Initiative meeting following WHI results on HRT study			
10657	CHIRBY-D 0000991	CHIRBY-D 0000991		PSM bulletin re: Provera promotion (duplicate of EX 10426)			
10658	NDA-PRO 0000202	NDA-PRO 0000202	7/19/1983	Letter from FDA re: NDA 11-839 (Provera tablets) re additional adverse reactions added by Upjohn to package insert			
10659	Widlitz-M 0000001	Widlitz-M 0000005	2/12/2002	Email re: Review Draft: femhrt IND Safety Report -- AER#001 -0376- M0200035, 0376-421-046, pt # 0846/A-R			
10660	PATEL-M 0007587	PATEL-M 0007597	8/4/1989	memo: Harwin to List: HT and Breast Cancer, NEJM Study			
10661	LEWIS-R 0001105	LEWIS-R 0001112	8/4/2003	MEMO re: Provera -Geriatric Labeling Supplement			
10662	KENNALLY-W 0000132	KENNALLY-W 0000140	10/00/1972	Depo-provera draft labeling			
10663	ENGELS-D 0000966	ENGELS-D 0000973	10/11/2002	EMAIL RE: Expert Advisor's Opinion on Provera (WHI)			
10664	ENGELS D 0000256	ENGELS D 0000303	7/00/1998	Contract Sales Organization (Syncom) OGEN Training			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10665	EDWARDS-A 0000345	EDWARDS-A 0000414	7/18/2001	JALA presentation : FEMhrt First			
10666	RM_NY_MOPS 0081780	RM_NY_MOPS 0081790	5/13/1997	Memo re: Sales of Bulk MPA to Solvay and Barr by P&U			
10667			00/00/1962	Provera Physicians' Desk Reference 1962			
10668			00/00/1963	Provera Physicians' Desk Reference 1963			
10669			00/00/1964	Provera Physicians' Desk Reference 1964			
10670			00/00/1965	Provera Physicians' Desk Reference 1965			
10671			00/00/1966	Provera Physicians' Desk Reference 1966			
10672			00/00/1967	Provera Physicians' Desk Reference 1967			
10673			00/00/1968	Provera Physicians' Desk Reference 1968			
10674			00/00/1969	Provera Physicians' Desk Reference 1969			
10675			00/00/1970	Provera Physicians' Desk Reference 1970			
10676			00/00/1971	Provera Physicians' Desk Reference 1971			
10677			00/00/1972	Provera Physicians' Desk Reference 1972			
10678			00/00/1973	Provera Physicians' Desk Reference 1973			
10679			00/00/1974	Provera Physicians' Desk Reference 1974			
10680			00/00/1975	Provera Physicians' Desk Reference 1975			
10681			00/00/1976	Provera Physicians' Desk Reference 1976			
10682			00/00/1977	Provera Physicians' Desk Reference 1977			
10683			00/00/1978	Provera Physicians' Desk Reference 1978			
10684			00/00/1979	Provera Physicians' Desk Reference 1979			
10685			00/00/1980	Provera Physicians' Desk Reference 1980			
10686			00/00/1981	Provera Physicians' Desk Reference 1981			
10687			00/00/1982	Provera Physicians' Desk Reference 1982			
10688			00/00/1983	Provera Physicians' Desk Reference 1983			
10689			00/00/1984	Provera Physicians' Desk Reference 1984			
10690			00/00/1985	Provera Physicians' Desk Reference 1985			
10691			00/00/1986	Provera Physicians' Desk Reference 1986			
10692			00/00/1987	Provera Physicians' Desk Reference 1987			
10693			00/00/1988	Provera Physicians' Desk Reference 1988			
10694			00/00/1989	Provera Physicians' Desk Reference 1989			
10695			00/00/1990	Provera Physicians' Desk Reference 1990			
10696			00/00/1991	Provera Physicians' Desk Reference 1991			
10697			00/00/1992	Provera Physicians' Desk Reference 1992			
10698			00/00/1993	Provera Physicians' Desk Reference 1993			
10699			00/00/1994	Provera Physicians' Desk Reference 1994			
10700			00/00/1995	Provera Physicians' Desk Reference 1995			
10701			00/00/1996	Provera Physicians' Desk Reference 1996			
10702			00/00/1997	Provera Physicians' Desk Reference 1997			
10703			00/00/2000	Provera Physicians' Desk Reference 2000			
10704			00/00/2001	Provera Physicians' Desk Reference 2001			
10705			00/00/2002	Provera Physicians' Desk Reference 2002			
10706				Provera label 2004			
10708	CHIRBY-D 0000202	CHIRBY-D 0000202	11/8/1996	Message re: list of potential pivotal studies for the PROVERA 505(b) New Indication Claim project			
10709	CHIRBY-D 0000714	CHIRBY-D 0000718	3/19/1984	Technical Report: An Evaluation of the Bioavailability of a Potential Reformulation of C.T. PROVERA 2.5 mg			
10710	CHIRBY-D 0002201	CHIRBY-D 0002202	7/21/1992	Memo re: Questions/Answers from the PROVERA HRT Scientific Review			
10711	CHIRBY-D 0002309	CHIRBY-D 0002309	10/13/1993	Memo re: PROVERA TABLETS — Milled vs. micronized for Puerto Rico mfg			
10712	CHIRBY-D 0002639	CHIRBY-D 0002639	2/10/1994	Memo re: Cycrin vs. Provera - TR to be issued to go with FDA packet			
10713	CHIRBY-D 0002910	CHIRBY-D 0002941	8/22/1990	Brook Lodge Investigators Publication/Presentation Workshop Multiclinic Summary Data (Draft) CE/PROVERA® Menopause Study Protocol M5410/0132/0138			
10714	CHIRBY-D 0003202	CHIRBY-D 0003204	5/31/1998	Technical Report: The Effects of Estrogens and a Progestogen on Coagulation and Lipid Profiles in Postmenopausal Women			
10715	Chirby-D 0003283	Chirby-D 0003380	6/24/1999	Technical Report: Evaluation of Endometrial Histology and Bone Mineral Density (BMD) in Post Menopausal Women Receiving OGEN®/PROVERA® Hormone Replacement Therapy (HRT); DEPO: Schoenfeld, Michael 8/03/2007 EX 11			
10716	CHIRBY-D 0004465	CHIRBY-D 0004470	5/5/1995	Memo re: Proposal to Address Potential Non-bioequivalence of PROVERA Tablets (2.5, 5, 10 mg Low Dose) Formulations			
10717	CHIRBY-D 0005030	CHIRBY-D 0005058	12/8/1995	Safety Evaluation for Micronized PROVERAUsing Spontaneous Report Data			
10718	CHIRBY-D 0002030	CHIRBY-D 0002102	9/25/1995	Technical Report: Continuous Oestrone Sulphate and Medroxyprogesterone Acetate Hormonal Replacement Therapy - A Study of Endometrial, Lipid, Bone Density, and Bleeding Pattern Response Over Two years			
10719	CHIRBY-D 0003183	CHIRBY-D 0003183	6/8/1990	Memo re: not enough info on combined continuous regimen to change Corporate Product Statement for Provera			
10720	Deters-M 0000144	Deters-M 0000151	7/17/2000	Letter to FDA re: Amendment of IND 13,530			
10721	DETERS-M 0000153	DETERS-M 0000176	6/8/1993	Statistical Analysis of Protocols MJ5410/0174 and M/5410/0179: "Infrequent Cyclic Estrogen/Progestin Therapy for Treatment of Menopausal Patients: Endometrial and Lipid Effects"			
10722	DETERS-M 0001363	DETERS-M 0001517	11/23/1994	Letter to FDA re: Amendment #53 of IND 13,530			
10723	DETERS-M 0002065	DETERS-M 0002068	10/11/1993	Letter to FDA re: Amendment #40 of IND 13,530 Information to Amendment #39			
10724	Deters-M 0002467	Deters-M 0002514	5/5/1992	Provera® (U-8839) and Ogen®: A Three-Week Estrous Cycle Interference Study in the Rat			
10725	Deters-M 0004704	Deters-M 0004704		Individual Study Summary for IN 13,530 reporting period 5/1/01 - 4/30/02			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10726	Deters-M 0005249	Deters-M 0005283	6/1/1990	Letter to FDA re: Amendment #20 of IND 13,530 w/Annual Report Number 13; DEPO; Schoenfeld, Michael 8/03/2007 EX 5			
10727	Deters-M 0005291	Deters-M 0005303	6/21/1989	ND #13,530 DEPO-PROVERA® Sterile Aqueous Suspension (Use in Menopause) CLINICAL			
10728	Deters-M 0005311	Deters-M 0005326	7/6/1988	IND #13,530 DEPO-PROVERA® Sterile Aqueous Suspension (Use in Menopause) CLINICAL; DEPO: Schoenfeld, Michael 8/03/2007 EX 4			
10729	DUROJ046-018051		5/2/2002	Email re: request to meet with JAMA editor			
10730	DUROJ046-018052		4/24/2002	Wyeth advertising expenditures in JAMA			
10731	DUROJ046-018053		5/1/2002	Email re: request to meet with JAMA editor			
10732	DUROJ046-018054		5/1/2002	Letter from Wyeth to C DeAngeles re: JAMA coverage of ERT/HRT			
10733	HUGHES-J 0000254	HUGHES-J 0000254	4/26/1988	Statistical Report for Protocol 80-01 (M5400/0029): DEPO—PROVERA® Compared to Premarin for the Treatment of Vasomotor Symptoms of Menopause			
10734	Hughes-J 0000290	Hughes-J 0000294	06/00/1999	Bone Density Effects of Continuous Estrone Sulfate and Varying Doses of Medroxyprogesterone Acetate			
10735	Masone-D 0004389	Masone-D 0004390	6/8/2001	Agenda - Femhrt Advocacy Network Speaker Training Program June 8-10, 2001, The Fairmont Mirama, Santa Monica, CA			
10736	NDA-PRO 0007481	NDA-PRO 0007482	3/9/1989	The Upjohn Company Regulatory Affairs Minutes, Meeting With John P. Hunt On Provera Micronization			
10737	NDA-PRO 0007483	NDA-PRO 0007484	3/15/1989	Studies for Biopharmaceutics Section of NDA for Medroxyprogesterone Acetate and Conjugated Estrogens Combination Package			
10738	NDA-PRO 0007540	NDA-PRO 0007547	1/27/1989	The Effects of Estrogen only and Estrogen and PROVERA® on The Lipid Profiles of Postmenopausal Women			
10739	NDA-PRO 0012854	NDA-PRO 0012870	5/3/1984	PROVERA® (Medroxyprogesterone Acetate) Reformulation of the 2.5 mg and 10 mg Tablets			
10740	NDA-PRO 0070504	NDA-PRO 0070509	2/24/1989	Letter to FDA re: supplements for NDA 11-839 Provera tablets			
10741	NDA-PRO 0103230	NDA-PRO 0103278	8/31/1989	Clinical Data Unpublished re: Comparative Hormone Therapy in the Menopausal Syndrome. PROVERA Versus Combination Therapy.			
10742	Oliphant-T 0000001	Oliphant-T 0000020	7/11/2003	Email with attached list of clinical studies for Provera			
10743	Polvani-F 0002203	Polvani-F 0002210	00/00/1998	Menopausal Symptom Control And Side-Effects On Continuous Estrone Sulfate And Three Doses Of Medroxyprogesterone Acetate			
10744	Quinn-S 0000491	Quinn-S 0000515	3/26/2004	Email re: Statistical Report 362			
10745	RM_AA 0101770	RM_AA 0101771	7/23/1990	Minutes of the Operating Team Meeting: Estrogen Plus PROVERA FDA Advisory Meeting; DEPO: Schoenfeld, Michael 8/03/2007 EX 15			
10746	RM_AA 0102111	RM_AA 0102326	6/20/1991	Transcript of Proceedings - Dept. of Health & Human Svcs Public Health Svcs FDA - Fertility & Maternal Health Drugs Advisory Committee Workshop on Current Status of Combined Hormone Replacement Therapy			
10747	RM_AA 0102328	RM_AA 0102575	6/21/1991	Dept. of Health & Human Svcs Public Health Svcs FDA - Fertility & Maternal Health Drugs Advisory Committee Workshop on Current Status of Combined Hormone Replacement Therapy			
10748	RM_AA 0153914	RM_AA 0153923	4/6/1995	Memo re: PEPI Trial Question/Answer			
10749	RM_AA 0208634	RM_AA 0208712	8/23/1994	Technical Report: A Randomized Prospective Controlled Double Blind Parallel Comparative Study to Determine the Effects of Two Estrogens on the Quality of Life in Post-Menopausal Women			
10750	RM_AA 0318455	RM_AA 0318457	12/2/1986	Letter to Betsy Roof, M.D. re: Provera Osteoporosis Study			
10751	RM_AA 0318470	RM_AA 0318470	4/25/1986	Letter to Betsy Roof, M.D. re: IND study 21,260			
10752	RM_AA 0318471	RM_AA 0318471	4/24/1986	Letter to Betsy Roof, M.D. E6676			
10753	RM_AA 0318668	RM_AA 0318673	2/22/1988	Memo with attached copy of the protocol for TR Code No: 9153—88—1, Continuous Estrogen/Progestin Therapy in Menopause			
10754	RM_AA 0318674	RM_AA 0318681	2/15/1988	Technical Report: Continuous Estrogen/Progestin Therapy in Menopause			
10755	RM_AA_0021250	RM_AA_0021251	2/21/2000	Letter to Dr. Superko closing his study Re: "Investigation of Possible Genetic Determinants of Lipoprotein Changes Induced by Post-Menopausal Hormone Replacement Therapy (HRT)", protocol M154 10/0213.			
10756	RM_NY_MOPS 0068864	RM_NY_MOPS 0068919	1/7/1988	Letter to FDA re: Amendment #4 of IND 13,530 w/Clinical and Protocol Amendments			
10757	RM_NY_MOPS 0069413	RM_NY_MOPS 0069428	6/7/1989	Letter to FDA re: Amendment #14 of IND 13,530 w/Clinical and Informational Amendments			
10758	RM_NY_MOPS 0070202	RM_NY_MOPS 0070229	5/4/1990	Letter to FDA re: Amendment #19 of IND 13,530 to include 2 Technical Reports; DEPO; Schoenfeld, Michael 8/03/2007 EX 3			
10759	RM_NY_MOPS 0070288	RM_NY_MOPS 0070319	9/11/1992	Technical report: The Treatment of Menopausal Patients with Combined Estrogen and Progestin Therapy			
10760	RM_NY_MOPS 0158897	RM_NY_MOPS 0158935		Tabular Summary of Animal Toxicology Studies on Medroxyprogesterone Acetate and ADME Studies in Humans with Medroxygesterone Acetate			
10761	RM_NY_MOPS 0159814	RM_NY_MOPS 0159814	9/13/1988	Technical report: Combined Premarin Plus PROVERA® Tablets for the Treatment of Menopause			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10762	RM_NY_MOPS 0190074	RM_NY_MOPS 0190104	9/8/1995	Upjohn Worldwide Advisory Board on Women's Healthcare June 16-18, 1985, Washington DC			
10763	RM_NY_MOPS 0269258	RM_NY_MOPS 0269259	12/13/1995	Memo re: Provera Prescription Date 1980-1984			
10764	RM_NY_MOPS 0307240	RM_NY_MOPS 0307267	06/00/1997	Draft of Statistical Report: A Study of Endometrial Histology and Lipid Changes Over 12 Months Associated with Continuous Equine Estrogens and Continuous Medroxyprogesterone Acetate Hormone Replacement Therapy			
10765	RM_NY_MOPS 0373639	RM_NY_MOPS 0373823	7/19/1982	DEPO: Austin, Donald 03/12/09 EX 3 & Schoenfeld, Michael 8/03/2007 EX 2; Long-term Depo-Provera Study in Dogs			
10766	VOLPE-G-0002065	VOLPE-G 0002066	5/23/1989	Technical report: The Treatment of Menopausal Patients with Combined Estrogen and Progestin Therapy			
10767	VOLPE-G 0002610	VOLPE-G 0002846	1/29/1996	Technical report: subject comparison of serum oestrogen & progestagen bioavailability following single doses of estropipate			
10768	VOLPE-G 0004856	VOLPE-G 0004862		Synopsis of 9/11/92 report: The Treatment of Menopausal Patients with Sequential Combined Estrogen and Progestin Therapy			
10769	VOLPE-G 0004903	VOLPE-G 0004904	10/1/1999	Email re: Provera sequential HRT claim: DEPO: Schoenfeld, Michael 8/03/2007 EX 13			
10770	VOLPE-G 0005019	VOLPE-G 0005021	3/15/1989	Memo re: meeting with John Hunt on Provera micronization; DEPO: Schoenfeld, Michael 8/03/2007 EX 14			
10771	VOLPE-G 0005026	VOLPE-G 0005026	4/26/1988	MEMO re: Provera micronization labeling problem			
10772	VOLPE-G 0000969	VOLPE-G 0001016	9/11/1992	The Treatment of Menopausal Patients with Sequential Combined Estrogen and Progestin Therapy			
10773	Widlitz-M 0000124	Widlitz-M 0000126	2/15/2002	Email and Final Investigator Letter from Pfizer re: serious adverse event for participants in a study of norethindrone acetate / ethinyl estradiol (protocol number 0376-42 1)			
10774	Widlitz-M 0000401	Widlitz-M 0000401	9/18/2001	Email re: FEMHRT -- Potential Outlicense vs. Acquisition of non-exclusive license to WPP			
10775	Widlitz-M 0000650	Widlitz-M 0000653	1/15/2002	Email and Monthly Reports for Women's Health Group			
10776	NDA-PRO 0001475	NDA-PRO 0001475	11/19/1970	Dear Doctor letter re: Provost			
10777	NDA-PRO 0023985	NDA-PRO 0023986	7/31/1968	FDA letter to Upjohn			
10778	NDA-PRO 0028414	NDA-PRO 0028415	4/00/1979	Provera ad			
10779	RM_NY_MOPS 0189639	RM_NY_MOPS 0189644	9/13/2000	Email from M. Schoenfeld regarding breast cancer class labeling; DEPO: Schoenfeld, Michael 8/03/2007 EX 16			
10880	RM_NY_MOPS 0373824	RM_NY_MOPS 0373979		Final Report Long Term Depo-Provera Study in Dogs			
10882	ALAIMO-L-0000947	ALAIMO-L-0000948	7/12/1985	MSDS: Material Safety Data Sheet			
10900	EDWARDS-A-0002187	EDWARDS-A-0002189		YBMM FemHRT script			
10901	ENGELS-D-0000113	ENGELS-D-0000114		Detail Ad for ogen			
10902	GORDON-P-0003069	GORDON-P-0003072		"Postmenopausal Hormone Therapy and the Risk of Breast Cancer";			
10903	GULOTTA-D-0002612	GULOTTA-D-0002613		Response to Femhrt labeling question			
10904	GULOTTA-D-0000704	GULOTTA-D-0000705	7/23/2002	Email from David Wetherholt re Femhrt Medical Inquiries			
10905	GULOTTA-D-0002612	GULOTTA-D-0002613		Response to Femhrt labeling question			
10906	HUGHES-J-0001130	HUGHES-J-0001174		Depo-Provera: a highly effective contraception option with proven long-term safety			
10907	HUGHES-J-0003499	HUGHES-J-0003500		Q&A re FDA Requested HT Black Box and Labeling Changes			
10908	HUGHES-J-0003937	HUGHES-J-0003938		FDA proposed ERT/HRT class labeling with suggestions from Pharmacia and Novo Nordisk			
10909	JONES-K-0000153	JONES-K-0000237	00/00/2000	HRT Learning System			
10910	NDA-PRO 0055671	NDA-PRO 0055674	6/10/1983	Letter from Upjohn, Howard Angell, to the FDA			
10911	NDA-PRO 0024068	NDA-PRO 0024094	2/1/1966	Upjohn Supplement to NDA 11-839			
10912	NDA-PRO 0023985	NDA-PRO 0023986	7/31/1968	FDA letter			
10913				Approval of P for menopausal use is removed			
10914	NDA-PRO 0020816	NDA-PRO 0020817	4/14/1971	Letter from Upjohn to FDA			
10915	KENNALLY-W-0000010	KENNALLY-W-0000010	10/30/1980	Reprint "Estrogen After the Menopause"			
10916			00/00/1981	Beagle Dog Warning			
10917				ACOG technical bulletin			
10918	NDA-PRO 0000200	NDA-PRO 0000200	9/20/1994	Upjohn memo from K.B. Haas			
10919	RM_NY_MOPS 0103384	RM_NY_MOPS 0103390	3/00/1985	Provera Ad - the other half of hormone therapy			
10920	NDA-PRO 0011671	NDA-PRO 0011982	4/7/1986	Upjohn filed another application with FDA requesting approval for use with E			
10921	HUGHES-J-0000254	HUGHES-J-0000254	4/26/1988	Upjohn Statistical Report for Protocol 80-01			
10922			1/12/1989	Progestin labeling guideline			
10923	NDA-PRO 0002025	NDA-PRO 0002025	10/30/1990	Letter from FDA to Upjohn re S-55 Supplement Blister pack of 28 pills of Provera			
10924	RM_AA 0101745	RM_AA 0101752	8/2/1990	Letter from The Degge Group to Upjohn			
10925				Hormone Replacement Therapy Highlights from the Sixth International Congress on Menopause			
10926			12/17/1990	The Degge Group: Progestins and Breast Cancer: An Epidemiologic Review			
10927	RM_AA 0154266	RM_AA 0154268	6/23/1991	FDA Advisory Committee Summary Minutes			
10928	RM_AA 0102049	RM_AA 0102069	6/18/1991	The Upjohn Company Position Paper			
10929			2/00/1991	The Provera Press Newsletter 02/91			
10930	NDA-PRO 0001867		1/28/1992	FDA Guidance document for E and P			
10931	NDA-PRO 0001867	NDA-PRO 0001872	1/28/1992	FDA Guidance document for E and P (complete copy)			
10932			3/00/1992	Degge Group paper - published in Fertility and Sterility			
10933	NDA-PRO 0000052	NDA-PRO 0000052	4/13/1992	Email version of FDA contact sheet			
10934	ENGELS-D-0000411	ENGELS-D-0000416		Potential Physician Questions about Provera following a detail of Ogen			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
10935	ENGELS-D-0000410	ENGELS-D-0000410	2/9/1994	Internal Memo re Progestin Questions- Revision			
10936	ENGELS-D-0000437	ENGELS-D-0000440	2/16/1994	The Best of the Ogen Practice Details from Ogen Launch Conference			
10937				Sanford study			
10938				Merger: Corporation is now called "Pharmacia & Upjohn"			
10939	LEWIS-R-0000583	LEWIS-R-0000597	3/25/1996	Provera Tablets 5-Year Safety Update			
10940	ENGELS-D-0000656	ENGELS-D-0000657	4/00/1996	Provera ad "Restoring the Hormonal Balance"			
10950	NDA-PRO 0002167	NDA-PRO 0002167	7/31/1997	Upjohn submits application for approval of E+P			
10951	NDA-PRO 0000007	NDA-PRO 0000008	9/16/1997	FDA Telephone Contact			
10952			12/1/1998	21CFR – Off Label Use			
10953	NDA-PRO 0001545	NDA-PRO 0001546	8/4/1998	Provera gets approval for use with E			
10954	HUGHES-J-0000252	HUGHES-J-0000253	2/4/2000	Adverse Event Form for MPA			
10955	LEWIS-R-0000614	LEWIS-R-0000616	2/11/2000	Final Report - Evaluation of Endometrial and Menopausal Changes in Women with Breast Cancer or Adjuvant Tamoxifen with/without MPA			
10956	HUGHES-J-0005544	HUGHES-J-0005545	08/00/2000	FDA letter to Novo Nordisk re Activella NDA			
10957			7/15/2004	Merger with Monsanto – Corporation is called only "Pharmacia"			
10958	LEWIS-R-0000556	LEWIS-R-000572	3/9/2001	Provera Product Safety Update Report			
10959	HUGHES-J-0002341	HUGHES-J-0002357	3/9/2001	Provera Product Safety Update Report			
10960	JONES-K-0000315	JONES-K-0000316	5/7/2001	Email re HRT Helps Maintain Sexual Function in Older Women			
10961	JONES-K-0000323	JONES-K-0000324	5/20/2001	Email re Ground Round talk to HRT			
10962	EDWARDS-A-0001544	EDWARDS-A-0001546	7/25/2001	Email re Sales Training Competitive Backgrounder			
10963	EDWARDS-A-0002757	EDWARDS-A-0002807	6/13/2001	FEMHRT POA2 PPT			
10964	Widlitz-M 0000008	Widlitz-M 0000009	8/21/2001	Upjohn email re spreadsheet			
10965	EDWARDS-A-0002374	EDWARDS-A-0002441	10/8/2001	FemHRT PPT			
10966	HUGHES-J-0001818	HUGHES-J-0001831	12/20/2001	Clinical Expert Report - Provera			
10967	HUGHES-J-0001787	HUGHES-J-0001817		Clinical Expert Statement - Farlutal			
10968	Widlitz-M 0000001	Widlitz-M 0000005	2/12/2002	Email re: FemHrt adverse event			
10969	EDWARDS-A-0002367	EDWARDS-A-0002372	3/15/2002	Agreement between Pfizer and Nanette Santoro, M.D.			
10970	GULOTTA-D-0001303	GULOTTA-D-0001329	4/9/2002	Email re FemHRT dossier			
10971	ENGELS-D-0000872	ENGELS-D-0000911	4/24/2002	Email re Provera product profile			
10972	GULOTTA-D-0001037	GULOTTA-D-0001046	5/14/2002	Email re breast cancer risk letter			
10973	GULOTTA-D-0001998	GULOTTA-D-0002004	6/6/2002	Email re HRT letters			
10974	HERSHBERGER-K-0000063	HERSHBERGER-K-0000065		Letter to Femhrt sales rep re Managing the NIH Press Release on WHI			
10975	HERSHBERGER-K-0000071	HERSHBERGER-K-0000071		Press Releases Issued in Response to WHI Decision			
10976	GULOTTA-D-0000083	GULOTTA-D-0000087	7/9/2002	Email re JAMA article on WHI			
10977	GULOTTA-D-0000178	GULOTTA-D-0000180	7/9/2002	Email re FemHRT and WHI			
10978	GULOTTA-D-0002090	GULOTTA-D-0002090	7/10/2002	E-mail re retire HRT letters			
10979	LEWIS-R-0001511	LEWIS-R-0001513	7/11/2002	Australian TGA Report on WHI findings			
10980	GULOTTA-D-0000031	GULOTTA-D-0000037	7/26/2002	Email re Backgrounder to Managing WHI study questions and related issues			
10981	GULOTTA-D-0000706	GULOTTA-D-0000707	7/29/2002	Email re FEMHRT Medical Inquiries			
10982	HUGHES-J-0005704	HUGHES-J-0005708		DRAFT Provera labeling			
10983	HUGHES-J-0001996	HUGHES-J-0002013		Summary of Changes to Provera Product Monograph			
10984	LEWIS-R-0000625	LEWIS-R-0000627		Handwritten Notes re WHI			
10985	GULOTTA-D-0000754	GULOTTA-D-0000767	8/12/2002	Email re FemHRT PPT Presentation			
10986	HUGHES-J-0004142	HUGHES-J-0004148		Proposed Wording re Ovarian Cancer Study			
10987	GULOTTA-D-0000731	GULOTTA-D-0000731	8/5/2002	Email re medical letters			
10988	MCELROY-P-0001010	MCELROY-P-0001010	8/6/2002	Email re Package Insert			
10989	EDWARDS-A-0002442	EDWARDS-A-0002570	8/23/2002	FemHRT PPT - WHC Satellite Broadcast			
10990	LEWIS-R-0000286	LEWIS-R-0000287	9/5/2002	Email re FDA Correspondence received concerning WHI			
10991	MOORE-D-0004157	MOORE-D-0004165	9/12/2002	Breast Cancer/Cardiovascular Reconciliation PPT			
10992	ENGELS-D-0001579	ENGELS-D-0001581	10/25/2002	Email re Comments on Dear HCP Letters for Provera			
10993	ENGELS-D-0001327	ENGELS-D-0001329	10/28/2002	Email re HCP letter for Provera			
10994	HUGHES-J-0004789	HUGHES-J-0004791	1/8/2003	FDA letter to Upjohn re Estring NDA			
10995	MCELROY-P-0000543	MCELROY-P-0000544	1/14/2003	Email re MPA			
10996	HUGHES-J-0004986	HUGHES-J-0004986	1/24/2003	Email re Estring and FDA			
10997	HUGHES-J-0004985	HUGHES-J-0004985	1/27/2003	Email re Estring and FDA Response			
10998	MAYSTEAD-K-0000090	MAYSTEAD-K-0000092	1/29/2003	Email re Product Info from S&OP Meeting			
10999	HUGHES-J-0003496	HUGHES-J-0003498	2/4/2003	MPA Core Data Sheet			
11000	HUGHES-J-0003496	HUGHES-J-0003498	2/4/2003	Amendment to Supplement # 005 ERT/HRT Labeling Changes Activella NDA 20,907			
11001	EDWARDS-A-0000521	EDWARDS-A-0000523	3/21/2003	[Femhrt, Plizer's HRT]			
11003	HUGHES-J-0000964	HUGHES-J-0000970	4/28/2003	Implications of the Women's Health Initiative: Making Hormone Therapy Selection Based on Progestin Considerations			
11004	LEWIS-R-0001395	LEWIS-R-0001434	4/28/2003	Safety Statement For: Medroxyprogesterone Acetate (Provera Low-Dose)			
11005	LADENHEIM-D-0000111	LADENHEIM-D-0000126	5/8/2003	Proposed Questions for FDA June 11 Meeting / Responses			
11006	LEWIS-R-0001367	LEWIS-R-0001394	6/25/2003	Safety Statement For: Medroxyprogesterone Acetate (Provera Low-Dose)			
11007	HUGHES-J-0005720	HUGHES-J-0005725	7/00/2003	Clinical Expert Statement For: Medroxyprogesterone Acetate (Provera Low-Dose)			
11008	LEWIS-R-0001102	LEWIS-R-0001102	9/11/2002	Provera Study (CTN M5410 0384) the Effects of Hormone Replacement Therapy on Large Artery Stiffness and Myocardial Ischaemia in Post Menopausal Women.			
11009	EDWARDS-A-0000105	EDWARDS-A-0000139	4/29/2004	NPWH Presentation			
11010	RM_NY_MOPS 0379103	RM_NY_MOPS 0379377	5/15/1968	Upjohn Supplement to NDA 14-412			
11011	CHIRBY-D 0002197	CHIRBY-D 0002198	7/21/1992	Internal Memo re HRT Scientific Review			
11012	CHIRBY-D 0002199	CHIRBY-D 0002200		Attachment 1			
11013	PATEL-M-0007576	PATEL-M-0007584	8/21/1989	Upjohn letter to Sales Directors re NEJM article			
11014	CHIRBY-D-0000124	CHIRBY-D-0000125	2/21/1995	Upjohn letter to FDA re changes in protocol for IND 45, 949			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
11015	CHIRBY-D-0001040	CHIRBY-D-0001040	7/30/1959	FDA to Upjohn re NDA 11-839			
11016	CHIRBY-D-0001041	CHIRBY-D-0001041	5/22/1961	FDA to Upjohn re NDA 11-839			
11017	CHIRBY-D-0001911	CHIRBY-D-0001921		Handwritten Notes			
11018	CHIRBY-D-0001934	CHIRBY-D-0001937		Handwritten Notes			
11019	CHIRBY-D-0002030	CHIRBY-D-0002102	9/25/1995	Technical Report: Continuous Oestrone Sulphate and Medroxyprogesterone Acetate Hormonal Replacement Therapy - A Study of Endometrial, Lipid, Bone Density, and Bleeding Pattern Response Over Two years			
11020	CHIRBY-D-0009411	CHIRBY-D-0009411		FDA letter to Arnold & Porter			
11021	CHIRBY-D-0009633	CHIRBY-D-0009635	10/30/2000	FDA Telephone Contact re Estring			
11022	CHITTY-D-0000442	CHITTY-D-0000443	10/30/2002	FDA letter to Upjohn re Estring and Provera NDA			
11023	CHITTY-D-0000684	CHITTY-D-0000685	11/14/2002	Pharmacia letter to FDA re NDA 11-839			
11024	CHITTY-D-0001000	CHITTY-D-0001005	1/8/2003	FDA letter to Upjohn re supplements to NDA			
11025	CHITTY-D-0001151	CHITTY-D-0001174	1/14/2003	FDA Guidance for Noncontraceptive Estrogen Drug Products			
11026	DETERS-M-0000017	DETERS-M-0000083	1/22/1997				
11027	DETERS-M-0000116	DETERS-M-0000126	11/5/2001	Upjohn letter to FDA re Depo-Provera NDA			
11028	DETERS-M-0001939	DETERS-M-0002007	11/30/1993	Depo-Provera IND			
11029	DETERS-M-0003948	DETERS-M-0004330	6/2/1977	Depo-Provera IND			
11030	DETERS-M-0004332	DETERS-M-0004653	10/1/1980	Depo-Provera IND			
11031	DETERS-M-0004847	DETERS-M-0004860		Depo-Provera IND			
11032	ENGELS-D-0028943	ENGELS-D-0028943	8/15/2004	Email re PDR Expenses			
11033	JONES-J-0000042	JONES-J-0000047	12/18/2002	Email re Dear HCP Letter			
11034	NDA-PRO 0000551	NDA-PRO 0000552	6/2/1961	Department of Health, Education, and Welfare Food and Drug Administration DESI 11839 and DESI 9238 Docket No. FDC-D-662 NDA 9-238 Etc. Medroxyprogesterone Acetate Norethindrone Norethindrone Acetate Progesterone Dydrogesterone and Hydroxyprogesterone Caproate Follow-up			
11035	NDA-PRO 0020638	NDA-PRO 0020648	10/4/1973	Special New Drug Application Supplement - Changes Being Effected. NDA 12-541/S-014, S-016, S-019 and S-020 Depo-Provera (Medroxyprogesterone Acetate) Sterile Aqueous Solution			
11036	NDA-PRO 0020781	NDA-PRO 0020782	3/28/1972	The Upjohn Company General Control Procedure Automated Single Tablet - UV Assay			
11037	NDA-PRO 0024028	NDA-PRO 0024037	1/26/1965	Compressed Tablets Provera (Medroxyprogesterone Acetate)			
11038	NDA-PRO 0027435	NDA-PRO 0027435	11/1/1990	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use NDA No. N11839			
11039	NDA-PRO 0027436	NDA-PRO 0027437	08/00/1990	In Menopausal Therapy when Unscheduled Bleeding Occurs with Estrogen.... Make Provera the Other Half of Hormone Replacement Therapy			
11040	NDA-PRO 0027455	NDA-PRO 0027455	9/18/1990	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use NDA No. N11839			
11041	NDA-PRO 0027456	NDA-PRO 0027470	07/00/1990	Issues in Menopausal Hormone Replacement Therapy			
11042	NDA-PRO 0027471	NDA-PRO 0027492	09/00/1989	Prevention and Management of Cardiovascular Risk in Women			
11043	NDA-PRO 0027493	NDA-PRO 0027493	05/00/1987	Compliance with Hormone Therapy			
11044	NDA-PRO 0027494	NDA-PRO 0027495	06/00/1999	Provera Brand of Medroxyprogesterone Acetate Tablets, USP			
11045	NDA-PRO 0027496	NDA-PRO 0027496		Compliance with Hormone Therapy			
11046	NDA-PRO 0027497	NDA-PRO 0027500	07/00/1990	Issues in Menopausal Hormone Replacement Therapy			
11047	NDA-PRO 0027501	NDA-PRO 0027505	07/00/1990	Provera Brand of Medroxyprogesterone Acetate Tablets, USP			
11048	NDA-PRO 0027507	NDA-PRO 0027507	9/14/1990	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use NDA No. N11839			
11049	NDA-PRO 0027508	NDA-PRO 0027508		Provera Tablets (Medroxyprogesterone Acetate)			
11050	NDA-PRO 0027509	NDA-PRO 0027517	07/00/1990	Provera Tablets (Medroxyprogesterone Acetate)			
11051	NDA-PRO 0027518	NDA-PRO 0027520	07/00/1990	Provera Brand of Medroxyprogesterone Acetate Tablets, USP			
11052	NDA-PRO 0027771	NDA-PRO 0027771	4/10/1985	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use NDA No. N11839			
11053	NDA-PRO 0027772	NDA-PRO 0027778		The Other Half of Estrogen Replacement Therapy. Provera 10 Mg Tablets for 10 Days (Medroxyprogesterone Acetate Tablets)			
11054	NDA-PRO 0027779	NDA-PRO 0027783	03/00/1985	Provera 10 Mg Tablets for 10 Days (Medroxyprogesterone Acetate Tablets)			
11055	NDA-PRO 0027870	NDA-PRO 0027874	06/00/1983	Estrogen Replacement Therapy			
11056	NDA-PRO 0027904	NDA-PRO 0027904	12/8/1982	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
11057	NDA-PRO 0027905	NDA-PRO 0027914	10/00/1982	Menopausal Management			
11058	NDA-PRO 0027915	NDA-PRO 0027925	00/00/1982	Dysfunctional Bleeding in the Perimenopausal Woman			
11059	NDA-PRO 0027926	NDA-PRO 0027929		Provera Tablets (Medroxyprogesterone Acetate Tablets, USP)			
11060	NDA-PRO 0027930	NDA-PRO 0027930		Management Alternatives for Three Types of Postmenopausal Women			
11061	NDA-PRO 0027931	NDA-PRO 0027931	11/00/1982	Provera Tablets Medroxyprogesterone Acetate Tablets, USP 2.5 and 10 Mg			
11062	NDA-PRO 0027932	NDA-PRO 0027935	03/00/1982	Provera Tablets (Medroxyprogesterone Acetate Tablets, USP)			
11063	NDA-PRO 0027937	NDA-PRO 0027937	9/29/1982	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
11064	NDA-PRO 0027947	NDA-PRO 0027949	05/00/1982	Provera Tablets (Medroxyprogesterone Acetate Tablets, USP)			
11065	NDA-PRO 0027950	NDA-PRO 0027953	03/00/1982	Provera Tablets (Medroxyprogesterone Acetate Tablets, USP)			
11066	NDA-PRO 0028412	NDA-PRO 0028412	3/14/1979	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 310.300 (B)(3) and 431.60(B)(3)) NDA Number N11839			
11067	NDA-PRO 0028413	NDA-PRO 0028413		[Photograph]			
11068	NDA-PRO 0028416	NDA-PRO 0028419	11/00/1978	Provera Tablets (Medroxyprogesterone Acetate Tablets, USP)			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
11069	NDA-PRO 0028692	NDA-PRO 0028692	12/22/1976	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 310.300 (B)(3) and 431.60(b)(3)) NDA Number N11839			
11070	NDA-PRO 0028693	NDA-PRO 0028694	00/00/1977	Abnormal Uterine Bleeding: Progesterone Replacement... to Oppose Unopposed Estrogen			
11071	NDA-PRO 0028695	NDA-PRO 0028695	01/00/1977	To Control Abnormal Uterine Bleeding in the Absence of Organic Pathology Provera 10 Mg Medroxyprogesterone Acetate Tablets, U.S.P., Upjohn			
11072	NDA-PRO 0028696	NDA-PRO 0028698	08/00/1976	Tablets Provera (Medroxyprogesterone Acetate Tablets, U.S.P.)			
11073	NDA-PRO 0028887	NDA-PRO 0028887	12/11/1970	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11074	NDA-PRO 0028888	NDA-PRO 0028901	02/00/1971	During the Menopause: a Potential Problem			
11075	NDA-PRO 0028902	NDA-PRO 0028902	11/20/1970	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11076	NDA-PRO 0028903	NDA-PRO 0028903	11/19/1970	[Recent Discontinuance of Provest]			
11077	NDA-PRO 0028904	NDA-PRO 0028904	11/5/1970	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11078	NDA-PRO 0028905	NDA-PRO 0028915	00/00/1970	[Tips to Manage the Symptoms of the Menopause]			
11079	NDA-PRO 0028939	NDA-PRO 0028939	8/21/1970	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.12(b)(3) and 146.14(b)(3)) NDA Number N11839			
11080	NDA-PRO 0028940	NDA-PRO 0028942	00/00/1970	For Act 3, the Menopause... Bleeding according to Plan New Feminone 0.05 Mg. Tablets Ethinyl Estradiol, Upjohn Upjohn's Femininity Factor' to Help Manage the Symptoms of the Menopause Provera 10 Mg. Tablets Medroxyprogesterone Acetate			
11081	NDA-PRO 0028943	NDA-PRO 0028947	08/00/1970	Provera Tablets-2.5 & 10 Mg. (Medroxyprogesterone Acetate, Upjohn)			
11082	NDA-PRO 0028998	NDA-PRO 0028998	3/11/1970	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11083	NDA-PRO 0028999	NDA-PRO 0028999		The Glamorous Grandmother"			
11084	NDA-PRO 0029000	NDA-PRO 0029000	00/00/1970	Menopause Estrogen Replacement Therapy May Replace One Problem with Another			
11085	NDA-PRO 0029001	NDA-PRO 0029005		Provera Tablets 2.5 & 10 Mg. (Medroxyprogesterone Acetate, Upjohn)			
11086	NDA-PRO 0029006	NDA-PRO 0029006	2/12/1970	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11087	NDA-PRO 0029007	NDA-PRO 0029009	00/00/1970	The Glamorous Grandmother"			
11088	NDA-PRO 0029010	NDA-PRO 0029014	2/00/1970	Provera Tablets 2.5 & 10 Mg. (Medroxyprogesterone Acetate, Upjohn)			
11089	NDA-PRO 0029024	NDA-PRO 0029024	9/17/1969	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11090	NDA-PRO 0029029	NDA-PRO 0029033		Provera Tablets 2.5 & 10/Mg. (Medroxyprogesterone Acetate, Upjohn)			
11091	NDA-PRO 0029034	NDA-PRO 0029037		The Case of the Glamorous Grandmother'..."			
11092	NDA-PRO 0029038	NDA-PRO 0029042		Provera Tablets 2.5 & 10/Mg. (Medroxyprogesterone Acetate, Upjohn)			
11093	NDA-PRO 0029043	NDA-PRO 0029046		The Case of the Glamorous Grandmother'..."			
11094	NDA-PRO 0029047	NDA-PRO 0029051		Provera Tablets 2.5 & 10/Mg. (Medroxyprogesterone Acetate, Upjohn)			
11095	NDA-PRO 0029052	NDA-PRO 0029052	9/3/1969	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11096	NDA-PRO 0029057	NDA-PRO 0029060	09/00/1969	Provera 2.5 Mg. and 10 Mg. (Medroxyprogesterone Acetate, Upjohn)			
11097	NDA-PRO 0029062	NDA-PRO 0029062	8/15/1969	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11098	NDA-PRO 0029070	NDA-PRO 0029074		Provera Tablets 2.5 & 10/Mg. (Medroxyprogesterone Acetate, Upjohn)			
11099	NDA-PRO 0029077	NDA-PRO 0029077	6/11/1969	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11100	NDA-PRO 0029083	NDA-PRO 0029087	07/00/1969	Tablets Provera (Medroxyprogesterone Acetate, Upjohn)			
11101	NDA-PRO 0029088	NDA-PRO 0029093		[Physiologic Endocrine Internal Environment, Progesterational Withdrawal Bleeding, Breakthrough Bleeding, Endometrial Hyperlasia, the Menopausal Woman and Sex Hormones and Liver Function, Adrenocortical Function, Physical Examination, Placebo Therapy, Uterine Bleeding]			
11102	NDA-PRO 0029094	NDA-PRO 0029097		Tablets Provera 2.5 & 10 Mg. (Medroxyprogesterone Acetate, Upjohn)			
11103	NDA-PRO 0029110	NDA-PRO 0029110	4/10/1969	[Illegible] of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11104	NDA-PRO 0029118	NDA-PRO 0029122		Tablets Provera (Medroxyprogesterone Acetate, Upjohn)			
11105	NDA-PRO 0030749	NDA-PRO 0031111	8/13/1987	NDA 11-819 Provera Tablets Annual Report			

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
11106	NDA-PRO 0032481	NDA-PRO 0032686		Transmittal of Annual Reports for Drugs for Human Use (21 CFR 314.81) Distribution Data NDA 11-839 Provera Tablets (Medroxyprogesterone Acetate) Labeling Provera Brand of Medroxyprogesterone Acetate Tablets, USP Manufacturing and Control Information Provera Tablets NDA 11-839 (Medroxyprogesterone Acetate) Update Summary Annual Update For: Provera Tablets NDA #11-839 Nonclinical Data Nonclinical Laboratory Data Technical Report Provera (U-8839) and Duramed Conjugated Estrogens: A 3-Week Oral Estrous Cycle Interference Study in the Rat Technical Report Provera and Ogen: A Three-Week Estrous Cycle Interference Study in the Rat Clinical Data Scientific Program and Abstracts 39th Annual Meeting Technical Report The Effects of the Treatment of Menopausal Patients with Sequential and Combined Estrogen and Progestin Therapy on Coagulation Parameters Technical Report Symptomatic Effects of Continuous Oestrogen Progesterone Replacement Therapy in Post Menopausal Women Assessed in a Double Blind Randomised Controlled Two Year Study. Prevention of Postmenopausal Osteoporosis a Comparative Study of Exercise, Calcium Supplementation, and Hormone-Replacement Therapy Technical Report A Study to Assess the Effect of Provera 10 Mg Given Once Daily for 28 Days on Mineral Homeostasis in Post-Menopausal Females Leeds University Medical School Department of Obstetrics & Gynaecology Volunteer Informed Consent: Protocol 9261 Provera and Mineral Homeostasis Study			
11107	NDA-PRO 0032898	NDA-PRO 0033525	8/10/1990	Transmittal of Annual Reports for Drugs for Human Use (21 CFR 314.81) NDA or ANDA Number N11839			
11108	PATEL-M 0004492	PATEL-M 0004513	4/6/1995	Interoffice Memo: PEPI Trial: Question/Answer document			
11109	RM_AA 0019509	RM_AA 0019523					
11110	RM_AA 0155906	RM_AA 0155956					
11111	RM_AA 0208634	RM_AA 0208712	8/23/1994	Upjohn Company Technical Report TR No.: 9173/94/111 Randomized Prospective Controlled Double Blind Parallel Comparative Study to Determine the Effects of Two Estrogens on the Quality of Life Post-Menopausal Women - M/5410/0344			
11112	RM_NY_MOPS 0070230	RM_NY_MOPS 0070235	5/2/1990	Letter from J Assenzo to FDA re: IND 13530, Depo-Provera Sterile Aqueous Suspension			
11113	RM_NY_MOPS 0159530	RM_NY_MOPS 0159531	5/30/1989	Letter to sales re: 1st quarter data for Provera			
11114	RM_NY_MOPS 0301790	RM_NY_MOPS 0301795	4/14/2000	Protocol Summary for Clinical Studies / Provera / Korea; DEPO: Carlson, Rodney 2/20/2007 EX 36			
11115	RM_NY_MOPS 0302410	RM_NY_MOPS 0302414	00/00/1995	Continuos Combined Peiperazine Oestrone Sulphate and Medroxyprogesterone Acetate Hormone Replacement Therapy -- A Study of Bleeding Pattern, Endometrial Response, Serum Lipid and Bone Density Changes; DEPO: Carlson, Rodney 2/20/2007 EX 40			
11116	RM_NY_MOPS 0321184	RM_NY_MOPS 0321213	6/16/1992	A Study of Endometrial Histology and Lipid Changes over 12 months associated with continuous Equine Oestrogens and continuous Medroxyprogesterone Acetate Hormone Replacement Therapy			
11117	RM_NY_MOPS 0368199	RM_NY_MOPS 0368219	1/28/1976	Long Term Intramuscular Study in Female Beagle Dogs (Final Report) submitted 01/28/1976			
11118	SVENSSON-L-0000005	SVENSSON-L-0000093	4/20/2004	Ogen Provera Studies (M54100362 & M54100363) Ogen Provera Studies Clinical Protocol Ogen/Provera, Efficacy of Continuous Hormone Replacement Therapy (HRT) on the Relief of Symptoms of Menopause Protocol Number: M/5410/0362			
11119	VOLPE-G-0002068	VOLPE-G-0002103		[Postmenopausal Condition]			
11120	VOLPE-G-0004579	VOLPE-G-0004580	11/14/2002				
11121	VOLPE-G-0004595	VOLPE-G-0004606	08/00/1998	Provera Medroxyprogesterone Acetate Tablets, USP			
11122	VOLPE-G-0004607	VOLPE-G-0004625	08/00/1998	Provera Medroxyprogesteroneacetate Tablets, USP			
11123	VOLPE-G-0004626	VOLPE-G-0004644	08/00/1998	Provera Medroxyprogesteroneacetate Tablets, USP			
11124	VOLPE-G-0004645	VOLPE-G-0004658	12/5/2002	Pharmacia Core Data Sheet Medroxyprogesterone Acetate (MPA) Injectable Suspension, Oral Suspension, Granules, and Tablets			
11125	NDA-PRO 0109410		2/12/1970	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use NDA Number N11839			
11125A	WHALEY-S-0001400	WHALEY-S-0001402					
11126	NDA-PRO 0109411	NDA-PRO 0109419	2/00/1970	The "Glamorous Grandmother"			
11127	NDA-PRO 0109462		9/3/1969	Transmittal of Advertisements and Promotional Labeling for Durgs for Human Use (21 CFR 130.13(b)(3) and 146.14(b)(3)) NDA Number N11839			
11128	NDA-PRO 0109463	NDA-PRO 0109470	00/00/1969	Estrogen...Helps Manage Symptoms of Menopause.			
11129	NDA-PRO 0111751	NDA-PRO 0111757	2/00/1971	Feminone 0.05 Mg. Tablets (Ethyl Estradiol (Upjohn), U.S.P.			
11130	NDA-PRO 0111099	NDA-PRO 0111104	1/23/1980	Transmittal of Advertisement and Promotional Labeling for Drugs for Human Use (21 CFR 310.300(b)(3) and 431.60(b)(3)) DNA Number N11839			
11131	NDA-PRO 0110840	NDA-PRO 0110854		Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use (21 CFR 310.300 (B)(3) and 431.60(b)(3)) NDA Number N11839			
11132	NDA-PRO 0110757	NDA-PRO 0110767	00/00/1982	Hormonal Therapy in the Menopause a Lecture Program			
11133	NDA-PRO 0110701	NDA-PRO 0110721	1/6/1984	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
11134	NDA-PRO 0110665	NDA-PRO 0110674	4/4/1984	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
11135	NDA-PRO 0110649	NDA-PRO 0110654	9/18/1984	Tranmittal of Advertisements and Promotional Labeling for Drugs for Human Use			EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
11136	NDA-PRO 0110617	NDA-PRO 0110629	4/10/1985	Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
11137	NDA-PRO 0110630	NDA-PRO 0110637		Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
11138	NDA-PRO 0110638	NDA-PRO 0110648		Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use			
11139	NDA-PRO 0111616		8/3/1977	Reprint, I-6165-4: "Dysfunctional Uterine Bleeding by J. V. Reyniak, MD			
11140	RM_NY_MOPS 0269258	RM_NY_MOPS 0269259	12/13/1995	Provera Prescription Data - 1980 through 1984			
11141	MERKATZ-R-0023441		5/22/1998				
11142	DUDA-RACKI-H-0000904	DUDA-RACKI-H-0000912	02/00/1991	Effect of Progestin Therapy on Cortical and Trabecular Bone: Comparison with Estrogen			
11143	RM_AA 0325443	RM_AA 0325451	12/1/1980	[Enclosed Material Relating to the Protocol from J.C. Gallagher]			
11144	RM_AA 0203979	RM_AA 0203982	6/00/1987	Efficacy of a Continuous Estrogen-Progestin Regimen in the Menopausal Patient			
11145	PATEL-M-0008050	PATEL-M-0008053	2/00/1988	Endometrial Histology and Bleeding Patterns in Menopausal Women Treated with Estrogen and Continuous or Cyclic Progestin			
11146	CHIRBY-D-0003226	CHIRBY-D-0003230	01/00/1988	Clinical and Metabolic Responses of Menopausal Women to Sequential versus Continuous Estrogen and Progestin Replacement Therapy			
11147	RM_NY_MOPS 0167078	RM_NY_MOPS 0167079	6/1/1988	Technical Report the Effects of Estrogens and a Progestogen on Coagulation and Lipid Profiles in Postmenopausal Women (Investigator T.C. Smith) Protocol No.: M54100088			
11148	RM_AA 0019830	RM-AA-0019839	7/15/1985	Coagulation and Lipid Profile - Estrogen and Provera Protocol			
11149	RM_NY_MOPS 0068943	RM_NY_MOPS 0068997	9/15/1987	IND 13,530 Depo-Provera Sterile Aqueous Suspension (Use in Menopause) Miscellaneous Studies Part 6a Protocol Announcement			
11150	RM_NY_MOPS 0269066	RM_NY_MOPS 0269077	6/00/1990	Evaluation of a Continuous Combined Low-dose Regimen of Estrogen-Progestin for Treatment of the Menopausal Patient			
11151	VOLPE-G-0013791	VOLPE-G-0013829	5/30/1989	Protocol M5410/0119: the Treatment of Menopausal Patients with Combined Estrogen and Progestin Therapy (Investigators: J.C. Gallagher, MD, Omaha, NE and L. Weinstein, MD, Tucson, AZ)			
11152	RM_NY_MOPS 0302437	RM_NY_MOPS 0302444	3/00/1993	Evaluation of Low-Dose Estrogen and Progestin Therapy in Postmenopausal Women a Double-Blind, Prospective Study of Sequential versus Continuous Therapy			
11153	RM_NY_MOPS 0302426	RM_NY_MOPS 0302431	9/1/1992	Effect of Sequential and Daily Continuous Hormone Replacement Therapy on Indexes of Mineral Metabolism			
11154	RM_NY_MOPS 0069140	RM_NY_MOPS 0069306	9/15/1987	IND 13,530 Depo-Provera Sterile Aqueous Suspension (Use in Menopause)			
11155	CHIRBY-D-0002020	CHIRBY-D-0002027		Evaluation of Low-Dose Estrogen and Progestin Therapy in Postmenopausal Women a Double-Blind, Prospective Study of Sequential versus Continuous Therapy			
11156	CHIRBY-D-0003272			Evaluation of Sequential versus Continuous Estrogen/Progestin Replacement Therapy on Uterine Bleeding Patterns and Endometrial Histology			
11157	CHIRBY-D-0003273			Comparison of Sequential versus Continuous Estrogen/Progestin Replacement Therapy on Serum Lipid Patterns			
11158	CHIRBY-D-0002028		3/20/1991	Comparison of Sequential versus Continuous Estrogen/Progestin Replacement Therapy on Serum Lipid Patterns.			
11159	RM_NY_MOPS 0069748	RM_NY_MOPS 0069759	2/22/1989	IND 13,530 Depo-Provera Sterile Aqueous Suspension (Use in Menopause)			
11160	RM_NY_MOPS 0069106	RM_NY_MOPS 0069139					
11161	RM_NY_MOPS 0069830	RM_NY_MOPS 0069836		Part 6b - Qualifications of Investigators IND #13,530 Depo-Provera Sterile Aqueous Suspension (Use in Menopause) Miscellaneous Studies Part 6b Protocol Amendment Qualifications of Investigators			
11162	RM_NY_MOPS 0069837	RM_NY_MOPS 0069843		Part 7 - Chemistry Data IND #13, 530 DEPO-Provera Sterile Aqueous Suspension (Use in Menopause) Miscellaneous Studies			
11163	RM_AA 0150048	RM_AA 0150378					
11164	RM_NY_MOPS 0302458	RM_NY_MOPS 0302493	5/31/1989	Ogen/Provera - HRT: Australia			
11165	NDA-PRO 0106079	NDA-PRO 0106085	12/12/1997	Bleeding Pattern and Endometrial Changes during Continuous Combined Hormone Replacement Therapy			
11166	GULOTTA-D-0028871	GULOTTA-D-0028888	10/5/1998	Symptom Experience of Filipino American Midlife Women			
11167	PATEL-M-0008152	PATEL-M-0008158	11/00/1994	Assessment of Less than Monthly Progestin Therapy in Postmenopausal Women Given Estrogen Replacement			
11168	NDA-PRO 0104504	NDA-PRO 0104664	9/13/1994	F. Clinical Data NDA 11-839 Provera Tablets Annual Report			
11169	RM_NY_MOPS 0070802	RM_NY_MOPS 0070886	1/28/1992	Department of Health and Human Services Investigational New Drug Application IND Number 13,530			
11170	NDA-PRO 0103977	NDA-PRO 0104029	3/21/1992	Technical Report 9153-91-02 the Effects of the Treatment of Menopausal Patients with Sequential and Copmbined Estrogen and Prostegin Therapy on Coagulation Parameters			
11171	LEWIS-R-000613		11/23/1994	Abstract/Summary of Report: 9153-94-015			
11172	RM_AA 0213979	RM_AA 0214085	7/00/1992	Clinical Protocol Protocol Summary Evaluation of Indometrial Histology and Bone Mineral Density (BMD) in Post Menopausal Women Receiving Ogen/Provera Hormone Replacement Therapy (HRT) Protocol Number: M5410/0336			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
11173	VOLPE-G-0000216	VOLPE-G-0000223	9/13/2000	Effects of Estrone Sulfate Alone or with Medroxyprogesterone Acetate on Serum Lipoprotein Levels in Postmenopausal Women			
11174	FEINER-C-0016773	FEINER-C-0016797	7/8/2004	Statistical Report for Protocol 80-01 (M5410/0363): OGEN—PROVERA® Efficacy of Sequential HRT on the Relief of Symptoms of Menopause			
11175	CHIRBY-D-0001448	CHIRBY-D-0001449	4/29/1992	The Upjohn Company Technical Report a Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial to Assess the Side Effects of Medroxyprogesterone Acetate in Hormone Replacement Therapy in Canadian Women TR No. 917392009			
11176	RM_AA 0046518	RM_AA 0046554	6/22/1992	Search Report Estrogen Replacement Therapy and Depression			
11177	RM_AA 0151023	RM_AA 0151043	2/26/1996	memo re: expo exemption			
11178	CHIRBY-D-0000223	CHIRBY-D-000224	07/00/1992	Clinical Protocol Protocol Summary Protocol Number: M/5410/0367 Ogen/Premarin/Provera a Study of the Effects of Three Different Regimens of Sequential Hormone Replacement Therapy (HRT)			
11179	LIGGERI-E-0002085	LIGGERI-E-0002087	9/11/2002				
11180	RM_NY_MOPS 0302375	RM_NY_MOPS 0302407	2/10/1992	Statistical Analysis of Menopause Data			
11181	RM_NY_MOPS 0075724	RM_NY_MOPS 0075962	8/12/1998	IND 45,949 Provera Tablets Hormone Replacement Therapy Information Amendment Clinical Data			
11182	PATEL-M-0004581		2/17/1988	Technical Report Continuous Estrogen/Progestin Therapy in Menopause Investigator: Janet Sheperd, M.D. Dept. of Obstetrics and Gynecology University of South Alabama Mobile, Alabama			
11183	RM_NY_MOPS 0075597	RM_NY_MOPS 0075610	6/2/2000	Serial No. 045 IND 45,949 Provera Tablets Hormone Replacement Therapy Information Amendment Clinical Data			
11184	VOLPE-G-0004594		1/3/2003	[Email without Message]			
11185	RM_NY_MOPS 0075572	RM_NY_MOPS 0075585	7/31/2000	Serial No. 046 IND 45,949 Provera Tablets Hormone Replacement Therapy Information Amendment Clinical Data			
11186	RM_NY_MOPS 0075586	RM_NY_MOPS 0075596	11/23/1999	Continous Low-Dose Estrogen/Progestin in Elderly Women			
11187	CHIRBY-D-0003055	CHIRBY-D-0003061	11/19/1992	[Proportionality Study Using an Extracted Radioimmunoassay]			
11188	AYERS-A-0008981	AYERS-A-0009009					
11189	CHIRBY-D-0009627	CHIRBY-D-0009628	9/14/2000	ERT/HRT Class Labelling: Working Group			
11190	VOLPE-G-0006229	VOLPE-G-0006231	9/5/2000	ERT/HRT Class Labelling Counterproposal			
11191	VOLPE-G-0006225	VOLPE-G-0006225	9/21/2000	email re: class labeling			
11192	VOLPE-G-0006226	VOLPE-G-0006227		class labeling counter proposal			
11193	PATEL-M 0010269	PATEL-M 0010271		Letter from Dpt of Health to Upjohn RE: withdrawal of approval of new drug application			
11200	PATEL-M 0010269	PATEL-M 0010271	6/28/1971	Letter from Dpt of Health to Upjohn RE: withdrawal of approval of new drug application			
11201							
11202			8/4/1998	Medical Officer's Review			
11203			2/00/2007	2007 Provera Label			
11205	NDA-PRO 0029006	NDA-PRO 0029009	2/12/1970	transmittal of advertising materials			
11206	DUDA-RACKI-H-0001128	DUDA-RACKI-H-0001186	7/00/1992	Title: New Indication Candidate Proposal for Provera Tablets for HRT			
11207				Upjohn 10K for 1994			
11208				Upjohn 10K for 1995			
11209				Upjohn 10K for 1996			
11210				Upjohn 10K for 1997			
11211	BERELOWITZ-M-0000009	BERELOWITZ-M-0000032	4/16/2004	Oporia Osteo Treatment Study			
11212	WHALEY-S 0001400	WHALEY-S 0001402	8/2/2002	Email string re: WHI			
11213	NDA-PRO 0001016	NDA-PRO 0001030	12/3/1990	The Relative Bioavailability of MPA			
11214	NDA-PRO 0001016	NDA-PRO 0001016	12/3/1990	letter to Dr. Dighe			
11215			4/26/1984	FDA Advisory Committee Meeting			
11216	CHIRBY-D 0001003		11/9/1990	Provera letter to FDA			
11217	WADE-S 0000144	WADE-S 0000145	4/30/1990	HealthCare Communications Letter			
11218	NDA-PRO 0028053	NDA-PRO 0028093	00/00/1981	HRT Toward a rational approach			
11219	ENGELS_D-0000008	ENGELS_D-00000063		Hormone Replacement Therapy Slides			
11220	PATEL-M 0007053	PATEL-M 0007056	5/9/1997	Endometrial Cancer and CC Hrt			
11221			4/27/2006	NCI website- E + P slide			
11222			9/16/2002	NCI website- uterine cancer			
11223				NCI website- Risk Factors and Possible Causes			
11224	KENNALLY-W 0000051	KENNALLY-W 0000053		Memo re Bergvist			
11225	RM_NY_MOPS-0102854	RM_NY_MOPS0102857	11/00/1992	provera sales rep strategy and tactics			
11226	BOND-B 0000215		8/27/1992	Provera product details			
11240	Berger-H-0000083	Berger-H-0000193	4/10/2003	Update on Pharmacia Data Access- Brand Specifics			
11240A	Berger-H-0000083	Berger-H-0000202	4/10/2003	Update on Pharmacia Data Access- Brand Specifics			
11241	RM_AA 0009429	RM-AA-0009431	5/7/1994	Letter from Upjohn's John Jacob to Smith of John Hopkins re Ogen/Provera and endometrial history and bone density			
11242	RM_AA 0010465	RM-AA-0010473	6/30/1998	Project Review in Kalamazoo. Contract History and revised budget			
11243	RM_AA 0015627	RM-AA-0015635	4/3/1995	Upjohn Interoffice Memo on Protocol M541 0/036 Regulatory Documents.			
11244	RM_AA 0010691	RM-AA-0010726	9/8/1995	Amendment to Research Protocol. Evaluation of Endometrial Histology and Bone Mineral Density in Post Menopausal Women Receiving Ogen/Provera HRT.			
11245	Demke-D-0001063	Demke-D-0001068	6/3/1996	Frequency of events by body System- Upjohn report of adverse events			
11246	RM_AA 0016473	RM-AA-0016473	8/29/1997	Letter from the Clinical Research Review System re further year of study period			
11247	RM_AA 0016477	RM-AA-0016477	8/16/1996	Letter from the Clinical Research Review System: recertification for further study period			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
11248	RM_AA 0016479	RM-AA-0016479	5/13/1996	Letter to Dr. Rosenblatt of Irvine Clinical Research re IND safety report re breast cancer			
11255	RM_AA 0021377	RM-AA-0021378	12/15/1994	Letter to Dr. Superko enclosing grant payment for study			
11256	Engels-D-0039539	Engels-D-0039565		Provera Market Shares			
11257	RM_AA 0151363	RM-AA-0151365	3/7/1995	Summary tables- Product Report Projects to start in 1995			
11258	McElroy-P 0154537	McElroy-P 0154568	9/00/2001	September Sales 2001 of MPA			
11258A	McElroy-P 0154535	McElroy-P 0154584	9/00/2001	September Sales 2001 of MPA and EUTRX summary			
11259	RM_AA 0210850	RM-AA-0210851	11/17/1983	Letter to Hendrix of Upjohn re financial statements on Provera Osteoporosis grant			
11260	RM_AA 0325346	RM-AA-0325354		Medical Affairs tracking report. Gallagher site, he plans to submit lipid findings shortly			
11261	RM_AA 0325399	RM-AA-0325428		Medical Affairs tracking report. Gallagher site as well as letters to and from			
11262	RM_AA 0325452	RM-AA-0325456	2/26/1982	CRPC report- funding to Gallagher site as well as letter from Gallagher requesting additional grants			
11263	Paipanadiker-k-0010400	Paipanadiker-k-0010408	1/31/2002	Sales Monthly Reports- Osteo/menopause market			
11264	McElroy-P 0011917	McElroy-P 0012040	00/00/2002	Pharmacia 2002 Budget			
11265	McElroy-P 0100709	McElroy-P 0100754	12/00/2001	December 2001 Sales Summary			
11265A	McElroy-P 0100709	McElroy-P 0100756	12/00/2001	December 2001 Sales Summary			
11266			4/24/2007	GOVERNMENT'S SENTENCING MEMORANDUM			
11267	Demke-D-0000854	Demke-D-0000862	8/7/1997	Annual Report information- IND provera hrt- Study Events			
11268	Demke-D-0001069	Demke-D-0001075	5/31/1995	Frequence of events by body System- Upjohn report of adverse events			
11269	SAMULAK-K 0005476	SAMULAK-K 0005476	00/00/2002	Provera and Ogen Gross Profit Chart			
11270	Chao-D 0056662	Chao-D 0056828	7/00/2000	Strategic Overview of Women's Health Market			
11271	RM_NY_MOPS0102989	RM_NY_MOPS0102992	11/00/1993	Provera Strategy and Tactics- Sales Rep manual			
11272	RM_AA 0155879	RM-AA-0155883		Proposal for Product Line extension for a combination			
11273	RM_AA 0155884	RM-AA-0155888	8/1/1988	Upjohn Revised Sales Projection			
11274	RM_AA 0155890	RM-AA-0155897	12/21/1987	Pharmaceutical Manufacturing Impact Statement			
11275	RM_AA 0155899	RM-AA-0155904	9/30/1987	Upjohn Internal Memo re Control Input to Orange Book Proposal			
11276	RM_AA 0155902	RM-AA-0155902	8/18/1987	medical review- Fixed provera tablets for menopause			
11277	RM_AA 0155904	RM-AA-0155904	12/24/1987	P/T studies for Provera Dose pack of continuous use Therapy			
11278	RM_NY_MOPS-0074162	RM_NY_MOPS-0074183	10/00/1996	Physicians Practice Options			
11279	Unred_RM_NY_MOPS-0175167	Unred_RM_NY_MOPS-0175231	11/13/1997	Women's Health Care November 1997 Business Plan			
11280	RM_AA 0156155	RM-AA-0156157	12/1/1983	Financial assumptions- Provera Sales estimates			
11281	RM_AA 0156141	RM-AA-0156144	1/12/1984	Revised 1986 to 1990 Provera Sales Estimates			
11282	RM_AA 0156140	RM-AA-0156140	11/7/1984	Provera Preliminary Proposal- Upjohn internal memo from Penrose to Amann			
11283	RM_AA 0156139	RM-AA-0156139	6/18/1985				
11284			5/13/2004	Letter from Sullivan of US Department of Justice District of Mass to Warner Lambert plea agreement			
11285			5/13/2004	Warner Lambert Violations charges Puerto Rico			
11286			6/7/2004	Warner Lambert- Waiver, Change of Plea and Sentencing Hearing transcript			
11287	Chirby-D-0004701	Chirby-D-0004701	2/2/1995	Memo from Buboettin re Ogen Provera study			
11288	WADE-S 0000154	WADE-S 0000155	1/10/1994	Upjohn Letter to Dr. McClung re being an independent consultant			
11290	Hughes-j-0005711	Hughes-j-0005717	8/8/2003	Internal Upjohn Memo re Provera Geriatric labeling Supplement			
11291	RM_AA 0101465	RM_AA 0101472	6/20/1991	DEPO: Schoenfeld, Michael 8/03/2007 EX 18			
11291A				Pfizer Causality Assessment protocols			
11292	RM_AA 0155608	RM_AA0155646	9/29/1992	DEPO: Carlson, Rodney 2/20/2007 EX 3			
11293	RM_NY_MOPS 0321184	RM_NY_MOPS 0321213	6/16/1992	DEPO: Carlson, Rodney 2/20/2007 EX 20			
11294	RM_NY_MOPS 0369569	RM_NY_MOPS 0369569		DEPO: Parisian, Suzanne 12/20/2007 EX 6			
11295	Svensson-L 0000039	Svensson-L 0000070		DEPO: Carlson, Rodney 2/20/2007 EX 30			
11296	VOLPE-G 0002670	VOLPE-G 0002728	6/8/1995	DEPO: Carlson, Rodney 2/20/2007 EX 32			
11297	VOLPE-G 0006053	VOLPE-G 0006054		DEPO: Schoenfeld, Michael 8/03/2007 EX 17			
11298			6/2/2006	Plaintiffs' Notice of Corporate Deposition of Defendant Pfizer Pursuant to P.A.R.C.P. 4007.1(e) re: Aromasin and Elence			
11299			2/1/2006	The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27 (North Central Cancer Treatment Group)			
11300			12/00/2002	A Randomized Study of The Effect of Exemestane (Aromasin) vs Placebo on Breast Density in Postmenopausal Women at Increased Risk for Development of Breast Cancer (National Cancer Institute of Canada Clinical Trials Group (NCIC CTG))			
11301				Effects of Exemestane and Raloxifene on Breast Density by Mammography and MRI in Postmenopausal Women: Preliminary data from a Pilot Chemoprevention Trial by MN Dickler, E Morris, M Robson, J Choi, A Hummer, K Panageas, D Ballon, P Borgen, L Norton, C Hudis			
11302			8/28/2004	CV of Rodney Frederick Carlson, MD			
11303				Plaintiffs' Amended Notice of Corporate Deposition of Defendant Pfizer Pursuant to P.A.R.C.P. 4007.1 (e)			
11304				Provera Label 2009			
20000			12/8/2006	Report of Valerie Montgomery-Rice, MD w/ letter from Williams & Connolly requesting it			
20000a				Designations Valerie Montgomery-Rice			
20001			12/00/2006	Report of Paul D. Stolley,MD MPH			
20002			3/20/2007	Expert Report Susan S. Allen MD, MPH			
20002A				Marketing Strategy and Selling Issues			
20003			3/1/2007	Expert Report Susan S. Allen MD, MPH			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
20004				Report of Adriene Fugh-Berman dated 2-16-06, depo notice			
20005			8/30/2007	Report of Phillip O. Warner, MD			
20006			3/19/2007	Supplemental Expert Report of Suzanne Parisian, MD			
20007			9/19/2007	Expert Report of Dr. Lucio Miele			
20008				Expert Report of Barbara S. Levy, MD, PS			
20009			10/30/2007	Supplemental Report of Raquel D. Arias, MD Regarding Design Defect Claim			
20010			2/25/2008	Expert Witness Report of Lisa Bailey, MD (Generic Report)			
20011				Supplemental Expert Report of Suzanne Parisian, MD (no date)			
20030			12/8/2006	Report of Valerie Montgomery-Rice, MD			
20031			5/1/2006	CV of Valerie Montgomery-Rice, MD			
20032				Chart titled: Premarin Family VSB Speakers sorted by # of events scheduled from 1/2002 through 12/2002			
20033				Handwritten notes on Loews Vanderbilt Hotel Nashville paper			
20034			11/3/2006	Letter from Michelle Fujimoto of Shook, Hardy & Bacon to Valerie Montgomery-Rice re: enclosed materials discussed at Wednesday's meeting			
20035				Handwritten notes, invoices, multiple articles			
20036				Handwritten notes on Loews Vanderbilt Hotel Nashville paper w/ highlights			
20037				Chart titled: Top 100 Premarin Family VSP Speakers for 2001			
20038			12/00/2006	Slide titled: Lobular Proportion of All Invasive Breast Cancers by Year (Revised as of December 2006 Report)			
20039				Graphs titled: Proportion of ILC to All Invasive Breast Cancers Among Women Aged 50 and Older, All Races (SEER 1974-2003), second is Women Aged 30-49			
20040			1/2/2007	2 Donald Austin invoices billed to Mike Williams @ Williams Love O'Leary			
20041			3/8/2007	Amended Notice of Videotaped Deposition of Donald Austin MD			
20042			1/5/2007	Multiple e-mails from Mike Williams to Scott Graham re: Austin disclosures			
20043				HT Breast Cancer General Causation - Instructions and Questions for Potential Experts			
20044			00/00/2006	Table 84: Use of mammography among women 40 years of age and over by selected characteristics: United States, selected years 1987-2003 (in Health, United States)			
20045			9/13/2006	Study CPC-06094-L (eIRB #3009) - Lay Summary, Investigators: Donald Austin & David Buckley			
20046				Breast Cancer Incidence Trends, by Histology and ER Status by Donald Austin & David Buckley			
20047				Slide titled: Initial Observation Age Adjusted Invasive Breast Cancer Incidence 7% Decrease in 2003 Relative to 2002			
20048				Slide titled: Does the magnitude of the effect seem reasonable?			
20049				Slide Presentation titled: Hypothesis #3: Hormone therapy influences cancer etiology, Breast Cancer Trends and Etiology and Related Phenomenon by Donald Austin			
20050				Fax from David Buckley to Scott Graham re: attached disclosure for deposition on 3-20			
20051				Chart titled: All Invasive ILC			
20052				Chart titled: All Invasive ILC, Mixed, All Invasive ER+, ILC ER+			
20053				Multiple graphs and charts			
20054			12/00/2006	Slide titled: Lobular Proportion of All Invasive Breast Cancers by Year (Revised as of December 2006 Report)			
20055				Graph titled: Endometrial Cancer Incidence Rates, White Females Ages (unreadable), Alameda and Contra Costa Counties, California 1969-1979			
20056			1/11/2007	David Buckley invoice #10 to Mike Williams			
20057			1/11/2007	David Buckley invoice #11 to Mike Williams			
20058			4/10/2007	Amended Notice to Take the Videotaped Deposition of Susan S. Allen MD			
20059				Susan Allen MD, MPH Employment Highlights			
20060				Multiple Susan Allen Invoices billed to Wyeth			
20061			1/12/1976	Memorandum of Conference between Ayerst Laboratories & Food and Drug Administration re: Premarin - Letter Issued by Ayerst December 31, 1975			
20062				CV of Michael Jay Schoenfeld			
20063			10/12/2007	Notice to take Videotaped Deposition of Adriane Fugh-Berman, MD			
20064			8/31/2007	Plaintiffs' Identification of Case Specific and Generic Experts and Proffer of Expert Reports			
20065			10/11/2007	Adriane Fugh-Berman invoice to Bubalo			
20066				CV of Adriane Fugh-Berman MD			
20067				CV of Adriane Fugh-Berman MD			
20068				AFB Publications (updated through January 2007)			
20069			8/23/2006	The Dog Ate My Disclosure by Adriane Fugh-Berman in Bioethics Forum			
20070			11/11/2006	Doctors Must Not be Lapdogs to Drug Firms by Adriane Fugh-Berman in BMJ			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
20071				Doctors Must Not be Lapdogs to Drug Firms by Adriane Fugh-Berman			
20072			00/00/2007	BMJ Competing Interests - Guidance for authors and referees			
20073			06/00/2006	Advertising in Medical Journals: Should Current Practices Change? By Adriane Fugh-Berman, Karen Alladin, Jarva Chow in PLoS Medicine			
20074				Lauren Hutton pamphlet Hot Flash			
20075			10/24/2007	E-mail from Steven Rotman to Adriane Fugh-Berman re: Thursday meeting (HRT Deposition)			
20076				HT file w/ multiple articles w/ handwritten notes on the articles			
20077				HT file w/ multiple articles			
20078				File w/ multiple articles published			
20079			06/00/2002	Pinpointing the Persuaders by Archibald A. Anderson in Pharmaceutical Executive			
20080			10/12/2007	Notice to take Videotaped Deposition of Matthew F. Hollon, MD, MPH			
20081			8/31/2007	Plaintiffs' Identification of Case Specific and Generic Experts and Proffer of Expert Reports			
20082			1/00/2002	Multiple magazines w/ Lauren Hutton Hot Flash ad			
20083			11/1/2007	Matthew Hollon invoice to Steven Rotman, and invoice to Zoe Littlepage			
20084			00/00/2007	CV of Matthew F. Hollon, MD MPH FACP (2007)			
20085				List of articles			
20086			4/23/2007	Multiple articles			
20087				Slide titled: Best Drug or Best Marketed Drug? By Matthew F. Hollon, MD MPH FACP			
20088				Matthew Hollon Undertaking Pursuant to Confidentiality Order			
20089				What All Women Need to Know in OsetoEd			
20089a	POLVANI-F 0000241	POLVANI-F 0000241		ALERT Serious Event 96 50036 - MPA (follow-up) Case Comment			
20090				Slide titled: EBM resources			
20091				Slides titled: Proponents Argue; Critics Argue			
20092				Slide titled: Industry Marketing Effort			
20093				Slide titled: DTC Spending			
20094				Table 3: The 15 Drugs with the Highest BTC Spending, 2000			
20095			10/25/2007	Notice of Intention to Take the Videotaped Deposition of Dr. Phillip Warner			
20096			11/26/2007	E-mail from Scott Graham to Michelle Fujimoto, Lpruit, Jmayesh, & Mike Williams re: HRT Litigation - Dr. Warner Deposition 48 hour disclosure w/ attachments of material provided and invoices			
20097				CV of Phillip O. Warner, MD			
20098				CV of Phillip O. Warner, MD			
20099				CV of Phillip O. Warner, MD			
20100			11/16/2003	Stipulated Findings of Fact, Conclusions of Law and Agreed Order			
20101				Just like your own Progesterone (difficult to see)			
20102			12/00/2004	Prometrium (progesterone, USP) Capsules 100mg & 200mg Prescription Insert			
20103			12/1/2007	Suzanne Parisian invoices to Tobi Millrood			
20104				Copy of CD titled: Suzanne Parisian Materials			
20105				History of Wyeth, Medroxyprogesterone Acetate ("MPA") and Prempro			
20106				Active Ingredient Search Results from "OB_Rx" table for query on "testosterone"			
20107			11/00/2005	Prescribing Information for Androderm			
20108			10/00/2004	Prescribing Information for Estraderm			
20109				Definition of Gail Model & Bi-Rads in NCI Dictionary of Cancer Terms; Gail Model Description; Breast Cancer Gail Model Risk Calculation Methods			
20110			3/19/2007	Signature of Suzanne Parisian on 3 (unknown) documents			
20111			12/12/2007	E-mail from Bill Murray to Michelle Fujimoto re: Susan Parisian, Expert Meeting pdf.			
20112				Notice of Videotaped Deposition of Raquel D. Anias, MD			
20113			10/31/2007	Raquel Arias Invoice to Shook Hardy, & Bacon for \$4250.00			
20114			9/12/2007	Raquel Arias Invoice to Shook Hardy, & Bacon for \$1000.00			
20115			12/00/2004	Prometrium (progesterone, USP) Capsules 100mg & 200mg Prescription Insert			
20116				DEPO: Bailey, Lisa 4/25/08 EX 4: CV of Lisa Bailey MD			
20117				DEPO: Bailey, Lisa 4/25/08 EX 5: Lisa Bailey invoices for Generic Report, Woods, Woodhouse			
20118				DEPO: Bailey, Lisa 4/25/08 EX 6: Handwritten note			
20119				Plaintiff, Lucy Trevino's Amended Notice of Intent to Take the Oral and Video Deposition with Subpoena Duces Tecum of Jeffrey Buchalter			
20120				Wyeth's Cross-Notice of Plaintiff Trevino's Amended Notice of Intent to Take Oral and Video Deposition with Subpoena Duces Tecum of Jeffrey Buchalter			
20121				Jeffrey H. Buchalter Biography			
20122				Handwritten diagram of Rick Winneker school & work history			
20123			6/25/2009	Plaintiffs' Notice of Intention to Take Oral Videotaped Deposition of Donald Lewis			
20124				CV of Donald F. Lewis			
20125			04/00/2009	Prempro/Premphase Prescription Information			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
20126			03/00/2009	Highlights of Prescribing Information - Premarin			
20127			3/6/2009	Study: Hormone therapy caused breast cancer for thousands by Anne Harding in CNN.com			
20128	LEWDO001-019557	LEWDO001-019560	12/20/2007	Wyeth Safety Review Team Meeting Minutes Dec. 20, 2007			
20129			8/5/2009	Plaintiffs' Notice of 30(b)(6) Deposition of Wyeth and Wyeth Pharmaceuticals Inc.			
20130	BURRG005-000857	BURRG005-000857	10/30/1997	DEPO: Utian, Wulf 8/11/2009 EX 87			
20131	BURRG005-001977	BURRG005-001979		DEPO: Utian, Wulf 8/11/2009 EX 18			
20132	CHOOM007-001071	CHOOM007-001071	3/12/1998	DEPO: Utian, Wulf 8/11/2009 EX 19			
20133	COBBP002-002702	COBBP002-002702	6/8/1995	DEPO: Utian, Wulf 8/11/2009 EX 84			
20134	COBBP002-002703	COBBP002-002703		DEPO: Utian, Wulf 8/11/2009 EX 85			
20135	COBBP002-002705	COBBP002-002709		DEPO: Utian, Wulf 8/11/2009 EX 86			
20136	CONTA013-000983	CONTA013-000986	4/00/2001	DEPO: Utian, Wulf 8/11/2009 EX 10			
20137	CONTA023-002672	CONTA023-002672		DEPO: Utian, Wulf 8/11/2009 EX 12			
20138	CONTA025-008235	CONTA025-008236	9/26/2002	DEPO: Utian, Wulf 8/11/2009 EX 81			
20139	CONTA025-013901	CONTA025-013902	11/14/2002	DEPO: Utian, Wulf 8/11/2009 EX 69			
20140	CONTA025-013903	CONTA025-013909	10/28/2002	DEPO: Utian, Wulf 8/11/2009 EX 70			
20141	CONTA025-013910	CONTA025-013914	10/28/2002	DEPO: Utian, Wulf 8/11/2009 EX 71			
20142	CONTA025-013915	CONTA025-013921	11/8/2002	DEPO: Utian, Wulf 8/11/2009 EX 72			
20143	CONTA025-013922	CONTA025-013927	10/27/2002	DEPO: Utian, Wulf 8/11/2009 EX 73			
20144	DELCA031-020200	DELCA031-020202		DEPO: Utian, Wulf 8/11/2009 EX 67			
20145	DEVAN010-001459	DEVAN010-001461		DEPO: Utian, Wulf 8/11/2009 EX 80			
20146	DUROJ041-000758	DUROJ041-000759	11/16/1992	DEPO: Utian, Wulf 8/11/2009 EX 16			
20147	DUROJ044-000657	DUROJ044-000666		DEPO: Utian, Wulf 8/11/2009 EX 89			
20148	DUROJ044-006074	DUROJ044-006075	6/29/2001	DEPO: Utian, Wulf 8/11/2009 EX 91			
20149	DUROJ046-014153	DUROJ046-014156		DEPO: Utian, Wulf 8/11/2009 EX 78			
20150	DUROJ046-016976	DUROJ046-016976	5/16/2002	DEPO: Utian, Wulf 8/11/2009 EX 76			
20151	DUROJ046-016977	DUROJ046-016979	5/16/2002	DEPO: Utian, Wulf 8/11/2009 EX 77			
20152	DUROJ204-002132	DUROJ204-002132		DEPO: Utian, Wulf 8/11/2009 EX 65			
20153	GOLDG001-000005	GOLDG001-000005	4/19/2002	DEPO: Utian, Wulf 8/11/2009 EX 58			
20154	GOLDG001-000008	GOLDG001-000008	4/24/2002	DEPO: Utian, Wulf 8/11/2009 EX 60			
20155	GOLDG001-000013	GOLDG001-000013	4/10/2002	DEPO: Utian, Wulf 8/11/2009 EX 59			
20156	GOLDG001-000035	GOLDG001-000035	3/20/2002	DEPO: Utian, Wulf 8/11/2009 EX 62			
20157	GOLDG001-000062	GOLDG001-000062		DEPO: Utian, Wulf 8/11/2009 EX 52			
20158	GOLDG001-000080	GOLDG001-000080		DEPO: Utian, Wulf 8/11/2009 EX 46			
20159	GOLDG001-000096	GOLDG001-000097	3/26/2001	DEPO: Utian, Wulf 8/11/2009 EX 51			
20160	GOLDG001-000098	GOLDG001-000098	10/3/2001	DEPO: Utian, Wulf 8/11/2009 EX 49			
20161	GOLDG001-000100	GOLDG001-000101	10/3/2001	DEPO: Utian, Wulf 8/11/2009 EX 48			
20162	GOLDG001-000108	GOLDG001-000108	3/26/2001	DEPO: Utian, Wulf 8/11/2009 EX 47			
20163	GOLDG001-000109	GOLDG001-000109	3/20/2001	DEPO: Utian, Wulf 8/11/2009 EX 50			
20164	GOLDG001-000111	GOLDG001-000111	3/26/2001	DEPO: Utian, Wulf 8/11/2009 EX 53			
20165	GOLDG001-000115	GOLDG001-000115	7/18/2001	DEPO: Utian, Wulf 8/11/2009 EX 55			
20166	GOLDG001-000116	GOLDG001-000116	2/20/2001	DEPO: Utian, Wulf 8/11/2009 EX 54			
20167	GOLDG001-000140	GOLDG001-000142		DEPO: Utian, Wulf 8/11/2009 EX 56			
20168	GOLDG001-000147	GOLDG001-000148	2/3/2000	DEPO: Utian, Wulf 8/11/2009 EX 44			
20169	GOLDG001-000149	GOLDG001-000149	12/29/1999	DEPO: Utian, Wulf 8/11/2009 EX 30			
20170	GOLDG001-000151	GOLDG001-000172	8/00/1999	DEPO: Utian, Wulf 8/11/2009 EX 15			
20171	GOLDG001-000174	GOLDG001-000175	2/11/2000	DEPO: Utian, Wulf 8/11/2009 EX 42			
20172	GOLDG001-000176	GOLDG001-000176	2/11/2000	DEPO: Utian, Wulf 8/11/2009 EX 43			
20173	GOLDG001-000177	GOLDG001-000178	2/11/2000	DEPO: Utian, Wulf 8/11/2009 EX 40			
20174	GOLDG001-000179	GOLDG001-000179	2/11/2000	DEPO: Utian, Wulf 8/11/2009 EX 41			
20175	GOLDG001-000180	GOLDG001-000181	2/11/2000	DEPO: Utian, Wulf 8/11/2009 EX 38			
20176	GOLDG001-000184	GOLDG001-000187	3/30/2000	DEPO: Utian, Wulf 8/11/2009 EX 34			
20177	GOLDG001-000188	GOLDG001-000189	4/10/2000	DEPO: Utian, Wulf 8/11/2009 EX 36			
20178	GOLDG001-000195	GOLDG001-000196	3/21/2000	DEPO: Utian, Wulf 8/11/2009 EX 35			
20179	GOLDG001-000197	GOLDG001-000197	3/9/2000	DEPO: Utian, Wulf 8/11/2009 EX 33			
20180	GOLDG001-000198	GOLDG001-000198	2/4/2000	DEPO: Utian, Wulf 8/11/2009 EX 32			
20181	GOLDG001-000212	GOLDG001-000212	7/19/2000	DEPO: Utian, Wulf 8/11/2009 EX 37			
20182	GOLDG001-000221	GOLDG001-000224	3/29/1999	DEPO: Utian, Wulf 8/11/2009 EX 26			
20183	GOLDG001-000232	GOLDG001-000234	9/22/1999	DEPO: Utian, Wulf 8/11/2009 EX 27			
20184	GOLDG001-000238	GOLDG001-000239	8/25/1999	DEPO: Utian, Wulf 8/11/2009 EX 28			
20185	GOLDG001-000240	GOLDG001-000242	12/21/1998	DEPO: Utian, Wulf 8/11/2009 EX 24			
20186	GOLDG001-000267	GOLDG001-000269	12/12/2001	DEPO: Utian, Wulf 8/11/2009 EX 64			
20187	GOLDG001-000275	GOLDG001-000279	11/13/2001	DEPO: Utian, Wulf 8/11/2009 EX 63			
20188	JANEC010-003214	JANEC010-003214	9/9/1999	DEPO: Utian, Wulf 8/11/2009 EX 29			
20189	JANEC010-003219	JANEC010-005076		DEPO: Utian, Wulf 8/11/2009 EX 39			
20190	JANEC010-005077	JANEC010-005077	1/4/2000	DEPO: Utian, Wulf 8/11/2009 EX 31			
20191	JANEC010-005078	JANEC010-005078	4/13/2000	DEPO: Utian, Wulf 8/11/2009 EX 57			
20192	LAWT023-043668	LAWT023-043722		DEPO: Utian, Wulf 8/11/2009 EX 11			
20193	OLIVS019-015628	OLIVS019-015665	7/19/2002	DEPO: Utian, Wulf 8/11/2009 EX 68			
20194	PANAA017-000617	PANAA017-000617	12/9/1994	DEPO: Utian, Wulf 8/11/2009 EX 17			
20195	PANAA040-013061	PANAA040-013062		DEPO: Utian, Wulf 8/11/2009 EX 75			
20196	SOLOJ027-040077	SOLOJ027-040078	3/20/2002	DEPO: Utian, Wulf 8/11/2009 EX 88			
20197	DWRITE 164098	DWRITE 164098	1/24/2001	DEPO: Utian, Wulf 8/11/2009 EX 14			
20198	GOLDG001-00231	GOLDG001-00231	9/29/1999	DEPO: Utian, Wulf 8/11/2009 EX 23			
20199			00/00/2008	2008 Prempro PDR (rev 6/07)			
20200			00/00/2009	2009 Prempro PDR (rev 6/08)			
20201				Montgomery Rice website.			
20202	LUDMG003-000482	LUDMG003-000484	7/26/1999	market planning internal memo: BC tearsheet development research			
20203	PARKA001-000101	PARKA001-000101	6/11/2001	PO for Klemtnr: \$13k for Prempro preferred objection handlers			
20204	ROSSC025-000814	ROSSC025-000814	7/30/2001	PO for Klemtnr: \$170k for Premarin unbranded key messages			
20205	HENRL206-000247	HENRL206-000247	5/18/2000	PO for Ehrenthal: \$731k for unbranded Lauren Hutton TV spot			
20206	HENRL206-000248	HENRL206-000248	11/19/1999	PO for Ehrenthal: \$480k for unbranded Lauren Hutton TV spot			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
20207	HENRL206-000278	HENRL206-000278	5/18/2000	PO for Ehrenthal: \$171k for unbranded Hormone for Life posters			
20208	HENRL206-000279	HENRL206-000280	12/8/1999	PO for Ehrenthal: \$162k for unbranded Hormone for Life posters			
20209	HENRL206-000384	HENRL206-000384	5/23/2000	PO for Ehrenthal: \$827k for unbranded Lauren Hutton TV ad			
20210	HENRL206-000385	HENRL206-000385	5/8/2000	PO for Ehrenthal: \$785k for unbranded Lauren Hutton TV ad			
20211	HENRL002-001922	HENRL002-001932	12/7/1999	Wyeth's supplier report card for Ketchum re: Premarin			
20212	CHOOM029-000270	CHOOM029-000270	2/25/1999	PO for John F Murray: funding for DTC 1999 - branded and un, Prem fam			
20213	PANAA025-001705	PANAA025-001706	11/26/1990	Essner letter to sales reps re: Colditz			
20214	HUNTH004-000007	HUNTH004-000007		Summary of product characteristics re: HRT and BrCa - text change			
20215	PANAA029-000373	PANAA029-000373	1/14/1992	Burson-Marsteller memo re: Premarin crisis plan			
20216	VICTJ003-000504	VICTJ003-000504	2/10/2000	Breast cancer communications plan			
20217	CONTA019-001312	CONTA019-001313	2/8/2000	breast cancer communications action summary			
20218	DELCA021-000314	DELCA021-000316	2/8/2000	breast cancer communications advocate contact summary			
20219	DELCA021-000308	DELCA021-000311	2/8/2000	breast cancer communications action summary			
20220	PANAA029-000371		8/5/1992	internal Smith Cox memo re: upcoming Henrich article			
20221	PANAA025-000614	PANAA025-000618	10/25/1996	1996 Burson Marsteller budget			
20222	SOLOJ022-001376	SOLOJ022-001382	4/1/1996	internal memo re: BrCa and HRT: prelim long-term issue mgmt recomms			
20223	DUROJ044-006082	DUROJ044-006083	6/26/2001	WHI update: communication plan			
20224	DUROJ044-000677	DUROJ044-000678	6/15/2001	Durocher memo re: key actions in response to recent media reports			
20225	DELMG020-000266	DELMG020-000277	7/12/1995	Montgomery Rice clinical research agreement re: HOPE			
20226	PANAA216-000242	PANAA216-000242	1/13/2004	Henry letter re: \$10k for Montgomery Rice grant			
20227	PANAA226-000858	PANAA226-000858	7/29/2003	Henry email to Ketchum re: GMA backgrounder & Montgomery Rice			
20228	GOLDG006-002100	GOLDG006-002100	9/8/2000	Endocrine Society letter to Montgomery Rice re: HRT symposium			
20229	DEMAE014-002410	DEMAE014-002410	8/10/2001	Wyeth letter to U-Kansas re: Montgomery Rice payment for study			
20230	DEMAE009-001321	DEMAE009-001324	2/15/2001	confidential disclosure agreement between Montgomery Rice & Wyeth			
20231	HENRL018-001318	HENRL018-001319	2/18/2000	Houston Chronicle letter to the editor: Dr. Thorneycroft			
20232	HENRL018-001320	HENRL018-001321	2/17/2000	USA Today letter to the editor: Dr. Montgomery Rice			
20233	BURRG005-001094	BURRG005-001094		HERS follow-up public relations plan			
20234	BROWS002-002871	BROWS002-002871	12/14/1998	Blanton memo re: HRT speakers/NP program			
20235	DEMAE014-002407	DEMAE014-002407	8/10/2001	Wyeth letter to U-Kansas re: Montgomery Rice payment for study			
20236	CHOOM047-000268	CHOOM047-000268	8/10/2000	Montgomery Rice letter to Wyeth re: grant payment			
20237	DEMAE014-002205	DEMAE014-002211		consent form for 0713X1-013			
20238	PANAA029-000382	PANAA029-000382	12/27/1991	Marmontello memo re: Premarin - working session			
20239	BARBM301-055612	BARBM301-055612	11/21/2003	Law email re: 11-14 combined premarin lists			
20240	CHOOM057-001441	CHOOM057-001441	2/26/1996	Buchalter memo to Breast Cancer Working Group re: assignments			
20241	BARBM023-012561	BARBM023-012561	7/17/2002	DesignWrite email to Hugh Taylor re: VSB slides			
20242	DEMAE014-000967	DEMAE014-000974	1/31/2001	informed consent for study 0713X1-013			
20243	CHOOM067-000567	CHOOM067-000567	8/16/1994	Burson Marsteller invoice for media training			
20244	CHOOM057-000878	CHOOM057-000878	3/29/1995	Colditz letter to NEJM's Schwartz			
20245	SDRVE003-0007616	SDRVE003-0007623		Monthly business review - Gregory			
20246				Table of contents from Bland and Copeland, et al; The Breast: Comprehensive Management of Benign and Malignant Disorders, Second Edition			
20246A				Ch 11: In Situ Carcinomas of the Breast			
20246B				Ch 23: Risk Factors for Breast Carcinoma in Women with Proliferative Breast Disease			
20247			7/20/2006	Stipulation as to Wyeth's ability to fund studies			
20248	CONNS004-000893	CONNS004-000898		HERS consent agreement			
20249				Adams Shands at UF			
20249A				Adams Shands at UF - breast cancer			
20255	CONTA023-003317	CONTA023-003317	1/17/2002	Memo from Corporate GMA: Summary of JAMA Article (Jan, 9, 2002) - Serum Estradiol Level and Risk of Breast Cancer During Treatment with Ralozifene			
20256			4/9/2010	NCI website			
20257A			2/7/2007	Trial Testimony of Dr. Suzanne Klimberg from <i>Rush v. Wyeth</i>			
20257B			5/1/2006	Deposition of Dr. William Creasman (Wyeth's expert): Gynecological Oncology			
20257C			5/27/2010	Deposition testimony from Dr. Stovall: Wyeth's expert			
20257D			9/27/2007	Trial Testimony of Dr. Ginger Constantine from <i>Rowatt v. Wyeth</i>			
20257E			9/6/2006	Trial Testimony of Dr. Lewis Chodosh from <i>Reeves v. Wyeth</i>			
20258A			5/1/2006	Deposition of Dr. William Creasman			
20258B			10/1/2007	Trial Testimony of Dr. Robert Langer from <i>Rowatt v. Wyeth</i>			
20258C			5/10/2006	Deposition of Dr. Robert Langer			
20259A			9/21/2005	Deposition of Dr. James Pickar, Asst VP of Women's Health for Wyeth			
20259B			5/1/2006	Deposition of Dr. William Creasman			
20260A			2/9/2010	Trial Testimony of Dr. Ginger Constantine from <i>Singelton v. Wyeth</i>			
20260B				Deposition excerpts from Dr. Michael Dey, President of Wyeth – PX 20260B			
20260C				Trial Testimony by Dr. James Pickar, Asst VP of Science & Development of Prempro for Wyeth – PX 20260C			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
20260D				Dr. Naftalis – Frye hearing in Esposito v. Wyeth (4/8/10)			
20261	HOLSN016-001440	HOLSN016-001440	3/19/2002	Wyeth Justification document re: Fibrocystic changes in breast			
20261A	W-MDL527-00045016		3/19/2002	Wyeth Justification document re: Fibrocystic changes in breast			
20262			6/11/2010	Cummings Deposition (Date: 6/11/10)			
20263A			1/5/2010	Affidavit of Dr. Richard Hirschman			
20263B			10/20/2009	Affidavit of Dr. Paul Goldfarb			
20263C			4/27/2006	Trial testimony of Dr. Suzanne Klimberg from <i>Reeves v. Wyeth and Rush v. Wyeth</i>			
20263D			1/18/2010	Affidavit of Dr. Rene Rubin			
20263E			9/20/2007	Trial testimony of Dr. Roy MacIntosh from <i>Rowatt v.</i>			
20263F			7/20/2006	Declaration of Dr. James Waldron			
20263G				Press Statement of Dr. Tina Rizack			
20264			9/8/2009	Frye hearing in <i>Barton v. Wyeth Testimony Dr. Ling</i>			
20266				Albert Einstein Website			
20267				Wyeth Causality assessments			
20269			10/27/2007	Oncolink Website: "Ask the Experts" - Hormone Receptors			
20555			00/00/2008	Wyeth.com ADAM - section on breast cancer			
20580				Med lit relied on Dr. Naftalis			
20595			6/00/2002	Mass General web site: drug therapy			
20598				Table of articles - ERT/HRT (Colditz exhibit 2)			
20621	CORRA302-000104	CORRA302-000108	4/20/2001	Charles Payne Release and Settlement			
20621A	PANAA024-000732	PANAA024-000733	10/22/1990	Buatti memo to Olsen re: Clinical Radiology Testing Laboratory			
20801				Dr. Michael Dey trial testimony			
20802				Marc Deitch depo text			
20802A				Pam Cobb depo text			
20805			7/22/2003	Senate Aging Committee: Direct to Consumer Advertising of Prescription Drugs: What are the Consequences?			
20806	WEBEM014-000236	WEBEM014-000250	5/7/2003	Breast Cancer Realtime Risk: Introduction draft			
20807	PICKJ007-000955	PICKJ007-000957	2/2/2000	Breast Cancer Communication draft			
20851				Pepi Consent form			
20852	Various	Various		Handwritten Notes			
20852A			10/1/2001	Postmenopausal Hormone Therapy and Breast Cancer: A review for Clinicians			
20853	DESIGN017956	DESIGN017956	8/24/2001	Letter from Karen Mittleman to Stephen Parker RE: Outline for review paper			
20854	DUROJ006-000319	DUROJ006-000324		hers			
20855	W-MDL527-00039543			HERS study – Background Soundbites for HERS			
20856	FONTL035-001559	FONTL035-001560	7/15/2002	Attendance Sheet for Labeling Executive Committee			
20857	ROSSC034-000921	ROSSC034-000922	7/10/1995	Letter from Wyeth to Mr. Kenneth Feather FDA			
20858	Various	Various	1/12/1998	Wyeth Meeting Agenda			
20859	VICTJ005-001352	VICTJ005-001338	2/7/1995	Letter to Mr. Sobel			
20871	PANAA029-000395	PANAA029-000408	12/26/1991	Burson-Marsteller- Wyeth Premarin Crisis / E7799Issue Management			
20872				Call Notes			
20874			8/26/1998	Controlled Correspondance Response from Susan Allen to Lisa Rarick			
20875	ALIVJ02-000644	ALIVJ02-000644	5/3/1991	FDA letter to Morrison re: "Milestones in Medicine"			
20876	BURKM017-000990	BURKM017-000990	8/3/2000	Maida Burka - FDA Telephone Contact			
20877	BURKM029-030338	BURKM029-030341	11/8/2000	FDA - user fee cover sheet form - Jennifer Philips			
20878	BURKM005-000491	BURKM005-000492		Letter to Mr. Sonk (NDA 20-303)			
20878A	W-MDL303-00085228	W-MDL303-00085229	6/8/2000	Letter to Mr. Sonk re: NDA for Prempro/Premphase post-HERS			
20879	VOLPE-G 0006205	VOLPE-G 0006206	9/26/2000	Letter to Susan Allen			
20880	BURKM014-002512	BURKM014-002513		FDA letter to Wyeth re Premarin labeling revisions for prevention of osteoporosis			
20880A			10/20/2009	total payments to Allen from July 2006-July 2009			
20881			10/20/2009	Regulatory payment- Allen			
20922	SOLOJ020-000552	SOLOJ020-000560	3/24/2000	Finance Committee Authorization			
20923	DEMAE007-002178	DEMAE007-002179	9/21/1992	finance committee authorization for WHI			
20925	CONNS004-000893	CONNS004-000898	7/6/1994	UCSD: Heart & Estrogen Replacement Study			
20927			1/5/2007	Affidavit of CL Baggett (handwriting analysis expert)			
20928	BUCHJ003-001784	BUCHJ003-001784	5/26/1995	Marmontello letter to Burson Marsteller re: performance for Premarin			
20928A	BUCHJ003-001782	BUCHJ003-001783	5/25/1995	Memo - Nick Marmontello re: Burston Martseller Evaluation			
20929	RHUDM012-000132	RHUDM012-000132	9/29/1997	Meta-Reanalysis of Breast Cancer			
20940	DUROJ019-001029	DUROJ019-001029	4/19/2000	handwritten notes re: Dr. Lindsay			
20941	WEBEM015-009222	WEBEM015-009222	1/10/2001	Breast Cancer Pepi Data			
20942	PANAA025-001374	PANAA025-001374	8/00/1989	Memo to Sales Force - re BERGKIVIST			
20943				Woman's Day - Premarin beach ad			
20944				Prempro necklace ad			
20945	GASTM011-004808	GASTM011-004808	6/4/2002	email from Durocher re: Outreach to Drs Blumenthal & Davidson			
20946	HENRL002-002191	HENRL002-002198	1/19/2001	Ketchum agreement with Gookie for Patti LaBelle			
20947	HENRL206-000731	HENRL206-000731	1/10/2001	Ketchum invoice for Patti LaBelle payment			
20948	LAWT023-027020	LAWT023-027020	2/18/2002	Highfill email to Law re: Patti LaBelle			
20949	DUROJ213-044370	DUROJ213-044375	5/00/2003	Premarin media monitoring report - 05/08 to 05/09 2003			
20949A	CONTA213-011857	CONTA213-011839	6/00/2003	Premarin media monitoring report - 06/24 to 06/25 2003			
20949B	DUROJ213-044587	DUROJ213-044590	5/00/2003	Premarin media monitoring report - 05/06 to 05/07 2003			
20949C	MARRA209-027926	MARRA209-027927	5/00/2003	Premarin media monitoring report - 05/13 to 05/14 2003			
20950	W-MDL303-00081439	W-MDL303-00081447	6/23/1995	Prempro DTC ads and revisions			
20951	DEYMI206-003194	DEYMI206-003195	2/21/2003	Nagle email re: HRP Patti LaBelle ads (March-July 2002) - ROI analysis			
20952	CONTA023-002787	CONTA023-002788	2/4/2000	Breast cancer communications plan			
20953	CONTA019-001050	CONTA019-001051	2/3/2000	breast cancer communications draft			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
20957	CHOOM031-000843	CHOOM031-000843	10/6/1997	Internal memo from Flint to salesforce re: breast cancer study			
20958	MKTAR069-001284	MKTAR069-001288	6/23/1995	Chilton doc - Colditz awareness survey - consumer version			
20959	DELCA032-002312	DELCA032-002312	12/6/2001	email re: Dr. Jo Ann Pinkerton's 2 lectures			
20960			3/16/2009	set of financial docs sent after 02/25/2009 hearing for Kalvert v Wyeth/Grimsley v Wyeth			
20961	W-LABELS-000043	W-LABELS-000051	00/00/2001	Physicians' Desk Reference - Prempro entry			
20962	W-LABELS-005292	W-LABELS-005295	00/00/1997	Physicians' Desk Reference - Premarin entry			
20962B			00/00/1994	Physicians' Desk Reference - Premarin entry			
20963	W-MDL303-00000002	W-MDL303-00000007	12/22/1992	letter to FDA re: NDA for CE/MPA			
20964	DWRITE 027129	DWRITE 027129	12/18/2001	letter to LoMonaco re: NHC/CHE budget			
20965	W-MDL04782-00052238	W-MDL04782-00052238	3/16/1976	letter from Charles Hammond to Ayerst			
20966	GASTM011-030875	GASTM011-030875	3/30/2000	email from Brown to Gast re: MPA - Hammond			
20967	SDRVE003-0010324	SDRVE003-0010333		monthly business review - Gregory			
20970				1995 Time Magazine Article			
20991	CHOOM057-000846	CHOOM057-000850	5/30/1995	NEJM Breast Cancer Strategy			
20992	LEWDO00-043446	LEWDO00-043508	7/1/2008	Executive Safety Committee			
20993			6/26/1995	News RX			
20994	MARRA209-027933	MARRA209-027933	5/14/2003	email from Ketchum re: Premarin media highlights of 05/14/2003			
20994A	MARRA209-027934	MARRA209-027935	5/14/2003	Premarin media highlights of 05/14/2003			
20995	LEWDO001-043446	LEWDO001-043508	7/1/2008	slides: HRT Executive Safety Committee Meeting			
20996	DELGM020-000018	DELGM020-000031	8/00/1995	testing agreement - HOPE study docs			
20997	FISHG001-000577	FISHG001-000577	2/1/2000	Victoria memo re: mtg to discuss Lippert Publication on Oncologic Potential of Estrogen Components			
20998	DEYMI022-000321	DEYMI022-000326	8/12/1998	meeting report: FDA/Wyeth meeting on HERS			
20999	HENRL002-000157	HENRL002-000159	8/17/1998	market planning memo re: DRI - Body of Evidence TV ad - final report			
21000	ISENR002-003105	ISENR002-003106	1/29/2003	Email: HT monograph: is br ca outcome statistically significant or not?			
21001	PANAA025-001462	PANAA025-001462	8/8/1989	Ashby memo re: stories on the NEJM article			
21003	CHOOM028-000248	CHOOM028-000248	8/7/1998	Burson-Marsteller memo re: Good Housekeeping			
21004	PINIM020-000272	PINIM020-000275		CE/MPA protocol 0713D2-309-US, GMR-38605			
21004A	PINIM020-000284	PINIM020-000288	10/22/1996	set of test results for an adverse event for 713B-309-US			
21004B	PINIM020-000289	PINIM020-000294	7/14/1998	set of test results for an adverse event - Linda Carson			
21004C	PINIM020-000345	PINIM020-000349		set of test results for an adverse event in Nebraska			
21004D	PINIM020-000278	PINIM020-000278		set of test results for an adverse event for 713D2-309-US. Site in Florida.			
21004E	PINIM020-000341	PINIM020-000343		set of test results for an adverse event. Site in Virginia.			
21004F	Various	Various		set of test results for an adverse event for 713D2-309-US. Site in Kansas.			
21004G	Various	Various		set of test results for an adverse event for 713D2-309-US. Site in Indiana.			
21004H	Various	Various		set of test results for an adverse event for 713D2-309-US. Site in Indiana.			
21004I	Various	Various	7/3/1997	set of test results for an adverse event for protocol 95-207.			
21004J	Various	Various	5/15/1998	set of test results for an adverse event. Study site in Massachusetts			
21004K	PINIM020-000326	PINIM020-000328	7/20/1999	set of test results for an adverse event. Study site in Arizona			
21004L	PINIM020-000329	PINIM020-000340		set of test results for an adverse event. Study site in Virginia.			
21005	WHALEY-S 0001400	WHALEY-S 0001402	8/2/2002	Email re: HRT and breast cancer risk			
21006	W-LABELS-005291	W-LABELS-005295	00/00/1997	1997 Physician's Desk Reference			
21007			12/30/2006	excerpts from Colditz deposition			
21008			5/27/2004	excerpt from Pickar deposition			
21009			1/17/2006	excerpts from Marder deposition			
21010	W-LABELS-005331	W-LABELS-005337	00/00/1997	1997 PDR			
21011	DESIGN177196	DESIGN177196	3/26/2001	Email re: Trudy paper			
21012	MARTN010-005744	MARTN010-005753	3/15/2001	Strategic publication plan tracking report			
21013				excerpts from Poussot testimony and Dey deposition			
21014	CONKJ217-000552	CONKJ217-000552	4/25/2003	Letter re: investigation involving sales rep Carlos Monteiro, 72FAF			
21015	CORRA302-000002	CORRA302-000002	2/28/2001	Keefer memo re: reassignment of Richards			
21016	CORRA302-000066	CORRA302-000066		Two benefits vs a risk of ERT			
21017	OLIVS020-008538	OLIVS020-008863		Trimegestrone study -> causality assessments			
21018	W-MDL04782-00063597	W-MDL04782-00063597	11/00/1974	Letter re Kerr			
21019	W-MDL04782-00017197	W-MDL04782-00017204	7/00/1974	First flush of menopause ad			
21020	HOLSON017-002627	HOLSON017-002629		Estrogen deficient brochure			
21021	CONSG204-000348	CONSG204-000368		Executive Safety Review Powerpoint			
21022	KUSIV201-005240	KUSIV201-005242	7/8/2003	Internal memo re: PDR audit - Wyeth U.S.			
21023	W-PUBLIC-004136	W-PUBLIC-004148		CDER medical review			
21024	SOLOJ022-001055	SOLOJ022-001056	2/13/1996	Burson Marsteller re Trudi Bush			
21025	CHOOM057-001146	CHOOM057-001146	9/26/1997	Internal memo from Michaels re: meta-reanalysis of breast cancer diagnosis in HRT users			
21026	CHOOM057-001200	CHOOM057-001206	10/6/1997	Revised confidential draft Lancet response plan			
21027				Celgene Corp's proposed changes to approved Thalomid PI			
21027A				Celgene Corp's proposed changes to approved Thalomid PI (one page)			
21028				Roche's Accutane labeling			
21028A				Roche's Accutane labeling (one page)			
21029	DUROJ213-038809	DUROJ213-038809	6/16/2003	Pickar email to Durocher re: WHI			
21029A	DUROJ213-038810	DUROJ213-038812		Letter re: WHI impact on clinical decision-making with respect to HRT use			
21030	DUROJ042-000773	DUROJ042-000733		CME proposals - professional conventions			
21031A	ZUCAV212-000134	ZUCAV212-000135		subject narrative - adverse event info for CE/TMG study 915A3-300-US			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
21031B	ZUCAV212-000167	ZUCAV212-000167		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031C	ZUCAV212-000162	ZUCAV212-000163		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031D	ZUCAV212-000211	ZUCAV212-000212		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031E	ZUCAV212-000221	ZUCAV212-000222		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031F	ZUCAV212-000175	ZUCAV212-000176		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031G	ZUCAV212-000190	ZUCAV212-000190		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031H	ZUCAV212-000106	ZUCAV212-000106		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031I	ZUCAV212-000123	ZUCAV212-000123		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031J	ZUCAV212-000181	ZUCAV212-000181		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031K	OLIVS020-008847	OLIVS020-08847		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031L	ZUCAV212-000206	ZUCAV212-000207		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031M	ZUCAV212-000229	ZUCAV212-000230		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031N	ZUCAV212-000143	ZUCAV212-000143		subject narrative - adverse event info for CE/TMG study 915A3-300-US			
21031O	ZUCAV212-000117	ZUCAV212-000118	11/6/2002	Medwatch report - adverse event info for study 915A3-300			
21032A	ZUCAV212-000389	ZUCAV212-000389		patient narrative - AE for 17beta-estradiol/TMG study 915A2-302-EU			
21032B	ZUCAV212-000390	ZUCAV212-000390		patient narrative - AE for 17beta-estradiol/TMG study 915A2-302-EU			
21032C	ZUCAV212-000384	ZUCAV212-000384		patient narrative - AE for 17beta-estradiol/TMG study 915A2-302-EU			
21032D	ZUCAV212-000386	ZUCAV212-000386		patient narrative - AE for 17beta-estradiol/TMG study 915A2-302-EU			
21032E	ZUCAV212-000385	ZUCAV212-000385		patient narrative - AE for 17beta-estradiol/TMG study 915A2-302-EU			
21032F	ZUCAV212-000387	ZUCAV212-000387		patient narrative - AE for 17beta-estradiol/TMG study 915A2-302-EU			
21032G	ZUCAV212-000388	ZUCAV212-000388		patient narrative - AE for 17beta-estradiol/TMG study 915A2-302-EU			
21033	STEPW201-001061	STEPW201-001063		table re: adverse events for study 301 EU continuous combined			
21033A	ZUCAV212-000379	ZUCAV212-000379		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21033B	ZUCAV212-000374	ZUCAV212-000374		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21033C	ZUCAV212-000381	ZUCAV212-000381		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21033D	ZUCAV212-000375	ZUCAV212-000375		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21033E	ZUCAV212-000376	ZUCAV212-000376		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21033F	ZUCAV212-000378	ZUCAV212-000378		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21033G	ZUCAV212-000190	ZUCAV212-000190		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21033H	ZUCAV212-000383	ZUCAV212-000383		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21033I	ZUCAV212-000380	ZUCAV212-000380		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21033J	ZUCAV212-000382	ZUCAV212-000382		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21033K	ZUCAV212-000373	ZUCAV212-000373		patient narrative - AE for 17beta-estradiol/TMG study 915A2-301-EU			
21034	ISENR002-003105	ISENR002-003106	1/29/2003	Isenberg email re: HT monograph: is the br ca outcome statistically signif?			
21035	CORRA302-000240	CORAA302-000242	1/11/2001	Letter from Richards to Whatley re: disagreement on a sales call			
21036	DUROJ020-000533	DUROJ020-000533	11/9/1998	Premarin Media Highlights			
21037			12/13/1966	Nobel prize cancer regression			
21037A	PICKJ042-010211	PICKJ042-010211	4/20/1999	Internal memo to Prempro science team steering cmte from Pickar			
21038	STRIS016-001455	STRIS016-001458		VSB			
21038A	BROWS002-000370	BROWS002-000370	5/15/2000	Internal memo from Brown re: menopause handbook			
21039			6/14/1995	VMS transcript from NBC Nightly News re: considering ERT/HRT			
21040	DEYMI206-023097	DEYMI206-023104	2/20/2004	Press release re: lower effective dose of Prempro			
21041	HENRL001-000103	HENRL001-000111	00/00/1997	Raloxifene defense plan and Premarin program PR budgets			
21042	DUROJ013-000363	DUROJ013-000372	11/00/1997	National Council on the Aging's Myths and Misperceptions			
21043	SOLOJ015-000353	SOLOJ015-000355	2/3/2000	Frontiers in Estrogen Action estimate investment summary			
21044	SOLOJ015-000338	SOLOJ015-000340	4/12/2000	Email from Landers re: 4th Annual Update			
21045	SOLOJ019-001325	SOLOJ019-001329		5th annual frontiers in estrogen action guest activity list			
21046	CONTA023-032272	CONTA023-032288	2/27/1998	W-A domestic direct marketing spend: 1998 budget			
21047	W-MDL527-00046537	W-MDL527-00046560	2/24/2000	FDA form: MD alert letter re: breast cancer			
21048	FONTL213-000370	FONTL213-000377	3/19/2002	EU core SPC for HRT labeling comparison			
21049	SOLOJ015-000124	SOLOJ015-000126	4/23/1998	List of invitees: Frontiers in Estrogen Action			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
21050	LYTTR016-007782	LYTTR016-007782		Dear dr invitation for co-chairs at 5th Annual Frontiers in Estrogen Action symposium			
21051	RHUDM006-000749	RHUDM006-000752	6/14/1995	Wyeth Press Release			
21051A	LYTTR016-007778	LYTTR016-007778		Dear dr invitation for session chairs at 5th annual frontiers in estrogen action symposium			
21052	SOLOJ015-000363	SOLOJ015-000363	3/6/2000	McGettigan Partners letter re: 4th Annual Frontiers in Estrogen Action			
21053	SOLOJ015-000349	SOLOJ015-000351		4th annual frontiers in estrogen guest list			
21054	CHOOM003-000101	CHOOM003-000104	5/00/1998	Premarin News Net letter re: breast cancer prevention			
21055	W-MDL04782-00034713	W-MDL04782-00034714	6/10/1991	Sasson letter to FDA re: lit review of E+P therapy for advisory cmte mtng			
21056			12/00/1995	Prempro Ad with HCP "Office" Perspective			
21061				Generic Expert Report - Warren F. Rumble			
21062				Generic Expert Report - Edward Sickles, M.D.			
21063	CHOOM057-001044	CHOOM057-001044	10/5/1997	Internal memo re HRT and breast cancer			
21064	CHOOM057-001052	CHOOM057-001077	10/5/1997	HRT and Breast Cancer - Product Crisis Action Plan			
21065	FONTL037-002568	FONTL037-002568	8/1/2002	Fontaine email for response to TGA re: labeling text post-WHI			
21066	FONTL037-001215	FONTL037-001218	5/8/2002	Letter to TGA re: Premia safety related notification			
21067	FONTL037-001213	FONTL037-001214	7/24/2002	Email from Wright re: comments on TGA request dated 07/19/2002			
21068	FONTL037-009106	FONTL037-009106	8/30/2002	Notification of Labeling Decision			
21069				U Penn Protocol			
21070	CEPPM201-000433	CEPPM201-000448		Lyons vrbo			
21071	BARBM301-033102	BARBM301-033125	8/31/2003	Lyon vrbo			
21072				Lyon call notes			
21072b				Lyon IMS			
21073			2/11/2010	San Antonio Breast Cancer Symposium - 2009			
21074			4/19/2007	New Evidence Supports Hrt and Breat Cancer Link: Susan Love			
21075			11/1/2007	What you need to know about breast cancer - National Cancer Inst			
21079	SOLOJ028-030675	SOLOJ028-030809		Slide presentation: Premarin family net sales			
21080			12/00/2009	Prempro Label 2009 (rev 12/30/09)			
21081	W-VSBSLIDES-000001	W-VSBSLIDES-000063		VSB Slides			
21082			6/00/2009	M. Wertheimer cv			
21083			10/1/2009	R. Patten CV			
21084				P Michaels CV			
21085	ZUCAV007-012629	ZUCAV007-012668	5/20/2001	Reporting Adverse Events			
21086	PICKJ021-002265		3/9/1993	WHI memo			
21087	PICKJ008-000898	PICKJ008-000899	3/27/1995	Wyeth Internal Correspondence re: HRT Guidance			
21088	PICKJ021-002563	PICKJ021-002564	7/10/1992	Wyeth Internal Correspondence re: WHI Drug Supply Specifics			
21089				MD Anderson Website			
21089A				US best ranking hospitals			
21090			11/9/2009	Susan G. Komen website			
21091			9/00/2009	Beth Israel website			
21094			00/00/2009	Study: Hormone therapy caused breast cancer for thousands by Anne Harding in CNN.com			
21096				Georgetown adverse event report form			
21097			4/21/2010	Georgetown press release re density			
21099				Georgetown website prevention			
21101			4/9/2010	Georgetown Adam Breast cancer website			
21102				Moffitt website			
21103				Breaking News on Breast Cancer - Oprah.com			
21104				Minkin site			
21105			10/27/2005	The email 10/27/05 between laura smith and himmelberg-			
21106			10/1/2007	Inv. No. 16087 from Anderson, Murphy and Hopkins LLP, dated October 1, 2007			
21106A			8/3/2007	Letter to Dr. Robert O. Lawrence dated August 3, 2007			
21107				DEPOSITION OF DR. SONGUN XUE			
21107a				DR. JAMES PICKAR			
21107b			3/9/2004	Stovall article on fibroids			
21108	WINNR401-013149	WINNR401-013275		Durocher 2005 powerpoint			
21108a	PINI-019-008008			Reporting adverse Events			
21109	W-MDL-527-00044496	W-MDL-527-00044533	6/7/2002	FDA letter to Holston			
21110	PINIM019-008007	PINIM019-008065		Recording and Reporting Adverse Events Powerpoint Presentation by Global Safety Surveillance & Epidemiology			
21111			6/24/2010	Ghostwriting in Medical Literature / Minority Staff Report / Sen. Charles E Grassley			
21112			00/00/2000	Pharmacoeidemiology: 3rd Edition / edited by Brian L. Strom			
21113			8/5/2009	Clariant website: E-Cadherin			
21114			00/00/1998	Prometrium Label			
21115	DUROJ045-000486	DUROJ045-000486	12/7/2000	Field Marketing Support: Dr. Leon Speroff Invitations			
21116			00/00/0000	21 CFR 314.80			
21117			00/00/2008	Prempro PDR Label			
21118			1/11/1996	Memo to Jeff Buchalter			
21120				pastner report			
21120			3/13/2011	Generic Expert Report - Bruce Patsner, M.D.			
21121				Pastner CV			
21121			03/00/2011	CV for Dr. Bruce Patsner			
21122				Tilley report			
21122			03/00/2008	Generic Expert Report - Wayne Tilley PhD			
21123				Tilley cv			
21123			12/12/2007	CV for Dr. Wayne Tilley			
21124				Pfizer Website			

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
21125			8/27/2010	Division of Drug Marketing Advertising and Communications of the FDA letter signed by Carrie A. Newcomer			
21126				Austin Seer Data May 2011			
21127			3/20/1995	1995 FDA guidance			
21127B				Guidance for Clinical Evaluation of Combination Estrogen/Progestin-Containing Drug Products Used for Hormone Replacement Therapy (Hrt) of Postmenopausal Women			
21129			9/1/2011	FDA questions and answer regarding Estrogen- Fda website			
8078A				Sloane Kettering -Breast Cancer: New Concepts Hudis			
8078B			1/20/2010	Norton speech "BREAST CANCER MEDICINE, PRESENT AND FUTURE"			
9299A				Lauren Hutton Ad			
M0001			7/1/2006		Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.	Anderson et al.	Maturitas 2006
M0002			6/25/2003		Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.	Chlebowski, RT, Hendrix, SL, Langer, RD, Stefanick, ML, Gass, ML, Lane, DS, Rodabough, RJ, Gilligan, MA, Cyr, MG, Thomson, CA, Khandekar, J, Petrovitch, H, McTiernan, A, WHI Investigators	JAMA 2003;289:3243-53; 289(24):3243-53.
M0003			6/15/1995		The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.	Colditz, GA, Hankinson, SE, Hunter, DJ, Willett, WC, Manson, JE, Stampfer, MJ, Hennekens, C, Rosner, B, Speizer, FE	N Engl J Med 1995;332:1589-93
M0004			10/7/2002		Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality.	Durna, EM, Wren, BG, Heller, GZ, Leader, LR, Sjoblom, P, Eden, JA	Med J Aust 2002;177:347-51
M0005			7/15/2002		Failure Of Estrogen Plus Progestin Therapy For Prevention.	Fletcher, SW, Colditz, GA	JAMA. 2002 Jul 17;288(3):366-8.
M0007			7/3/2002		Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen / progestin Replacement Study follow-up (HERS2).	Grady, D, Herrington, DM, Bittner, V, Blumenthal, R, Davidson, M, Hlatky, MA, Hsia, J, Hulley, S, Herd, A, Kahn, S, Newby, LK, Waters, D, Vittinghoff, E, Wenger, N, HERS Research Group	JAMA. 2002;288(1):49-57.
M0008			5/21/2003		Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.	Greenspan, SL, Resnick, NM, Parker, RA	JAMA. 2003 May 21; 289(19):2525-33.
M0009			2/13/2003		Understanding the divergent data on postmenopausal hormone therapy.	Grodstein, F, Clarkson, TB, Manson, JE	N Engl J Med. 2003 Feb 13; 348(7):645-50.
M0010			5/8/2003		Effects of estrogen plus progestin on health-related quality of life.	Hays, J, Ockene, JK, Brunner, RL, Kotchen, JM, Manson, JE, Patterson, RE, Aragaki, AK, Shumaker, SA, Brzyski, RG, LaCroix, AZ, Granek, IA, Valanis, BG, Women's Health Initiative Investigators	N Engl J Med. 2003 May 8; 348(19):1935-7.
M0011			8/7/2003		From presumed benefit to potential harm - hormone therapy and heart disease.	Herrington, DM, Howard, TD	N Engl J Med. 2003 Aug 7; 349(6):519-21.
M0012			2/6/2002		Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen / Progestin Replacement Study (HERS) trial.	Hlatky, MA; Boothroyd, D; Vittinghoff, E; Sharp, P; Whooley, MA; Heart and Estrogen / Progestin Replacement Study (HERS) Research Group	JAMA. 2002 Feb 6; 287(5):591-7.
M0013			8/7/2003		Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women.	Hodis, HN, Mack, WJ, Azen, SP, Lobo, RA, Shoupe, D, Mahrer, PR, Faxon, DP, Cashin-Hemphill, L, Sanmarco, ME, French, WJ, Shook, TL, Gaarden, TD, Mehra, AO, Rabbani, R, Sevanian, A, Shil, AB, Torres, M, Vogelbach, KH, Selzer, RH, Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group	N Engl J Med. 2003 Aug 7; 349(6):535-45.
M0014			7/3/2002		Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen / Progestin Replacement Study follow-up (HERS 2).	Hulley, S, Furberg, C, Barrett-Connor, E, Cauley, J, Grady, D, Haskell, W, Knopp, R, Lowery, M, Satterfield, S, Schrott, H, Vittinghoff, E, Hunninghake, D, HERS Research Group	JAMA. 2002;288(1):58-66.
M0015			7/17/2002		Menopausal hormone replacement therapy and risk of ovarian cancer.	Lacey, JV, Mink, PJ, Lubin, JH, Sherman, ME, Troisi, R, Hartge, P, Schatzkin, A, Schairer, C	JAMA. 2002 Jul 17; 288(3):334-41.
M0017			3/19/2003		Trends in incidence rates of invasive lobular and ductal breast carcinoma.	Li, CI, Anderson, BO, Daling, JR, Moe, RE	JAMA. 2003 Mar 19; 289(11):1421-4.
M0018			6/25/2003		Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.	Li, CI, Malone, KE, Porter, PL, Weiss, NS, Tang, MT, Cushing-Haugen, KL, Daling, JR	JAMA. 2003 Jun 25; 289(24):3254-63.
M0019			8/7/2003		Estrogen plus progestin and the risk of coronary heart disease.	Manson, JE, Hsia, J, Johnson, KC, Rossouw, JE, Assaf, AR, Lasser, NL, Trevisan, M, Black, HR, Heckbert, SR, Detrano, R, Strickland, OL, Wong, ND, Crouse, JR, Stein, E, Cushman, M, Women's Health Initiative Investigators	N Engl J Med. 2003 Aug 7; 349(6):523-34.

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0020			6/27/2002		Oral contraceptives and the risk of breast cancer.	Marchbanks, PA, McDonald, JA, Wilson, HG, Folger, SG, Mandel, MG, Daling, JR, Bernstein, L, Malone, KE, Ursin, G, Strom, BL, Norman, SA, Wingo, PA, Burkman, RT, Berlin, JA, Simon, MS, Spirtas, R, Weiss, LK	N Engl J Med. 2002 Jun 27; 346(26):2025-32.
M0021			8/19/1999		The million women study: Design and characteristics of the study population.	Million Women Study Collaborative Group (Beral, V)	Breast Cancer Res1999 ;1(1):73-80
M0022			10/11/1997		Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.	Collaborative Group on Hormonal Factors in Breast Cancer (Beral),	Lancet. 1997 Oct 11;350(9084):1047-59;
M0027			7/3/2002		Hormone replacement therapy for prevention: more evidence, more pessimism.	Petitti, DB	JAMA. 2002 Jul 3; 288(1):99-101.
M0029			5/28/2003		Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.	Rapp, SR, Espeland, MA, Shumaker, SA, Henderson, VW, Brunner, RL, Manson, JE, Gass, ML, Stefanick, ML, Lane, DS, Hays, J, Johnson, KC, Coker, LH, Dailey, M, Bowen, D, WHIMS Investigators	JAMA. 2003 May 28; 289(20):2663-72.
M0030			7/17/2002		Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.	Writing Group WHI, Writing Groups for the Women's Health Initiative Investigators	JAMA. 2002 Jul 17 288(3):321-33.
M0031			3/15/1995		Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus.	Sanchez-Guerrero, J, Liang, MH, Karlson, EW, Hunter, DJ, Colditz, GA	Ann Intern Med. 1995 Mar 15; 122(6):430-3.
M0032			5/28/2003		Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.	Shumaker, SA, Legault, C, Rapp, SR, Thal, L, Wallace, RB, Ockene, JK, Hendrix, SL, Jones, BN, Assaf, AR, Jackson, RD, Kotchen, JM, Wassertheil-Smolter, S, Wactawski-Wende, J, WHIMS Investigators	JAMA. 2003 May 28; 289(20):2651-62.
M0033			2/1/2002		Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer.	Ursin, G, Tseng, CC, Paganini-Hill, A, Enger, S, Wan, PC, Formenti, S, Pilo, MC, Ross, RK	J Clin Oncol. 2002 Feb 1; 20(3):699-706.
M0034			5/28/2003		Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.	Wassertheil-Smolter, S, Hendrix, SL, Limacher, M, Heiss, G, Kooperberg, C, Baird, A, Kotchen, T, Curb, JD, Black, HR, Rossouw, JE, Aragaki, AK, Safford, M, Stein, E, Laowattana, S, Mysiw, WJ, WHI Investigators	JAMA. 2003 May 28; 289(20):2717-9.
M0035			12/00/2002		Hormone replacement therapy regimens and breast cancer risk (1).	Weiss, LK, Burkman, RT, Cushing-Haugen, KL, Voigt, LF, Simon, MS, Daling, JR, Norman, SA, Bernstein, L, Ursin, G, Marchbanks, PA, Strom, BL, Berlin, JA, Weber, AL, Doody, DR, Wingo, PA, McDonald, JA, Malone, KE, Folger, SG, Spirtas, R	Obstet Gynecol 2002;100:1148-58
M0038			10/1/2003		Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.	Anderson, GL, Judd, HL, Kaunitz, AM, Barad, DH, Beresford, SA, Pettinger, M, Liu, J, McNeely, SG, Lopez, AM, Women's Health Initiative Investigators	JAMA. 2003 Oct 1; 290(13):1739-48.
M0039			12/00/1998		Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study.	O'Connor, IF, Shembekar, MV, Shousha, S.	J Clin Pathol. 1998 Dec; 51(12):935-8.
M0040			01/00/1995		Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy.	Bonnier, P, Romain, S, Giacalone, PL, Laffargue, F, Martin, PM, Piana, L	Obstet Gynecol. 1995 Jan; 85(1):11-7.
M0041			10/15/1995		Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women.	Newcomb, PA, Longnecker, MP, Storer, BE, Mittendorf, R, Baron, J, Clapp, RW, Bogdan, G, Willett, WC	Am J Epidemiol. 1995 Oct 15; 142(8):788-95.
M0042			04/00/2003		Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States).	Newcomer, LM, Newcomb, PA, Potter, JD, Yasui, Y, Trentham-Dietz, A, Storer, BE, Longnecker, MP, Baron, JA, Daling, JR	Cancer Causes Control. 2003 Apr 14(3):225-33.
M0044			07/00/2002		Postmenopausal estrogen and progestin use in relation to breast cancer risk.	Newcomb, PA, Titus-Ernstoff, L, Egan, KM, Trentham-Dietz, A, Baron, JA, Storer, BE, Willett, WC, Stampfer, MJ	Cancer Epidemiol Biomarkers Prev. 2002 Jul; 11(7):593-600.
M0046			10/00/2002		Changing incidence of lobular carcinoma in situ of the breast.	Li, CI, Anderson, BO, Daling, JR, Moe, RE	Breast Cancer Res Treat. 2002 Oct; 75(3); 259-68.
M0047			12/15/2002		Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.	Daling, JR, Malone, KE, Doody, DR, Voigt, LF, Bernstein, L, Coates, RJ, Marchbanks, PA, Norman, SA, Weiss, LK, Ursin, G, Berlin, JA, Burkman, RT, Deapen, D, Folger, SG, McDonald, JA, Simon, MS, Strom, BL, Wingo, PA, Spirtas, R	Cancer. 2002 Dec 15; 95(12):2455-64.
M0048			10/15/2000		Changing incidence rate of invasive lobular breast carcinoma among older women.	Li, CI, Anderson, BO, Porter, PL, Holt, SK, Daling, JR, Moe, RE	Cancer. 2000 Oct 15; 89(8):1867-8.
M0049			6/1/2000		Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women.	Li CI, Weiss NS, Stanford JL, Daling JR	Cancer. 2000 Jun 1;88(11):2570-7
M0051			1/1/2003		Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998.	Li, CI, Daling, JR, Malone, KE	J Clin Oncol. 2003 Jan 1; 21(1):28-34.
M0052			9/21/2002		Evidence from randomized trials on the long-term effects of hormone replacement therapy.	Beral, V, Banks, E, Reeves, G	Lancet 2002;360:942-944
M0053			2/13/2002		Hormone replacement therapy in relation to breast cancer.	Chen, C-L, Weiss, NS, Newcomb, P, Barlow, W, White, E,	JAMA 2002;287:734-741

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0054			8/24/2000		Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.	Herrington, DM, Reboussin, DM, Brosnihan, KB, Sharp, PC, Shumaker, SA, Snyder, TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D.	N Engl J Med. 2000 Aug 24;343(8):522-9
M0055			7/19/1997		Impact of postmenopausal hormone therapy on cardiovascular events and cancer:: pooled data from clinical trials.	Hemminki, E, McPherson, K	BMJ. 1997 Jul 19;315(7101):149-53
M0056			12/3/2003		Press release: further advice on safety of hormone replacement therapy (HRT).	United Kingdom Department of Health	UKDH 2003/0492
M0057			9/26/2003		Public Citizen Letter to FDA concerning potentially dangerous patient information on Hormone Replacement Therapy (HRG Pub #1677).	Sasich, LD, Lurie, P	Public Citizen's Health Research Group: HRG1677
M0058			10/00/1999		Epidemiologic studies of environmental agents and systemic autoimmune diseases.	Mayes, MD	Environ Health Perspect. 1999 Oct; 107 Suppl 5:743-8.
M0060					Preliminary study for Wyeth	Hulka	
M0061			10/24/1985		Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study.	Wilson, PW, Garrison, RJ, Castelli, WP	N Engl J Med. 1985 Oct 24; 313(17):1038-43.
M0062			10/24/1985		A prospective study of postmenopausal estrogen therapy and coronary heart disease.	Stampfer, MJ, Willett, WC, Colditz, GA, Rosner, B, Speizer, FE, Hennekens, CH	N Engl J Med. 1985 Oct 24; 343(17):1044-9.
M0063			1/26/2000		Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.	Schairer, C, Lubin, J, Troisi, R, Sturgeon, S, Brinton, L, Hoover, R	JAMA 2000;283:485-491
M0064			11/00/1995		The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women.	Grodstein, F, Stampfer, MJ	Prog Cardiovasc Dis. 1995 Nov-Dec; 38(3):199-210.
M0065			9/12/1991		Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study.	Stampfer, MJ, Colditz, GA, Willett, WC, Manson, JE, Rosner, B, Speizer, FE, Hennekens, CH	N Engl J Med. 1991 Sep 12; 325(11):756-62.
M0067			8/19/1998		Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.	Hulley, S, Grady, D, Bush, TL, Furberg, C, Herrington, D, Riggs, B, Vittinghoff, E	JAMA 1998;280:605-13; 280(7):605-13.
M0068			11/20/2002		Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.	Waters, DD, Alderman, EL, Hsia, J, Howard, BV, Cobb, FR, Rogers, WJ, Ouyang, P, Thompson, P, Tardif, JC, Higginson, L, Bittner, V, Steffes, M, Gordon, DJ, Proschan, M, Younes, N, Verter, JT	JAMA. 2002 Nov 20; 288(19):2432-40.
M0069			6/10/2002		Post-menopausal hormonal therapy and gallbladder cancer risk.	Gallus, S, Negri, E, Chatenoud, L, Bosetti, C, Franceschi, S, La Vecchia, C	Int J Cancer. 2002 Jun 10; 99(5):762-3.
M0071			09/00/2002		A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study.	Clarke, SC, Kelleher, J, Lloyd-Jones, H, Slack, M, Scofield, PM	BJOG 2002;109:1056-62; 1056-62.
M0072			06/00/2002		Cancer risk in menopausal women.	La Vecchia, C, Brinton, LA, McTernan, A	Best Pract Res Clin Obstet Gynaecol. 2002;16:293-307; 16(3):293-307.
M0074			12/15/1992		Hormone therapy to prevent disease and prolong life in postmenopausal women.	Grady, D, Rubin, SM, Petitti, DB, Fox, CS, Black, D, Ettinger, B, Ernster, VL, Cummings, SR	Ann Intern Med. 1992 Dec 15; 117(12):1016-37.
M0076			8/7/2003		Hormone-replacement therapy and cardiovascular diseases.	Bailar, J	N Engl J Med. 2003 Aug 7; 349(6):521-2.
M0077			1/7/2004		National Use of Postmenopausal Hormone Therapy: Annual Trends and Response to Recent ; Evidence.	Hersh, AL, Stefanick, ML, Stafford, RS	JAMA 2004;291:47-53
M0078			4/25/1980		A case control study of menopausal estrogen therapy and breast cancer.	Ross, RK, Paganini-Hill, A, Gerkins, VR, Mack, TM, Pfeffer, R, Arthur, M, Henderson, BE	JAMA 1980;243:1635-1639
M0079			8/9/2003		Breast Cancer and Hormone Replacement Therapy in the Million Women Study.	Million Women Study Collaborators (Beral)	Lancet 2003; 362:419-27
M0080			1/11/1999		Letter to Dr. Sonk @ Wyeth from FDA re: False or misleading ad claims.	Peterson, J	N/A
M0081			5/20/1988		Leter to Dr. Sonk @ Wyeth from FDA re: misleading ads, off label use promotion.	Stockbridge, LL	N/A
M0083			9/1/1999		Hormone replacement therapy and incident arthritis.	Wilkins, K	Health Reports (Canada) Autumn 1999, Vol. 11, No. 2 49-57
M0085			4/28/1999		Hormone replacement therapy and high S phase in breast cancer.	Cobleigh, MA, Norlock, FE, Oleske, DM, Starr, A	JAMA 1999;281:1528-1530
M0086			11/28/1990		Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women.	Colditz, GA, Stampfer, MJ, Willet, WC, Hennekens, CH, Rosner, B, Speizer, FE	JAMA 1990;264:2648-2653
M0094			2/1/1995		Recent cancer trends in the United States.	Devesa, SS, Blot, WJ, Stone, BJ, Miller, BA, Tarone, RE, Fraumeni, JF	J Natl Cancer Inst 87:175-182, 1995
M0096			6/1/1995		Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: How many kinds of breast cancer are there?	Potter, JD, Cerham, JR, Sellers, TA, McGovern PG, Drinkard, C, Kushi, LR, Folsom, AR	Cancer Epidemiol Biomarkers Prev 1995;4(4):319-326
M0097			8/1/2002		Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada.	Kirsh, V, Krieger, N	Cancer Causes Control 2002;13:583-590
M0098			2/16/2000		Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin.	Ross, RK, Paganini-Hill, A, Wan, PC, Pike, MC,	J Natl Cancer Inst 2000;92:328-332
M0102			4/1/1979		Experience with lobular carcinoma of the breast.	Davis, RP, Nora, PF, Kooy, RG, Hines, JR	Arch Surg 114:485-488, 1979
M0104			7/1/1993		Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer: Correlation of histopathology and prognostic factors.	Stierer, M, Rosen, H, Weber, R, Hanak, H, Spona, J, Tuchler	Ann Surg 1993;218:13-21
M0107			1/1/1995		Use of menopausal estrogens and Medroxyprogesterone in the United States, 1982-1992.	Wysowski, DK, Golden, L, Burke, L,	Obstet Gynecol 1995;85:6-10
M0108			11/1/1988		Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-1986.	Hemminki, E, Kennedy, DL, Baum, C, McKinlay, SM	AJPH 1988;78:1478-1481
M0109			3/1/1985		Noncontraceptive estrogens and progestins: Use patterns over time.	Kennedy, DL, Baum, C, Forbes, MB	Obstet Gynecol 1985;65:441-6
M0110			9/1/1999		Use of HRT and the subsequent risk of cancer.	Beral, V, Banks, E, Reeves, G, Appleby, P,	J Epidemiol Biostat 1999;4(3):191-215
M0113			6/1/2001		Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses.	Banks, E, Beral, V, Cameron, R, Hogg, A, Langley, N, Barnes, I, Bull, D, Elliman, J, Harris, CL	J Epidemiol Biostat 2001;6(4):357-363
M0114			8/6/1997		Estrogen-Progestin replacement therapy and endometrial cancer.	Pike, MC, Peters, RK, Cozen, W, Probst-Hensch, NM, Feliz, JC, Wan, PC, Mack, TM	J Natl Cancer Inst 1997;89:1110-1116

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0115			7/7/1999		Risk of endometrial cancer following estrogen replacement with and without progestins.	Weiderpass, E, Adami, H, Baron, JA, Magnusson, C, Bergstrom, R, Lindgren, A, Correia, N, Persson, I	J Natl Cancer Inst 1999;91:1131-1137
M0116			3/1/2003		Patterns of post-menopausal progestin use with estrogen in relation to endometrial cancer (United States); .	Newcomb, PA, Trentham-Dietz, A	Cancer Causes Control 2003;14(2):195-201
M0117			5/5/1999		Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy.	Magnusson, C, Baron, JA, Correia, N, Bergstrom, R, Adami, H, Persson, I	Int J Cancer 1999;81:339-344
M0118			12/1/2003		Progestins initiate adverse events of menopausal estrogen therapy.	Thomas, T, Rhodin, J, Clark, I, Garces, A	Climacteric 2003;6:293-301
M0119			4/12/1997		Hormone replacement therapy and high incidence of breast cancer between mammographic screens.	Beral, V, Banks, E	Lancet 1997;349:1103-1107
M0120			10/27/2001		Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58209 women with breast cancer and 101986 without the disease.	Collaborative Group on Hormonal Factors in Breast Cancer	Lancet 2001;358:1389-1399
M0123			1/1/2004		Significance of the Detection of Esters of p- Hydroxybenzoic Acid (Parabens) in Human Breast Tumours.	Harvey, P, Everett, D	J. Appl. Toxicol. 24:1-4
M0124			2/3/2004		HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped.	Holmberg, L, Anderson, H,	Lancet 2004, 363:453-455
M0126			12/19/1998		Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy.	Sourander, L, Rajala, T, Raiha, I, Makinen, J, Erkkola, R, Helenius, H	Lancet 1998;352:1965-9
M0130			2/5/2004		AHA Guidelines: Evidence based guidelines for cardiovascular disease prevention in women.	Lori Mosca, MD, PhD (Chair)†; Lawrence J. Appel, MD†; Emelia J. Benjamin, MD†; Kathy Berra, MSN, ANP§; Nisha Chandra-Strobo, MD†; Rosalind P. Fabunmi, PhD†; Deborah Grady, MD, MPH†; Constance K. Haan, MD ; Sharonne N. Hayes, MD†; Debra R. Judelson, MD#; Nora L. Keenan, PhD††; Patrick McBride, MD, MPH†; Suzanne Oparil, MD†; Pamela Ouyang, MD†; Mehmet C. Oz, MD†; Michael E. Mendelsohn, MD†; Richard C. Pasternak, MD†; Vivian W. Pinn, MD§§; Rose Marie Robertson, MD†; Karin Schenck-Gustafsson, MD, PhD†; Cathy A. Sila, MD†; Sidney C. Smith, Jr, MD¶¶; George Sopko, MD, MPH‡‡; Anne L. Taylor, MD***; Brian W. Walsh, MD ; Nanette K. Wenger, MD†; Christine L. Williams, MD, MPH†;	Circ 2004;109:672-693
M0131			2/1/2004		Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.	Evio, s, Tiitinen, A, Laitinen, K, Ylikorkala, O, Valimaki, MJ	J Clin Endocrinol Metab 2004, 89:626-631
M0133			1/1/1982		The decreasing incidence of endometrial cancer: Public health implications.	Austin, DF, Roe, KM	AJPH 1982;72(1)65-68
M0134			2/10/2004		Estrogen plus progestin and the risk of peripheral arterial disease.	Hsia, J, Criqui, M, Rodabough, R, Langer, R, Resnick, H, Phillips, L, Allison, M, Bonds, D, Masaki, K, Caralis, P, Kotchen, J,	Circulation 2004;109:620-6
M0137			2/17/2004		Benefits and harms associated with hormone replacement therapy: clinical decision analysis.	Minelli, C, Abrams, K, Sutton, A, Cooper, N	BMJ 2004;328:371
M0139			2/18/2004		Antibiotics and Breast Caner - What's the Meaning of This?	Ness, R, Cauley, J	JAMA 2004;291:880-1
M0148			1/7/2004		Hormone therapy and risk of gynecologic cancers.	Utian, W,	JAMA 2004;291:42
M0151			2/1/2004		Weight gain, body mass index, hormone replacement threapy, and postmenopausal breast cancer in a large prospective study.	Feigelson, H, Jonas, C, Teras, L, Thun, M, Calle, E	Cancer epidemiol Biomarkers Prev Vol.33, 220-224
M0152			1/1/2004		Hormone replacement therapy and lung cancer risk: a casecontrol analysis.	Schabath, M, Wu, X, Sellin, R, Vaporciyan, A, Spitz, M	Clinical cancer research Vol.10, 113-123
M0154			2/1/2004		Hormone use and cognitive performance in women of advanced age.	Buckwalter, JG, Crooks, V, Robins, S, Petitti, D	J Am Geri Soc 2004;182-6
M0157			1/1/2004		Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies; .	Garbe, E, Suissa, S	Hum Reprod. 2004 Jan;19(1):8-13;
M0163			1/1/2004		Menopausal hormone therapy decisions; insights from a multi-attribute model.	Schapira, M, Gilligan, M, McAuliffe, T, Nattinger, A	Patient Educ Couns. 2004 Jan;52(1):89-95;
M0165			1/1/2004		Estrogen plus progestin and colorectal cancer in postmenopausal women.	Chlebowski, R, Wactawski-Wende, J, Ritenbaugh, C, Hubbell, A, Ascensao, J, Rodabough, R, Rosenberg, C, Taylor, V, Harris, R, Chen, C, Adams-Campbell, White, E	N Engl J Med 2004;350:991-1004
M0167			5/1/2003		Myocardial infarction during menses: lessons from trial and errors.	Grady, D	Am J Med. 2003 May;114(7):611-2;
M0173			02/00/1995		Hormone Replacement Therapy And Endometrial Cancer Risk: A Meta-Analysis.	Grady, D, Gebretsadik, T, Kerlikowske, K, Ernster, V, Petitti, D	Obstet Gynecol. 1995 Feb;85(2):304-13;
M0174			8/6/1997		Hormone Replacement Therapy And Endometrial Cancer: Are Current Regimens Safe?	Grady, D, Ernster, V	J Natl Cancer Inst. 1997 Aug 6;89(15):1088-9.;
M0176			1/1/2004		Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe.	Stahlberg, C, Pedersen, A, Lyng, E, Anderson, Z, Keiding, N, Hundrup, Y, Obel, E, Ottesen, B	Int. J. Cancer:109,721-727 (2004)
M0177			6/19/1999		The effect of Raloxifene on risk of breast cancer in postmenopausal women: results from the more randomized trial. multiple outcomes of Raloxifene evaluation.	Cummings, S, Eckert, S, Krueger, K, Grady, D, Powles, T, Cauley, J, Norton, L, Nickelsen, T, Bjarnason, N, Morrow, M, Lippman, M, Black, D, Glusman, J, Costa, A, Jordan, V	JAMA. 1999 Jun 16;281(23):2189-97;
M0178			12/1/1997		Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women.	Hunter, DJ, Manson, JE, Colditz, GA, Chasan-Taber, L, Troy, L, Stampfer, MJ, Speizer, FE, Willett, WC	Contraception 1997;56:373-8
M0179			01/00/2001		Postmenopausal hormones and incontinence: the heart and Estrogen/Progestin Replacement Study.	Grady, D, Brown, J, Vittinghoff, E, Applegate, W, Varner, E, Snyder, T	Obstet Gynecol. 2001 Jan;97(1):116-20;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0182			1/1/2003		A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the lund area (WHILA) study (Sweden).	Jernstrom, H, Bendahl, P, Lidfeldt, J, Nerbrand, C, Agardh, C, Samsioe, G	Cancer Causes Control 2003;14:673-680
M0187			1/1/2003		Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the women's health initiative randomized controlled trial.	Shapiro, S; Tucker G	Climacteric 2003;6:302-310
M0190			5/8/2003		Postmenopausal hormones-therapy for symptoms only.	Grady, D	N Engl J Med. 2003 May 8;348(19):1835-7;
M0191			4/1/2001		The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: the heart and estrogen/progestin replacement study, a randomized, double-blind, placebo-controlled trial.	Nevitt, M, Felson, D, Williams, E, Grady, D	Arthritis Rheum. 2001 Apr;44(4):811-8;
M0192			4/18/1990		Rising incidence of breast cancer: relationship to stage and receptor status.	Glass, A, Hoover, R	82 J Nat Cancer Inst 1990, 693-696
M0194			3/8/2004		Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women.	Lobo, R	Arch Intern Med 2004;164:482-84
M0200			2/2/2004		Risk factors for breast cancer according to estrogen and progesterone receptor status.	Colditz, G, Rosner, B, Chen, W, Holmes, M, Hankinson, S	J Nat Cancer Inst 2004;96:218-28
M0205			10/1/1992		Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County.	Bernstein, L, Ross, RK	Cancer Res. 1992 Oct 1;52(19 Suppl):5510s-5515s
M0210			1/1/2002		Combined hormone replacement therapy and risk of breast cancer in a french cohort study of 3175 women.	de Lignieres, B, Vathaire, F, Fournier, S, Urbinelli, R, Allaert, F, Le, M, Kuttenn, F	Climacteric 2002;5:332-40
M0217			11/1/1999		Alcohol consumption in relation to breast cancer risk in a cohort of united states women 25-42 years of age.	Garland, M, Hunter, DJ, Colditz, GA, Spiegelman, DL, Manson, JE, Stampfer, MJ, Willett, WC	Cancer Epidemiol Biomarkers Prev 1999;8:1017-21
M0219			3/1/1999		The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.	Haiman, CA, Hankinson, SE, Spiegelman, D, Colditz, GA, Willett, WC, Speizer, FE, Kelsey, KT, Hunter, DJ	Cancer Reasearch 1999;59:1015-20
M0220			1/1/2001		Polymorphic repeat in AIB1 does not alter breast cancer risk.	Haiman, CA, Hankinson, SE, Speigelman, D, Colditz, GA, Willett, WC, Speizer, FE, Brown, M, Hunter, DJ	Breast Cancer Res 2000;2:378-85
M0226			1/1/2001		Ethnic differences in mammographic densities.	Maskarinec, G, Meng, L, Ursin, G	Inter J Epidemiol 2001;30:959-65
M0229			11/1/2003		Adolescent diet and incidence of proliferative benign breast disease.	Baer, HJ, Schnitt, SJ, Connolly, JL, Byrne, C, Cho, E, Willett, WC, Colditz, GA	Cancer Epidemiol Biomarkers Prev. 2003;12:1159-67
M0232			7/1/1997		Glutathione S-transferase class u deletion polymorphism and breast cancer: results from prevalent versus incident cases.	Kelsey, KT, Hankinson, SE, Colditz, GA, Springer, K, Garcia-Closas, M, Spiegelman, D, Manson, JE, Garland, M, Stampfer, MJ, Willett, WC, Speizer, FE, Hunter, DJ	Cancer Epidemiol Biomarkers Prev. 1997;6:511-5
M0237			1/1/1997		A prospective study of oral contraceptive use and risk of breast cancer (Nurses' health study, United States).	Hankinson, SE, Colditz, GA, Manson, JE, Willett, WC, Hunter, DJ, Stampfer, MJ, Speizer, FE	Cancer Causes Control 1997;8:65-72
M0239			1/1/1995		Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in Nurses' Health Study (United States).	Hankinson, SE, Colditz, GA, Hunter, DJ, Manson, JE, Willett, WC, Stampfer, MJ, Longcope, C, Speizer, FE	Cancer Causes Control 1995;6:217-24
M0242			1/1/1994		Dual effect of parity on breast cancer risk.	Hsieh, C, Pavia, M, Lambe, M, Lan, SJ, Colditz, GA, Ekbohm, A, Adami, HO, Trichopoulos, D, Willett, WC	Eur J Cancer 1994;7:969-73
M0254			1/2/2003		Adolescent diet and risk of breast cancer.	Frazier, LA, Ryan, CT, Rockett, H, Willett, WC, Colditz, GA	Breast Cancer Res 2003;5:R59-64
M0255			1/1/2003		Reduced COMT activity as possible environmental risk factor for breast cancer. Opinion.	Creveling, CR	Neurotox Res 2003;5:473-4
M0261			6/1/2000		Early-life physical activity and postmenopausal breast cancer: effect of body size and weight change.	Shoff, SM, Newcomb, PA, Trentham-Dietz, A, Remington, PL, Mittendorf, R, Greenberg, ER, Willett, WC	Cancer Epidemiol Biomarkers Prev. 2000;9:591-5
M0265			2/15/2001		Plasma organochlorine levels and the risk of breast cancer: an extended follow-up in the nurses' health study.	Laden, F, Hankinson, SE, Wold, MS, Colditz, GA, Willett, WC, Speizer, FE, Hunter, DJ	Int J Cancer 2001;91:568-74
M0272			11/1/2000		Dietary fat intake and endogenous sex steroid hormone levels in postmenopausal women.	Holmes, MD, Spiegelman, D, Willett, WC, Manson, JE, Hunter, DJ, Barbieri, RL, Colditz, GA, Hankinson, SE	J Clin Oncol 2000;18:3668-76
M0276			11/1/2003		Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women.	Liu, S, Willett, WC, Manson, JE, Hu, FB, Rosner, B, Colditz, G	Am J Clin Nutr 2003;78:920-7
M0277			8/1/2003		Alcohol consumption in relation to risk of cholecystectomy in women.	Leitzmann, MF, Tsai, CJ, Stampfer, MJ, Rtmn, EB, Colditz, GA, Willett, WC, Giovannucci, EL	Am J Clin Nutr 2003;78:339-47
M0279			08/00/1987		Reproducibility and validity of self-reported menopausal status in a prospective cohort study.; ; .	Colditz GA, Stampfer MJ, Willett WC, Stason WB, Rosner B, Hennekens CH, Speizer FE.	Am J Epidemiol. 1987 Aug;126(2):319-25;
M0280			11/1/1987		A prospective sudty of age at menarche, parity, age at first birth, and coronary heart disease in women.	Colditz, GA, Willett, WC, Stampfer, MJ, Rosner, B, Speizer, FE, Hennekens, CH	Am J Epidemiol 1987;126:861-70
M0281			4/15/1994		Reproductive risk factors in a prospective study of breast cancer: the nurses' health study.	Rosner, B, Colditz, GA, Willett, WC	Am J Epidemiol 1994;139:819-35
M0282			7/1/1990		Lactation and risk of breast cancer in a cohort of US women.	London, SJ, Colditz, GA, Stampfer, MJ, Willett, WC, Rosner, BA, Corsano, K, Speizer, FE	Am J Epidemiol 1990;132:17-26
M0284			7/1/2002		Deitary fat intake and ovarian cancer in a cohort of US women.	Bertone, ER, Rosner, BA, Hunter, DJ, Stampfer, MJ, Speizer, FE, Colditz, GA, Willett, WC, Hankinson, SE	Am J Epidemiol 2002;156:22-31
M0285			12/15/1999		Waist circumference, waist: hip ratio, and risk of breast cancer in the nurses' health study.	Huang, Z, Willett, WC, Colditz, GA, Hunter, DJ, Manson, JE, Rosner, B, Speizer, FE, Hankinson, SE	Am J Epidemiol 1999;150:1316-24
M0287			10/1/1995		Menopause, postmenopausal estrogen preparations, and the risk of adult-on set asthma.	Troisi, RJ, Speizer, FE, Willett, WC, Trichopoulos, D, Rosner, B	Am J REspir Crit Care Med 1995;152:1183-8
M0289			1/1/1990		Menopause and heart disease. A review.	Stampfer, MJ, Colditz, GA, Willett, WC	Am J Med Sci 1990;542:193-203

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0294			7/1/1990		Exogenous sex hormone and the risk of rheumatoid arthritis.	Hernandez-Avila, M, Liang, MH, Willett, WC, Stampfer, MJ, Colditz, GA, Rosner, B, Chang, RW, Hennekens, CH, Speizer, FE	Arthritis Rheum 1990;33:947-53
M0298			9/1/2003		Physical activity and risk of breast cancer in premenopausal women.	Colditz, GA, Feskanich, D, Chen, WY, Hunter, DJ, Willett, WC	Br J Cancer 2003;89:847-51
M0299			11/1/1999		Oral contraceptive use and risk of melanoma in premenopausal women.	Feskanich, D, Hunter, DJ, Willett, WC, Spiegelman, D, Stampfer, MJ, Speizer, FE, Colditz, GA	Br J Cancer 1999;81:918-23
M0300			1/1/1989		Oral contraceptives, replacement oestrogens and the risk of rheumatoid arthritis.	Hernandez-Avila, M, Liang, MH, Willett, WC, Stampfer, MJ, Colditz, GA, Rosner, B, Chang, RW, Hennekens, CH, Speizer, FE	Br J Rheumatol 1989;28:42-5
M0303			7/15/1995		A prospective study of reproductive factors and risk of epithelial ovarian cancer.	Hankinson, SE, Colditz, GA, Hunter, DJ, Willett, WC, Stampfer, MJ, Rosner, B, Hennekens, CH, Speizer, FE	Cancer 1995;76:284-90
M0305			9/1/1999		Dietary factors and the survival of women with breast carcinoma.	Holmes, MD, Stampfer, MJ, Colditz, GA, Rosner, B, Hunter, DJ, Willett, WC	Cancer 1999;86:826-35
M0306			11/1/2003		Premenopausal dietary carbohydrate, glycemic index, glycemic load, and fiber in relation to risk of breast cancer.	Cho, E, Spiegelman, D, Hunter, DJ, Chen, WY, Colditz, GA, Willett, WC	Cancer Epidemiol Biomarkers Prev 2003;12:1153-8
M0307			8/1/2003		Premenopausal intakes of vitamins A, C, and E, folate, and carotenoids, and risk of breast cancer.	Cho, E, Spiegelman, D, Hunter, DJ, Chen, WY, Zhang, SM, Colditz, GA, Willett, WC	Cancer Epidemiol Biomarkers Prev 2003;12:713-20
M0310			2/15/2002		The androgen receptor CAG repeat polymorphism and risk of breast cancer in the nurses' health study.	Haiman, CH, Brown, M, Hankinson, SE, Spiegelman, D, Colditz, GA, Willett, WC, Kantoff, PW, Hunter, DJ	Cancer Res 2002;62:1045-9
M0312			5/1/2003		The experience of Japan as a clue to the etiology of breast and ovarian cancers: relationship between death from both malignancies and dietary practices.	Li, XM, Ganmaa, D, Sato, A	Med Hypotheses 2003;60:724-30
M0315			7/1/1990		Reproductive factors, smoking, and the risk for rheumatoid arthritis.	Hernandez-Avila, M, Liang, MH, Willett, WC, Stampfer, MJ, Colditz, GA, Rosner, B, Roberts, WN, Hennekens, CH, Speizer, FE	Epidemiology 1990;1:285-91
M0317			3/1/2002		Active and passive smoking in breast cancer: prospective results from the nurses' health study.	Egan, KM, Stampfer, MJ, Hunter, DJ, Hankinson, S, Rosner, BA, Holmes, M, Willett, WC, Colditz, GA	Epidemiology 2002;13:138-45
M0322			12/1/2002		Coffee intake is associated with lower risk of symptomatic gallstone disease in women.	Leitzmann, MF, Stampfer, MJ, Willett, WC, Spiegelman, D, Colditz, GA, Giovannucci, EL	Gastroenterology 2002;123:1823-30
M0326			3/20/2003		Meat, fish, and egg intake and risk of breast cancer.	Holmes, MD, Colditz, GA, Hunter, DJ, Hankinson, SE, Rosner, B, Speizer, FE, Willett, WC	Int J Cancer 2003;104:221-7
M0329			8/1/1987		Use of permanent hair dyes and risk of breast cancer.	Green, A, Willett, WC, Colditz, GA, Stampfer, MJ, Bain, C, Rosner, B, Hennekens, CH, Speizer, FE	J Natl Cancer Inst 1987;79:253-7
M0331			7/16/2003		Premenopausal fat intake and risk of breast cancer.	Cho, E, Spiegelman, D, Hunter, DJ, Chen, WY, Stampfer, MJ, Colditz, GA, Willett, WC	J Natl Cancer Inst 2003;95:1079-85
M0332			2/2/2000		Prospective study of talc use and ovarian cancer.	Gertig, DM, Hunter DJ, Cramer, DW, Colditz, GA, Speizer, FE, Willett, WC, Hankinson, SE	J Natl Cancer Inst 2000;92:249-52
M0334			9/2/1998		Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.	Hankinson, SE, Willett, WC, Manson, JE, Colditz, GA, Hunter, DJ, Spiegelman, D, Barbieri, RL, Speizer, FE	J Natl Cancer Inst 1998;90:1292-9
M0335			4/7/1999		Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women.	Hankinson, SE, Willett, WC, Michaud, DS, Manson, JE, Colditz, GA, Longcope, C, Rosner, B, Speizer, FE	J Natl Cancer Inst 1999;91:629-34
M0339			1/1/1996		The women's health initiative: will it resolve the issues?	Michels, KB, Willett, WC	Recent Results Cancer Res 1996;140:295-305
M0340			11/1/1989		Prospective study of smoking and the risk of breast cancer.	London, SJ, Colditz, GA, Stampfer, MJ, Willett, WC, Rosner, BA, Speizer, FE	J Natl Cancer Inst 1989; Vol. 81, No. 21:1625-31
M0347			8/1/2002		Obesity, weight gain, and ovarian cancer.	Fairfield, KM, Willett, WC, Rosner, BA, Manson, JE, Speizer, FE, Hankinson, SE	Obstet Gynecol 2002;100:288-96
M0351			10/1/2003		Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.	Cauley, JA, Robbins, J, Chen, Z, Cummings, SR, Jackson, RD, LaCroix, AZ, LeBoff, M, Lewis, CE, McGowan, J, Neuner, J, Pettinger, M, Stefanick, ML, Wactawski-Wende, J, Watts, NB	JAMA 2003;290:1729-38
M0353			8/15/1996		Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.	Grodstein, F, Stampfer, MJ, Manson, JE, Colditz, GA, Willett, WC, Rosner, B, Speizer, FE, Hennekens, CH	N Engl J Med 1996;335:453-61
M0354			6/19/1997		Postmenopausal hormone therapy and mortality.	Grodstein, F, Stampfer, MJ, Colditz, GA, Willett, WC, Manson, JE, Joffe, M, Rosner, B, Fuchs, C, Hankinson, SE, Hunter, DJ, Hennekens, CH, Speizer, FE	N Engl J Med 1997;336:1769-75

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0355			3/10/1999		Association of dietary intake of fat and fatty acids with risk of breast cancer.	Holmes, MD, Hunter, DJ, Colditz, GA, Stampfer, MJ, Hankinson, SE, Speizer, FE, Rosner, B, Willett, WC	JAMA 1999;281:914-20
M0356			10/30/1997		Plasma organochlorine levels and the risk of breast cancer.	Hunter, DJ, Hankinson, SE, Laden, F, Colditz, GA, Manson, JE, Willett, WC, Speizer, FE, Wolff, MS	N Engl J Med 1997;337:1253-8
M0361			2/18/1998		Alcohol and breast cancer in women: a pooled analysis of cohort studies.	Smith-Warner, SA, Spiegelman, D, Yaun, SS, Brandt, PA, Folsom, AR, Goldbohm, A, Graham, S, Holmberg, L, Howe, GR, Marshall, JR, Miller, AB, Potter, JD, Speizer, FE, Willett, WC, Wolk, A, Hunter, DJ	JAMA 1998;279:535-40
M0362			12/1/1995		Distribution and correlates of plasma fibrinogen in middleaged women: initial findings of the postmenopausal estrogen/progestin interventions (PEPI) study.	Stefanick, ML, Legault, C, Tracy, RP, Howard, G, Kessler, CM, Lucas, DL, Bush, TL	Arterioscler Thromb Vasc Biol 1995;15:2085-93
M0365			1/26/2000		Postmenopausal estrogens-opposed, unopposed, or none of the above.	Willett, WC, Colditz, GA, Stampfer, MJ	JAMA 2000;283:534-5
M0366			3/1/2004		Rapid loss of hip fracture protection after estrogen cessation: evidence from the national osteoporosis risk assessment.	Yates, J, Barrett-Connor, E, Barlas, S, Chen, YT, Miller, PD, Siris, ES	Obstet Gynecol 2004;103:440-6
M0368			11/1/2000		Adherence to the dietary guidelines for americans and risk of major chronic disease in women.	McCullough, ML, Feskanich, D, Stampfer, MJ, Rosner, BA, Hu, FB, Hunter, DJ, Varyiam, JN, Colditz, GA, Willett, WC	Am J Clin Nutr 2000;72:1214-22
M0372			7/1/2000		Hormone replacement therapy in the prevention and treatment of atherosclerosis.	Mosca, L	Curr Atheroscler Rep 2000;2:297-302
M0375			6/1/2003		New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy.	Davison, S, Davis, SR, Hunskaar, S, Skolbekken, JA	J Clin Endocrinol Metab 2003;88:2470-8
M0376			2/12/2000		Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease.	Hemminki, E, McPherson, K	Lancet 2000;355:566-9
M0389			6/20/2002		Hormone replacement and the prevention of cardiovascular disease.	Langer, RD	Am J Cardiol 2002;89:36E-46E
M0392			10/1/2002		Hormone replacement therapy and coronary heart disease in women: a review of the evidence.	Low, AK, Russell, LD, Holman, HE, Shepherd, JM, Hicks, GS, Brown, CA	Am J Med Sci 2002;324:180-4
M0393			5/7/2002		Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. preventive services task force.	Miller, J, Chan, BK, Nelson, HD	Ann Intern Med 2002;136:680-90
M0405			5/1/2003		Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial.	Ossewaarde, ME, Dallinga-Thie, GM, Bots, ML, van der Schouw, YT, Rabelink, TJ, Grobbee, DE, Westerveld, HT	Eur J Clin Invest 2003;33:376-82
M0406			9/1/2001		Comparative cardiovascular effects of different progestins in meopause.	Rosano, GM, Fini, M	Int J Fertil Womens Med 2001;46:248-56
M0407			1/1/2003		How useful are unpulised data from the food and drug administration in meta-analysis?	MacLean, CH, Morton, SC, Ofman, JJ, Roth, EA, Shekelle, PG	J Clin Epidemiol 2003;56:44-51
M0415			1/1/2004		Clinical monograph: hormone replacement therapy.	Deady, J	J Manag Care Pharm 2004;10:33-47
M0421			9/1/1992		Relation between the hormonal and epidemiological aspects of ovarian patients in Japan.	Kodama, M, Kodama, T, Totani, R, Suzuoki, Y, Kodama, M	Anticancer Res 1992;12:1593-602
M0424			1/1/2003		Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative.	Kuller, LH	Arterioscler Thromb Vasc Biol 2003;23:11-6
M0437			7/1/1979		Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems.	Nachtigall, LE, Nachtigall, RH, Nachtigall, RD, Beckman, EM	Obstet Gynecol 1979;54:74-9
M0438			5/1/1995		Estrogen replacement therapy and fatal ovarian cancer.	Rodriguez, C, Calle, EE, Coates, RJ, Miracle-McMahill, HL, Thun, MJ, Heath, CW Jr	Am J Epidemiol 1995;141:828-35
M0440			3/1/1994		Coronary heart disease and estrogen replacement therapy can compliance bias explain the results of observational studies?	Petitti, DB	Ann Epidemiol 1994;4:115-8
M0442			4/15/2003		Postmenopausal hormone therapy a reversal of fortune.	Michels, KB, Manson, JE	Circulation 2003;107:1830-3
M0444			12/6/1995		Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. the postmenopausal estrogen/progestin interventions (PEPI) trial. the writing group for the PEPI trial.	Writing Group for the PEPI Trial	JAMA 1995;273:199-208
M0454			5/10/2003		Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland.	Verkooyen, HM, Fioretta, G, Fioretta, G, Vlastos, G, Morabia, A, Schubert, H, Sappino, AP, Pelte, MF, Schafer, P, Kurtz, J, Bouchardy, C	Int J Cancer 2003;104:778-81
M0463			5/1/1999		Postmenopausal estrogen therapy and selected (less-often-considered) disease outcomes.	Barrett-Connor, E	Menopause 1999;6:14-20
M0466			7/1/2003		Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures.	Li, AJ, Baldwin, RL, Karlan, BY	Am J Obstet Gynecol 2003;189:22-7
M0467			8/1/1990		Oestrogen receptor expression and the effects of oestrgen and tamoxifen on the growth of human ovarian carcinoma cell lines.	Langdon, SP, Hawkes, MM, Lawrie, SS, Hawkins, RA, Tesdale, AL, Crew, AJ, Miller, WR, Smyth, JF	Br J Cancer 1990;62:213-6
M0473			9/30/1993		Contrasting effects of 17 beta-estradiol on the growth of human ovarian carcinoma cell in vitro and in vivo.	Langdon, SP, Ritchie, A, Young, K, Crew, AJ, Sweeting, V, Bramley, T, Hillier, S, Hawkins, RA, Tesdale, AL, Smyth, JF	Int J Cancer 1993;55:459-64
M0474			8/1/1994		The regulation of growth and protein expression by estorgen in vitro: a study of 8 human ovarian carcinoma cell lines.	Langdon, SP, Hirst, GL, Miller, EP, Hawkins, RA, Tesdale, AL, Smyth, JF, Miller, WR	J Steroid Biochem Mol Biol 1994;50:131-5
M0485			4/14/2004		Effects of conjugated equine estrogen in postmenopausal women with hysterectomy.	Women's Health Initiative Steering Committee	JAMA 2004;291:1701-12
M0486			5/1/2000		A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines.	Chen, Y, Liu, X, Pisha, E, Constantinou, A, Hua, Y, Shen, L, van Breemen, R, Elguindi, E, Blond, S, Zhang, F, Bolton, J	Che Res Toxicol 2000;13:342-50
M0487			4/1/2002		A unified mechanism in the initiation of cancer.	Cavaliere, E, Rogan, E	Ann N Y Acad Sci 2002;959:341-54
M0489			2/1/1998		Alkylation of 2'-deoxynucleosides and DNA by the premarin metabolite 4-hydroxyequilenin semiquinone radical.	Shen, L, Qiu, S, Chen, Y, Zhang, F, van Breemen, R, Nikolic, D, Bolton, J	Chem Res Toxicol 1998;11:94-101
M0490			7/1/2002		Comparative effects of tibolone and conjugated equine estrogens with and without medroxyprogesterone acetate on the reproductive tract of female cynomolgus monkeys.	Cline, J, Register, T, Clarkson, T	Menopause 2002;9:242-52
M0492			12/1/2001		Equine estrogen metabolite 4hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-stand breaks, apurinic sites, stable adducts and oxidized bases.	Zhang, F, Swanson, S, van Breemen, R, Liu, X, Yang, Y, Gu, C, Bolton, J	Chem Res Toxicol 2001;14:1654-9
M0493			4/14/2004		The WHI estrogen-alone trial- do things look any better?	Hulley, S, Grady, D	EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0495			4/7/2004		Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review.	Nelson, H	JAMA 2004;291:1610-20
M0496			4/1/2004		A comparative review of the risks and benefits of hormone replacement therapy regimens.	Warren, M	Am J Obstet Gynecol 2004;190:1141-67
M0497			9/1/1998		The equine estrogen metabolite 4-hydroxyequilenin causes DNA single-strand breaks and oxidation of DNA bases of vitro.	Chen, Y, Shen, L, Zhang, F, Lau, S, van Breemen, R, Nikolic, D, Bolton, J	Chem Res Toxicol 1998;11:1105-11
M0499			5/1/2001		Metabolism of equilenin in MCF-7 and MDA-MB-231 human breast cancer cells.	Spink, D, Zhang, F, Hussain, M, Katz, B, Liu, X, Hilker, D, Bolton, J	Chem Res Toxicol 2001;14:572-81
M0500			4/1/2002		Oxidative DNA damage induced by equine estrogen metabolites: role of estrogen receptor alpha.	Liu, X, Yao, J, Pisha, E, Yang, Y, Hua, Y, van Breemen, R, Bolton, J	Chem Res Toxicol 2002;15:512-9
M0501			4/27/2004		Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease: recommendation statement from the Canadian Task Force on preventive health care.	Canadian Task Force on Preventive Health Care	CMAJ 2004;170:1388-1389
M0503			6/1/2001		Synthesis and reactivity of the catechol metabolites from the equine estrogen, 8,9-dehydroestrone.	Zhang, F, Yao, D, Hua, Y, van Breemen, R, Bolton, J	Chem Res Toxicol 2001;14:754-63
M0504			2/1/1999		Synthesis of the equine estrogen metabolites 2-hydroxyequilin and 2-hydroxyequilenin.	Zhang, F, Bolton, J	Chem Res Toxicol
M0506			8/1/1998		A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms.	Hammar, M, Christau, S, Nathorst-Boos, J, Rud, T, Garre, K	Br J Obstet Gynaecol 1998;105:904-11
M0509			1/1/1991		Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.	van Leeuwen, F	Acta Endocrinol (Copenh) 1991;125:13-26
M0516			6/1/1988		Update: cardiovascular effects of oral contraception and hormonal replacement therapy.	Meade, T	Am J Obstet Gynecol 1988;158:1646-1652
M0518			6/4/2003		Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.	Stearns, V, Beebe, K, Iyengar, M, Dube, E	JAMA 2003;289:2827-34
M0522			2/19/1997		Medical history risk factors for non-Hodgkin's lymphoma in older women.	Cerhan, JR, Wallace, RB, Folsom, AR, Potter, JD, Sellers, TA, Zheng, W, Lutz, CT	J Natl Cancer Inst. 1997 Feb 19;89(4):314-8
M0523			3/14/1998		Effect of postmenopausal hormone therapy on lipoprotein (a) concentration.	Espeland, M, Marcovina, S, Miller, V, Wood, P, Wasilauskas, C, Sherwin, R, Schrott, H, Bush, T	Circulation 1998;97:979-86
M0524			8/14/2000		The role of hormone replacement therapy in the prevention of postmenopausal heart disease.	Mosca, L	Arch Intern Med. 2000;160:2263-72
M0527			2/1/2001		Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial.	Angerer, P, Stork, S, Koithy, W, Schmitt, P, von Schacky, C	Arterioscler Thromb Vasc Biol 2001;21:262-8
M0528			12/19/2000		A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.	Grodstein, F, Manson, J, Colditz, G, Willett, W, Speizer, F, Stampfer, M	Ann Intern Med 2000;133:933-41
M0531			3/1/2001		Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin's lymphoma in women.	Nelson, RA, Levine, AM, Bernstein, L	J Clin Oncol. 2001 Mar 1;19(5):1381-7
M0533			1/7/2003		WHI protocol for clinical trial and observational study components.	WHI	
M0538			5/12/2004		Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women.	Banks, E, Beral, V, Reeves, G, Balkwill, A, Barnes, I	JAMA 2004;291:2212-20
M0539			1/1/1961		[Appearance of mammary tumors in the male rat subjected to combined estrogen and progesterone treatment] French article.	Riviere, M, Chouroulinkovi, I, Guerin, M	C R Seances Soc Biol Fil 1961;155:2102-4
M0542			4/3/2002		Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.	Riman, T, Dickman, P, Nilsson, S, Correia, N, Nordlinder, H, Magnusson, C, Weiderpass, E, Persson, I	J Natl Cancer Inst 2002;94:467-504
M0543			1/1/1999		Chapter 17: Role of progestins and progesterone receptors in breast cancer biology.	Guiochon-Mantel, A, Milgrom, E	In: Endocrinology of breast cancer: Humana Press, 1999, p. 245-259
M0545			5/13/2004		Homocysteine and osteoporotic fractures-culprit or bystander?	Raisz, L	N Engl J Med 2004;350:2089-90
M0546			1/1/1992		Chapter 2: General Considerations.	Tavassoli, F	In: Pathology of the breast: Appleton & Lange, 1999, p. 27-74
M0548			5/11/2004		Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian task force on preventive health care.	Wathen, C, Feig, D, Feightner, J, Abramson, B, Cheung, A	CMAJ 2004;170:1535-7
M0556			1/1/1978		Estrogen use, hypertension and stroke in postmenopausal women.	Pfeffer, RI	J Chronic Dis. 1978;31:389-98
M0562			10/1/1992		The risk of acute myocardial infarction after oestrogen and oestrogen-progesterone replacement.	Falkeborn, M, Persson, I, Adami, H, Bergstrom, R, Eaker, E, Lithell, H, Mohsen, R, Naessen, T	Br J Obstet Gynaecol. 1992;99:821-8
M0569			9/1/1992		Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study.	Colditz, GA, Stampfer, MJ, Willett, WC, Hunter, DJ, Manson, JE, Hennekens, CH, Rosner, BA, Speizer, FE	Cancer Causes Control. 1992;3:433-9
M0570			9/1/1992		Noncontraceptive hormone use and risk of breast cancer.	Yang, CP, Daling, JR, Band, PR, Gallagher, RP, White, E, Weiss, NS	Cancer Causes Control. 1992;3:475-9
M0571			2/1/1992		Menopausal hormone replacement therapy and breast cancer: A meta-analysis.	Sillero-Arenas, M, Delgado-Rodriguez, M, Rodriguez-Canteras, R, Bueno-Cavanillas, A, Galvez-Vargas, R	Obstet Gynecol. 1992;79:286-94
M0580			1/1/1991		Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.	Stampfer, MJ, Colditz, GA	Prev Med. 1991;20:47-63
M0586			1/1/1991		Decreased mortality in users of estrogen replacement therapy.	Henderson, BE, Paganini-Hill, A, Ross, RK	Arch Intern Med. 1991;151:75-8
M0587			2/1/1991		Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort.	Wolf, PH, Madans, JH, Finucane, FF, Higgins, M, Kleinman, JC	Am J Obstet Gynecol. 1991;164:489-94
M0589			3/1/1990		Use of replacement estrogens and the risk of myocardial infarction.	Hernandez-Avila, M, Walker, AM, Jick, H	Epidemiology. 1990;1:128-33
M0594			12/1/1990		Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women.	Sullivan, JM, Vander Zwaag, R, Hughes, JP, Maddock, V, Droetz, FW, Ramanathan, KB, Mirvis, DM	Arch Intern Med. 1990;150:2557-62
M0595			11/1/1990		Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of effect of added progesterone.	Adams, MR, Kaplan, JR, Manuck, SB, Koritnik, DR, Parks, JS, Wolfe, MS, Clarkson, TB	Arteriosclerosis. 1990;10:1051-7
M0600			8/3/1989		The risk of breast cancer after estrogen and estrogen-progestin replacement.	Bergkvist, L, Adami, HO, Persson, I, Hoover, R, Schairer, C	N Engl J Med. 1989 Aug 3;321(5):293-7
M0603			11/15/1989		Risk of cancer in women receiving hormone replacement therapy.	Adami, HO, Persson, I, Hoover, R, Schairer, C, Bergkvist, L	Int J Cancer. 1989 Nov 15;44(5):833-9
M0604			12/1/1989		Noncontraceptive estrogen use and epithelial ovarian cancer.	Kaufman, DW, Kelly, JP, Welch, WR, Rosenberg, L, Stolley, PD, Warshawer, ME, Lewis, J, Woodruff, J, Shapiro, S	Am J Epidemiol. 1989 Dec;130(6):1142-51

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0605			6/1/1989		The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women.	Thompson, SG, Meade, TW, Greenberg, G	J Epidemiol Community Health. 1989 Jun;43(2):173-8
M0612			1/1/1985		Noncontraceptive estrogen use and cardiovascular disease.	Bush, TL, Barrett-Connor, E	Epidemiol Rev. 1985;7:89-104
M0619			1/1/1987		Mammographic parenchymal patterns and breast cancer risk.	Saftlas, AF, Szklo, M	Epidemiol Rev. 1987;9:146-74
M0622			3/7/1988		Oestrogen therapy after the menopause--boon or bane?	Armstrong, BK	Med J Aust. 1988 Mar 7;148(5):213-4
M0623			5/1/1988		Menopause and ovarian cancer.	Hartge, P, Hoover, R, McGowan, L, Leshner, L, Norris, HJ	Am J Epidemiol. 1988 May;127(5):990-8
M0628			6/1/1987		Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study.	Bush, TL, Barrett-Connor, E, Cowan, LD, Criqui, MH, Wallace, RB, Suchindran, CM, Tyroler, HA, Rifkind, BM	Circulation. 1987 Jun;75(6):1102-9
M0629			8/1/1987		Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study.	Kannel, WB	Am Heart J. 1987 Aug;114(2):413-9
M0630			9/1/1987		Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study.	Petitti, DB, Perlman, JA, Sidney, S	Obstet Gynecol. 1987 Sep;70(3 Pt 1):289-93
M0633			9/1/1986		Arteriosclerosis risk. The roles of oral contraceptives and postmenopausal estrogens.	Knopp, RH	J Reprod Med. 1986 Sep;31(9 Suppl):913-21
M0636			11/15/1985		Estrogen receptor status of breast cancer in Ontario.	McKeown-Eyssen, GE, Rogers-Melamed, I, Clarke, EA	CMAJ. 1985 Nov 15;133(10):997-1000
M0639			3/15/1982		Actions of progestins on the morphology and biochemistry of the endometrium of postmenopausal women receiving low-dose estrogen therapy.	Whitehead, MI, Townsend, PT, Pryse-Davies, J, Ryder, T, Lane, G, Siddle, N, King, RJ	Am J Obstet Gynecol. 1982 Mar 15;142(6 Pt 2):791-5
M0643			3/1/1984		The effect of a progestin on gallbladder function in young women.	Shaffer, EA, Taylor, PJ, Logan, K, Gadamski, S, Corenblum, B	Am J Obstet Gynecol. 1984 Mar 1;148(5):504-7
M0645			7/22/1983		Oral contraceptives and the risk of cardiovascular disease.	N/A	Med Lett Drugs Ther. 1983 Jul 22;25(640):69-70
M0646			6/30/1983		'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer.	Pike, MC, Krailo, MD, Henderson, BE, Casagrande, JT, Hoel, DG	Nature. 1983 Jun 30;303(5920):767-70
M0654			9/15/1995		Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group.	Purdie, D, Green, A, Bain, C, Siskind, V, Ward, B, Hacker, N, Quinn, M, Wright, G, Russell, P, Susill, B	Int J Cancer. 1995 Sep 15;62(6):678-84
M0658			7/12/1995		Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.	Stanford, JL, Weiss, NS, Voigt, LF, Dealing, JR, Habel, LA, Rossing, MA	JAMA. 1995 Jul 12;274(2):137-42
M0659			7/1/1995		Hormone replacement treatment and breast cancer risk: a cooperative Italian study.	La Vecchia, C, Negri, E, Franceschi, S, Favero, A, Nanni, O, Filiberti, R, Conti, E, Montella, M, Veronesi, A, Ferraroni, M	Br J Cancer. 1995 Jul;72(1):244-8
M0660			8/1/1995		Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern.	Laya, MB, Gallagher, JC, Schreiman, JS, Larson, EB, Watson, P, Weinstein, L	Radiology. 1995 Aug;196(2):433-7
M0663			8/1/1995		Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women; .	Folsom, AR, Mink, PJ, Sellers, TA, Hong, CP, Zheng, W, Potter, JD	Am J Public Health. 1995 Aug;85(8 Pt 1):1128-32
M0664			8/1/1995		Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared with nonusers.	Derby, CA, Hume, AL, McPhillips, JB, Barbour, MM, Carleton, RA	Am J Obstet Gynecol. 1995 Aug;173(2):544-50
M0668			7/1/1995		17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease.	Collins, P, Rosano, GM, Sarrel, PM, Ulrich, L, Adamopoulos, S, Beale, CM, McNeill, JG, Poole-Wilson, PA	Circulation. 1995 Jul 1;92(1):24-30
M0669			7/1/1995		How do we explain the clinical benefits of estrogen? From bedside to bench.	Gerhard, M, Ganz, P	Circulation. 1995 Jul 1;92(1):5-8
M0671			11/1/1994		Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States).; ;	Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. ;	Cancer Causes Control. 1994 Nov;5(6):491-500.;
M0676			12/1/1994		Heart disease in women.	Barrett-Connor, E	Fertil Steril. 1994 Dec;62(6 Suppl 2):127S-132S
M0684			8/1/1994		Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study.	Brenner, DE, Kukull, WA, Stergachis, A, van Belle, G, Bowen, JD, McCormick, WC, Teri, L, Larson, EB	Am J Epidemiol. 1994 Aug 1;140(3):262-7
M0692			3/1/1994		A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women.	Mann, RD, Lis, Y, Chukwujindu, J, Chanter, DO	J Clin Epidemiol. 1994 Mar;47(3):307-12
M0693			4/1/1994		Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study.	Risch, HA, Howe, GR	Am J Epidemiol. 1994 Apr 1;139(7):670-83
M0704			4/15/1993		Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.	Nabulsi, AA, Folsom, AR, White, A, Patsch, W, Heiss, G, Wu, KK, Szklo, M	N Engl J Med. 1993 Apr 15;328(15):1069-75
M0706			1/1/1993		Mammographic parenchymal patterns: a marker of breast cancer risk.	Oza, AM, Boyd, NF	Epidemiol Rev. 1993;15(1):196-208
M0709			1/11/1993		Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort.	Finucane, FF, Madans, JH, Bush, TL, Wolf, PH, Kleinman, JC	Arch Intern Med. 1993 Jan 11;153(1):73-9
M0711			1/1/1993		A case-control study of myocardial infarction in relation to use of estrogen supplements.	Rosenberg, L, Palmer, JR, Shapiro, S	Am J Epidemiol. 1993 Jan 1;137(1):54-63
M0712			5/26/1993		Estrogen replacement therapy and cognitive function in older women.	Barrett-Connor, E, Kritz-Silverstein, D	JAMA. 1993 May 26;269(20):2637-41
M0714			5/1/1993		Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies.	Colditz, GA, Egan, KM, Stampfer, MJ	Am J Obstet Gynecol. 1993 May;168(5):1473-80
M0716			6/28/1993		A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women.	Psaty, BM, Heckbert, SR, Atkins, D, Siscovick, DS, Koepsell, TD, Wahl, PW, Longstreth, WT, Weiss, NS, Wagner, EH, Prentice, R	Arch Intern Med. 1993 Jun 28;153(12):1421-7
M0717			1/1/1996		Reduced mortality associated with long-term postmenopausal estrogen therapy.	Ettinger, B, Friedman, GD, Bush, T, Quesenberry, CP	Obstet Gynecol. 1996 Jan;87(1):6-12
M0720			9/1/1995		Exogenous hormone use and the risk of postmenopausal breast cancer: results from The Netherlands Cohort Study.	Schuurman, AG, van den Brandt, PA, Goldbohm, Ra	Cancer Causes Control. 1995 Sep;6(5):416-24
M0722			1/1/1996		Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques.	Cline, JM, Soderqvist, G, von Schoutz, E, Skoog, L, von Schoutz, B	Am J Obstet Gynecol. 1996 Jan;174(1 Pt 1):93-100
M0723			11/1/1995		Cardiovascular risk profiles of oral contraceptive users and nonusers: a population-based study.	Flint, PM, Lapane, KL, Barbour, MM, Derby, CA, Carleton, RA, Hume, AL	Prev Med. 1995 Nov;24(6):586-90
M0731			10/1/1995		Lifetime alcohol consumption and breast cancer risk among postmenopausal women in Los Angeles.	Longnecker, MP, Paganini-Hill, A, Ross, RK	Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):721-5
M0733			8/12/1996		Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.	Kim, CJ, Min, YK, Ryu, WS, Kwak, JW, Ryoo, UH	Arch Intern Med. 1996 Aug 12-26;156(15):1693-700

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0735			7/29/1996		Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.	Persson, I, Yuen, J, Bergkvist, L, Schairer, C	Int J Cancer. 1996 Jul 29;67(3):327-32
M0736			8/17/1996		Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.	Tang, MX, Jacobs, D, Stern, Y, Marder, K, Schofield, P, Gurland, B, Andrews, H, Mayeux, R	Lancet. 1996 Aug 17;348(9025):429-32
M0741			11/1/1995		[Gallbladder cancer: immunohistochemical expression of the protein related to estrogen receptor (p29) and of the protein induced by estrogen (pS2)] Article in Spanish.	Roa, I, Araya, JC, Vilaseca, M, de Artxabala, X, Ferreira, A, Roa, JC	Rev Med Chil. 1995 Nov;123(11):1333-40
M0743			1/1/1996		Prognostic characteristics in breast cancers after hormone replacement therapy.	Magnusson, C, Holmberg, L, Norden, T, Lindgren, A, Persson, I	Breast Cancer Res Treat. 1996;38(3):325-34
M0745			1/1/1996		Hormonal and environmental factors affecting cell proliferation and neoplasia in the mammary gland.	Snedeker, SM, Diaugustine, RP	In: Cellular and molecular mechanisms of hormonal carcinogenesis: Environmental influences: Wiley-Liss, Inc., 1996. p. 211-253
M0746			1/26/1996		An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins.	Haines, CJ, Chung, TK, Masarel, JR, Tomlinson, B, Lau, JT	Atherosclerosis. 1996 Jan 26;119(2):215-22
M0747			7/1/1996		Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States.	Willis, DB, Calle, EE, Miracle-McMahill, HL, Heath, CW	Cancer Causes Control. 1996 Jul;7(4):449-57
M0750			10/12/1996		Risk of venous thromboembolism in users of hormone replacement therapy.	Daly, E, Vessey, MP, Hawkins, MM, Carson, JL, Gough, P, Marsh, S	Lancet. 1996 Oct 12;348(9033):977-80
M0752			10/12/1996		Prospective study of exogenous hormones and risk of pulmonary embolism in women.	Grodstein, F, Stampfer, MJ, Goldhaber, SZ, Manson, JE, Colditz, GA, Speizer, FE, Willett, WC, Hennekens, CH	Lancet. 1996 Oct 12;348(9033):983-7
M0756			8/1/1996		Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy.	Bush, TL	Eur Heart J. 1996 Aug;17 Suppl D:9-14
M0759			10/28/1996		Estrogen replacement therapy and risk of Alzheimer disease.	Paganini-Hill, A, Henderson, VW	Arch Intern Med. 1996 Oct 28;156(10):2213-7
M0760			8/1/1996		Oral contraceptives, menopausal hormone replacement treatment and breast cancer risk.	Levi, F, Lucchini, F, Pasche, C, La Vecchia, C	Eur J Cancer Prev. 1996 Aug;5(4):259-66
M0762			11/1/1996		Estrogen replacement therapy and risk of epithelial ovarian cancer.	Risch, HA	Gynecol Oncol. 1996 Nov;63(2):254-7
M0767			1/1/1997		Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis.	Adams, MR, Register, TC, Golden, DL, Wagner, JD, Williams, JK	Arterioscler Thromb Vasc Biol. 1997 Jan;17(1):217-21
M0769			3/1/1997		Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm.	Miyagawa, K, Rosch, J, Stanczyk, F, Hermsmeyer, K	Nat Med. 1997 Mar;3(3):324-7
M0775			1/1/1997		Cause-specific mortality in women receiving hormone replacement therapy.	Schairer, C, Adami, HO, Hoover, R, Persson, I	Epidemiology. 1997 Jan;8(1):59-65
M0778			1/1/1997		Mammographic changes in postmenopausal women on hormonal replacement therapy.	Marugg, RC, van der Mooren, MJ, Hendriks, JH, Rolland, R, Ruijs, SH	Eur Radiol. 1997;7(5):749-55
M0781			6/1/1997		Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study.	Hempling, RE, Wong, C, Piver, MS, Natarajan, N, Mettlin, CJ	Obstet Gynecol. 1997 Jun;89(6):1012-6
M0782			5/1/1997		Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics.	Persson, I, Bergkvist, L, Lindgren, C, Yuen, J	J Clin Epidemiol. 1997 May;50(5):611-8
M0787			8/4/1997		Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening.	Persson, I, Thurfjell, E, Bergstrom, R, Holmberg, L	Int J Cancer. 1997 Sep 4;72(5):758-61
M0788			10/1/1997		Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women.	Sidney, S, Petitti, DB, Quesenberry, CP	Ann Intern Med. 1997 Oct 1;127(7):501-8
M0798			11/1/1997		Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.	Scarabin, PY, Alhenc-Gelas, M, Plu-Bureau, G, Taisne, P, Agher, R, Aiach, M	Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3071-8
M0799			12/1/1997		Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect?	Resnick, SM, Metter, EJ, Zonderman, AB	Neurology. 1997 Dec;49(6):1491-7
M0800			12/1/1997		The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer.	Sellers, TA, Mink, PJ, Cerhan, JR, Zheng, W, Anderson, KE, Kushi, LH, Folsom, AR	Ann Intern Med. 1997 Dec 1;127(11):973-80
M0803			2/1/1998		Progestin regulation of vascular endothelial growth factor in human breast cancer cells.	Hyder, SM, Murthy, L, Stancel, GM	Cancer Res. 1998 Feb 1;58(3):392-5
M0805			2/1/1998		Cognitive function in nondemented older women who took estrogen after menopause.	Jacobs, DM, Tang, MX, Stern, Y, Sano, M, Marder, K, Bell, KL, Schofield, P, Dooneief, G, Gurland, B, Mayeux, R	Neurology. 1998 Feb;50(2):368-73
M0811			4/15/1998		Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk.	Pike, MC, Ross, RK, Spicer, DV	Am J Epidemiol. 1998 Apr 15;147(8):718-21
M0813			5/1/1998		Estradiol and progesterone regulate the proliferation of human breast epithelial cells.	Foidart, JM, Colin, C, Denoo, X, Desreux, J, Belliard, A, Fournier, S, de Lignieres, B	Fertil Steril. 1998 May;69(5):963-9
M0823			9/1/1998		Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis.	Garg, PP, Kerlikowske, K, Subak, L, Grady, D	Obstet Gynecol. 1998 Sep;92(3):472-9
M0824			8/25/1998		Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.	Ridker, PM, Buring, JE, Shih, J, Mattias, M, Hennekens, CH	Circulation. 1998 Aug 25;98(8):731-3
M0829			9/1/1998		Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?	Rodriguez, GC, Walmer, DK, Cline, M, Krigman, H, Lessey, BA, Whitaker, RS, Dodge, R, Hughes, CL	J Soc Gynecol Investig. 1998 Sep-Oct;5(5):271-6
M0830			10/1/1998		Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy.	Brinton, LA, Borgan, DR, Coates, RJ, Swanson, CA, Potischman, N, Stanford, JL	Menopause. 1998 Fall;5(3):145-51
M0833			11/1/1998		Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.	Lufkin, EG, Whitaker, MD, Nickelsen, T, Argueta, R, Caplan, RH, Knickerbocker, RK, Riggs, BL	J Bone Miner Res. 1998 Nov;13(11):1747-54
M0841			12/1/1998		The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia.	Shumaker, SA, Reboussin, BA, Espeland, MA, Rapp, SR, McBee, WL, Dailey, M, Bowen, D, Terrell, T, Jones, BN	Control Clin Trials. 1998 Dec;19(6):604-21
M0846			2/3/1999		Estrogen replacement therapy and breast cancer survival in a large screening study.	Schairer, C, Gail, M, Byrne, C, Rosenberg, PS, Sturgeon, SR, Brinton, LA, Hoover, Rn	J Natl Cancer Inst. 1999 Feb 3;91(3):264-70
M0847			2/16/1999		Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.	Greendale, GA, Reboussin, BA, Sie, A, Singh, HR, Olson, LK, Gatewood, O, Bassett, LW, Wasilauskas, C, Bush, T, Barrett-Connor, E	Ann Intern Med. 1999 Feb 16;130(4 Pt 1):262-9

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0849			3/15/1999		Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies.	Negri, E, Tzonou, A, Beral, V, Laggiou, P, Trichopoulos, D, Parazzini, F, Franceschi, S, Booth, M, La Vecchia, C	Int J Cancer. 1999 Mar 15;80(6):848-51
M0851			12/1/1998		Postmenopausal estrogen use and invasive versus in situ breast cancer risk.	Henrich, JB, Kornuth, PJ, Viscoli, CM, Horwitz, RI	J Clin Epidemiol. 1998 Dec;51(12):1277-83
M0856			4/6/1999		Use of hormone replacement therapy by postmenopausal women in the United States.	Keating, NL, Cleary, PD, Rossi, AS, Zazlavsky, AM, Ayanian, JZ	Ann Intern Med. 1999 Apr 6;130(7):545-53
M0857			4/7/1999		Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks.	Shaywitz, SE, Shaywitz, BA, Pugh, KR, Fullbright, RK, Skudlarski, P, Mend, WE, Constable, RT, Naftolin, F, Palter, SF, Marchione, KE, Katz, L, Shonkweiler, DP, Fletcher, JM, Lacadie, C, Keltz, M, Gore, JC	JAMA. 1999 Apr 7;281(13):1197-202
M0860			5/1/1999		Estrogen replacement therapy and cognitive decline in older community women.	Matthews, K, Cauley, J, Yaffe, K, Zmuda, JM	J Am Geriatr Soc. 1999 May;47(5):518-23
M0862			1/1/1999		Cardiovascular risks: perception versus reality.	Mishell, DR	Contraception. 1999 Jan;59(1 Suppl):21S-24S
M0866			6/9/1999		Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study.	Gapstur, SM, Morrow, M, Sellers, TA	JAMA. 1999 Jun 9;281(22):2091-7
M0870			4/1/1999		Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells.	Kandouz, M, Lombet, A, Perrot, JY, Jacob, D, Carvajal, S, Kazem, A, Rostene, W, Therwath, A, Gompel, A	J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):463-71
M0872			8/17/1999		Hormone replacement therapy and increased plasma concentration of C-reactive protein.	Ridker, PM, Hennekens, CH, Rifai, N, Buring, JE, Manson, JE	Circulation. 1999 Aug 17;100(7):713-6
M0873			8/17/1999		Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study.	Cushman, M, Legault, C, Barrett-Connor, E, Stefanick, ML, Kessler, C, Judd, HL, Sakkinen, PA, Tracy, RP	Circulation. 1999 Aug 17;100(7):717-22
M0874			8/1/1999		Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).	Glueck, CJ, Wang, P, Fontaine, RN, Tracy, T, Sieve-Smith, L, Lang, JE	Am J Cardiol. 1999 Sep 1;84(5):549-54
M0876			10/1/1999		Hormone replacement therapy and risk of epithelial ovarian cancer.	Purdie, DM, Bain, CJ, Siskind, V, Russell, P, Hacker, NF, Ward, BG, Quinn, MA, Green, AC	Br J Cancer. 1999 Oct;81(3):559-63
M0881			12/1/1999		Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast.	Hofseth, LJ, Raafat, AM, Osuch, JR, Pathak, DR, Slomski, CA, Haslam, SZ	J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65
M0891			3/23/2000		C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.	Ridker, PM, Hennekens, CH, Buring, JE, Rifai, N	N Engl J Med. 2000 Mar 23;342(12):836-43
M0892			4/1/2000		Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status.	Huang, WY, Newman, B, Milikan, RC, Schell, MJ, Hulka, BS, Moorman, PG	Am J Epidemiol. 2000 Apr 1;151(7):703-14
M0896			4/1/2000		A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer.	Coughlin, SS, Giustozzi, A, Smith, SJ, Lee, NC	J Clin Epidemiol. 2000 Apr;53(4):367-75
M0915			11/2/2000		Progestin effects on long-term growth, death, and Bcl-xL in breast cancer cells.	Moore, MR, Conner, JL, Franks, KM	Biochem Biophys Res Commun. 2000 Nov 2;277(3):650-4
M0917			11/13/2000		How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial.	Greendale, GA, Wells, B, Marcus, R, Barrett-Connor, E	Arch Intern Med. 2000 Nov 13;160(20):3065-71
M0919			10/1/2000		Progestins and cardiovascular risk markers.	Sitruk-Ware, R	Steroids. 2000 Oct-Nov;65(10-11):651-8
M0920			10/1/2000		Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer.	Pike, MC, Ross, RK	Steroids. 2000 Oct-Nov;65(10-11):659-64
M0921			12/1/2000		Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women.	Rosano, GM, Webb, CM, Chierchia, S, Morgani, GL, Gabraele, M, Sarrel, PM, de Ziegler, D, Collins, P	J Am Coll Cardiol. 2000 Dec;36(7):2154-9
M0924			2/1/2001		Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells.	Otsuki, M, Saito, H, Xu, X, Sumitani, S, Kouhara, H, Kishimoto, T, Kasayama, S	Arterioscler Thromb Vasc Biol. 2001 Feb;21(2):243-8
M0930			3/21/2001		Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.	Rodriguez, C, Patel, AV, Calle, EE, Jacob, EJ, Thun, MJ	JAMA. 2001 Mar 21;285(11):1460-5
M0940			4/1/2001		Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.	Vehkavaara, S, Silveira, A, Hakala, Ala-Pietila, T, Virkamaki, A, Hovatta, O, Hamsten, A, Taskinen, MR, Yki-Jarvinen, H	Thromb Haemost. 2001 Apr;85(4):619-25
M0943			2/1/1999		Progestogens and cardiovascular disease. A critical review.	Clarkson, TB	J Reprod Med. 1999 Feb;44(2 Suppl):180-4
M0947			9/1/2002		The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.	Lemay, A	J Obstet Gynaecol Can. 2002 Sep;24(9):711-5
M0949			7/1/2001		Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women.	Ryan, N, Rosner, A	Clin Ther. 2001 Jul;23(7):1099-115
M0951			10/1/2001		Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO.	Reynolds, RF, Walker, AM, Obermeyer, CM, Rahman, O, Guilbert, D	J Clin Epidemiol. 2001 Oct;54(10):1056-64
M0956			2/15/2002		Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells.	Richer, JK, Jacobsen, BM, Manning, NG, Abel, MG, Wolf, DM, Horwitz, KB	J Biol Chem. 2002 Feb 15;277(7):5209-18
M0962			1/2/2002		Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta.	Rodriguez, GC, Nagarsheth, NP, Lee, KL, Bentley, RC, Walmer, DK, Cline, M, Whitaker, RS, Isner, P, Berchuck, A, Dodge, RK, Hughes, CL	J Natl Cancer Inst. 2002 Jan 2;94(1):50-60
M0964			1/16/2002		Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina.	Schulman, SP, Thiernann, DR, Ouyang, P, Chandra, NC, Schulman, DS, Reis, SE, Terrin, M, Forman, S, de Albuquerque, CP, Bahr, RD, Townsend, SN, Cosgriff, R, Gerstenblith, G	J Am Coll Cardiol. 2002 Jan 16;39(2):231-7
M0967			2/26/2002		Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned.	Furberg, CD, Vittinghoff, E, Davidson, M, Herrington, DM, Simon, JA, Wenger, NK, Hulley, S	Circulation. 2002 Feb 26;105(8):917-22
M0977			5/1/2002		Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations.	Skouby, SO, Gram, J, Andersen, LF, Sidelmann, J, Petersen, KR, Jespersen, J	Am J Obstet Gynecol. 2002 May;186(5):969-77

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M0983			8/1/2002		Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma.	Sit, AS, Modugno, F, Weissfeld, JL, Berga, SL, Ness, RB	Gynecol Oncol. 2002 Aug;86(2):118-23
M0984			8/1/2002		Postmenopausal hormone use and skeletal fracture: does the size of the benefit decrease with increasing age?	Weiss, NS, Treggiari, MM	Obstet Gynecol. 2002 Aug;100(2):364-8
M0991			9/3/2002		Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.	Decensi, A, Omodei, U, Robertson, C, Bonanni, B, Guerrieri-Gonzaga, A, Ramazzotto, F, Johansson, H, Mora, S, Sandri, MT, Cazzaniga, M, Franchi, M, Recorelli, S	Circulation. 2002 Sep;3;106(10):1224-8
M0994			2/23/1976		More critics raise voices against estrogen therapy.	N/A	J Am Med Assoc. 1976 Feb 23;235(8):787-8
M0999			10/1/2002		Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes.	Manning, PJ, Sutherland, WH, Allum, AR, de Jong, SA, Jones, SD	Diabet Med. 2002 Oct;19(10):847-52
M1001			9/1/2002		Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen.	Modena MG, Bursi F, Fantini G, Cagnacci A, Carbonieri A, Fortuna A, Rossi R	Am J Med. 2002 Sep;113(4):331-4
M1003			10/1/2002		Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy.	Byington, RP, Furberg, CD, Herrington, DM, Herd, JA, Hunninghake, D, Lowery, M, Riley, W, Craven, T, Chaput, L, Ireland, CC, Applegate, WB	Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1692-7
M1006			11/1/2002		The randomized world is not without its imperfections: reflections on the Women's Health Initiative Study.	McDonough, PG	Fertil Steril. 2002 Nov;78(5):951-6
M1007			12/1/2002		Are some progestins genotoxic liver carcinogens?	Brambilla, G, Martelli, A	Mutat Res. 2002 Dec;512(2-3):155-63
M1016			4/15/2003		Risks and benefits of hormone replacement therapy: the evidence speaks.	Humphries, KH, Gill, S	CMAJ. 2003 Apr 15;168(8):1001-10
M1018			2/1/2003		The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells.	Seeger, H, Wallwiener, D, Mueck, AO	Horm Metab Res. 2003 Feb;35(2):76-80
M1025			5/1/2003		Are pharmacological considerations of relevance in hormone replacement therapy for prevention of chronic disease?	Lippert, TH, Seeger, H, Mueck, AO	J Obstet Gynaecol. 2003 May;23(3):263-6
M1027			8/1/2003		Issues to debate on the Women's Health Initiative: failure of estrogen plus progestin therapy for prevention of breast cancer risk.	Luukkainen, T	Hum Reprod. 2003 Aug;18(8):1559-61
M1028			8/1/2003		Issues to debate on the Women's Health Initiative: estrogen: an instrument or the conductor of the orchestra?	Bodis, J, Koppa, M, Garai, J, Zambo, K, Torok, A	Hum Reprod. 2003 Aug;18(8):1561-3
M1034			9/1/2003		An economic analysis of hormone replacement therapy for the prevention of fracture in young postmenopausal women.	Lamy, O, Krieg, MA, Burckhardt, P, Wasserfallen, JB	Expert Opin Pharmacother. 2003 Sep;4(9):1479-88
M1039			9/1/2003		Hormone therapy: the Women's Health Initiative has caused confusion and concern.	Reid, RL	Fertil Steril. 2003 Sep;80(3):491-3
M1050			10/1/2003		Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.	Barrett-Connor, E, Wehren, LE, Siris, ES, Miller, P, Chen, YT, Abbott, TA, Berger, ML, Santora, AC, Sherwood, LM	Menopause. 2003 Sep-Oct;10(5):412-9
M1060			11/1/2003		Estrogen therapies, lipids, and the heart disease prevention controversy.	Knopp, RH, Aikawa, K, Knopp, EA	Curr Cardiol Rep. 2003 Nov;5(6):477-82
M1061			10/20/2003		Breast cancer and hormone-replacement therapy in the Million Women Study.	Crosignani, PG	Maturitas. 2003 Oct 20;46(2):91-2
M1063			9/1/2003		Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.	Mueck, AO, Seeger, H, Wallwiener, D	Climacteric. 2003 Sep;6(3):221-7
M1064			10/1/2003		HT and breast cancer risk.	Geller, ML, Chlebowski, RT	Fertil Steril. 2003 Oct;80 Suppl 4:5-9
M1066			10/1/2003		Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup.	Cotterchio, M, Kreiger, N, Theis, B, Slon, M, Bahl, S	Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1053-60
M1071			9/1/2003		Use of hormone replacement therapy in the asymptomatic postmenopausal woman: what is the current evidence?	Loh, FH	Ann Acad Med Singapore. 2003 Sep;32(5):605-9; quiz 610
M1072			11/20/2003		Hormone therapy and cardiovascular disease.	Sullivan, JL	N Engl J Med. 2003 Nov 20;349(21):2075-6
M1073			11/1/2003		Decision analysis of hormone replacement therapy after the Women's Health Initiative.	Kim, C, Kwok, YS	Am J Obstet Gynecol. 2003 Nov;189(5):1228-33
M1079			10/1/2003		Controversy of hormone treatment and cardiovascular function: need for strengthened collaborations between preclinical and clinical scientists.	Miller, VM, Shuster, LT, Hayes, SN	Curr Opin Investig Drugs. 2003 Oct;4(10):1220-32
M1080			11/1/2003		Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.	Daling, JR, Malone, KE, Doody, DR, Voigt, LF, Bernstein, L, Marchbanks, PA, Coates, RJ, Norman, SA, Weiss, LK, Ursin, G, Burkman, RT, Deapen, D, Folger, SG, McDonald, JA, Simon, MS, Strom, BL, Spirtas, R	Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1175-81
M1084			11/1/2003		Risk of breast cancer with progestins: critical assessment of current data.	Santen, RJ	Steroids. 2003 Nov;68(10-13):953-64
M1085			12/15/2003		Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.	Prasad, R, Boland, GP, Cramer, A, Anderson, E, Knox, WF, Bundred, NJ	Cancer. 2003 Dec 15;98(12):2539-46
M1087			12/10/2003		Differential effects of progestogens on breast cancer cell lines.	Franke, HR, Vermes, I	Maturitas. 2003 Dec 10;46 Suppl 1:S55-8
M1097			2/10/2004		Evidence-based guidelines for cardiovascular disease prevention in women.	Mosca, L, Appel, LJ, Benjamin, EJ, Berra, K, Chandra-Strobo, N, Fabunmi, RP, Grady, D, Haan, CK, Hayes, SN, Judelson, DR, Keenan, NL, McBride, P, Oparil, S, Ouyang, P, Oz, MC, Mendelsohn, ME, Pasternak, RC, Pinn, VW, Robertson, RM, Schenck-Gustafsson, K, Sila, CA, Smith, SC, Sopko, G, Taylor, AL, Walsh, BW, Wenger, NK, Williams, CL	Circulation. 2004 Feb 10;109(5):672-93
M1098			6/1/2004		Hormone replacement therapy in relation to breast carcinoma incidence rate ratios.	Tjonneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Møllerhøjgaard L	Cancer. 2004 Jun 1;100(11):2328-2337
M1099			12/1/2003		Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.	Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA	J Clin Oncol. 2003 Dec 1;21(23):4314-23
M1128			6/7/2004		Pharmacological profile of progestins.	Sitruk-Ware, R	Maturitas. 2004 Apr 15;47(4):277-83
M1137			5/1/2004		A prospective study of breast cancer risk using routine mammographic breast density measurements.	Vacek, PM, Geller, BM	Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):715-22

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M1143			5/29/2004		Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study.	Banks, E, Reeves, G, Beral, V, Bull, D, Crossley, B, Simmonds, M, Hilton, E, Bailey, S, Barrett, N, Briers, P, English, R, Jackson, A, Kutt, E, Lavelle, J, Rockall, L, Wallis, MG, Wilson, M, Patrick, J	BMJ. 2004 May 29;328(7451):1291-2
M1144			5/24/2004		Benefits of 2 years of intense exercise on bone density, physical fitness, and blood lipids in early postmenopausal osteopenic women: results of the Erlangen Fitness Osteoporosis Prevention Study (EFOPS).	Kemmler, W, Lauber, D, Weineck, J, Hensen, J, Kalender, W, Engelke, K,	Arch Intern Med. 2004 May 24;164(10):1084-91
M1145			1/1/1999		Chapter 2: Interactions between estradiol and progesterone in normal breast. Implications for mammary carcinogenesis.	Plu-Bureau, G, Touraine, P, Mauvais-Jarvis, P	In: Endocrinology of breast cancer: Humana Press, 1999. p. 21-37
M1152			4/1/2004		Considerations in the choice of oral vs. transdermal hormone therapy: a review.	Minkin, MJ	J Reprod Med. 2004 Apr;49(4):311-20
M1172			11/1/1997		Does estrogen prevent skin aging? Results from the First National Health and Nutrition Examination Survey (NHANES I).	Dunn LB, Damesyn M, Moore AA, Reuben DB, Greendale GA	Arch Dermatol. 1997 Mar;133(3):339-42
M1179			5/1/2002		Hormonal manipulations and breast cancer.	Benshushan, A, Brzezinski, A	Obstet Gynecol Surv. 2002 May;57(5):314-23
M1180			9/1/2002		Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women.	Li, R, Gilliland, FD, Baumgartner, K, Samet, J	Cancer. 2002 Sep 1;95(5):960-8
M1182			6/1/2004		Caregiving stress, endogenous sex steroid hormone levels, and breast cancer incidence.	Kroenke, CH, Hankinson, SE, Schenhammer, ES, Colditz, GA, Kawachi, I, Holmes, MD	Am J Epidemiol. 2004 Jun 1;159(11):1019-27
M1184			2/1/1998		Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys.	Minshall, RD, Stanczyk, FZ, Miyagawa, K, Uchida, B, Azthelm, M, Novy, M, Hermsmeyer, K	J Clin Endocrinol Metab. 1998 Feb;83(2):649-59
M1187			9/2/2003		Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling.	Nilsen, J, Brinton, RD	Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10506-11
M1196			11/1/2003		All progestins are not created equal.	Stanczyk, FZ	Steroids. 2003 Nov;68(10-13):879-90
M1200			11/5/1973		The Coronary Drug Project: findings leading to discontinuation of the 2.5-mg/day estrogen group.	Coronary Drug Project Research Group	J Am Med Assoc. 1973 November 5;226(6):652-7
M1202			6/10/2004		A prospective study of dietary lactose and ovarian cancer.	Fairfield, KM, Hunter, DJ, Colditz, GA, Fuchs, CS, Cramer, DW, Speizer, FE, Willett, WC, Hankinson, SE	Int J Cancer. 2004 Jun 10;110(2):271-7
M1207			1/1/2004		Clinical features of familial ovarian cancer lacking mutations in BRCA1 or BRCA2.	Menkiszak, J, Gronwald, J, Gorski, B, Byrski, T, Huzarski, T, Jakubowska, A, Foszczynska-Kloda, M, Brzosko, M, Flcinski, J, Rzepka-Gorska, I, Narod, SA, Lubinski, J	Eur J Gynaecol Oncol. 2004;25(1):99-100
M1210			4/1/2004		Endometriosis and the development of malignant tumours of the pelvis: A review of literature.	Van Gorp, T, Amant, F, Neven, P, Vergote, I, Moerman, P	Best Pract Res Clin Obstet Gynaecol. 2004 Apr;18(2):349-71
M1211			4/1/2004		Familial association of specific histologic types of ovarian malignancy with other malignancies.	Lorenzo Bernajo, J, Rawal, R, Hemminki, K	Cancer. 2004 Apr 1;100(7):1507-14
M1216			5/1/2004		Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.	Shih, IeM, Kurman, RJ,	Am J Pathol. 2004 May;164(5):1511-8
M1218			4/5/2004		Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study.	Kumle, M, Weiderpass, E, Braaten, T, Adami, HO, Lund, E	Br J Cancer. 2004 Apr 5;90(7):1386-91
M1221			10/10/2003		Oral contraceptive use and risk of breast cancer by histologic type.	Newcomer, LM, Newcomb, PA, Trentham-Dietz, A, Longnecker, MP, Greenberg, ER	Int J Cancer. 2003 Oct 10;106(6):961-4
M1222			12/1/2001		Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study.	Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR.	Gynecol Oncol. 2001 Dec;83(3):575-85
M1227			4/17/2002		Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.	Endogenous Hormones and Breast Cancer Collaborative Group	J Natl Cancer Inst. 2002 Apr 17;94(8):606-16
M1240			3/15/2003		Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.	Olsson, HL, Ingvar, C, Bladstrom, A	Cancer. 2003 Mar 15;97(6):1387-92
M1241			6/15/2001		Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy.	Manjer, J, Malina, J, Berglund, G, Bondeson, L, Garne, JP, Janzon, L	Int J Cancer. 2001 Jun 15;92(6):919-22
M1242			4/20/2001		Prognosis of breast cancers detected in women receiving hormone replacement therapy.	Delgado, RC, Lubian Lopez, DM	Maturitas. 2001 Apr 20;38(2):147-56
M1246			1/1/2003		Chapter 2: Tumours of the ovary and peritoneum.	International agency for research on cancer (IARC)	In: Pathology and Genetics. Tumours of the breast and female genital organs: IARC, 2003. p. 113-145
M1256			2/1/2002		The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States).	Tarone, RE, Chu, KC	Cancer Causes Control. 2002 Feb;13(1):7-14
M1263			5/1/2004		A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast.	Korhonen, T, Huhtala, H, Holli, K	Breast Cancer Res Treat. 2004 May;85(1):23-9
M1267			7/1/1999		Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients.	Jernstrom, H, Frenander, J, Ferno, M, Olsson, H	Br J Cancer. 1999 Jul;80(9):1453-8
M1276			2/15/2004		Polymorphism in the androgen receptor and mammographic density in women taking and not taking estrogen and progestin therapy.	Lillie, EO, Bernstein, L, Ingles, SA, Gauderman, WJ, Rivas, GE, Gagalang, V, Kronitris, T, Ursin, G	Cancer Res. 2004 Feb 15;64(4):1237-41
M1278			1/1/2004		Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer.	Santen, RJ, Song, RX, Zhang, Z, Yue, W, Kumar, R	Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):337S-45S
M1287			10/1/2001		Estrogen receptor and breast cancer.	Sommer, S, Fuqua, SA	Semin Cancer Biol. 2001 Oct;11(5):339-52
M1304			10/18/2003		Breast cancer and hormone-replacement therapy: the Million Women Study. Letter series and author reply.	Garlon M, Bliss JM, Gray R, Bundred NJ, Helmond FA, Van Leeuwen FE, Nijrjesy I, Million Women Study Collaborators (Beral, Banks, Reeves, Bull)	Lancet. 2003 Oct 18;362(9392):1329; author reply 1330-1
M1319			1/1/2002		Predictors of outcome of mammography in the National Health Service Breast Screening Programme.	Banks, E, Reeves, G, Beral, V, Bull, D, Crossley, B, Simmonds, M, Hilton, E, Bailey, S, Barrett, N, Briers, P, English, R, Jackson, A, Kutt, E, Lavelle, J, Rockall, L, Wallis, MG, Wilson, M	J Med Screen. 2002;9(2):74-82
M1322			6/15/2004		Lifestyle and Demographic Factors in Relation to Vasomotor Symptoms: Baseline Results from the Study of Women's Health Across the Nation.	Gold, EB, Block, G, Crawford, S, Lachance, L, FitzGerald, G, Miracle, H, Sherman, S	Am J Epidemiol. 2004 Jun 15;159(12):1189-99
M1325			6/1/2004		Testosterone effects on the breast: implications for testosterone therapy for women.	Somboonporn, W, Davis, SR	Endocr Rev. 2004 Jun;25(3):374-88

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M1332			12/7/1996		Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.	Black, DM, Cummings, SR, Karpf, DB, Cauley, JA, Thompson, DE, Nevitt, MC, Bauer, DC, Genant, HK, Haskell, WL, Marcus, R, Ott, SM, Torner, JC, Quandt, SA, Reiss, TF, Ensrud, KE	Lancet. 1996 Dec 7;348(9041):1535-41
M1334			6/23/2004		Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.	Shumaker, SA, Lagault, C, Kuller, L, Rapp, SR, Thal, L, Lane, DS, Fillit, H, Stefanick, ML, Hendrix, SL, Lewis, CE, Masaki, K, Coker, LH	JAMA. 2004 Jun 23;291(24):2947-58
M1335			6/23/2004		Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.	Espeland, MA, Rapp, SR, Shumaker, SA, Brunner, R, Manson, JE, Sherwin, BB, Hsia, J, Margolis, KL, Hogan, PE, Wallace, R, Dailey, M, Freeman, R, Hays, J	JAMA. 2004 Jun 23;291(24):2959-68
M1338			11/1/2003		Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis.	Ganz, PA, Guadagnoli, E, Landrum, MB, Lash, TL, Rakowski, W, Silliman, RA	J Clin Oncol. 2003 Nov 1;21(21):4027-33
M1344			8/1/2004		Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: Supporting the Women's Health Initiative study.	Nozaki, M, Koera, K, Nagata, H, Nakano, H	J Obstet Gynaecol Res. 2004 Aug;30(4):297-302
M1353			6/23/2004		Estrogen and dementia: insights from the Women's Health Initiative Memory Study.	Schneider, LS	JAMA. 2004 Jun 23;291(24):3005-7
M1357			11/1/2002		Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.	Cerhan, JR, Vachon, CM, Habermann, TM, Ansell, SM, Witzig, TE, Kurtin, PJ, Janney, CA, Zheng, W, Potter, JD, Sellers, TA, Folsom, AR	Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1466-71
M1360			7/1/2003		Hormone replacement therapy and risk of breast cancer: the role of progestins.	Stahlberg, C, Pederson, AT, Lyng, E, Ottesen, B	Acta Obstet Gynecol Scand. 2003 Jul;82(7):335-44
M1375			3/1/1996		Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?	Roy, JA, Sawka, CA, Pritchard, KI	J Clin Oncol. 1996 Mar;14(3):997-1006
M1385			9/1/2000		The Role of Vascular Endothelial Growth Factor (VEGF) in Tumor Angiogenesis and Early Clinical Development of VEGF-Receptor Kinase Inhibitors.	Verheul, HM, Pinedo, HM	Clin Breast Cancer. 2000 Sep;1 Suppl 1:S80-4
M1388			1/1/2004		Women's ischemic syndrome evaluation. Current status and future research directions report of the national heart, lung and blood institute workshop 10. 2-4, 2002. Section 4. Lessons from hormone replacement trials.	Waters, DD, Gordon, D, Rossouw, JE, Cannon, RO, Collins, P, Herrington, DM, Hsia, J, Langer, R, Mosca, L, Ouyang, P, Sopko, G, Stefanick, ML	Circulation. 2004;109:e53-55.
M1391			11/15/1997		Dissociation between steroid receptor expression and cell proliferation in the human breast.	Clarke, RB, Howell, A, Potten, CS, Anderson, E	Cancer Res. 1997 Nov 15;57(22):4987-91
M1392			4/1/1998		Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques.	Cline, JM, Soderqvist, G, von Schoultz, E, Skoog, L, von Schoultz, B	Breast Cancer Res Treat. 1998 Apr;48(3):221-9
M1393			11/30/2000		Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer.	Gustafsson, JA, Warner, M	J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):245-8
M1400			7/15/2004		Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the postmenopausal estrogen/progestin interventions (PEPI) trial.	Ursin, G, Palla, SL, Reboussin, BA, Stone, S, Wasilauskas, C, Pike, MC, Greendale, GA	J Clin Oncol. 2004;22:2842-48
M1401			1/1/2003		Postmenopausal hormone therapy and change in mammographic density.	Greendale, GA, Reboussin, BA, Stone, S, Wasilauskas, C, Pike, MC, Ursin, G	J Natl Cancer Inst. 2003 Jan 1;95(1):30-7
M1404			1/1/1995		Chapter 12: Breast Cancer.	Henderson, IC	In: Clinical Oncology (1995), American Cancer Society:198-219
M1405			10/1/2002		Breast cancer risk in healthy and symptomatic women: results of a multivariate analysis. A case-control study.; .	Lumachi F, Ermani M, Brandes AA, Basso U, Paris M, Basso SM, Boccagni P,	Biomed Pharmacother. 2002 Oct;56(8):416-20;
M1410			3/18/2004		Ten years' experience with alendronate for osteoporosis in postmenopausal women.	Bone, HG, Hosking, D, Devogelaer, JP, Tucci, JR, Emkey, RD, Tonino, RP, Rodriguez-Portales, JA, Downs, RW, Gupta, J, Santora, AC, Liberman, UA	N Engl J Med. 2004 Mar 18;350(12):1189-99
M1416			8/11/2004		Effects of estrogen-only treatment in postmenopausal women.	Beral, V, Banks, E, Reeves, G	JAMA. 2004 Aug 11;292(6):684; author reply 685-6
M1423			2/1/2001		Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity.	McCarty, MF	Med Hypotheses. 2001 Feb;56(2):213-6
M1424			7/1/2004		Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study.	Pike, MC, Pearce, CL, Peters, R, Cozen, W, Wan, P, Wu, AH	Fertil Steril. 2004 Jul;82(1):186-95
M1425			6/1/2004		Ovarian cancer risk after the use of ovulation-stimulating drugs.	Brinton, LA, Lamb, EJ, Moghissi, KS, Scoccia, B, Althuis, MD, Mabie, JE, Westhoff, CL	Obstet Gynecol. 2004 Jun;103(6):1194-203
M1427			7/1/2004		Estrogens and epithelial ovarian cancer.	Cunat, S, Hoffmann, P, Pujol, P	Gynecol Oncol. 2004 Jul;94(1):25-32
M1428			6/30/2004		Estrogen and progesterone receptors in ovarian epithelial tumors.	Lindgren, PR, Cajander, S, Backstrom, T, Gustafsson, JA, Makela, S, Olofsson, JI	Mol Cell Endocrinol. 2004 Jun 30;221(1-2):97-104
M1429			5/1/1997		Past use of oral contraceptives and the risk of developing systemic lupus erythematosus.	Sanchez-Guerrero, J, Karlson, EW, Liang, MH, Hunter, DJ, Speizer, FE, Colditz, GA	Arthritis Rheum. 1997 May;40(5):804-8
M1432			5/1/2004		Risk factors for different histological types of ovarian cancer.	Parazzini, F, Chiaffarino, F, Negri, E, Surace, M, Benzi, G, Franceschi, S, Fedele, L, La Vecchia, C	Int J Gynecol Cancer. 2004 May-Jun;14(3):431-6
M1437					Statement on the estrogen plus progestin trial of the women's health initiative by the american college of obstetricians and gynecologists.	ACOG	The American College of Obstetricians and Gynecologists web site
M1453			1/1/1996		Chapter 20: Perspectives in hormonal carcinogenesis: animal models to human disease.	Li, JJ	In: Cellular and Molecular Mechanisms of Hormonal Carcinogenesis: Environmental Influences: Wiley-Liss, 1996 p. 447-455
M1459			1/1/1985		Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines.	Danel, L, Menouni, M, Cohen, JH, Magaud, JP, Lenoir, G, Revillard, JP, Saez, S	Leuk Res. 1985;9(11):1373-8

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M1460			3/1/1999		Alcohol consumption and breast cancer oestrogen and progesterone receptor status.	Enger, SM, Ross, RK, Paganini-Hill, A, Longnecker, MP, Bernstein, L	Br J Cancer. 1999 Mar;79(7-8):1308-14
M1461			7/1/2000		Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.	Enger, SM, Ross, RK, Paganini-Hill, A, Carpenter, CL, Bernstein, L	Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):681-7
M1464			8/16/2004		Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy.	Stahlberg, C, Pedersen, AT, Andersen, ZJ, Keiding, N, Hundrup, YA, Obel, EB, Moller, S, Rank, F, Ottesen, B, Lynge, E	Br J Cancer. 2004 Aug 16;91(4):644-50
M1467			7/1/2004		Current Status of Aromatase Inhibitors in the Management of Breast Cancer and Critique of the NCIC MA-17 Trial.	Baum, M	Cancer Control. 2004 Jul-Aug;11(4):217-21
M1468			7/1/2004		Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.	Chang, TC, Lien, YR, Chen, M, Cheng, SP, Chen, RJ, Chow, SN	Acta Obstet Gynecol Scand. 2004 Jul;83(7):661-6
M1470			8/1/2004		Estrogen Receptor beta (par; ESR2) Polymorphisms and Endometrial Cancer (United States).	Setiawan, VW, Hankinson, S, Colditz, G, Hunter, D, Vivo, ID,	Cancer Causes Control. 2004 Aug;15(6):627-33
M1472			2/15/2001		Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma.	Goggins, WB, Finkelstein, DM, Tsao, H	Cancer. 2001 Feb 15;91(4):874-80
M1474			6/1/2003		Increasing incidence of non-Hodgkin's lymphoma in Canada, 1970-1996: age-period-cohort analysis.	Liu, S, Semenciw, R, Mao, Y	Hematol Oncol. 2003 Jun;21(2):57-66
M1475			3/1/2002		Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women's health study (United States).	Cerhan, JR, Habermann, TM, Vachou, CM, Putnam, SD, Zheng, W, Potter, JD, Folsom, AR	Cancer Causes Control. 2002 Mar;13(2):131-6
M1481			3/1/2002		Postmenopausal cancer risk after self-reported endometriosis diagnosis in the Iowa Women's Health Study.	Olson, JE, Cerhan, JR, Janney, CA, Anderson, KE, Vachon, CM, Sellers, TA	Cancer. 2002 Mar 1;94(5):1612-8
M1485			5/1/2004		Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women.	Zhang, Y, Holford, TR, Leaderer, B, Zahm, SH, Boyle, P, Morton, LM, Zhang, B, Zou, K, Flynn, S, Tallini, G, Owens, PH, Zheng, T	Cancer Causes Control. 2004 May;15(4):419-28
M1492			10/7/1997		Differential effects of estrogen and medroxyprogesterone on basal and stress-induced growth hormone release, IGF-1 levels, and cellular immunity in postmenopausal women.	Malarkey, WB, Burleson, M, Cacioppo, JT, Poehlmann, K, Glaser, R, Kiecolt-Glaser, JK	Endocrine. 1997 Oct;7(2):227-33
M1493			8/28/2004		Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study.	Banks, E, Reeves, G, Beral, V, Bull, D, Crossley, B, Simmonds, M, Hilton, E, Bailey, S, Barrett, N, Briers, P, English, R, Jackson, A, Knutt, E, Lavelle, J, Rockall, L, Wallis, MG, Wilson, M, Patrick, J	BMJ. 2004 Aug 28;329(7464):477
M1495			9/1/2004		Factors associated with treatment initiation after osteoporosis screening.	Brennan, RM, Wactawski-Wende, J, Crespo, CJ, Dmochowski, J	Am J Epidemiol. 2004 Sep 1;160(5):475-83
M1497			8/21/2004		Ejecting the FDA from the courtroom.	Lancet Editorial Board	Lancet. 2004 Aug 21;364(9435):638
M1506			11/1/1993		Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group.	Manolio, TA, Furberg, CD, Shemanski, L, Psaty, BM, O'Leary, DH, Tracy, RP, Bush, TL	Circulation. 1993 Nov;88(5 Pt 1):2163-71
M1507			3/15/1985		Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone.	Ottoson, UB, Johansson, BG, von Schoultz, B	Am J Obstet Gynecol. 1985 Mar 15;151(6):746-50
M1518			1/4/2001		Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells.	Balana, ME, Labriola, L, Salatino, M, Movsichoff, F, Peters, G, Charreau, EH, Elizalde, PV	Oncogene. 2001 Jan 4;20(1):34-47
M1521			5/1/2004		After the Women's Health Initiative: Postmenopausal women's experiences with discontinuing estrogen replacement therapy.	Haskell, SG	J Womens Health (Larchmt). 2004 May;13(4):438-42
M1525			12/1/2001		Breast cancer and hormone replacement therapy: putting the risk into perspective.	Campagnoli, C, Abba, C, Ambroggio, S, Biglia, N, Ponzzone, R	Gynecol Endocrinol. 2001 Dec;15 Suppl 6:53-60
M1527			3/1/2001		Breast-feeding duration and the risk of malignant diseases in childhood in Sweden.	Hardell, L, Dreifaldt, AC	Eur J Clin Nutr. 2001 Mar;55(3):179-85
M1533			12/10/2003		Differential effects of progestins on the circulating IGF-1 system.	Campagnoli, C, Abba, C, Ambroggio, S, Peris, C	Maturitas. 2003 Dec 10;46 Suppl 1:S39-44
M1536			7/1/2004		Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial.	Margolis, KL, Bonds, DE, Rodabough, RJ, Tinker, L, Phillips, LS, Allen, C, Bassford, T, Burke, G, Torrens, J, Howard, BV	Diabetologia. 2004 Jul;47(7):1175-87. Epub 2004 Jul 14
M1538			8/1/2004		Effects of Conjugated Equine Estrogen in Postmenopausal Women Having Undergone Hysterectomy: The Women's Health Initiative Randomized, Controlled Trials.	Women's Health Initiative Steering Committee	Obstet Gynecol Surv. 2004 Aug;59(8):599-600
M1547			6/1/2004		Hip fracture prevention in postmenopausal women.	Kessel, B	Obstet Gynecol Surv. 2004 Jun;59(6):446-55
M1550			11/4/1999		Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas.	Balana, ME, Lupu, R, Labriola, L, Charreau, EH, Elizalde, PV	Oncogene. 1999 Nov 4;18(46):6370-9
M1555			6/1/2004		Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy.	Conner, P, Svane, G, Azavedo, E, Soderqvist, G, Carlstrom, K, Graser, T, Walter, F, von Schoultz, B	Fertil Steril. 2004 Jun;81(6):1617-23
M1556			12/1/2003		Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.	Nugent, AG, Leung, KC, Sullivan, D, Reutens, AT, Ho, KK	Clin Endocrinol (Oxf). 2003 Dec;59(6):690-8
M1558			7/1/2004		Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis.	Salpeter, SR, Walsh, JM, Greyber, E, Ormiston, TM, Salpeter, EE	J Gen Intern Med. 2004 Jul;19(7):791-804
M1567			1/17/1997		Pregnancy and risk of non-Hodgkin's lymphoma: a prospective study.	Adami, HO, Tsaih, S, Lambe, M, Hsieh, C, Adami, J, Trichopoulos, D, Melbye, M, Glimelius, B	Int J Cancer. 1997 Jan 17;70(2):155-8
M1568			12/10/2003		Progestins and their effects on the breast.	Druckmann, R	Maturitas. 2003 Dec 10;46 Suppl 1:S59-69
M1583			6/1/2004		The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition.	Nafolin, F, Taylor, HS, Karas, R, Brinton, E, Newman, I, Clarkson, TB, Mendelsohn, M, Lobo, RA, Judelson, DR, Nachtigall, LE, Heward, CB, Hecht, H, Jaff, MR, Harman, SM	Fertil Steril. 2004 Jun;81(6):1498-501
M1587			6/15/2004		Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy.	Lindh-Astrand, L, Nedstrand, E, Wyon, Y, Hammer, M	Maturitas. 2004 Jun 15;48(2):97-105;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M1590			9/9/2004		Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells.	Simoncini, T, Mannella, P, Fornari, L, Caruso, A, Willis, MY, Garibaldi, S, Baldacci, C, Genazzani, AR	Endocrinology 2004 Sep 9 [Epub ahead of print]. doi: 10.1210/en.2004-0510 ;
M1595			12/1/2003		Predictors of difficulty when discontinuing postmenopausal hormone therapy.	Grady, D, Ettinger, B, Tosteson, AN, Pressman, A, Macer, JL	Obstet Gynecol. 2003 Dec;102(6):1233-9
M1597			7/20/2004		Use of menopausal hormones in the United States, 1992 through June, 2003.	Wysowski, DK, Governale, LA	Pharmacoepidemiol Drug Saf. 2004 Jul 20 [Epub ahead of print]
M1601			12/1/1990		Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis.	Hunt, K, Vessey, M, McPherson, K	Br J Obstet Gynaecol. 1990 Dec;97(12):1080-6
M1602			10/6/2004		Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statemnt of the North American Menopause Society.	North American Menopause Society	Position Statement of The North American Menopause Society. 2004 Oct 6:1-24
M1603			10/6/2004		Estrogen plus progestin and risk of venous thrombosis.	Cushman, M, Kuller, LH, Prentice, R, Rodabough, RJ, Psaty, BM, Stafford, RS, Sidney, S, Rosendaal, FR	JAMA. 2004 Oct 6;292(13):1573-80
M1610			10/21/2004		Failing the public health - Rofecoxib, Merck, and the FDA.	Topol, E	N Engl J Med. 2004 Oct 21;351(17):1707-1708
M1617			1/1/2004		Hormone replacement therapy and obstructive airway diseases.	Barr, RG, Camargo, CA	Treat Respir Med. 2004;3(1):1-7
M1622			4/12/2000		Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. .	Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Møllgaard A, Ravn P, Øvst P, Kanis JA, Christiansen C	Bone. 2004 Apr;34(4):728-35
M1623			10/20/2004		Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study.; .	Bakken K, Alsaker E, Eggen AE, Lund E	Int J Cancer. 2004 Oct 20;112(1):130-4
M1624			9/21/2003		Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study.; .	McTiernan A, Kooperberg C, White E, Wilcox S, Coates R, Adams-Campbell LL, Woods N, Ockene J, Women's Health Initiative Cohort Study.	JAMA. 2003 Sep 10;290(10):1331-6;
M1628			10/1/2004		Bone Health and Osteoporosis: A Report of the Surgeon General: Full Report.	Carmona, RH; Office of the Surgeon General; Department of Health and Human Services	NLM: WE 225 B71259 2004
M1630			10/15/2004		Menopause and Hormones: What can you believe?	FDA Office of Women's Health	FDA Office of Women's Health Press Release 10/15/2004
M1644			11/1/2004		Estrogens and stroke: Use of oral contraceptives and post-menopausal use of estrogen: Current recommendations.	Brass, LM	Curr Treat Options Neurol. 2004 Nov;6(6):459-467
M1647			11/19/2002		Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer.	Chen WY, Colditz GA, Rosner B, Hankinson SE, Hunter DJ, Manson JE, Stampfer MJ, Willett WC, Speizer FE	Ann Intern Med. 2002 Nov 19;137(10):798-804;
M1651			11/15/2000		Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study.; .	Colditz GA, Rosner B	Am J Epidemiol. 2000 Nov 15;152(10):950-64
M1659			7/1/1979		Cancer of the corpus uteri: increasing incidence in the United States, 1970-1975.	Walker AM, Jick H	Am J Epidemiol. 1979 Jul;110(1):47-51
M1662			11/1/1980		Replacement estrogens and breast cancer.; .	Jick H, Walker AM, Watkins RN, D'Ewart DC, Hunter JR, Danford A, Madsen S, Dinan BJ, Rothman KJ	Am J Epidemiol. 1980 Nov;112(5):586-94;
M1664			3/1/1980		The epidemic of endometrial cancer: a commentary.; .	Jick H, Walker AM, Rothman KJ.,	Am J Public Health. 1980 Mar;70(3):264-7.;
M1674			11/1/1979		Postmarketing follow-up.; .	Jick H, Walker AM, Spriet-Pourra C.	JAMA. 1979 Nov 23;242(21):2310-4;
M1679			2/1/1979		Replacement estrogens and endometrial cancer.; .	Jick H, Watkins RN, Hunter JR, Dinan BJ, Madsen S, Rothman KJ, Walker AM,	N Engl J Med. 1979 Feb 1;300(5):218-22;
M1682			9/1/2004		Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies.; .	Riman T, Nilsson S, Persson IR, .	Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95;
M1690			10/27/2004		Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative.; .	Majumdar SR, Almasi EA, Stafford RS,	JAMA. 2004 Oct 27;292(16):1983-8;
M1691			11/5/2004		Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells.	Oishi A, Ohmichi M, Takahashi K, Takahashi T, Mori-Abe A, Kawagoe J, Otsu R, Mochizuki Y, Inaba N, Kurachi H,	Biochem Biophys Res Commun. 2004 Nov 5;324(1):193-8;
M1692			1/1/1988		Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice	Nagasawa	Breast Can Res Treat 12:59-66 (1988).
M1704			9/1/1991		A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.; .	Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL,	JAMA. 1991 Apr 17;265(15):1985-90;
M1708			11/1/1997		Additional effects of medroxyprogesterone acetate on mammary tumors in oophorectomized, estrogenized, DMBA-treated rats.; .	Sakamoto S, Kudo H, Suzuki S, Mitamura T, Sassa S, Kuwa K, Chun Z, Yoshimura S, Maemura M, Nakayama T, Shinoda H,	Anticancer Res. 1997 Nov-Dec;17(6D):4583-7;
M1709			3/15/1982		Cardiovascular effects and progestins in oral contraceptives.	Wynn V	Am J Obstet Gynecol. 1982 Mar 15;142(6 Pt 2):718
M1711			8/3/1989		Postmenopausal estrogen replacement and breast cancer.; .	Barrett-Connor E.	N Engl J Med. 1989 Aug 3;321(5):319-20;
M1714			9/1/1981		Gross and histopathologic effects of medroxyprogesterone acetate and progesterone on the mammary glands of adult beagle bitches.; .	Concannon PW, Spraker TR, Casey HW, Hansel W,	Fertil Steril. 1981 Sep;36(3):373-87;
M1719			3/1/1998		Promoter effect of medroxyprogesterone acetate (MPA) in N-methyl-N-nitrosourea (MNU) induced mammary tumors in BALB/c mice.; .	Pazos P, Lanari C, Elizalde P, Montecchia F, Charreau EH, Molinolo AA,	Carcinogenesis. 1998 Mar;19(3):529-31;
M1722			5/16/2004		Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality.; .	O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS	J Natl Cancer Inst. 2001 May 16;93(10):754-62
M1723			11/8/2004		Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.; .	Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, Bock JE, Blaakaer J.	Arch Intern Med. 2004 Nov 8;164(20):2253-9;
M1724			4/1/2002		Changing incidence of non-Hodgkin lymphomas in the United States.; .	Clarke CA, Glaser SL,	Cancer. 2002 Apr 1;94(7):2015-23;
M1725			1/1/2004		Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications.; .	Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA,	Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):138-43;
M1748			1/1/2002		Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990-1999.	Clarke, CA, Glaser, SL, West, DW, Ereman, RR, Erdmann, CA, Barlow, JM, Wrensch, MR	Breast Cancer Res. 2002;4(6):R13. Epub 2002 Jul 26
M1750			7/1/2004		Breast and uterine effects of soy isoflavones and conjugated equine estrogens in postmenopausal female monkeys.	Wood, CE, Register, TC, Anthony, MS, Kock, ND, Cline, JM	J Clin Endocrinol Metab. 2004 Jul;89(7):3462-8

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M1751			8/1/1995		The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Introduction.	Bush, TL, Espeland, MA, Mebane-Sims, I	Control Clin Trials. 1995 Aug;16(4 Suppl):1S-2S
M1755			12/1/1995		Comparison of the histological changes in the dog after treatment with the progestins medroxyprogesterone acetate and proligestone.	Selman, PJ, van Garderen, E, Mol, JA, van den Ingh, TS	Vet Q. 1995 Dec;17(4):128-33
M1760			8/1/1995		Rationale, design, and conduct of the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions.	Espeland, MA, Bush, TL, Mebane-Sims, I, Stefanick, ML, Johnson, S, Sherwin, R, Wacławski, M	Control Clin Trials. 1995 Aug;16(4 Suppl):3S-19S
M1765			11/12/1992		FDA gives final approval to Depo amid concerns over safety, cost and coercion.	N/A	Wash Memo Alan Guttmacher Inst. 1992 Nov 12;(17):2-3
M1766			9/1/1977		FDA studies of estrogen, progestogens, and estrogen/progestogen combinations in the dog and monkey.	Geil, RG, Lamar, JK	J Toxicol Environ Health. 1977 Sep;3(1-2):179-93
M1773			2/26/1996		Leisure, home, and occupational physical activity and cardiovascular risk factors in postmenopausal women. The Postmenopausal Estrogens/Progestins Intervention (PEPI) Study.	Greendale, GA, Bodin-Dunn, L, Ingles, S, Haile, R, Barrett-Connor, E	Arch Intern Med. 1996 Feb 26;156(4):418-24
M1774			6/5/2003		Postmenopausal hormone therapy.	Krieger, N	N Engl J Med. 2003 Jun 5;348(23):2363-4; author reply 2363-4
M1776			9/15/2003		Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative.	Harris, RE, Chlebowski, RT, Jackson, RD, Frid, DJ, Ascenso, JL, Anderson, G, Liao, A, Rodabough, RJ, White, E, McTiernan, A	Cancer Res. 2003 Sep 15;63(18):6096-101
M1785			12/1/2004		Alcohol exposure and breast cancer: results of the women's contraceptive and reproductive experiences study.;	McDonald, JA, Mandel, MG, Marchbanks, PA, Folger, SG, Daling, JR, Ursin, G, Simon, MS, Berstein, L, Strom, BL, Norman, SA, Malone, KE, Weiss, LK, Burkman, RT, Weber, AL, Apirtas, R	Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2106-16
M1786			5/22/2002		Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.	Lindsay, R, Gallagher, JC, Kleerekoper, M, Pickar, JH	JAMA. 2002 May 22-29;287(20):2668-76
M1788			8/1/1995		Baseline characteristics of the PEPI participants. Postmenopausal Estrogen/Progestin Interventions.	Miller, VT, Byington, RL, Espeland, MA, Langer, R, Marcus, R, Shumaker, S, Stern, MP	Control Clin Trials. 1995 Aug;16(4 Suppl):54S-65S
M1793			3/1/2004		The Million Women Study: potential biases do not allow uncritical acceptance of the data.	Shapiro, S	Climacteric. 2004 Mar;7(1):3-7
M1794			3/1/2004		Guidelines for the hormone treatment of women in the menopausal transition and beyond.	Naftolin, F, Schneider, HP, Sturdee, DW	Climacteric. 2004 Mar;7(1):8-11
M1801			6/1/2004		Use and perception of hormone therapy following media reports of the Women's Health Initiative: a survey of Australian WISDOM participants.	Paine, BJ, Stocks, NP, Ramsay, EN, Ryan, P, MacLennan, AH	Climacteric. 2004 Jun;7(2):143-52
M1807			2/7/1996		Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.	Writing Group for the PEPI Trial	JAMA. 1996 Feb 7;275(5):370-5
M1814			10/1/1993		Progesterone induction of mammary carcinomas in BALB/c female mice. Correlation between progestin dependence and morphology.	Kordon, EC, Molinolo, AA, Pasqualini, CD, Charreau, EH, Pazos, P, Dran, G, Lanari, C	Breast Cancer Res Treat. 1993 Oct;28(1):29-39
M1825			1/1/2004		Second Thoughts on the Women's Health Initiative Study: the Effect of Age on the Safety of HRT.	Studd, J	Climacteric 2004;7:412-414
M1828			5/1/1994		Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group.	Woodruff, JD, Pickar, JH	Am J Obstet Gynecol. 1994 May;170(5 Pt 1):1213-23
M1831			12/1/2003		Geographic excess of estrogen receptor-positive breast cancer.;	Benz CC, Clarke CA, Moore DH 2nd,	Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1523-7;
M1833			1/1/2004		The characteristics of malignant breast tumors in hormone replacement therapy users versus nonusers.;	Pappo I, Meirshon I, Karni T, Siegelmann-Danielli N, Stahl-Kent V, Sandbank J, Wasserman I, Halevy A,	Ann Surg Oncol. 2004 Jan;11(1):52-8;
M1834			10/1/2002		Increase in breast cancer incidence in middle-aged women during the 1990s.;	Prehn A, Clarke C, Topol B, Glaser S, West D,	Ann Epidemiol. 2002 Oct;12(7):476-81;
M1845			1/19/2005		Effect of estrogen therapy on gallbladder disease.;	Cirillo DJ, Wallace RB, Rodabough RJ, Greenland P, LaCroix AZ, Limacher MC, Larson JC,	JAMA. 2005 Jan 19;293(3):330-9;
M1861			6/20/2003		Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies.;	Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C,	Int J Cancer. 2003 Jun 20;105(3):408-12;
M1866			9/10/1977		Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer.;	Hoover R, Gray LA Sr, Fraumeni JF Jr,	Lancet. 1977 Sep 10;2(8037):533-4;
M1869			4/25/1995		Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis.;	Nandi S, Guzman RC, Yang J,	Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3650-7;
M1901			1/3/1998		Role of hormones in mammary cancer initiation and progression.	Russo IH, Russo J.	J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):49-61
M1905			5/13/2004		Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma.	Skibola CF, Holly EA, Forrest MS, Hubbard A, Bracci PM, Skibola DR, Hegedus C, Smith MT	Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86
M1910			11/1/2002		Case-control study of increased mammographic breast density response to hormone replacement therapy.	Vachon CM, Sellers TA, Vierkant RA, Wu FF, Brandt KR	Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1382-8
M1916			1/20/2005		Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility.	Cheng TC, Chen ST, Huang CS, Fu YP, Yu JC, Cheng CW, Wu PE, Shan CY	Int J Cancer. 2005 Jan 20;113(3):345-53
M1918			1/1/2005		Risk factors for estrogen receptor-positive breast cancer.	Hwang ES, Chew T, Shiboski S, Farren G, Benz CC, Wrensch M	Arch Surg. 2005 Jan;140(1):58-62
M1920			11/1/1991		A discussion of the roles of oestrogen and progestin in human mammary carcinogenesis.	King RJ	J Steroid Biochem Mol Biol. 1991 Nov;39(5B):811-8
M1922			10/1/1999		Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen.;	Atkinson C, Warren R, Bingham SA, Day NE,	Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):863-6;
M1923			9/9/1967		Thromboembolism and oestrogen therapy.;	Bailar JC 3rd,	Lancet. 1967 Sep 9;2(7515):560;
M1924			12/1/2004		Association between hormone replacement therapy and subsequent stroke: a meta-analysis.	Bath, PMW; Gray, LJ	BMJ 12/01/2004 early online e-pub
M1929			8/1/1970		Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate.;	Blackard CE, Doe RP, Mellinger GT, Byar DP,	Cancer. 1970 Aug;26(2):249-56;
M1933			9/1/2001		Hormone replacement therapy and breast cancer: a qualitative review.;	Bush TL, Whitteman M, Flaws JA,	Obstet Gynecol. 2001 Sep;98(3):498-508;
M1941			11/16/1970		The Coronary Drug Project. Initial findings leading to modifications of its research protocol.;	Coronary Drug Project Research Group	JAMA. 1970 Nov 16;214(7):1303-13;
M1943			4/1/2002		An analysis of factors associated with interval as opposed to screen-detected breast cancers, including hormone therapy and mammographic density.	Crane CE, Luke CG, Rogers JM, Playford PE, Roder DM,	Breast. 2002 Apr;11(2):131-6.;
M1944			8/5/1967		Puerperal thromboembolism and suppression of lactation.;	Daniel DG, Campbell H, Turnbull AC,	Lancet. 1967 Aug 11;2(7524):287-9;

EXHIBIT 14

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M1950			2/26/1976		Liver-cell adenomas associated with use of oral contraceptives.;	Edmondson HA, Henderson B, Benton B,	N Engl J Med. 1976 Feb 26;294(9):470-2;
M1953			11/30/2001		Mammographic density increase in women receiving different hormone replacement regimens.;	Erel CT, Esen G, Seyisoglu H, Elter K, Uras C, Ertungealp E, Aksu MF,	Maturitas. 2001 Nov 30;40(2):151-7;
M1955			12/15/1988		Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark.;	Ewertz M,	Int J Cancer. 1988 Dec 15;42(6):832-8
M1957			10/7/1967		Hormonal pregnancy tests and congenital malformation.;	Gal I, Kirman B, Stern J, , ,	Nature. 1967 Oct 7;216(110):83;
M1958			10/1/1963		Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users.;	Gambrell RD Jr, Maier RC, Sanders BI,	Obstet Gynecol. 1983 Oct;62(4):435-43;
M1959			9/1/2004		The women's health initiative reports in perspective: facts or fallacies?	Gambrell RD Jr	Climacteric. 2004 Sep;7(3):225-8
M1965			12/1/1991		Invited commentary: Does postmenopausal hormone therapy cause breast cancer?	Grady D, Ernster, V	Am J Epidemiol 1991;134(120):1396-1400
M1966			5/1/1972		Oral contraceptive use in patients with thromboembolism following surgery, trauma, or infection.;	Greene GR, Sartwell PE,	Am J Public Health. 1972 May;62(5):680-5;
M1967			8/12/1971		Vaginal cancer after maternal treatment with synthetic estrogens.;	Greenwald P, Barlow JJ, Nasca PC, Burnett WS,	N Engl J Med. 1971 Aug 12;285(7):390-2;
M1970			4/15/1971		Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. 1971.;	Herbst AL, Ulfelder H, Poskanzer DC, Longo LD,	N Engl J Med. 1971 Apr 15;284(15):878-81;
M1971			9/1/1972		Vaginal and cervical abnormalities after exposure to stilbestrol in utero.;	Herbst AL, Kurman RJ, Scully RE,	Obstet Gynecol. 1972 Sep;40(3):287-98;
M1972			3/1/1974		The effects of local progesterone on stilbestrol-associated vaginal adenosis.;	Herbst AL, Robboy SJ, Macdonald GJ, Scully E,	Am J Obstet Gynecol. 1974 Mar 1;118(5):607-15;
M1973			2/13/1975		Prenatal exposure to stilbestrol. A prospective comparison of exposed female offspring with unexposed controls.;	Herbst AL, Poskanzer DC, Robboy SJ, Friedlander L, Scully RE,	N Engl J Med. 1975 Feb 13;292(7):334-9;
M1974			11/1/2004		The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program.;	Hillman JJ, Zuckerman IH, Lee E, 92;	J Womens Health (Larchmt). 2004 Nov;13(9):986-
M1976			1/1/2003		High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer.;	Hoogerbrugge N, Bult P, de Wit-Leverit LM, Bex LV, Kiemeny LA, Ligtenberg MJ, Massuger LF, Boetes C, Manders P, Brunner HG, , ,	J Clin Oncol. 2003 Jan 1;21(1):41-5;
M1977			8/19/1976		Menopausal estrogens and breast cancer.;	Hoover R, Gray LA Sr, Cole P, MacMahon B,	N Engl J Med. 1976 Aug 19;295(8):401-5;
M1981			4/27/1968		Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age.	Inman WH, Vessey MP	Br Med J. 1968 Apr 27;2(569):193-9
M1982			4/25/1970		Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs.	Inman WH, Vessey MP, Westerholm B, Englund A	Br Med J. 1970 Apr 25;2(703):203-9
M1984			10/3/1974		Oral contraceptives and congenital limb-reduction defects.	Janerich DT, Piper JM, Glebatis DM	N Engl J Med. 1974 Oct 3;291(14):697-700
M1985			2/14/2005		Influence of different HRT regimens on mammographic density.	Junkermann H, von Holst T, Lang E, Rakov V	Maturitas. 2005 Feb 14;50(2):105-10
M1988			12/15/1991		Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study.	Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zaubler AG, Shapiro S	Am J Epidemiol. 1991 Dec 15;134(12):1375-85; discussion 1396-401
M1996			11/1/1973		Cancer and stilbestrol. A follow-up of 1,719 persons exposed to estrogens in utero and born 1943-1959.	Lanier AP, Noller KL, Decker DG, Elveback LR, Kurland LT	Mayo Clin Proc. 1973 Nov;48(11):793-9
M1997			10/1/1997		Mammographic density in women on postmenopausal hormone replacement therapy.	Leung W, Goldberg F, Zee B, Sterns E	Surgery. 1997 Oct;122(4):669-73; discussion 673-4
M1998			3/17/1973		Hormone treatment during pregnancy and congenital heart defects.	Levy EP, Cohen A, Fraser FC	Lancet. 1973 Mar 17;1(7803):611
M2000			8/1/1999		Mammographic breast density during hormone replacement therapy: differences according to treatment.	Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B	Am J Obstet Gynecol. 1999 Aug;181(2):348-52
M2001			6/3/1976		Estrogens and endometrial cancer in a retirement community.	Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, Brown SE	N Engl J Med. 1976 Jun 3;294(23):1262-7
M2002			5/3/1975		Myocardial infarction in young women with special reference to oral contraceptive practice.	Mann JI, Vessey MP, Thorogood M, Doll SR	Br Med J. 1975 May 3;2(5965):241-5
M2003			5/3/1975		Oral contraceptives and death from myocardial infarction.	Mann JI, Inman WH	Br Med J. 1975 May 3;2(5965):245-8
M2005			2/16/1976		Hepatic changes in young women ingesting contraceptive steroids. Hepatic hemorrhage and primary hepatic tumors.	Mays ET, Christopherson WM, Mahr MM, Williams HC	JAMA. 1976 Feb 16;235(7):730-2
M2017			8/15/1997		Risk factors for breast carcinoma in Singaporean Chinese women: the role of central obesity.	Ng EH, Gao F, Ji CY, Ho GH, Soo KC	Cancer. 1997 Aug 15;80(4):725-31
M2019			4/28/1973		Birth defects and oral contraceptives.	Nora JJ, Nora AH	Lancet. 1973 Apr 28;1(7809):941-2
M2021			4/26/1973		Oral contraception and increased risk of cerebral ischemia or thrombosis. Collaborative group for the study of stroke in young women.	Collaborative group for the study of stroke in young women.	N Engl J Med. 1973 Apr 26;288(17):871-8
M2022			00/00/1967		Oral contraception and thrombo-embolic disease.	Royal College of General Practitioners	J Coll Gen Practit, 1967;13:267-279
M2023			6/23/1973		Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours. Report from the Boston Collaborative Drug Surveillance Programme.	Boston Collaborative Drug Surveillance Programme	Lancet. 1973 Jun 23;1(7817):1399-404
M2024			2/17/1975		Oral contraceptives and stroke in young women. Associated risk factors.	Collaborative Group for the Study of Stroke in Young Women	JAMA. 1975 Feb 17;231(7):718-22
M2028			8/1/1999		Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement.;	Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C,	Cancer Causes Control. 1999 Aug;10(4):253-60;
M2029			5/1/1976		Estrogen use and stroke risk in postmenopausal women.	Pfeffer RI, Van Den Noort	Am J Epidemiol. 1976 May;103(5):445-56
M2031			10/8/2002		Estrogen-progestin replacement therapy: regulatory action needed.;	Pike MC, Ross ,	Breast Cancer Res. 2002;4(6):222-3. Epub 2002 Oct ;
M2035			6/3/1976		Myocardial infarction and estrogen therapy in post-menopausal women.	Rosenberg L, Armstrong B, Jick H	N Engl J Med. 1976 Jun 3;294(23):1256-9
M2037			11/1/1969		Thromboembolism and oral contraceptives: an epidemiologic case-control study.;	Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE,	Am J Epidemiol. 1969 Nov;90(5):365-80;
M2041			9/1/2001		Mammographic density changes during different postmenopausal hormone replacement therapies.;	Sendag F, Cosan Terek M, Ozsener S, Oztekin K, Bilgin O, Bilgin I, Memis A, , ,	Fertil Steril. 2001 Sep;76(3):445-50;
M2043			10/1/1974		Cervical-vaginal adenosis after in utero exposure to synthetic estrogens.;	Sherman AI, Goldrath M, Berlin A, Vakhariya V, Banooni F, Michaels W, Goodman P, Brown S,	Obstet Gynecol. 1974 Oct;44(4):531-45;
M2046			12/4/1975		Association of exogenous estrogen and endometrial carcinoma.	Smith DC, Prentice R, Thompson DJ, Herrmann WL,	N Engl J Med. 1975 Dec 4;293(23):1164-7;
M2047			1/1/1974		Clinical diagnosis of vaginal adenosis.;	Staffl A, Mattingly RF, Foley DV, Fetherston WC,	Obstet Gynecol. 1974 Jan;43(1):118-28;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M2050			9/1/1975		Thrombosis with low-estrogen oral contraceptives.;;	Stolley PD, Tonascia JA, Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP,	Am J Epidemiol. 1975 Sep;102(3):197-208;
M2056			10/1/1967		Carcinoma of the prostate: treatment comparisons.;	Veterans Administration Cooperative Urological Group	J Urol. 1967 Oct;98(4):516-;
M2059			6/14/1969		Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report.;;	Vessey MP, Doll R,	Br Med J. 1969 Jun 14;2(658):651-7;
M2060			7/18/1970		Postoperative thromboembolism and the use of oral contraceptives.;;	Vessey MP, Doll R, Fairbairn AS, Glover G,	Br Med J. 1970 Jul 18;3(715):123-6;
M2063			11/1/2004		Changes in bone density and turnover after alendronate or estrogen withdrawal.;;	Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, Yates JJ, Ross PD, Alexandersen P, Ravn P, Christiansen C, Santora AC 2nd; Early Postmenopausal Intervention Cohort Study Group.,	Menopause. 2004 Nov-Dec;11(6 Pt 1):622-30;
M2065			6/3/1976		Increasing incidence of endometrial cancer in the United States.;;	Weiss NS, Szekely DR, Austin DF,	N Engl J Med. 1976 Jun 3;294(23):1259-62;
M2068			12/4/1975		Increased risk of endometrial carcinoma among users of conjugated estrogens.;;	Ziel HK, Finkle WD,	N Engl J Med. 1975 Dec 4;293(23):1167-70;
M2070			1/15/2005		Estrogen, estrogen plus progestin therapy, and risk of breast cancer.;;	Colditz GA,	Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):909s-17s;
M2071			11/1/2004		The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002).;;	Barber CA, Margolis K, Luepker RV, Arnett DK,	J Womens Health (Larchmt). 2004 Nov;13(9):975-85;
M2076			9/1/2001		Effects of a short-term suspension of hormone replacement therapy on mammographic density.;;	Colacurci N, Fornaro F, De Francis P, Mele D, Palermo M, del Vecchio W,	Fertil Steril. 2001 Sep;76(3):451-5;
M2087			12/1/2003		Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women.;;	Morton LM, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang Y, Flynn S, Tallini G, Zhang B, Owens PH, Zheng T,	Br J Cancer. 2003 Dec 1;89(11):2087-92
M2089			3/1/2005		Postmenopausal hormone therapy: Critical reappraisal and a unified hypothesis.;;	Phillips LS, Langer RD,	Fertil Steril. 2005 Mar;83(3):558-66;
M2091			1/10/2001		Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy.;;	Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S,	JAMA. 2001 Jan 10;285(2):171-6;
M2095			3/1/2004		Non-Hodgkin's lymphoma and type of tobacco smoke.;;	Stagnaro E, Tumino R, Parodi S, Crosignani P, Fontana A, Masala G, Miligi L, Nanni O, Ramazzotti V, Rodella S, Senioir Constantini A, Viganò C, Vindigni C, Vineis P.,	Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):431-7;
M2096			9/24/2004		Hormones and mammographic breast density.	Warren R	Maturitas. 2004 Sep 24;49(1):67-78
M2097			4/6/2005		Progestins and recurrence in breast cancer survivors.;;	Chlebowski RT, Anderson GL,	J Natl Cancer Inst. 2005 Apr 6;97(7):471-2;
M2098			4/11/2005		Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study.;;	Ewertz M, Mellemkjaer L, Poulsen AH, Friis S, Sorensen HT, Pedersen L, McLaughlin JK, Olsen JH.,	Br J Cancer. 2005 Apr 11;92(7):1293-7;
M2099			4/10/2005		Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.;;	Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F.,	Int J Cancer. 2005 Apr 10;114(3):448-54;
M2100			4/1/2005		Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001.;;	Li CI, Daling JR, Malone KE,	Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1008-11;
M2101			4/6/2005		Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.;;	von Scholtz E, Rutqvist LE; Stockholm Breast Cancer Study Group,	J Natl Cancer Inst. 2005 Apr 6;97(7):533-5;
M2102			4/20/2005		Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.	Twoorger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE	J Natl Cancer Inst. 2005 Apr 20;97(8):595-602
M2103			6/1/2000		Menopausal hormones and breast cancer in a biracial population.;;	Moorman PG, Kuwabara H, Millikan RC, Newman B,	Am J Public Health. 2000 Jun;90(6):966-71;
M2149			1/1/2005		Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers.;;	Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR.,	Am J Clin Pathol. 2005 Jan;123(1):21-7.;
M2220			4/13/2005		A 60-year-old woman trying to discontinue hormone replacement therapy, 2 years later.	Reynolds EE.	JAMA. 2005 Apr 13;293(14):1780.
M2221			11/6/2002		Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study.	Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC; Cache County Memory Study Investigators.	JAMA. 2002 Nov 6;288(17):2123-9.
M2223			8/28/2002		Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.	Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM.	JAMA. 2002 Aug 28;288(8):980-7.
M2228			4/1/2005		The impact of comorbidities on hormone use. After the 2000 release of the Women's Health Initiative.	Newton KM, Buist DS, Miglioretti DL, Beverly K, Hartsfield CL, Chan KA, Andrade SE, Wei F, Connelly MT, Kessler L.	J Gen Intern Med. 2005 Apr;20(4):350-6.
M2237			3/1/2005		Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options.	Bachmann GA.	J Reprod Med. 2005 Mar;50(3):155-65.
M2238			6/18/1905		Marked Regression of a Nonpalpable Breast Cancer after Cessation of Hormone Replacement Therapy	Harvey	AJR. Vol. 167:394-5 (1996)
M2264			1/1/2003		Physician specialty is significantly associated with hormone replacement therapy use.	Levy BT, Ritchie JM, Smith E, Gray T, Zhang W.	Obstet Gynecol. 2003 Jan;101(1):114-22.
M2288			5/28/2003		AACE Press Release: AACE Statement on Women's Health Initiative Studies Related to Cognition and Dementia published in JAMA, May 28, 2003	Kleerekoper M, Cobin R, Petak S, AACE Rapid Response Team	JAMA, May 28, 2003
M2289					AACE Press Release: AACE Position: Women's Health Initiative	AACE	
M2292			7/9/2002		ACOG New Release: Statement of the Estrogen Plus Progestin Trial of the Women's Health Initiative		
M2300			5/22/2003		Detailed Questions and Answers about the Women's Health Initiative and the Women's Health Initiative Memory Study		
M2301					American Society for Reproductive Medicine Statement on Combined Hormone Therapy and the Women's Health Initiative		
M2302			11/19/2002		Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale.	U.S. Preventive Services Task Force.	Ann Intern Med. 2002 Nov 19;137(10):834-9.
M2318			3/1/2005		Women's perceptions of hormone replacement therapy: risks and benefits (1980-2002). A literature review.	Buick D, Crook D, Horne R.	Climacteric. 2005 Mar;8(1):24-35.
M2324			5/9/2005		National Guideline Clearinghouse		www.guideline.gov
M2325			4/5/2005		Use of postmenopausal hormone therapy since the Women's Health Initiative findings.	Kelly JP, Kaufman DW, Rosenberg L, Kelley K, Cooper SG, Mitchell AA.	Pharmacoevidenciol Drug Saf. 2005 Apr 5; [Epub ahead of print]

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M2328			6/1/2005		Effects of oral and transdermal estradiol administration on levels of sex hormone-binding globulin in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy.	Ropponen A, Aittomaki K, Vihma V, Tikkanen MJ, Ylikorkala O.	J Clin Endocrinol Metab. 2005 Jun;90(6):3431-4. Epub 2005 Mar 22.
M2336			7/21/1993		Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study.	Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, Rosner BA.	JAMA. 1993 Jul 21;270(3):338-43.
M2338			1/1/2003		Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer.	Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Yamashita H, Fukuda M.	Breast Cancer. 2003;10(2):120-8.
M2343			7/1/1987		Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy.	Hunt K, Vessey M, McPherson K, Coleman M.	Br J Obstet Gynaecol. 1987 Jul;94(7):620-35.
M2347			9/1/2002		The view of The International Menopause Society on the Women's Health Initiative.	Schneider HP; Executive Committee of the IMS.	Climacteric. 2002 Sep;5(3):211-6.
M2351			8/1/2001		Exogenous female sex steroid hormones and risk of asthma and asthma-like symptoms: a cross sectional study of the general population.	Lange P, Parner J, Prescott E, Ulrik CS, Vestbo J.	Thorax. 2001 Aug;56(8):613-6.
M2352			9/24/2004		Lessons to be learned from animal studies on hormones and the breast.	Clarkson TB, Appt SE, Wood CE, Cline JM.	Maturitas. 2004 Sep 24;49(1):79-89.
M2371			3/1/2005		Clinical applications of hormonal therapy in ovarian cancer.	Rao GG, Miller DS.	Curr Treat Options Oncol. 2005 Mar;6(2):97-102.
M2394			4/30/2005		Endometrial cancer and hormone-replacement therapy in the Million Women Study.	Beral V, Bull D, Reeves G; Million Women Study Collaborators.	Lancet. 2005 Apr 30;365(9470):1543-51.
M2403			8/1/2004		Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone ooreductase (NQO1) genetic polymorphisms.	Fowkes JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT, Zheng W.	Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1308-15.
M2406			7/1/2004		Induction of androgen receptor activity by norgestimate and norelgestromin in MDA-MB 231 breast cancer cells.	Prifti S, Lelle I, Strowitzki T, Rabe T.	Gynecol Endocrinol. 2004 Jul;19(1):18-21.
M2411			10/1/2004		Assessing breast cancer risk: genetic factors are not the whole story.	Korde LA, Calzone KA, Zujewski J.	Postgrad Med. 2004 Oct;116(4):6-8, 11-4, 19-20.
M2432			5/1/2004		Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone.	Herrmsmeyer RK, Mishra RG, Pavcnik D, Uchida B, Axthelm MK, Stanczyk FZ, Burry KA, Illingworth DR, Juan C, Nordt FJ.	Arterioscler Thromb Vasc Biol. 2004 May;24(5):955-61. Epub 2004 Mar 18.
M2439			6/17/1905		<i>Breast cancer response to hormone replacement therapy withdrawal</i>	Powles	Lancet, Vol. 345 (1995)
M2453			4/10/2005		Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.	Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M.	J Clin Oncol. 2005 Apr 10;23(11):2469-76. Epub 2005 Mar 7.
M2457			10/1/2000		Biological features of premalignant disease in the human breast.	Allred DC, Mohsin SK.	J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):351-64.
M2467			3/1/2005		Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy.	Misso ML, Jang C, Adams J, Tran J, Murata Y, Bell R, Boon WC, Simpson ER, Davis SR.	Menopause. 2005 Mar;12(2):210-5.
M2469			6/16/2005		Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations.	Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, Li Y.	Oncogene. 2005 Jun 16;24(26):4220-31.
M2474			4/1/1997		Sex steroid hormones, bone mineral density, and risk of breast cancer.	Kuller LH, Cauley JA, Lucas L, Cummings S, Browner WS.	Environ Health Perspect. 1997 Apr;105 Suppl 3:593-9.
M2475			11/6/1996		Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group.	Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR.	JAMA. 1996 Nov 6;276(17):1404-8.
M2483			6/6/2005		An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.	Lee SA, Ross RK, Pike MC.	Br J Cancer. 2005 Jun 6;92(11):2049-58.
M2486			10/1/2004		Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.	Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA.	Cancer. 2004 Oct 1;101(7):1490-500.
M2488			3/1/2005		Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement.	Chatterton RT Jr, Geiger AS, Mateo ET, Helenowski IB, Gann PH.	J Clin Endocrinol Metab. 2005 Mar;90(3):1686-91. Epub 2004 Nov 30.
M2489			8/1/2004		Effect of hormone therapy, tibolone and raloxifene on circulating vascular endothelial growth factor in Greek postmenopausal women.	Christodoulakos G, Lambrinoudaki I, Panoulis C, Papadias C, Sarandakou A, Liakakos T, Alexandrou A, Creatsas G.	Eur J Endocrinol. 2004 Aug;151(2):187-92.
M2513			5/1/2005		Estrogen--the good, the bad, and the unexpected.	Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, Kovacic A, Zhou J, Clyne CD.	Endocr Rev. 2005 May;26(3):322-30. Epub 2005 Apr 7.
M2518			5/1/2005		Hormone replacement therapy, percent mammographic density, and sensitivity of mammography.	Kavanagh AM, Cawson J, Byrnes GB, Giles GG, Marr G, Tong B, Gertig DM, Hopper JL.	Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1060-4.
M2532			3/2/2005		Are breast density and bone mineral density independent risk factors for breast cancer?	Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E, Cummings SR.	J Natl Cancer Inst. 2005 Mar 2;97(5):368-74.
M2536			4/21/2005		Proliferation of Endothelial and Tumor Epithelial Cells by Progesterin-Induced VEGF from Human Breast Cancer Cells: Paracrine and Autocrine Effects.	Liang Y, Hyder SM.	Endocrinology. 2005 Apr 21; [Epub ahead of print]
M2538			9/1/1998		Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.	Holli K, Isola J, Cuzick J.	J Clin Oncol. 1998 Sep;16(9):3115-20.
M2539			5/1/2005		Mammographic features and subsequent risk of breast cancer: a comparison of qualitative and quantitative evaluations in the guernsey prospective studies.	Torres-Mejia G, De Stavola B, Allen DS, Perez-Gavilan JJ, Ferreira JM, Fentiman IS, Dos Santos Silva I.	Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1052-9.
M2553			1/15/2001		Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women.	Rodriguez C, Calle EE, Patel AV, Tatham LM, Jacobs EJ, Thun MJ.	Am J Epidemiol. 2001 Jan 15;153(2):145-52.
M2556				Sex Hormones, Risk Factors, and Risk of Estrogen Receptor-Positive Breast Cancer in Older Women: A Long-term Prospective Study	Cummings		
M2557			9/1/1996		Smoking and postmenopausal hormone replacement therapy.	Jensen J.	Br J Clin Pract Suppl. 1996 Sep;86:6-8.
M2563			3/1/2004		Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women.	Valdivia I, Campodonico I, Tapia A, Capetillo M, Espinoza A, Lavin P.	Fertil Steril. 2004 Mar;81(3):617-23.
M2564			3/15/2005		Chapter 11: Postmenopausal Hormones. An Overview	Wassertheil-Smoller S	In: Controversies in Science and Technology : From Maize to Menopause (Science & Technology In Society): The University of Wisconsin Press, 2005.p. 181-197

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M2565			1/1/2003		Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.; ;	Coskun U, Gunel N, Toruner FB, Sancak B, Onuk E, Bayram O, Cengiz O, Yilmaz E, Elbeg S, Ozkan S., ,	Neoplasma. 2003;50(1):41-6.;
M2566			4/1/2005		The rise in breast cancer incidence, 1978-2003, is largely confined to ER+ tumors.	Glass AG, Lacey JV, Hoover RN	Presented 2005 Meeting AACR: Proceedings of the AACR Vol 46, 2005, Abstract # 4045 ; AACR=American Assoc. for Cancer Research
M2568			1/1/1988		The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer.	Key TJ, Pike MC.	Eur J Cancer Clin Oncol. 1988 Jan;24(1):29-43.
M2578			4/1/2005		Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial.	Ness J, Aronow WS, Newkirk E, McDanel D.	J Gerontol A Biol Sci Med Sci. 2005 Apr;60(4):460-2.
M2586			6/1/2005		Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status.	Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, Stram D, West D, Wright WE, Zogas A, Ross RK.	J Natl Cancer Inst. 2005 Jun 1;97(11):805-12.
M2596			11/1/2003		Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.	Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L.	Fertil Steril. 2003 Nov;80(5):1234-40.
M2598			7/1/2001		Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism.	Lobo RA, Bush T, Carr BR, Pickar JH.	Fertil Steril. 2001 Jul;76(1):13-24.
M2599			6/1/2001		Prospective study of recreational physical activity and ovarian cancer.	Bertone ER, Willett WC, Rosner BA, Hunter DJ, Fuchs CS, Speizer FE, Colditz GA, Hankinson SE, Nurses' Health Study.	J Natl Cancer Inst. 2001 Jun 20;93(12):942-8.
M2601			12/1/2004		Mammographic density and estrogen receptor status of breast cancer.	Ziv E, Tice J, Smith-Bindman R, Shepherd J, Cummings S, Kerlikowske K.	Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2090-5.
M2624			5/15/2001		Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells.	Hyder SM, Chiappetta C, Stancel GM.	Int J Cancer. 2001 May 15;92(4):469-73.
M2639			6/1/2005		Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women.	Aiello EJ, Tworoger SS, Yasui Y, Stanczyk FZ, Potter J, Ulrich CM, Irwin M, McTiernan A.	Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1411-7.
M2663			4/1/2005		Clinical appraisal of the Women's Health Initiative.	Speroff L.	J Obstet Gynaecol Res. 2005 Apr;31(2):80-93.
M2666			3/15/2004		Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.	Wu J, Richer J, Horwitz KB, Hyder SM.	Cancer Res. 2004 Mar 15;64(6):2238-44.
M2672			1/1/2002		Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model.	Haslam SZ, Osuch JR, Raafat AM, Hofseth LJ.	J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):93-105.
M2683			1/1/2005		Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases.	Collins LC, Botero ML, Schnit SJ.	Am J Clin Pathol. 2005 Jan;123(1):16-20.
M2691			5/17/2005		Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force.	U.S. Preventive Services Task Force	Ann Intern Med. 2005 May 17;142(10):855-60.
M2696			6/1/2005		Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women.	Beral V, Reeves G, Banks E.	BJOG. 2005 Jun;112(6):692-5.
M2710			5/1/2005		Increased estrogen receptor betax expression during mammary carcinogenesis.	Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA, Rochefort H.	Clin Cancer Res. 2005 May 1;11(9):3170-4.
M2719			5/31/2005		Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: A large-scale population-based cohort study.	Liu Y, Inoue M, Sobue T, Tsugane S.	Int J Cancer. 2005 May 31; [Epub ahead of print]
M2729			5/20/2005		Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.	Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrion F.	J Steroid Biochem Mol Biol. 2005 May 20; [Epub ahead of print]
M2732			5/18/2005		Re: Are breast density and bone mineral density independent risk factors for breast cancer?	Harvey JA.	J Natl Cancer Inst. 2005 May 18;97(10):778.
M2734			5/4/2005		Medroxyprogesterone acetate and metastases: of mice and (wo)men.	Jordan VC.	J Natl Cancer Inst. 2005 May 4;97(9):619-21.
M2743			6/3/2005		Postmenopausal hormone therapy and mammographic breast density.	Marchesoni D, Driul L, Ianni A, Fabiani G, Della Martina M, Zuiani C, Bazzocchi M.	Maturitas. 2005 Jun 3; [Epub ahead of print]
M2744			6/8/2005		Use of hormone replacement therapy in the Hong Kong public health sector after the Women's Health Initiative trial.	Leung KY, Ling M, Tang GW.	Maturitas. 2005 Jun 8; [Epub ahead of print]
M2757			11/1/2002		Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys.	Cline JM, Register TC, Clarkson TB.	Menopause. 2002 Nov-Dec;9(6):422-9.
M2760			6/1/2005		Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.	Proietti C, Salatino M, Rosembit C, Carnevale R, Pecci A, Kornblihtt AR, Molinolo AA, Frahm I, Charreau EH, Schillaci R, Elizalde PV.	Mol Cell Biol. 2005 Jun;25(12):4826-40.
M2763			5/1/2005		The Nurses' Health Study: lifestyle and health among women.	Colditz GA, Hankinson SE.	Nat Rev Cancer. 2005 May;5(5):388-96.
M2773			6/10/2005		Molecular and cellular basis of cardiovascular gender differences.	Mendelsohn ME, Karas RH.	Science. 2005 Jun 10;308(5728):1583-7.
M2777			9/23/1989		Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.	Paul C, Skegg DC, Spears GF.	BMJ. 1989 Sep 23;299(6702):759-62.
M2778			8/1/1981		Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast.	Ferguson DJ, Anderson TJ.	Br J Cancer. 1981 Aug;44(2):177-81.
M2780			11/1/2002		Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States).	Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE.	Cancer Causes Control. 2002 Nov;13(9):847-54.
M2781			11/1/1986		Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice.	Lanari C, Molinolo AA, Pasqualini CD.	Cancer Lett. 1986 Nov;33(2):215-23.
M2784			1/1/1993		Endogenous hormones and breast cancer risk.	Bernstein L, Ross RK.	Epidemiol Rev. 1993;15(1):48-65.
M2785			5/1/1988		Re-evaluating the role of progestogen therapy after the menopause.	Henderson BE, Ross RK, Lobo RA, Pike MC, Mack TM.	Fertil Steril. 1988 May;49(5 Suppl 2):9S-15S.
M2788			1/1/1973		Etiology of human breast cancer: a review.	MacMahon B, Cole P, Brown J.	J Natl Cancer Inst. 1973 Jan;50(1):21-42.
M2789			12/1/1987		A case-control study of breast cancer and hormonal contraception in Costa Rica.	Lee NC, Rosero-Bixby L, Oberle MV, Grimaldo C, Whatley AS, Rovira EZ.	J Natl Cancer Inst. 1987 Dec;79(6):1247-54.
M2792			4/18/1981		Menopausal oestrogen therapy and protection from death from ischaemic heart disease.	Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE.	Lancet. 1981 Apr 18;1(8225):858-60.
M2797			3/1/2005		Hot flash, hot topic: conceptualizing menopausal symptoms from a cognitive-behavioral perspective.	Keefer L, Blanchard EB.	Appl Psychophysiol Biofeedback. 2005 Mar;30(1):75-82.
M2804					AACE Position: Women's Health Initiative	AACE	
M2812			8/1/2002		Postmenopausal Hormone Replacement Therapy for the Primary Prevention of Chronic Conditions: A Summary of the Evidence for the U.S. Preventive Services Task Force.	Nelson H, Humphrey L, LeBlanc E, Miller J, Takano L, Chan B, Nygren P, Allan J, Teutsch S.	AHRQ. 2002 Aug:1-23
M2814			10/14/2004		Chapter 9: Prevention and Treatment for Those Who Have Bone Diseases	U.S. Department of Health and Human Services	In: A Report of the Surgeon General; Bone Health and Osteoporosis;2004; USDHHS
M2815			4/1/2003		Physicians' Guide to Prevention and Treatment of Osteoporosis.	National Osteoporosis Foundation.	National Osteoporosis Foundation; 2003 Apr:37

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M2817			10/1/2004		Frequently Asked Questions About Hormone Therapy; New Recommendations Based on ACOG's Task Force Report on Hormone Therapy.	American College of Obstetricians and Gynecologists	www.acog.org.from_home/publications/press_releases/nr10-0...
M2822			6/27/2005		Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.	Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C.	Maturitas. 2005 Jun 27; [Epub ahead of print]
M2823			6/1/2005		Prenatal and perinatal correlates of adult mammographic breast density.	Cerhan JR, Sellers TA, Janney CA, Pankratz VS, Brandt KR, Vachon CM.	Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1502-8.
M2826			12/15/2004		Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.	Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE.	J Natl Cancer Inst. 2004 Dec 15;96(24):1856-65.
M2827			6/1/2005		Hormone therapy use among postmenopausal French women before the publication of the Women's Health Initiative study: duration of use and factors associated with discontinuation.	Ringa V, Varnoux N, Piau S, Breart G.	Fertil Steril. 2005 Jun;83(6):1771-9.
M2849					Serum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene	Cummings	JAMA. Vol. 287, No. 2, (2002)
M2850			11/1/2001		Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the study of osteoporotic fractures.	Beck TJ, Stone KL, Oreskovic TL, Hochberg MC, Nevitt MC, Genant HK, Cummings SR.	J Bone Miner Res. 2001 Nov;16(11):2103-10.
M2860			3/23/1995		Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.	Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM.	N Engl J Med. 1995 Mar 23;332(12):767-73.
M2862			7/1/2005		Making sense of breast pathology.	Bilous M, Brennan M, French J, Boyages J.	Aust Fam Physician. 2005 Jul;34(7):581-6.
M2865			6/1/2005		The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.	Menendez JA, Oza BP, Colomer R, Lupu R.	Int J Oncol. 2005 Jun;26(6):1507-15.
M2874			2/1/2005		Bone density screening: a new level of evidence?;	Cummings SR	Ann Intern Med. 2005 Feb 1;142(3):217-9.
M2876			10/14/1996		Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group.;	Nevitt MC, Cummings SR, Lane NE, Hochberg MC, Scott JC, Pressman AR, Genant HK, Cauley JA.	Arch Intern Med. 1996 Oct 14;156(18):2073-80.
M2880			12/13/2004		Postmenopausal bilateral oophorectomy is not associated with increased fracture risk in older women.;	Antoniucci DM, Sellmeyer DE, Cauley JA, Ensrud KE, Schneider JL, Vesco KK, Cummings SR, Melton LJ 3rd; Study of Osteoporotic Fractures Research Group. .	J Bone Miner Res. 2005 May;20(5):741-7. Epub 2004 Dec 13.
M2882			12/1/2004		Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.	Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators. .	J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.
M2885			11/1/1986		Progesterone and breast cancer.;;	Ernster VL, Cummings SR.;	Obstet Gynecol. 1986 Nov;68(5):715-7. ;
M2889			10/1/1982		Estrogen and progesterone receptors in mammary tumors induced in rats by simultaneous administration of 17 beta-estradiol and progesterone.	Hannouche N, Samperez S, Riviere MR, Jouan P.;	J Steroid Biochem. 1982 Oct;17(4):415-9.
M2894			9/2/1961		Influence of reduction of serum lipids on prognosis of coronary heart-disease. A five-year study using oestrogen.;;	OLIVER MF, BOYD GS.;	Lancet. 1961 Sep 2;2:499-505. ;
M2896			10/20/2003		Increase in lobular breast cancer incidence in Switzerland.	Levi F, Te VC, Randimbison L, La Vecchia C. .	Int J Cancer. 2003 Oct 20;107(1):164-5; author reply 166.
M2899			10/1/2004		Executive summary. Hormone therapy.;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):1S-4S. ;
M2900			10/1/2004		Body mass index and insulin resistance.;;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):5S-10S.;
M2901			10/1/2004		Breast cancer.;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):11S-16S.;
M2902			10/1/2004		Cholecystitis, biliary tract surgery, and pancreatitis.;;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):17S-24S.;
M2903			10/1/2004		Cognition and dementia.;;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):25S-40S. ;
M2904			10/1/2004		Coronary heart disease.;;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):41S-48S.;
M2905			10/1/2004		Depression.;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):49S-55S.;
M2907			10/1/2004		Genitourinary tract changes.;;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):56S-61S;
M2908			10/1/2004		Osteoarthritis.;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):62S-65S.;
M2909			10/1/2004		Osteoporosis.;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):66S-76S.;
M2910			10/1/2004		Ovarian, endometrial, and colorectal cancers.;;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):77S-84S.;
M2911			10/1/2004		Sexual dysfunction.;	American College of Obstetricians and Gynecologists Women's Health Care Physicians. .	Obstet Gynecol. 2004 Oct;104(4 Suppl):85S-91S.;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M2912			10/1/2004		Skin.	American College of Obstetricians and Gynecologists Women's Health Care Physicians.	Obstet Gynecol. 2004 Oct;104(4 Suppl):92S-96S. ;
M2913			10/1/2004		Stroke.	American College of Obstetricians and Gynecologists Women's Health Care Physicians.	Obstet Gynecol. 2004 Oct;104(4 Suppl):97S-105S. ;
M2914			10/1/2004		Summary of balancing risks and benefits.	American College of Obstetricians and Gynecologists Women's Health Care Physicians.	
M2915			10/1/2004		Vasomotor symptoms.;	American College of Obstetricians and Gynecologists Women's Health Care Physicians.	Obstet Gynecol. 2004 Oct;104(4 Suppl):106S-117S.;
M2916			10/1/2004		Venous thromboembolic disease.;;	American College of Obstetricians and Gynecologists Women's Health Care Physicians.	Obstet Gynecol. 2004 Oct;104(4 Suppl):118S-127S.;
M2922			7/1/2005		Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis.;;	Baillargeon JP, McClish DK, Essah PA, Nestler JE.;	J Clin Endocrinol Metab. 2005 Jul;90(7):3863-70. Epub 2005 Apr 6. ;
M2926			6/1/2005		The relationship between mammographic density and duration of hormone therapy: effects of estrogen and estrogen-progestin.;	Chen FP, Cheung YC, Teng LF, Soong YK.;	Hum Reprod. 2005 Jun;20(6):1741-5. Epub 2005 Apr 21. ;
M2929			11/1/1988		Stroke incidence and risk factors for stroke in Copenhagen, Denmark.	Boysen G, Nyboe J, Appleyard M, Sorensen PS, Boas J, Somnier F, Jensen G, Schnohr P.;	Stroke. 1988 Nov;19(11):1345-53. ;
M2935			4/1/2005		Epidemiology and prevention of breast cancer.;;	Colditz GA	Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):768-72;
M2936			9/1/2005		Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial.;;	Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J. ;	Am J Epidemiol. 2005 Sep 1;162(5):404-14. Epub 2005 Jul 20. ;
M2938			9/1/1988		Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community.;;	Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C.;	Am J Epidemiol. 1988 Sep;128(3):606-14.;
M2940			8/1/2005		Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review.;;	Dietel M, Lewis MA, Shapiro S. ;	Hum Reprod. 2005 Aug;20(8):2052-60. Epub 2005 Jun 2. ;
M2943			8/1/2005		Effect of 17beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells.;	Mirkin S, Wong BC, Archer DF.;	Fertil Steril. 2005 Aug;84(2):485-91.;
M2946			7/1/2005		Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.;	Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C.;	Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1724-31.;
M2948			10/1/1998		Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy.;	Hargreaves DF, Knox F, Swindell R, Potten CS, Bundred NJ. ;	Br J Cancer. 1998 Oct;78(7):945-9. ; ;
M2953			11/1/1982		Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases.;;	Thomas DB, Persing JP, Hutchinson WB.;	J Natl Cancer Inst. 1982 Nov;69(5):1017-25. ;
M2958			7/1/2005		Hormone therapy does not affect depression severity in older women.;	Goldstein KM, Harpole LH, Stechuchak KM, Coffman CJ, Bosworth HB, Steffens DC, Bastian LA. ;	Am J Geriatr Psychiatry. 2005 Jul;13(7):616-23.;
M2961			3/1/2002		In-vivo angiogenesis and progestogens.;	Hague S, MacKenzie IZ, Bicknell R, Rees MC.;	Hum Reprod. 2002 Mar;17(3):786-93.;
M2962			1/1/2005		Is the estrogen controversy over? Deconstructing the Women's Health Initiative Study: a critical evaluation of the evidence.	Harman MS, Naftolin F, Brinton EA, Judelson DR	Ann NY Acad Sci 1052:43-56
M2964			7/21/2005		Benign breast disease and the risk of breast cancer.;	Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW.;	N Engl J Med. 2005 Jul 21;353(3):229-37. ; ;
M2966			8/1/1988		Estrogen replacement therapy and protection from acute myocardial infarction.;	Henderson BE, Paganini-Hill A, Ross RK.;	Am J Obstet Gynecol. 1988 Aug;159(2):312-7. ;
M2967			9/1/2005		Efficacy and tolerability of alendronate once weekly in asian postmenopausal osteoporotic women.;	Ho AY, Kung AW.;	Ann Pharmacother. 2005 Sep;39(9):1428-33. Epub 2005 Aug 2. ; ;
M2969			9/1/2005		Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives.;	Krieger N, Lowy I, Aronowitz R, Bigby J, Dickersin K, Garner E, Gaudilliere JP, Hinesrosa C, Hubbard R, Johnson PA, Miesmer SA, Norsigian J, Pearson C, Rosenberg CE, Rosenberg L, Rosenkrantz BG, Seaman B, Sonnenschein C, Soto AM, Thornton J, Weisz G. ;	J Epidemiol Community Health. 2005 Sep;59(9):740-8. ;
M2980			9/24/2004		Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist.;;	Li CI. ;	Maturitas. 2004 Sep 24;49(1):44-60.;
M2984			6/1/1962		Clinical studies of long-term estrogen therapy in men with mvocardial infarction.;;	MARMORSTON J, MOORE FJ, HOPKINS CE, KUZMA OT, WEINER J. ;	Proc Soc Exp Biol Med. 1962 Jun;110:400-8.;
M2986			1/1/1967		A clinical trial of Premarin in cerebrovascular disease.	McDowell F, Louis S, McDevitt E	J Chron Dis. 1967;20:679-684
M2988			9/1/1999		Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function.;	Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW. ;	Cancer Res. 1999 Sep 1;59(17):4276-84. ;
M2990			5/1/2002		The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer.;	Lantzsch T, Heffler L, Krause U, Kehl A, Goepel C, Koelbl H, Dunst J, Lampe D.;	Anticancer Res. 2002 May-Jun;22(3):1925-8. ;
M2991			7/13/2005		Symptom experience after discontinuing use of estrogen plus progestin.;	Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smolter S, Manson JE, Barnabei VM, Lane DS, Brzyski RG, Rosal MC, Wylie-Rosett J, Hays J. ;	JAMA. 2005 Jul 13;294(2):183-93. ; ;
M2993			7/16/2005		Assessment of DNA damage in postmenopausal women under hormone replacement therapy.;	Ozcagli E, Sardas S, Biri A. ;	Maturitas. 2005 Jul 16;51(3):280-5. ; ;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M2995			7/13/2005		Some surprises, some answers, and more questions about hormone therapy: further findings from the Women's Health Initiative.;	Pettitt DB	JAMA. 2005 Jul 13;294(2):245-6.;
M2996			1/1/1992		Prolonged effects of a novel, low-dosage continuous progestin-cyclic estrogen replacement program in postmenopausal women.;	Plunkett ER, Wolfe BM. ;	Am J Obstet Gynecol. 1992 Jan;166(1 Pt 1):117-21. ; ;
M3000			9/1/2005		Prentice et Al. Respond to "how far can epidemiologists get with statistical adjustment?" ; ;	Prentice RL, Langer R, Anderson G, Barad D. ;	Am J Epidemiol. 2005 Sep 1;162(5):419-20. Epub 2005 Jul 20.;
M3016			2/1/1963		Long-term effects of high-dosage estrogen therapy in men with coronary heart disease.;	ROBINSON RW, HIGANO N, COHEN WD. ;	J Chronic Dis. 1963 Feb;16:155-61.;
M3019			1/1/2000		Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy.;	Agrawal R, Prelevic G, Conway GS, Payne NN, Ginsburg J, Jacobs HS. ;	Fertil Steril. 2000 Jan;73(1):56-60. ;
M3023			1/1/2004		Exogenous progestagens and the human breast.	Sitruk-Ware R, Piu-Bureau G	Maturitas 49 (2004):58-66
M3025			8/1/2005		Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy--a prospective observational study.;	Stahberg C, Lyngge E, Andersen ZJ, Keiding N, Ottesen B, Rank F, Hundrup YA, Obel EB, Pedersen AT. ;	Int J Epidemiol. 2005 Aug;34(4):931-5.;
M3026			2/23/1963		Effectiveness of estrogens for therapy of myocardial infarction in middle-age men.;	STAMLER J, PICK R, KATZ LN, PICK A, KAPLAN BM, BERKSON DM, CENTURY D.	JAMA. 1963 Feb 23;183:632-8.;
M3027					Estrogens and androgens in the treatment of hyperlipidemia.	Stamler J, Lewis LA, Page IH, Berkson DM, Kaplan, B.M., Katz, L.N, Pick R, Century, D.	Estrogens and Androgens. 353-363.
M3028			1/1/1983		Pharmacological trials: primary and secondary prevention of coronary heart disease.;	Stamler J.	Prev Med. 1983 Jan;12(1):196-203. ;
M3032			5/28/2002		Synergistic tumor promoter effects of estrone and progesterone in methylnitrosourea-induced rat mammary cancer.;	Bigsby RM.	Cancer Lett. 2002 May 28;179(2):113-9. ; ;
M3033			6/1/2000		The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort.;	Herrington DM, Reboussin DM, Klein KP, Sharp PC, Shumaker SA, Snyder TE, Geisinger KR. ;	Control Clin Trials. 2000 Jun;21(3):257-85.;
M3036			2/1/1999		The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone.;	Zhang F, Chen Y, Pisha E, Shen L, Xiong Y, van Breemen RB, Bolton JL. ;	Chem Res Toxicol. 1999 Feb;12(2):204-13. ; ;
M3037			5/1/1966		An evaluation of estrogenic substances in the treatment of cerebral vascular disease. Report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section.;	No Authors Listed	Circulation. 1966 May;33(5 Suppl):II3-9. ;
M3038			7/1/1990		Systolic blood pressure and cardiovascular mortality among 13,740 Dutch women.;	van der Giezen AM, Schopman-Geurts van Kessel JG, Schouten EG, Slotboom BJ, Kok FJ, Collette HJ. ;	Prev Med. 1990 Jul;19(4):456-65. ; ;
M3045			8/1/2005		Women, hormones, and clinical trials: a beginning, not an end.;	Miller VM, Clarkson TB, Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Naftolin F, Santoro N. ;	J Appl Physiol. 2005 Aug;99(2):381-3.;
M3046			12/1/1983		Evolution and funding of the Coronary Drug Project.;	Zukel WJ.	Control Clin Trials. 1983 Dec;4(4):281-312. ; ;
M3054			5/1/2003		Gabapentin for the management of hot flushes: a case series.	Albertazzi P, Bottazzi M, Purdie DW.	Menopause. 2003 May-Jun;10(3):214-7.
M3055			8/1/1985		The prevalence of carcinoma in situ in normal and cancer-associated breasts.	Alpers CE, Wellings SR.	Hum Pathol. 1985 Aug;16(8):796-807.
M3061			7/15/1982		Breast cancer and estrogen replacement therapy.	Huika BS, Chamblless LE, Deubner DC, Wilkinson WE.	Am J Obstet Gynecol. 1982 Jul 15;143(6):638-44.
M3062			12/15/1991		Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study.	Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S.	Am J Epidemiol. 1991 Dec 15;134(12):1386-95; discussion 1396-401.
M3067			5/1/1991		A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women.	Chute CG, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Speizer FE.	Epidemiology. 1991 May;2(3):201-7.
M3072			10/1/1981		Conjugated estrogens and breast cancer risk in women.	Hoover R, Glass A, Finkle WD, Azevedo D, Milne K.	J Natl Cancer Inst. 1981 Oct;67(4):815-20.
M3084			6/25/1905		Does hormone replacement therapy increase the frequency of breast atypical hyperplasia in postmenopausal women? Results from the Bouches du Rhone district screening campaign	Gayet	European J. of Cancer, Vol. 39: 1738-1745 (2003).
M3086			2/28/1973		The Extrapolation of Experimental Findings (Animal to Man): The Dilemma of the Systemically Administered Contraceptives	Finkel MJ, Berliner VR.	Presented at the 62nd Annual Meeting of the Internaional Academy of Pathology.
M3090					<i>Exogenous Estrogen and Breast Cancer After Bilateral Oophorectomy</i>	Hiatt	Cancer, Vol. 54, p. 139 (1984)
M3091			1/1/1983		Exogenous estrogens and development of breast and endometrial cancer.	Vakil DV, Morgan RW, Halliday M.	Cancer Detect Prev. 1983;6(4-5):415-24.
M3097			2/1/1991		Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.	Gallagher JC, Kable WT, Goldgar D.	Am J Med. 1991 Feb;90(2):171-8.
M3099			4/1/1982		The menopause: benefits and risks of estrogen-progestogen replacement therapy.	Gambrell RD Jr.	Fertil Steril. 1982 Apr;37(4):457-74.
M3101			1/1/2005		Pharmacological management of severe postmenopausal osteoporosis.	Gaudio A, Morabito N.	Drugs Aging. 2005;22(5):405-17.
M3107			1/1/1981		[Hormonal dependency of experimental mammary tumors induced by an estro-progestational combination] [Article in French]	Hannouche N, Sampedez S, Riviere MR, Jouan P.	C R Seances Soc Biol Fil. 1981;175(6):744-8.
M3110			3/1/2005		KEEPS: The Kronos Early Estrogen Prevention Study.	Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N.	Climacteric. 2005 Mar;8(1):3-12.
M3123			11/1/2004		Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.	Kanis JA, Borgstrom F, Johnell O, Jonsson B.	Osteoporos Int. 2004 Nov;15(11):862-71. Epub 2004 Jun 3.
M3125			1/1/2005		Non-pharmacological means to prevent fractures among older adults.	Kannus P, Uusi-Rasi K, Palvanen M, Parkkari J.	Ann Med. 2005;37(4):303-10.
M3129			1/1/1994		Is there evidence of an estrogen effect on age-related lens opacities? The Beaver Dam Eye Study.	Klein BE, Klein R, Ritter LL.	Arch Ophthalmol. 1994 Jan;112(1):85-91.
M3132			5/1/2003		Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma.	Lamb CA, Helguero LA, Fabris V, Lucas C, Molinolo AA, Lanari C.	Breast Cancer Res Treat. 2003 May;79(1):25-35.
M3133			6/1/2005		Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study.	Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE, Hendrix SL, LaCroix AZ, Ridker PM.	Thromb Haemost. 2005 Jun;93(6):1108-16.
M3134			8/1/1999		Hormone replacement therapy: patterns of use studied through British general practice computerized records.	Lawrence M, Jones L, Lancaster T, Daly E, Banks E.	Fam Pract. 1999 Aug;16(4):335-42.
M3135			7/1/2002		Bone mineral density testing in healthy postmenopausal women. The role of clinical risk factor assessment in determining fracture risk.	Leslie WD, Metge C, Salamon EA, Yuen CK.	J Clin Densitom. 2002 Summer;5(2):117-30.
M3138			6/1/1998		A review of the effectiveness of Ciniicifuga racemosa (black cohosh) for the symptoms of menopause.	Lieberman S.	J Womens Health. 1998 Jun;7(5):525-9.
M3147			6/1/2005		The relationship between bone mineral density and fracture risk.	McClung MR.	Curr Osteoporos Rep. 2005 Jun;3(2):57-63.
M3152			8/25/2005		Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via PI3K/Akt/NF(kappa)B cascade in human breast cancer cells.	Saitoh M, Ohmichi M, Takahashi K, Kawagoe J, Ohta T, Doshida M, Takahashi T, Igarashi H, Mori-Abe A, Du B, Tsutsumi S, Kurachi H.	Endocrinology. 2005 Aug 25; [Epub ahead of print]

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M3154			11/1/1986		Menopausal oestrogens and breast cancer risk: an expanded case-control study.	Brinton LA, Hoover R, Fraumeni JF Jr.	Br J Cancer. 1986 Nov;54(5):825-32.
M3156			10/1/1999		Mammary growth hormone and tumorigenesis--lessons from the dog.	Mol JA, Lantinga-van Leeuwen IS, van Garderen E, Selman PJ, Oosterlaken-Dijksterhuis MA, Schalken JA, Rijnberk A.	Vet Q. 1999 Oct;21(4):111-5.
M3157			4/10/1998		Involvement of EGF in medroxyprogesterone acetate (MPA)-induced mammary gland hyperplasia and its role in MPA-induced mammary tumors in BALB/c mice.	Molinolo A, Simian M, Vanzulli S, Pazos P, Lamb C, Montecchia F, Lanani C.	Cancer Lett. 1998 Apr 10;126(1):49-57.
M3160			1/1/1996		New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans.	Mol JA, van Garderen E, Rutteman GR, Rijnberk A.	J Steroid Biochem Mol Biol. 1996 Jan;57(1-2):67-71.
M3162			3/7/1988		Non-contraceptive exogenous oestrogen therapy and breast cancer.	Rohan TE, McMichael AJ.	Med J Aust. 1988 Mar 7;148(5):217-21.
M3163					2.04 for more than 2years of use-- see abstract and p. 854 at bottom rt hand side of paper and table III on p. 855	LaVecchia	1986
M3164			7/6/1984		Noncontraceptive estrogen use and the risk of breast cancer.	Kaufman DW, Miller DR, Rosenberg L, Helmrich SP, Stolley P, Schottenfeld D, Shapiro S.	JAMA. 1984 Jul 6;252(1):63-7.
M3166			7/1/2005		Expression of p53 and markers for apoptosis in breast tissue during long-term hormone therapy in cynomolgus monkeys.	Conner P, Register TC, Skoog L, Tani E, von Schoutz B, Cline JM.	Am J Obstet Gynecol. 2005 Jul;193(1):58-63.
M3170			2/1/2003		Pharmacological modulation of IGF serum concentrations as a therapeutic approach to control the growth of malignant breast tumors.	Singer CF, Hudelist G, Schreiber M, Kubista E.	Drugs Today (Barc). 2003 Feb;39(2):115-25.
M3174			12/6/2000		Re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.;	Archer DF, Bush T, Nachtigall LE.	J Natl Cancer Inst. 2000 Dec 6;92(23):1950-2.
M3176			1/1/2001		Evidence that a metabolite of equine estrogens, 4-hydroxyequilenin, induces cellular transformation in vitro.	Plisha E, Lui X, Constantinou AI, Bolton JL.	Chem Res Toxicol. 2001 Jan;14(1):82-90.
M3177			8/16/2005		Morphometric evaluation of effects of two sex steroids on mammary gland of female rats.	Pompei LM, Carvalho FM, Ortiz SC, Motta MC, Cruz RJ, Melo NR.	Maturitas. 2005 Aug 16;51(4):370-9. Epub 2004 Nov 11.
M3178			7/1/1985		Post-menopausal estrogen replacement: the prevention of osteoporosis and systemic effects.	Lafferty FW, Helmuth DO.	Maturitas. 1985 Jul;7(2):147-59.
M3184			12/15/1990		Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinoma cells.	Papa V, Reese CC, Brunetti A, Vigneri R, Sileri PK, Goldfine ID.	Cancer Res. 1990 Dec 15;50(24):7858-62.
M3186			2/1/2001		Proliferative effects of combination estrogen and progesterone replacement therapy on the normal postmenopausal mammary gland in a murine model.	Raafat AM, Hofseth LJ, Haslam SZ.	Am J Obstet Gynecol. 2001 Feb;184(3):340-9.
M3187			4/1/2001		Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model.	Raafat AM, Li S, Bennett JM, Hofseth LJ, Haslam SZ.	J Cell Physiol. 2001 Apr;187(1):81-9.
M3188			1/1/2000		Regulation of VEGF in the reproductive tract by sex-steroid hormones.	Hyder SM, Stancel GM.	Histol Histopathol. 2000 Jan;15(1):325-34.
M3201			1/1/2001		Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy.	Santen RJ, Pinkerton J, McCartney C, Petroni GR.	J Clin Endocrinol Metab. 2001 Jan;86(1):16-23.
M3202			11/1/2003		Venlafaxine hydrochloride for the treatment of hot flashes.	Schober CE, Ansani, NT.	Ann Pharmacother. 2003 Nov;37(11):1703-7.
M3203			1/1/2004		Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study.	Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA.	Bone. 2004 Jan;34(1):195-202.
M3210			5/1/1997		Mood and symptom reporting among middle-aged women: the relationship between menopausal status, hormone replacement therapy, and exercise participation.	Slaven L, Lee C.	Health Psychol. 1997 May;16(3):203-8.
M3213			5/1/2003		Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys.	Suparto IH, Williams JK, Cline JM, Anothony MS, Fox JL.	Am J Obstet Gynecol. 2003 May;188(5):1132-40.
M3217			1/1/1997		The influence of endogenous and exogenous reproductive hormones on the mammary glands with emphasis on experimental studies in rhesus monkeys.	Tavassoli FA.	Verh Dtsch Ges Pathol. 1997;81:514-20.
M3219					<i>The Association of Replacement Estrogens with Breast Cancer</i>	Nomura	Int'l. J. Cancer. Vol. 37: 49-53 (1986)
M3224			1/1/2000		Effect on sensitivity and specificity of mammography screening with or without comparison of old mammograms.	Thurfjell MG, Vitak B, Azavedo E, Svane G, Thurfjell E.	Acta Radiol. 2000 Jan;41(1):52-6.
M3226			12/1/1999		The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers.	Umland EM, Rinaldi C, Parks SM, Boyce EG.	Ann Pharmacother. 1999 Dec;33(12):1315-28.
M3227			4/1/2003		Mammographic density and breast cancer in three ethnic groups.	Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC.	Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):332-8.
M3229			5/1/2002		p21, p27 and p53 in estrogen and antiprogesterin-induced tumor regression of experimental mouse mammary ductal carcinomas.	Vanzulli S, Efeyan A, Benavides F, Helguero LA, Peters G, Shen J, Conti CJ, Lanari C, Molinolo A.	Carcinogenesis. 2002 May;23(5):749-58.
M3231			3/1/1999		Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women.	Washburn S, Burke GL, Morgan T, Anthony M.	Menopause. 1999 Spring;6(1):7-13.
M3234			3/3/1983		[The alternative to hormonal treatment of menopausal vasomotor flushes: veralipride] [Article in French]	Wesel S, Bosuma WB.	Sem Hop. 1983 Mar 3;59(9):596-9.
M3250			12/1/2000		Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding.	Archer DF, Pickar JH.	Obstet Gynecol. 2000 Dec;96(6):899-905.
M3253			12/1/2004		Published results on breast cancer and hormone replacement therapy in the Million Women Study are correct.	Banks E, Beral V, Reeves G; The Million Women Study Collaborators.	Climacteric. 2004 Dec;7(4):415-6; author reply 416-7.
M3255			12/1/2002		Menopausal symptoms in older women and the effects of treatment with hormone therapy.	Barnabei VM, Grady D, Stovall DW, Cauley JA, Lin F, Stuenkel CA, Stefanick ML, Pickar JH.	Obstet Gynecol. 2002 Dec;100(6):1209-18.
M3264			3/1/2002		Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis.	Mote PA, Bartow S, Tran N, Clarke CL.	Breast Cancer Res Treat. 2002 Mar;72(2):163-72.
M3265			9/1/2005		Postmenopausal hormone therapy and body composition--a substudy of the estrogen plus progestin trial of the Women's Health Initiative.	Chen Z, Bassford T, Green SB, Cauley JA, Jackson RD, Lacroix AZ, Leboff M, Stefanick ML, Margolis KL.	Am J Clin Nutr. 2005 Sep;82(3):651-6.
M3270			11/15/2004		Insulin, physical activity, and caloric intake in postmenopausal women: breast cancer implications.	Chlebowski RT, Pettinger M, Stefanick ML, Howard BV, Mossavar-Rahmani Y, McTiernan A.	J Clin Oncol. 2004 Nov 15;22(22):4507-13.
M3273			1/1/2005		Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence.	Col NF, Kim JA, Chlebowski RT.	Breast Cancer Res. 2005;7(4):R535-40. Epub 2005 May 19.
M3275			8/1/2005		Changes in HT prescriptions in Australia since 1992.	Coomb NJ, Boyages J.	Aust Fam Physician. 2005 Aug;34(8):697-8.
M3276			10/18/1975		Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting.	Coope J, Thomson JM, Poller L.	Aust Med J. 1975 Oct 18;4(5989):139-43.
M3283			1/1/2005		Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland.	Cheng G, Li Y, Omoto Y, Wang Y, Berg T, Nord M, Vinko P, Warner M, Piao YS, Gustafsson JA.	J Clin Endocrinol Metab. 2005 Jan;90(1):435-44. Epub 2004 Oct 26.

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M3289			5/1/2003		Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue from surgically postmenopausal cynomolgus macaques.	Isaksson E, Wang H, Sahlin L, von Schouttz B, Cline JM, von Schouttz E.	Breast Cancer Res Treat. 2003 May;79(2):233-9.
M3293			8/1/2002		Expression of estrogen receptors (alpha, beta) and insulin-like growth factor-I in breast tissue from surgically postmenopausal cynomolgus macaques after long-term treatment with HRT and tamoxifen.	Isaksson E, Wang H, Sahlin L, von Schouttz B, Masironi B, von Schouttz E, Cline JM.	Breast. 2002 Aug;11(4):295-300.
M3305			2/1/2005		Progestins and estrogens and Alzheimer's disease.	Honjo H, Iwasa K, Kawata M, Fushiki S, Hosoda T, Tatsumi H, Oida N, Mihara M, Hirasugi Y, Yamamoto H, Kikuchi N, Kitawaki J.	J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):305-8. Epub 2005 Jan 24.
M3313			4/1/2000		Hormone replacement therapy and endometrial cancer in Ontario, Canada.	Jain MG, Rohan TE, Howe GR.	J Clin Epidemiol. 2000 Apr;53(4):385-91.
M3322			9/1/2005		Searching one or two databases was insufficient for meta-analysis of observational studies.	Lemeshow AR, Blum RE, Berlin JA, Stoto MA, Colditz GA.	J Clin Epidemiol. 2005 Sep;58(9):867-73.
M3339			9/16/2005		New evidence regarding hormone replacement therapies is urgently required Transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.	Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignieres B, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; The TREAT.	Maturitas. 2005 Sep 16;52(1):1-10
M3340			4/1/1999		Participation rates in a case-control study: the impact of age, race, and race of interviewer.	Moorman PG, Newman B, Millikan RC, Tse CK, Sandler DP.	Ann Epidemiol. 1999 Apr;9(3):188-95.
M3344			9/16/2005		Clean up: Gynecologists' attitudes towards hormone therapy in the post "Women's Health Initiative" study era.	Nassar AH, Essamad HM, Awwad JT, Khoury NG, Usta IM.	Maturitas. 2005 Sep 16;52(1):18-25.
M3361			3/1/1998		Effects of different hormone replacement regimens on postmenopausal women with abnormal lipid levels. Menopause Study Group.	Pickar JH, Wild RA, Walsh B, Hirvonen E, Lobo RA.	Climacteric. 1998 Mar;1(1):26-32.
M3362			3/1/2002		The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: a review of methodology and recommendations for reporting of the data.	Archer DF, Pickar JH.	Climacteric. 2002 Mar;5(1):45-59.
M3372			10/1/1991		Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.	Musgrove EA, Lee CS, Sutherland RL.	Mol Cell Biol. 1991 Oct;11(10):5032-43.
M3379			8/2/2005		Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma.	Riva C, Dainese E, Caprara G, Rocca PC, Massarelli G, Tot T, Capella C, Eusebi V.	Virchows Arch. 2005 Aug 2;:1-6 [Epub ahead of print]
M3390			7/1/2005		After the Women's Health Initiative: decision making and trust of women taking hormone therapy.	Schonberg MA, David RB, Wee CC.	Womens Health Issues. 2005 Jul-Aug;15(4):187-95.
M3405			6/30/2003		The effect of various regimens of hormone replacement therapy on mammographic breast density.	Christodoulakos GE, Lambrinoudaki IV, Panoulis KP, Vourtsi AD, Vlachos L, Georgiou E, Creatsas GC.	Maturitas. 2003 Jun 30;45(2):109-18.
M3406			3/1/2004		Current issues in hormone replacement therapy.	Timins JK.	N J Med. 2004 Mar;101(3):21-7.
M3409			1/1/1998		The detection of changes in mammographic densities.	Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV.	Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):43-7.
M3411			6/1/2001		Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.	Utian WH, Shoupe D, Bachman G, Pinkerton JV, Pickar JH.	Fertil Steril. 2001 Jun;75(6):1065-79.
M3422			7/1/2005		Is mammographic density, as currently measured, a robust surrogate marker for breast cancer?	Yaffe M, Hendrix S, Pike M, Santen R, Eden J, Genazzani A.	Gynecol Endocrinol. 2005 Jul;21 Suppl 1:17-21.
M3424			8/1/2005		Folate intake and risk of breast cancer characterized by hormone receptor status.	Zhang SM, Hankinson SE, Hunter DJ, Giovannucci EL, Colditz GA, Willett WC.	Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2004-8.
M3432			9/1/2004		WHI, WHI, WHI?	MacLennan AH, Sturdee DW.	Climacteric. 2004 Sep;7(3):221-4.
M3438			9/9/2005		Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells.	Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR.	J Steroid Biochem Mol Biol. 2005 Sep 9; [Epub ahead of print]
M3440			8/24/2005		Progesterone Pre-treatment Potentiates EGF Pathway Signaling in the Breast Cancer Cell Line ZR-75.	Carvajal A, Espinoza N, Kato S, Pinto M, Sadarangani A, Monso C, Aranda E, Villalon M, Richer JK, Horwitz KB, Brosens JJ, Owen GI.	Breast Cancer Res Treat. 2005 Aug 24; [Epub ahead of print]
M3446			9/8/2005		Breast cancer risk with postmenopausal hormonal treatment.	Collins JA, Blake JM, Crosignani PG.	Hum Reprod Update. 2005 Sep 8; [Epub ahead of print]
M3448			8/6/2005		Hormone replacement therapy and breast cancer: estimate of risk.	Coombs NJ, Taylor R, Wilcken N, Boyages J.	BMJ. 2005 Aug 6;331(7512):347-9.
M3449			8/1/2005		HRT and breast cancer: impact on population risk and incidence.	Coombs NJ, Taylor R, Wilcken N, Boyages J.	Eur J Cancer. 2005 Aug;41(12):1775-81.
M3460			11/1/1995		Characterization of progesterone receptor A and B expression in human breast cancer.	Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL.	Cancer Res. 1995 Nov 1;55(21):5063-8.
M3461			9/21/2005		The Association of Endogenous Sex Steroids and Sex Steroid Binding Proteins with Mammographic Density: Results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study.	Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA.	Am J Epidemiol. 2005 Sep 21; [Epub ahead of print]
M3462			9/8/2005		Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials.	Greiser CM, Greiser EM, Doren M.	Hum Reprod Update. 2005 Sep 8; [Epub ahead of print]
M3475			10/15/2005		Mammographic density and breast cancer risk: the multiethnic cohort study.	Maskarinec G, Pagano I, Lurie G, Wilkens LR, Kolonel LN.	Am J Epidemiol. 2005 Oct 15;162(8):743-52. Epub 2005 Sep 8.
M3476			9/21/2005		Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial.	McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS; Women's Health Initiative Mammogram Density Study Investigators.	J Natl Cancer Inst. 2005 Sep 21;97(18):1366-76.
M3479			7/4/2005		Mammographic densities and circulating hormones: A cross-sectional study in premenopausal women.	Noh JJ, Maskarinec G, Pagano I, Cheung LW, Stanczyk FZ.	Breast. 2005 Jul 4; [Epub ahead of print]
M3482			7/1/2005		The role of mammographic density in evaluating changes in breast cancer risk	Pike MC.	Gynecol Endocrinol. 2005 Jul;21 Suppl 1:1-5
M3491			6/1/2005		Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer.	Sharma R, Beith J, Hamilton A.	Breast. 2005 Jun;14(3):181-91. Epub 2005 Apr 26.
M3495			6/1/2005		A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.	Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J.	Health Technol Assess. 2005 Jun;9(22):1-160. EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M3496			9/1/2005		Plasma levels of enterolactone and percentage mammographic density among postmenopausal women.	Stuedal A, Gram IT, Bremnes Y, Adlercreutz H, Veierod MB, Ursin G.	Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2154-9.
M3498			1/1/2005		Greatly increased occurrence of breast cancers in areas of mammographically dense tissue.	Ursin G, Hovanessian-Larsen L, Parisky YR, Pike MC, Wu AH.	Breast Cancer Res. 2005;7(5):R605-8. Epub 2005 Jun 8.
M3499			9/1/2005		Urinary hydroxysterogens and breast cancer risk among postmenopausal women: a prospective study.	Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S.	Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2137-42.
M3506			7/1/2005		Menopausal symptom management and prevention counseling after the Women's Health Initiative among women seen in an internal medicine practice.	Schonberg MA, Wee CC.	J Womens Health (Larchmt). 2005 Jul-Aug;14(6):507-14.
M3507			9/1/2000		A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.	Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D.	Am J Med. 2000 Sep;109(4):267-76.
M3508			9/5/1992		Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.	Overgaard K, Hansen MA, Jensen SB, Christiansen C.	BMJ. 1992 Sep 5;305(6853):556-61.
M3509			3/1/1995		Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.	Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez de Buergo M.	Calcif Tissue Int. 1995 Mar;56(3):181-5.
M3510			1/1/1986		Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.	Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palumieri E, Cervellini GF, Gonnelli S, Francini G.	Calcif Tissue Int. 1986 Jan;38(1):3-8.
M3511			10/1/1990		Effects of salmon calcitonin on the bone loss induced by ovariectomy.	Mazzuoli GF, Tabolli S, Bigi F, Valtorta C, Minisola S, Diacinti D, Scarnecchia L, Bianchi G, Piolini M, Dell'Acqua S.	Calcif Tissue Int. 1990 Oct;47(4):209-14.
M3514			6/1/2004		Publishing the results of the estrogen-only arm of WHI.	MacLennan A, Sturdee DW.	Climacteric. 2004 Jun;7(2):117-9.
M3523			09/00/2009		Obesity and Cardiovascular Risk Factors in Younger Breast Cancer Survivors: The Cancer and Menopause Study (CAMS).	Herman DR, Ganz PA, Petersen L, Greendale GA.	Breast Cancer Res Treat. 2005 Sep;93(1):13-23.
M3525			11/1/2005		Oral Contraceptive Use and Risk of Breast Cancer among Women with a Family History of Breast Cancer: a Prospective Cohort Study.	Silvera SA, Miller AB, Rohan TE.	Cancer Causes Control. 2005 Nov;16(9):1059-63.
M3526			10/1/2005		The Relationship Between Various Measures of Cigarette Smoking and Risk of Breast Cancer Among Older Women 65-79 years of Age (United States).	Li CI, Malone KE, Daling JR.	Cancer Causes Control. 2005 Oct;16(8):975-85.
M3528			9/1/2005		Fruits and vegetables and ovarian cancer risk in a pooled analysis of 12 cohort studies.	Koushik A, Hunter DJ, Spiegelman D, Anderson KE, Arslan AA, Beeson WL, van den Brandt PA, Buring JE, Cerhan JR, Colditz GA, Fraser GE, Freudenheim JL, Genkinger JM, Goldbohm RA, Hankinson SE, Koenig KL, Larsson SC, Leitzmann M, McCullough ML, Miller AB, Patel A, Rohan TE, Schatzkin A, Smit E, Willett WC, Wolk A, Zhang SM, Smith-Warner SA.	Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2160-7.
M3534			7/1/2005		Dental implant failure rates and associated risk factors.	Moy PK, Medina D, Shetty V, Aghaloo TL.	Int J Oral Maxillofac Implants. 2005 Jul-Aug;20(4):569-77.
M3551			9/1/2005		Is there overlap between the genetic determinants of mammographic density and bone mineral density?	Dite GS, Wark JD, Giles GG, English DR, McCredie MR, Hopper JL.	Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2266-8.
M3562			4/1/2002		Aromatization of androgens in women: current concepts and findings.	Simpson ER.	Fertil Steril. 2002 Apr;77 Suppl 4:S6-10.
M3564			2/1/1994		Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age.	Bulun SE, Simpson ER.	J Clin Endocrinol Metab. 1994 Feb;78(2):428-32.
M3565			7/1/2000		Biology of aromatase in the mammary gland.	Simpson ER.	J Mammary Gland Biol Neoplasia. 2000 Jul;5(3):251-8.
M3568			1/1/2000		Tissue-specific synthesis and oxidative metabolism of estrogens.	Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, Naftolin F, Mor G, Berstein L.	J Natl Cancer Inst Monogr. 2000;(27):95-112.
M3569			5/1/1998		Concentration of sex steroids in adipose tissue after menopause.	Szymczak J, Milewicz A, Thijssen JH, Blankenstein MA, Daroszewski J.	Steroids. 1998 May-Jun;63(5-6):319-21.
M3574			5/1/1999		Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis.	Grodstein F, Newcomb PA, Stampfer MJ.	Am J Med. 1999 May;106(5):574-82.
M3594			11/5/1997		Dual effects of weight and weight gain on breast cancer risk.	Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, Hennekens CH, Rosner B, Speizer FE, Willett WC.	JAMA. 1997 Nov 5;278(17):1407-11. JAMA. 1997 Nov 5;278(17):1407-11.
M3609			9/1/2005		Management of early breast cancer--the current approach.	Brennan M, Wilcken N, French J, Ung O, Boyages J.	Aust Fam Physician. 2005 Sep;34(9):755-60.
M3613			9/15/2005		Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.	Buchanan G, Birrell SN, Peters AA, Bianco-Motto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM, Tilley WD.	Cancer Res. 2005 Sep 15;65(18):8487-96.
M3617			12/1/2001		Timing of estrogen replacement therapy for optimal osteoporosis prevention.	Cauley JA, Zmuda JM, Ensrud KE, Bauer DC, Ettinger B; Study of Osteoporotic Fractures Research Group.	J Clin Endocrinol Metab. 2001 Dec;86(12):5700-5.
M3626			10/16/2005		The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.	Eilertsen AL, Holbraaten E, Os I, Andersen TO, Sandvik L, Sandset PM.	Maturitas. 2005 Oct 16;52(2):111-8.
M3628			9/21/1999		Hormone replacement therapy: a survey of Ontario physicians' prescribing practices.	Elinson L, Cohen MM, Elmslie T.	CMAJ. 1999 Sep 21;161(6):695-8.

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M3643			6/1/2005		Hormone replacement therapy and breast density changes.	Harvey J, Scheurer C, Kawakami FT, Quebe-Fehling E, de Palacios PI, Ragavan VV.	Climacteric. 2005 Jun;8(2):185-92.
M3647			8/20/2002		Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease.	Humphrey LL, Chan BK, Sox HC.	Ann Intern Med. 2002 Aug 20;137(4):273-84.
M3660			12/1/2000		Comparison of the effects of continuous combined and sequential combined medroxyprogesterone acetate-estradiol treatment on the proliferation of MCF-7 cells.	Lippert C, Seeger H, Wallwiener D, Mueck AO.	Climacteric. 2000 Dec;3(4):271-7.
M3671			8/21/2002		Postmenopausal hormone replacement therapy: scientific review.	Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD.	JAMA. 2002 Aug 21;288(7):872-81.
M3673			10/16/2005		The Herbal Alternatives for Menopause (HALT) Study: background and study design.	Newton KM, Reed SD, Grothaus L, Ehrlich K, Guiltinan J, Ludman E, Lacroix AZ.	Maturitas. 2005 Oct 16;52(2):134-46.
M3679			1/1/1999		Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group.	Polis HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Sych B.	Osteoporos Int. 1999;9(5):461-8.
M3704			10/1/2003		Implementation of the Women's Health Initiative study design.;	Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL.	Ann Epidemiol. 2003 Oct;13(9 Suppl):S5-17.;
M3705			5/1/2005		Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.;	Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O'Sullivan MJ, Chen B, Schenken R, Johnson SR, Women's Health Initiative Investigators.;	Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73. ;;
M3706			10/1/2002		Radiographic measurements, bone mineral density, and the Singh Index in the proximal femur of white and black postmenopausal women.;	Barondess DA, Singh M, Hendrix SL, Nelson DA.;	Dis Mon. 2002 Oct;48(10):637-46. ;
M3707			11/1/2002		Results of an adjunct dietary intervention program in the Women's Health Initiative.;	Bowen D, Ehret C, Pedersen M, Snetelaar L, Johnson M, Tinker L, Hollinger D, Ilona L, Bland K, Sivertsen D, Ocke D, Staats L, Beedoe JW. ;	J Am Diet Assoc. 2002 Nov;102(11):1631-7.;
M3708			4/1/1998		The effects of insurance coverage and ethnicity on mammography utilization in a postmenopausal population.;;	Bush RA, Langer RD.;	West J Med. 1998 Apr;168(4):236-40.;
M3709			1/1/2000		Correlates of serum lycopene in older women.;;	Casso D, White E, Patterson RE, Agurs-Collins T, Kooperberg C, Haines PS. ;	Nutr Cancer. 2000;36(2):163-9.;
M3710			10/15/2003		Habitual tea consumption and risk of osteoporosis: a prospective study in the women's health initiative observational cohort.;	Chen Z, Pettinger MB, Ritenbaugh C, LaCroix AZ, Robbins J, Caan BJ, Barad DH, Hakim IA. ;	Am J Epidemiol. 2003 Oct 15;158(8):772-81. ;
M3711			3/14/2005		Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.;;	Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS. ;	Arch Intern Med. 2005 Mar 14;165(5):552-8. ;;
M3712			5/1/2004		Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials.;;	Chen Z, Kooperberg C, Pettinger MB, Bassford T, Cauley JA, LaCroix AZ, Lewis CE, Kipersztok S, Borne C, Jackson RD. ;	Menopause. 2004 May-Jun;11(3):264-74.;
M3713			3/16/2005		Ethnicity and breast cancer: factors influencing differences in incidence and outcome.;	Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R. ;	J Natl Cancer Inst. 2005 Mar 16;97(6):439-48. ;
M3714			12/1/2003		Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy.;;	Chlebowski RT, Kim JA, Col NF. ;	Semin Oncol. 2003 Dec;30(6):776-88.;
M3715			10/1/2003		Outcomes ascertainment and adjudication methods in the Women's Health Initiative.;;	Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, Daugherty S; WHI Morbidity and Mortality Committee.;	Ann Epidemiol. 2003 Oct;13(9 Suppl):S122-8.;
M3716			2/1/2005		Association between reported alcohol intake and cognition: results from the Women's Health Initiative Memory Study.;;	Espeland MA, Gu L, Masaki KH, Langer RD, Coker LH, Stefanick ML, Ockene J, Rapp SR. ;	Am J Epidemiol. 2005 Feb 1;161(3):228-38.;
M3717			12/1/1996		Estrogens for prevention of coronary heart disease. Putting the brakes on the bandwagon.;;	Rossouw JE.	Circulation. 1996 Dec 1;94(11):2982-5. Review.;
M3718			11/15/2002		Vigorous leisure activity through women's adult life: the Women's Health Initiative Observational Cohort Study.;;	Evenson KR, Wilcox S, Pettinger M, Brunner R, King AC, McTiernan A; Women's Health Initiative Observational Cohort Study. ;	Am J Epidemiol. 2002 Nov 15;156(10):945-53.;
M3719			12/1/1996		Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative.;	Freedman L, Anderson G, Kipnis V, Prentice R, Wang CY, Rossouw J, Wittes J, DeMets D.;	Control Clin Trials. 1996 Dec;17(6):509-25. ;
M3720			7/1/2001		Risk factors for kidney stones in older women in the southern United States.;;	Hall WD, Pettinger M, Oberman A, Watts NB, Johnson KC, Paskett ED, Limacher MC, Hays J. ;	Am J Med Sci. 2001 Jul;322(1):12-8. ;
M3721			1/1/2004		Progression and remission of pelvic organ prolapse: a longitudinal study of menopausal women.;	Handa VL, Garrett E, Hendrix S, Gold E, Robbins J.	Am J Obstet Gynecol. 2004 Jan;190(1):27-32. ;;
M3722			10/1/2003		The Women's Health Initiative recruitment methods and results.;;	Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw JE. ;	Ann Epidemiol. 2003 Oct;13(9 Suppl):S18-77.;
M3723			10/1/2003		Differences between estimated caloric requirements and self-reported caloric intake in the women's health initiative.;;	Hebert JR, Patterson RE, Gorfine M, Ebbeling CB, St Jeor ST, Chlebowski RT. ;	Ann Epidemiol. 2003 Oct;13(9):629-37. ;;
M3724			12/15/2004		Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative.;;	Heckbert SR, Kooperberg C, Safford MM, Psaty BM, Hsia J, McTiernan A, Gaziano JM, Frishman WH, Curb JD. ;	Am J Epidemiol. 2004 Dec 15;160(12):1152-8.;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M3725			6/1/2002		Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity.;;	Hendrix SL, Clark A, Nygaard I, Aragaki A, Barnabei V, McTiernan A.;	Am J Obstet Gynecol. 2002 Jun;186(6):1160-6.;;
M3726			2/23/2005		Effects of estrogen with and without progestin on urinary incontinence.;	Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, Aragaki A, Naughton MJ, Wallace RB, McNeely SG.;	JAMA. 2005 Feb 23;293(8):935-48.;
M3727			6/1/2004		The women's health initiative: a potential resource for future studies of autoimmune diseases.;;	Howard BV	Autoimmunity. 2004 Jun;37(4):265-8.;
M3728			3/29/2005		Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study.;;	Howard BV, Kuller L, Langer R, Manson JE, Allen C, Assaf A, Cochrane BB, Larson JC, Lasser N, Rainford M, Van Horn L, Stefanick ML, Trevisan M.;	Circulation. 2005 Mar 29;111(12):1462-70. Epub 2005 Mar 21.;;
M3729			8/1/2004		Insulin resistance and weight gain in postmenopausal women of diverse ethnic groups.;;	Howard BV, Adams-Campbell L, Allen C, Black H, Passaro M, Rodabough RJ, Rodriguez BL, Safford M, Stevens VJ, Wagenknecht LE.;	Int J Obes Relat Metab Disord. 2004 Aug;28(8):1039-47.;;
M3730			3/1/2003		Risk factor clustering in the insulin resistance syndrome and its relationship to cardiovascular disease in postmenopausal white, black, hispanic, and Asian/Pacific Islander women.;;	Howard BV, Ciqui MH, Curb JD, Rodabough R, Safford MM, Santoro N, Wilson AC, Wylie-Rosett J.;	Metabolism. 2003 Mar;52(3):362-71.;
M3731			8/1/2003		Usefulness of prior hysterectomy as an independent predictor of Framingham risk score (The Women's Health Initiative).;;	Hsia J, Barad D, Margolis K, Rodabough R, McGovern PG, Limacher MC, Oberman A, Smoller S; Women's Health Initiative Research Group.;	Am J Cardiol. 2003 Aug 1;92(3):264-9.;
M3732			3/15/2004		Predictors of angina pectoris versus myocardial infarction from the Women's Health Initiative Observational Study.;;	Hsia J, Aragaki A, Bloch M, LaCroix AZ, Wallace R; WHI Investigators.;	Am J Cardiol. 2004 Mar 15;93(6):673-8.;;
M3733			10/1/2002		Compliance with National Cholesterol Education Program dietary and lifestyle guidelines among older women with self-reported hypercholesterolemia. The Women's Health Initiative.	Hsia J, Rodabough R, Rosal MC, Cochrane B, Howard BV, Snetselaar L, Frishman WH, Stefanick ML.	Am J Med. 2002 Oct 1;113(5):384-92.
M3734			1/1/2005		Physical activity and diabetes risk in postmenopausal women.;;	Hsia J, Wu L, Allen C, Oberman A, Lawson WE, Torrens J, Safford M, Limacher MC, Howard BV; Women's Health Initiative Research Group.;	Am J Prev Med. 2005 Jan;28(1):19-25.;;
M3735			12/1/2004		Progression of coronary calcification in healthy postmenopausal women.;;	Hsia J, Khouj A, Prasad A, Burt J, Adams-Campbell LL, Howard BV.;	BMC Cardiovasc Disord. 2004 Dec 1;4:21.;
M3736			10/1/2000		Is insurance a more important determinant of healthcare access than perceived health? Evidence from the Women's Health Initiative.;;	Hsia J, Kemper E, Sofaer S, Bowen D, Kiefe CI, Zapka J, Mason E, Lillington L, Limacher M.;	J Womens Health Gend Based Med. 2000 Oct;9(8):881-9.;
M3737			9/1/2003		The importance of health insurance as a determinant of cancer screening: evidence from the Women's Health Initiative.;;	Hsia J, Kemper E, Kiefe C, Zapka J, Sofaer S, Pettinger M, Bowen D, Limacher M, Lillington L, Mason E.;	Prev Med. 2000 Sep;31(3):261-70.;;
M3738			6/1/2000		Post-menopausal bone loss and its relationship to oral bone loss.;;	Jeffcoat MK, Lewis CE, Reddy MS, Wang CY, Redford M.;	Periodontol 2000. 2000 Jun;23:94-102.;
M3739			5/1/2002		Influences on older women's adherence to a low-fat diet in the Women's Health Initiative.;;	Kearney MH, Rosal MC, Ockene JK, Churchill LC.	Psychosom Med. 2002 May-Jun;64(3):450-7.;;
M3740			4/1/2003		Coronary artery calcification in black women and white women.;;	Khurana C, Rosenbaum CG, Howard BV, Adams-Campbell LL, Detrano RC, Khouj A, Hsia J.;	Am Heart J. 2003 Apr;145(4):724-9;
M3741			7/15/2003		Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study.;;	LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeely SG, Passaro MD, Jackson RD.;	Ann Intern Med. 2003 Jul 15;139(2):97-104.;;
M3742			10/1/2003		The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants.;;	Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR.;	Ann Epidemiol. 2003 Oct;13(9 Suppl):S78-86.;
M3743			6/1/2002		Recruitment of Hispanic women to the Women's Health Initiative. the case of Embajadoras in Arizona.;;	Larkey LK, Staten LK, Ritenbaugh C, Hall RA, Buller DB, Bassford T, Altman BR.;	Control Clin Trials. 2002 Jun;23(3):289-98.;;
M3744			6/1/2003		Reliability and validity of the Women's Health Initiative Insomnia Rating Scale.;	Levine DW, Kripke DF, Kaplan RM, Lewis MA, Naughton MJ, Bowen DJ, Shumaker SA.;	Psychol Assess. 2003 Jun;15(2):137-48.;
M3745			6/1/2003		Factor structure and measurement invariance of the Women's Health Initiative Insomnia Rating Scale.;;	Levine DW, Kaplan RM, Kripke DF, Bowen DJ, Naughton MJ, Shumaker SA.;	Psychol Assess. 2003 Jun;15(2):123-36.;
M3746			1/1/2005		Validation of the Women's Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial.;;	Levine DW, Dailey ME, Rockhill B, Tipping D, Naughton MJ, Shumaker SA.;	Psychosom Med. 2005 Jan-Feb;67(1):98-104.;;
M3747			9/5/2002		Walking compared with vigorous exercise for the prevention of cardiovascular events in women.;;	Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, Perri MG, Sheps DS, Pettinger MB, Siscovick DS.;	N Engl J Med. 2002 Sep 5;347(10):716-25.;;
M3748			3/14/2005		Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study.	Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, Grimm RH Jr, Howard BV, Assaf AR, Prentice R; Women's Health Initiative Research Group.	Arch Intern Med. 2005 Mar 14;165(5):500-8.
M3749			2/1/1997		Women's health initiative. Why now? What is it? What's new?	Matthews KA, Shumaker SA, Bowen DJ, Langer RD, Hunt JR, Kaplan RM, Klesges RC, Ritenbaugh C.	Am Psychol. 1997 Feb;52(2):101-16.

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M3750			6/1/2005		Comparing SF-36 scores across three groups of women with different health profiles.	Yost KJ, Haan MN, Levine RA, Gold EB.	Qual Life Res. 2005 Jun;14(5):1251-61.
M3751			11/1/2004		Relationship of social support and social burden to repeated breast cancer screening in the women's health initiative.	Messina CR, Lane DS, Glanz K, West DS, Taylor V, Frishman W, Powell L.	Health Psychol. 2004 Nov;23(6):582-94.
M3752			10/1/2002		Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States).	Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A.	Cancer Causes Control. 2002 Oct;13(8):741-51.
M3753			1/1/2004		Additional self-monitoring tools in the dietary modification component of The Women's Health Initiative.	Mossavar-Rahmani Y, Henry H, Rodabough R, Bragg C, Brewer A, Freed T, Kinzel L, Pedersen M, Soule CO, Vosburg S.	J Am Diet Assoc. 2004 Jan;104(1):76-85.
M3754			10/1/2000		Cross-sectional geometry, bone strength, and bone mass in the proximal femur in black and white postmenopausal women.	Nelson DA, Barondess DA, Hendrix SL, Beck TJ.	J Bone Miner Res. 2000 Oct;15(10):1992-7.
M3755			9/1/2004		Pelvic organ prolapse in older women: prevalence and risk factors.	Nygaard I, Bradley C, Brandt D; Women's Health Initiative.	Obstet Gynecol. 2004 Sep;104(3):489-97.
M3756			12/10/2004		Clean up. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative.	Pastore LM, Carter RA, Hulka BS, Walls E.	Maturitas. 2004 Dec 10;49(4):292-303.
M3757			4/1/1999		Measurement characteristics of the Women's Health Initiative food frequency questionnaire.	Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T.	Ann Epidemiol. 1999 Apr;9(3):178-87.
M3758			7/1/1996		Low-fat diet practices of older women: prevalence and implications for dietary assessment.	Patterson RE, Kristal AR, Coates RJ, Tyllavsky FA, Ritenbaugh C, Van Horn L, Caggliola AW, Snetselaar L.	J Am Diet Assoc. 1996 Jul;96(7):670-9.
M3759			4/1/2003		Clean up. Changes in food sources of dietary fat in response to an intensive low-fat dietary intervention: early results from the Women's Health Initiative.	Patterson RE, Kristal A, Rodabough R, Caan B, Lillington L, Mossavar-Rahmani Y, Simon MS, Snetselaar L, Van Horn L.	J Am Diet Assoc. 2003 Apr;103(4):454-60.
M3760			7/20/2004		Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.	Pradhan AD, LaCroix AZ, Langer RD, Trevisan M, Lewis CE, Hsia JA, Oberman A, Kotchen JM, Ridker PM.	Circulation. 2004 Jul 20;110(3):292-300. Epub 2004 Jul 6.
M3761			5/1/2003		Baseline experience with Modified Mini Mental State Exam: The Women's Health Initiative Memory Study (WHIMS).	Rapp SR, Espeland MA, Hogan P, Jones BN, Dugan E; The WHIMS investigators.	Aging Ment Health. 2003 May;7(3):217-23.
M3762			10/1/2003		The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants.	Ritenbaugh C, Patterson RE, Chlebowski RT, Caan B, Fels-Tinker L, Howard B, Ockene J.	Ann Epidemiol. 2003 Oct;13(9 Suppl):S87-97.
M3763			10/1/2003		Foreward to special supplement.	Rossouw JE, Anderson GL, Oberman A.	Ann Epidemiol 2003;S9:S1-S4
M3764			1/1/1999		The Women's Health Initiative: recruitment complete--looking back and looking forward.	Rossouw JE, Hurd S.	J Womens Health. 1999 Jan-Feb;8(1):3-5.
M3765			3/1/1995		The evolution of the Women's Health Initiative: perspectives from the NIH.	Rossouw JE, Finnegan LP, Harlan WR, Pinn VW, Clifford C, McGowan JA.	J Am Med Womens Assoc. 1995 Mar-Apr;50(2):50-5.
M3766			3/1/2003		Antioxidant supplement use in Women's Health Initiative participants.	Shikany JM, Patterson RE, Agurs-Collins T, Anderson G.	Prev Med. 2003 Mar;36(3):379-87.
M3767			9/22/2003		Prevalence and correlates of panic attacks in postmenopausal women: results from an ancillary study to the Women's Health Initiative.	Smoller JW, Pollack MH, Wassertheil-Smoller S, Barton B, Hendrix SL, Jackson RD, Dicken T, Oberman A, Sheps DS; Women's Health Initiative Investigators.	Arch Intern Med. 2003 Sep 22;163(17):2041-50.
M3768			4/1/2005		Reanalysis of the Women's Health Initiative oral contraceptive data reveals no evidence of delayed cardiovascular benefit.	Stefanick ML, Prentice RL, Anderson G, Gass M, Manson JE, Hendrix SL, Vista-Deck D, McNeeley G; Women's Health Initiative Steering Committee.	Fertil Steril. 2005 Apr;83(4):853-4.
M3769			6/1/2002		The effects of physical and emotional status on adherence to a low-fat dietary pattern in the Women's Health Initiative.	Tinker LF, Perri MG, Patterson RE, Bowen DJ, McIntosh M, Parker LM, Sevik MA, Wodarski LA.	J Am Diet Assoc. 2002 Jun;102(6):789-800, 888.
M3770			9/1/2000		Sexual orientation and health: comparisons in the women's health initiative sample.	Valanis BG, Bowen DJ, Bassford T, Whitlock E, Charney P, Carter RA.	Arch Fam Med. 2000 Sep-Oct;9(9):843-53.
M3771			9/1/1999		Estimation of the correlation between nutrient intake measures under restricted sampling.	Wang CY, Anderson GL, Prentice RL.	Biometrics. 1999 Sep;55(3):711-7.
M3772			2/9/2004		Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI).	Wassertheil-Smoller S, Shumaker S, Ockene J, Talavera GA, Greenland P, Cochrane B, Robbins J, Aragaki A, Dunbar-Jacob J.	Arch Intern Med. 2004 Feb 9;164(3):289-98.
M3773			12/15/2004		Association between cardiovascular outcomes and antihypertensive drug treatment in older women.	Wassertheil-Smoller S, Psaty B, Greenland P, Oberman A, Kotchen T, Mouton C, Black H, Aragaki A, Trevisan M.	JAMA. 2004 Dec 15;292(23):2849-59.
M3774			2/1/1998		Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.	The Women's Health Initiative Study Group.	Control Clin Trials. 1998 Feb;19(1):61-109.
M3775			2/1/2001		Correlates of serum alpha- and gamma-tocopherol in the Women's Health Initiative.	White E, Kristal AR, Shikany JM, Wilson AC, Chen C, Mares-Perlman JA, Masaki KH, Caan BJ.	Ann Epidemiol. 2001 Feb;11(2):136-44.
M3776			6/1/2001		Promoting adherence and retention to clinical trials in special populations: a women's health initiative workshop.	Wilcox S, Shumaker SA, Bowen DJ, Naughton MJ, Rosal MC, Ludlam SE, Dugan E, Hunt JR, Stevens S.	Control Clin Trials. 2001 Jun;22(3):279-89.
M3777			9/1/2003		The effects of widowhood on physical and mental health, health behaviors, and health outcomes: The Women's Health Initiative.	Wilcox S, Evenson KR, Aragaki A, Wassertheil-Smoller S, Mouton CP, Loevinger BL.	Health Psychol. 2003 Sep;22(5):513-22.

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M3778			3/19/2003		Frequency and predictive value of a mammographic recommendation for short-interval follow-up.	Yasmeen S, Romano PS, Pettinger M, Chlebowski RT, Robbins JA, Lane DS, Hendrix SL.	J Natl Cancer Inst. 2003 Mar 19;95(6):429-36.
M3782			3/1/1985		Long-term estrogen replacement therapy prevents bone loss and fractures.	Ettinger B, Genant HK, Cann CE;	Ann Intern Med. 1985 Mar;102(3):319-24.;
M3786			3/16/1996		Age at menopause as a risk factor for cardiovascular mortality.	van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD.	Lancet. 1996 Mar 16;347(9003):714-8.
M3819			10/31/2005		Clinical characteristics of different histologic types of breast cancer.	Li CI, Uribe DJ, Daling JR. ;	Br J Cancer. 2005 Oct 31;93(9):1046-52.
M3825					<i>Hormone-Replacement Therapy and the Risk of Breast Cancer</i>	Hulka	CA- A Cancer Journal for Clinicians, Vol. 40, No. 5 (1990)
M3840			1/1/2000		Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors.	Bamberger AM, Milde-Langosch K, Schulte HM, Loning T.	Horm Res. 2000;54(1):32-7.
M3846			2/1/1998		Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.	Women's Health Initiative Study Group.	Control Clin Trials. 1998 Feb;19(1):61-109.
M3847			10/1/2005		Mammographic breast density as an intermediate phenotype for breast cancer.	Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, Paterson AD.	Lancet Oncol. 2005 Oct;6(10):798-808.
M3848			3/1/1996		Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast.	Bulun SE, Sharda G, Rink J, Sharma S, Simpson ER.	J Clin Endocrinol Metab. 1996 Mar;81(3):1273-7.
M3849			10/31/2005		Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells.	Garvin S, Nilsson UW, Dabrosin C.	Br J Cancer. 2005 Oct 31;93(9):1005-10.
M3850			10/21/2005		Pregnancy, progesterone and progestins in relation to breast cancer risk.	Campagnoli C, Abba C, Ambroggio S, Peris C.	J Steroid Biochem Mol Biol. 2005 Oct 21; [Epub ahead of print]
M3851			10/7/2003		Further Analyses of Prior Hormone Therapy on Breast Cancer: The WHI Estrogen + Progestin Trial. (PowerPoint Presentation)	Anderson, G	Meeting Presentation
M3852			8/22/2005		Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study.	Chen W, Petitti DB, Geiger AM.	Br J Cancer. 2005 Aug 22;93(4):392-8.
M3853			4/1/2005		An analysis of the effect of selection bias on the association of hormone replacement therapy and breast cancer risk.	Csizmadi I, Friedreich CM, Bryant HE, Courmeya KS.	Chronic Dis Can. 2005 Spring-Summer;26(2-3):73-9.
M3854			7/1/2005		IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Combined Estrogen-Progestin Menopausal Therapy - DRAFT	International Agency for Research on Cancer	DRAFT-Vol 91, Monograph 2, Section 5, 3rd Draft, rev. 3, July 2005
M3855			6/1/2005		Pamphlet: Facts about Menopausal Hormone Therapy.	NIH, DHHS, NHLBI	NIH Publication # 05-5200; Revised June 2005
M3856			1/1/2004		Epidemiology of Breast Cancer	Vogel VG	IN: The Breast: Comprehensive Management of Benign and Malignant Disorders 3rd Edition, Black and Copeland, eds., Saunders Publishing 2004 Vol. 1:341-354.
M3857			11/2/2005		Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.	Suzuki R, Ye W, Rylander-Rudqvist T, Saij S, Colditz GA, Wolk A.	J Natl Cancer Inst. 2005 Nov 2;97(21):1601-8.
M3862			6/3/1998		Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer.;	Colditz GA	J Natl Cancer Inst. 1998 Jun 3;90(11):814-23.
M3866			12/1/2001		Tamoxifen for early breast cancer.;	Early Breast Cancer Trialists' Collaborative Group.;	Cochrane Database Syst Rev. 2001;(1):CD000486.;
M3867			9/16/1998		Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study;	Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. ;	J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88. ;
M3869			10/3/2001		Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.;	Jordan VC, Gapstur S, Morrow M. ;	J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57.;
M3873			1/1/2003		Non-genomic progesterone receptors in the mammalian ovary: some unresolved issues.	Bramley, T	Reproduction, 125;3-15 (2003)
M3874			1/1/1999		Mechanisms of Transcriptional Activation of bcl-2 Gene expression by 17?-estradiol in Breast Cancer Cells.	Dong et al.	J. Biol. Chem. 274(45); 32099-32107 (1999).
M3875			1/1/2003		Bidirectional Signaling between the Estrogen Receptor and the Epidermal Growth Factor Receptor.	Levin, E.	Molec. Endo. 17(3);309-317 (2003).
M3876			1/1/1998		Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.	Migliaccio et al.	The EMBO J. 17(7);2008-2018 (1998).
M3877			1/1/1999		Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.	Castoria et al.	The EMBO J. 18(9);2500-2510 (1999).
M3878			1/1/2000		Estrogen Receptor ? Rapidly Activates th IGF-1 Receptor Pathway.	Kahlert et al.	J. Biol. Chem. 275(24);18447-18453 (2000).
M3879			1/1/2000		Steroid-induced androgen receptor-oestradiol receptor ?-Src complex triggers prostate cancer cell proliferation.	Migliaccio et al.	The EMBO J. 19(20); 5406-5417 (2000).
M3889			12/1/1997		Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find?	Welch HG, Black WC	Ann Intern Med. 1997 Dec 1;127(11):1023-8.
M3892			6/1/1976		Breast patterns as an index of risk for developing breast cancer.	Wolfe JN;	AJR Am J Roentgenol. 1976 Jun;126(6):1130-7.
M3893			4/1/2002		Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.	Lundstrom E, Christow A, Kersemaekers W, Svane G, Azavedo E, Soderqvist G, Mol- Arts M, Barkfeldt J, von Schoutz B. ;	Am J Obstet Gynecol. 2002 Apr;186(4):717-22.
M3895			8/1/2000		Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States).	Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. ;	Cancer Causes Control. 2000 Aug;11(7):653-62.
M3896			12/1/1998		Mammographic densities and breast cancer risk.;	Boyd NF;Lockwood GA;Byng JW;Tritchler DL;Yaffe MJ;	Cancer Epidemiol Biomarkers Prev 1998 Dec;7(12):1133-44. ;
M3899			3/1/1982		Mammographic features of the breast and breast cancer risk.	Brisson J, Merletti F, Sadowsky NL, Twaddle JA, Morrison AS, Cole P.	Am J Epidemiol. 1982 Mar;115(3):428-37.
M3901			10/1/1996		Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer.	Hall RE, Aspinall JO, Horsfall DJ, Birrell SN, Bentel JM, Sutherland RL, Tilley WD. ;	Br J Cancer. 1996 Oct;74(8):1175-80.
M3902			1/1/1995		Estrogen replacement therapy withdrawal and regression of metastatic breast cancer.	Dhodapkar MV, Ingle JN, Ahmann DL.	Cancer. 1995 Jan 1;75(1):43-6.
M3903			1/1/1993		Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.	Pike MC, Spicer DV, Dahmough L, Press MF.	Epidemiol Rev. 1993;15(1):17-35.
M3904			5/3/1995		Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study.	Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL, Yaffe MJ.	J Natl Cancer Inst. 1995 May 3;87(9):670-5.
M3905			11/1/1995		Mammographic features and breast cancer risk: effects with time, age, and menopause status.	Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R.;	J Natl Can J Natl Cancer Inst. 1995 Nov 1;87(21):1622-9. ; per Inst. 1995 Nov 1;87(21):1622-9.
M3906			10/24/1992		Combined oestrogen-progestogen replacement and breast cancer risk.	Persson I, Yuen J, Bergkvist L, Adami HO, Hoover R, Schairer C.	Lancet. 1992 Oct 24;340(8826):1044.
M3907			7/1/2001		Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias.	Joffe MM, Byrne C, Colditz GA.;	Epidemiology. 2001 Jul;12(4):429-38.

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M3912			3/11/2005		A transmembrane intracellular estrogen receptor mediates rapid cell signaling.	Revankar C; Cimino D; Sklar L; Arterburn J; Prossnitz E	Science 2005 Mar 11;307(5715):1625-30
M3914			3/1/2003		Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology.;;	Conner P; Söderqvist G; Skoog L; Gräser T; Walter F; Tani E; Carlström K; von Schoultz B	Breast Cancer Res Treat 2003 Mar;78(2):159-65. ;
M3915			12/1/2005		Observational Studies of Drugs and Mortality.	Ray WA	N Engl J Med 2005;353(22):2319-2321
M3916			6/1/2005		Dose and duration of hormone use: understanding the effects of combined menopausal hormones on breast cancer better, 1976-2004.	McPherson K, Mant R	J Epidemiol Community Health 2005;59:1078-1079
M3921			2/1/1985		Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women.	Bhathal PS, Brown RW, Lesueur GC, Russell IS.	Br J Cancer. 1985 Feb;51(2):271-8. ; ;
M3922			12/1/1987		Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies.;;	Nielsen M, Thomsen JL, Prindahl S, Dyreborg U, Andersen JA. ;	Br J Cancer. 1987 Dec;56(6):814-9.
M3924			12/1/1987		Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study.;;	Barlow SA, Pathak DR, Black WC, Key CR, Teaf SR.;	Cancer. 1987 Dec 1;60(11):2751-60. ; ;
M3925			8/15/1984		Precancerous and cancerous breast lesions during lifetime and at autopsy. A study of 83 women.;	Nielsen M, Jensen J, Andersen J.	Cancer. 1984 Aug 15;54(4):612-5.;
M3929			1/7/2000		The hallmarks of cancer.;;	Hanahan D, Weinberg RA. ;	Cell. 2000 Jan 7;100(1):57-70.;
M3932			8/1/1975		An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions.;;	Wellings SR, Jensen HM, Marcum RG. ;	J Natl Cancer Inst. 1975 Aug;55(2):231-73. ;
M3935			3/1/2004		Sex steroids and growth factors in the regulation of mammary gland proliferation, differentiation, and involution.;	Lamole I, Meyer E, Massart-Leen AM, Burvenich C.;	Steroids. 2004 Mar;69(3):145-59. Review. ;
M3936			1/1/2003		AACE Position: Women's Health Initiative	American Association of Clinical Endocrinologists	http://www.aace.com/pub/pdf/guidelines/AACEWHI_position.pdf
M3937			10/16/2005		Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.;	Neven P, Quail D, Marin F, Creatsas G, Depypere H, Rechberger T, Liu-Leage S, Pavo I, Schmitt H, Nickelsen T. ;	Maturitas. 2005 Oct 16;52(2):87-101.
M3938			7/1/2005		Million Women Study Newsletter - July 2005	Million Women Study Collaborators	http://www.millionwomenstudy.org/news-jul2005.html ;
M3939			8/1/2005		Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base.	Singletary SE, Patel-Parekh L, Bland KL. ;	Ann Surg. 2005 Aug;242(2):281-9. ; ;
M3940			11/16/2005		Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.;;	Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. ;	J National cancer Inst. 2005;97(22):1652-1662
M3941			9/26/2005		Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial.	Brunner RL, Gass M, Aragaki A, Hays J, Granek I, Woods N, Mason E, Brzyski R, Ockene J, Assaf A, LaCroix A, Matthews K, Wallace R; Women's Health Initiative Investigators.;	Arch Intern Med. 2005 Sep 26;165(17):1976-86.
M3942			3/25/2002		Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.;;	Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E; PEPI Safety Follow-Up Study (PSFS) Investigators. ;	Arch Intern Med. 2002 Mar 25;162(6):665-72. ; ;
M3943			10/1/2002		Dose-response analysis of effects of tibolone on climacteric symptoms.	Landgren MB, Bennink HJ, Helmond FA, Engelen S.	BJOG. 2002 Oct;109(10):1109-14.
M3944			9/1/2004		Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy.	Bruce D, Robinson J, Rymmer J.;	Climacteric. 2004 Sep;7(3):261-6.
M3945			8/1/2000		Postmenopausal estrogen therapy and depressive symptoms in older women.;;	Whooley MA, Grady D, Cauley JA. ;	J Gen Intern Med. 2000 Aug;15(8):535-41. ;
M3946			10/1/1999		Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women.	Steffens DC, Norton MC, Plassman BL, Tschanz JT, Wyse BW, Welsh-Bohmer KA, Anthony JC, Breitner JC.	J Am Geriatr Soc. 1999 Oct;47(10):1171-5.
M3947			2/28/1981		Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy.	Christiansen C, Christensen MS, Transbol I.	Lancet. 1981 Feb 28;1(8218):459-61.
M3948			7/1/1992		Estrogen use and depressive symptoms in postmenopausal women.	Palinkas LA, Barrett-Connor E.	Obstet Gynecol. 1992 Jul;80(1):30-6.
M3949			9/1/2001		Estrogen replacement therapy and antidepressant response to sertraline in older depressed women.	Schneider LS, Small GW, Clary CM.	Am J Geriatr Psychiatry. 2001 Fall;9(4):393-9.
M3950			10/21/2005		Hormone replacement therapy, body mass index, and asthma in peri-menopausal women: a cross-sectional survey.;	Real FG, Svanes C, Björnsson EH, Franklin KA, Gislason D, Gislason T, Gulsvik A, Janson C, Jogi R, Kiserud T, Norback D, Nystrom L, Toren K, Wentzel-Larsen T, Omenaas ER. ;	Thorax. 2005 Oct 21; [Epub ahead of print]
M3951			11/1/2002		Mood symptoms and cognitive performance in women estrogen users and nonusers and men.	Miller KJ, Conney JC, Rasgon NL, Fairbanks LA, Small GW. ;	J Am Geriatr Soc. 2002 Nov;50(11):1826-30.
M3952			7/30/2005		Treatment of menopausal symptoms: what shall we do now?;	Hickey M, Davis SR, Sturdee DW. ;	Lancet. 2005 Jul 30-Aug 5;366(9483):409-21.;
M3953			11/1/2005		Hormone replacement therapy and breast cancer risk in California.;	Coombs NJ, Taylor R, Wilcken N, Fiorica J, Boyages J. ;	Breast J. 2005 Nov-Dec;11(6):410-5. ; ;
M3954			3/3/2004		Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women.;;	Woodson K, Flood A, Green L, Tangrea JA, Hanson J, Cash B, Schatzkin A, Schoenfeld P.;	J Natl Cancer Inst. 2004 Mar 3;96(5):407-10. ; ;
M3955			2/18/1983		Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study;	Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, Tyroler HA, Rifkind BM. ;	JAMA. 1983 Feb 18;249(7):903-6. ;
M3956			2/1/1996		Hormones, mood, and cognitive functioning in postmenopausal women.;;	Sherwin BB.;	Obstet Gynecol. 1996 Feb;87(2 Suppl):20S-26S.
M3957			9/22/1997		Estrogen, cognition, and a woman's risk of Alzheimer's disease.;;	Henderson VW	Am J Med. 1997 Sep 22;103(3A):11S-18S. ;
M3958			1/9/1959		Estrogens, endometrial hyperplasia, and endometrial carcinoma.;;	GREENE RR, RODDICK JW Jr, MILLIGAN M.	Ann N Y Acad Sci. 1959 Jan 9;75:586-600.;
M3959			9/25/1981		Histopathologic distinctions in the relationship of estrogens and endometrial cancer.;;	Horwitz RI, Feinstein AR, Vidone RA, Sommers SC, Robboy SJ. ;	JAMA. 1981 Sep 25;246(13):1425-7. ;
M3960			1/1/1995		Detection of occult endometrial carcinoma.;	Koss LG	J Cell Biochem Suppl. 1995;23:165-73.;
M3961			7/1/1984		Detection of endometrial carcinoma and hyperplasia in asymptomatic women.;	Koss LG, Schreiber K, Oberlander SG, Moussouris HF, Lesser M.;	Obstet Gynecol. 1984 Jul;64(1):1-11.;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M3962			4/1/1998		Concomitant endometrial hyperplasia in patients with endometrial carcinoma.;	Gucer F, Reich O, Tamussino K, Bader AA, Pieber D, Scholl W, Haas J, Petru E. ;	Gynecol Oncol. 1998 Apr;69(1):64-8. ;
M3963			7/1/1986		Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review.;	Gambrell RD Jr, Bagnell CA, Greenblatt RB. ;	Am J Obstet Gynecol. 1983 Jul 15;146(6):696-707.;
M3964			2/15/1997		Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.;	Beresford SA, Weiss NS, Voigt LF, McKnight B.;	Lancet. 1997 Feb 15;349(9050):458-61. ;
M3965			12/1/2000		Continuous combined hormone replacement therapy and risk of endometrial cancer.;	Hill DA, Weiss NS, Beresford SA, Voigt LF, Daling JR, Stanford JL, Self S. ;	Am J Obstet Gynecol. 2000 Dec;183(6):1456-61. ;
M3966			10/1/2004		Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer.;	Reed SD, Voigt LF, Beresford SA, Hill DA, Doherty JA, Weiss NS. ;	Am J Obstet Gynecol. 2004 Oct;191(4):1146-51. ;
M3967			10/1/2005		The lady aspirin for cardiovascular disease.;	Verheugt FW, Smith SC Jr.;	Lancet. 2005 Oct 1;366(9492):1148-50. ;
M3968			2/23/2004		Prospective study of postmenopausal hormone use and newly diagnosed asthma and chronic obstructive pulmonary disease.;	Barr RG, Wentowski CC, Grodstein F, Somers SC, Stampfer MJ, Schwartz J, Speizer FE, Camargo CA Jr. ;	Arch Intern Med. 2004 Feb 23;164(4):379-86.;
M3969			2/1/2001		Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997.;	Pukkala E, Tulenheimo-Silfvast A, Leminen A.;	Cancer Causes Control. 2001 Feb;12(2):111-5. ;
M3970			9/1/2000		Tibolone actions on normal and breast cancer cells.;	Gompel A, Siromachkova M, Lombet A, Kloosterboer HJ, Rostene W. ;	Eur J Cancer. 2000 Sep;36 Suppl 4:S76-7. ;
M3971			8/18/1999		Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.;	Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. ;	JAMA. 1999 Aug 18;282(7):637-45.;
M3972			1/1/2005		An interdisciplinary analysis of the hormone replacement therapy saga.;	Ashton JR, Alvarez-Dardet C	J Epidemiol Comm health 2005;59:713
M3973			7/3/2002		Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence.;	Hu FB, Grodstein F.;	Am J Cardiol. 2002 Jul 3;90(1A):26F-29F.;
M3974			2/6/2002		Postmenopausal hormone therapy and quality of life: no cause for celebration.;	Rexrode KM, Manson JE	JAMA. 2002 Feb 6;287(5):641-2. ;
M3975			12/11/2005		Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.	Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H 3rd, Gennari C, Christiansen C, Arnaud CD, Delmas PD. ;	Arch Intern Med. 2000 Dec 11-25;160(22):3444-50. ;
M3976			6/1/1984		Hip fracture mortality. Relation to age, treatment, preoperative illness, time of surgery, and complications.	Kenzora JE, McCarthy RE, Lowell JD, Sledge CB. ;	Clin Orthop Relat Res. 1984 Jun;(186):45-56.
M3977			3/1/2005		Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures.;	Jiang HX, Majumdar SR, Dick DA, Moreau M, Raso J, Otto DD, Johnston DW.;	J Bone Miner Res. 2005 Mar;20(3):494-500. Epub 2004 Nov 29. ; ;
M3978			2/2/1990		Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group.	Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, Mascioli SR, Scott JC, Seeley DG, Steiger P, et al. ;	JAMA. 1990 Feb 2;263(5):665-8.
M3979			2/1/1994		Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis.	Riggs BL, O'Fallon WM, Lane A, Hodgson SF, Wahner HW, Muhs J, Chao E, Melton LJ 3rd.	J Bone Miner Res. 1994 Feb;9(2):265-75.
M3980			5/1/2002		Risk factors for fractures of the proximal humerus: results from the EPIDOS prospective study.;	Lee SH, Dargent-Molina P, Breat G, EPIDOS Group. Epidemiologie de l'Osteoporose Study.	J Bone Miner Res. 2002 May;17(5):817-25.
M3981			12/29/1988		Risk factors for falls among elderly persons living in the community.	Tinetti ME, Speechley M, Ginter SF. ;	N Engl J Med. 1988 Dec 29;319(26):1701-7.
M3983			12/3/2003		FURTHER ADVICE ON SAFETY OF HRT : RISK:BENEFIT UNFAVOURABLE FOR FIRST-LINE USE IN PREVENTION OF OSTEOPOROSIS.	Duff GJ (Chairman, Committe on Safety of Medicines, United Kingdom)	CEM/CMO/2003/19
M3984			1/1/1987		Factors affecting hip fracture mortality.	Sexson SB, Lehner JT. ;	J Orthop Trauma. 1987;1(4):298-305.
M3985			3/1/2001		Disturbance type and gait speed affect fall direction and impact location.	Smeesters C, Hayes WC, McMahon TA.	J Biomech. 2001 Mar;34(3):309-17.
M3986			2/1/2000		Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.	Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A.	J Clin Endocrinol Metab. 2000 Feb;85(2):720-6.
M3987			7/28/1999		Alendronate and fracture prevention.	Cummings SR, Black D, Barrett-Connor E, Scott J, Wallace RB.	JAMA. 1999 Jul 28;282(4):324-5.
M3988			12/4/1997		Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.	Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C.	N Engl J Med. 1997 Dec 4;337(23):1641-7.
M3990			2/1/1997		A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.	Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Sitt LW, Adachi JD, Taves DH, Drost D.	J Clin Endocrinol Metab. 1997 Feb;82(2):620-8.
M3991			5/10/2001		Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.;	Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. ;	N Engl J Med. 2001 May 10;344(19):1434-41. ;
M3992			12/21/1999		Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.	Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balsek A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G.	Ann Intern Med. 1999 Dec 21;131(12):935-42.

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M3993			4/1/2000		Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.	Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daiiotis A, Fuleihan GE.	J Clin Endocrinol Metab. 2000 Apr;85(4):1492-7.
M3994			6/1/2000		Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.	Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsmann AB, Kendler DL, Rosen CJ.	J Clin Endocrinol Metab. 2000 Jun;85(6):2129-34.
M3995			7/1/1992		Treatment of postmenopausal osteoporosis with transdermal estrogen.	Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL.	Ann Intern Med. 1992 Jul 1;117(1):1-9.
M3997			1/1/2006		Hormone Therapy and Coronary Heart Disease: The Role of Time since Menopause and Age at Hormone Initiation.; ;	Grodstein F, Manson JE, Stampfer MJ.	J Womens Health (Larchmt). 2006 January/February;15(1):35-44. ;
M4000			12/23/2005		Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect.	Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patrick J.	Breast Cancer Res. 2005 Dec 23;8(1):R8 [Epub ahead of print]
M4004			9/22/2005		Positive association between mammographic breast density and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study.	Crandall C, Palla S, Reboussin BA, Ursin G, Greendale GA. ;	Breast Cancer Res. 2005 Sep 22;7(6):R922-R928
M4005			1/1/2006		Gynecologists and estrogen: An affair of the heart.	Fugh-Berman A, Scialli AR	Perspectives Biol Med 2006;49(1):115-130
M4010			1/19/2006		Estrogen carcinogenesis in breast cancer.	Yager JD, Davidson NE.	N Engl J Med. 2006 Jan 19;354(3):270-82.
M4016			9/1/2003		A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk.	De Vivo I, Hankinson SE, Colditz GA, Hunter DJ.	Cancer Res. 2003 Sep 1;63(17):5236-8.
M4029			10/20/2005		Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.	Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. ;	J Clin Oncol. 2005 Oct 20;23(30):7721-35.
M4030			6/15/1980		The effects of exogenous estrogen replacement therapy of the breast: breast cancer risk and mammographic parenchymal patterns.	Bland KI, Buchanan JB, Weisberg BF, Hagan TA, Gray LA Sr.	Cancer. 1980 Jun 15;45(12):3027-33.
M4032			7/1/2001		Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention.	Boyd NF, Martin LJ, Stone J, Greenberg C, Minkin S, Yaffe MJ.	Curr Oncol Rep. 2001 Jul;3(4):314-21
M4036			9/1/2000		Effect of tamoxifen on mammographic density.	Chow CK, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski J.	Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):917-21.
M4039			6/1/2005		Menopausal hormone therapy after breast cancer.;	Colditz GA.	Breast Cancer Res. 2005;7(4):168-70. Epub 2005 Jun 1. ;
M4060			1/25/2001		Estrogen and the risk of breast cancer.	Clemons M, Goss P. ;	N Engl J Med. 2001 Jan 25;344(4):276-85.
M4061			7/1/2005		Evaluating hormone therapy-associated increases in breast density comparison between reported and simultaneous assignment of BI-RADS categories, visual assessment, and quantitative analysis.	Harvey JA, Bovbjerg VE, Smolkin ME, Williams MB, Petroni GR.	Acad Radiol. 2005 Jul;12(7):853-62.
M4063			11/1/1977		FDA acts on estrogen, progestin labeling.	[No authors listed]	FDA Consum. 1977 Nov;11(9):3.
M4064			1/3/2001		Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo.	Freedman M, San Martin J, O'Gorman J, Eckert S, Lippman ME, Lo SC, Walls EL, Zeng J.	J Natl Cancer Inst. 2001 Jan 3;93(1):51-6.
M4075			12/2/1998		Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone.	Risch HA	J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86.
M4085			2/1/1997		The Nurses' Health Study: 20-year contribution to the understanding of health among women.	Colditz GA, Manson JE, Hankinson SE. ;	J Womens Health. 1997 Feb;6(1):49-62.
M4089			6/7/1975		Editorial; Eternal Youth	No Authors Listed	Lancet 1975;7919:1282-1283
M4091			4/14/1989		Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited.	Barrett-Connor E, Wingard DL, Criqui MH. ;	JAMA. 1989 Apr 14;261(14):2095-100.
M4094			5/15/1981		Menopausal estrogen use and risk of breast cancer.	Brinton LA, Hoover RN, Szklo M, Fraumeni JF Jr.	Cancer. 1981 May 15;47(10):2517-22.
M4097			12/17/1997		DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 97D-0188] International Conference on Harmonisation; Guidance on General Considerations for Clinical Trials;	FDA:HHS	FR 62;242:66113-66119
M4099			12/1/1998		Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial.	Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, Barrett-Connor E.;	Obstet Gynecol. 1998 Dec;92(6):982-8.
M4100			1/1/1996		Chapter 57: Estrogens and Progestins	Williams CL, Stancel GM	IN: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., 1996 McGraw-Hill:1411-1440
M4104			3/1/2004		Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas.	Reed SD, Cushing-Haugen KL, Daling JR, Scholes D, Schwartz SM.	Menopause. 2004 Mar-Apr;11(2):214-22.
M4106			3/1/1982		Definition of endometrial carcinoma precursors.	Scully RE	Clin Obstet Gynecol. 1982 Mar;25(1):39-48.
M4112			11/1/2005		Mammographic breast density and the gail model for breast cancer risk prediction in a screening population.	Tice JA, Cummings SR, Ziv E, Kerlikowske K.	Breast Cancer Res Treat. 2005 Nov;94(2):115-22.
M4118			2/15/1995		Randomized trials of magnesium in acute myocardial infarction: big numbers do not tell the whole story.	Antman EM. ;	Am J Cardiol. 1995 Feb 15;75(5):391-3.
M4119			1/1/2005		Do the progesterone receptors have a role to play in gallbladder cancer?	Baskaran V, Vij U, Sahni P, Tandon RK, Nundy S. ;	Int J Gastrointest Cancer. 2005;35(1):61-8.
M4120			6/22/2000		A comparison of observational studies and randomized, controlled trials.	Benson K, Hartz AJ. ;	N Engl J Med. 2000 Jun 22;342(25):1878-86.
M4121			5/1/1995		Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age.	Black WC, Nease RF Jr, Tosteson AN. ;	J Natl Cancer Inst. 1995 May 17;87(10):720-31.
M4122			10/6/2004		Factors contributing to mamnography failure in women aged 40-49 years.	Buist DS, Porter PL, Lehman C, Taplin SH, White E. ;	J Natl Cancer Inst. 2004 Oct 6;96(19):1432-40.
M4123			10/23/1996		Large trials vs meta-analysis of smaller trials: how do their results compare?	Cappelleri JC, Ioannidis JP, Schmid CH, de Ferranti SD, Aubert M, Chalmers TC, Lau J. ;	JAMA. 1996 Oct 23-30;276(16):1332-8.
M4124			7/12/1999		Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.	Col NF, Pauker SG, Goldberg RJ, Eckman MH, Orr RK, Ross EM, Wong JB. ;	Arch Intern Med. 1999 Jul 12;159(13):1458-66.
M4125			4/1/1989		How study design affects outcomes in comparisons of therapy. I: Medical.	Colditz GA, Miller JN, Mosteller F.	Stat Med. 1989 Apr;8(4):441-54.
M4126			6/1/2000		Randomized, controlled trials, observational studies, and the hierarchy of research designs.	Concato J, Shah N, Horwitz RJ. ;	N Engl J Med. 2000 Jun 22;342(25):1887-92.
M4127			2/1/2004		The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study.	Doran MF, Crowson CS, O'Fallon WM, Gabriel SE. ;	J Rheumatol. 2004 Feb;31(2):207-13. ; ;
M4128			3/1/2004		Tailored computer-based cancer risk communication: correcting colorectal cancer risk perception.	Emmons KM, Wong M, Puleo E, Weinstein N, Fletcher R, Colditz G. ;	J Health Commun. 2004 Mar-Apr;9(2):127-41.

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M4129			1/1/1994		Postmenopausal hormone use and cholecystectomy in a large prospective study.	Grodstein F, Colditz GA, Stampfer MJ.;	Obstet Gynecol. 1994 Jan;83(1):5-11.
M4130			1/1/1991		IOM Report: Adverse effects of pertussis and rubella vaccines.	Institute of Medicine	National Academies Press, Washington DC, 1991
M4131			3/18/1995		ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.	ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.;	Lancet. 1995 Mar 18;345(8951):669-85.;
M4132			1/22/2000		Hormone replacement therapy and accuracy of mammographic screening.	Kavanagh AM, Mitchell H, Giles GG. ;	Lancet. 2000 Jan 22;355(9200):270-4.
M4133			12/1/1994		Non-contraceptive hormones and the risk of rheumatoid arthritis in menopausal women.	Koepsell TD, Dugowson CE, Nelson JL, Voigt LF, Daling JR.;	Int J Epidemiol. 1994 Dec;23(6):1248-55.
M4134			3/1/2004		Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review.	MacLennan A, Lester S, Moore V. ;	Climacteric. 2001 Mar;4(1):58-74.
M4135			10/1/2003		Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women.	Merlino LA, Cerhan JR, Criswell LA, Mikuls TR, Saag KG.;	Semin Arthritis Rheum. 2003 Oct;33(2):72-82.
M4136			1/1/2005		Validation of a decision model for preventive pharmacological strategies in postmenopausal women.	Perreault S, Levinton C, Laurier C, Moride Y, Ste-Marie LG, Crott R. ;	Eur J Epidemiol. 2005;20(1):89-101.
M4137			1/1/1980		Unrealistic optimism about future life events.	Weinstein, N	J Personality Social Psychol 1980;39:806-820
M4138			8/1/1983		Cost-effectiveness of hormone replacement therapy in the menopause.	Weinstein MC, Schiff I. ;	Obstet Gynecol Surv. 1983 Aug;38(8):445-55.
M4139			10/1/1998		Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study.	Zhang Y, McAlindon TE, Hannan MT, Chaisson CE, Klein R, Wilson PW, Felson DT. ;	Arthritis Rheum. 1998 Oct;41(10):1867-73.
M4140			1/1/2004		Colon cancer: risk perceptions and risk communication.	Weinstein ND, Atwood K, Puleo E, Fletcher R, Colditz G, Emmons KM. ;	J Health Commun. 2004 Jan-Feb;9(1):53-65.
M4141			6/1/2005		Guide to Clinical Preventative Services 2005: Recommendations of the U.S. Preventative Services Task Force	DHHS, AHRQ, USPSTF	Guide to Clinical Preventative Services 2005: Recommendations of the U.S. Preventative Services Task Force: AHRQ PUB. NO. 05-0570
M4142			1/1/1994		IOM report: Veterans and Agent orange: Health effects of herbicides used in Vietnam	Institute of Medicine	National Academies Press, Washington DC, 1994
M4143			1/1/1996		Cost-effectiveness in health and medicine.	Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, M.C.	IN: Cost-effectiveness in health and medicine, (Oxford University Press, New York, 1996).;
M4144			1/1/1987		Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42.	International Agency for Research on Cancer	IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440.
M4164			1/1/1999		Hormonal contraception and post-menopausal hormone therapy.	International Agency for Research on Cancer (IARC)	Lyon, France: IARC, 1999
M4165			1/1/1939		Relationships of hormones and mammary adenocarcinoma in the mouse.	Lacassagne A	Am J Cancer 1939;37:414-424.
M4180			1/1/2003		FDA approves new labeling and provides new advice to postmenopausal women who use or who are considering using estrogen and estrogen with progestin.	U.S. Food and Drug Administration (FDA).	FDA Fact Sheet 2003 (www.fda.gov/oc/factsheets/WHI.html < http://www.fda.gov/oc/factsheets/WHI.html >)
M4182			2/9/2006		American Cancer Cancer Reference Information: What are the risk factors for breast cancer?	American Cancer Society	www.cancer.org - Accessed 2/27/2006
M4183			1/2/2006		Observational studies and clinical trials of menopausal hormone therapy: can they both be right?;	Allison MA, Manson JE	Menopause 2006;13(1):1-3
M4184			2/8/2006		Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.	Beresford SA, Johnson KC, Ritenbaugh C, Lasser NL, Snetselaar LG, Black HR, Anderson GL, Assaf AR, Bassford T, Bowen D, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Harrigan RC, Hays J, Heber D, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Kotchen JM, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lewis CE, Manson JE, Margolis KL, Mossavar-Rahmani Y, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Stefanick ML, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Whitlock E.	JAMA. 2006 Feb 8;295(6):643-54.
M4185			3/1/2004		Management of risk of breast carcinoma in postmenopausal women.	Biglia N, Defabiani E, Ponzzone R, Mariani L, Marengo D, Sismondi P.	Endocr Relat Cancer. 2004 Mar;11(1):69-83.
M4187			5/18/2002		Epidemiology and outcomes of osteoporotic fractures.	Cummings SR, Melton L.J.	Lancet. 2002 May 18;359(9319):1761-7.
M4188			5/1/2003		Progestins and breast cancer.	Eden J	Am J Obstet Gynecol. 2003 May;188(5):1123-31.
M4191			1/1/2006		Osteoporosis: A guide to prevention and treatment	Slovic DM, ed.	2006 Harvard Health Publications, Boston MA

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M4192			2/8/2006		Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.	Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, Mysiw WJ, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf AR, Bassford T, Beresford SA, Black HR, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Granek I, Greenland P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson KC, Kotchen JM.	JAMA. 2006 Feb 8;295(6):655-66.
M4193			2/13/2006		Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative.	Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R.	Arch Intern Med. 2006 Feb 13;166(3):357-65.
M4194			3/1/2006		Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort.	Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M. ;	Int J Cancer. 2006 Mar 1;118(5):1285-91.
M4195			6/1/2001		Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable?	Lobo RA, Whitehead MI.	Climacteric. 2001 Jun;4(2):110-9.
M4196			1/1/2006		Epidemiology and the causes of breast cancer.	MacMahon B	Int J Cancer 2006;118: 2373-2378 ;
M4197			12/1/2001		Estrogen replacement therapy after breast cancer: a 12-year follow-up.	Peters GN, Fodera T, Sabol J, Jones S, Euhus D.	Ann Surg Oncol. 2001 Dec;8(10):828-32.
M4198			2/8/2006		Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.	Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller LH, Ockene JK, Margolis KL, Limacher MC, Manson JE, Parker LM, Paskett E, Phillips L, Robbins J, Rossouw JE, Sarto GE, Shikany JM, Stefanick ML, Thomson CA, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Wassertheil-Smoller S, Whitlock E, Yano K, Adams-Campbell L, Anderson GL, Assaf AR, Beresford SA, Black HR, Brunner RL, Brzyski RG, Ford L, Gass M, Hays J, Heber D, Heiss G, Hendrix SL, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Kotchen JM, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Henderson MM.	JAMA. 2006 Feb 8;295(6):629-42.
M4199			5/1/2004		New clinical markers predictive of cardiovascular disease: the role of inflammatory mediators.	Rackley CE	Cardiol Rev. 2004 May-Jun;12(3):151-7.
M4200			2/17/2006		Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study.	Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW	Breast Cancer Research 2006, 8:R11 (doi:10.1186/bcr1378);
M4203			7/1/2002		A prospective study of obesity and risk of coronary heart disease among diabetic women.	Cho E, Manson JE, Stampfer MJ, Solomon CG, Colditz GA, Speizer FE, Willett WC, Hu FB.	Diabetes Care. 2002 Jul;25(7):1142-8.
M4206			8/24/2000		Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women.	Hu FB, Stampfer MJ, Manson JE, Grodstein F, Colditz GA, Speizer FE, Willett WC. ;	N Engl J Med. 2000 Aug 24;343(8):530-7.
M4212			5/15/1996		Prior to use of estrogen replacement therapy, are users healthier than nonusers?	Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P.	Am J Epidemiol. 1996 May 15;143(10):971-8.
M4226			10/27/1962		The roles of estrogen and progesterone in breast and genital cancer.	Wilson RA	JAMA. 1962 Oct 27;182:327-31
M4234			8/15/1966		FDA Investigating Doctor who Wrote Feminine Forever	Lardner, G.	The Washington Post, Times Herald, Aug. 15, 1966;
M4236			1/1/1987		IARC Monograph: Oestrogen Replacement Therapy	International Agency for Research on Cancer	Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42:1987; Supplement 7:280;
M4237			1/1/1987		IARC Monograph: Medroxyprogesterone Acetate (Group 2B)	International Agency for Research on Cancer	Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42:1987; Supplement 7:289
M4239			1/1/2006		Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study. ; ;	Pentti K, Honkanen R, Tuppurainen MT, Sandini L, Kroger H, Saarikoski S.	Eur J Endocrinol. 2006 Jan;154(1):101-7.

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M4250			11/15/2006		Age-related lobular involution and risk of breast cancer.	Milanese T, Hartmann L, et. al.	Journal of the National Cancer Institute, Vol. 98, No. 22, November 15, 2006
M4257			10/1/1999		A Comparative Study of Estrogen Receptors a and b in the Rat Uterus.;	Wang H, Masironi B, Eriksson H, Sahlin L.;	Biol Reprod. 1999 Oct;61(4):955-64. ;
M4277			5/20/1993		Vitamin E consumption and the risk of coronary disease in women.	Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC.	NEJM 1993;328:1444-9.
M4286			3/13/2006		BI-RADS: New catagories (Web page)	American College of Radiology	www.acr.org
M4287			1/1/2003		ACR Breast Imaging Reporting and Data System (BI-RADS) Introduction	American College of Radiology	ACR Breast Imaging Reporting and Data System (BI-RADS) Introduction
M4288			2/1/2001		Effects of mammographic density and benign breast disease on breast cancer risk (United States).; ;	Byrne C, Schairer C, Brinton LA, Wolfe J, Parekh N, Salane M, Carter C, Hoover R.	Cancer Causes Control. 2001 Feb;12(2):103-10. ;
M4291			12/20/1989		Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. ; ;	Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. ;	J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86. ; ;
M4292			3/1/2001		Growth factors and stromal matrix proteins associated with mammographic densities. ; ;	Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, Khokha R, Boyd NF.;	Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):243-8.;
M4293			1/1/2000		Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable?; ;	Stiems EE, Zee B. ;	Breast Cancer Res Treat. 2000 Jan;59(2):125-32. ;
M4295			3/1/2006		Influence of Estrogen Receptor (alpha) and Progesterone Receptor Polymorphisms on the Effects of Hormone Therapy on Mammographic Density.;;	van Duijnhoven FJ, Peeters PH, Warren RM, Bingham SA, Utterlinden AG, van Noord PA, Monnikhof EM, Grobbee DE, van Gils CH. ;	Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):462-7.;
M4296			12/20/2005		An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology. ; ;	Rybaczky LA, Bashaw MJ, Pathak DR, Moody SM, Gilders RM, Holzschu DL.;	BMC Womens Health. 2005 Dec 20;5:12.;
M4300			11/1/1990		Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate.	Kordon E, Lanari C, Meiss R, Elizalde P, Charreau E, Paasqualini CD	Breast Cancer Res Treat 1990;33-43
M4306			1/1/1998		Patient noncompliance a hormone replacement therapy: a nationwide estimate using a large prescription claims data base	Faulkner DL, Young C, Hutchins D, McCollam JS	Menopause 1998;5:226-9
M4372			3/1/2001		Histological and biological evolution of human premalignant breast disease. ; ;	Alfred DC, Mohsin SK, Fuqua SA. ;	Endocr Relat Cancer. 2001 Mar;8(1):47-61. ;
M4378			6/1/1998		Tooth loss and hormone use in postmenopausal women. ; ;	Grodstein F, Colditz GA, Stampfer MJ.;	Compend Contin Educ Dent Suppl. 1998;(22):S9-16.;
M4382			5/1/1996		Tamoxifen label		PDR 1996:2482
M4384			5/1/2000		Tamoxifen label		PDR 2000:556
M4387			10/20/2005		Women's health and the FDA.;	Wood SF	N Engl J Med. 2005 Oct 20;353(16):1650-1. ;
M4388			1/1/2004		Estrogen replacement therapy and ovarian cancer.;;	Folsom AR, Anderson JP, Ross JA. ;	Epidemiology. 2004 Jan;15(1):100-4. ;
M4390			8/1/2004		Ovarian cancer risk associated with varying causes of infertility. ; ;	Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. ;	Fertil Steril. 2004 Aug;82(2):405-14.
M4391			8/1/2001		The wisdom of hormone-replacement therapy in survivors of ovarian and endometrial cancer.;	Lin K, Runowicz CD. ;	Surg Clin North Am. 2001 Aug;81(4):987-93.;
M4392			2/1/1999		Hormonal interactions in ovarian cancer.;	Emons G, Kavanagh JJ. ;	Hematol Oncol Clin North Am. 1999 Feb;13(1):145-61. ix.;
M4393			9/20/2005		Premalignant and in situ breast disease: biology and clinical implications. ; ;	Arpino G, Laucirica R, Elledge RM.	Ann Intern Med. 2005 Sep 20;143(6):446-57.;
M4394			3/1/2000		Prophylactic mastectomy: pathologic findings in high-risk patients. ; ;	Khurana KK, Loosmann A, Numann PJ, Khan SA. ;	Arch Pathol Lab Med. 2000 Mar;124(3):378-81.;
M4395			6/15/2005		The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. ; ;	Sanders ME, Schuyler PA, Dupont WD, Page DL. ;	Cancer. 2005 Jun 15;103(12):2481-4. ;
M4396			1/1/2004		Breast lesions, pathology and cancer risk.;	Page DL	Breast J. 2004 Jan-Feb;10 Suppl 1:S3-4.;
M4397			10/1/2000		Historical and epidemiologic background of human premalignant breast disease. ; ;	Page DL, Jensen RA, Simpson JF, Dupont WD. ;	J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):341-9.;
M4398			5/1/1998		Direct action of estrogen on sequence of progression of human preneoplastic breast disease. ; ;	Shekhar MP, Nangia-Makker P, Wolman SR, Tait L, Heppner GH, Visscher DW. ;	Am J Pathol. 1998 May;152(5):1129-32. ;
M4399			2/1/2005		Reduction mammaplasty specimens and occult breast carcinomas;	Kakagia D, Fragia K, Grekou A, Tsoutsos D. ;	Eur J Surg Oncol. 2005 Feb;31(1):19-21. ;
M4401			9/1/2006		Relationship between Nuclear Grade of Ductal Carcinoma in situ and Cell Origin Markers. ; ;	Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu SI.;	Ann Clin Lab Sci. 2006 Winter;36(1):16-22. ;
M4402			3/22/2006		Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. ; ;	Bouchardy C, Morabia A, Verkoijen HM, Fioretta G, Wespi Y, Schafer P. ;	BMC Cancer. 2006 Mar 22;6(1):78 [Epub ahead of print] ;
M4408			6/1/2002		Sex steroids and the construction and conservation of the adult skeleton.;	Riggs BL, Khosla S, Melton LJ 3rd. ;	Endocr Rev. 2002 Jun;23(3):279-302. ;
M4409			11/15/1984		Relative contributions of aging and estrogen deficiency to postmenopausal bone loss.	Richelson LS, Wahner HW, Melton LJ 3rd, Riggs BL.	N Engl J Med. 1984 Nov 15;311(20):1273-5. ; ;
M4410			5/1/2003		A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. ; ;	Ma J, Stafford RS, Cockburn IM, Finkelstein SN. ;	Clin Ther. 2003 May;25(5):1503-17. ;
M4411			2/1/1991		Bilateral and multifocal breast carcinoma. A clinical and autopsy study with special emphasis on carcinoma in situ. ; ;	Ringberg A, Palmer B, Linell F, Rychterova V, Ljungberg O. ;	Eur J Surg Oncol. 1991 Feb;17(1):20-9. ; ;
M4414			7/1/1993		The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. ; ;	Simon JA, Robinson DE, Andrews MC, Hildebrand JR 3rd, Rocci ML Jr, Blake RE, Hodgden GD. ;	Fertil Steril. 1993 Jul;60(1):26-33. ;
M4415			10/13/1978		Estrogen and the postmenopausal breast. Mammographic considerations.;	Peck DR, Lowman RM.;	JAMA. 1978 Oct 13;240(16):1733-5. ; ;
M4416			1/1/2006		Incidence of malignancy in hormone therapy users with indeterminate calcifications on mammogram.;	Lochner DM, Brubaker KL.	Am J Obstet Gynecol. 2006 Jan;194(1):82-5. ;
M4421			1/1/1993		Benign breast diseases, carcinoma in situ, and breast cancer risk. ; ;	Bodian CA. ;	Epidemiol Rev. 1993;15(1):177-87.;
M4423			11/20/1980		The epidemiology and etiology of breast cancer. ; ;	Miller AB, Bulbrook RD.;	N Engl J Med. 1980 Nov 20;303(21):1246-8.;
M4424			7/21/2005		Benign breast disorders.;	Santen RJ, Mansel R. ;	N Engl J Med. 2005 Jul 21;353(3):275-85.;

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M4429			4/12/2006		Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.	Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT; WHI Investigators.;	JAMA. 2006 Apr 12;295(14):1647-57.;
M4435			3/1/1989		Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.;	Poulin R, Baker D, Poirier D, Labrie F.;	Breast Cancer Res Treat. 1989 Mar;13(2):161-72. ;
M4436			5/1/1995		Androgens induce divergent proliferative responses in human breast cancer cell lines.;	Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD. ;	J Steroid Biochem Mol Biol. 1995 May;52(5):459-67. ; ;
M4441			5/4/2005		The Research on Adverse Drug Events and Reports (RADAR) project.	Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKay JM, Carson KR, Belknap SM, Trifilio SM, Schumock GT, Yarnold PR, Davidson CJ, Evens AM, Kuzel TM, Parada JP, Cournoyer D, West DP, Sartor O, Tallman MS, Raisch DW. ;	JAMA. 2005 May 4;293(17):2131-40. ;
M4442			5/3/2000		Biologic characteristics of interval and screen-detected breast cancers.;	Gilliland FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, Key CR. ;	J Natl Cancer Inst. 2000 May 3;92(9):743-9. ; ;
M4445			12/1/1987		Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies.;	Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. ;	Br J Cancer. 1987 Dec;56(6):814-9. ; ;
M4446			9/1/2003		Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.;;	Geisler J	J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):245-53. ;
M4448			7/1/2005		Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?;	Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. ;	Clin Cancer Res. 2005 Jul 1;11(13):4835-42. ; ;
M4459			11/1/2005		Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.	Sartorius CA, Harvell DM, Shen T, Horwitz KB. ;	Cancer Res. 2005 Nov 1;65(21):9779-88.
M4460			9/1/2003		Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.	Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL. ;	J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):477-86.
M4461			1/16/2006		Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas.;	Lindblad M, Garcia Rodriguez LA, Chandanos E, Lagergren J. ;	Br J Cancer. 2006 Jan 16;94(1):136-41.;
M4462			11/1/2005		Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer.	Horiguchi J, Koibuchi Y, Iijima K, Yoshida T, Takata D, Rokutanda N, Nagaoka R, Oyama T, Iino Y, Morishita Y. ;	Oncol Rep. 2005 Nov;14(5):1109-16
M4463			6/1/2006		Interactions between Body Mass Index and Hormone Therapy and Postmenopausal Breast Cancer Risk (United States).	Li CI, Malone KE, Daling JR. ;	Cancer Causes Control. 2006 Jun;17(5):695-703.
M4464			5/1/2006		Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer.	Li CI, Daling JR, Malone KE, Bernstein L, Marchbanks PA, Liff JM, Strom BL, Simon MS, Press MF, McDonald JA, Ursin G, Burkman RT, Deapen D, Spirtas R. ;	Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):946-54.
M4465			9/1/1989		Mammographic parenchymal patterns in women receiving noncontraceptive estrogen treatment.	Bergkvist L, Tabar L, Adami HO, Persson I, Bergstrom R. ;	Am J Epidemiol. 1989 Sep;130(3):503-10.
M4466			4/1/2006		The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.;;	Alexandersen P, Tanko LB, Bagger YZ, Qin G, Christiansen C. ;	Climacteric. 2006 Apr;9(2):108-18. ; ;
M4468			3/1/1992		Progestins and breast cancer: an epidemiologic review	Staffa JA, Newschaffer CJ, Jones JK, Miller V. ;	Fertil Steril. 1992 Mar;57(3):473-91. Review.
M4470			8/1/2005		Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment	IARC monograph working group	Lancet (oncology) August 2005 Vol. 16:552-553.
M4470-A			1/1/2004		IARC Monographs on the Evaluation of Carcinogenic Risks to Humans	IARC	http://monographs.iarc.fr/
M4470-B			1/1/2004		IARC Monographs on the Evaluation of Carcinogenic Risks to Humans	IARC	http://monographs.iarc.fr/
M4470-C			1/1/2004		IARC Publications Program	IARC	http://www.iarc.fr?IARCPress/index.php
M4471			1/7/2004		National use of postmenopausal hormone therapy: annual trends and response to recent evidence.;	Hersh AL, Stefanick ML, Stafford RS. ;	JAMA. 2004 Jan 7;291(1):47-53. ;
M4481A			00/00/2004		CHART: SEER Incidence White women 55-64	Hersh et al	JAMA 2004;291:47-53
M4482			1/1/2001		Sick Individuals and Sick Populations	Rose G	Int J Epidemiol 2001;30:427-432
M4483			11/25/2004		New highlights on stroma-epithelial interactions in breast cancer.;;	Barcellos-Hoff MH, Medina D.;	Breast Cancer Res. 2005;7(1):33-6.;
M4484			12/1/2004		Postmarketing surveillance--lack of vigilance, lack of trust.;;	Fontanarosa PB, Rennie D, DeAngelis CD.;	JAMA. 2004 Dec 1;292(21):2647-50.;
M4492			1/23/2006		Hormone replacement therapy, brain volumes and white matter in postmenopausal women aged 60-64 years.;;	Low LF, Anstey KJ, Maller J, Kumar R, Wen W, Lux O, Salonikas C, Naidoo D, Sachdev P. ;	Neuroreport. 2006 Jan 23;17(1):101-4. ;
M4494			4/1/2006		Prempro 2006 PDR	Physicians Desk Reference	
M4501			6/1/2006		FDA drug prescribing warnings: is the black box half empty or half full?;	Wagner AK, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Lafata JE, Davis RL, Gunwitz JH, Soumerai SB, Platt R. ;	Pharmacoepidemiol Drug Saf. 2006 Jun;15(6):369-86. ;
M4507			7/1/2006		Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003.;;	Hing E, Brett KM.;	Obstet Gynecol. 2006 Jul;108(1):33-40.;
M4508			1/22/2002		Use of postmenopausal estrogen replacement therapy from 1981 to 1997.;;	Csizmadi I, Benedetti A, Boivin JF, Hanley JA, Collet JP. ;	CMAJ. 2002 Jan 22;166(2):187-8.;
M4509			12/15/1997		Personal use of postmenopausal hormone replacement therapy by women physicians in the United States.;	McNaghy SE, Wenger NK, Frank E. ;	Ann Intern Med. 1997 Dec 15;127(12):1093-6. ;
M4510			7/1/2002		The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988-1994.;;	Friedman-Koss D, Crespo CJ, Bellantoni MF, Andersen RE. ;	Menopause. 2002 Jul-Aug;9(4):264-72.
M4511			11/1/1999		Ethnic differences in hormone replacement prescribing patterns.;;	Brown AF, Perez-Stable EJ, Whitaker EE, Posner SF, Alexander M, Gaihe J, Washington AE. ;	J Gen Intern Med. 1999 Nov;14(11):663-9. ;
M4514			8/1/2006		Reducing the problems of the progestogen.;;	Sturdee DW, MacLennan AH. ;	Ann Intern Med. 2006 Jun 9;144(12):924-3. ;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M4517			9/1/2006		Progesterone metabolites in breast cancer.;	Wiebe JP	Endocr Relat Cancer. 2006 Sep;13(3):717-38. ;
M4518			8/1/2006		Expression of Syndecan-1 in histologically normal breast tissue from postmenopausal women with breast cancer according to mammographic density.;	Lundstrom E, Sahlin L, Skoog L, Hagerstrom T, Svane G, Azavedo E, Sandelin K, von Schoultz B.;	Climacteric. 2006 Aug;9(4):277-82. ;
M4519			9/1/2006		Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study.;	Samsioe G, Boschitsch E, De Geyter C, Ehrenberg A	Climacteric 2006;9:368-379
M4523			1/1/2003		Off-Label or Out of Bounds? Prescriber and Marketer Liability for Unapproved Uses of FDA-Approved Drugs	O'Reilly J, Dalal A	Ann Health Law 2003;12:295-324
M4529			8/1/2006		Chapter 24: Exogenous Hormones	Lacey JV, Colditz GA, Schottenfeld D	In: Cancer Epidemiology and Prevention, 3rd; Schottenfeld and Fraumeni eds., Oxford University Press 2006
M4532			12/1/2004		Quantitative assessment of percent breast density: analog versus digital acquisition.	Harvey JA	Technol Cancer Res Treat. 2004 Dec;3(6):611-6.
M4533			9/1/2006		Exogenous steroids for menopausal symptoms and breast/endometrial cancer risk. ;	Mourits MJ, DE Bock GH.;	Int J Gynecol Cancer. 2006 Sep-Oct;16 Suppl 2:494-6. ;
M4537			1/1/2001		Carcinogenicity of estrogens in human breast epithelial cells. ;	Russo J, Hu YF, Tahin Q, Mihaila D, Slater C, Lareef MH, Russo IH. ;	APMIS. 2001 Jan;109(1):39-52. ;
M4539			9/1/1992		A primer of drug safety surveillance: an industry perspective. Part II: Product labeling and product knowledge. ;	Allan MC	J Pharm Technol. 1992 Sep-Oct;8(5):198-202. ;
M4541			3/15/1977		Exogenous estrogen and endometrial carcinoma: case-control and incidence study.	McDonald TW, Annegers JF, O'Fallon WM, Dockerty MB, Malkasian GD Jr, Kurland LT. ;	Am J Obstet Gynecol. 1977 Mar 15;127(6):572-80.
M4542			11/1/2005		Polymorphisms in the estrogen receptor alpha gene and mammographic density.	van Duijnhoven FJ, Bezemer ID, Peeters PH, Roest M, Uitterlinden AG, Grobbee DE, van Gils CH.	Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2655-60.
M4546			11/28/1980		Predominance of early endometrial cancers after long-term estrogen use.	Hulka BS, Kaufman DG, Fowler WC Jr, Grimson RC, Greenberg BG.	JAMA. 1980 Nov 28;244(21):2419-22.
M4556			9/26/2006		The Future of Drug Safety: Promoting and Protecting the Health of the Public - Prepublication Copy: Uncorrected Proofs ;	Committee on the Assessment of the US Drug Safety System; Board on Population Health and Public Health Practice; Alina Baciuc, Kathleen Stratton, Sheila P. Burke, Editors;	ISBN: 0-309-66600-7, 350 pages, 6 x 9, (2006) http://www.nap.edu/catalog/11750.html ;
M4568			5/1/2006		Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer.	Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G, Yaffe MJ, Minkin S.	Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):961-6.
M4571			10/13/2006		Contributions of estrogen to ER-negative breast tumor growth.	Gupta PB, Kuperwasser C.;	J Steroid Biochem Mol Biol. 2006 Oct 13; [Epub ahead of print]
M4572			10/1/1986		Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancers.	McTiernan A, Thomas DB, Johnson LK, Roseman D.	J Natl Cancer Inst. 1986 Oct;77(4):849-54.
M4577			10/25/2006		Progesterone, progestins, pregnancy and breast cancer risk.	Ferretti G	Breast Cancer Res Treat. 2006 Oct 25; [Epub ahead of print]
M4579			10/25/2006		Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women.	Reinier KS, Vacek PM, Geller BM.	Breast Cancer Res Treat. 2006 Oct 25; [Epub ahead of print]
M4579			11/15/2006		Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study.	Cantwell MM, Lacey JV Jr, Schairer C, Schatzkin A, Michaud DS. ;	Int J Cancer. 2006 Nov 15;119(10):2398-401.
M4580			11/1/2006		Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.	Reeves GK, Beral V, Green J, Gathani T, Bull D; for the Million Women Study Collaborators.	Lancet Oncol. 2006 Nov 7;7(11):910-8.
M4581			5/1/2003		Catechol estrogen 4-hydroxyequilenin is a substrate and an inhibitor of catechol-O-methyltransferase.	Yao J, Li Y, Chang M, Wu H, Yang X, Goodman JE, Liu X, Liu H, Mesecar AD, Van Breemen RB, Yager JD, Bolton JL. ;	Chem Res Toxicol. 2003 May;16(5):668-75.
M4582			7/1/2002		Inhibition of cellular enzymes by equine catechol estrogens in human breast cancer cells: specificity for glutathione S-transferase P1-1.	Yao J, Chang M, Li Y, Pisha E, Liu X, Yao D, Elguindi EC, Blond SY, Bolton JL.;	Chem Res Toxicol. 2002 Jul;15(7):935-42.
M4583			6/4/2004		Equine estrogen metabolite 4-hydroxyequilenin induces anchorage-independent growth of human mammary epithelial MCF-10A cells: differential gene expression.	Cuendet M, Liu X, Pisha E, Li Y, Yao J, Yu L, Bolton JL.;	Mutat Res. 2004 Jun 4;550(1-2):109-21.
M4584			1/1/2006		Metabolite ligands of estrogen receptor-beta reduce primate coronary hyperreactivity.	Mishra RG, Stanczyk FZ, Burry KA, Oparil S, Katzenellenbogen BS, Nealen ML, Katzenellenbogen JA, Hermsmeyer RK.;	Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H295-303. Epub 2005 Sep 30
M4585			7/10/2006		Response of human mammary epithelial cells to DNA damage induced by 4-hydroxyequilenin: Lack of p53-mediated G1 arrest.	Cuendet M, Bolton JL.;	Chem Biol Interact. 2006 Jul 10;161(3):271-8. Epub 2006 Apr 28.
M4586			11/20/2006		Recent declines in HT utilization and breast cancer incidence.	Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ.;	J Clin Oncol. 2006 Nov 20;24(33):e49-50.
M4587			12/1/2006		Risk factors for hormone receptor-defined breast cancer in postmenopausal women.	Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P, Magnusson C.;	Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2482-8.
M4588			4/26/2006		Re: "combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women's health initiative clinical trial".	Willett WC, Manson JE, Grodstein F, Stampfer MJ, Colditz GA.	Am J Epidemiol. 2006 Jun 1;163(11):1067-8; author reply 1068-9. Epub 2006 Apr 26. No abstract available.
M4589			12/14/2006		A sharp decrease in breast cancer incidence in the United States in 2003.	Ravdin PM, Cronin KA, Howlander N, Chlebowski RT, Berry DA	San Antonio Breast Cancer Symposium Abstract #5, 12/14/2006 General Session
M4590			9/1/2006		Sex-steroid regulation of vascular endothelial growth factor in breast cancer.	Hyder SM	Endocr Relat Cancer. 2006 Sep;13(3):667-87.
M4592			12/1/2006		Environmental tobacco smoke exposure and risk of breast cancer in nonsmoking women: a review with meta-analyses.	Lee PN, Hamling J. ;	Inhal Toxicol. 2006 Dec;18(14):1053-70. Review.
M4595			1/1/2005		Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays.	Sonneveld E, Jansen HJ, Riteco JA, Brouwer A, van der Burg B. ;	Toxicol Sci. 2005 Jan;83(1):136-48. Epub 2004 Oct 13.
M4596			9/1/2003		Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds.	Ouatat T, Halverson D, Steeg PS.	Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3763-72.
M4598			11/1/2002		Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. ;	Lindenfeld EA, Langer RD.	Obstet Gynecol. 2002 Nov;100(5 Pt 1):853-63. ;
M4599			1/1/2005		Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. ;	Sumino H, Ichikawa S, Sawada Y, Sakamoto H, Kumakura H, Takayama Y, Sakamaki T, Kurabayashi M. ;	Thromb Res. 2005;115(5):359-66. ;
M4600			12/10/2003		Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women.;	Yilmazer M, Fenkci V, Fenkci S, Sonmezer M, Aktepe O, Altindis M, Kurtay G. ; ;	Maturitas. 2003 Dec 10;46(4):245-53. ; ;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M4601			4/2/2003		The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer.;	Lillie EO, Bernstein L, Ursin G.;	Breast Cancer Res. 2003;5(3):164-73. ;
M4602			2/14/2005		Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women.;	Gambacciani M, Ciapponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, Vacca F, Genazzani AR. ;	Maturitas. 2005 Feb 14;50(2):91-7. ;
M4603			12/12/2006		Hormone effects on fMRI and cognitive measures of encoding: importance of hormone preparation.;	Gleason CE, Schmitz TW, Hess T, Koscik RL, Trivedi MA, Ries ML, Carlsson CM, Sager MA, Asthana S, Johnson SC. ;	Neurology. 2006 Dec 12;67(11):2039-41.;
M4604			9/1/1988		Adrenal androgens and human breast cancer: a new appraisal.;	Adams JB. ;	Breast Cancer Res Treat. 1998 Sep;51(2):183-8. Review. ;
M4606			5/1/2000		Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey.;	Wang DY, Allen DS, De Stavola BL, Fentiman IS, Brussen J, Bulbrook RD, Thomas BS, Hayward JL, Reed MJ. ;	Br J Cancer. 2000 May;82(9):1577-84. ; ;
M4610			1/1/1998		Role of the androgen receptor in human breast cancer.;	Birrell SN, Hall RE, Tilley WD. ;	J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):95-103. Review. ;
M4611			3/1/2001		Safety of estrogen/androgen regimens.;	Simon JA ;	J Reprod Med. 2001 Mar;46(3 Suppl):281-90. ;
M4612			6/1/2003		Androgens in women.	Davison SL, Davis SR. ;	J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):363-6. ;
M4613			1/1/1996		Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids.;	Hackenberg R, Schulz KD. ;	J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):113-7. ;
M4614			12/27/2006		Androgens and androgen receptors: A clinically neglected sector in breast cancer biology.;	Moe RE, Anderson BO. ;	J Surg Oncol. 2006 Dec 27; [Epub ahead of print] ;
M4615			2/17/1978		Human breast cancer: androgen action mediated by estrogen receptor.;	Zava DT, McGuire WL. ;	Science. 1978 Feb 17;199(4330):787-8. ;
M4617			8/15/2006		Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor-Positive, HER-2/neu-Positive Breast Cancer.	Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. ;	Cancer Res. 2006 Aug 15;66(16):8266-73. ;
M4618			10/1/2000		Biphasic effect of medroxyprogesterone-acetate (MPA) treatment on proliferation and cyclin D1 gene transcription in T47D breast cancer cells.;	Thuncke I, Schulte HM, Bamberger AM. ;	Breast Cancer Res Treat. 2000 Oct;63(3):243-8. ; ;
M4619			8/1/1995		Effect of medroxyprogesterone acetate (MPA) and serum factors on cell proliferation in primary cultures of an MPA-induced mammary adenocarcinoma.;	Dran G, Luthy IA, Molinolo AA, Montecchia F, Charreau EH, Pasqualini CD, Lanari C. ;	Breast Cancer Res Treat. 1995 Aug;35(2):173-86. ;
M4620			6/1/2005		Progesterone receptor testing: not the right time to be buried.	Colozza M, Larsimont D, Piccart MJ. ;	J Clin Oncol. 2005 Jun 1;23(16):3867-8; author reply 3869-70. ;
M4621			8/1/1991		Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women.	Moorjani S, Dupont A, Labrie F, De Lignieres B, Cusan L, Dupont P, Mailloux J, Lupien PJ. ;	J Clin Endocrinol Metab. 1991 Aug;73(2):373-9. ;
M4622			7/1/1995		Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.	Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD. ;	J Clin Oncol. 1995 Jul;13(7):1572-7. ;
M4623			4/1/1993		Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells.;	Classen S, Possinger K, Pelka-Fleischer R, Wilmanns W. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8499339&query_hl=6&itool=pubmed_docsum>;	J Steroid Biochem Mol Biol. 1993 Apr;45(4):315-9. ;
M4624			8/20/1999		Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.;	Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD. ;	Mol Cell Endocrinol. 1999 Aug 20;154(1-2):11-20. ; ;
M4625			10/1/2000		In vitro characterization of trimegestone: a new potent and selective progestin.;	Zhang Z, Lundeen SG, Zhu Y, Carver JM, Winneker RC. ;	Steroids. 2000 Oct-Nov;65(10-11):637-43. ;
M4626			9/1/2006		Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones.;	Liang Y, Brekken RA, Hyder SM. ;	Endocr Relat Cancer. 2006 Sep;13(3):905-19. ;
M4627			10/1/1985		[Utrogestan]	Csech J, Gervais C. ;	Soins Gynecol Obstet Pueric Pediatr. 1985 Feb;(45):1-11. French. ;
M4628			4/1/1990		Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells.	Labrie F, Poulin R, Simard J, Zhao HF, Labrie C, Dauvois S, Dumont M, Hattori AC, Poirier D, Merand Y. ;	Ann N Y Acad Sci. 1990;595:130-48. ;
M4629			8/1/1970		Proceedings: Oestrogen and androgen receptors in human breast cancer.	Engelsman E, Korsten CB, Persijn JP, Cleton FJ. ;	Br J Cancer. 1974 Aug;30(2):177. ;
M4630			12/1/1976		The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.	Lippman M, Bolan G, Huff K. ;	Cancer Res. 1976 Dec;36(12):4610-8. ;
M4631			7/1/1980		Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer.	Teulings FA, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J. ;	Cancer Res. 1980 Jul;40(7):2557-61. ;
M4632			12/15/1989		Improved measurement of androgen receptors in human breast cancer.;	Lea OA, Kvinnslund S, Thorsen T. ;	Cancer Res. 1989 Dec 15;49(24 Pt 1):7162-7. ;
M4634			12/14/2006		[1052] Change in mammographic density after cessation of tamoxifen: results from international breast cancer intervention study I (IBIS I).;	Gao JN, Forbes JF, Warren RML, Cuzick J, Howell A, D'Este C, Warren-Forward H. ;	Presentation - San Antonio Breast Cancer Symposium 2006
M4635			12/14/2006		[6048] Hormone replacement therapy, and not mammography screening, causes shift in age-specific incidence of breast cancer.	Verkoijen HM, Fioretta G, van der Heiden M, Koot VCM, Rapiti E, Vlastos G, Peeters PHM, Bouchardy C. ;	Presentation - San Antonio Breast Cancer Symposium 2006
M4636			12/14/2006		[6049] Invasive lobular breast cancer trends in populations with high versus low use of hormone replacement therapy.;	Verkoijen HM, Fioretta G, Koot VCM, van der Heiden M, Schipper MEI, Rapiti E, Peterse JL, Bouchardy C, Peeters PHM. ;	Presentation - San Antonio Breast Cancer Symposium 2006
M4637			12/13/2006		[5041] Risk factors for luminal, HER2, and basal-like breast cancer sub-types: results from a tissue microarray-based analysis of 3167 breast cancers from women enrolled in the nurses health study.;	Collins LC, Schnitt SJ, Colditz GA, Deitz AC, Baer HJ, Chen WY, Connolly JL, Rubin MA, Fu Y, Rosner B, Tamimi RM. ;	Presentation - San Antonio Breast Cancer Symposium 2006
M4639			1/16/1995		The androgenicity of progestins.;	Darney PD. ;	Am J Med. 1995 Jan 16;98(1A):104S-110S. ;
M4640			9/1/2000		Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis.	Heald A, Selby PL, White A, Gibson JM. ;	Am J Obstet Gynecol. 2000 Sep;183(3):593-600. ;
M4641			8/15/2003		Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.;	Moifar F, Okcu M, Tsybrowsky O, Reglinig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H. ;	Cancer. 2003 Aug 15;98(4):703-11. ; ;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M4643			9/22/1998		Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women.	Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, Ganz P, Creager MA. ;	Circulation. 1998 Sep 22;98(12):1158-63.
M4645			1/1/1987		The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss.	Riis BJ, Thomsen K, Strom V, Christiansen C.	Am J Obstet Gynecol. 1987 Jan;156(1):61-5.
M4654			3/1/2006		DRUG SAFETY Improvement Needed in FDA's Postmarket Decision-making and Oversight Process	United States Government Accountability Office	GAO-06-402 March 2006
M4655			1/11/2007		Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women.	Grady D, Vittinghoff E, Lin F, Hanes V, Ensrud K, Habel LA, Wallace R, Macer J, Cummings SR, Shepherd J. ;	Menopause. 2007 Jan 11; [Epub ahead of print]
M4657			1/18/2007		Mammographic Density and the Risk and Detection of Breast Cancer.	Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Histop G, Chiarelli A, Minkin S, Yaffe MJ.	N Engl J Med. 2007 Jan 18;356(3):227-236.
M4664			3/1/1988		Benefits and risks of menopausal estrogen and/or progestin hormone use.	Ernster VL, Bush TL, Huggins GR, Hulka BS, Kelsey JL, Schottenfeld D.	Prev Med. 1988 Mar;17(2):201-23. Review.
M4667			4/21/2006		Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer.	Schippinger W, Reglinig P, Dandachi N, Wennecke KD, Bauernhofer T, Samonigg H, Moirfar F. ;	Virchows Arch. 2006 Jul;449(1):24-30. Epub 2006 Apr 21.
M4672			1/1/1999		[Results of an observation study with Estrogel and Utrogestan in patients with climacteric symptoms.];	Hartl W, Wilfert HC, Heinz R	Journal für Menopause 1999; 6 (4) (Ausgabe für Deutschland) 19-24;
M4673					Cigarette smoking and Risk of Breast Carcinoma In Situ	Trentham-Dietz	Epidemiology, Vol. 18, No 5 (2007)
M4680			3/4/2002		Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women.;	Clavel-Chapelon F; E3N-EPIC Group. ;	Br J Cancer. 2002 Mar 4;86(5):723-7.
M4681			1/1/2006		A Comprehensive Review of the Safety and Efficacy of Bioidentical Hormones for the Management of Menopause and Related Health Risks.;	Moskowitz D	Alternative Medicine Review 2006;11(3):208-223
M4682			9/1/1982		[Utrogestan]	Csech J, Gervais C. ;	Soins Gynecol Obstet Pueric Pediatr. 1982 Sep;(16):45-6. French.
M4687			9/13/1979		Estrogen Use and Postmenopausal Women: National Institutes of Health Consensus Development Conference Statement, September 13-14, 1979; ;	Not Listed	Estrogen Use and Postmenopausal Women. NIH Consens Statement Online 1979 Sep 13-14 [cited year month day];2(8):45-48.;
M4689			11/1/2004		Comment on "Bioidentical hormone therapy: a review". (and author reply)	Moskowitz D.	Menopause. 2004 Nov-Dec;11(6 Pt 1):639; author reply 639-41.
M4691			2/15/2007		Different types of postmenopausal hormone therapy and mammographic density in Norwegian women.	Bremnes Y, Ursin G, Bjurstam N, Lund E, Gram IT. ;	Int J Cancer. 2007 Feb 15;120(4):880-4.
M4701			1/25/2007		NSAID trials and the choice of comparators--questions of public health importance.	Psaty BM, Weiss NS. ;	N Engl J Med. 2007 Jan 25;356(4):328-30.
M4702			1/12/2006		Reform of drug regulation--beyond an independent drug-safety board.	Ray WA, Stein CM. ;	N Engl J Med. 2006 Jan 12;354(2):194-201.
M4706			3/1/1998		Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response.	Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Tittley JC, Dowsett M.	Breast Cancer Res Treat. 1998 Mar;48(1):11-20.
M4711					Hot Flushes, Menstrual Status, and Hormone Levels in a Population-Based Sample of Midlife Women	Guthrie	Obstetrics & Gynecology, Vol. 88, No. 3 (1996)
M4713					The Relationship of Longitudinal Change in Reproductive Hormones and Vasomotor Symptoms during the Menopausal Transition	Randolph	J. of Clin. Endocrin & Metabolism, Vol. 90(11): 6106-6112 (2005)
M4716			9/1/2002		Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities.;	United States General Accounting Office;	GAO-02-958;
M4717			6/21/2005		National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms.	National Institutes of Health. ;	Ann Intern Med. 2005 Jun 21;142(12 Pt 1):1003-13. Epub 2005 May 27.
M4719			4/1/1995		Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo.	Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignieres B.	Fertil Steril. 1995 Apr;63(4):785-91.
M4720			3/3/2007		Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk;	Shantakumar S, Terry MB, Paykin A, Teitelbaum SL, Britton JA, Moorman PG, Kritchevsky SB, Neugut AI, Gammon MD	American J Epidemiol; Advance ePub 3/3/2007 DOI: 10.1093/aje/kwm006 ;
M4721			2/20/2007		Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.	Canonica M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group. ;	Circulation. 2007 Feb 20;115(7):840-5.
M4722			2/27/2007		Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.	Fournier A, Berrino F, Clavel-Chapelon F. ;	Breast Cancer Res Treat. 2007 Feb 27; [Epub ahead of print]
M4723			3/1/2007		Breast cancer trends.	Weiss NS. (Tarone);	Epidemiology. 2007 Mar;18(2):284; author reply 284-5. No abstract available.
M4725			3/8/2007		Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy.;	Tannen RL, Weiner MG, Xie D, Barnhart K	Human reproduction 3/8/2007 Advance Access doi:10.1093/humrep/dem031;
M4727			1/1/2007		The Biology of Cancer Chapters 11.14 and 11.15	Weinberg, RA	2007 Taylor and Francis
M4728			1/1/2003		Ch. 53, "Endometrial Cancer," p. 1027	Cook, L et al.	in Cancer Epidemiology and Prevention, 3d Ed., Schottenfeld and Fraumeni, Eds. (Oxford Univ. Press 2003)
M4729			5/15/2007		Breast tumours following combined hormone replacement therapy express favourable prognostic factors.	Borgquist S, Anagnostaki L, Jimstrom K, Landberg G, Majer J	Int J Cancer 120(10):2202-7
M4730			4/1/2003		Progesterone receptors in mammary gland development and tumorigenesis.	Conneely OM, Jericevic BM, Lydon JP	J Mammary Glad Biol Neoplasia; 8(2):205-14.
M4734			1/1/2006		The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.	Ma Y, Katiyar P, Jones LP, Fan S, Zhang Y, Furth PA, Rosen EM	Mol Endocrinol 20(1):14-34.
M4736			4/4/2007		Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause	Rossouw JE, Prentice RL, Manson JE, Wu L P, Barad d, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML.	JAMA 297(13):1465-77
M4737			2/1/2007		Relation of body mass and sex steroid hormone levels to hot flushes in a sample of mid-life women.	Schilling C, Gallicchio L, Miller SR, Langenberg P, Zacur H, Flaws JA	Climacteric 2007 Feb;10(1):27-37
M4738			3/26/2007		[Hormone replacement therapy in postmenopausal women: all the treatments are not the same.] TRANSLATION ATTACHED	Ribot C, Tremollieres F	Gynecol Obstet Fertil 2007 Mar 26; [Epub ahead of print]
M4739			4/1/2003		Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. ;Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status.	Randolph, Sowers et al.	J Clin Endocrinol Metab 2003 Apr;88(4):1516-22
M4740			4/5/2007		Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer.	Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD	FASEB J 2007 Apr 5; Epub ahead of print
M4741			4/1/2007		Breast response to menopausal hormone therapy--aspects on proliferation, apoptosis and mammographic density.;;	Conner, P	Proc R Soc Med. 1973 Feb;66(2):183-5.
M4742			1/1/1972		The climacteric.	Zussman, L	

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M4743			4/18/2007		The Decrease in Breast Cancer Incidence in 2003 in the United States	Ravdin PM, Cronin KA, Howlander N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA	N England J Med 356;16:1670-1674
M4744			9/1/2002		Effects of progestogens on the postmenopausal breast.	de Lignieres B. ;	Climacteric. 2002 Sep;5(3):229-35.
M4745			11/14/2006		Type and duration of exogenous hormone use affects breast cancer histology.	Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES. ;	Ann Surg Oncol. 2007 Feb;14(2):695-703. Epub 2006 Nov 14.
M4746			3/13/2007		Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations.	Verkoijen HM, Koot VC, Fioretta G, van der Heiden M, Schipper ME, Rapiti E, Peeters PH, Peterse JL, Bouchardy C. ;	Breast Cancer Res Treat. 2007 Mar 13; [Epub ahead of print]
M4747			2/1/2007		IMS reaction to recent breast cancer data.	Pines A, Sturdee DW, Birkhauser M, The International Menopause Society. ;	Climacteric. 2007 Feb;10(1):9-10. No abstract available.
M4748			2/1/2007		Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review.	Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. ;	Climacteric. 2007 Feb;10(1):23-6. Review.
M4749			4/17/2007		Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study.	Sellers TA, Jensen LE, Vierkant RA, Fredericksen ZS, Brandt KR, Giuliano AR, Pankratz VS, Cerhan JR, Vachon CM.	Cancer Causes Control. 2007 Apr 17; [Epub ahead of print]
M4750			4/19/2007		Ovarian cancer and hormone replacement therapy in the Million Women Study.	Beral V, Million Women Study Collaborators	Published Online April 19, 2007; DOI:10.1016/S0140-6736(07)60534-0;
M4751			9/8/2005		FDA Standards — Good Enough for Government Work?	Avorn J	N Engl J Med 2005; 353:969-972
M4752			3/17/2005		What ails the FDA?	Okie S	N Engl J Med 2005; 352:1063-1066
M4753			3/1/2006		Drug Safety: Improvement needed in FDA's postmarket decision-making and oversight process.	US Government Accountability Office	GAO-06-402
M4754			4/24/2007		Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy.	Katalinic A, Rawal R.	Breast Cancer Res Treat. 2007 Apr 24; [Epub ahead of print]
M4755			1/1/2005		Carcinogenesis	Malarkey DE, Maronpot RR	David E. Malarkey & Robert R. Maronpot, Carcinogenesis in Encyclopedia of Toxicology 445-466 (Philip Wexler, et al. eds., Elsevier 2nd ed. 2005)
M4757			11/10/2006		High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol.	Blumenfeld, Z, Boulman, N., Leiba, R., Siegler, E., Shachar, S., Linn, R. and Levy, Y.	Scandinavian Journal of Clinical and Laboratory Investigation, 67:3, 257-263
M4758			11/11/2006		Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease.	Yeboah, J., Reboussin, D.M., Waters, D., Kowalchuk, G., Herrington, D.	Am Heart J. Mar 2007 153 (3): 439-444
M4759			3/21/2001		Treatment of Postmenopausal Osteoporosis.	Altkorn, D., Vokes, T.	JAMA. Mar 21, 2001 285 (11); 1415-1418 In Reply: JAMA. Jun 13, 2001. 285 (22): 2858
M4760			6/21/2007		Estrogen Therapy and Coronary-Artery Calcification.	Manson J. E., Allison, M.A., Rossouw, J.E., Carr, J.J., Langer, R.D., Hsia, J., Kuller, L.H., Cochrane, B.B., Hunt, J.R., Ludlam, S.E., Pettinger, M.B., Gass M., Margolis, K.L., Nathan, L., Ockene, J.K., Prentice, R.L., Robbins, J., Stefanick, M.L.	New England Jour of Med. Jun 21, 2007 356 (25): 2591-2602
M4761			12/00/1997		Low-Dose Esterified Estrogen Therapy Effects on bone, Plasma Estradiol Concentrations, Endometrium, and Lipid Levels.	Genant H.K., Lucas J., Weiss, S., Akin, M., Emkey, R., McNaney-Flint H., Downs R., Mortola J., Watts N., Yang H.M., Banav N., Brennan, J.J., Nolan J.C.	Arch Intern Med. 1997; 157:2609-2615
M4762			00/00/1980		The Influence of High Doses of Oral Medroxyprogesterone Acetate on glucose Tolerance, Serum Insulin Levels and Adrenal Response to ACTH.	Leis, D., Bottermann P., Ermier, R., Henderkott, U., Gluck H.	Arch Gynecol 230, 9-13 (1980)
M4763			00/00/1996		Cushing's syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate.	Malik, K.J., Wakelin, K., Dean, S., Cove, D.H. Wood, P.J.	Ann Clin Biochem 1996; 33: 187-189
M4764			6/13/2001		Hormone Replacement Therapy and Prevention of Nonvertebral Fractures A Meta-analysis of Randomized Trials	Torgerson, D.J., Bell-Syer, S.E.M.	JAMA. 2001; 285: 2891-2897
M4765			12/17/1984		FDA board investigates Depo-Provera safety.		Contracept Technol Update. 1938, Mar, 4(3): 25-7.
M4767					Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study	Zahl	
M4770			6/25/2007		Regional Changes in Hormone Therapy Use and Breast Cancer Incidence in California From 2001 to 2004.	Robbins AS, Clarke CA.	J Clin Oncol. 2007 Jun 25; [Epub ahead of print]
M4771			7/6/2007		Declines in breast cancer after the WHI: apparent impact of hormone therapy.	Clarke CA, Glaser SL	Cancer Causes Control. 2007 Jul 6; [Epub ahead of print]
M4772			7/2/2007		Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.	Vickers et al.	BMJ. Jul 2007; doi:10.1136/bmj.39266.425069.AD
M4773			4/1/1980		Growth hormone, prolactin, and cortisol in dogs developing mammary nodules and an acromegaly-like appearance during treatment with medroxyprogesterone acetate.	Concannon P, Altszuler N, Hampshire J, Butler WR, Hansel W.	Endocrinology. 1980 Apr;106(4):1173-7.
M4774			7/24/2007		Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status.	Glass AG, Lacey JV Jr, Carreon JD, Hoover RN.	J Natl Cancer Inst. 2007 Jul 24; [Epub ahead of print]
M4775			7/24/2007		Breast Cancer Trends: A Marriage Between Clinical Trial Evidence and Epidemiology.	Berry DA, Ravdin PM	J Natl Cancer Inst. 2007 Jul 24; [Epub ahead of print] No abstract available.
M4780			7/1/2007		Effects of estradiol with oral or intravaginal progesterone on risk markers for breast cancer in a postmenopausal monkey model	Wood CE, Sitruk-Ware RL, Tsong YY, Register TC, Lees CJ, Cline JM	Menopause. 2007 Jul-Aug;14(4):639-47
M4788			11/1/2003		Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations	Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ	Am. J. Clin. Pathol. 2003 Nov;120(5):725-31
M4791			4/1/2002		Androgens and mammary growth and neoplasia	Dimitrakakis C, Zhou J, Bondy CA	Fertil. Steril. 2002 Apr;77 Suppl 4:S26-33
M4796			2/1/2004		Therapeutic targeting in the estrogen receptor hormonal pathway	Katzenellenbogen BS, Frasor J	Semin. Oncol. 2004 Feb;31(1 Suppl 3):28-38
M4820			7/1/2007		Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer	Chen WY, Colditz GA	Nat Clin Pract Oncol. 2007 Jul;4(7):415-23
M4850			3/1/2003		Current concepts of tumour metastasis	Barbour A, Gotley DC	Ann Acad Med Singapore. 2003 Mar;32(2):176-84
M4852			00/00/2007		Hot Flashes, Hormones & Your health	Manson J, Bassuk S	McGraw Hill 2007 ISBN 0-07-146862-5

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M4855			00/00/1991		Chapter 9: Deciding whether your treatment has done harm.	Sackett DL et al.	IN: Clinical Epidemiology: A Basic Science for Clinical Medicine, 2nd Ed., Little Brown 1991
M4856			1/1/2006		Chapter 51: Breast Cancer	Colditz GA, Baer HJ, Tamimi RM	IN: Cancer Epidemiology and Prevention, 3rd Edition, Schottenfeld and Fraumani, eds., Oxford University Press 2006: 995-1012
M4868			1/1/2009		The Decline in Breast Cancer Incidence; Real or Imaginary?	Kurian AW, Clarke CA, Carlson RW	Current Oncology Reports 2009 Jan;11(1):21-8.
M4870			12/13/2008		Breast cancer after stopping estrogen plus progestin in postmenopausal women in the women's health initiative - Poster abstract and slides;	Chlebowski RT, Kuller L, Anderson G, Mason JA, Schenken R, Rajkovic A, Stefanick M, Sarto G, Ravdin P, Prentice R;	San Antonio Breast Cancer Symposium 2008
M4871			11/10/2008		Expression of the androgen receptor and syndecan-1 in breast tissue during different hormonal treatments in cynomolgus monkeys.;	Hofling M, Ma L, Sahlin L, Haglund C, Nordling S, von Schultz B, Cline JM	Climacteric 2008, Early online; URL: http://dx.doi.org/10.1080/13697130802448387;
M4873			2/24/2009		Moderate alcohol intake and cancer incidence in women. ;	Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, Green J, Million Women Study Collaborators. ;	J Natl Cancer Inst. 2009 Mar 4;101(5):296-305. Epub 2009 Feb 24. ;
M4875			3/20/2008		Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy. ;	Bitzer J, Kenemans P, Mueck AO, FSDeducation Group. ;	Maturitas. 2008 Mar 20;59(3):209-18. Epub 2008 Mar 14. ;
M4879			03/00/2009		Review of an article: Canonico M, Plu-Bureau G, Lowe G, Scarabin P. (2008). Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. British Medical Journal 10(336):1227-1231. ;	Nunnelee JD. ;	J Vasc Nurs. 2009 Mar;27(1):17. ;
M4881			2/5/2009		Breast cancer after use of estrogen plus progestin in postmenopausal women. ;	Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G; WHI Investigators. ;	N Engl J Med. 2009 Feb 5;360(6):573-87. ;
M4885			4/17/2008		Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status. ;	Dai J, Jian J, Bosland M, Frenkel K, Bernhardt G, Huang X. ;	Breast. 2008 Apr;17(2):172-9. Epub 2007 Oct 24. ;
M4888			1/23/2009		Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis;	Dören M.;	Eur Heart J. 2009 Jan 23. [Epub ahead of print];
M4889			2/18/2009		Re: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. ;	Eisinger F, Huiart L. ;	J Natl Cancer Inst. 2009 Feb 18;101(4):277; author reply 277-8. Epub 2009 Feb 10. ;
M4893			1/21/2009		Hormone replacement therapy to maintain cognitive function in women with dementia. ;	Hogervorst E, Yaffe K, Richards M, Huppert FA. ;	Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003799. ;
M4894			2/11/2009		Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? ;	Parkin DM. ;	Eur J Cancer. 2009 Feb 11. [Epub ahead of print] ;
M4901			07/00/2008		Extracellular matrix, Rac1 signaling, and estrogen-induced proliferation in MCF-7 breast cancer cells. ;	Xie JW, Haslam SZ. ;	Breast Cancer Res Treat. 2008 Jul;110(2):257-68. Epub 2007 Sep 13. ;
M4902			00/00/2009		The use of tamoxifen and raloxifene for the prevention of breast cancer.;	Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N. ;	Recent Results Cancer Res. 2009;181:113-9. ;
M4903			3/00/2009		The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. ;	Sener SF, Winchester DJ, Winchester DP, Du H, Barrera E, Bilimoria M, Krantz S, Rabbitt S. ;	Am J Surg. 2009 Mar;197(3):403-7. ;
M4905			01/00/2009		The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? ;	Holtorf K. ;	Postgrad Med. 2009 Jan;121(1):73-85. ;
M4906			2/11/2009		Alcohol Intake and Cigarette Smoking and Risk of a Contralateral Breast Cancer: The Women's Environmental Cancer and Radiation Epidemiology Study. ;	Knight JA, Bernstein L, Largent J, Capanu M, Begg CB, Mellemkjaer L, Lynch CF, Malone KE, Reiner AS, Liang X, Haile RW, Boice JD Jr; WECARE Study Collaborative Group, Bernstein JL. ;	Am J Epidemiol. 2009 Feb 11. [Epub ahead of print] ;
M4913			1/12/2009		Influence of estrogen plus testosterone supplementation on breast cancer. ;	Ness RB, Albano JD, McTiernan A, Cauley JA. ;	Arch Intern Med. 2009 Jan 12;169(1):41-6. ;
M4914			3/1/2008		Interactions between intakes of alcohol and postmenopausal hormones on risk of breast Interactions between intakes of alcohol and postmenopausal hormones on risk of breast cancer.	Nielsen NR, Grønbaek M.	Int J Cancer. 2008 Mar 1;122(5):1109-13.
M4915			00/00/1989		Importance of estrogen sulfates in breast cancer. ;	Pasqualini JR, Gelly C, Nguyen BL, Vella C. ;	J Steroid Biochem. 1989;34(1-6):155-63. ;
M4916			1/27/2009		Progestins in the menopause in healthy women and breast cancer patients;	Pasqualini JR. ;	Maturitas. 2009 Jan 27. [Epub ahead of print] ;
M4919			2/10/2009		Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. ;	Reeves GK, Pirie K, Green J, Bull D, Beral V; Million Women Study Collaborators. ;	Br J Cancer. 2009 Feb 10;100(3):538-44. ;
M4922			01/00/2008		Estrogen and progesterone are critical regulators of Stat5a expression in the mouse mammary gland. ;	Santos SJ, Haslam SZ, Conrad SE. ;	Endocrinology. 2008 Jan;149(1):329-38. Epub 2007 Sep 20. ;
M4930			3/17/2009		Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. ;	Lacey JV Jr, Kreimer AR, Buys SS, Marcus PM, Chang SC, Leitzmann MF, Hoover RN, Prorok PC, Berg CD, Harige P, Plooc Cancer Screening Trial Project Team PL. ;	BMC Cancer. 2009 Mar 17;9(1):84. [Epub ahead of print];
M4932			1/29/2009		Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? ;	Haskell SG, Bean-Mayberry B, Gordon K. ;	Menopause. 2009 Jan 29. [Epub ahead of print] ;
M4933			1/1/2009		Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk? ;	Becker S, Kaaks R. ;	Recent Results Cancer Res. 2009;181:135-57. Review. ;
M4934			3/23/2009		Hormone Replacement Therapy and Cardiovascular Health in the United States.;	Shetty KD, Vogt WB, Bhattacharya J. ;	Med Care. 2009 Mar 23. [Epub ahead of print];
M4935			9/4/2008		HRT and breast cancer: recent findings in the context of the evidence to date.;	Banks E, Canfell K, Reeves G. ;	Womens Health (Lond Engl). 2008 Sep;4(5):427-31. Review. ;
M4937			2/24/2009		Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. ;	Vankrunkelsven P, Kellen E, Lousbergh D, Cloes E, Op de Beeck L, Faes C, Bruckers L, Mertens R, Coebergh JW, Van Leeuwen FE, Buntinx F. ;	Breast Cancer Res Treat. 2009 Feb 24. [Epub ahead of print] ;
M4944			2/16/2009		Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. ;	Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. ;	Menopause. 2009 Jan-Feb;16(1):30-6. ;
M4945			2/15/2008		The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. ;	Gupta P, Ozel B, Stanczyk FZ, Felix JC, Mishell DR Jr. ;	Menopause. 2008 Jan-Feb;15(1):94-7. ;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M4948			02/00/2009		Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. ;	Lin HY, Sun M, Lin C, Tang HY, London D, Shih A, Davis FB, Davis PJ. ;	J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):182-8. Epub 2008 Dec 30. ;
M4959			2/15/2009		A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. ;	Jordan VC. ;	Cancer Res. 2009 Feb 15;69(4):1243-54. Epub 2009 Feb 10. ;
M4961			5/1/2007		Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. ; ;	Aupperlee MD, Haslam SZ. ;	Endocrinology. 2007 May;148(5):2290-300. Epub 2007 Feb 22. ;
M4966			7/1/2008		Increases in serum estrone sulfate level are associated with increased mammographic density during menopausal hormone therapy. ;	Crandall CJ, Guan M, Laughlin GA, Ursin GA, Stanczyk FZ, Ingles SA, Barrett-Connor E, Greendale GA. ;	Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1674-81. ;
M4973			05/00/2008		Progesterone-regulated luminal cell and myoepithelial cell-specific responses in mammary organoid culture. ;	Haslam SZ, Drolet A, Smith K, Tan M, Aupperlee M. ;	Endocrinology. 2008 May;149(5):2098-107. Epub 2008 Jan 24. ;
M4977			1/1/2009		Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. ;	Jick SS, Hagberg KW, Kaye JA, Jick H. ;	Obstet Gynecol. 2009 Jan;113(1):74-80. ;
M4978			3/26/2009		THE DIFFERENCES IN NEUROPROTECTIVE EFFICACY OF PROGESTERONE AND MEDROXYPROGESTERONE ACETATE CORRELATE WITH THEIR EFFECTS ON BDNF EXPRESSION. ;	Jodhka PK, Kaur P, Underwood W, Lydon JP, Singh M. ;	Endocrinology. 2009 Mar 26. [Epub ahead of print]
M4991			4/1/2006		Androgens and menopause: more fuel for the fire. ;	Shulman LP. ;	Menopause. 2006 Mar-Apr;13(2):168-70. ;
M4992			4/1/2009		Menopausal hormone therapy and risk of clinical breast cancer subtypes. ;	Slanger TE, Chang-Claude JC, Olt N, Kropp S, Berger J, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Flesch-Janys D. ;	Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1188-96. Epub 2009 Mar 31. ;
M5011			3/1/2009		Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype.;	Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C. ;	Cancer. 2009 Mar 1;115(5):936-45;
M5012			2/10/2009		RE: "ESTROGEN PLUS PROGESTIN THERAPY AND BREAST CANCER IN RECENTLY POSTMENOPAUSAL WOMEN" - FIVE AUTHORS REPLY;	Prentice RL, Chlebowski RT et al.	Am. J. Epidemiol. 2009 169: 785-786;
M5013			5/15/2009		Hormone Replacement Therapy, Family History, and Breast Cancer Risk Among Postmenopausal Women.;	Gramling R, Eaton CB, Rothman KJ, Cabral H, Silliman RA, Lash TL. ;	Epidemiology. 2009 May 15. [Epub ahead of print] PubMed PMID: 19451819;
M5014			4/1/2009		Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006.;	Séradour B, Allemand H, Weill A, Ricordeau P. ;	Bull Cancer. 2009 Apr 1;96(4):E1-E6. PubMed PMID: 19435691;
M5015			5/19/2009		The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004.	Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. ;	Cancer Epidemiol Biomarkers Prev. 2009 May 19. [Epub ahead of print] PubMed PMID: 19454615
M5016			5/28/2009		Breast Cancer and Hormone Therapy in Postmenopausal Women. Letter and Authors reply. (Includes supplemental E3N Data sheet)	Fournier A, Boutran-Ruault M, Clavel-Chapelon F, Prentice R, Chlebowski RT	N Engl J Med 2009;360(22):2366
M5017			11/1/2008		Sustained lower rates of breast cancer in the United States.	Cronin KA, Ravdin PM, Edwards BK. ;	Breast Cancer Res Treat. 2008 Nov 1. [Epub ahead of print]
M5018			11/00/2007		Parenteral versus oral treatment of postmenopausal women with estrogen.;	Stanczyk FZ. ;	Menopause. 2007 Nov-Dec;14(6):985-94. ;
M5019			01/00/2009		Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.;	Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. ;	Menopause. 2009 Jan-Feb;16(1):30-6. ;
M5020			5/25/2009		Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause;	Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE. ;	Am J Epidemiol. 2009 May 25. ;
M5021			2/26/2009		Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy;	Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. ;	Menopause. 2009 Feb 26. ;
M5022			12/00/2007		Gynecologic and hormonal effects of raloxifene in premenopausal women.;	Premkumar A, Venzon DJ, Avila N, Johnson DV, Remaley AT, Forman MR, Eng-Wong J, Zujewski J, Stratton P. ;	Fertil Steril. 2007 Dec;88(6):1637-44. Epub 2007 Jul 26. ;
M5023			3/18/2009		Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk;	Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K. ;	J Natl Cancer Inst. 2009 Mar 18;101(6):384-98. ;
M5024			03/00/2009		Hormone replacement therapy: real concerns and false alarms.;	Bluming AZ, Tavis C. ;	Cancer J. 2009 Mar-Apr;15(2):93-104;
M5025			5/25/2009		Invited Commentary: Hormone Therapy Risks and Benefits--The Women's Health Initiative Findings and the Postmenopausal Estrogen Timing Hypothesis.;	Banks E, Canfell K. ;	Am J Epidemiol. 2009 May 25. ;
M5026			04/00/2009		The effects of hormones on urinary incontinence in postmenopausal women.;	Quinn SD, Donomey C. ;	Climacteric. 2009 Apr;12(2):106-13;
M5027			3/18/2009		Menopausal hot flashes after breast cancer.;	Fenlon DR, Corner JL, Haviland J. ;	Eur J Cancer Care (Engl). 2009 Mar;18(2):140-8;
M5028			03/00/2009		Women's trust in and use of information sources in the treatment of menopausal symptoms.;	Huston SA, Jackowski RM, Kirking DM. ;	Womens Health Issues. 2009 Mar-Apr;19(2):144-53. ;
M5029			02/00/2009		Expression of the androgen receptor and syndecan-1 in breast tissue during different hormonal treatments in cynomolgus monkeys;	Hoffling M, Ma L, Sahlin L, Haglund C, Nordling S, von Schoutz B, Cline JM. ;	Climacteric. 2009 Feb;12(1):72-9. ;
M5030			01/00/2009		Membrane androgen receptor activation in prostate and breast tumor cells: molecular signaling and clinical impact.;	Papadopoulou N, Papakonstanti EA, Kallergi G, Alevizopoulos K, Stournaras C. ;	IUBMB Life. 2009 Jan;m
M5031			01/00/2009		The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.;	Brodie A, Njar V, Macedo LF, Vasailis TS, Sabnis G. ;	Urol Oncol. 2009 Jan-Feb;27(1):53-63;
M5032			04/00/2009		Continuing decline in hormone therapy use: population trends over 17 years.;	MacLennan AH, Gill TK, Broadbent JL, Taylor AW. ;	Climacteric. 2009 Apr;12(2):122-30. ;
M5033			3/25/2009		Autoimmune progesterone dermatitis diagnosed by intravaginal progesterone provocation in a hysterectomised woman.;	Nemeth H, Kovacs E, Godeny S, Simics E, Pfliegler G. ;	Gynecol Endocrinol. 2009 Mar 25:1-3. ;
M5034			12/00/2008		Progestagen-only treatment before menopause: increased risk of breast cancer.;	No authors listed]. ;	Prescrire Int. 2008 Dec;17(98):243. ;
M5035			06/00/2009		Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. ;	Studd J. ;	Climacteric. 2009 Jun;12(3):206-9. ;
M5036			03/00/1999		Micronized progesterone: a new therapeutic option. ;	Langer RD. ;	Int J Fertil Womens Med. 1999 Mar-Apr;44(2):67-73. ;
M5037			5/22/2009		Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. ;	Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ. ;	Breast Cancer Res. 2009 May 22;11(3):R31. [Epub ahead of print];
M5038			00/00/1999		Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. ; ;	Plu-Bureau G, Lè MG, Thalabard JC, Struk-Ware R, Mauvais-Jarvis P. ;	Cancer Detect Prev. 1999;23(4):290-6. ; ;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M5039			12/00/1995		Micronized progesterone: vaginal and oral uses. ;	Simon JA. ;	Clin Obstet Gynecol. 1995 Dec;38(4):902-14. ;
M5040			4/10/1981		Even oral progesterone may be effective. ;	González ER. ;	JAMA. 1981 Apr 10;245(14):1394. ;
M5041			04/00/1998		Topical progesterone cream application and overdosing. ;	Ilyia EF, McLure D, Farhat MY. ;	J Altern Complement Med. 1998 Spring;4(1):5-6. ;
M5042			05/00/2009		DMPA's effect on bone mineral density: A particular concern for adolescents. ;	Schrager SB. ;	J Fam Pract. 2009 May;58(5):E1-8. ;
M5043			4/25/1998		Use of Pro-Gest cream in postmenopausal women. ;	MacFarland SA. ;	Lancet. 1998 Sep 12;352(9131):905; author reply 906. ;
M5044			6/26/2009		Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. ;	Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. ;	Menopause. 2009 Mar 26. [Epub ahead of print] ;
M5045			09/00/2002		Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study.;	Cicinelli E, de Ziegler D, Galantino P, Pinto V, Barba B, Morgese S, Schonauer S. ;	Am J Obstet Gynecol. 2002 Sep;187(3):556-60. ;
M5046			04/00/2009		Up-regulation of nuclear receptor corepressor (NCoR) in progesterin-induced growth suppression of endometrial hyperplasia and carcinoma. ;	Kashima H, Horiuchi A, Uchikawa J, Miyamoto T, Suzuki A, Ashida T, Konishi I, Shiozawa T. ;	Anticancer Res. 2009 Apr;29(4):1023-9. ;
M5047			04/00/2009		Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy.;	Moe BT, Vereide AB, Orbo A, Jaeger R, Sager G. ;	Anticancer Res. 2009 Apr;29(4):1047-52. ;
M5048			5/4/2009		Estrogen and Progesterone Receptor Expression is not Always Specific for Mammary and Gynecologic Carcinomas: A Tissue Microarray and Pooled Literature Review Study.;	Wei S, Said-Al-Naief N, Hameed O. ;	Appl Immunohistochem Mol Morphol. 2009 May 4. [Epub ahead of print] ;
M5049			06/00/2009		Understanding the functions of BRCA1 in the DNA-damage response. ;	Yun MH, Hiom K. ;	Biochem Soc Trans. 2009 Jun;37(Pt 3):597-604. ;
M5050			5/11/2009		MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.;	Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. ;	Breast Cancer Res. 2009 May 11;11(3):R27. [Epub ahead of print] ;
M5051			5/13/2009		Green tea consumption and breast cancer risk or recurrence: a meta-analysis.;	Ogunleye AA, Xue F, Michels KB. ;	Breast Cancer Res Treat. 2009 May 13. [Epub ahead of print] ;
M5052			05/00/2009		Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.;	Gaudet MM, Milne RL, Cox A, Camp NJ, Goode EL, Humphreys MK, Dunning AM, Morrison J, Giles GG, Severi G, Baglietto L, English DR, Couch FJ, Olson JE, Wang X, Chang-Claude J, Flesch-Janys D, Abbas S, Salazar R, Mannermaa A, Kataja V, Kosma VM, Lindblom A, Margolin S, Heikkinen T, Kämpjärvi K, Aaltonen K, Nevanlinna H, Bogdanova N, Coinac I, Schürmann P, Dörk T, Bartram CR, Schmutzler RK, Tchatchou S, Burwinkel B, Brauch H, Torres D, Hamann U, Justenhoven C, Ribas G, Arias JI, Benitez J, Bojesen SE, Nordestgaard BG, Flyger HL, Peto J, Fletcher O, Johnson N, Dos Santos Silva I, Fasching PA, Beckmann MW, Strick R, Ekici AB, Broeks A, Schmidt MK, van Leeuwen FE, Van't Veer LJ, Southey MC, Hopper JL, Apicella C, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Kristensen V, Grenaker Alnaes G, Hunter DJ, Kraft P, Cox DG, Hankinson SE, Seynaeve C, Vermeulen J, et al. ;	Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1610-6. ;
M5053			5/11/2009		Cannabinoids in the treatment of cancer.;	Alexander A, Smith PF, Rosengren RJ. ;	Cancer Lett. 2009 May 11. [Epub ahead of print] ;
M5054			00/00/2009		Adrenoceptors: non conventional target for breast cancer? ;	Lüthy IA, Bruzzone A, Piñero CP, Castillo LF, Chiesa IJ, Vázquez SM, Sarappa MG. ;	Curr Med Chem. 2009;16(15):1850-62. ;
M5055			5/7/2009		PROGESTERONE RECEPTOR A (PRA) AND PRB -INDEPENDENT EFFECTS OF PROGESTERONE ON GNRH RELEASE.;	Sleiter N, Pang Y, Park C, Horton TH, Dong J, Thomas P, Levine JE. ;	Endocrinology. 2009 May 7. [Epub ahead of print] ;
M5056			00/00/2009		Differentiated expression of estrogen receptors (ER) and progesterone receptors (PgR) in ductal breast cancers.;	Wojnar A, Drozd K, Podhorska-Oko?ów M, Pude?ko M, Szuba A, Zabel M, Dziegiel P. ;	Folia Histochem Cytobiol. 2009;47(1):55-60. ;
M5057			12/00/1999		By the way, doctor. I'm interested in having vertebroplasty, the treatment for vertebral fractures mentioned in your august issue. When I called Medicare to see if the procedure is covered, I was told "Only if the FDA has approved it." but when I checked with the FDA, I found that no one had applied for approval. Why is this? Is there some way to get vertebroplasty?;	Robb-Nicholson C. ;	Harv Womens Health Watch. 1999 Dec;7(4):8. ;
M5058			02/00/1996		Morphometric, immunohistological and three-dimensional evaluation of the endometrium of menopausal women treated by oestrogen and Crinone, a new slow-release vaginal progesterone.;	Casanas-Roux F, Nisolle M, Marbaix E, Smets M, Bassif S, Donnez J. ;	Hum Reprod. 1996 Feb;11(2):357-63. ;
M5059			06/00/2000		Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens.;	de Ziegler D, Ferriani R, Moraes LA, Bulletti C. ;	Hum Reprod. 2000 Jun;15 Suppl 1:149-58. ;
M5060			03/00/1999		Uses of progesterone in clinical practice.;	Warren MP, Shantha S. ;	Int J Fertil Womens Med. 1999 Mar-Apr;44(2):96-103. ;
M5061			04/00/2009		Postmenopausal hormone therapy and the risk of cardiovascular disease. ;	Stramba-Badiale M. ;	J Cardiovasc Med (Hagerstown). 2009 Apr;10(4):303-9. ;
M5062			5/5/2009		Progesterone Activates a Progesterone Receptor Membrane Component 1-dependent Mechanism That Promotes Human Granulosa/Luteal Cell Survival But Not Progesterone Secretion.;	Peluso JJ, Liu X, Gawkowska A, Johnston-Macananny E. ;	J Clin Endocrinol Metab. 2009 May 5. [Epub ahead of print] ;
M5063			09/00/2008		Reprint of Are all estrogens the same? ;	Bennink HJ. ;	Maturitas. 2008 Sep-Oct;61(1-2):195-201. ;
M5064			09/00/2008		Classification and pharmacology of progestins. ;	Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. ;	Maturitas. 2008 Sep-Oct;61(1-2):171-80. ;
M5065			09/00/2009		Pharmacological profile of progestins. ;	Sitruk-Ware R. ;	Maturitas. 2008 Sep-Oct;61(1-2):151-7. ;
M5066			09/00/2008		The normal menopause transition. ;	McKinlay SM, Brambilla DJ, Posner JG. ;	Maturitas. 2008 Sep-Oct;61(1-2):4-16. ;
M5067			09/00/2008		Breast cancer: hormones and other risk factors;	Hulka BS, Moorman PG. ;	Maturitas. 2008 Sep-Oct;61(1-2):203-13; discussion 213. ;
M5068			5/22/2009		'Cure' from breast cancer among two populations of women followed for 23 years after diagnosis. ;	Woods LM, Rachet B, Lambert PC, Coleman MP. ;	Ann Oncol. 2009 May 22. [Epub ahead of print] ;
M5069			5/25/2009		Possible role of mammography in increased incidence of breast cancer not considered.;	Hanigan MH. ;	Arch Intern Med. 2009 May 25;169(10):998-9. ;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M5070			5/25/2009		Spontaneous regression of breast cancer. ;	Richards C. ;	Arch Intern Med. 2009 May 25;169(10):996. ;
M5072			5/25/2009		Spontaneous regression of invasive breast cancer: does this study answer the question? ;	Kalager M, Bretthauer M. ;	Arch Intern Med. 2009 May 25;169(10):997. ;
M5073			5/25/2009		Breast cancer overdiagnosis with screening mammography. ;	Jatoi I, Anderson WF. ;	Arch Intern Med. 2009 May 25;169(10):999-1000, author reply 1000-1. ;
M5074			5/25/2009		Unaccounted breast cancers do not infer regression of tumors. ;	Chu DZ. ;	Arch Intern Med. 2009 May 25;169(10):999. ;
M5075			03/00/2009		Epidemiological and molecular mechanisms aspects linking obesity and cancer. ;	Osório-Costa F, Rocha GZ, Dias MM, Carvalho JB. ;	Arq Bras Endocrinol Metabol. 2009 Mar;53(2):213-26. ;
M5076			05/00/2008		Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. ;	Eilertsen AL, Karssmeijer N, Skaane P, Qvigstad E, Sandset PM. ;	BJOG. 2008 May;115(6):773-9. Epub 2008 Mar 19. ;
M5077			11/00/1963		THE HORMONE-DEPENDENT CANCERS. ;	HUGGINS CB. ;	Bull N Y Acad Med. 1963 Nov;39:752-7. ;
M5078			04/00/2009		Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. ;	Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C. ;	Cochrane Database Syst Rev. 2009 Apr 15;(2):CD000402. ;
M5079			10/8/2008		Oestrogens and progestins for preventing and treating postpartum depression. ;	Dennis CL, Ross LE, Herxheimer A. ;	Cochrane Database Syst Rev. 2008 Oct 8(4):CD001690. ;
M5080			5/20/2009		Long-term meat intake and risk of breast cancer by oestrogen and progesterone receptor status in a cohort of Swedish women. ;	Larsson SC, Bergkvist L, Wolk A. ;	Eur J Cancer. 2009 May 20. [Epub ahead of print] ;
M5081			10/16/2008		Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization. ;	Hampton RM, Fisher AC, Pagano S, Laguardia KD. ;	Fertil Steril. 2008 Oct 16. [Epub ahead of print] ;
M5082			4/7/2009		Effects of either Tibolone or Continuous Combined Transdermal Estradiol with Medroxyprogesterone Acetate on Coagulatory Factors and Lipoprotein(a) in Menopause. ;	Perrone G, Capri O, Galoppi P, Brunelli R, Bevilacqua E, Ceci F, Ciarla MV, Strom R. ;	Gynecol Obstet Invest. 2009 Apr 7;68(1):33-39. [Epub ahead of print] ;
M5083			06/00/2008		The effects of estrogen therapy and estrogen combined with different androgenic progestins on carbohydrate and lipid metabolism in overweight-obese younger postmenopausal women. ;	Demir B, Ozturkoglu E, Solaroglu A, Baskan B, Kandemir O, Karabulut E, Haberal A. ;	Gynecol Endocrinol. 2008 Jun;24(6):347-53. ;
M5084			09/00/2008		Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. ;	Phillips TJ, Symons J, Menon S, HT Study Group. ;	J Am Acad Dermatol. 2008 Sep;59(3):397-404.e3. Epub 2008 Jul 14. ;
M5085			5/20/2008		Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow. ;	Fernandes CE, Pompei LM, Machado RB, Ferreira JA, Melo NR, Peixoto S. ;	Maturitas. 2008 Mar 20;59(3):249-58. Epub 2008 Mar 21. ;
M5086			4/20/2009		Progesterone and medroxyprogesterone acetate differentially regulate alpha4 subunit expression of GABA(A) receptors in the CA1 hippocampus of female rats. ;	Pazol K, Northcutt KV, Patisaul HB, Wallen K, Wilson ME. ;	Physiol Behav. 2009 Apr 20;97(1):58-61. Epub 2009 Feb 7. ;
M5087			08/00/2008		A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. ;	Tierney MC, Oh P, Moineddin R, Greenblatt EM, Snow WG, Fisher RH, Iazzetta J, Hyslop PS, MacLusky NJ. ;	Psychoneuroendocrinology. 2009 Aug;34(7):1065-74. Epub 2009 Mar 17. ;
M5088			00/00/2008		A comparison of hormone therapies on the urinary excretion of prostacyclin and thromboxane A2. ;	Bruce D, Frick A, Rymer J, Robinson J, Ylikorkala O. ;	Climacteric. 2008;11(6):447-53. ;
M5089			5/2/2009		Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish women. ;	Fournier A, Weiderpass E. ;	Climacteric. 2009 May 2:1-15. [Epub ahead of print] ;
M5090			04/00/2009		Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. ;	Al-Baghdadi O, Ewies AA. ;	Climacteric. 2009 Apr;12(2):91-105. ;
M5091			05/00/2009		Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. ;	Germano S, O'Driscoll L. ;	Curr Cancer Drug Targets. 2009 May;9(3):398-418. ;
M5092			05/00/2009		Targeting tumors using estrogen receptor ligand conjugates. ;	Keely NO, Meegan MJ. ;	Curr Cancer Drug Targets. 2009 May;9(3):370-80. ;
M5093			04/00/1959		On hormone-dependent cancers. ;	HUGGINS CB. ;	J R Coll Surg Edinb. 1959 Apr;4(3):191-8. ;
M5094			02/00/1996		Department of Obstetrics and Gynaecology, University College Hospital, Galway, Ireland. ;	Bolaji II, Mortimer G, Grimes H, Tallon DF, O'Dwyer E, Fottrell PF. ;	Gynecol Endocrinol. 1996 Feb;10(1):41-7. ;
M5095			06/00/2006		Hormone replacement therapy and cardiovascular disease revisited; ;	Stevenson JC. ;	Menopause Int. 2009 Jun;15(2):55-7. ;
M5096			06/00/2009		More reports link falling breast cancer rates to change in use of hormone replacement therapy. ;	Brown S. ;	Menopause Int. 2009 Jun;15(2):48-51. ;
M5097			05/00/2009		HER-2 signaling and inhibition in breast cancer; ;	Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. ;	Curr Cancer Drug Targets. 2009 May;9(3):419-38. ;
M5098			6/1/2009		Postmenopausal Hormone Treatment ;	Hulley S, Grady D	JAMA. 2009;301(23):2493-2495. ;
M5102			1/1/2007		Weinberg, The Biology of Cancer, Chapter 6.11 ;	Weinberg, RA	Weinberg The Biology of Cancer 2007, Page 190-192
M5103			6/26/2009		Recent trends in breast cancer incidence in US white women by urban/rural and poverty status. ;	Hausauer AK, Keegan TH, Chang ET, Glaser SL, Howe H, Clarke CA. ;	BMC Med. 2009 Jun 26;7(1):31. [Epub ahead of print] ;
M5104			2/4/2009		AFP: Hormone therapy doubles breast cancer risk: study ;		"Hormone therapy doubles breast cancer risk: study"; AFP Feb 4, 2009
M5105			00/00/2009		Drop in Breast Cancer Rates Due to Drop in HRT Use - healthfinder.gov ;	Kathleen Doheny	"Drop in breast cancer rates due to drop in HRT use"; HealthDay, Feb 4, 2009
M5106			00/00/2009		Study: Hormone therapy caused breast cancer for thousands - CNN.com ;	Anne Harding	"Study: Hormone therapy caused breast cancer for thousands"; CNN Health, Feb 4, 2009
M5107			00/00/2009		Breast cancer risk falls after hormones halted ;	Kyung Song	Breast cancer risk falls after hormones halted; The Seattle Times, Feb 4, 2009
M5108			2/4/2009		Breast cancer risk drops one year after end of hormone therapy"; Bloomberg News, Feb 4, 2009 ;	Elizabeth Lopatto	Breast cancer risk drops one year after end of hormone therapy"; Bloomberg News, Feb 4, 2009
M5109			2/4/2009		Study finds a greater link between hormone replacement therapy, breast cancer. ;	Krieger, Lisa M.	The Mercury News. Feb 4, 2009 www.mercurynews.com/science/ci_11627351
M5110			2/4/2009		"Halting Hormone Therapy reduces breast cancer risk quickly"; Time Magazine Feb 4, 2009 ;	Alice Park	"Halting Hormone Therapy reduces breast cancer risk quickly"; Time Magazine Feb 4, 2009
M5113			9/24/2009		Signaling inputs to progesterone receptor gene regulation and promoter selectivity. ;	Daniel AR, Knutson TP, Lange CA. ;	Mol Cell Endocrinol. 2009 Sep 24;308(1-2):47-52. Epub 2009 Jan 20. ;
M5115			8/17/2001		Biological effects of hormone replacement therapy in relation to serum estradiol levels. ;	Yasui T, Uemura H, Tezuka M, Yamada M, Irahara M, Miura M, Aono T. ;	Horm Res. 2001;56(1-2):38-44. ;
M5116			6/2/2009		Short-term hormone therapy suspension and mammography recall: a randomized trial. ;	Buist DS, Anderson ML, Reed SD, Aiello Bowles EJ, Fitzgibbons ED, Gandara JC, Seger D, Newton KM. ;	Ann Intern Med. 2009 Jun 2;150(11):752-65. ;
M5117			10/9/2008		The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. ;	Horwitz KB. ;	Mol Endocrinol. 2008 Dec;22(12):2743-50. Epub 2008 Oct 9. ;
M5120			5/22/2002		The psychological effect of mastectomy with or without breast reconstruction: a prospective, multicenter study. ;	Harcourt DM, Rumsey NJ, Ambler NR, Cawthorn SJ, Reid CD, Maddox PR, Kenealy JM, Rainsbury RM, Umpleby HC. ;	Plast Reconstr Surg. 2003 Mar;111(3):1060-8. ;

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M5123			7/18/1999		Psychological adjustment in breast cancer: processes of emotional distress. ;	Epping-Jordan JE, Compas BE, Osowiecki DM, Oppedisano G, Gerhardt C, Primo K, Krag DN. ;	Health Psychol. 1999 Jul;18(4):315-26. ;
M5124			2/12/2009		Decreasing hormonal promotion is key to breast cancer prevention.;	Rajkumar L, Canada A, Esparza D, Collins K, Moreno E, Duong H. ;	Endocrine. 2009 Apr;35(2):220-6. Epub 2009 Feb 12. ;
M5128			3/16/2009		The benefits of oestrogen following menopause: why hormone replacement therapy should be offered to postmenopausal women.	Wren BG. ;	Med J Aust. 2009 Mar 16;190(6):321-5. ;
M5129			3/14/2009		Use of menopausal hormones in the United States, 1992 through June, 2003. ;	Wysowski DK, Governale LA.;	Pharmacoepidemiol Drug Saf. 2005 Mar;14(3):171-6. ; ;
M5130			5/15/2009		Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms. ;	Lin MC, Burkholder KA, Viswanathan AN, Neuberg D, Mutter GL. ;	Cancer. 2009 May 15;115(10):2111-8. ;
M5131			7/15/2009		Hormone therapy and ovarian cancer.;	March LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O.	JAMA. 2009 Jul 15;302(3):298-305
M5132			4/19/2009		Progesterone receptor A-regulated gene expression in mammary organoid cultures. ;	Santos SJ, Aupperlee MD, Xie J, Durairaj S, Mikisek R, Conrad SE, Leiprandt JR, Tan YS, Schwartz RC, Haslam SZ. ;	J Steroid Biochem Mol Biol. 2009 Jul;115(3-5):161-72. Epub 2009 Apr 19. ;
M5133			1/1/1986		Childhood and recent eating patterns and risk of breast cancer. ;	Hislop TG, Coldman AJ, Elwood JM, Brauer G, Kan L. ;	Cancer Detect Prev. 1986;9(1-2):47-58.;
M5134			8/1/1989		Breast cancer and breastfeeding: results from an Australian case-control study. ;	Siskind V, Schofield F, Rice D, Bain C.;	Am J Epidemiol. 1989 Aug;130(2):229-36. ;
M5135			11/15/1992		Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. ;	Miller AB, Baines CJ, To T, Wall C. ;	CMAJ. 1992 Nov 15;147(10):1459-76. ;
M5136			3/1/1992		Consistent lack of association between breast cancer and oral contraceptives using either hospital or neighborhood controls.;	Morabia A, Szklo M, Stewart W, Schuman L, Thomas DB. ;	Prev Med. 1993 Mar;22(2):178-86.;
M5137			8/24/2009		Hormone therapy, mammographic density, and breast cancer risk.	Martin LJ, Minkin S, Boyd NF. ;	Maturitas. 2009 Aug 24. [Epub ahead of print].;
M5138			8/24/2009		The incidence of breast cancer and changes in the use of hormone replacement therapy: A review of the evidence.;	Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. ;	Maturitas. 2009 Aug 24. [Epub ahead of print].;
M5139			9/1/2007		Digital mammography: novel applications.;	Rafferty EA.;	Radiol Clin North Am. 2007 Sep;45(5):831-43. vii.;
M5140			3/7/2007		Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk.;	Kerlikowske K, Ichikawa L, Miglioretti DL, Buist DS, Vacek PM, Smith-Bindman R, Yankaskas B, Carney PA, Ballard-Barbash R; National Institutes of Health Breast Cancer Surveillance Consortium.;	J Natl Cancer Inst. 2007 Mar 7;99(5):386-95.;
M5141			12/1/1999		Conjugated estrogens and breast cancer risk. ;	Campagnoli C, Ambroggio S, Biglia N, Sismondi P. ;	Gynecol Endocrinol. 1999 Dec;13 Suppl 6:13-9.;
M5142			4/9/2009		Trends in hormone therapy and breast cancer incidence - results from the German Network of Cancer Registries. ;	Katalinic A, Lemmer A, Zawinell A, Rawal R, Waldmann A. ;	Pathobiology. 2009;76(2):90-7. Epub 2009 Apr 9. ;
M5143			06/00/1992		Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. ;	Winkleby MA, Jatulis DE, Frank E, Fortmann SP.;	Am J Public Health. 1992 Jun;82(6):816-20. ;
M5145			7/10/2009		Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva.	Bouchardy C, Usel M, Verkooijen HM, Fioretta G, Benhamou S, Neyroud-Caspar I, Schaffar R, Vlastos G, Wespi Y, Schäfer P, Rapiti E.	Breast Cancer Res Treat. 2009 Jul 25. [Epub ahead of print]
M5147			9/14/2009		Estrogen-Progestagen Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause Onset to Treatment Initiation Influence Risks?	Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F.	J Clin Oncol. 2009 Sep 14. [Epub ahead of print]
M5201			7/8/2009		A case-control study on hormone therapy as a risk factor for breast cancer in; Finland: Intrauterine system carries a risk as well.	Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E.	Int J Cancer. 2009 Jul 8. [Epub ahead of print]
M5205			1/6/2011		Relationship between Menopausal Symptoms and Risk of Postmenopausal Breast Cancer.	Huang, Yi, Malone, Kathleen E., Cushing-Haugen, Kara L., et al.	Amer Assoc for Cancer Research Jan 6, 2011 [Epub ahead of print]. DOI:10.1158/1055-9965.EPI-10-0998
M5206			2/16/2011		The Influence of Time From Menopause and Mammography on Hormone Therapy-Related Breast Cancer Risk Assessment	Chelbowski, Rowan T., Anderson, Garnet L.	J Natl Cancer Inst. Feb 16, 2001. 103 (4): 1-2
M5207			2/16/2011		Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy	Beral, Valerie, Reeves, Gillian, Bull, Diana, Green, Jane for the MWSC	J Natl Cancer Inst. 2011;103:296-305
M5208			00/00/2011		Menopausal Hormone Therapy & Breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition	Bakken, K., Fournier, A., Lund, E., Waaseth, M., Dumeaux, V., Clavel-Chapelon, F., Fabre, A., Hemon, B., Rinaldi, S., Chajes, V., Slimani, N., Allen, N., Reeves, G., Bingham, S., Khaw, K.T., Olsen, A., Tjønneland, A., Rodriguez, L., Sanchez, M., Etxezarreta, P.A., ARdanaz, E., Tormo, M.J., Peeters, P. H., van Gils, C.H., Seffen, A., Schulz, M., Chang-Claude, J., Kaaks, R., Tumino, R., Gallo, V., Norat, T., Riboli, E., Panico S., Masala, G., Gonzalez, C., Berrino, F.	Int. J. Cancer: 128, 144-156 (2011)
M5209			7/19/2006		Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies	Yuiyan Ma, Leslie Bernstein, Malcom C. Pike and Giske Ursin	Breast Cancer Research 2006, 8:R43 (doi: 10.1186/bcr1525)
M5210			1/15/2005		Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement	Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristenen VN, Lonning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS	Clinical Cancer Research 2005;11:861s-864s
M5211			11/00/2008		Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort	Louise A. Brinton, Douglas Richesson, Michael F. Ieltzmann, Gretchen L. Gierach, Arthur Schatzkin, Traci Mouw, Albert R. Hollenbeck and James V. Lacey, Jr.	Cancer Epidemiol Biomarkers Prev 2008; 17(11). November 2008 (DOI: 10.1158/1055-9965.EPI-08-0435)

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M5212			6/17/2010		Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen	Janet S. Hildebrand, Susan M. Gapstur, Heather Spencer Feigelson, Lauren R. Teras, Michael J. Thun and Alpa v. Patel	Int. J. Cancer: 127, 2928-2935 (2010)
M5213			9/22/2009		The natural history of invasive breast cancers detected by screening mammography.	Zahl PH, Maehlen J, Welch HG.	Arch Intern Med. 2008 Nov 24;168(21):2311-6.
M5214			00/00/2007		Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities	Suleiman Massarweh and Rachel Schiff	Clin Cancer Res (DOI: 1158/1078-0432.CCR-06-2540)
M5215			09/00/2008		Estrogen plus Progestin and Risk of Benign Proliferative Breast Disease	Thomas E. Rohan, Abdissa Negassa, Rowan T. Chlebowski, Norman I. Lasser, Anne McTiernan, Robert S. Schenken, Mindy Ginsberg, Sylvia Wassertheil-Smolter and David L. Page	Cancer Epidemiol Biomarkers Prev. 2008 September; 17(9): 2337-2343, doi: 10.1158/1055/9965.EPI-08-0380
M5216			00/00/2000		HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor-Positive, Node-Positive breast cancer	Donald A. Berry, Hyman B. Muss, Ann D. Thor, Lynn Dressler, Edison T. Liu, Gloria Broadwater, Dan R. Budman, I. Craig Henderson, Maurice Barcos, Daniel Hayes and Larry Norton	J. Clinical Oncology 18:3471-3479 (2000) by American Society of Clinical Oncology
M5217			9/1/2009		Reproductive and hormonal risk factors for postmenopausal luminal, HER2-overexpressing, and triple-negative breast cancer	Amanda I. Phipps, MPH, Kathleen E. Malone, PhD, Peggy L. Porter, MD, Janet R. Daling, PhD and Christopher I. Li, MD, PhD	Cancer. 2008 Oct 1; 113(7):1521-6
M5218					<i>Letrozole is More Effective Neoadjuvant Endocrine Therapy than Tamoxifen for erbB-1 and/or ErbB-2-Positive, Estrogen Receptor-Positive Primary Breast Cancer: Evidence from a Phase III Randomized Trial.</i>	Ellis	J. Clinical Oncology, 19:3808-3816 (2001)
M5219			10/12/2009		New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk.	Crandall CJ, Aragaki AK, Chlebowski RT, McTiernan A, Anderson G, Hendrix SL, Cochrane BB, Kuller LH, Cauley JA.	Arch Intern Med. 2009;169(18):1684-1691
M5219A					Preinvasive Breast Cancer	Dennis C. Sgroi	
M5220			12/15/2010		Menstrual and Reproductive Factors, Exogenous Hormone Use, and Gastric Cancer Risk in a Cohort of Women From the European prospective investigation Into Cancer and Nutrition	Eric J. Duell, Noemie Travier, Leila Lujan-Barroso, M.C. Boutron-Ruault, F. Clavel-Chapelon, Domenico Palli, Vittorio Krogh, Amalia Mattiello, Rosario Tumino, Carlotta Sacerdote, Laudina Rodriguez, Emilio Sanchez-Cantalejo, Carmen Navarro, Aurelio Barricarte, Miren Dorronsoro, Kay-Tee Khaw, Nicholas Wareham, Naomi E. Allen, Konstantinos K. Tsilidis, H. Bas Bueno-de-Mesquita, Suzanne, M. Jeurnick, Me.E. numans, Petra H. M. Peeters, pagona Lagiou, Elisabeth Valanou, Antonia Trichopoulou, Rudolf Kaaks, Annekatrin Lukanova-McGregor, Manuela M. Bergman, Heiner Boeing, Jonas Manjer, Bjorn Lindkvist, Roger Stenling, Goran Hallmans, Christina C. Dahm, Kim Overvad, Anja Olsen, Anne Tjønneland, Kjersti Bakken, Eiliv Lund, Mazda Jenab, Valerie McCormack, Sabina Rinaldi, Dominique Michaud, Traci Mouw, Gabriella Nesi, Fatima Carneiro, Elio Riboli	Am J Epidemiol 2010 Dec 15; 172(12); 1384-93
M5221					Health Outcomes After Stopping Conjugated		LaCroix, PhD
M5238			9/14/2009		Use of dydrogesterone in hormone replacement therapy.	Mueck AO, Seeger H, Böhling KJ.	Maturitas. 2009 Oct 15. [Epub ahead of print]
M5262			12/00/2009		Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.	Gadducci A, Biglia N, Cosio S, Sismonti P, Genazzani AR.	Gynecol Endocrinol. 2009;25(12):807-15.
M5267			10/21/2009		Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years.	Lambe M, Wigertz A, Holmqvist M, Adolfsson J, Bardage C, Fornander T, Karlsson P, Ollind V, Persson I, Ahlgren J, Bergkvist L.	Breast Cancer Res Treat. 2009 Nov 6. [Epub ahead of print]
M5290			6/2/2008		Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia.	Canfell K, Banks E, Moa AM, Beral V.	Med J Aust. 2008 Jun 2;188(11):641-4.
M5335			11/29/2009		Comparative analysis of the uterine and mammary gland effects of progesterone and medroxyprogesterone acetate.	Otto C, Fuchs I, Vonk R, Fritzscheier KH.	Maturitas. 2009 Dec 24. [Epub ahead of print]
M5344			1/6/2009		Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy.	Sharpe KH, McClements P, Clark DI, Collins J, Springbett A, Brewster DH.	Eur J Cancer. 2010 Jan 30. [Epub ahead of print]
M5353			2/10/2010		Decline in US Breast Cancer Rates After the Women's Health Initiative: Socioeconomic and Racial/Ethnic Differentials.	Krieger N, Chen JT, Waterman PD.	Am J Public Health. 2010 Feb 10. [Epub ahead of print]
M5358			1/8/2010		Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort.	Marshall SF, Clarke CA, Deapen D, Delellis Henderson K, Largent J, Neuhausen SL, Reynolds P, Ursin G, Horn-Ross PL, Stram DO, Templeman C, Bernstein L.	Breast Cancer Res. 2010 Jan 8;12(1):R4. [Epub ahead of print]
M5406			7/10/2007		Spontaneous regression of a breast carcinoma: a case report.	Dussan C, Zubor P, Fernandez M, Yabar A, Szunyogh N, Visnovsky J.	Gynecol Obstet Invest. 2008;65(3):206-11. Epub 2007 Dec 10.
M5407			00/00/1978		Spontaneous regression of breast carcinoma.	Krutchik AN, Buzdar AU, Blumenschein GR, Lukeman JM.	Arch Intern Med. 1978 Nov;138(11):1734-5.
M5408			11/12/1998		[Spontaneous remission of breast cancer. A literature review]	Larsen SU, Rose C.	Ugeskr Laeger. 1999 Jun 28;161(26):4001-4.

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M5409			03/00/2003		Granted Marketing Authorisations (MAs) Published in March/April 2003		http://www.mhra.gov.uk/home/groups/1-reg/documents/licensing/con026455.pdf
M5410			03/00/2009		Levels of Evidence (March 2009)	Oxford Centre for Evidence Based Medicine	http://www.cebm.net/index.aspx?o=1025
M5411			8/7/1997		Food and Drug Administration, [Docket No. 97N-0326], Sterling Drug, Inc., et al.; Withdrawal of Approval of 28 New Drug Applications, 9 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications. AGENCY: Food and Drug Administration, HHS.		Federal Register / Vol. 62, No. 152 / Thursday, August 7, 1997 / Notices 42575
M5412			12/00/2007		Old Ideas Spur New Approaches in Cancer Fight	Kolata, G	NY Times 12/29/2009
M5413			12/16/1975		Obstetrics and Gynecology Advisory Committee - Transcript of Proceedings	Department of Health, Education and Welfare - Food and Drug Administration	
M5414			3/10/2010		ELITE: Early Versus Late Intervention Trial With Estradiol	National Institute on Aging	ClinicalTrials.gov; Identifier NCT00114517; Study ID Numbers AG0025, R01AG024154
M5415					Medical Papers By Ghostwriters Pushed Therapy	Singer N.	http://www.nytimes.com/2009/08/05/health/research/05ghost.html?pagewanted=print
M5450			5/00/2009		Colorectal Cancer in Relation to Postmenopausal Estrogen and Estrogen Plus Progestin in the Women's Health Initiative Clinical Trial and Observational Study	Ross L. Prentice,1 Mary Pettinger; Shirley A.A. Beresford;2 Jean Wactawski-Wende;3 F. Allan Hubbell;4 Marcia L. Stefanick;5 and Rowan I. Chlebowski6	Anderson CL, Kooperberg C, Celler N, Rossouw JE, Pettinger M, Prentice RL. Monitoring and reporting in the Women's Health Initiative randomized hormone therapy trials. Clinical Trials 2007;4:
M5656					Breast Cancer Risk by Breast Density, Menopause and Postmenopausal Hormone Therapy Use	Kerlikowske	J. of Clinical Oncology , (July 19, 2010)
M5751			4/28/2003	Bloom ross	The Her-2/ <i>neu</i> Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy	Jeffrey S. Ross, Jonathan A. Fletcher, Gerald P. Linette, James Stec, Edward Clark, Mark Ayers, W. Fraser Symmans, Lajos Pusztai, Kenneth J. Bloom	The Oncologist 2003; 8:307-325
M5752			6/5/2011	Goss	Exemestane for Breast-Cancer Prevention in Postmenopausal Women	Goss, P. E. Ingle, J. N. Ales-Martinez, J. E. Cheung, A. M. Chlebowski, R. T. Wactawski-Wende, J. McTiernan, A. Robbins, J. Johnson, K. C. Martin, L. W. Winquist, E. Sarto, G. E. Garber, J. E. Fabian, C. J. Pujol, P. Maunsell, E. Farmer, P. Gelmon, K. A. Tu, D. Richardson, H.	N Engl J Med 2011
M5753			02/00/2011		Update in hormone therapy use in menopause.	Hugh S. Taylo & JoAnn E. Manson	J Clin Endocrinol Metab. February 2011, 96(2):255-264
M5754			11/16/2010		The molecular pathology of breast cancer progression	Alessandro Bombonati and Dennis C Sgroi	J Pathol 2011; 223: 307-317
M5755			00/00/2008		Estrogen and progestogen therapy in postmenopausal women		doi:10.1016/j.ferndert.2008.08.091
M5756			00/00/2011	Han	Hormone Receptor Status Rather Than HER2 Status Is Significantly Associated With Increased Ki-67 and p53 Expression in Triple-Negative Breast Carcinomas, and High Expression of Ki-67 but Not p53 Is Significantly Associated With Axillary Nodal Metastasis in Triple-Negative and High-Grade Non-Triple-Negative Breast Carcinomas	Jeong S. Han, MD, PhD,1 Dengfeng Cao, MD, PhD,2 Kyle H. Molberg, MD,1 Venetia R. Sarode, MD,1 Roshni Rao, MD,3 Lisa M. Sutton, MD,1 and Yan Peng, MD, PhD1	Am J Clin Pathol 2011;135:230-237
M5782					Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) Multicenter Double Blind Randomized Trial	Smith, et al	J. Clin Oncology, Vol. 23:5108-5116 (2005)
M5790			2/24/2009		Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors	Thomas Frogne, Anne-Vibeke Laenholm, Maria B. Lyng, Katrine Lutken Henriksen and Anne E Lykkesfeldt	Breast Cancer Research 2009, 11:R11 (doi: 10.1186/bcr2230)
M6000			12/00/2008	Cuzick J.	Treatment emergent endocrine symptoms and the risk of breast cancer recurrence- a retrospective analysis at the ATAC trial. Lancet Oncol 2008;9(12):1 143-1148.	Cuzick, J. Sestak, I. Cella, D. Fallowfield, L.	1078-0432 (Print) 1078-0432 (Linking)
M6001			4/27/2007	Mortimer600	Women's Healthy Eating and Living	Joanne E. Mortimer, Shirley W. Flatt, Barbara A. Parker, Ellen B Gold, Linda Wasserman, Loli Natarajan, John P. Pierce	1078-0432.CCR-09-0957 [pii] 10.1158/1078-0432.CCR-09-0957
M6002			00/00/1998	Ettinger et al. 83 (7): 2239 -- Journal of Clinical Endocrinology & Metabolism	Ghost Marketing - pharmaceutical companies and ghostwritten journal articles Associations between Low Levels of Serum Estradiol, Bone Density, and Fractures among Elderly Women	Barton Moffatt and Carl Elliott Bruce Ettinger, Alice Pressman, Peter Sklarin, Douglas C. Bauer, Jane A. Cauley, Steven R. Cummings	J. Clin Endocrinol. Metab. 1998 83:2239-2243. doi 10.1210/jc.83.7.2239
M6003				Zera RT et al. Atypical hyperplasia, proliferative fibrocystic change, and exogenous hormone use. Surgery 2001;130:732-737.	Atypical hyperplasia, proliferative fibrocystic change, and exogenous hormone use.	Zera RT et a	
M6004			5/9/2008	Huang, <i>Persistent Hot Flashes in Older Postmenopausal women</i> , Arch Intern Med., Vol. 168, No. 8 (2008)	Persistent Hot Flashes in Older Postmenopausal women,	Huang, A. J. Grady, D. Jacoby, V. L. Blackwell, T. L. Bauer, D. C. Sawaya, G. F.	168/8/840 [pii] 10.1001/archinte.168.8.840
M6004A					Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events	Naranjo, Lanciot	Clinical Pharmacology and Therapeutics, Vol. 58: 692-8 (1995)
M6005							

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M6006			12/18/2009	Boyle, Bofetta, <i>Alcohol Consumption & Breast Cancer Risk</i> , Breast Cancer Research, Vol. 11, Supp. 3 (2009).	Alcohol Consumption & Breast Cancer Risk,	Boyle, Bofetta	10.1186/bcr2422
M6007			12/20/2008	Wine, liquor, beer and risk of breast cancer in a large population	Wine, liquor, beer and risk of breast cancer in a large population	Li, Y. Baer, D. Friedman, G. D. Udaltsova, N. Shim, V. Klatsky, A. L.	S0959-8049(08)00903-9 [pii] 10.1016/j.ejca.2008.11.001
M6008			00/00/2001	<u>Safer drugs for the American people.</u>	Complete Resolution of Metastatic Breast Cancer by Withdrawal of Hormone Replacement Therapy	R. Jena, C. B. Wilson	Clinical Oncology (2001)13:200-201
M6009			1/22/2008	Abdominal adiposity and hot flashes among midlife women	Abdominal adiposity and hot flashes among midlife women	Thurston, R. C. Sowers, M. R. Sutton-Tyrrell, K. Everson-Rose, S. A. Lewis, T. T. Edmundowicz, D. Matthews, K. A.	10.1097/gme.0b013e31815879cf
M6010			8/14/2009	Gains in Body Fat and Vasomotor Symptom Reporting Over the Menopausal Transition	Gains in body fat and vasomotor symptom reporting over the menopausal transition: the study of women's health across the nation	Thurston, R. C. Sowers, M. R. Stemfeld, B. Gold, E. B. Bromberger, J. Chang, Y. Joffe, H. Crandall, C. J. Waetjen, L. E. Matthews, K. A.	kwp203 [pii] 10.1093/aje/kwp203
M6011			9/4/2008	Hot Flashes and Subclinical Cardiovascular Disease Findings From the Study of Women's Health Across the Nation Heart Study	Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study	Thurston R. C. Sutton-Tyrrell, K. Everson-Rose, S. A. Hess, R. Matthews, K. A.	CIRCULATIONAHA.108.776823 [pii] 10.1161/CIRCULATIONAHA.108.776823
M6012			05/00/2007	the role of local vaginal estrogen for treatment of vaginal atrophy	The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society	North American Menopause Society NAMS	1078-0432 (Print) 1078-0432 (Linking)
M6013			1/22/2010	DHEA for postmenopausal women: A review of the evidence	DHEA for postmenopausal women: a review of the evidence	Mary Panjari, Susan R. Davis	10.1016/j.maturitas.2009.12.017
M6014			7/2/2008	Dyspareunia in postmenopausal women:	Dyspareunia in postmenopausal women: a critical review	Kao, A. Binik, Y. M. Kapuscinski, A. Khalife, S.	
M6015			4/22/1983	The importance of sexual activity and hormones.	Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones	Leiblum, S. Bachmann, G. Kemmann, E. Colburn, D. Swartzman, L.	
M6016			6/23/2010	An Endocrine Society Scientific Statement	Postmenopausal hormone therapy: an Endocrine Society scientific statement	Santen, R. J. Altred, D. C. Ardoin, S. P. Archer, D. F. Boyd, N. Braunstein, G. D. Burger, H. G. Colditz, G. A. Davis, S. R. Gambacciani, M. Gower, B. A. Henderson, V. W. Jarjour, W. N. Karas, R. H. Kleerekoper, M. Lobo, R. A. Manson, J. E. Marsden, J. Martin, K. A. Martin, L. Pinkerton, J. V. Rubinow, D. R. Teede, H. Thiboutot, D. M. Utian, W. H.	jc:2009-2509 [pii] 10.1210/jc.2009-2509
M6018				Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study		rosenberg	
M6019			00/00/2007	Differential Diagnosis of Seizure associated with tropical Lidocaine in a Patient With Vestibulodynia	Differential Diagnosis of Seizure associated with tropical Lidocaine in a Patient With Vestibulodynia	Frank W. Ling, Candace Brown, Gloria Bachmann	Arch Oral Biol 2001;46:1091-8
M6020			10/00/2005	kerl	Mammographic breast density as an intermediate phenotype for breast cancer	Norman F. Boyd, Johanna M Rommens, Kelly Vogt, Vivian Lee, John L. Hopper, Martin J Yaffe, Andrew D Paterson	Lancet Oncol 2005; 6:798-808
M6042			00/00/2010	Change in mammographic density with estrogen and progestin therapy: A measure of breast-abstract	Change in mammographic density with estrogen and progestin therapy: A measure of breast cancer risk in the Women's Health Initiative	Byrne	
M6043			00/00/2000	Historical and Epidemiologic Background of Human Premalignant Breast Disease	Historical and Epidemiologic Background of Human Premalignant Breast Disease	David L. Page, Roy A. Jensen, Jean F. Simpson, William D. Dupont	1083-302
M6044			9/14/2009	The impact of changes in hormone therapy on breast cancer incidence in the US population	The impact of changes in hormone therapy on breast cancer incidence in the US population	Nathan J. Coombs • Kathleen A. Cronin • Richard J. Taylor, Andrew N. Freedman, John Boyages	1078-0432 (Print) 1078-0432 (Linking)

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M6046			00/00/2010	IGFBP2 and IGFBP3 Protein Expressions in Human Breast Cancer: Association with Hormonal Factors and Obesity	IGFBP2 and IGFBP3 Protein Expressions in Human Breast Cancer: Association with Hormonal Factors and Obesity	Probst-Hensch, N. M. Steiner, J. H. Schraml, P. Varga, Z. Zurrer-Hardi, U. Storz, M. Korol, D. Fehr, D. Pestalozzi, B. C. Lutolf, U. M. Theurillat, J. P. Moch, H.	1078-0432.CCR-09-0957 [pii] 10.1158/1078-0432.CCR-09-0957
M6047			8/9/2010	Incidence of Breast Cancer and Its Subtypes in Relation to Individual and Multiple Low-Penetrance Genetic	Incidence of Breast Cancer and Its Subtypes in Relation to Individual and Multiple Low-Penetrance Genetic Susceptibility Loci	Gillian K. Reeves; Ruth C. Travis; Jane Green; et al	Jama 2010;304(4):426-434 (Doi:10.1001/jama.2010.1042)
M6048			00/00/2009	Complex prolactin crosstalk in breast cancer: New therapeutic implications	Complex prolactin crosstalk in breast cancer: New therapeutic implications	Kristopher C. Carver, Lisa M. Arendt, Linda A. Schuler	
M6049			11/20/2008	Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility	Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population based sample of postmenopausal African-America and European-American women	Timothy R. Rebbeck, Angela DeMichiele, Teo V Tran, Saarene Panossian, Greta R. Burin, Andrea B. Troxel, Brian L. Strom	Carcinogenesis vol.30 no.2 pp.269-274, 2009
M6050				Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.	Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.	Richard J. Santen, Ping Fan, Zhenguo Zhang, Yongde Bao, Robert X. -D Song, Wei Yue	0039-128x/s
M6051			7/22/2010	Acs Chapter- Mechanisms of Ocogenesis	Postmenopausal Hormone Replacement Therapy and Breast Cancer - Clinicopathologic Associations and Molecular Mechanisms	Geza Acs	Mechanisms of Oncogenesis, Cancer Growth and Progression
M6052			7/20/2010	Cancer Statistics	Cancer Statistics, 2010	Ahmedin Jemal, Rebecca Siegel, Jiaquan XU, Elizabeth Ward	CA Cancer J clin 2010 doi: 10.3322/caac.20073
M6053			1/7/2009	Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women	Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women	Gunter, M. J. Hoover, D. R. Yu, H. Wassertheil-Smoller, S. Rohan, T. E. Manson, J. E. Li, J. Ho, G. Y. Xue, X. Anderson, G. L. Kaplan, R. C. Harris, T. G. Howard, B. V. Wyllie-Rosett, J. Burk, R. D. Strickler, H. D.	R01-CA93881-01/CA/NCI NIH HHS/United States
M6054				Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells			
M6055			1/31/2008	Mechanistic Aspects of Crosstalk Between GH and PRL and ErbB Receptor Family Signaling	Mechanistic Aspects of crosstalk between GH and PRL and ErbB Receptor Family Signaling	Stuart Frank	J mammary Gland Biol Neoplasia
M6056			9/30/2009	Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells	Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells	Robert X. -D Song, Yuchai Chen, Zhenguo Zhang, Yongde Bao, Wei You, Ji-Ping Wang, Ping Fan, Richard J. Santen	Journal of Steroid Biochemistry & Molecular Biology 118 (2010) 219-230
M6057			7/9/2009	Relationships between critical period of estrogen exposure and circulating levels of insulin-like growth factor-I (IGF-I) in breast cancer: evidence from a case-control study	Relationships between critical period of estrogen exposure and circulating levels of insulin-like growth factor-I (IGF-I) in breast cancer: evidence from a case-control study	Wu, M. H. Chou, Y. C. Chou, W. Y. Hsu, G. C. Chu, C. H. Yu, C. P. Yu, J. C. Sun, C. A.	10.1002/ijc.24722 Int J Cancer. 2010 Jan 15;126(2):508-14.
M6058				Estrogen Signaling via a Linear Pathway Involving Insulin-Like Growth Factor I	Estrogen Signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells	Robert X. -D Song, Zhenguo Zhang, Yacai Chen, Yongde Bao, Richard J. Santen	Endocrinology 148(8):1091-4101
M6060				Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1 and VEGFR-2 in breast cancer and endothelial cells		S Garvin1, UW Nilsson1 and C Dabrosin1,	
M6061			8/10/2010	Abeloff's Clinical Oncology- cover	Role of Environmental Agents In The Etiology of Human Cancers		
M6061a			8/10/2010	Chapter 9	Section-B Chapter 9 Environmental Factors	Paul T. Strickland, Thomas W. Kensler	
M6061b			8/10/2010	Chapter 14	Chapter 14 Progressing from gene mutations to cancer	Eric Fearon, Guido Bommer	
M6061c			8/10/2010	Chapter 26	Chapter 26 Cancer prevention, screening, and early detection	Jason A. Zell, Frank L. Meyskens	
M6061d			8/10/2010	Chapter 92	Chapter 92 Cancer of the endometrium	Catherine K. Park, Sachin Apte, Geza Acs, Eleanor E.R. Harris	
M6061e			8/10/2010	Chapter 95	Chapter 95 Cancer of the breast	Martin D. Abeloff, Antonio C. Wolff, Barbara L. Weber, Tai Z. Zaks, Vergilio Sacchini, Beryl McCormick	
M6062			8/10/2010	Menopausal Hormone Therapy and Subsequent Risk of Specific Invasive Breast Cancer Subtypes in the California Teachers Study	Menopausal Hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California teachers study	Tammai Saxena1, Eunjung Lee1, Katherine D. Henderson2, Christina A. Clarke3,4, Dee West3,	
M6062a				Menopausal Hormone Therapy and Subsequent Risk of Specific Invasive Breast Cancer Subtypes in the California Teachers Study- Sup data	RR estimates for the association between HT breast cancer stratified by tumor size		
M6063			8/31/2007	Effects of Hormone Therapy on estrogen synthesis	Effects of Hormone Therapy on estrogen synthesis from ES in the mammary gland of postmenopausal women	Petra Stute, Thomas Szuwart, Martina Schlueter, Martin Gotte, Jens Packeisen, Ludwig Kiesel	078-0432.CCR-09-0957 [pii] 10.1158/1078-0432.CCR-09-0957
M6064			5/24/2010	Breast cancer precursors revisited: molecular features and progression pathways	Breast cancer precursors revisited: molecular features and progression pathways	Maria A Lopez-Garcia1,2, Felipe C Geyer1, Magali Lacroix-Trik1,3, Caterina Marchi4, Jorge S Reis- Filho1	078-0432.CCR-09-0957 [pii]

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
m6065			5/24/2010		Breast cancer precursors revisited: molecular features and progression pathways	Maria A Lopez-Garcia1,2, Felipe C Geyer1, Magali Lacroix-Trik1,3, Caterina Marchi4, Jorge S Reis-Filho1	10.1158/1078-0432.CCR-09-0957
M6066			5/1/2010		Association Between Mammographic Density and Age-Related Lobular Involution of the breast	Karthik Ghosh, Lynn C Hartmann, Carol Reynolds, Daniel W. Visscher, Kathleen R. Brandt, Robert A. Vierkant, Christopher G. Scott, Derek C. Radisky, Thomas A. Sellers, V. Shane Pankratz, Celine M. Vachon	J Clin Oncol 28:2207-2212
M6067			00/00/2008		Mammographic Density, lobular involution, and risk of breast cancer	Ginsburg boyd	2008 Cancer Research UK
m6075			2/14/2002	REDUCED VAGINAL BLEEDING IN Postmenopausal women who receive combined	REDUCED VAGINAL BLEEDING IN Postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy	Simon	2003 Mosby Inc
M6076			00/00/2009	MF-101, an estrogen receptor beta agonist for the treatment of	MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri-menopausal women	Dale Stovall, JoAnn V Pinkerton	GHG(589-5990 K/J clin pril
M6077			4/20/2010		Vasomotor symptoms, estradiol levels and cardiovascular risk profile in women	Gast, G. C. Samsioe, G. N. Grobbee, D. E. Nilsson, P. M. van der Schouw, Y. T. mango	S0378-S122(10)00124-6 [pii] 10.1016/j.maturitas.2010.03.015
M6078							
M6079			10/5/2010	Short-term anastrozole therapy	Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial	Mattar, A. Logullo, A. F. Facina, G. Nonogaki, S. Soares, F. A. Gebirim, L. H.	10.1007/s00432-010-0950-4
M6080			00/00/2006	. et al. Clinical Opinion: The Biologic and Pharmacologic Principles of Estrogen Therapy for Symptomatic Menopause. Medscape General Medicine. 2006	Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for symptomatic menopause	Netelovitz M	1531-0132 (Electronic)
M6081				Hot Flashes May Be Good News for Breast-Cancer Patients		Beth Israel	
M6082			10/21/2010	Estrogen Plus Progestin and Breast Cancer Incidenceand Mortality in Postmenopausal Women	Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women	Chlebowski, R. T. Anderson, G. L. Gass, M. Lane, D. S. Aragaki, A. K. Kuller, L. H. Manson, J. E. Stefanick, M. L. Ockene, J. Sarto, G. E. Johnson, K. C. Wactawski-Wende, J. Ravdin, P. M. Schenken, R. Hendrix, S. L. Rajkovic, A. Rohan, T. E. Yasmeen, S. Prentice, R. L.	304/15/1684 [pii] 10.1001/jama.2010.1500
M6083						Rowan T. Chlebowski, Peter B. Bach	
M6084					Completeness of Published Case Reports on Suspected Adverse Drug Reactions: Evaluation of 100 Reports from a Company Safety Database	Piero Impicciatore, Massimiliano Mucci	Drug Saf 2010; 33 (9): 765-773
M6084					Completeness of Published Case Reports on Suspected Adverse Drug Reactions: Evaluation of 100 Reports from a Company Safety Database	Piero Impicciatore, Massimiliano Mucci	Drug Saf 2010; 33 (9): 765-773
M6085					Guidelines for submitting adverse event reports for publication	Kelly WN, Barnes J, Bergman U, et. al.	Pharmacoevidence and Drug Safety 2007; 16: 581-587
M6085					Guidelines for submitting adverse event reports for publication	Kelly WN, Barnes J, Bergman U, et. al.	Pharmacoevidence and Drug Safety 2007; 16: 581-587
M6086			4/25/2008		Physician's guide to pharmacovigilance: Terminology and causality assessment	Rehan HS, Chopra D, Kakkar AK	European Journal of Internal Medicine 20 (2009) 3-8
M6088					RADAR assessment of quality of reporting of serious adverse drug reactions (SADRs) to an Institutional Review Board (IRB) for 14 clinical trials with imatinib mesylate.	Bennett CL, Lagman JL, McKoy JM, Courtney DM, Belknap SM, Sartor AO, Djulbegovic B, West DP	J Clin Oncol 26: 2008 (May 20 suppl; abstr 6588)
M6090			11/00/2009		Rates of Atypical Ductal Hyperplasia Have Declined with Less Use of Postmenopausal Hormone Treatment: Findings from the Breast cancer Surveillance Consortium	Menes TS, Kerlikowske K, Jaffer S, Seger D, Miglioretti DL	Cancer Epidemiol Biomarkers Prev 2009;18(11).
M6091			9/19/2010		Combined Hormone Therapy and Breast Cancer: A Single-Edged Sword	Gann PH, Morrow M	JAMA. 2003;289(24):3304-3306 (doi:10.1001/jama.289.24.3304)
M6092					Combined Hormone Therapy at Menopause and Breast Cancer: A Warning—Short-Term Use Increases Risk	Bernstein	
M6093					Breast Cancer Risk and Prevention		
M6094					A "Spontaneously Shrinking" Breast Mass: Unusual Presentation of Invasive Tubular Carcinoma	Mahal	
M6095					An Example of Breast Cancer Regression on imaging	Elizabeth S. Burnside	
M6096					Overview of The Endocrine Society		
M6097					Mutagen Sensitivity tobacco smoking and breast cancer risk	Willey	
M6098					Screening and Follow-Up of the patient at high risk for breast cancer	Willey	
M6099					prognostic significance of ki-67	Decensi	
M6100					Down-Regulation of Heat-Shock Protein 70	Yiu	
M6101					Epidemiology of Ductal Carcinoma In Situ	kerlikowske	
M6102					Changes in Invasive Breast cancer	Farhat	
M6103					The estrogen-cancer controversy	Greenblatt	
M6104					relationship between	Huang	
M6105			8/2/2011		Hormone Replacement Therapy and the risk of breast cancer	Steven A. Narod	Nat Rev Clin Oncol 2 Sugust 2011 (doi: 10.1038/nrclinonc.2011.110)
M6106						Taylor and Mason	

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M6107			00/00/2011		Menopausal hot flushes and night sweats: where are we now?	D.F. Archer, D. W. Sturdee, R. Baber, T. J. de Villiers, A. Pines, R.R. Freedman, A. Gompel, M. Hickey, M.S. Hunter, R.A. Lobo, M.A. Lumsden, A. H. MacLennan, P. Maki, S. Palacios, D. Shah, P. Villaseca, M. Warren	CLIMACTERIC 2011; Early Online 1-14 (doi: 10.3109/13697137.1011.308596)
M6108			2/3/2000		HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach	Ren L. Ridolfi, MD, Mehdi R. Jamehdor, MD, Janet M Arber, MD	Mod Pathol 2000; 13(8): 866-873
M6111			04/00/2010		Accurately Assessing Her-2/neu Status in Needle Core Biopsies of Breast Cancer Patients in the ERA of Neoadjuvant Therapy: Emerging Questions and Considerations Addressed	Timothy D'Alfonso, MD, Yi-Fang Liu, BSc, Stefano Monni PhD, Paul Peter Rosen, MD, Sandra J. Shin, MD	AM J Surg Pathol 2010; 34:575-581
M6112			2/1/2002		Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer	Charles L. Vogel, Melody A. Cobleigh, Debu Tripathy, John C. Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William F. Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Michael Press	J Clin Oncol 20:719-726 2002 by American Society of Clinical Oncology
M6113			5/15/2001		Clinical Activity of Trastuzumab and Vinorelbine in Woemn With Her2-Overexprssing Metastatic Breast Cancer	Harold J. Burstein, Irene Kuter, Susana M. Campos, Rebecca S. Gelman, Laure Tribou, Leroy M. Parker, Judith Manola, Jerry Younger, Ursula Matulonis Craig A. Bunnell, Ann H. Partridge, Pual G. Richardson, Kathryn Clarke, Lawrence N. Shulman and Eric P. Winer	J Clin Oncol 19:2722-2730 2001 by American Society of Clinical Oncology
M6114			00/00/2002		Comparison of HER-2/neu Oncogene Amplification Detected by Fluorescence In Situ Hybridization in Lobular and Ductal Breast Cancer	Seth I. Rosenthal, MD, Peter L. Depowski, MD, Christine E. Sheehan, BS, Jeffery S. Ross, MD	Applied Immunohistochemistry & Molecular Morphology 10(1): 40-46, 2002
M6115			3/4/2008		Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies	Christian F. Singer, Wolfgang J. Kostler, Gernot Hudelist	Biochimica et Biophysica Acta 1786 (2008) 105-113
M6116			01/00/2011		Biology, Detection, and Clinical Implications	Carolina Gutierrez, MD, Rachel Schiff, PhD	Arch Pathol Lab Med. 2011;135:55-62
M6117			9/13/2005		Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer	Gernot Hudelist, Wolfgang J. Kostler, Klaus Czerwenka, Ernst Kubista, Johannes Atems, Ruth Muller, Daphen Gschwantler-Kaulich, Mahmood Manavi, Isabell Huber, Heinz Hoschutsky, Christoph C. Zielinski, Christina F. Singer	Int. J. Cancer 118, 1126-1134 (2006)
M6118			11/2/2004		Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer	HJ Huang, P Neven, M Drijckoningen, R. Paridaens, H Wildiers, E Van Limbergen, P Berteloot, F Amant, I Vergote, MR Christiaens	J Clin Pathol 2005; 58: 611-616 (doi: 10.1136/jcp.2004.022772)
M6119			02/00/2002		HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization	Edith A. Perez, MD; Patrick C. Roche, PhD, Robert B. Jenkins, MD, PhD, Carol A. Reynolds, MD, Kevin C. Halling, MD, PhD, James N. Ingle, MD, Lester E. Wold, MD	Mayo ClinProc. 2002; 77:148-154
M6120			10/19/2010		Hormone Therapy Linked to Modest Increase in Breast Cancer Deaths		Nat Cancer Institute 7(20) 2010 (www.cancer.gov)
M6121			8/1/2004		Trastuzumab in Breast Cancer	Leisha A. Emens, MD, PhD, Nancy E. Davidson, MD	Oncology. 18 (9) August 1, 2004
M6122			02/00/2007	2007 Aromasin Label	Aromasin Label		
M6123				Response of Estrogen Receptor Positive Breast Cancer Tumorspheres to Antiestrogen Treatments	AO		
M6125				Biology Detection and Clinical Implications	Gutierrez		
M6126				Combination Therapy for Treating Breast Cancer Using Antiestrogen ERA 923 and the Mammalian arget of rapamycin inhibitor Temsirolimus.	Sadler		
M6127				Association of Hormone Related Characteristics and breast Cancer Risk by Estrogen Receptor/Progesterone Receptor status in the Shanghai Breast Cancer Study	Pao		
M6128					Zbuk		
M6129				Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women.			
M6130				<i>Estrogen receptor expression in benign breast epithelium and breast cancer risk , J</i>	Khan		
M6131				Do women taking hormone replacement	Fleming		
M6132				American Society of Clinical Oncology Pathologist Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer	Hammond		
M6133				Letter	Hammond		
M6134				AACR Progress Report 2011			
M6140				Endocrine and Targeted Manipulation of Breast Cancer: Summary Statement for the Sixth Cambridge Conference.	Come		
M6141				Breast tenderness after initiation of conjugate	Crandall		

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
M6142				Natural history of breast cancers detected in	Zahl		
M6143				Comparison of the effects of genetic and environmental risk factors on IN SITU and invasive ductal breast cancer	Reeves GK, Pirie K, Green J, Bull D, Beral V: For the Million Women Study Collaborators		
M6144				Hot Flash News Isn't All Bad			
M6145				Breast Cancer Incidence and Hormone Replacement Therapy In Canada	Pritwish		
M6146				Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials			
M7035				Mammographic Density, Response to Hormones, and Breast cancer risk	Boyd		
M8000					Lippert		
M8050			1987	Benign and Malignant Breast Disease: Initial Study Results of Serum and Breast Fluid Analyses of Endogenous Estrogens		Ernster	JNCI, Vol. 79, No. 5 (1987)
M8307				Avon Foundation Handout			
M8832			2007	Magnitude and Laterality of Breast Cancer Risk According to Histologic Type of Atypical Hyperplasia: Results from the Nurses' Health Study		Collins	Cancer, Vol. 109, Nol. 2 (2007)
M8992				Pfizer info re: Aromasin			
M9200				Progesterone and progestins in postmenopausal hormone therapy		Langer	
M9351A							
MA0003			1/1/1978		The estrogen--cancer controversy	Greenblatt RB, Stoddard LD	J Am Geriatrics Soc'y 1978 Jan;26(1):1-8
MA0005			1/1/1993		Premarin Label	1993 PDR	
MA0006			1/1/1994		Premarin Label	1994 PDR	
MA0007			5/1/1996		Prempro Label	1996 PDR	
MA0009			1/1/1997		Prempro Label	1997 PDR	
MA0020			1/1/2002		Prempro Label	2002 PDR	
MA0041			1/1/2004		Osteoporosis	ACOG Practice Bulletin - 2004	Obstetrics & Gynecology 2004; 103:203-216
MA0051			1/1/2004		The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer	Allred DC, Brown P, Medina D	Breast Cancer Research 2004;6:240-245
MA0052			1/1/1998		Biomarkers in Benign Breast Disease: Risk Factors for Breast Cancer	Allred DC, Hilsenbeck SG	JNCI 1998;90(17):1247-1251
MA0053			00/00/2003		Mammographic density is related to stroma and stomal proteoglycan expression	Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH	Breast Cancer Research 2003; 5:R129-R135
MA0070			1/1/2005		Early Life Factors and Incidence of Proliferative Benign Breast Disease	Baer HJ, Schnitt SJ, Connolly JL, Byrne C, Willett WC, Rosner B, Colditz GA	Cancer, Epidemiology Biomarkers & Prevention 2005;14(12):2889-2897
MA0072			1/1/2006		Editorial: What do we think about cognition and menopause?	Barlow, DH	Menopause 2006;13(1):4-5
MA0082			8/1/1989		Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy	Bergkvist L, Adami HO, Persson I, Bergstrom R, Kursemo UB	American Journal of Epidemiology 1989; 130:221-228
MA0083			1/1/1990		Hormonal Replacement Therapy: Mammographic Manifestations	Berkowitz JE, Gatewood Olga M, Goldblum LE, Gayler BW	Radiology 1990; 174: 199-201
MA0090			9/19/2002		Heritability of Mammographic Density, A Risk Factor for Breast Cancer	Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, Giles GG, Titchler D, Chiarelli A, Yaffe MJ, Hopper JL	N Engl J Med 2002, 347(12):886-894
MA0092			9/1/2002		The association of breast mitogens with mammographic densities	Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, Hammond G, Minkin S	British Journal of Cancer 2002;87:876-882
MA0093			1/1/1986		Hormonal Therapies for Breast Cancer: Can Progestogens Stimulate Growth?	Braunenberg H, Coldham NG, Wong W	Cancer Letters 1986; 30:213-218
MA0104			1/1/1998		Analysis of Mammographic Density and Breast Cancer Risk From Digitized Mammograms	Byng JW, Yaffe MJ, Jong RA, Shumak RS, Lockwood GA, Titchler DL, Boyd NF	RadioGraphics 1998; 18:1587-1598
MA0105			1/1/2000		Biopsy Confirmed Benign Breast Disease, Postmenopausal Use of Exogenous Female Hormones and Breast Carcinoma Risk	Byrne C, Connolly J, Colditz GA, Schnitt SJ	Cancer 2000;99:2046-2052
MA0123			1/1/2001		Hormone Replacement Therapy After Breast Cancer: A Systematic Review and Quantitative Assessment of Risk	Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J	J Clin Oncol 2001; 19:2357-2363
MA0124			1/1/1998		Use of Estrogen Plus Progestin is Associated with Greater Increase in Breast Cancer Risk Than Estrogen Alone	Colditz G, Rosner B	Am J Epidemiology 1998; 147:64s
MA0125			3/26/1996		Risk factors for breast cancer according to family history of breast cancer. For the Nurses' Health Study Research Group	Colditz GA, Rosner BA, Speizer FE	JNCI 1996;88:365-71
MA0132			1/15/2005		Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement	Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristenen VN, Lonning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS	Clinical Cancer Research 2005;11:861s-864s
MA0188			11/1/2000		Reproductive and hormonal factors associated with mammographic breast density by age (United States)	El-Bastawissi AY, White E, Mandelson MT, Taplin SH	Cancer Causes and Control 2000; 11:955-963
MA0193			1/1/2005		Body Size Changes in Relation to Postmenopausal Breast Cancer among Women on Long Island, New York	Eng SM, Gammon MD, Terry MB, Kushi LH, Teitelbaum, Britton JA, Neugut AI	American Journal of Epidemiology 2005; 162:229-237
MA0198			10/00/1998		Effect of Postmenopausal Hormone Therapy on Glucose and Insulin Concentrations	Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Wacławiw MA, Bush TL for the PEPI Investigators	Diabetes Care 1998; 21: 1589-1595
MA0222			06/00/1999		Postmenopausal Hormone Replacement Therapy: Effect on Diagnosis and Outcome in Early-Stage Invasive Breast Cancer Treated with Conservative Surgery and Radiation	Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Goldstein L	Journal of Clinical Oncology 1999; 17(6):1680-1688
MA0224			5/18/2005		Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application	Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM	J Natl Cancer Inst 2005; 97:715-723
MA0232			06/00/1996		Hormone Replacement Therapy and Breast Cancer Risk	Gambrell RD	Archives of Family Medicine 1996; 5:341-348
MA0249			08/00/1997		Physiological Action of Progesterone in Target Tissues	Graham JD, Clarke CL	Endocrine Reviews 1997;18(4):502-519

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA0257			5/9/1998		Circulation Concentrations of Insulin-Like Growth Factor I and Risk of Breast Cancer	Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M	Lancet 1998; 351:1393-1396
MA0267			1/1/1999		Expert Perspectives - Magnetic Resonance Imaging - directed Laser Lumpectomy	Harms SE, Mumtaz H, Klimberg VS, Westbrook K	Breast Diseases: A Year Book Quarterly Vol 9 No 4 1999: p336-338
MA0274			01/00/2004		Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk	Harvey JA, Bovbjerg VE	Radiology 2004; 230:29-41
MA0275			11/5/1997		Short-term Cessation of Hormone Replacement Therapy and Improvement of Mammographic Specificity	Harvey JA, Pinkerton JV, Herman CR	Journal of the National Cancer Institute 1997; 89:16231625
MA0276			12/10/2004		Histologic findings in mammographically dense breast tissue from postmenopausal women using and not using hormone replacement therapy	Harvey JA, Santen RJ, Petroni GR, Smolkin ME, Russo J	Abstract 5008, San Antonio Breast Symposium, December 2004
MA0290			11/00/2005		Comparison of Male and Female Breast Cancer Incidence Trends, Tumor Characteristics, and Survival	Hill TD, Khamis HJ, Tyczynski JE, Berkel HJ	Ann Epidemiol, Vol. 15, No. 10, November 2005
MA0304			2/11/1999		Radical Scars in Benign Breast Biopsy Specimens and the Risk of Breast Cancer	Jacobs TW, Byrne C, Colditz G, Connolly JL, Schnitt SJ	N Engl J Med 1999;340:430-6
MA0305			1/1/2001		Pathologic Features of Breast Cancers in Women with Previous Benign Breast Disease	Jacobs TW, Byrne C, Colditz G, Connolly JL, Schnitt Stuart	American Journal of Clinical Pathology 2001; 115:362-369
MA0310			1/23/1976		Preneoplastic Lesions in the Human Breast	Jensen HM, Rice JR, Wellings SR	Science 1976;191:295-296
MA0319			00/00/2005		The apoptotic action of estrogen following exhaustive antihormonal therapy: A new clinical treatment strategy	Jordan, VC, Lewis JS, Osipo Clodia, Cheng D	The Breast (2005) 14, 624639
MA0333			00/00/1998		Histology and Pathology	Kopans DB	Breast Imaging, 2nd edition, Lippincot Williams & Wilkins pp21, 160, 236-238; 242
MA0336			6/15/2003		A Simple Model of Breast Carcinoma Growth May Provide Explanations for Observations of Apparently Complex Phenomena	Kopans DB, Rafferty E, Georgian-Smith D, Yeh E, D'Alessandro H, Moore R, Hughes K, Halpern E	Cancer 2003;97:2951-2959
MA0357			1/3/1986		Oral Contraceptives and Breast Cancer A Prospective Cohort Study	Lipnick RJ, Buring JE, Hennekens CH, Rosner B, Willett W, Bain C, Stampfer MJ, Colditz GA, Peto R, Speizer FE	JAMA 1986; 255:58-61
MA0364			2/23/2005		Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study	Lord SJ, Mack WJ, VanDenBerg D, Pike MC, Ingles SA, Haiman CA, Wang W, Parisky YR, Hodis HN, Ursin G	Breast Cancer Research, Vol 7, No.3:R336-R344
MA0366			00/00/2006		Hormone therapy, timing of initiation and cognition in women aged older than 60 years: the REMEMBER pilot study	MacLennan AH, Henderson VM, Paine BJ, Mathias J, Ramsay EN, Ryan P, Stocks NP, Taylor AW	Menopause 2006;13(1):28-36
MA0369			1/1/2006		Editorial: Potential importance of early initiation of hormone therapy for cognitive benefit	Maki PM	Menopause 2006;13(1):6-7
MA0371			7/5/2000		Breast Density as a Predictor of Mammographic Detection: Comparison of Interval- and Screen-Detected Cancers	Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E	Journal of the National Cancer Institute 2000; 92(13):1081-1087
MA0375			05/00/1997		Risk of Breast Cancer Associated with Atypical Hyperplasia of Lobular and Ductal Types	Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA	Cancer Epidemiology, Biomarkers & Prevention 1997;6:297-301
MA0378			08/00/1994		Pain and Increased Mammographic Density in Women Receiving Hormone Replacement Therapy: A Prospective Study	McNicholas MM, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP	AJR 1994; 163:311-315
MA0391					Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer	Modugno F, Kip KE, Cochrane B, Kuller L, Klug TL, Rohan TE, Chlebowski RT, Lasser N, Stefanick ML	International Journal of Cancer 2006; 118:1292-1301
MA0399			11/00/2000		Hormone Replacement Therapy Rarely Complicates or Alters Interpretation on Screening Mammography: A Prospective Analysis	Moy L, Slanetz PJ, Yeh ED, Moore RH, Rafferty EA, Kopans DB	Radiology(Supplement), Vol. 217 (P), November 2000: 446
MA0401			11/00/1992		Incidence of breast cancer in a 22 year study of women receiving estrogen-progestin replacement therapy	Nachtigall MJ, Smilen SW, Nachtigall RD	Obstet Gynecol 1992; 80:827-830
MA0413			1/1/2003		Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women	Norman SA, Berlin JA, Weber AL, Strom BL, Daling JR, Weiss LK, Marchbanks PA, Bernstein L, Voigt LF, McDonald JA, Ursin G, Liff JM, Burkman RT, Malone KE, Simon MS, Folger SG, Deapen D, Wingo PA, Spirtas R	Cancer Causes and Control 2003;14:933-943
MA0443			10/22/1983		Breast Cancer in Young Women and Use of Oral Contraceptives: Possible Modifying Effect of Formulation and Age at Use	Pike MC, Henderson BE, Duke A, Krailo MD, Roy S	The Lancet, October 22, 1983;926-929
MA0444			12/17/1983		Letter to the Editor Breast Cancer and Oral Contraceptives: Reply to Critics	Pike MC, Henderson BE, Krailo MD, Duke A, Roy S	The Lancet, December 17, 1983:1414-1415
MA0449			00/00/2000		Bias in Breast Cancer Analyses Due to Error in Age at Menopause	Rockhill, B, Colditz GA, Rosner B	American Journal of Epidemiology 2000; 151:404-8
MA0452			12/1/1990		Oral Contraceptives and Breast Cancer	Romieu I, Berlin JA, Colditz G	Cancer 1990; 66:2253-2263
MA0453			9/6/1989		Prospective Study of Oral Contraceptive Use and Risk of Breast Cancer in Women	Romieu I, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE	Journal of the National Cancer Institute 1989; 81:1313-1321
MA0456			11/00/1998		Effects of Age, Breast Density, Ethnicity and Estrogen Replacement Therapy on Screening Mammographic Sensitivity and Cancer Stage at Diagnosis: Review of 183, 134 Screening Mammograms in Albuquerque, New Mexico	Rosenberg RD, Hunt WC, Williamson MR, Gilliland FD, West PW, Kelsey CA, Key CR, Linver MN	Radiology 1998; 209:511-518
MA0458			01/00/2004		Invasive Cancers Detected after Breast Cancer Screening Yielded a Negative Result: Relationship of Mammographic Density to Tumor Prognostic Factors	Roubidoux MA, Bailey JE, Wray LA, Helvie MA	Radiology 2004; 230:42-48
MA0472			00/00/1994		Progestins and antiprogestins in mammary tumour growth and metastasis	Shi YE, Liu YE, Lippman ME, Dickson RB	Human Reproduction Volume 9 Supplement I, 1994:162-173
MA0486			00/00/2002		Pharmacokinetics and Potency of Progestins used for Hormone Replacement Therapy and Contraception	Stanczyk FZ	Reviews in Endocrine & Metabolic Disorders 2002;3:211-224
MA0497			11/00/2005		Endogenous Sex Hormone Levels and Mammographic Density among Postmenopausal Women	Tamimi RM, Hankinson SE, Colditz GA, Byrne C	Cancer Epidemiology Biomarkers & Prevention 2005; 14(11):2641-2647
MA0523			00/00/2003		Can the stroma provide the clue to the cellular basis for mammographic density?	Warren R, Lakhani SR	Breast Cancer Research 2003;5:225-227
MA0531			7/20/1979		Endometrial Cancer in Relation to Patterns of Menopausal Estrogen Use	Weiss NS, Szekely DR, English DR, Schweid AI	JAMA 1979;242(3):261-264
MA0532			12/4/1975		Risks and Benefits of Estrogen Use	Weiss, NS	N Engl J Med 1975; 293:1200-1202
MA0535			6/17/1998		Variation in Mammographic Breast Density by Time in Menstrual Cycle Among Women Aged 40-49 Years	White E, Velentgas P, Mandelson MT, Lehman CD, Elmore JG, Porter P, Yasui Y, Taplin SH	Journal of the National Cancer Institute, Vol. 90, No. 19, October 1998

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA0540			00/00/2004		Breast cancer: Critical data analysis concludes that estrogens are not the cause, however lifestyle changes can alter risk rapidly	Wiseman RA	Journal of Clinical Epidemiology 2004; 57:766-772
MA0544			6/1/1996		Hormone Replacement Therapy and Breast Cancer	Stanford JL, Weiss NS	Archives of Family Medicine 1996; 3:349-350
MA0547			1/1/1988		Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells	Sutherland RL, Hall RE, Pang GY, Musgrove EA, Clarke CL	Cancer Research , Vol 48(18):5084-5091 (abstract)
MA2015			00/00/2001		Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974 -2000	Godsland I	Fertility & Sterility 2001;75:898-915
MA2033			01/00/2004		Steroid receptors and cell cycle in normal mammary epithelium.	Anderson, E and RB Clarke	J Mammary Gland Biol Neoplasia 2004; 9(1):3-13
MA2037			1/29/2004		Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial.	Antoine, C, F Liebens, et al.	Hum Reprod 2004;19(3):741-56
MA2057			1/8/2003		Questions and Answers for Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women	FDA	FDA/Center for Drug Evaluations & Research 1/8/03
MA2063			00/00/1997		Twenty two weeks of transdermal estradiol increases sex hormone-binding globulin in surgical menopausal women	Basbug M, Aygen E, Tayyar M	Eur J Obstet Gynecol Reprod Bio 1997;73:149-152
MA2064			00/00/2000		Insulin-like growth factors and mammographic density.	Byrne C, SE Hankinson, et al.	Growth Horm IGF Res 2000;10 Suppl A:S24-5
MA2066			01/00/2002		Epidemiology of endocrine-related risk factors for breast cancer	Bernstein L	Journal of Mammary Gland Biology & Neoplasia 2002;7(1):3-15
MA2067			00/00/2000		Postmenopausal Hormone Use Following a 3-year Randomized Clinical Trial	Barrett-Connor E	J Women's Health Gend Based Med 2000;9(6):633-643
MA2071			00/00/2002		Positive effects on cardiovascular and breast metabolic markers or oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate	Campagnoli C, Colombo P et al.	Maturitas 2002;41:299-311
MA2096			03/00/2002		Epidemiology, etiology, and prevention of lung cancer	Bilello KS, S Murin, et al.	Clin Chest Med 2002; 23(1):1-25
MA2103			03/00/1992		Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins	Crook D, Cust MP, Gangar KF	Am J Obstet Gynecol 1992;166:950-955
MA2106			00/00/1979		Progesterone and breast cancer	Diamond EJ, Hollander VP	Mt Sinai J Med 1979;46:225-235
MA2111			06/00/2003		The pathogenesis of cancer metastasis: the 'seed and soil'	Fidler IJ	Nat Rev Cancer 2003; 3(6):453-8
MA2115			01/00/2006		Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury	Jeanes H	Menopause 2006; 13(1):80-86
MA2138			00/00/1998		Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women	Bonduki CE, Lourenco DM, Baracat E	Acta Obstet Gynecol Scand 1998;77:330-333
MA2145			11/00/1996		Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora) versus placebo in postmenopausal symptoms	Good WR, John VA, Ramirez M	Clin Ther 1996;18:1093-1105
MA2155			05/00/1988		Non-contraceptive estrogen use and the risk of gallstone disease in women	Kakar F, Weiss NS, Strite SA	Am J Public Health 1988;78:564-566
MA2199			10/9/2003		Clinical Practice. Combination estrogen-progestin oral contraceptives [see comment] [erratum appears in N Engl J Med 2004 Jan 1;350 (1):92]	Petitti DB	N Engl J Med 2003;349(15):1443-1450
MA2216			06/00/1980		Use of the progestogen challenge test to reduce the risk of endometrial cancer	Gambrell RD Jr, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM	Obstet Gynecol. 1980 Jun;55(6):732-8.
MA2258			06/00/1991		The mammographic parenchymal patterns of women on hormonal replacement therapy	Kaufman Z, Garstin WI, Hayes R	Clin Radiol 1991;43:389-392
MA2261			06/00/1980		Effect of hormones on growth rates of malignant and nonmalignant human mammary epithelia in cell culture	Klevjer-Anderson P, Buehring GC	In Vitro 1980;16(6):491-501
MA2292			11/21/2001		The two faces of janus: sex steroids as mediators of both cell proliferation and cell death.	Soto AM and C Sonnenschein	J Natl Cancer Inst 2001; 93(22):1673-5
MA2298			00/00/1996		Efficacy and local tolerance of a low-dose 7 day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms	Speroff L, Whitcomb RW, Kempfert NJ	Obstet Gynecol 1996;88:587-591
MA2301			11/00/1996		Analysis of parenchymal density on mammograms in 1353 women 25-79 years old	Stomper PC, D'Souza DJ, DiNitto PA, Arredondo MA	American Journal of Roentgenology 167:1261-5
MA2310			02/00/1998		Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women	Uhler ML, Marks JW, Voig B	J Clin Endocrinol Metab 1998;83:410-414
MA2312			04/00/2003		Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women	Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I	J Am Coll Cardiol 2003;41:1358-1363
MA2320			06/00/1990		Aromatase within the breast.	Yue W, RJ Santen, et al.	Endocr Relat Cancer 1999; 6(2):157-64
MA2327			4/20/1994		Validation of the Gail model for predicting individual breast cancer risk	Spiegelman D, Colditz GA, Hunter D	JNCI 1994;86:600-607
MA2330			12/1/2001		Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels	Serin IS, Ozclik B, Basbug M	Eur J Obstet Gynecol Reprod Biol 2001;99:2222-225
MA2342			4/3/1978		Noncontraceptive estrogens and nonfatal myocardial infarction.	Jick H, Dinan B and Rothman KJ	JAMA 1978;239:1407-8
MA2346			06/00/1977		Estrogens, progestogens and endometrial cancer	Gambrell RD Jr	J Reprod Med 1977 Jun;18(6):301-6
MA2347			09/00/1979		Reduced incidence of endometrial cancer among postmenopausal women treated with progestogens	Gambrell RD, Massey FM, Casaneda TA, Ugenas AJ, Ricci CA	J Am Geriatr Soc 1979 Sep;27(9):389-94
MA2350			11/1/1990		Progesterone action in normal mouse mammary gland.	Wang S;Counterman LJ;Haslam SZ	Endocrinology 1990 Nov;127(5):2183-9
MA2351			1/1/1992		Influence of estrogen and progesterone on the induction of mammary carcinomas by 7,12-dimethylbenz(a)anthracene in ovariectomized rats.	Ohl Y;Yoshida H	Virchows Arch B Cell Pathol Incl Mol Pathol 1992;62(6):365-70
MA2370			4/30/1987		Menopause and the risk of Coronary Heart Disease in Women.	Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE and Hennekens CH	NEJM 1987;316:1105-1110;
MA2374			09/00/2005		Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivityBazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity	Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR	Endocrinology. 2005 Sep;146(9):3999-4008. Epub 2005 Jun 16
MA2377			02/00/2003		Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women	Jackson VP , San Martin JA , Secrest RJ , McNabb M , Carranza-Lira S , Figueroa-Casas P , Fernandes CE , Romaguera J	Am J Obstst Gynecol 2003 Feb;188(2):389-94
MA2384			05/00/1998		Association of family history and other risk factors with breast cancer risk (Sweden)	Magnusson C, Colditz GA, Rosner B, et at	Cancer Causes and Control 1998;9:259-67
MA2388			06/00/1980		Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function	Manni A, Pearson OH	Cancer Treat Rep 1980; 64:779-785
MA2389			3/29/1990		A prospective study of obesity and risk of coronary heart disease in women	Manson JE, Colditz GA, Stampfer MJ	N Engl J Med 1990;332:882-889
MA2394			02/00/1997		Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake.	Masamura S, SJ Santner, et al.	Breast Cancer Res Treat 1997; 42(3):215-26
MA2417			10/00/1997		Growth hormone treatment induces mammary hyperplasia in aging primates	NG ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA	Nat Med 1997; 3:1141-1144
MA2474			01/00/1997		Proliferation of breast epithelial cells in healthy women during the menstrual cycle	Soderqvist G, Isaksson E, von Schoultz BO	Am J Obstet Gynecol 1997;176:123-8
MA2498			02/00/1990		Mammographic changes associated with postmenopausal hormone replacement therapy; a longitudinal study	Stomper PC, Van Voorhis BJ, Ravnikar VA	Radiology 1990;174:487-490
MA2509			03/00/1972		Menopause and breast cancer risk	Trichopoulos D, MacMahon B, Cole P	JNCI 1972; 48:605-13
MA2522			02/00/1991		Different Hepatobiliary effects of oral and transdermal estradiol in postmenopausal	Van Erpecum KJ, Van Berge Henegouwen GP, Vershoor L	Gastroenterology 1991;100:482-488
MA2526			10/18/2003		Million Women Study (comment).	Van Leeuwen FE, Rookus, MA	Obstet 2003; 363:1390

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA2532			00/00/1998		Determinants of tissue estradiol levels and biologic responsiveness in breast tumors.	Yue W, SJ Santrner, et al.	Breast Cancer Res Treat 1998; 49 Suppl 1:S1-7; discussion S33-7
MA2537			3/1/1998		In situ aromatization enhances breast tumor estradiol levels and cellular proliferation.	Yue W, JP Wang, et al.	Cancer Res 1998; 58(5):927-32
MA2548			1/1/2004		The impact of hormones on menopausal sexuality: a literature review	Gloria Bachman, Sandra Leiblum	Menopause 11(1): 120-130.
MA2552			1/1/2002		Using a low-dose contraceptive in women 35 years of age and over: 20ug estradiol/100ug levonorgestrel	carr, DelConte	Contraception 65(2002):397-402
MA2554			1/1/2001		The use of hormone replacement therapy in postmenopausal women with Type 2 diabetes	Cefalu	J Wom Health Gen Med 10(3):241-256.
MA2555			1/1/2004		Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk	Cerquetani, Vitale, Mercuro, Rosano	Gyn Endo 2004 18:291-298
MA2559			1/1/1999		Selective estrogen receptor modulators: A controversial approach for managing postmenopausal health	Curtis M	J Wom Health 8(3):321-333
MA2561			9/23/2002		The role of hormone replacement therapy in the prevention of alzheimer's disease	Fillit	Arch Int Med 162(2002):1934-1942.
MA2562			1/1/2003		Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy?	Koh	Int J Cardio 87(2003):1-8
MA2563			1/1/2002		Quality of life and menopause: The role of estrogen	Freedman M	J womens Health 11(8):703-718.
MA2565			1/1/2003		Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy	Gambacciani, Ciaponi, Monteleone, Benussi, cappagli, Bevilacqua, Ganazzani	MAturitas 45(2003) 175-183
MA2567			1/1/2001		Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention	Curtis M	Drug Safety 2001;24(14):1039-1063.
MA2568			1/1/1998		Is there an association between hormone replacement therapy and breast cancer?	Creasman	J Women's Health 7(10):1231-1246.
MA2574			1/1/2001		The role of estrogens in the management of postmenopausal bone loss	Gallagher JC	Rheum Dis Clin N Amer 27(1):143-62.
MA2578			4/1/2000		Mild Cognitive Impairment: Potential Pharmacological Treatment Options	Sherwin B	J Am Ger Soc 48(4):431-41.
MA2579			1/1/2002		Is there a connection between estrogen and Parkinson's?	Shulman L	Park Rel Dis 8:289-295 (2002)
MA2593			7/13/2004		A prospective study of diet and benign breast disease	Webb PM , Byrne C , Schnitt SJ , Connolly JL , Jacobs TW Willett WC , Colditz GA ;	Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1106-13
MA2594			11/30/1998		Meta-analysis of multiple outcomes by regression with random effects	Berkey CS , Hoaglin DC , Antczak-Bouckoms A , Mosteller F , Colditz GA ;	Stat Med. 1998 Nov 30;17(22):2537-50.
MA2595			8/5/1999		Health behaviors, social networks, and helathy aging: Cross-sectional evidence from the Nurses' Health Study	Michael YL, Colditz GA, Coakley E, Kawachi I	Qaul Life Res 1999 Dec; 8(8):711-22.
MA2596			5/7/1987		Moderate alcohol consumption and the risk of breast cancer.	Willett Wc, Stampfer MJ, Colditz GA, Rosner BA, Hennekens CH, Speizer FE	NEJM 1987 May 7;316(19):1174-80.
MA2598			1/1/2006		Epidemiology - identifying the causes and preventability of cancer?	Colditz GA, Sellers TA, Trapido E	Nat Rev Cancer 2006 Jan;6(1):75-83.
MA2599			1/1/1997		Cancer incidence and mortality: the priority of screening frequency and population coverage.	Colditz GA, Hoaglin DC, Berkey CS	Milbank Q 1997;75(2):147-73.
MA2600			1/1/1995		Cancer prevention strategies for the future: risk identification and preventive intervention.	Colditz GA, Gortmaker SL	Milbank Q 1995;73(4):621-51.
MA2601			11/1/1999		Economic costs of obesity and inactivity.	COLDITZ GA	Med SCI Sports Exerc 1999 Nov;31(11 Suppl):S663-7.
MA2602			5/17/1980		Continung education and peer review.	Colditz GA	Med J Aust 1980 May 17;1(10):500-2.
MA2603			5/1/1985		The statistical content of published medical research: some implications for biomedical education.	Colditz GA, Emerson JD	Med Educ 1985 May;19(3):248-55.
MA2605			2/17/1996		Prospective assessment of breastfeeding and breast cancer incidence among 89,887 women.	Micohls KB, Willett WC, Rosner BA, Manson JE, Hunter DJ, Colditz GA, Hankinson SE, Speizer FE	Lancet 1996 Feb 17;347(8999):431-6.
MA2606			3/1/1996		Postmenopausal estrogens and breast cancer	Colditz	J Soc Gynecol Investigt 1996 Mar-Apr;3(2):50-6
MA2607			7/17/1996		Prospective Study of Regular Aspirin Use and the risk of Breast Cancer	Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA	JNCI 1996 Jul 17;88(14):988-93
MA2608			9/17/1997		Geographic variation in breast cancer incidence rates in a cohort of U.S. women.	Laden F, Spiegelman D, Neas LM, Colditz GA, Hankinson SE, Manson JE, Byrne C, Rosner BA, Speizer FE, Hunter DJ	JNCI 1997 Sept 17;89(18):1373-8.
MA2609			3/20/1996		Nurses' health study: log-incidence mathematical model of breast cancer incidence.	Rosner B, Colditz GA	JNCI 1996 Mar 20;88(6):359-64.
MA2611			4/5/1995		Prospective study of toenail selenium levels and cancer among women.	Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, Baskett CK, Rosner B, Speizer FE, Willett WC, Hunter DJ	JNCI 1995 Apr 5;87(7):497-505
MA2612			2/1/1995		Childhood socioeconomic status and risk of cardiovascular disease in middle aged US women: a prospective study	Glikeman MD, Kawachi I, Hunter D, Colditz GA, Manson JE, Stampfer MJ, Speizer FE, Willett WC, Hennekens CH	J Epi Comm Health 1995 Feb;49(1):10-5.
MA2613			12/1/2005		A candidate gene approach to searching for low-penetrance breast and prostate cancer genes	Colditz, Stampfer et al.	Nat Rev Cancer 2005 Dec;5(12):997-85
MA2614			10/1/1997		From public health science to prevention policy: placing science in its social and political contexts.	Atwood K, Colditz GA, Kawachi I	Am J Public Health. 1997 Oct;87(10):1603-6
MA2615			2/18/2005		Body fatness during childhood and adolescence and incidence of breast cancer in premenopausal women: a prospective cohort study.	Baer HJ, Colditz GA, Rosner B, Michels KB, Rich-Edwards JW, Hunter DJ, Willett WC	Breast Cancer Res. 2005;7(3):R314-25.
MA2616			6/1/1999		Adolescence and breast carcinoma risk.	Berkey CS, Frazier AL, Gardner JD, Colditz GA	Cancer. 1999 Jun 1;85(11):2400-9
MA2617			3/3/1999		The role of meta-analysis in the regulatory process for foods, drugs, and devices	Berlin JA, Colditz GA	JAMA. 1999 Mar 3;281(9):830-4
MA2618			1/1/2005		Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer	Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE	Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1991-7
MA2619			3/3/1999		Postmarketing surveillance and adverse drug reactions: current perspectives and future needs	Brewer T, Colditz GA	JAMA. 1999 Mar 3;281(9):824-9
MA2620			7/15/2000		Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density.	Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE.	Cancer Res. 2000 Jul 15;60(14):3744-8
MA2621			11/1/2002		Alcohol consumption and incidence of benign breast disease	Byrne C, Webb PM, Jacobs TW, Peiro G, Schnitt SJ, Connolly JL, Willett WC, Colditz GA	Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1369-74
MA2622			8/1/1986		Medical costs confounded by disease severity	Colditz GA	Am J Epidemiol. 1986 Aug;124(2):343-4
MA2623			1/1/2000		Illnesses caused by smoking cigarettes	Colditz GA	Cancer Causes Control. 2000 Jan;11(1):93-7
MA2624			5/1/2002		Improving standards of medical and public health research	Colditz GA	J Epidemiol Community Health. 2002 May;56(5):333-4
MA2625			8/1/2002		Disseminating research findings into public health practice	Colditz GA	Cancer Causes Control. 2002 Aug;13(6):503-4
MA2626			5/1/1995		Fat, estrogens, and the time frame for prevention of breast cancer	Colditz GA	Epidemiology. 1995 May;6(3):209-11.
MA2627			7/1/2000		Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention	Colditz GA, Atwood KA, Emmons K, Monson RR, Willett WC, Trichopoulos D, Hunter DJ	Cancer Causes Control. 2000 Jul;11(6):477-88
MA2628			3/1/2001		Cancer culture: epidemics, human behavior, and the dubious search for new risk factors	Colditz GA	Am J Public Health. 2001 Mar;91(3):357-9
MA2629			5/1/2005		Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study	Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ.	Cancer. 2005 May 1;103(9):1778-84.

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA2630			3/1/1999		Smoking, smoking cessation, and risk of hip fracture in women	Cornuz J, Feskanich D, Willett WC, Colditz GA	Am J Med. 1999 Mar;106(3):311-4
MA2631			5/1/2002		Association of CYP1B1 polymorphisms and breast cancer risk	De Vivo I, Hankinson SE, Li L, Colditz GA, Hunter DJ	Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):489-92
MA2632			1/1/2004		The progesterone receptor Val660-->Leu polymorphism and breast cancer risk	De Vivo I, Hankinson SE, Colditz GA, Hunter DJ	Breast Cancer Res. 2004;6(6):R636-9
MA2633			10/24/2005		Serum lipids, lipid-lowering drugs, and the risk of breast cancer.	Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE.	Arch Intern Med. 2005 Oct 24;165(19):2264-71
MA2634			4/15/2006		Tubal sterilization in relation to breast cancer risk	Eliassen AH, Colditz GA, Rosner B, Hankinson SE	Int J Cancer. 2006 Apr 15;118(8):2026-30.
MA2635			8/1/2002		Aspirin, other NSAIDs, and ovarian cancer risk (United States)	Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE	Cancer Causes Control. 2002 Aug;13(6):535-42
MA2636			1/2/2002		Vitamin A intake and hip fractures among postmenopausal women	Feskanich D, Singh V, Willett WC, Colditz GA	JAMA. 2002 Jan 2;287(1):47-54
MA2637			2/1/2003		Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women	Feskanich D, Willett WC, Colditz GA	Am J Clin Nutr. 2003 Feb;77(2):504-11
MA2638			1/1/1999		Vitamin K intake and hip fractures in women: a prospective study.	Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA	Am J Clin Nutr. 1999 Jan;69(1):74-9
MA2639			11/1/1994		The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men	Field AE, Colditz GA, Willett WC, Longcope C, McKinlay JB.	J Clin Endocrinol Metab. 1994 Nov;79(5):1310-6
MA2640			7/9/2001		Impact of overweight on the risk of developing common chronic diseases during a 10-year period	Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA	Arch Intern Med. 2001 Jul 9;161(13):1581-6
MA2641			9/1/2004		Association of weight change, weight control practices, and weight cycling among women in the Nurses' Health Study II	Field AE, Manson JE, Taylor CB, Willett WC, Colditz GA	Int J Obes Relat Metab Disord. 2004 Sep;28(9):1134-42
MA2642			12/8/1999		A prospective study of weight change and health-related quality of life in women	Fine JT, Colditz GA, Coakley EH, Moseley G, Manson JE, Willett WC, Kawachi I	JAMA. 1999 Dec 8;282(22):2136-42
MA2643			2/1/2004		Adolescent diet and risk of breast cancer.	Frazier AL, Li L, Cho E, Willett WC, Colditz GA	Cancer Causes Control. 2004 Feb;15(1):73-82
MA2644			8/1/2005		Dietary patterns and the risk of postmenopausal breast cancer	Fung TT, Hu FB, Holmes MD, Rosner BA, Hunter DJ, Colditz GA, Willett WC	Int J Cancer. 2005 Aug 10;116(1):116-21
MA2645			1/1/1998		The relation between dietary intake and adipose tissue composition of selected fatty acids in US women.	Garland M, Sacks FM, Colditz GA, Rimm EB, Sampson LA, Willett WC, Hunter DJ	Am J Clin Nutr. 1998 Jan;67(1):25-30
MA2646			4/1/2006		A pooled analysis of 12 cohort studies of dietary fat, cholesterol and egg intake and ovarian cancer	Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Beeson WL, Buring JE, Colditz GA, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Koenig KL, Larsson SC, Leitzmann M, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Ross JA, Schatzkin A, Schouten LJ, Smit E, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Zhang SM, Smith-Warner SA	Cancer Causes Control. 2006 Apr;17(3):273-85
MA2647			10/1/1999		Association of age and reproductive factors with benign breast tissue composition.	Gertig DM, Stillman IE, Byrne C, Spiegelman D, Schnitt SJ, Connolly JL, Colditz GA, Hunter DJ	Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):873-9
MA2648			2/26/1997		A prospective study of risk factors for pulmonary embolism in women	Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH	JAMA. 1997 Feb 26;277(8):642-5
MA2649			7/15/2000		A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk	Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, Colditz GA, Willett WC, Speizer FE, Hunter DJ	Int J Cancer. 2000 Jul 15;87(2):204-10
MA2650			12/1/2003		A prospective study of XRCC1 haplotypes and their interaction with plasma carotenoids on breast cancer risk	Han J, Hankinson SE, De Vivo I, Spiegelman D, Tamimi RM, Mohrenweiser HW, Colditz GA, Hunter DJ	Cancer Res. 2003 Dec 1;63(23):8536-41
MA2651			12/1/1988		Fractures and lifestyle: effect of cigarette smoking, alcohol intake, and relative weight on the risk of hip and forearm fractures in middle-aged women	Hemenway D, Colditz GA, Willett WC, Stampfer MJ, Speizer FE	Am J Public Health. 1988 Dec;78(12):1554-8
MA2652			8/1/1995		Body height and hip fracture: a cohort study of 90,000 womenBody height and hip fracture: a cohort study of 90,000 women	Hemenway D, Feskanich D, Colditz GA	Int J Epidemiol. 1995 Aug;24(4):783-6.
MA2653			10/1/2000		A prospective study of the effect of alcohol consumption and ADH3 genotype on plasma steroid hormone levels and breast cancer risk	Hines LM, Hankinson SE, Smith-Warner SA, Spiegelman D, Kelsey KT, Colditz GA, Willett WC, Hunter DJ	Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1099-105
MA2654			4/15/2004		Dietary carbohydrates, fiber, and breast cancer risk	Holmes MD, Liu S, Hankinson SE, Colditz GA, Hunter DJ, Willett WC	Am J Epidemiol. 2004 Apr 15;159(8):732-9
MA2655			5/25/2005		Physical activity and survival after breast cancer diagnosis	Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA	JAMA. 2005 May 25;293(20):2479-86
MA2656			3/5/2003		Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer	Zhang SM, Willett WC, Selhub J, Hunter DJ, Giovannucci EL, Holmes MD, Colditz GA, Hankinson SE	J Natl Cancer Inst. 2003 Mar 5;95(5):373-80
MA2657			6/14/2000		Physical activity and risk of stroke in women	Hu FB, Stampfer MJ, Colditz GA, Ascherio A, Rexrode KM, Willett WC, Manson JE	JAMA. 2000 Jun 14;283(22):2961-7
MA2658			6/1/2005		Calculating deaths attributable to obesity	Hu FB, Willett WC, Stampfer MJ, Spiegelman D, Colditz GA	Am J Public Health. 2005 Jun;95(6):932;
MA2659			12/23/2004		Adiposity as compared with physical activity in predicting mortality among women.	Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE.	N Engl J Med. 2004 Dec 23;351(26):2694-703

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA2660			9/5/1990		A prospective study of selenium status and breast cancer risk	Hunter DJ, Morris JS, Stampfer MJ, Colditz GA, Speizer FE, Willett WC	JAMA. 1990 Sep 5;264(9):1128-31
MA2661			11/1/1997		A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer	Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, Manson JE, Colditz GA, Willett WC, Speizer FE, Kelsey K	Carcinogenesis. 1997 Nov;18(11):2127-32
MA2662			1/17/2001		Intake of fish and omega-3 fatty acids and risk of stroke in women.	Iso H, Rexrode KM, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Hennekens CH, Willett WC	JAMA. 2001 Jan 17;285(3):304-12
MA2663			9/1/1999		Prospective study of aspirin use and risk of stroke in women.	Iso H, Hennekens CH, Stampfer MJ, Rexrode KM, Colditz GA, Speizer FE, Willett WC, Manson JE	Stroke. 1999 Sep;30(9):1764-71
MA2664			4/1/2004		Validation of the Harvard Cancer Risk Index: a prediction tool for individual cancer risk	Kim DJ, Rockhill B, Colditz GAKim DJ, Rockhill B, Colditz GA	J Clin Epidemiol. 2004 Apr;57(4):332-40
MA2665			5/15/2004		Functional impact of breast cancer by age at diagnosis	Kroenke CH, Rosner B, Chen WY, Kawachi I, Colditz GA, Holmes MD	J Clin Oncol. 2004 May 15;22(10):1849-56
MA2666			2/1/2003		Caregiving and risk of coronary heart disease in U.S. women: a prospective study.	Lee S, Colditz GA, Berkman LF, Kawachi I	Am J Prev Med. 2003 Feb;24(2):113-9
MA2667			1/31/2006		Obesity as compared with physical activity in predicting risk of coronary heart disease in women	Li TY, Rana JS, Manson JE, Willett WC, Stampfer MJ, Colditz GA, Rexrode KM, Hu FB	Circulation. 2006 Jan 31;113(4):499-506
MA2668			11/24/1989		Prospective study of relative weight, height, and risk of breast cancer	London SJ, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE	JAMA. 1989 Nov 24;262(20):2853-8
MA2669			9/14/1995		Body weight and mortality among women.	Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE	N Engl J Med. 1995 Sep 14;333(11):677-85
MA2670			1/1/2005		Dietary glycemic load, carbohydrate, sugar, and colorectal cancer risk in men and women	Michaud DS, Fuchs CS, Liu S, Willett WC, Colditz GA, Giovannucci E	Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):138-47
MA2671			12/1/2000		The persistent impact of breast carcinoma on functional health status: prospective evidence from the Nurses' Health Study	Michael YL, Kawachi I, Berkman LF, Holmes MD, Colditz GA	Cancer. 2000 Dec 1;89(11):2176-86
MA2672			11/1/1998		Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses' health study	Michels KB, Rosner BA, Walker AM, Stampfer MJ, Manson JE, Colditz GA, Hennekens CH, Willett WC	Cancer. 1998 Nov 1;83(9):2003-7
MA2673			2/1/2001		Being breastfed in infancy and breast cancer incidence in adult life: results from the two nurses' health studies	Michels KB, Trichopoulos D, Rosner BA, Hunter DJ, Colditz GA, Hankinson SE, Speizer FE, Willett WC	Am J Epidemiol. 2001 Feb 1;153(3):275-83
MA2674			4/1/2005		Fiber intake and incidence of colorectal cancer among 76,947 women and 47,279 men.	Michels KB, Fuchs CS, Giovannucci E, Colditz GA, Hunter DJ, Stampfer MJ, Willett WC	Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):842-9
MA2675			6/1/2003		Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study	Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE; Nurses' Health Study	Diabetes Care. 2003 Jun;26(6):1752-8
MA2676			2/1/2006		Preschool diet and adult risk of breast cancer	Michels KB, Rosner BA, Chumlea WC, Colditz GA, Willett WC	Int J Cancer. 2006 Feb 1;118(3):749-54
MA2677			7/20/2002		A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer	Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN, Hankinson SE	Int J Cancer. 2002 Jul 20;100(3):332-6
MA2678			6/1/2002		African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast	Newman LA, Mason J, Cote D, Vin Y, Carolin K, Bouwman D, Colditz GA	Cancer. 2002 Jun 1;94(11):2844-54
MA2679			3/20/2006		Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status	Newman LA, Griffith KA, Jatoti I, Simon MS, Crowe JP, Colditz GA	J Clin Oncol. 2006 Mar 20;24(9):1342-9
MA2680			6/1/2004		Plasma adrenal androgens and risk of breast cancer in premenopausal women	Page JH, Colditz GA, Rifai N, Barbieri RL, Willett WC, Hankinson SE	Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1032-6
MA2681			8/20/2005		CYP19 (aromatase) haplotypes and endometrial cancer risk	Paynter RA, Hankinson SE, Colditz GA, Kraft P, Hunter DJ, De Vivo I	Int J Cancer. 2005 Aug 20;116(2):267-74
MA2682			12/2/1998		Abdominal adiposity and coronary heart disease in women	Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE	JAMA. 1998 Dec 2;280(21):1843-8
MA2683			10/25/1999		A prospective study of recreational physical activity and breast cancer risk	Rockhill B, Willett WC, Hunter DJ, Manson JE, Hankinson SE, Colditz GA	Arch Intern Med. 1999 Oct 25;159(19):2290-6
MA2684			3/7/2001		Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention	Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA	J Natl Cancer Inst. 2001 Mar 7;93(5):358-66
MA2685			7/1/2005		Mathematical models of ovarian cancer incidence	Rosner BA, Colditz GA, Webb PM, Hankinson SE	Epidemiology. 2005 Jul;16(4):508-15
MA2686			1/7/2004		A prospective study of aspirin use and the risk of pancreatic cancer in women	Scherhammer ES, Kang JH, Chan AT, Michaud DS, Skinner HG, Giovannucci E, Colditz GA, Fuchs CS	J Natl Cancer Inst. 2004 Jan 7;96(1):22-8
MA2687			9/1/2005		Sugar-sweetened soft drink consumption and risk of pancreatic cancer in two prospective cohorts	Scherhammer ES, Hu FB, Giovannucci E, Michaud DS, Colditz GA, Stampfer MJ, Fuchs CS	Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2098-105

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA2688			6/4/2003		Night-shift work and risk of colorectal cancer in the nurses' health study	Schemhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS, Colditz GA	J Natl Cancer Inst. 2003 Jun 4;95(11):825-8
MA2689			10/17/2001		Rotating night shifts and risk of breast cancer in women participating in the nurses' health study	Schemhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA	J Natl Cancer Inst. 2001 Oct 17;93(20):1563-8
MA2690			9/4/2002		Intake of dairy products, calcium, and vitamin d and risk of breast cancer	Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett	J Natl Cancer Inst. 2002 Sep 4;94(17):1301-11
MA2691			5/1/1988		Alcohol intake and risk of breast cancer	Stampfer MJ, Colditz GA, Willett WC	Compr Ther. 1988 May;14(5):8-15
MA2692			7/1/1990		Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study	Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH	Am J Obstet Gynecol. 1990 Jul;163(1 Pt 2):285-91
MA2693			1/26/2004		Modifiable risk factors for cancer	Stein CJ, Colditz GA	Br J Cancer. 2004 Jan 26;90(2):299-303
MA2695			1/1/2004		Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case-control study	Tamimi RM, Hankinson SE, Spiegelman D, Kraft P, Colditz GA, Hunter D	Breast Cancer Res. 2004;6(4):R416-22
MA2696			1/1/2005		Benign breast disease, recent alcohol consumption, and risk of breast cancer: a nested case-control study	Tamimi RM, Byrne C, Baer HJ, Rosner B, Schnitt SJ, Connolly JL, Colditz GA	Breast Cancer Res. 2005;7(4):R555-62
MA2697			12/1/2003		The HRAS1 variable number of tandem repeats and risk of breast cancer	Tamimi RM, Hankinson SE, Ding S, Gagelang V, Larson GP, Spiegelman D, Colditz GA, Kroniris TG, Hunter D	Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1528-30
MA2698			6/1/2004		Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer	Tamimi RM, Hankinson SE, Spiegelman D, Colditz GA, Hunter DJ	Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):989-96
MA2699			1/15/2005		Plasma carotenoids, retinol, and tocopherols and risk of breast cancer	Tamimi RM, Hankinson SE, Campos H, Spiegelman D, Zhang S, Colditz GA, Willett WC, Hunter DJ	Am J Epidemiol. 2005 Jan 15;161(2):153-60
MA2700			5/10/2005		Smoking and the risk of endometrial cancer: results from the Nurses' Health Study	Viswanathan AN, Feskanich D, De Vivo I, Hunter DJ, Barbieri RL, Rosner B, Colditz GA, Hankinson SE	Int J Cancer. 2005 May 10;114(6):996-1001
MA2701			7/20/2002		Family history of breast cancer, age and benign breast disease	Webb PM, Byrne C, Schnitt SJ, Connolly JL, Jacobs T, Peiro G, Willett W, Colditz GA	Int J Cancer. 2002 Jul 20;100(3):375-8
MA2702			7/1/2002		Postmenopausal hormone use and lens opacities.	Weintraub JM, Taylor A, Jacques P, Willett WC, Rosner B, Colditz GA, Chylack LT, Hankinson SE	Ophthalmic Epidemiol. 2002 Jul;9(3):179-90
MA2703			8/3/2005		Underweight, overweight, obesity, and excess deaths	Willett WC, Hu FB, Colditz GA, Manson JE	JAMA. 2005 Aug 3;294(5):551
MA2704			5/5/1999		A prospective study of folate intake and the risk of breast cancer	Zhang S, Hunter DJ, Hankinson SE, Giovannucci EL, Rosner BA, Colditz GA, Speizer FE, Willett WC	JAMA. 1999 May 5;281(17):1632-7
MA2705			12/1/2003		A prospective study of plasma total cysteine and risk of breast cancer	Zhang SM, Willett WC, Selhub J, Manson JE, Colditz GA, Hankinson SE	Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1188-93
MA2706			10/1/2004		Cataract extraction and risk of breast cancer	Zhang SM, Willett WC, Hu FB, Giovannucci EL, Manson JE, Colditz GA, Hankinson SE	Cancer Causes Control. 2004 Oct;15(8):781-6
MA2707			3/17/1999		Dietary carotenoids and vitamins A, C, and E and risk of breast cancer	Zhang S, Hunter DJ, Forman MR, Rosner BA, Speizer FE, Colditz GA, Manson JE, Hankinson SE, Willett WC	J Natl Cancer Inst. 1999 Mar 17;91(6):547-56
MA2708			9/1/1999		Prospective Study of Calcium, Potassium, and Magnesium Intake and Risk of Stroke in Women	Iso H, Stampfer, Manson, Rexrode, Hennekens, Colditz, Speizer, Willett	Stroke September 1999;1772-1779.
MA2711			9/6/1995		Alcohol, Height, and Adiposity in Relation to Estrogen and Prolactin Levels in Postmenopausal Women	Hankinson, Willett, Manson, Hunter, Colditz, Stampfer, Longcope, Speizer	JNCI 87(17):1297-302 (1995)
MA2712			5/28/1999		Age at Natural Menopause and Risk of Cardiovascular Disease	Hu, Grodstein, Hennekens, Colditz, Johnson, Manson, Rosner, Stampfer	Arch Int Med 159(10):1061-6 (1999)
MA2714			11/1/2003		Sex steroid exposures and risk for meningioma	Jhawar, Fuchs, Colditz, Stampfer	J Neurosurg 2003; 99(5):848-53.
MA2715			9/1/1992		A Prospective Study of Postmenopausal Estrogen Therapy and Subsequent Incidence of Non-Insulin Dependent Diabetes Mellitus	Manson, Rimm, Colditz, Willett, Nathan, Arky, Rosner, Hennekens, Speizer, Stampfer	Ann Epi 1992; 2(5):665-73
MA2718			12/1/1988		Menopause and coronary disease	Stampfer, Colditz	Am Heart J 1988; 116(6pt1):1649
MA2742			5/15/2006		Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden	Gotzsche PC	Int J Cancer 118(10):2648
MA2744			5/15/2006		Comments to the letters by Per-Henrik Zahl and Jan Maehlen and by Peter C. Gotzsche concerning our article: Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden	Jonsson, Johansson, Lenner	Int J Cancer 2006;118(10):2649.
MA2745			4/10/2006		A prospective study of female hormone use and breast cancer among black women.;	Rosenberg L, Palmer JR, Wise LA, Adams-Campbell LL. ;	Arch Intern Med. 2006 Apr 10;166(7):760-5. ;
MA2746			1/1/1995		1995 Preamin PDR	1995 PDR	1995 PDR
MA2748			5/1/2005		2005 PDR Prempro	2005 PDR	2005 PDR
MA2749			9/7/2005		Prostate cancer and the Will Rogers phenomenon	Albertsen PC, Hanley JA, Barrows GH, Penson DF, Sanders MM, Fine J	JNCI 2005 Sep 7;97(17):1248-53
MA2750			11/18/1998		What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes	Zhang J, Yu KF	JAMA 1998 Nov 18;280(19):1690-1
MA2776			4/1/1976		Exogenous Estrogens and breast cancer in women with natural menopause	Casagrande, Gerkins, Henderson, Mack, Pike	JNCI 56(4)
MA2795			1/1/1983		Risks of endometrial and mammary cancer morbidity and mortality in long-term oestrogen treatment: Chapter 20	Lauritzen, Meier	The Climacteric
MA2823			11/21/1959		Prolonged estrogen therapy in postmenopausal women	Wallach S, Henneman P	JAMA 171(12):1637-1642.
MA2864			10/18/2003		Million Women Study (comment).	Bundred NJ, Morris J	Lancet 2003;362:1329.
MA2944			1/1/1997		Pathology of familial breast cancer.: differences between breast cancers in carriers on BRCA1 or BRCA2 mutations and sporadic cases	Breast Cancer Linkage Consortium	Lancet 1997;349:1505-10

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA2971			10/19/2005		Questions and Answers for; Estrogen and Estrogen with; Progestin Therapies for; Postmenopausal Women; (Updated)	FDA	FDA, 10/19/05; http://www.fda.gov/cder/drug/infopage/estrogensprogestins/Q&A.htm
MA3034			1/1/2000		New Imaging Modalities: The Use of Magnetic Resonance Imaging, Position Emission Tomography, and Computed Tomography Scanning in the Diagnosis of Breast Cancer	Henry-Tillman RS, Harms SE, Klimberg VS	Problems in General Surgery 2000;17(4):8-14
MA3035			8/1/1996		Controversies in Management: Hormone replacement therapy for all? Universal prescription is desirable	Toozs-Hobson P, Cardozo L	BMJ 1996;313:350-351
MA3038			1/1/2006		Histopathology of BRCA1- and BRCA2-associated breast cancer	Honrado E, Benitez J, Palacios J	Critical Review in Oncology Hematology 2006;
MA3066			1/1/1997		Breast Imaging-Chapter 3	Kopans	Lippincott 1997
MA3085			1/1/2000		The Association of Increased Weight, Body Mass Index, and Tissue Density with the Risk of Breast: Carcinoma in Vermont.	Lam PB, Vacek PM, Geller BM, Muss HB	Cancer 2000;89:369-75
MA3175			2/16/2006		Combined analysis of women's health initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.; ;	Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators.;	Am J Epidemiol. 2006 Apr 1;163(7):589-99. Epub 2006 Feb 16. ; ;
MA3192			1/1/2002		Cigarette smoking and risk of breast cancer	Russo IH	Lancet 2002;360:1033- 1034
MA3192			4/10/2004		Development of the human breast	Russo J, Russo IH	Maturitas 2004;49:2- 15
MA3311			1/1/2002		Is Pharmacological Prevention of Alzheimer's a Realistic Goal?	Zandi PP, Breitner JCS, Anthony JC	Expert Opinion Pharmacotherapy 2002;3(4): 365-380
MA3320			8/1/2002		Factors that influence breast density	Florica	Menopausal Medicine 10(2):2-5
MA3321			1/1/2005		Estrogens and the skin	Brintat, Baron, Galea	Climacteric 2005;8:110-123
MA3325			8/1/2004		Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones.	Hankinson, Colditz, Willett	Breast Can Res 2004;6(5):213-8. Epub 2004
MA3326			3/1/2006		Recent reports link bisphosphonates to osteonecrosis	Marunick, Miller, Gordon	Today's FDA 2006 18(3):26-31
MA3330			4/1/2006		The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women	Alexandersen, Tanko, Bagger, Qin, Christiansen	Climacteric 2006 Apr;9(2):108-18
MA3331			6/8/2006		Highlights and a Hidden Hazard- The FDA's New Labeling Regulations	Avorn, Shrank	NEJM 354(23):2409-2411
MA3332			1/1/2002		Chapter 6, Estrogens	Greendale, Cauley	Osteoporosis: An Evidence-Based Guide to Prevention and Management, Ed. Cummings, American college of Physicians, 2002
MA3333			6/27/2006		Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors	Clarke CA, Purdie DM, Glaser SL	BMC Cancer 2006 Jun 27;6(1):170 [Epub ahead of print]
MA3334			3/1/2005		Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome.	Anderson WF, Jatoi I, Devesa SS	Breast Cancer Res Treat 2005 Mar;90(2):127-37
MA3335			11/1/1957		Osteoporosis: its prevalence, diagnosis, and treatment	Seidel H	MD St Med J 1957 Nov;6(11):692-9
MA3337			7/1/2006		Established breast cancer risk factors by clinically important tumour characteristics		Br J Cancer 2006 Jul 3;95(1):123-9. Epub 2006 Jun 6
MA3338			6/1/2006		The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort.	<i>Norwegian women and cancer study</i> Gill JK, Maskarinec G, Pagano I, Kolonel LN	Breast Cancer Res 2006 Jun 23;8(3):R30 [Epub ahead of print]
MA3339			1/1/2006		Letter to the Editor	Goldstein	Menopause 13(3):538.
MA3340			9/1/1961		Osteoporosis: Diagnosis and treatment	Gordan G	Tex State J Med 1961 Sep;57:740-7.
MA3343			5/16/2006		Heart disease risk determines menopausal age rather than the reverse.	Kok et al.	J Am Coll Cardiol 2006 May 16;47(10):1976-83. Epub 2006 Apr 24.
MA3344			6/1/2006		The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits - an attempt to interpret the Women's Health Initiative results.	Kuhl, Stevenson	Gynecol Endocrinol 2006 Jun;22(6):303-17.
MA3345			6/1/2006		Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis.	McCormack VA, dos Santos Silva J	Cancer Epidemiol Biomarkers Prev 2006 Jun;15(6):1159-69.
MA3346			5/16/2006		Menopause and Cardiovascular Risk: Cause or Consequence	Bittner	JACC 2006;47(10):1984-7.
MA3347			5/1/2006		Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.	No authors Listed	Menopause 2006 May-Jun;13(3):340-67
MA3349			1/1/2006		A survey of obstetrician-gynecologists concerning practice patterns and attitudes toward hormone therapy	Power, Zinberg, Schulkin	Menopause 2006;13(3):434-441.
MA3350			5/1/2006		Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy?	Silvestri, Thomsen, Gozzini, Bagger, Brandi	Menopause 2006 May/June; 13(3):451-61.
MA3354			6/26/2006		Breast Cancer Trends Among Young Women in the United States.	Tarone RE	Epidemiology 2006 Jun 26; [Epub ahead of print]
MA3356			4/26/2006		Five Author Reply	Prentice R, Stefanick, Howard, Barad, Kuller	Am J Epidemiol 2006;163:1067-1069
MA3357			9/9/2005		Dissecting a Hidden breast cancer risk	Couzin J	Science Septemember 2005 309:1664-6.
MA3359			5/1/2006		Bisphosphonate-associated mandibular osteonecrosis.	Carneiro E, Vibhute P, Montazem A, Som PM	Am J Neuroradiol 2006 May;27(5):1096-7
MA3360			5/16/2006		Systematic review: bisphosphonates and osteonecrosis of the jaws	Woo SB, Hellstein JW, Kalmar JR	Ann Int Med 2006 May 16;144(10):753-61.
MA3362			3/20/2006		Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy	Mignogna MD, Lo Russo L, Fedele S, ciccarelli R, Lo Muzio L	J Clin Onc 2006 Mar 20;24(9):1475-7.
MA3363			6/1/2006		Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?	Zavras AI, Zhu S	J Oral Maxillofac Surg 2006 June;64(6):917-23.
MA3367			11/2/2005		The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells.	Ghatge RP, Jacobsen BM, Schiltone SA, Horwitz KB	Breast Cancer Res2005;7(6):R1036-50. Epub 2005 Nov 2
MA3368			5/23/2006		Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.	Hendrix, WHI Investigators	Circulation 2006 May 23;113(20):2425-34. Epub 2006 May 15
MA3379			12/1/2005		A critique of the Women's Health Initiative hormone therapy study	Klaiber EL, Vogel W, Rako S	Fertil Steril 2005 Dec;84(6):1589-601
MA3381			7/1/2000		A reappraisal of progesterone action in the mammary gland	Lydon JP, Sivaraman L, Conneely OM	J Mammary Glan Biol Neoplasia 2000 July;5(3):325-38.
MA3382			5/8/2006		Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish population-based cohort study.	Norgaard M, Poulsen AH, Pedersen L, Gregersen H, Friis S, Ewertz M, Johnson HE, Sorenson HT	Br J Cancer 2006 May 8;94(9):1339-41.
MA3387			11/1/2005		What influence does hormone replacement therapy have on endometrial cancer risk?	Beral, V	Nature Clinical Practice Oncology 2(5):546
MA3388			5/20/2006		HRT use in 2001 and 2004 in The Netherlands—a world of difference.	de Jong-van den Berg, Faber A, van den Berg PB	Maturitas 2006 May 20;54(2):193-7.
MA3391			1/1/1982		Mammographic signs as risk factors for breast cancer	Boyd NF, O'Sullivan, Campbell, Fishell, Simor, Cooke	British Journal of Cancer 45(2):185-93
MA3394			1/1/2006		Comment to Anderson WF, Jatoi I, Devesa SS: Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127-137, 2005.	Demicheli et al.	Breast Cancer Res Treat (2006) 97:341-343.
MA3401			1/1/2006		Proliferative effects of different hormone regimes on mammary glands in ovariectomized rats	Cirpan, Terek, Ozsener, Kanit, Pogun, Zekioglu, Yucebilgin	Eur J Gynecol Oncol. 2006 27(3):256-261.
MA3407			7/13/2006		Effects of Raloxifene on Cardiovascular events and breast cancer in postmenopausal women	Barrett-connor et al.	NEJM July 13, 2006 355(2):125-136.
MA3408			11/3/1999		Hormones and Breast Cancer: Evidence and implications for consideration of risks and benefits of hormone replacement therapy	Colditz	J Women's Health November 3, 1999 8(3):347-357.
MA3409			7/1/2006		Changes in US prescribing patterns of menopausal hormone therapy, 2001-2203	Hing E, Brett K	Obstet Gyn 108(1):33-40.
MA3419			1/1/1995		Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992	Wysowski, Goiden, Burke	Obstet Gynecol 1995 Jan;85(1):6-10

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA3420			7/14/2006		Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.	Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Mark Cline J	Breast Cancer Res Treat 2006 Jul 14; [Epub ahead of print]
MA3422			12/19/2005		Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration.	Stefanick	Am J Med 2005 Dec 19;118(12 Suppl 2):64-73.
MA3428			5/1/1986		Postmenopausal estrogens--current prescribing patterns of San Diego gynecologists.	Barrett-Connor	West J Med 1986 May;144(5):620-1.
MA3434			6/22/2006		Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication.	Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S	Pharmacoepidemiol Drug Saf 2006 Jun 22;[Epub ahead of print]
MA3436			7/1/2006		The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.	Zegura B et al.	Menopause 2006 Jul-Aug;13(4):643-50.
MA3437			6/30/2006		Medroxyprogesterone acetate attenuates long-term effects of 17beta-estradiol in coronary arteries from hyperlipidemic rabbits.	Pedersen et al.	Steroids 2006 Jun 30;[Epub ahead of print]
MA3438			7/1/2006		Loyalties in clinical research on drugs: The case of hormone replacement therapy.	Palmiund	Soc Sci Med 2006 Jul;63(2):540-51
MA3444			8/1/2006		Hormone replacement therapy in menopause and lung cancer: an update.	La Vecchia	Eur J Can Prev 2006 Aug;15(4):283-284.
MA3450			7/1/2006		Hormone replacement therapy is associated with increased C-reactive protein in women with Type 2 diabetes in the Diabetes Heart Study.	Bowden, Lohmna, Hsu, Langefeld, Carr, Lenchik, Wagenknechy, Freedman, Herrington	Diabet Med 2006 Jul;23(7):763-7
MA3451			7/1/2006		Hormone replacement therapy and mammographic screening outcomes in Western Australia.	Crouchley K, Wylie E, Khong E	J Med Screen 2006;13(2):93-7
MA3454			7/1/2006		Hormone therapy and age-related macular degeneration: the Women's Health Initiative Sight Exam Study.	Haan MN, Klein R, Deng Y, Blythe LK, Seddon JM, Musch DC, Kuller LH, Hyman LG, Wallace RB	Arch Ophthalmol 2006 Jul;124(7):988-92.
MA3455			6/30/2006		Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study.	Hall P, Ploner A, Bjohle et al.	BMC Med 2006 Jun 30;4(1):16 [Epub ahead of print]
MA3456			1/1/2006		Breast density changes associated with hormone replacement therapy in postmenopausal women. Effects on the specificity and sensitivity of mammographic screening.	Howard JM	Eur J Gynaecol Oncol 2006;27(1):104
MA3459			4/25/2006		Cardiovascular, anthropometric and neurocognitive features of healthy postmenopausal women: effects of hormone replacement therapy.	Magri F, Gabellieri E, Busconi L, uazzoni V, Cravello L, Valdes V, Sorrentino ARE, Chylitis S, Ferrari E	Life Sci 2006 Apr 25;78(22):2625-32.
MA3462			7/1/2006		Mammographic density correlation with gail model breast cancer risk estimates and component risk factors.	Palomares MR, Machia JR, Lahman CD, Daling JR, McTiernan A	Cancer Epi Biomarkers Prev 2006 Jul;15(7):1324-30.
MA3464			4/1/2006		Effect of clinical trial publicity on HRT prescribing in Ireland.	Usher, Teelingf, Bennett, Feely	Eur J Clin Pharmacol 2006 Apr;62(4):307-10.
MA3467			11/2/2006		Osteoporosis management in a medicaid population after the Women's Health Initiative Study.	Lee et al.	J Women's Health 2006;15(2):155-163
MA3470			7/1/2006		Influence of menopausal status and use of hormone replacement therapy on radiation dose from mammography in routine screening	Whitaker, Kelly, Faulkner, Stamp	Br J Radiology 2006;79:597-604
MA3472			6/26/2006		Progesterin-induced caveolin-1 expression mediates breast cancer cell proliferation	Salatino et al.	Oncogene 2006 1-17.
MA3475			5/1/2006		Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in medicaid.	Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK	J Bone Miner Res 2006 May;21(5):765-71.
MA3476			7/1/2006		Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.	Benakanakere I, Besch-Willifors, Schnell J, Brandt S, Ellersieck MR, molinolo A, Hyder SM	Clin Cancer Res 2006 Jul;12(13):4062-71
MA3477			7/1/1986		Postmarketing surveillance of adverse drug reactions: problems and solutions.	Lortie FM	CMAJ 1986 Jul;135(91):27-32
MA3479			7/24/2006		Complementary and Alternative Therapies for the Management of Menopause-Related Symptoms	Nedrow et al.	Arch Int Med 266(14):1453-1465.
MA3480			7/24/2006		Combined Estrogen and Testosterone Use and Risk of Breast Cancer in Postmenopausal Women	Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA	Arch Int Med 2006;166(14):1483-1489.
MA3481			9/1/1994		Rising levels of estrogen receptor in breast cancer over 2 decades.	Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM	Cancer 1994 Sept 1;74(5):1601-6.
MA3487			11/1/1987		Adverse drug events: identification and attribution.	Rogers AS	Drug Intell Clin Pharm 1987 Nov;21(11):915-20.
MA3491			9/1/1996		Rationale for estrogen with interrupted progestin as a new low-dose hormonal replacement therapy.	Casper RF, MacLusky NJ, Vanin C, Brown TJ	J Soc Gynecol Invest 1996 Sep-Oct;3(5):225-34.
MA3492			8/1/2001		Low-dosage esterified estrogens opposed by progestin at 6-month intervals.	Ettinger B, Pressman A, Van Gessel A	Obstet Gynecol 2001 Aug;98(2):205-11.
MA3493			7/1/2002		Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate.	Ylikorkala O, Wahlstrom T, Caubel P, Lane R	Acta Obstet gynecol Scand 2002 Jul;81(7):654-60.
MA3505			7/1/1992		A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.	Allan MC	J Pharm Technol 1992 Jul-Aug;8(4):162-7.
MA3508			1/1/1990		The menopause in perspective. From potions to patches.	Utian WH	Ann NY Acad Sci 1990;592:1-7
MA3510			1/1/2004		Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.	Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H	Cochrane Database Syst Rev 2004;(3):CD000402.
MA3513					Preneoplastic lesions of the human mammary gland transplanted into the nude athymic mouse.	Jensen HM, Wellings SR	Cancer Res 1976 Jul;36(7PT2):2605-10.
MA3514			1/1/1978		Uterine Cancer Incidence, San Francisco Bay Area 1960-1975	Resource for Cancer Epidemiology, Austin D	1/1/1978
MA3520			6/6/2006		What can be learnt from models of incidence rates?	Colditz GA, Rosner BA	Breast Cancer Res 2006 Jun 6;8(3):208[Epub ahead of print]
MA3524			5/8/2006		Unopposed estrogen therapy and the risk of invasive breast cancer.	Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, Colditz GA	Arch Intern Med 2006 May 8;166(9):1027-32.
MA3534			8/1/2006		17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells.	Russo J, Fernandez SV, Russo PA, Fembrough R, Sheriff FS, Lereef HM, Garber J, Russo IH	FASEB J 2006 Aug;20(10):1622-34
MA3542			12/16/2005		Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer.	Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Alfred DC	Breast Cancer Res 2006;8(1):R^Epub 2005 Dec 16
MA3543			8/1/2006		Reducing the problems of the progestogen.	Sturdee DW, MacLennan AH	Climacteric 2006 Aug;9(4):241-3.
MA3551			1/1/2003		Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study.	Gelfand MM, Moreau M, Avotte NJ, Hilditch JR, Lau CY	Menopause 2003 Jan-Feb;10(1):29-36.
MA3553			5/16/2005		Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.	Kenemans P, Speroff L	Maturitas 2005 May 16;51(1):21-8.
MA3557			1/1/1997		A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey.	Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY	Br J Cancer 1997;75(7):1075-9
MA3558			4/1/2004		Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age.	Randolph JF, Sowers M, Bonarenko IV, Harlow SD, Luborsky JL, Little RJ	J Clin Endocrinol Metab 2004 Apr;89(4):1555-61.
MA3559			7/1/2006		Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.	Pietras RJ	Oncologist 2006 Jul;11(7):704-17

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA3562			8/20/2006		Quality of life assessment in a chemoprevention trial: Fenretinide and oral or transdermal HRT.	Serrano D, Mariani L, Mora S, Guerrieri-Gonzaga A, Cazzaniga M, Daldoss C, Ramazzotto F, Feroce I, Decensi A, Bonanni B	Maturitas 2006 Aug 20;55(1):69-75
MA3565			6/1/2006		Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.	Rowan JP, Simon JA, Speroff L, Ellman H	Clin Ther 2006 Jun;28(6):921-32.
MA3566			7/1/2006		Progesterone reverses the spatial memory enhancements initiated by tonic and cyclic oestrogen therapy in middle-aged ovariectomized female rats.	Birmonte-Nelson HA, Francis KR, Umphlet CD, Granholm AC	Eur J Neurosci 2006 Jul;24(1):229-42.
MA3567			1/10/2005		Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women.	Yasui T, Uemura H, Umono Y, Takikawa M, Saito S, Kuwahara A, Matsuzaki T, Maegawa M, Furumoto H, Miura M, Irahara M	Maturitas 2005 Jan 10;50(1):19-29.
MA3569			6/1/2005		Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperactivity in intact male rhesus monkeys.	Mishra RG, Hermesmeyer RK, Miyagawa K, Sarrel P, Uchida B, Stanczyk FZ, Burry KA, Illingworth DR, Nordt FJ	J Clin endocrinol Metab 2005 Jun;90(6):3706-14.
MA3571			7/1/2005		Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study.	Koh KK, Han SH, Shin MS, Ahn JY, Lee Y, Shin EK	Eur Heart J 2005 Jul;26(14):1362-8.
MA3572			8/1/1998		Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics.	Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB	Control Clin Trials 1998 Aug;19(4):314-35
MA3577			9/1/2001		A population-based cohort study of HRT use and breast cancer in southern Sweden.	Olsson H, Bladstrom A, Ingvar C, Moller TR	Br J Cancer 2001 Spet 1;85(5):674-7.
MA3579			5/1/1979		Correlation of estrogen receptor levels with histology and cytomorphology in human mammary cancer.	Antoniades K, Spector H	Am J Clin Path 1979 May;71(5):497-503.
MA3583			5/1/2004		Prevention of coronary hyperactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone.	Hermesmeyer RK, Mishra RG, Pavcnik D, Uchida B, Axhelm MK, Stanczyk FZ, Burry KA, Illingworth DR, Juan C, Nordt FJ	Atheroscler thromb Vasc Biol 2004 May;24(5):955-61.
MA3584			2/26/2002		Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone.	Jondet M, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Pelissier C	Maturitas 2002 feb 26;41(2):115-21
MA3585			6/1/2005		Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.	Wildemeersch D, Janssens D, Schacht E, Pilyser K, de Wever N	Gynecol Endocrinol 2005 Jun;20(6):336-42.
MA3587			1/1/1975		Serum lipid levels and thromboembolic complications during estrogen therapy of prostatic cancer.	Sotaniemi EA, Kontturi MJ	Scand J Urol Nephrol 1975;9(2):89-93
MA3588			1/1/1981		Histopathological characteristics and oestrogen receptor content in primary breast carcinoma.	Rasmussen BB, Rose C, Thorpe SM, Hou-Jensen K, Daehnfeldt JL, Palshof T	Virchows Arch A Pathol Anat Histol 1981;390(3):347-51.
MA3605			2/10/2004		Evolving views of involution	Master SR, Chodosh LA	Breast Cancer Res 2004;6(2):89-92. Epub 2004 Feb 10
MA3612			7/11/2002		The reciprocal dance between cancer and development	Chodosh LA	NEJM 347(2):134-6
MA3693			7/1/1986		Assessment of results of estrogen and progesterone receptor assays performed in a community hospital.	Szakacs JG, Arroyo JG, Girgenti AJ	Ann Clin Lab Sci 16(4):266-73.
MA3703			7/1/2006		Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative.	Hsia J, Criqui MH, Herrington DM, Manson JE, Wu L, Heckbert SR, Allison M, McDermott MM, Robinson J, Masaki K	Am Heart J 152(1):170
MA3729			7/1/1984		Prescribing estrogen during menopause: physician survey of practices in 1974 and 1981.	Pasley BH, Standfast SJ, Katz SH	Public Health Rep 1984 Jul-Aug; 99(4):424-9.
MA3730			8/1/2006		Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women.	Warren R, Skinner J, Sala E, Denton E, Dowsett M, Folkers E, Healey CS, Dunning A, Doodly D, Ponder B, Luben RN, Easton D	Cancer Epi Biomarkers Prev 15(8):1502-8.
MA3731			8/3/2006		Elucidating progesterone effects in breast cancer: Cross talk with PDGF signaling pathway in smooth muscle cell.	Soares R, Guerreiro S, Botelho M	J Cell Biochem 2006 Aug 3; [Epub ahead of print]
MA3738			11/1/1978		Role of exogenous female hormones in altering the risk of benign and malignant neoplasms in humans.	Thomas DB	Cancer Res 38(11Pt2):3991-4000
MA3739			8/10/2006		The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease	Laura C. Collins, MD , Heather J. Baer, ScD , Rulla M. Tamimi, ScD , James L. Connolly, MD , Graham A. Colditz, MD, DrPh , Stuart J. Schnitt, MD	Cancer 10 Aug 2006 [Epub ahead of print]
MA3743			1/1/1978		Role of exogenous female hormones in altering the risk of breast cancer	Thomas DB	Cancer Research 38(11Pt2):3991-4000
MA3751			1/1/2000		Effects of Body Size and Skeletal Site on the estimated Prevalence of Osteoporosis in Women and Men	Melton L, Khosla S, Achenbach S, O'Connor M, O'Fallon, Riggs B	Osteoporosis Int 11:977-983
MA3752			11/12/2004		Population-based Study of Age and Sex Differences in Bone Volumetric Density, Size, Geometry, and structure at Different Skeletal Sites	Riggs B, Melton et al	J Bone Min Res 19(12)
MA3753			4/28/2006		Influence of baseline deformity definition on subsequent vertebral fracture risk in postmenopausal women	Melton L, Wenger D, Atkinson E, Achenbach S, Berquist T, Roggs B, Jiang G, eastell R	Osteo Int 17:978-985.
MA3754			1/1/2006		American Association of Clinical Endocrinologists Medical Guidelines For Clinical Practice for the Diagnosis and Treatment of Menopause	AACE Task Force	Endocrin Pract 2006;12(No.3)
MA3755			10/14/1999		Breast Cancer: Molecular genetics, pathogenesis, and therapeutics	Chodosh	NEJM 341:1244, 1999.
MA3756			11/1/2004		Endocrine Influences on Mammary Development and Breast Cancer Risk	Wysolmerski, Chodosh	J Mammary Gland Biol Neoplasia 7(1):1-2
MA3757			2/3/2004		Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results.	Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K	Ann Int Med 140(3):184-8.
MA3758			8/14/2006		Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.	Crandall CJ et al.	Arch Intern Med 166(15):1578-84
MA3761			9/6/2006		Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density.	Chen J, Pee D, Ayyagari, Graubard, Schairer, Byrne, Benichou, Gail	JNCI 2006 Sep 6;98(17):1215-26
MA3763			12/1/2002		Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.	Krajcik RA, Borofsky ND, Massardo S, Orentreich N	Cancer Epidemiol Biomarkers Prev 11(12):1566-73.
MA3765			2/1/1999		Western nutrition and the insulin resistance syndrome: a link to breast cancer.	Stolt BA	Eur J Clin Nutr 53(2):83-7.
MA3771			10/1/2006		Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study.	Suzuki R, Rylander T, ye W, Saij S, Wolk A	Int J Cancer 119(7):1683
MA3796			5/1/1997		Screening mammography: sensitivity and specificity in relation to hormone replacement therapy.	Thurfjell EL, Holmberg LH, Persson IR	Radiology 203(2):339-41.
MA3798			9/1/2000		A case-control study of mammographic densities in Hawaii.	Maskarinec G, Meng L	Breast Cancer Res Treat 63(2):153-61.
MA3799			12/1/1993		Mammographic changes in postmenopausal women undergoing hormonal replacement therapy.	Cyriak D, Wong CH	AJR Am J Roentigenol 161(6):1177
MA3800			9/12/2006		Breast Cancer Risk associated with different HRT formulations: A register-based case-control study.	Dinger JC, Heinemann LA, Moehner S, Thai DM, Assmann A	BMC Womens Health 6(1):13 [Epub ahead of print]
MA3801			9/6/2006		Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells.	Xu et al.	Epub ahead of print]

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA3802			4/1/2006		Changes in newspaper coverage about hormone therapy with the release of new ; medical evidence	Haas JS, Geller B, Miglioretti DL, Buist DS, Nelson DE, Kerlikowske K, ; Carney PA, Breslau ES, Dash S, Canales MK, Ballard-Barbash R	J Gen Intern Med. 2006 Apr;21(4):304-9. Epub 2006 Feb 22
MA3824			2/1/1999		Moderate physical activity in relation to mammographic patterns.	Gram, Funkhouser, Tabar	cancer Epi Biomarkers Prev 8(2):117-22.
MA3829			9/6/2006		Prospective breast cancer risk prediction model for women undergoing screening mammography.	Barlow WE, White E, Ballard-Barbash, Vacek, Titus-Ernstoff, Carney, Tice, Buist, Geller, Rosenberg, Yankaskas, Kerlikowske	JNCI 98(17):1204-14
MA3830			2/1/1999		Macronutrient intake and change in mammographic density at menopause: results from a randomized trial.	Knight JA, Martin, Greenberg, Lockwood, Byng, Yaffe, Trichler, Boyd	Cancer Epi Biomarkers Prev 8(2):123-8.
MA3833			1/1/2005		How do personal characteristics affect sensitivity and specificity of mammography?	kerlikowske	Natl Clin Pract Oncol 2(1):16-7.
MA3840			4/15/2006		Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells.	Fernandez SV, russo IH, Russo J	Int J Cancer 118(8):1862-8
MA3844			8/1/2005		Pharmacology of estrogens and progestogens: influence of different routes of administration.	kuhl H	Climacteric 8 Suppl 1:3-63.
MA3846			9/1/2006		Mammographic density, Hormone Therapy and Risk of Breast Cancer	Boyd	Cancer Epi Biomarkers Prev 15(9):1750
MA3847			9/1/2006		Mammographic Density, Hormone Therapy, and Risk of Breast Cancer	Ursin, Pike	Cancer Epi Biomarkers Prev 15(9):1750
MA3886			9/19/2006		Controversies Regarding Transdermal Androgen Therapy in Postmenopausal Women	Basaria S, Dobs AS	J Clin Endocrinol Metab 2006 Sept 19 [Epub ahead of print]
MA3894			6/3/1983		The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?	Rosenfield, Maine, Rochat, Shelton, Hatcher	JAMA 249(21):2922-8
MA3922			10/1/2006		Breast cancer risk in relation to abortion: Results from the EPIC study	Reeves GA, Sau-Wan Kan, Tim Key, Anne Tjenneland, Anja Olsen, Kim Overvad, Petra H. Peeters, Françoise Clavel-Chapelon, Xavier Paoletti, Franco Berrino, Vittorio Krogh Domenico Palli, Rosario Tumino, Salvatore Panico, Paulo Vineis, Carlos A. Gonzalez, Eva Ardanaz, Carmen Martinez, Pilar Amiano, José R. Quiros, Maria R. Tormo, Kay-Tee Khaw, Antonia Trichopoulou, Theodora Psaltopoulou, Victoria Kalapothaki, Gabriele Nagel, Jenny Chang-Claude, Heiner Boeing, Petra H. Lahmann, Elisabet Wirfält, Rudolf Kaaks	Int J Cancer 119(7):1741-45
MA3927			8/1/1972		Analysis of trends in age-adjusted incidence rates for 10 major sites of cancer	Sullivan PD, B Christine, R Connelly, and H Barrett	Am J Public Health. 1972 August; 62(8): 1065-1071
MA3932			9/20/2006		A comprehensive analysis of the AR gene and risk of breast cancer: results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).	Cox et al.	Breast Cancer Res 2006 Sep 20;8(5):R54 [Epub ahead of print]
MA3952			10/1/2005		Proliferation: The Most Prominent Predictor of Clinical Outcome in Breast Cancer.	Desmedt C, Sortirou C	Cell Cycle 2006 Oct 1:5(19)
MA3956			6/27/2005		Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.	Wysowski D, Swartz L	Arch Intern Med 165(12):1363-9
MA3957			9/29/2006		Ethnic and geographic differences in mammographic density and their association with breast cancer incidence.	Maskarinec G, Pagano I, Chen Z, Nagata C, Gram IT	Breast Cancer Res TReat 2006 Sept 29; [Epub ahead of print]
MA3958			7/1/1983		Postmarketing studies of drug efficacy: when must they be randomized?	Strom BL, Miettinen OS, Melmon KL	Clin Pharmacol Ther 34(1):1-7
MA3959			10/1/1987		The drug approval process and the information it provides.	Myers A, Moore SR	Crug Intell Clin Pharm 21(10):821
MA3961			11/1/1993		Postmarketing surveillance: curriculum for the clinical pharmacologist. Part II: Clinical and regulatory considerations.	Johnson JM, Tanner LA	J Clin Pharmacol 33(11):1015-22
MA3962			7/1/2003		Industry reneges on postmarketing trial commitments.	Bouchie A	Nat Biotechnol 21(7):718
MA3965			5/8/2006		Off-label prescribing among office-based physicians.	Radley DC, Finkelstein SN, Stafford RS	Arch Intern Med 166(9):1021-6
MA3966			9/28/2006		Effect of hormone therapy on risk of hip and knee joint replacement in the women's health initiative.	Cirillo DJ, Wallace RB, Wu L, Yood RA	Arthritis Rheum 54(10):3194-32
MA3970			10/4/2006		Common Genetic Variants for Breast Cancer: 32 Largely Refuted Candidates and Larger Prospects	Ioannidis JPA	JNCI 98(19):1350-1353
MA3995			8/1/2006		Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention.	Cavalieri E, Chakravati, Guttentplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T	Biochim Biophys Acta 1766(1):63-78
MA4001			10/1/2006		Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection.	Chiarelli AM, Kirsh VA, Klar NS, Shumak R, Jong R, Fishell E, Yaffe MJ, Boyd NF. ;	Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1856-62.
MA4002			9/1/2006		Accuracy of Assigned BI-RADS Breast Density Category Definitions	Nicholson BT, Alexander P, LoRusso, Mark Smolkinb, Viktor E. Bovbjergb, Gina R. Petroni and Jennifer A. Harvey	Acad Radiol 13(9):1143-49.
MA4005			8/9/2000		Estrogen-Progestin Replacement and Risk of Breast Cancer	Bazzano LA; Giuseppe Del Priore; Men-Jean Lee; Anthony N. Glaser; Jennifer A. Harvey; Craig J. Newschaffer; Kathy J. Helzlsouer; Catherine A. Roca; Peter J. Schmidt; Robert C. Daly; David R. Rubinow; Catherine Schairer; Jay Lubin; Rebecca Troisi; Susan Sturgeon; Louise Brinton; Robert Hoover	JAMA 284(6):691-4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA4007			8/17/2006		Should Symptomatic Menopausal Women Be Offered Hormone Therapy?	Lobo RA, MD; Serge Bélsis, MD, MSc; William T. Creasman, MD; Nancy R. Frankel, BS, MBA; Neil E. Goodman, MD, FACE; Janet E. Hall, MD; Susan Lee Ivey, MD, MHSA, FAAFP; Sheryl Kingsberg, PhD; Robert Langer, MD, MPH; Rebecca Lehman, MPAS, PA-C; Donna Behler McArthur, PhD, APRN, BC, FAANP; Valerie Montgomery-Rice, MD, Morris Notelovitz, MD, PhD, MB, BCh, FRCOG, FACOG; Gary S. Packin, DO, FACOG; Robert W. Rebar, MD; MaryEllen Rousseau, CNM; Robert S. Schenken, MD; Diane L. Schneider, MD, MSc; Katherine Sherif, MD; Susan Wysocki, NP	MEDGENMED 2006;8(2):1 p preceding 35
MA4010			10/18/2006		Effects of estradiol and medroxyprogesterone acetate on morphology, proliferation and apoptosis of human breast tissue in organ cultures	Eigeliene N, Pirkko Harkonen and Risto Erkkola	BMC Cancer 2006, 6:246
MA4020			10/1/2006		Raloxifene (Evista) for Breast Cancer Prevention in Postmenopausal Women	None listed	Obstet Gynecol 108(4):1023
MA4025			5/12/1984		Postmarketing surveillance of adverse drug reactions.	Castle WM, Lewis JA	Br Med J (Clin Res Ed) 288(6428):1458-9
MA4026			10/19/2006		Comparison of two forms of continuous combined hormone replacement therapy with respect to metabolic effects	Tugrul S, Yildirim G, et al.	Arch Gynecol Obstet 2006 Oct 19; [Epub ahead of print]
MA4032			10/16/2006		Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis.	Esslimani-Sahla et al	Int J Cancer 2006 Oct 16;[Epub ahead of print]
MA4040					Breast cancer in postmenopausal women with and without hormone replacement therapy: Preliminary results of the MISSION study.	Espeie M, Mares P, de Reileac P, Chavallier T, Daures JP	Gynecol Endocrinol 22(8):423-31
MA4119			12/10/2003		Differential effects of progestins: European Progestin Club	Schindler A	Maturitas 2003;46 Suppl 1:s3-s5
MA4120			12/10/2003		Classification and pharmacology of progestins	Schindler A, Campagnoli C, Drukman R, Huber J, Pasqualini J, Schweppe KW, Thijssen JH	Maturitas 46 Suppl 1:7-16
MA4121			12/10/2003		Metabolic and vascular effect of progestins in post-menopausal women ;Implications for cardioprotection	Rosano G, Vitale C, Silvestri A, Fini M	Maturitas 46 Suppl 1:17-29.
MA4128			11/6/2006		Mammographic densities during the menopausal transition: a longitudinal study of Australian-born women.	Guthrie JR, Milne RL, Hopper JL, Dennerstein L, Burger HG	Menopause 2006 Nov 6; [Epub ahead of print]
MA4131			3/1/2003		Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin	Kraemer GR, Kraemer RR, Ogdon BW, Kilpatrick RE, Gimpel TL, Castracane VD	Fertility & Sterility 79(3):534-542
MA4148			3/1/1997		Hormone replacement therapy with dydrogesterone and 17 α -oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up	Crook D, Goddard IF, Hull J, Stevenson JC	Br J Obstet Gyn 104:298.
MA4149			7/1/2006		Postmenopausal hormone therapy increases use of health services: Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]	Veerus P, Fischer K, Lic S, Hakams M, Ruhu M, Hemminki E	Am J Obstet Gyn 195(1):62-71
MA4150			9/20/2006		Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]	Veerus P, Hovi S, Fischer K, Rahu M, Hemminki E	Maturitas 55(2):162
MA4163			6/15/2006		Breast cancer incidence in U.S. radiologic technologists.	Doody MM, Freedman DM, Alexander BH, Hauptmann M, Miller JS, Rao RS, Mabuchi K, Ron E, Sigurdson AJ, Linet MS	Cancer 106(12):2707-15
MA4177			12/1/2006		The role of estrogen in the initiation of breast cancer.	Russo J, Russo I	J Steroid Biochem Mol Biol 102(1-5):89-96
MA4184			1/1/1984		Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins.	Ottosson UB	Acta Obstet Gynecol Scand Suppl 127:1-37
MA4213			11/1/2006		Body size, mammographic density, and breast cancer risk.	Boyd NE, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, Yaffe M, Minikin S	Cancer Epidemiol Biomarkers Prev 15(11):2086-92
MA4214			12/1/2006		Do breast cancer risk factors modify the association between hormone therapy and mammographic breast density? (United States).	Aiello EJ, Buist DS, White E	Cancer Causes Control 17(10):1227-35
MA4227			2/1/2003		Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology.	Conner P, Soderqvist G, Skoog L, Graser T, Walter F, Tani E, Carlstrom K, von Shultz B	Breast Cancer Res Treat 78(2):159-65
MA4229			1/1/2006		Estrogen and progesterone levels in nipple aspirate fluid of healthy premenopausal women: relationship to steroid precursors and response proteins.	Gann PH, Geiger AS, Helenowski IB, Vonesh EF, Chatterton RT	Cancer Epidemiol Biomarkers Prev 15(1):39-44
MA4230			5/20/2003		Plasma sex steroid hormones and breast cancer risk in Chinese women.	Yu H, Shu XO, Shi R, Dai Q, Jin F, Gao YT, Li BD, Zheng W	Int J Cancer 105(1):92-7
MA4238			12/1/2005		Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition.	Kaaks et al.	Endocr Relat Cancer 12(4):1071-82
MA4239			12/1/2006		Breast cancer risk factors in relation to breast density (United States).	Titus-Ernstoff L, Tosteson AN, Kasales C, Weiss J, Goodrich M, Hatch EE, Carney PA	Cancer Causes Control 17(10):1281-90
MA4243			11/14/2006		Type and Duration of Exogenous Hormone Use Affects Breast Cancer Histology.	Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES	Ann Surg Oncol 2006 Nov 14;[Epub ahead of print]
MA4249			11/27/2006		Different types of postmenopausal hormone therapy and mammographic density in Norwegian women.	Bremmes Y, Ursin G, Bjurstam N, Lund E, Gram IT	Int J Cancer 2006 Nov 27;[Epub ahead of print]
MA4250			11/15/2006		Age-related lobular involution and risk of breast cancer.	Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA, Maloney SD, Panikratz VS, Degen AC, Vachon CM, Reynolds CA, Thompson RA, Melton LJ, Goode EL, Visscher DW	JNCI 98(22):1600-7
MA4259			11/1/1985		Bioavailability of oral micronized progesterone.	Maxson WS, Hargrove JT	Fertil Steril 44(5):622-6
MA4260			4/1/1989		Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.	Hargrove JT, Maxson WS, Wentz AC, Burnett LS	Obstet Gynecol 73(4):606-12.
MA4264			10/1/2005		Estrogen metabolizing polymorphisms and breast cancer risk among older white women.	Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR, Stone KL, Morin PA, Greene D, Cauley JA	Breast Cancer Res Treat 93(3):261-70

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA4269			3/1/1979		Mammary tumors and serum hormones in the bitch treated with medroxyprogesterone acetate or progesterone for four years.	Frank DW, Kirtan KT, Murchison TE, Quinlan WJ, Colemand ME, Gilbertson TJ, Feenstra ES, Kimball FA	Fertil Steril 31(3):340-6
MA4274			3/22/2007		Rationale for use of lower estrogen doses for postmenopausal hormone therapy.	Ettinger B	Maturitas 2007 Mar 22:[Epub ahead of print]
MA4275			3/24/2007		Androgens and the breast.	von Scholtz B	Maturitas 2007 Mar 24:[Epub ahead of print]
MA4277			3/23/2007		Breast cancer: Are oestrogen metabolites carcinogenic?	Mueck AO, Seeger H	Maturitas 2007 Mar 23:[Epub ahead of print]
MA4290			1/1/1982		[The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue]	Morville R, Dray F, Reynier J, Barrai J	J Gynecol Obstet Biol reprod (Paris) 1982;11(3):355-63
MA4291			12/1/2006		Breast cancer risk in postmenopausal women using estrogen-only therapy.	Lytyinen H, Pukkala E, Ylikorkala O	Obstet Gynecol 2006 Dec;108(6):1354-60
MA4292			10/29/1983		Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium.	Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI	Br Med J (Clin Res Ed) 1983 Oct 29;287(6401):1241-5.
MA4293			7/1/2004		A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.	Decensi A, Bonanni B, Baglietto L, et al.	Clin Cancer Res 2004 Jul 1;10(13):4389-97
MA4294			11/1/1997		Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.	Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Alach M	Arterioscler Thromb Vasc Biol 1997 Nov;17(11):3071-8
MA4295			4/1/2006		Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women.	Garcia-Perez MA, Moreno-Mercer J, Tanin JJ, Cano A	Gynecol Endocrinol 2006 Apr;22(4):179-84.
MA4296			7/1/1975		Micronized 17 beta-estradiol for oral estrogen therapy in menopausal women.	Callantine MR, Martin PL, Bolding OT, Warner PO, Greaney MO	Obstet Gynecol 1975 Jul;46(1):37-41
MA4298			3/1/2005		Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.	Dias AR, Melo RN, Gebara OC, D'Amico EA, Nussbacher A, Halbe HW, Pinotti JA	Climacteric 2005 Mar;8(1):63-70
MA4300			1/1/1996		Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages.	Evans SF, Davie MW	Clin Endocrinol (Oxf). 1996 Jan;44(1):79-84
MA4304			5/1/1996		Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.	Lindoff C, Peterson F, Lecander I, Martinson G, Astedt B	Maturitas 1996 May;24(1-2):43-50
MA4307			8/1/1985		A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms.	Place VA, Powers M, Darley PE, Schenkel L, Good WR	Am J Obstet Gynecol 1985 Aug 15;152(8):1092-9
MA4311			1/1/2005		Levels of serum C-reactive protein during oral and transdermal estradiol in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy.	Ropponen A, Aittomaki K, Tikkanen MJ, Ylikorkala O	J Clin Endocrinol Metab 2005 Jan;90(1):142-6. Epub 2004 Nov 2
MA4317			10/1/2000		Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study.	Tiras MB, Noyan V, Yildiz A, Yildirim M, Daya S	Hum Reprod 2000 Oct;15(10):2087-92
MA4319			7/1/2002		Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women.	Cummings JA, Brizendine L	Menopause 9(4):253-63
MA4320			1/1/1984		Riguer ou la bonne politique pour traiter les menopause	Cazenave JC et al.	Medecine et Agress 12:155-168
MA4323			3/22/1980		Absorption and metabolism of oral progesterone.	Whitehead MI, Townsend PT, Gill DK, Collins WP, Campbell S	Br Med J 1980 Mar 22;280(6217):825-7.
MA4324			4/1/2005		Influence of hormone therapy on the cardiovascular responses to stress of postmenopausal women.	Matthews KA, Owens JF, Salomon K, Harris KF, Berga SL	Biol Psychol 2005 Apr;69(1):39-56. Epub 2005 Jan 4.
MA4389			4/10/2007		Postmenopausal hormone therapy and changes in mammographic density.	van Duijnhoven FJ, Peeters PH, Warren RM, Bingham SA, van Noord PA, Monnikhof EM, Grobbee DE, van Gils CH	J Clin Oncol 25(11):1323-8.
MA4392			5/3/2007		Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.	Jemal A, Ward E, Thun MJ	Breast Cancer Res 2007 May 3;9(3):R28
MA4407			7/1/2000		Estrogen receptor transcription and transactivation: Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action.	Curtis Hewitt S, Couse JF, Korach KS	Breast Cancer Res 2000;2(5):345-52.
MA4408			9/1/2000		Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression.	Zhou J, Ng S, Adesanya-Famiya O, Anderson K, Bondy Ca	FASEB J 14(12):1725
MA4409			4/1/2003		Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone.	Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, Pelletier G	Endocr Rev 2003 Apr;24(2):152-82
MA4413			4/24/2001		Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.	Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek SR, Weinmann R, Einspahr HM	Proc Natl Acad Sci USA 2001 Apr 24;98(9):4904-9
MA4414			8/1/2005		Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment	Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F	Lancet Oncol 6(8):552-3.
MA4415			2/19/2003		An in vitro long-term culture model for normal human mammary gland: expression and regulation of steroid receptors	Zhuang Y, Saaristo R, Ylikomi T	Cell Tissue Res 311(2):217-226.
MA4504			5/3/2007		Mammammographic Breast Density- Response to Boyd Jan 2007	Kopans D, Cuzick J, van Netten J, Boyd N, Minkin S, Yaffe M	N Engl J Med 356(18):1885-7
MA4584			7/1/2007		Bioidentical hormones for menopausal hormone therapy: variation on a theme.	Fugh-Berman A, Bythrow J	J Gen Intern Med 2007 Jul;22(7):1030-4.
MA4588					Hormone replacement therapy and breast cancer in former users of oral contraceptives-The Norwegian Women and Cancer study.	Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M	Int J Cancer 2007 Aug 1;121(3):645-8.
MA4664			7/1/2007		Breast cancer incidence and hormone replacement therapy: Results from the MISSION study, prospective phase	Espie M, Dares JP, Chevallier T, Mares P, Micheletti MC, de Reilhac P	Gynecol Endocrinol 2007 July;23(7):391-397
MA4667					Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women	Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Collins WP, Whitehead MI	AM J Obstet Gynecol 177(4):937-941
MA4672			8/14/2007		Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population.	Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA	J Natl Vaner Inst 2007 Aug 14:[Epub ahead of print]
MA4678			8/2/2007		A decline in breast-cancer incidence.	Bluming AZ, Effenbein GJ, Kiewer EV, Zahl P, Maehlen J, Cady B, Churg M, Michaelsson J, Robbins AS, Clarke CA, Signorelli LB, Tarore RE, Ravdin PM, Crorin KA, Chlebowski R	N Engl J Med 2007 Aug 2;357(5):509-513
MA4681			7/26/2007		Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin.	Colditz GA	Breast Cancer Res 2007 Jul 26;9(4):108
MA4697			5/24/2007		Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk;	Hankinson SE, Eliassen AH	J Steroid Biochem Mol Biol 2007 May 24:[Epub ahead of print]
MA4711			9/4/2007		Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation	Corrao G, Zambon A, Contl V, Nicotra F, La vecchia C, Fornari C, Cesana G, Contiero P, Tagliabue G, Nappi RE, Merlino L	Ann Oncol 2007 Sept 4:[Epub ahead of print]

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA4763					IMS updated recommendations on postmenopausal hormone therapy.	Pines A, Sturdee DW, Birkhouse MH, Schneider HP, Gambacciani M, Panay N, Board of the International Menopause Society	Climacteric 2007 Jun;10(3):181-94
MA4775			11/15/2005		Management of post-menopausal vaginal atrophy and atrophic vaginitis	Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD	Maturitas 2005 Nov15;52(Supp 1):S46-52.
MA4786			8/1/2007		Endogenous Hormone Levels, Mammographic Density, and Subsequent Risk of Breast Cancer in Postmenopausal Women	Tamimi RM, Byrne C, Colditz GA, Hankinson SE	J Natl Cancer Inst 2007 Aug 1;99(15):1178-87.
MA4788			5/1/2007		The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.	NAMS	Menopause 14(3):357-369
MA4789			10/4/2007		Association between premenopausal progestogen use and postmenopausal hormonal therapy in the GAZEL cohort	Ringa V, Fritel X, Varnoux N, Zins M, Piault S, Quelen C	Maturitas 2007 Oct 4;[Epub ahead of print]
MA4797			4/1/1982		Estrogen levels in postmenopausal women with hot flashes.	Erik Y, Meldrum DR, Judd HL	Obstet Gynecol 1982 Apr;59(4):403-7
MA4829			10/1/2007		Progesterone: Review of safety for clinical studies.	Goletiani NV, Keith DR, Gorsky SJ	Exp Clin Psychopharmacol. 2007 Oct;15(5):427-44
MA4844			10/11/2007		Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast.	Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO	Breast Cancer Res Treat 2007 Oct 11;[Epub ahead of print]
MA4854			1/15/2008		Haplotypes of the estrogen receptor beta gene and breast cancer risk.	Breast and Prostate Cancer Cohort Consortium, Cox DG, Brossky P, Kraft P, Pharoah P, Albanes D, Altshuler D, Amiano P, Berglund G, Boeing H, Buring J, Burt N, Calle EE, Canzian F, Chanock S, Clavel-Chapelon F, Colditz GA, Feigelson HS, Haiman CA, Hankinson SE, Hirschhorn J, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel L, LeMarchand L, Lund E, Palli D, Peeters PH, Pike MC, Riboli E, Stram DO, Thun M, Tjonneland A, Travis RC, Trichopoulos D, Yeager M	Int J Cancer 2008 Jan 15;122(2):387-92
MA4893			11/27/2007		Re: Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population	Robbins AS, Clarke CA, Anderson BO, Kerlikowske K, Buist DS, Walker R	J Natl Cancer Inst 99(23):1815-1816
MA4898			11/1/2007		Breast cancer: origins and evolution	Polyak K	J Clin Invest 2007 Nov;117(11):3155-63
MA4906			6/1/2007		Androgens and androgen receptors in breast cancer	Diaz-Chico BN, Rodriguez FG, Gonzalez A, Ramirez R, Bilbao C, de Leon AC, Jaime AA, Chirino R, Navarro D, Diaz-Chico JC	J Steroid Biochem Mol Biol 2007 Jun-Jul;105(1-5):1-15
MA4908			11/15/2007		CORRECTION: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin.	Colditz GA	Breast Cancer Res 2007 Nov 15;9(6):401 [Epub ahead of print]
MA4925			3/1/2007		Testosterone inhibits estrogen/progesterone-induced breast cell proliferation in postmenopausal women.	Hofling M, Hirschberg AL, Skoog L, Tani E, Hagerstrom T, von Schoultz B	Menopause 2007 Mar-Apr;14(2):183-90
MA4942			4/1/2006		Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study.	Lundstrom E, Soderqvist G, Svane G, Azavedo E, Olovsson M, Skoog L, von Schoultz E, von Schoultz B	Fertil Steril 2006
MA4957			11/1/2006		Recent results from clinical trials using SERMs to reduce the risk of breast cancer.	Vogel VG	Ann NY Acad Sci 2006 Nov;1089:127-42
MA4964			12/4/2007		Potential Mechanisms of Estrogen Quinone Carcinogenesis.	Bolton JL, Thatcher GR	Chem Res Toxicol 2007 Dec 4;[Epub ahead of print]
MA4972			1/1/1996		The role of randomized controlled trial in assessing the benefits and risks of long-term hormone replacement therapy: example of theWomen's Health Initiative.	Prentice R, Rossouw JR, Johnson SR, Freedman LS, McTiernan A	Menopause 1996;3:71-76
MA4981			9/1/2007		Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment.	Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P	Endocr Relat Cancer2007 Sept;14(3):549-67
MA4992			6/1/2007		Recent increase of breast cancer incidence among women under the age of forty;	Bouchardy C, Fioretta G, Verkoijen HM, Vlastos G, Schaefer P, Delaloye JF, Neyroud-Caspar I, Balmer Manjo S, Wespi Y, Forni M, Chappuis P, Sappino AP, Rapiti E	Br J Cancer 2007;96(11):1743-46
MA4998			12/21/2007		Combined Estrogen-Progesterone Contraceptives and Combined Estrogen-Progesterone Menopausal Therapy	IARC	IARC Monograph
MA5001			12/1/2007		Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004.	Li CI, Daling JR	Cancer Epidemiol Biomarkers Prev 2007 Dec;16(12):2773-80
MA5010			12/13/2007		Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.	Kurosumi M, Takatsuka Y, Watanabe T, Imoto S, Inaji H, Tsuda H, Akiyama F, Sakamoto G, Ikeda T, Noguchi S	J Cancer Res Clin Oncol 2007 Dec 13;[Epub ahead of print]
MA5030			10/1/2005		Use of the levonorgestrel-releasing intrauterine system and breast cancer.	Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A, Koskenvuo M	Obstet Gynecol 2005 Oct;106(4):813-7
MA5037			1/8/2008		Lack of expression of androgen receptor may play a critical role in transformation from in situ invasive basal subtype of high-grade ductal carcinoma of the breast.	Hanley K, Wang J, Bourne P, Yang Q, Gao AC, Lyman G, Tang P	Hum Pathol 2008 Jan 8 [Epub ahead of print]
MA5048			1/14/2008		Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort - a cross-sectional analysis	Wasseth M, Bakken K, Dumeaux V, Olsen KS, Rylander C, Figenschau Y, Lund E	BMC Women's Health 2008 Jan 14 [Epub ahead of print]
MA5053			1/1/2008		Relationship between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-Lobular Breast Carcinomas.	Li CI, Malone KE, Porter PL, Lawton TJ, Voigt LF, Cushing-Haugen KL, Lin MG, Yuan X, Daling JR	Cancer Epidemiol Biomarkers Prev 2008 Jan;17(1):43-50
MA5060			2/6/2008		Effects of hormone therapy on estrogen synthesis from E1S in the mammary gland of postmenopausal women	Stute P, Szuwart T, Schlueter M, Gotte M, Packeisen J, Kisel L	Maturitas 2008 Feb 6;[Epub ahead of print]
MA5061			2/7/2008		Medroxyprogesterone Abrogates the Inhibitory Effects of Estradiol on Vascular Smooth Muscle Cells by Preventing Estradiol Metabolism	Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Wunder D, Imthurn B, Rosselli M	Hypertension 2008 Feb 7;[Epub ahead of print]

EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA5065			4/2/2008		Age-specific Trends in Mammographic Density: The Minnesota Breast Cancer Family Study.	Kellemen LE , Pankratz VS , Sellers TA , Brandt KR , Wang A , Janney C , Fredericksen ZS , Cerhan JR, Vachon CM	Am J Epidemiol 2008 Apr 2 [Epub ahead of print]
MA5081			3/5/2008		Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.	Heiss G, Wallace R, Anderson G, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML, WHI Investigators	JAMA 2008 Mar 5;299(9):1036-45
MA5083			1/1/2005		Reproductive Tissue-Selective Actions of Progesterone Receptors	Mulac-Jericevic B, Conneely OM	Ernst Schering Research Foundation Workshop 2005;(52):19-37
MA5085			3/28/2008		Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections.	Krieger N	Int J Epidemiol 2008 mar 28 [Epub ahead of print]
MA5087			3/10/2008		Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.	Fournier A , Fabre A , Mesrine S , Boutron-Ruault MC , Berrino F , Clavel-Chapelon F	J Clin Oncol 2008 Mar 10;26(8):1260-8
MA5089			1/1/2005		GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.	Shen HC, Buchanan G, Butler LM, Prescott J, Henderson M, Tilley WD, Coetzee GA	biol Chem 2005 Jan;386(1):69-74
MA5091			7/1/2006		Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.	Ingle JN, Suman VJ, Maillard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA	Breast Cancer Res Treat 2006 Jul;98(2):217-22
MA5092			12/1/1982		Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD.	Nilsson CG, Haukkamaa M , Vierola H , Luukkainen T	Clin Endocrinol (Oxf) 1982 Dec;17(6):529-36.
MA5093			1/21/2008		Hormone Replacement Therapy and Symptomatic Gallstones - A Prospective Population Study in the EPIC-Norfolk Cohort.	Hart AR, Luben R, Welch A, Bingham S, Khaw KT	Digestion 77(1):4-9
MA5102			4/8/2008		Conjugated Equine Estrogen and Risk of Benign Proliferative Breast Disease: A Randomized Controlled Trial	Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL	J Natl Cancer Inst 2008 Apr 8;[Epub ahead of print]
MA5107			5/1/2000		Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.	Rose C, Kamby C, Mouridsen HT, Andersson M, Bastholt L, Moller KA< Andersen J, Munkholm P, Dombrowsky P, Christensen IJ	Breast Cancer Res Treat 61(2):103-10
MA5109			1/21/2008		Hormone Replacement Therapy and Gallstone Disease: A Real Association.	Dhiman RK, Chawla YK	Digestion 2008 Jan 21;77(1):1-3
MA5110			2/1/1995		Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy.	Suhonen SP, Holmstrom T, Allonen HO, Lahteenmaki P	Fertil Steril 1995 Feb;63(2):336-42
MA5114			1/15/2007		5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.	Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S, Sasano H	Int J Cancer 120(2):285-91
MA5115			12/15/2003		Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor.	Yeh S, Hu YC, Wang PH, Xie C, Xu Q, Tsai MY, Dong Z, Wang RS, Lee TH, Chang C	J Exp Med 2003 Dec 15;198(12):1899-908
MA5116			1/1/2005		Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income.	Wei F, Miglioretti D, Connelly MT, Andrade SE, Newton KM, Hartsfield CL, Chan KA, Buist DS	J Natl Cancer Inst Monogr 2005;(35):106-12
MA5117			9/1/1982		Beaton: hormones and the management of breast cancer.	Forrest AP	J R Coll Surg Edinb 27(5):253-63
MA5118			5/1/2007		Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms--a review.	Peled Y, Perri T, Pardo Y, Kaplan B	Menopause 2007 May-Jun;14(3 Pt 1):550-4
MA5119			7/1/2003		A physiologic role for testosterone in limiting estrogenic stimulation of the breast.	Dimitrakakis C , Zhou J , Wang J , Belanger A , LaBrie F , Cheng C , Powell D , Bondy C	Menopause 2003 Jul-Aug;10(4):292-8
MA5122			11/1/2004		Hormone therapy prescribing patterns in the United States.	Buist DS , Newton KM , Miglioretti DL , Beverly K , Connelly MT , Andrade S, Hartsfield CL , Wei F , Chan KA , Kessler L	Obstet Gynecol 2004 Nov;104(5 Pt 1):1042-50
MA5124			11/1/2003		Progesterone involvement in breast development and tumorigenesis--as revealed by progesterone receptor "knockout" and "knockin" mouse models.	Ismail PM, Amato P, Soyak SM, DeMayo FJ, Conneely OM, O'Malley BW, Lydon JP	Steroids 2003 Nov;68(10-13):779-87
MA5125			10/31/1979		High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.	Ganzina F	Tumori 1979 Oct 31;65(5):563-85
MA5126			09/31/1992		Deflazacort and flutimesterone in advanced, pretreated breast cancer.	Fornasiero A, Ferrazzi E, Aversa SM, Daniele O, Ghiotto C, Sileni VC, De Besi P, Fiorentino MV	Tumori 1992 Aug 31;78(4):266-9
MA5128			11/1/1996		Progesterone receptor A and B protein expression in human breast cancer	Graham JD, Yeates C, Balleine RL, Harvey SS, Miliken JS, Bilous AM, Clarke CL	J Steroid Biochem Mol Biol 1996;56:93-98
MA5129			12/7/2007		Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data	Seeger H, Mueck AO	J Steroid Biochem Mol Biol 109(1-2):11-15
MA5130			4/20/2008		Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors	Cops EJ, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM, Tilley WD	J Steroid Biochem Mol Biol 20 April 2008 [Epub ahead of print]
MA5131			1/1/2007		Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype.	Hausauer AK, Keegan TH, Chang ET, Clarke CA	Breast Cancer REs 2007;9(6):R90
MA5132			1/1/2007		Cancer statistics, 2007.	Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ	CA Cancer J Clin 2007 Jan-Feb;57(1):43-66
MA5133			1/1/2007		Prognostic markers in triple-negative breast cancer.	Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO	Cancer 2007 Jan 1;109(1):25-32
MA5134			1/1/1999		Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells.	Lapointe J, Fournier A, Richard V, Labrie C	Endocrinology 1999 Jan;140(1):416-21
MA5135			10/1/1993		Developmental effects of endocrine-disrupting chemicals in wildlife and humans.	Colborn T, vom Saal FS, Soto AM	Environ Health Perspect 1993 Oct;101(5):378-84
MA5136			11/9/2001		Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2.	He B, Bowen NT, Minges JT, Wilson EM	J Biol Chem 2001 Nov;276(45):42293-301
MA5137			3/1/1999		Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone.	Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM	Mol Endocrinol 13(3):440-54 EXHIBIT 4

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA5138			1/23/2007		Cofactor Restriction by Androgen Receptor N-terminal and C-terminal Interaction.	Toumazou C, Li J, Wong J	Mol Endocrinol 2007 Jan 23 [Epub ahead of print]
MA5139			8/15/2004		Structural and functional consequences of glutamine tract variation in the androgen receptor.	Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufiling PJ, Coetzee GA, Tilley WD	Hum Mol Genet 2004 Aug 15;13(16):1677-92
MA5140			1/2/1998		Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity.	Langley E, Kempainen JA, Wilson EM	J Biol Chem 1998 Jan2;273(1):92-101
MA5141			4/11/2008		Transcriptional profiles of progesterone effects in the postmenopausal breast.	Wood CE, Register TC, Cline JM	Breast Cancer Res Treat 2008 Apr 11 [Epub ahead of print]
MA5142			10/5/1991		Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.	WHO Collaborative Study	Lancet 1991 Oct 5;338(8771):833-8
MA5143			10/21/1992		Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer.	Kuonen-Boumeester V, Van Der Kwast TH, van Putten WL, Claassen C, van Ooljen B, Henzen-Logmans SC	Int J Cancer 1992 Oct 21;52(4):581-4
MA5144			1/1/2008		Effects of estradiol and medroxyprogesterone acetate on expression of the cell cycle proteins cyclin D1, p21 and p27 in cultured human breast tissues.	Eigelen R, Harkonen P, Erkkola R	Cell Cycle 2008 Jan;7(1):71-81
MA5164					Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history	Welsh	Breast Cancer Res Treat. (2008)
MA5167			3/27/2008		Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women.	Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, Jo O'Sullivan M, Rossouw JE, Anderson GL	Am J Epidemiol 2008 Mar 27 [Epub ahead of print]
MA5169			4/29/2008		Conjugated Equine Estrogens and Breast Cancer Risk in the Women's Health Initiative Clinical Trial and Observational Study	Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O'Sullivan MJ, Rossouw JE, Anderson GL	Am J Epidemiol 2008 Apr 29 [Epub ahead of print]
MA5174			5/20/2008		Problems and Solutions in the Evaluation of Hormone Receptors in Breast Cancer	Allred DC	J Clin Oncol 2008;26(15):2433-2435
MA5175			10/1/2007		Hormone therapy and breast cancer risk	Foidart JM, Desreux J, Pintiaux A, Gompel A	Climacteric 10 (Supp 2):54-61
MA5178			5/1/2008		Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast.	Cho LC, Hsu YH	Kaohsiung J Med Sci 2008 May;24(5):227-32
MA5183			5/1/2008		The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions.	Brandt SM, Young GQ, Hoda SA	Adv Anat Pathol 2008 May;15(3):140-6
MA5216			5/1/2008		A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women.	Shifren JL, Rifai N, Deslandes S, McIlwain M, Doros G, Mazer NA	J Clin Endocrinol Metab 2008 May;93(5):1702-10
MA5224			6/3/2008		Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity?	Hermesmeier RK, Thompson TL, Pohost GM, Kaski JC	Nat Clin Pract Cardiovasc Med 2008 Jun 3 [Epub ahead of print]
MA5229			5/31/2008		Type of HRT and risk of venous thromboembolism	Roberts H	BMJ 2008 May 31;3367(7655):1203-4
MA5230			5/31/2008		Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis	Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY	BMJ 2008 May 31;336(7655):1227-31
MA5243			11/1/2007		NIH and WHI: time for a mea culpa and steps beyond.	Utian WH	Menopause 14(6):1056-9
MA5259			6/1/2007		Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model.	Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF, Key T, Hankinson SE, Howell A, Ingle J	Endocr Relat Cancer 2007 Jun;14(2):169-87
MA5291			4/23/2003		Stopping medical research to save money: a broken pact with researchers and patients.	Psaty BM, Rennie D	JAMA 2003 Apr 23;30:289(16):2128-31
MA5292			5/21/2008		Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis	Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS	JAMA 2003 May 21;289(19):2534-44
MA5293			7/8/2008		Prevention of cardiovascular events in early menopause: A possible role for hormone replacement therapy	Antonicelli R, Olivieri F, Morichi V, Urbani E, Mais V	Int J Cardiol 2008 Jul 8 [Epub ahead of print]
MA5295			1/1/2008		Drug-Induced Urinary Incontinence	Tsakiris P, Oelke M, Michel MC	Drugs Aging 2008;25(7):541-9
MA5297			8/15/2008		Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy	Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J	Int J Cancer 2008 Aug 15;123(4):933-41
MA5298			7/10/2008		Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study.	Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G	BMJ 2008 Jul 10;337:a386
MA5301			1/9/2008		Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence.	Martin LJ, Boyd NF	Breast Cancer REs 2008;10(1):201
MA5326			7/22/2008		Progestins in hormone replacement therapies reactivate cancer stem cells in women with pre-existing cancers: a hypothesis	Horwitz KB, Sartorius CA	J Clin Endocrin Metab 2008 July 22 [Epub ahead of print]
MA5354					Could transdermal estradiol+progesterone be a safer postmenopausal HRT? A review.	L'hermite M, Simoncini T, Fuller S, Genazzani AR	Matitas 2008 Sept 4 [Epub ahead of print]
MA5377			10/9/2008		The Year in Hormones and Cancer Lecture*: Update of Estrogen plus Progestin Therapy for Menopausal Hormone Replacement Implicating Stem Cells in the Increased Breast Cancer Risk	Horwitz K	Mol Endocrinol 2008 Oct 9; [Epub ahead of print]
MA5386			11/1/2008		Progestogens and the climacteric female	Schindler AE, Druckmann R	Maturitas 2008 Nov 1 [Epub ahead of print]
MA5389					Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005	Hemminki E, Kyronen P, Pukkala RA	Maturitas 2008 Nov 7 [Epub ahead of print]
MA5409			9/1/2004		Height Change and Bone Mineral Density	Thornton MJ, Sedlak CA, Doherty MO	Orthop Nurs 23(5):315-320
MA5415			11/1/2008		Mammographic density, lobular involution, and risk of breast cancer.	Ginsburg OM, Martin LJ, Boyd NF	Br J Cancer 2008 Nov 4;99(9):1369-74
MA5420			10/22/2008		Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)?	Ringa V, Fournier A	Rev Epidemiol Sante Publique 2008 Oct;56(5):297-301. Epub 2008 Oct 22
MA5423			2/24/2009		Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg	Vankrunkelsven P, Kellen E, Iousbergh D, Cloes E, de Beeck L, Faes C, Bruckers L, Mertens R, Coebergh JW, Van Leeuwen FE, Buntinx F	Breast Cancer Res Treat February 24, 2009 [Epub ahead of print]
MA5440			12/1/2008		Breast Cancer After Estrogen and Progestin in Postmenopausal Women in the Women's Health Initiative	Chlebowski RL et al.	Power Point Presentation San Antonio Breast Cancer Symposium December 2008
MA5447			2/10/2009		Re: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.	Langer RD	Am J Epidemiol 2009 Mar 15;169(6):784-5; author reply 789-90

Exhibit 4

Edi v. Wyeth et al.
Plaintiffs' Exhibit L-1

EX_NO	BEGBATES	ENDBATES	DOCDATE	DESCRIPTION	TITLE	AUTHOR	CITATION
MA5469					International Union of Pharmacology LXIV		
MA5471	Notelovitz				The Biologic and Pharmacologic Principles of estrogen therapy		
MA5500			00/00/2010	Banks	Recent Declines in Breast Cancer Incidence: Mounting Evidence That Reduced use of Menopausal Hormones is Largely Responsible		